(lp0
(dp1
S'line'
p2
S'Real-time RT-PCR was used to demonstrate the expression of prohormone convertase (PC)1/3, PC2 and furin in prostate cancer cell lines.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I59
sS'uniprot'
p8
VP09958
p9
sS'lengthInChars'
p10
I29
sS'name'
p11
Vprohormone convertase (PC)1/3
p12
sS'lengthInWords'
p13
I3
sa(dp14
g7
I90
sg8
VP16519
p15
sg10
I3
sg11
VPC2
p16
sg13
I1
sa(dp17
g7
I98
sg8
VP09958
p18
sg10
I5
sg11
Vfurin
p19
sg13
I1
sasS'diseases'
p20
(lp21
(dp22
g7
I90
sS'cui'
p23
VC1721007
p24
sg10
I3
sg11
VPC2
p25
sg13
I1
sa(dp26
g7
I107
sg23
VC0600139
p27
sg10
I15
sg11
Vprostate cancer
p28
sg13
I2
sasa(dp29
g2
S'The RWPE-1 and RWPE-2 normal prostate-derived cell lines and the LNCaP, DU145, and PC3 prostate cancer cell lines express GOAT and at least one other enzyme that is necessary to produce mature, acylated ghrelin from proghrelin (PC1/3, PC2 or furin).\n'
p30
sg4
(lp31
(dp32
g7
I235
sg8
VP16519
p33
sg10
I3
sg11
VPC2
p34
sg13
I1
sa(dp35
g7
I228
sg8
VP29120
p36
sg10
I5
sg11
VPC1/3
p37
sg13
I1
sa(dp38
g7
I122
sg8
S''
p39
sg10
I4
sg11
VGOAT
p40
sg13
I1
sa(dp41
g7
I242
sg8
VP09958
p42
sg10
I5
sg11
Vfurin
p43
sg13
I1
sa(dp44
g7
I203
sg8
g39
sg10
I23
sg11
Vghrelin from proghrelin
p45
sg13
I3
sa(dp46
g7
I83
sg8
VP42025
p47
sg10
I3
sg11
VPC3
p48
sg13
I1
sasg20
(lp49
(dp50
g7
I87
sg23
VC0600139
p51
sg10
I15
sg11
Vprostate cancer
p52
sg13
I2
sa(dp53
g7
I235
sg23
VC1721007
p54
sg10
I3
sg11
VPC2
p55
sg13
I1
sa(dp56
g7
I228
sg23
VC1706595
p57
sg10
I3
sg11
VPC1
p58
sg13
I1
sasa(dp59
g2
S"Finally, to evaluate the importance of PSA's proteolytic activity, the PSA-null Du145 human prostate cancer cell line was engineered to express either enzymatically inactive pro-PSA (WT) or a furin-activated variant (FR) with high enzymatic activity.\n"
p60
sg4
(lp61
(dp62
g7
I39
sg8
VP55786
p63
sg10
I3
sg11
VPSA
p64
sg13
I1
sa(dp65
g7
I192
sg8
VP09958
p66
sg10
I28
sg11
Vfurin-activated variant (FR)
p67
sg13
I3
sa(dp68
g7
I174
sg8
VP55786
p69
sg10
I7
sg11
Vpro-PSA
p70
sg13
I1
sa(dp71
g7
I71
sg8
VP55786
p72
sg10
I14
sg11
VPSA-null Du145
p73
sg13
I2
sasg20
(lp74
(dp75
g7
I39
sg23
VC1519176
p76
sg10
I3
sg11
VPSA
p77
sg13
I1
sa(dp78
g7
I92
sg23
VC0600139
p79
sg10
I15
sg11
Vprostate cancer
p80
sg13
I2
sa(dp81
g7
I39
sg23
VC1519176
p82
sg10
I3
sg11
VPSA
p83
sg13
I1
sa(dp84
g7
I39
sg23
VC1519176
p85
sg10
I3
sg11
VPSA
p86
sg13
I1
sasa(dp87
g2
S'Functionally parallel to v-akt murine thymoma viral oncogene homolog (AKT)/protein kinase B, SGK3 serves as a hallmark mediating glycogen synthase kinase-Beta (GSK3-Beta), B-cell lymphoma (Bcl)-2-associated death promoter, forkead family of transcription factors, Bcl-extra large, Bcl-2, mammalian target of rapamycin, C-X-C chemokine receptor type 4 (CXCR4) and numerous other molecules in cell proliferation, growth, survival, migration and even tumor angiogenesis.\n'
p88
sg4
(lp89
(dp90
g7
I129
sg8
VP13807
p91
sg10
I29
sg11
Vglycogen synthase kinase-Beta
p92
sg13
I3
sa(dp93
g7
I352
sg8
VP61073
p94
sg10
I5
sg11
VCXCR4
p95
sg13
I1
sa(dp96
g7
I281
sg8
VP10415
p97
sg10
I5
sg11
VBcl-2
p98
sg13
I1
sa(dp99
g7
I93
sg8
g39
sg10
I4
sg11
VSGK3
p100
sg13
I1
sa(dp101
g7
I319
sg8
VP61073
p102
sg10
I31
sg11
VC-X-C chemokine receptor type 4
p103
sg13
I5
sa(dp104
g7
I223
sg8
VP19883
p105
sg10
I39
sg11
Vforkead family of transcription factors
p106
sg13
I5
sa(dp107
g7
I25
sg8
g39
sg10
I66
sg11
Vv-akt murine thymoma viral oncogene homolog (AKT)/protein kinase B
p108
sg13
I9
sasg20
(lp109
(dp110
g7
I189
sg23
VC0079731
p111
sg10
I3
sg11
VBcl
p112
sg13
I1
sa(dp113
g7
I189
sg23
VC0079731
p114
sg10
I3
sg11
VBcl
p115
sg13
I1
sa(dp116
g7
I189
sg23
VC0079731
p117
sg10
I3
sg11
VBcl
p118
sg13
I1
sa(dp119
g7
I448
sg23
VC1519670
p120
sg10
I18
sg11
Vtumor angiogenesis
p121
sg13
I2
sa(dp122
g7
I38
sg23
VC0040100
p123
sg10
I7
sg11
Vthymoma
p124
sg13
I1
sa(dp125
g7
I396
sg23
VC0334094
p126
sg10
I13
sg11
Vproliferation
p127
sg13
I1
sa(dp128
g7
I172
sg23
VC0079731
p129
sg10
I15
sg11
VB-cell lymphoma
p130
sg13
I2
sasa(dp131
g2
S'Tissue blocks containing pulmonary small cell carcinoma, pulmonary carcinoid, large cell neuroendocrine carcinoma, pancreatic neuroendocrine tumor, gastrointestinal carcinoid, and Merkel cell carcinoma were evaluated for CD200 expression by immunohistochemistry.\n'
p132
sg4
(lp133
(dp134
g7
I221
sg8
VP41217
p135
sg10
I5
sg11
VCD200
p136
sg13
I1
sasg20
(lp137
(dp138
g7
I180
sg23
VC0007129
p139
sg10
I21
sg11
VMerkel cell carcinoma
p140
sg13
I3
sa(dp141
g7
I78
sg23
VC1265996
p142
sg10
I35
sg11
Vlarge cell neuroendocrine carcinoma
p143
sg13
I4
sa(dp144
g7
I115
sg23
VC1337011
p145
sg10
I31
sg11
Vpancreatic neuroendocrine tumor
p146
sg13
I3
sa(dp147
g7
I67
sg23
VC0007095
p148
sg10
I9
sg11
Vcarcinoid
p149
sg13
I1
sa(dp150
g7
I67
sg23
VC0007095
p151
sg10
I9
sg11
Vcarcinoid
p152
sg13
I1
sa(dp153
g7
I35
sg23
VC0262584
p154
sg10
I20
sg11
Vsmall cell carcinoma
p155
sg13
I3
sasa(dp156
g2
S'CD200 was expressed in 87% of the neuroendocrine neoplasms studied, including 60 of 72 (83%) pulmonary small cell carcinomas, 15 of 22 (68%) pulmonary carcinoids, three of four (75%) pulmonary large cell neuroendocrine carcinomas, 125 of 146 (86%) Merkel cell carcinomas, 79 of 83 (95%) gastrointestinal luminal carcinoids, and 56 of 60 (93%) pancreatic neuroendocrine tumors.\n'
p157
sg4
(lp158
(dp159
g7
I0
sg8
VP41217
p160
sg10
I5
sg11
VCD200
p161
sg13
I1
sasg20
(lp162
(dp163
g7
I151
sg23
VC0007095
p164
sg10
I10
sg11
Vcarcinoids
p165
sg13
I1
sa(dp166
g7
I354
sg23
VC0206754
p167
sg10
I21
sg11
Vneuroendocrine tumors
p168
sg13
I2
sa(dp169
g7
I204
sg23
VC0206695
p170
sg10
I25
sg11
Vneuroendocrine carcinomas
p171
sg13
I2
sa(dp172
g7
I114
sg23
VC0007097
p173
sg10
I10
sg11
Vcarcinomas
p174
sg13
I1
sa(dp175
g7
I151
sg23
VC0007095
p176
sg10
I10
sg11
Vcarcinoids
p177
sg13
I1
sa(dp178
g7
I103
sg23
VC0262584
p179
sg10
I21
sg11
Vsmall cell carcinomas
p180
sg13
I3
sa(dp181
g7
I49
sg23
VC0027651
p182
sg10
I9
sg11
Vneoplasms
p183
sg13
I1
sasa(dp184
g2
S'In hepatocytes of alcoholic fatty liver disease (AFLD), ethanol increases the expression of lipin-1 through the AMPK-SREBP-1 signaling and the Lpin1Beta/Alfa ratio by SIRT1-SFRS10- Lpin1Beta/Alfa axis.\n'
p185
sg4
(lp186
(dp187
g7
I173
sg8
VP62995
p188
sg10
I6
sg11
VSFRS10
p189
sg13
I1
sa(dp190
g7
I167
sg8
g39
sg10
I5
sg11
VSIRT1
p191
sg13
I1
sa(dp192
g7
I112
sg8
VP36956
p193
sg10
I12
sg11
VAMPK-SREBP-1
p194
sg13
I1
sa(dp195
g7
I92
sg8
g39
sg10
I7
sg11
Vlipin-1
p196
sg13
I1
sasg20
(lp197
(dp198
g7
I18
sg23
VC0015696
p199
sg10
I21
sg11
Valcoholic fatty liver
p200
sg13
I3
sasa(dp201
g2
S'The lack of WRN results in Werner syndrome, a rare autosomal recessive genetic disorder, which causes premature aging accompanied by many complications such as rare forms of cancer and type 2 diabetes.\n'
p202
sg4
(lp203
sg20
(lp204
(dp205
g7
I12
sg23
VC0043119
p206
sg10
I3
sg11
VWRN
p207
sg13
I1
sa(dp208
g7
I185
sg23
VC0011860
p209
sg10
I15
sg11
Vtype 2 diabetes
p210
sg13
I3
sa(dp211
g7
I71
sg23
VC0019247
p212
sg10
I16
sg11
Vgenetic disorder
p213
sg13
I2
sa(dp214
g7
I27
sg23
VC0043119
p215
sg10
I15
sg11
VWerner syndrome
p216
sg13
I2
sa(dp217
g7
I174
sg23
VC0006826
p218
sg10
I6
sg11
Vcancer
p219
sg13
I1
sa(dp220
g7
I102
sg23
VC0231341
p221
sg10
I15
sg11
Vpremature aging
p222
sg13
I2
sasa(dp223
g2
S'As an analogy of the mechanism in natural aging, we described a hypothetical mechanism of premature aging in WS: telomere dysfunction induced by WRN mutation causes multiple premature aging phenotypes of WS, including shortened cellular lifespan and inflammation induced by ROS, such as diabetes mellitus.\n'
p224
sg4
(lp225
(dp226
g7
I145
sg8
VP02545
p227
sg10
I12
sg11
VWRN mutation
p228
sg13
I2
sasg20
(lp229
(dp230
g7
I90
sg23
VC0231341
p231
sg10
I15
sg11
Vpremature aging
p232
sg13
I2
sa(dp233
g7
I145
sg23
VC0043119
p234
sg10
I3
sg11
VWRN
p235
sg13
I1
sa(dp236
g7
I250
sg23
VC0021368
p237
sg10
I12
sg11
Vinflammation
p238
sg13
I1
sa(dp239
g7
I90
sg23
VC0231341
p240
sg10
I15
sg11
Vpremature aging
p241
sg13
I2
sa(dp242
g7
I287
sg23
VC0011849
p243
sg10
I17
sg11
Vdiabetes mellitus
p244
sg13
I2
sasa(dp245
g2
S"Mutations in NADH dehydrogenase ubiquinone flavoprotein 2 (NDUFV2) are responsible for schizophrenia, bipolar disorder and Parkinson's disease.\n"
p246
sg4
(lp247
(dp248
g7
I13
sg8
VP49366
p249
sg10
I44
sg11
VNADH dehydrogenase ubiquinone flavoprotein 2
p250
sg13
I5
sa(dp251
g7
I59
sg8
VP19404
p252
sg10
I6
sg11
VNDUFV2
p253
sg13
I1
sasg20
(lp254
(dp255
g7
I102
sg23
VC0005586
p256
sg10
I16
sg11
Vbipolar disorder
p257
sg13
I2
sa(dp258
g7
I123
sg23
VC0030567
p259
sg10
I19
sg11
VParkinson's disease
p260
sg13
I2
sa(dp261
g7
I87
sg23
VC0036341
p262
sg10
I13
sg11
Vschizophrenia
p263
sg13
I1
sasa(dp264
g2
S'The aim of this study is to examine the mitochondrial targeting of NDUFV2 and dissect the pathogenetic mechanism of one human deletion mutation present in patients with early-onset hypertrophic cardiomyopathy and encephalopathy.\n'
p265
sg4
(lp266
(dp267
g7
I67
sg8
VP19404
p268
sg10
I6
sg11
VNDUFV2
p269
sg13
I1
sasg20
(lp270
(dp271
g7
I181
sg23
VC0007194
p272
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p273
sg13
I2
sa(dp274
g7
I213
sg23
VC0085584
p275
sg10
I14
sg11
Vencephalopathy
p276
sg13
I1
sasa(dp277
g2
S'The deletion mutant mimicking the human early-onset hypertrophic cardiomyopathy and encephalopathy lacked 19-40 residues in NDUFV2 and exhibited a significant reduction in its mitochondrial targeting ability.\n'
p278
sg4
(lp279
(dp280
g7
I124
sg8
VP19404
p281
sg10
I6
sg11
VNDUFV2
p282
sg13
I1
sasg20
(lp283
(dp284
g7
I13
sg23
VC0596988
p285
sg10
I6
sg11
Vmutant
p286
sg13
I1
sa(dp287
g7
I52
sg23
VC0007194
p288
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p289
sg13
I2
sa(dp290
g7
I84
sg23
VC0085584
p291
sg10
I14
sg11
Vencephalopathy
p292
sg13
I1
sasa(dp293
g2
S'The results of human disease cell model established that the impairment of mitochondrial localization of NDUFV2 as a mechanistic basis for early-onset hypertrophic cardiomyopathy and encephalopathy.\n'
p294
sg4
(lp295
(dp296
g7
I105
sg8
VP19404
p297
sg10
I6
sg11
VNDUFV2
p298
sg13
I1
sasg20
(lp299
(dp300
g7
I61
sg23
VC0684336
p301
sg10
I10
sg11
Vimpairment
p302
sg13
I1
sa(dp303
g7
I183
sg23
VC0085584
p304
sg10
I14
sg11
Vencephalopathy
p305
sg13
I1
sa(dp306
g7
I151
sg23
VC0007194
p307
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p308
sg13
I2
sasa(dp309
g2
S'To determine the serum sCD93 level and its association with clinical parameters in patients with systemic sclerosis (SSc).\n'
p310
sg4
(lp311
sg20
(lp312
(dp313
g7
I97
sg23
VC0036421
p314
sg10
I18
sg11
Vsystemic sclerosis
p315
sg13
I2
sa(dp316
g7
I117
sg23
VC0036421
p317
sg10
I3
sg11
VSSc
p318
sg13
I1
sasa(dp319
g2
S'Serum sCD93 levels were examined by enzyme-linked immunosorbent assay in 59 patients with SSc, 24 patients with systemic lupus erythematosus and 47 healthy individuals.\n'
p320
sg4
(lp321
sg20
(lp322
(dp323
g7
I112
sg23
VC0024141
p324
sg10
I28
sg11
Vsystemic lupus erythematosus
p325
sg13
I3
sasa(dp326
g2
S'Patients with diffuse cutaneous SSc showed greater levels of sCD93 than those with limited cutaneous SSc (P&lt;0*01) or systemic lupus erythematosus (P&lt;0*01).\n'
p327
sg4
(lp328
sg20
(lp329
(dp330
g7
I120
sg23
VC0024141
p331
sg10
I28
sg11
Vsystemic lupus erythematosus
p332
sg13
I3
sasa(dp333
g2
S'Interestingly, the NZB/W F1 strain, which serves as a murine model of Lupus, also expresses an identical CD93 sequence polymorphism.\n'
p334
sg4
(lp335
(dp336
g7
I105
sg8
g39
sg10
I13
sg11
VCD93 sequence
p337
sg13
I2
sasg20
(lp338
(dp339
g7
I70
sg23
VC0024131
p340
sg10
I5
sg11
VLupus
p341
sg13
I1
sasa(dp342
g2
S'Aim of the study was to compare the expression of monocytes C1qRp (CD93) in patients with systemic lupus erythematosus (SLE) with that of healthy controls and to determine the influence of glucocorticoids and LPS on C1qRp expression.\n'
p343
sg4
(lp344
(dp345
g7
I67
sg8
g39
sg10
I4
sg11
VCD93
p346
sg13
I1
sa(dp347
g7
I60
sg8
g39
sg10
I5
sg11
VC1qRp
p348
sg13
I1
sa(dp349
g7
I60
sg8
g39
sg10
I5
sg11
VC1qRp
p350
sg13
I1
sasg20
(lp351
(dp352
g7
I120
sg23
VC0024141
p353
sg10
I3
sg11
VSLE
p354
sg13
I1
sa(dp355
g7
I209
sg23
VC0175697
p356
sg10
I3
sg11
VLPS
p357
sg13
I1
sa(dp358
g7
I90
sg23
VC0024141
p359
sg10
I28
sg11
Vsystemic lupus erythematosus
p360
sg13
I3
sasa(dp361
g2
S'In this study, we show that both heterozygous and homozygous mice deficient for lipocalin-type prostaglandin D(2)  (PGD(2) ) synthase (Ptgds) presented unilateral cryptorchidism affecting the second phase of testicular descent in 16% and 24% of cases, respectively.\n'
p362
sg4
(lp363
(dp364
g7
I135
sg8
VP41222
p365
sg10
I5
sg11
VPtgds
p366
sg13
I1
sa(dp367
g7
I80
sg8
VP52209
p368
sg10
I53
sg11
Vlipocalin-type prostaglandin D(2)  (PGD(2) ) synthase
p369
sg13
I7
sasg20
(lp370
(dp371
g7
I152
sg23
VC0431664
p372
sg10
I25
sg11
Vunilateral cryptorchidism
p373
sg13
I2
sasa(dp374
g2
S'These observations led us to investigate the role of the PGD(2)  signaling pathway in human testicular migration through PTGDS sequencing of DNA from 29 children with cryptorchidism.\n'
p375
sg4
(lp376
sg20
(lp377
(dp378
g7
I167
sg23
VC0010417
p379
sg10
I14
sg11
Vcryptorchidism
p380
sg13
I1
sasa(dp381
g2
S'Nevertheless, our results identify the PTGDS enzyme as a novel component in the cryptorchidism puzzle.\n'
p382
sg4
(lp383
(dp384
g7
I39
sg8
VP41222
p385
sg10
I12
sg11
VPTGDS enzyme
p386
sg13
I2
sasg20
(lp387
(dp388
g7
I80
sg23
VC0010417
p389
sg10
I14
sg11
Vcryptorchidism
p390
sg13
I1
sasa(dp391
g2
S'Using stringent filtering criteria, Apolipoprotein A-IV (APOA-IV), Albumin and Antithrombin 3 (ANT3) were detected at significantly higher levels in PCG AH compared to control, whereas Transthyretin (TTR), Prostaglandin-H2 D-isomerase (PTGDS), Opticin (OPT) and Interphotoreceptor Retinoid Binding Protein (IRBP) were detected at significantly lower levels.\n'
p392
sg4
(lp393
(dp394
g7
I307
sg8
VP48200
p395
sg10
I4
sg11
VIRBP
p396
sg13
I1
sa(dp397
g7
I206
sg8
VP41222
p398
sg10
I28
sg11
VProstaglandin-H2 D-isomerase
p399
sg13
I2
sa(dp400
g7
I57
sg8
VP06727
p401
sg10
I7
sg11
VAPOA-IV
p402
sg13
I1
sa(dp403
g7
I95
sg8
VP12236
p404
sg10
I4
sg11
VANT3
p405
sg13
I1
sa(dp406
g7
I36
sg8
VP08519
p407
sg10
I19
sg11
VApolipoprotein A-IV
p408
sg13
I2
sa(dp409
g7
I200
sg8
VP02766
p410
sg10
I3
sg11
VTTR
p411
sg13
I1
sa(dp412
g7
I262
sg8
VP48200
p413
sg10
I43
sg11
VInterphotoreceptor Retinoid Binding Protein
p414
sg13
I4
sa(dp415
g7
I67
sg8
VP00441
p416
sg10
I7
sg11
VAlbumin
p417
sg13
I1
sa(dp418
g7
I185
sg8
VP02766
p419
sg10
I13
sg11
VTransthyretin
p420
sg13
I1
sa(dp421
g7
I79
sg8
VP05546
p422
sg10
I14
sg11
VAntithrombin 3
p423
sg13
I2
sa(dp424
g7
I236
sg8
VP41222
p425
sg10
I5
sg11
VPTGDS
p426
sg13
I1
sasg20
(lp427
sa(dp428
g2
S'We compared the diagnostic performance of cystatin C and beta-trace protein with serum creatinine and the Schwartz formula for the estimation of glomerular filtration rate in children with spina bifida.\n'
p429
sg4
(lp430
(dp431
g7
I42
sg8
VP01034
p432
sg10
I10
sg11
Vcystatin C
p433
sg13
I2
sa(dp434
g7
I57
sg8
VP41222
p435
sg10
I18
sg11
Vbeta-trace protein
p436
sg13
I2
sasg20
(lp437
(dp438
g7
I189
sg23
VC0080178
p439
sg10
I12
sg11
Vspina bifida
p440
sg13
I2
sasa(dp441
g2
S'Correlation coefficients for cystatin C were 0.45 and 0.84 in the spina bifida and control groups, respectively, while correlation coefficients for beta-trace protein were 0.31 and 0.75, respectively.\n'
p442
sg4
(lp443
(dp444
g7
I29
sg8
VP01034
p445
sg10
I10
sg11
Vcystatin C
p446
sg13
I2
sasg20
(lp447
(dp448
g7
I66
sg23
VC0080178
p449
sg10
I12
sg11
Vspina bifida
p450
sg13
I2
sasa(dp451
g2
S'Mice lacking both LDL receptor (LDLR) and Arhgef1 were protected from high-fat diet-induced atherosclerosis.\n'
p452
sg4
(lp453
(dp454
g7
I18
sg8
VP01130
p455
sg10
I12
sg11
VLDL receptor
p456
sg13
I2
sa(dp457
g7
I42
sg8
g39
sg10
I7
sg11
VArhgef1
p458
sg13
I1
sa(dp459
g7
I32
sg8
VP01130
p460
sg10
I4
sg11
VLDLR
p461
sg13
I1
sasg20
(lp462
(dp463
g7
I92
sg23
VC0004153
p464
sg10
I15
sg11
Vatherosclerosis
p465
sg13
I1
sasa(dp466
g2
S'Moreover, reconstitution of Ldlr-/- mice with Arhgef1-deficient BM prevented high-fat diet-induced atherosclerosis, while reconstitution of Ldlr-/- Arhgef1-/- with WT BM exacerbated atherosclerotic lesion formation, supporting Arhgef1 activation in leukocytes as causal in the development of atherosclerosis.\n'
p467
sg4
(lp468
(dp469
g7
I28
sg8
VP01130
p470
sg10
I4
sg11
VLdlr
p471
sg13
I1
sa(dp472
g7
I28
sg8
VP01130
p473
sg10
I4
sg11
VLdlr
p474
sg13
I1
sasg20
(lp475
(dp476
g7
I99
sg23
VC0004153
p477
sg10
I15
sg11
Vatherosclerosis
p478
sg13
I1
sa(dp479
g7
I99
sg23
VC0004153
p480
sg10
I15
sg11
Vatherosclerosis
p481
sg13
I1
sasa(dp482
g2
S'Thus, our data highlight the importance of Arhgef1 in cardiovascular disease and suggest targeting Arhgef1 as a potential therapeutic strategy against atherosclerosis.\n'
p483
sg4
(lp484
(dp485
g7
I43
sg8
g39
sg10
I7
sg11
VArhgef1
p486
sg13
I1
sasg20
(lp487
(dp488
g7
I151
sg23
VC0004153
p489
sg10
I15
sg11
Vatherosclerosis
p490
sg13
I1
sa(dp491
g7
I54
sg23
VC0007222
p492
sg10
I22
sg11
Vcardiovascular disease
p493
sg13
I2
sasa(dp494
g2
S'In summary, LSC-1 cells exhibit activated HSC phenotype characteristics, and therefore are useful tool to study the pathogenesis of liver cirrhosis and portal hypertension.\n'
p495
sg4
(lp496
(dp497
g7
I42
sg8
VP19526
p498
sg10
I3
sg11
VHSC
p499
sg13
I1
sasg20
(lp500
(dp501
g7
I116
sg23
VC0699748
p502
sg10
I12
sg11
Vpathogenesis
p503
sg13
I1
sa(dp504
g7
I152
sg23
VC0020541
p505
sg10
I19
sg11
Vportal hypertension
p506
sg13
I2
sa(dp507
g7
I132
sg23
VC0023890
p508
sg10
I15
sg11
Vliver cirrhosis
p509
sg13
I2
sasa(dp510
g2
S'The mRNA and protein levels of JAK2/ARHGEF1 signalling components were analysed in 49 human liver samples and correlated with clinical parameters of portal hypertension in these patients.\n'
p511
sg4
(lp512
(dp513
g7
I36
sg8
g39
sg10
I7
sg11
VARHGEF1
p514
sg13
I1
sa(dp515
g7
I31
sg8
g39
sg10
I4
sg11
VJAK2
p516
sg13
I1
sasg20
(lp517
(dp518
g7
I149
sg23
VC0020541
p519
sg10
I19
sg11
Vportal hypertension
p520
sg13
I2
sasa(dp521
g2
S'Hepatic transcription of JAK2/ARHGEF1 pathway components was upregulated in liver cirrhosis dependent on aetiology, severity and complications of human liver cirrhosis (Model for End-stage Liver disease (MELD) score, Child score as well as ascites, high-risk varices, spontaneous bacterial peritonitis).\n'
p522
sg4
(lp523
(dp524
g7
I25
sg8
g39
sg10
I4
sg11
VJAK2
p525
sg13
I1
sa(dp526
g7
I30
sg8
g39
sg10
I7
sg11
VARHGEF1
p527
sg13
I1
sasg20
(lp528
(dp529
g7
I259
sg23
VC0042345
p530
sg10
I7
sg11
Vvarices
p531
sg13
I1
sa(dp532
g7
I76
sg23
VC0023890
p533
sg10
I15
sg11
Vliver cirrhosis
p534
sg13
I2
sa(dp535
g7
I268
sg23
VC0275551
p536
sg10
I33
sg11
Vspontaneous bacterial peritonitis
p537
sg13
I3
sa(dp538
g7
I76
sg23
VC0023890
p539
sg10
I15
sg11
Vliver cirrhosis
p540
sg13
I2
sa(dp541
g7
I189
sg23
VC0023895
p542
sg10
I13
sg11
VLiver disease
p543
sg13
I2
sasa(dp544
g2
S'Hepatic JAK2/ARHGEF1/ROCK expression is associated with portal hypertension and decompensation in human cirrhosis.\n'
p545
sg4
(lp546
(dp547
g7
I21
sg8
g39
sg10
I4
sg11
VROCK
p548
sg13
I1
sa(dp549
g7
I8
sg8
g39
sg10
I4
sg11
VJAK2
p550
sg13
I1
sa(dp551
g7
I13
sg8
g39
sg10
I7
sg11
VARHGEF1
p552
sg13
I1
sasg20
(lp553
(dp554
g7
I56
sg23
VC0020541
p555
sg10
I19
sg11
Vportal hypertension
p556
sg13
I2
sa(dp557
g7
I104
sg23
VC0023890
p558
sg10
I9
sg11
Vcirrhosis
p559
sg13
I1
sasa(dp560
g2
S'Arhgef1 was identified as a RhoA guanine exchange factor involved in angiotensin II (Ang II)-mediated regulation of vascular tone and hypertension in mice.\n'
p561
sg4
(lp562
(dp563
g7
I28
sg8
VP61586
p564
sg10
I28
sg11
VRhoA guanine exchange factor
p565
sg13
I4
sa(dp566
g7
I0
sg8
g39
sg10
I7
sg11
VArhgef1
p567
sg13
I1
sa(dp568
g7
I85
sg8
VP01019
p569
sg10
I6
sg11
VAng II
p570
sg13
I2
sa(dp571
g7
I69
sg8
VP01019
p572
sg10
I14
sg11
Vangiotensin II
p573
sg13
I2
sasg20
(lp574
(dp575
g7
I134
sg23
VC0020538
p576
sg10
I12
sg11
Vhypertension
p577
sg13
I1
sasa(dp578
g2
S'Although no difference of in vitro proliferation of NSCs was observed in the presence of epidermal growth factor, maturation of oligodendrocytes (defined by process number and length) was enhanced in hyperthyroidism, suggesting a more mature state than in control animals.\n'
p579
sg4
(lp580
(dp581
g7
I89
sg8
VP01133
p582
sg10
I23
sg11
Vepidermal growth factor
p583
sg13
I3
sasg20
(lp584
(dp585
g7
I35
sg23
VC0334094
p586
sg10
I13
sg11
Vproliferation
p587
sg13
I1
sa(dp588
g7
I200
sg23
VC0020550
p589
sg10
I15
sg11
Vhyperthyroidism
p590
sg13
I1
sasa(dp591
g2
S'In conclusion, we report that EGF treatment for 4 weeks in Goettingen minipigs reduces circulating IGF-I and IGFBP-3, increases circulating IGFBP-1, IGFBP-2 and IGFBP-4, and induces a slight hyperthyroidism as judged from increased circulating levels of T3.\n'
p592
sg4
(lp593
(dp594
g7
I109
sg8
VP17936
p595
sg10
I7
sg11
VIGFBP-3
p596
sg13
I1
sa(dp597
g7
I140
sg8
VP17936
p598
sg10
I7
sg11
VIGFBP-1
p599
sg13
I1
sa(dp600
g7
I161
sg8
VP22692
p601
sg10
I7
sg11
VIGFBP-4
p602
sg13
I1
sa(dp603
g7
I30
sg8
VP01133
p604
sg10
I3
sg11
VEGF
p605
sg13
I1
sa(dp606
g7
I149
sg8
VP18065
p607
sg10
I7
sg11
VIGFBP-2
p608
sg13
I1
sa(dp609
g7
I99
sg8
VP01343
p610
sg10
I5
sg11
VIGF-I
p611
sg13
I1
sasg20
(lp612
(dp613
g7
I191
sg23
VC0020550
p614
sg10
I15
sg11
Vhyperthyroidism
p615
sg13
I1
sasa(dp616
g2
S'We examined long-term effects of neonatal hyperthyroidism on salivary secretions of nerve growth factor and epidermal growth factor in male and female mice at the age of 31 days.\n'
p617
sg4
(lp618
(dp619
g7
I84
sg8
VP01138
p620
sg10
I19
sg11
Vnerve growth factor
p621
sg13
I3
sa(dp622
g7
I108
sg8
VP01133
p623
sg10
I23
sg11
Vepidermal growth factor
p624
sg13
I3
sasg20
(lp625
(dp626
g7
I33
sg23
VC0869147
p627
sg10
I24
sg11
Vneonatal hyperthyroidism
p628
sg13
I2
sasa(dp629
g2
S'EIF5A2 is highly expressed in testis and colorectal adenocarcinoma and at moderate levels in the brain, in contrast to the ubiquitously expressed EIF5A1 gene.\n'
p630
sg4
(lp631
(dp632
g7
I0
sg8
g39
sg10
I6
sg11
VEIF5A2
p633
sg13
I1
sa(dp634
g7
I146
sg8
VP63241
p635
sg10
I11
sg11
VEIF5A1 gene
p636
sg13
I2
sasg20
(lp637
(dp638
g7
I41
sg23
VC1319315
p639
sg10
I25
sg11
Vcolorectal adenocarcinoma
p640
sg13
I2
sasa(dp641
g2
S"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson's disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.\n"
p642
sg4
(lp643
(dp644
g7
I379
sg8
g39
sg10
I7
sg11
VATP13A2
p645
sg13
I1
sa(dp646
g7
I186
sg8
g39
sg10
I4
sg11
VFA2H
p647
sg13
I1
sa(dp648
g7
I458
sg8
VP26358
p649
sg10
I29
sg11
Vsensory neuropathy DNMT1 gene
p650
sg13
I4
sa(dp651
g7
I424
sg8
VP49638
p652
sg10
I4
sg11
VTPP1
p653
sg13
I1
sa(dp654
g7
I239
sg8
g39
sg10
I5
sg11
VSPG15
p655
sg13
I1
sa(dp656
g7
I231
sg8
g39
sg10
I7
sg11
VZFYVE26
p657
sg13
I1
sasg20
(lp658
(dp659
g7
I388
sg23
VC0027877
p660
sg10
I30
sg11
Vneuronal ceroid lipofuscinosis
p661
sg13
I3
sa(dp662
g7
I121
sg23
VC0037772
p663
sg10
I18
sg11
Vspastic paraplegia
p664
sg13
I2
sa(dp665
g7
I165
sg23
VC1846564
p666
sg10
I4
sg11
VSPG7
p667
sg13
I1
sa(dp668
g7
I239
sg23
VC1849128
p669
sg10
I5
sg11
VSPG15
p670
sg13
I1
sa(dp671
g7
I121
sg23
VC0037772
p672
sg10
I18
sg11
Vspastic paraplegia
p673
sg13
I2
sa(dp674
g7
I121
sg23
VC0037772
p675
sg10
I18
sg11
Vspastic paraplegia
p676
sg13
I2
sa(dp677
g7
I437
sg23
VC0027888
p678
sg10
I39
sg11
Vhereditary motor and sensory neuropathy
p679
sg13
I5
sa(dp680
g7
I343
sg23
VC0030567
p681
sg10
I19
sg11
VParkinson's disease
p682
sg13
I2
sasa(dp683
g2
S'DACT1 has been shown to participate in the development of many types of tumors; however, its role and precise molecular mechanisms in leukemia are unclear.\n'
p684
sg4
(lp685
(dp686
g7
I0
sg8
g39
sg10
I5
sg11
VDACT1
p687
sg13
I1
sasg20
(lp688
(dp689
g7
I134
sg23
VC0023418
p690
sg10
I8
sg11
Vleukemia
p691
sg13
I1
sa(dp692
g7
I72
sg23
VC0027651
p693
sg10
I6
sg11
Vtumors
p694
sg13
I1
sasa(dp695
g2
S'In this study, we investigated the effect of DACT1 on KG-1Alfa leukemia cells to further understand the mechanisms of DACT1-mediated tumor suppression.\n'
p696
sg4
(lp697
(dp698
g7
I45
sg8
g39
sg10
I5
sg11
VDACT1
p699
sg13
I1
sa(dp700
g7
I45
sg8
g39
sg10
I5
sg11
VDACT1
p701
sg13
I1
sasg20
(lp702
(dp703
g7
I133
sg23
VC0027651
p704
sg10
I5
sg11
Vtumor
p705
sg13
I1
sa(dp706
g7
I63
sg23
VC0023418
p707
sg10
I8
sg11
Vleukemia
p708
sg13
I1
sa(dp709
g7
I139
sg23
VC0221103
p710
sg10
I11
sg11
Vsuppression
p711
sg13
I1
sasa(dp712
g2
S'These findings revealed an inhibitory role for DACT1 in leukemogenesis and provided evidence that DACT1 is an attractive target for the development of novel anti-leukemia therapies.\n'
p713
sg4
(lp714
(dp715
g7
I47
sg8
g39
sg10
I5
sg11
VDACT1
p716
sg13
I1
sa(dp717
g7
I47
sg8
g39
sg10
I5
sg11
VDACT1
p718
sg13
I1
sasg20
(lp719
(dp720
g7
I162
sg23
VC0023418
p721
sg10
I8
sg11
Vleukemia
p722
sg13
I1
sa(dp723
g7
I56
sg23
VC0598766
p724
sg10
I14
sg11
Vleukemogenesis
p725
sg13
I1
sasa(dp726
g2
S'Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to detect messenger RNA (mRNA) expression levels of Wnt antagonists (Wnt5a, HDPR1, DKK1 and DKK3) in patients with AL and in normal controls; pyrophosphate sequencing was performed to detect the methylation status of the Wnt5a promoter; and western blotting was performed to detect the overall expression levels of Wnt5a protein and histone H4K20me1 in patients with acute myeloid leukemia (AML) and in normal controls.\n'
p727
sg4
(lp728
(dp729
g7
I306
sg8
VP41221
p730
sg10
I14
sg11
VWnt5a promoter
p731
sg13
I2
sa(dp732
g7
I177
sg8
g39
sg10
I4
sg11
VDKK3
p733
sg13
I1
sa(dp734
g7
I400
sg8
VP41221
p735
sg10
I13
sg11
VWnt5a protein
p736
sg13
I2
sa(dp737
g7
I161
sg8
g39
sg10
I5
sg11
VHDPR1
p738
sg13
I1
sa(dp739
g7
I154
sg8
VP41221
p740
sg10
I5
sg11
VWnt5a
p741
sg13
I1
sa(dp742
g7
I168
sg8
g39
sg10
I4
sg11
VDKK1
p743
sg13
I1
sa(dp744
g7
I418
sg8
VP62805
p745
sg10
I16
sg11
Vhistone H4K20me1
p746
sg13
I2
sasg20
(lp747
(dp748
g7
I452
sg23
VC0023467
p749
sg10
I22
sg11
Vacute myeloid leukemia
p750
sg13
I3
sa(dp751
g7
I476
sg23
VC0023467
p752
sg10
I3
sg11
VAML
p753
sg13
I1
sasa(dp754
g2
S'We subsequently validated the upregulated gene panel in the Cancer Genome Atlas CRC datasets (379 patients), which identified a five-gene signature (S100A2, VIP, HOXC6, DACT1, KIF26B) associated with poor overall survival (OS, log-rank test P-value: 1.19 x 10-4) and poor disease-free survival (DFS, log-rank test P-value: 0.002).\n'
p755
sg4
(lp756
(dp757
g7
I162
sg8
VP31260
p758
sg10
I5
sg11
VHOXC6
p759
sg13
I1
sa(dp760
g7
I149
sg8
VP29034
p761
sg10
I6
sg11
VS100A2
p762
sg13
I1
sa(dp763
g7
I176
sg8
g39
sg10
I6
sg11
VKIF26B
p764
sg13
I1
sa(dp765
g7
I169
sg8
g39
sg10
I5
sg11
VDACT1
p766
sg13
I1
sa(dp767
g7
I157
sg8
VP01282
p768
sg10
I3
sg11
VVIP
p769
sg13
I1
sasg20
(lp770
(dp771
g7
I80
sg23
VC1527249
p772
sg10
I3
sg11
VCRC
p773
sg13
I1
sa(dp774
g7
I60
sg23
VC0006826
p775
sg10
I6
sg11
VCancer
p776
sg13
I1
sasa(dp777
g2
S'DACT1Alfa was silenced in all gastric cancer cell lines (8/8), but expressed in normal gastric tissue.\n'
p778
sg4
(lp779
sg20
(lp780
(dp781
g7
I30
sg23
VC0024623
p782
sg10
I14
sg11
Vgastric cancer
p783
sg13
I2
sasa(dp784
g2
S'Ectopic expression of DACT1Alfa in silenced gastric cancer cell lines (AGS, BGC823 and MGC803) by stable transfection significantly suppressed cancer cell spreading (P &lt; 0.05), migration (P &lt; 0.01) and invasion (P &lt; 0.01).\n'
p785
sg4
(lp786
sg20
(lp787
(dp788
g7
I44
sg23
VC0024623
p789
sg10
I14
sg11
Vgastric cancer
p790
sg13
I2
sa(dp791
g7
I52
sg23
VC0006826
p792
sg10
I6
sg11
Vcancer
p793
sg13
I1
sa(dp794
g7
I71
sg23
VC0796126
p795
sg10
I3
sg11
VAGS
p796
sg13
I1
sa(dp797
g7
I208
sg23
VC2699153
p798
sg10
I8
sg11
Vinvasion
p799
sg13
I1
sasa(dp800
g2
S'DACT1Alfa promoter methylation was detected in 205 gastric cancers and 20 normal controls by direct bisulfite genomic sequencing.\n'
p801
sg4
(lp802
sg20
(lp803
(dp804
g7
I51
sg23
VC0024623
p805
sg10
I15
sg11
Vgastric cancers
p806
sg13
I2
sasa(dp807
g2
S'DACT1Alfa methylation was detected in 29.3% (60/205) of gastric cancer patients, but not in normal tissues.\n'
p808
sg4
(lp809
sg20
(lp810
(dp811
g7
I56
sg23
VC0024623
p812
sg10
I14
sg11
Vgastric cancer
p813
sg13
I2
sasa(dp814
g2
S'DACT1Alfa methylation was associated with poor survival of gastric cancer patients.\n'
p815
sg4
(lp816
sg20
(lp817
(dp818
g7
I59
sg23
VC0024623
p819
sg10
I14
sg11
Vgastric cancer
p820
sg13
I2
sasa(dp821
g2
S'In conclusion, DACT1Alfa plays a pivotal role as a potential tumor suppressor in migration and invasion of gastric cancer.\n'
p822
sg4
(lp823
sg20
(lp824
(dp825
g7
I95
sg23
VC2699153
p826
sg10
I8
sg11
Vinvasion
p827
sg13
I1
sa(dp828
g7
I61
sg23
VC0027651
p829
sg10
I5
sg11
Vtumor
p830
sg13
I1
sa(dp831
g7
I107
sg23
VC0024623
p832
sg10
I14
sg11
Vgastric cancer
p833
sg13
I2
sasa(dp834
g2
S'DACT1Alfa methylation may serve as a biomarker for the prognosis of gastric cancer.\n'
p835
sg4
(lp836
sg20
(lp837
(dp838
g7
I68
sg23
VC0024623
p839
sg10
I14
sg11
Vgastric cancer
p840
sg13
I2
sasa(dp841
g2
S'Furthermore, MIZ1 can promote the proliferation of breast cancer MDA-MB-231 and BT-549 cells through Wnt signalling and reverse the anti-proliferative effect of Dpr1 on colorectal cancer Caco-2.\n'
p842
sg4
(lp843
(dp844
g7
I13
sg8
g39
sg10
I4
sg11
VMIZ1
p845
sg13
I1
sa(dp846
g7
I169
sg8
VP31749
p847
sg10
I24
sg11
Vcolorectal cancer Caco-2
p848
sg13
I3
sa(dp849
g7
I161
sg8
g39
sg10
I4
sg11
VDpr1
p850
sg13
I1
sasg20
(lp851
(dp852
g7
I137
sg23
VC0334094
p853
sg10
I13
sg11
Vproliferative
p854
sg13
I1
sa(dp855
g7
I51
sg23
VC0678222
p856
sg10
I13
sg11
Vbreast cancer
p857
sg13
I2
sa(dp858
g7
I169
sg23
VC1527249
p859
sg10
I17
sg11
Vcolorectal cancer
p860
sg13
I2
sa(dp861
g7
I34
sg23
VC0334094
p862
sg10
I13
sg11
Vproliferation
p863
sg13
I1
sasa(dp864
g2
S'The frequency of IFNA1 -1823 (rs1332190) GG genotype was significantly higher in control subjects than CCHF patients (20% vs. 8%; P = 0.01).\n'
p865
sg4
(lp866
(dp867
g7
I17
sg8
VP01562
p868
sg10
I5
sg11
VIFNA1
p869
sg13
I1
sasg20
(lp870
sa(dp871
g2
S'For IFNA17 Ile184Arg (rs9298814) polymorphism, CCHF patients having TG genotype had a higher frequency than the control subjects (38% vs. 32.4%; P = 0.039).\n'
p872
sg4
(lp873
(dp874
g7
I4
sg8
VP01571
p875
sg10
I16
sg11
VIFNA17 Ile184Arg
p876
sg13
I2
sasg20
(lp877
sa(dp878
g2
S'The results show that IFNA1 rs1332190 and IFNA17 rs9298814 SNPs may play an important role in CCHF susceptibility.\n'
p879
sg4
(lp880
(dp881
g7
I22
sg8
VP01562
p882
sg10
I15
sg11
VIFNA1 rs1332190
p883
sg13
I2
sa(dp884
g7
I42
sg8
VP01571
p885
sg10
I21
sg11
VIFNA17 rs9298814 SNPs
p886
sg13
I3
sasg20
(lp887
sa(dp888
g2
S'Determining the existence of other connections for IFNA SNPs and CCHF severity and fatality requires further investigations.\n'
p889
sg4
(lp890
(dp891
g7
I51
sg8
VP05000
p892
sg10
I9
sg11
VIFNA SNPs
p893
sg13
I2
sasg20
(lp894
sa(dp895
g2
S'We also sequenced a 1.8-kb region encoding the RNA polymerase II second largest subunit (RPB2) from 126 additional pathogenic isolates to better understand how the keratitis outbreak isolates fit within the full phylogenetic spectrum of clinically important fusaria.\n'
p896
sg4
(lp897
(dp898
g7
I89
sg8
VP30876
p899
sg10
I4
sg11
VRPB2
p900
sg13
I1
sa(dp901
g7
I47
sg8
VP19388
p902
sg10
I17
sg11
VRNA polymerase II
p903
sg13
I3
sasg20
(lp904
(dp905
g7
I164
sg23
VC0022568
p906
sg10
I9
sg11
Vkeratitis
p907
sg13
I1
sa(dp908
g7
I192
sg23
VC0036572
p909
sg10
I3
sg11
Vfit
p910
sg13
I1
sasa(dp911
g2
S'Ruxolitinib was found to fully inhibit IL-6-mediated repression of CYP (CYP1A2, CYP2B6 and CYP3A4) and transporter (NTCP, OATP1B1 and OCT1) mRNA levels in primary human hepatocytes and differentiated hepatoma HepaRG cells.\n'
p912
sg4
(lp913
(dp914
g7
I116
sg8
g39
sg10
I4
sg11
VNTCP
p915
sg13
I1
sa(dp916
g7
I39
sg8
VP05231
p917
sg10
I4
sg11
VIL-6
p918
sg13
I1
sa(dp919
g7
I72
sg8
VP05177
p920
sg10
I6
sg11
VCYP1A2
p921
sg13
I1
sa(dp922
g7
I122
sg8
g39
sg10
I7
sg11
VOATP1B1
p923
sg13
I1
sa(dp924
g7
I67
sg8
g39
sg10
I3
sg11
VCYP
p925
sg13
I1
sa(dp926
g7
I134
sg8
VP14859
p927
sg10
I4
sg11
VOCT1
p928
sg13
I1
sasg20
(lp929
(dp930
g7
I200
sg23
VC0023903
p931
sg10
I8
sg11
Vhepatoma
p932
sg13
I1
sasa(dp933
g2
S'To investigate the impact of polymorphisms in the FPGS, GGH and SLCO1B1 genes on high dose methotrexate (HD-MTX) related toxicity in Chinese patients with non-Hodgkin lymphoma (NHL).\n'
p934
sg4
(lp935
(dp936
g7
I50
sg8
g39
sg10
I4
sg11
VFPGS
p937
sg13
I1
sa(dp938
g7
I56
sg8
g39
sg10
I3
sg11
VGGH
p939
sg13
I1
sa(dp940
g7
I64
sg8
g39
sg10
I13
sg11
VSLCO1B1 genes
p941
sg13
I2
sasg20
(lp942
(dp943
g7
I155
sg23
VC0024305
p944
sg10
I20
sg11
Vnon-Hodgkin lymphoma
p945
sg13
I2
sa(dp946
g7
I177
sg23
VC0024305
p947
sg10
I3
sg11
VNHL
p948
sg13
I1
sasa(dp949
g2
S'After adjusting for disease stage, dosage, infusion time and therapy method, SLCO1B1 rs4149056 genotype remained significantly associated with hepatotoxicity (p = 0.028).\n'
p950
sg4
(lp951
(dp952
g7
I77
sg8
g39
sg10
I26
sg11
VSLCO1B1 rs4149056 genotype
p953
sg13
I3
sasg20
(lp954
sa(dp955
g2
S'Solute carrier organic anion transporter family member 1B1 (SLCO1B1), cytochrome P450 2E1 (CYP2E1), and UDP glucuronosyltransferase 1A1 (UGT1A1) were selected as candidate genes to explore their association with susceptibility to anti-tuberculosis drug-induced hepatotoxicity (ATDH).\n'
p956
sg4
(lp957
(dp958
g7
I0
sg8
g39
sg10
I58
sg11
VSolute carrier organic anion transporter family member 1B1
p959
sg13
I8
sa(dp960
g7
I70
sg8
VP05181
p961
sg10
I19
sg11
Vcytochrome P450 2E1
p962
sg13
I3
sa(dp963
g7
I91
sg8
VP05181
p964
sg10
I6
sg11
VCYP2E1
p965
sg13
I1
sa(dp966
g7
I60
sg8
g39
sg10
I7
sg11
VSLCO1B1
p967
sg13
I1
sa(dp968
g7
I137
sg8
VP35504
p969
sg10
I6
sg11
VUGT1A1
p970
sg13
I1
sa(dp971
g7
I104
sg8
VP22309
p972
sg10
I31
sg11
VUDP glucuronosyltransferase 1A1
p973
sg13
I3
sasg20
(lp974
(dp975
g7
I235
sg23
VC0041296
p976
sg10
I12
sg11
Vtuberculosis
p977
sg13
I1
sasa(dp978
g2
S'Moreover, treatment outcomes in tuberculosis patients were further affected by genetic variants of SLCO1B1.\n'
p979
sg4
(lp980
(dp981
g7
I99
sg8
g39
sg10
I7
sg11
VSLCO1B1
p982
sg13
I1
sasg20
(lp983
(dp984
g7
I32
sg23
VC0041296
p985
sg10
I12
sg11
Vtuberculosis
p986
sg13
I1
sasa(dp987
g2
S"Membrane-spanning 4-domains, subfamily A, member 6A (MS4A6A) has been identified as susceptibility loci of Alzheimer's disease (AD) by several recent genome-wide association studies (GWAS), whereas little is known about the potential roles of these variants in the brain structure and function of AD.\n"
p988
sg4
(lp989
sg20
(lp990
(dp991
g7
I107
sg23
VC1521724
p992
sg10
I19
sg11
VAlzheimer's disease
p993
sg13
I2
sa(dp994
g7
I128
sg23
VC1521724
p995
sg10
I2
sg11
VAD
p996
sg13
I1
sa(dp997
g7
I128
sg23
VC1521724
p998
sg10
I2
sg11
VAD
p999
sg13
I1
sasa(dp1000
g2
S'To investigate the role of phosphorylated JNK in Dectin-1-induced IL-1Beta production and the role of Dectin-1 in apoptosis in mouse Aspergillus fumigatus (A. fumigatus) keratitis.\n'
p1001
sg4
(lp1002
(dp1003
g7
I42
sg8
VP53779
p1004
sg10
I3
sg11
VJNK
p1005
sg13
I1
sa(dp1006
g7
I66
sg8
VP01584
p1007
sg10
I8
sg11
VIL-1Beta
p1008
sg13
I1
sasg20
(lp1009
(dp1010
g7
I170
sg23
VC0022568
p1011
sg10
I9
sg11
Vkeratitis
p1012
sg13
I1
sasa(dp1013
g2
S'Furthermore, Dectin-1 deficiency resulted in increased ratio of Bax/Bcl-2, release of cyt-c, activation of caspase-9 and caspase-3 in mouse A. fumigatus keratitis.\n'
p1014
sg4
(lp1015
(dp1016
g7
I121
sg8
VP42574
p1017
sg10
I9
sg11
Vcaspase-3
p1018
sg13
I1
sa(dp1019
g7
I68
sg8
VP99999
p1020
sg10
I23
sg11
VBcl-2, release of cyt-c
p1021
sg13
I4
sa(dp1022
g7
I107
sg8
VP55211
p1023
sg10
I9
sg11
Vcaspase-9
p1024
sg13
I1
sasg20
(lp1025
(dp1026
g7
I153
sg23
VC0022568
p1027
sg10
I9
sg11
Vkeratitis
p1028
sg13
I1
sasa(dp1029
g2
S'Being an important inflammatory PRR to mediate host inflammatory response, Dectin-1 induced IL-1Beta production is JNK dependent in mouse A. fumigatus keratitis, and suppressed apoptosis mediated anti-inflammatory response.\n'
p1030
sg4
(lp1031
(dp1032
g7
I92
sg8
VP01584
p1033
sg10
I8
sg11
VIL-1Beta
p1034
sg13
I1
sa(dp1035
g7
I115
sg8
VP53779
p1036
sg10
I3
sg11
VJNK
p1037
sg13
I1
sasg20
(lp1038
(dp1039
g7
I52
sg23
VC1155266
p1040
sg10
I21
sg11
Vinflammatory response
p1041
sg13
I2
sa(dp1042
g7
I151
sg23
VC0022568
p1043
sg10
I9
sg11
Vkeratitis
p1044
sg13
I1
sa(dp1045
g7
I52
sg23
VC1155266
p1046
sg10
I21
sg11
Vinflammatory response
p1047
sg13
I2
sasa(dp1048
g2
S'Using single receptor-deficient mice we identified Dectin-2, but not Mincle or Dectin-1, as a predominant mediator of fungal-promoted uveitis.\n'
p1049
sg4
(lp1050
(dp1051
g7
I51
sg8
g39
sg10
I8
sg11
VDectin-2
p1052
sg13
I1
sa(dp1053
g7
I69
sg8
g39
sg10
I6
sg11
VMincle
p1054
sg13
I1
sasg20
(lp1055
(dp1056
g7
I134
sg23
VC0042164
p1057
sg10
I7
sg11
Vuveitis
p1058
sg13
I1
sasa(dp1059
g2
S'neutrophils were the main cell lineage of IL-1Beta to take part in the innate anti-fungi immunity in the cornea; IL-1Beta generation induced by fungal infection might not be through the pre-excitation in the classical signal pathway; TLR4/TRIF pathway was not involved in pro-IL-1Beta generation; while Dectin-1/syk pathway was involved in IL-1Beta generation in the fungal keratitis; Caspase-l participated in the modification of IL-1Beta to change from the precursor into the mature body; but NLRP3 inflammasome and ASC inflammasome were not involved in IL-1Beta generation; Caspase-11 was involved in IL-1Beta generation through regulating the modified process of Caspase-l to turning from precursor into mature body.\n'
p1060
sg4
(lp1061
(dp1062
g7
I42
sg8
VP01584
p1063
sg10
I8
sg11
VIL-1Beta
p1064
sg13
I1
sa(dp1065
g7
I239
sg8
g39
sg10
I4
sg11
VTRIF
p1066
sg13
I1
sa(dp1067
g7
I312
sg8
VP43405
p1068
sg10
I3
sg11
Vsyk
p1069
sg13
I1
sa(dp1070
g7
I42
sg8
VP01584
p1071
sg10
I8
sg11
VIL-1Beta
p1072
sg13
I1
sa(dp1073
g7
I42
sg8
VP01584
p1074
sg10
I8
sg11
VIL-1Beta
p1075
sg13
I1
sa(dp1076
g7
I42
sg8
VP01584
p1077
sg10
I8
sg11
VIL-1Beta
p1078
sg13
I1
sa(dp1079
g7
I42
sg8
VP01584
p1080
sg10
I8
sg11
VIL-1Beta
p1081
sg13
I1
sa(dp1082
g7
I272
sg8
VP01584
p1083
sg10
I12
sg11
Vpro-IL-1Beta
p1084
sg13
I1
sa(dp1085
g7
I577
sg8
VP39880
p1086
sg10
I10
sg11
VCaspase-11
p1087
sg13
I1
sa(dp1088
g7
I42
sg8
VP01584
p1089
sg10
I8
sg11
VIL-1Beta
p1090
sg13
I1
sa(dp1091
g7
I385
sg8
VP39880
p1092
sg10
I9
sg11
VCaspase-l
p1093
sg13
I1
sa(dp1094
g7
I385
sg8
VP39880
p1095
sg10
I9
sg11
VCaspase-l
p1096
sg13
I1
sa(dp1097
g7
I518
sg8
VP08842
p1098
sg10
I16
sg11
VASC inflammasome
p1099
sg13
I2
sasg20
(lp1100
(dp1101
g7
I367
sg23
VC1262117
p1102
sg10
I16
sg11
Vfungal keratitis
p1103
sg13
I2
sa(dp1104
g7
I144
sg23
VC0026946
p1105
sg10
I16
sg11
Vfungal infection
p1106
sg13
I2
sasa(dp1107
g2
S'To explore the possibility that inhibiting triggering receptor expressed on myeloid cells-1 (TREM-1) and Dendritic cell-associated C-type lectin-1(Dectin-1) could modulate the innate immune response and alleviate the severity of corneal fungal keratitis.\n'
p1108
sg4
(lp1109
(dp1110
g7
I43
sg8
g39
sg10
I19
sg11
Vtriggering receptor
p1111
sg13
I2
sa(dp1112
g7
I131
sg8
g39
sg10
I15
sg11
VC-type lectin-1
p1113
sg13
I2
sasg20
(lp1114
(dp1115
g7
I237
sg23
VC1262117
p1116
sg10
I16
sg11
Vfungal keratitis
p1117
sg13
I2
sa(dp1118
g7
I176
sg23
VC1155265
p1119
sg10
I22
sg11
Vinnate immune response
p1120
sg13
I3
sasa(dp1121
g2
S'The expression of TREM-1 and Dectin-1 increased significantly and correlated positively with the progression of fungal keratitis.\n'
p1122
sg4
(lp1123
(dp1124
g7
I18
sg8
g39
sg10
I6
sg11
VTREM-1
p1125
sg13
I1
sasg20
(lp1126
(dp1127
g7
I112
sg23
VC1262117
p1128
sg10
I16
sg11
Vfungal keratitis
p1129
sg13
I2
sasa(dp1130
g2
S'TREM-1 and Dectin-1 function concurrently in the corneal innate immune response by regulating inflammatory cytokine expression in fungal keratitis.\n'
p1131
sg4
(lp1132
(dp1133
g7
I0
sg8
g39
sg10
I6
sg11
VTREM-1
p1134
sg13
I1
sasg20
(lp1135
(dp1136
g7
I130
sg23
VC1262117
p1137
sg10
I16
sg11
Vfungal keratitis
p1138
sg13
I2
sa(dp1139
g7
I57
sg23
VC1155265
p1140
sg10
I22
sg11
Vinnate immune response
p1141
sg13
I3
sasa(dp1142
g2
S'To observe Dectin-1 expression in fungal keratitis on rat models and to determine the role of Dectin-1 in innate immune response to Aspergillus fumigatus.\n'
p1143
sg4
(lp1144
sg20
(lp1145
(dp1146
g7
I106
sg23
VC1155265
p1147
sg10
I22
sg11
Vinnate immune response
p1148
sg13
I3
sa(dp1149
g7
I34
sg23
VC1262117
p1150
sg10
I16
sg11
Vfungal keratitis
p1151
sg13
I2
sasa(dp1152
g2
S'Dectin-1 in early period of innate immune responses in rat fungal keratitis might work through IL-1Beta, IL-6, CCL2, CXCL1, CXCL2 to recruit neutrophils and macrophages to participate anti-fungal immunity.\n'
p1153
sg4
(lp1154
(dp1155
g7
I124
sg8
VP19875
p1156
sg10
I5
sg11
VCXCL2
p1157
sg13
I1
sa(dp1158
g7
I95
sg8
VP01584
p1159
sg10
I8
sg11
VIL-1Beta
p1160
sg13
I1
sa(dp1161
g7
I117
sg8
VP09341
p1162
sg10
I5
sg11
VCXCL1
p1163
sg13
I1
sa(dp1164
g7
I105
sg8
VP05231
p1165
sg10
I4
sg11
VIL-6
p1166
sg13
I1
sa(dp1167
g7
I111
sg8
VP13500
p1168
sg10
I4
sg11
VCCL2
p1169
sg13
I1
sasg20
(lp1170
(dp1171
g7
I59
sg23
VC1262117
p1172
sg10
I16
sg11
Vfungal keratitis
p1173
sg13
I2
sa(dp1174
g7
I28
sg23
VC1155265
p1175
sg10
I23
sg11
Vinnate immune responses
p1176
sg13
I3
sasa(dp1177
g2
S'The concentrations of sTM and sEPCR in 19 CVST patients without protein C and protein S deficiency were measured by ELISA and compared with 53 healthy controls.\n'
p1178
sg4
(lp1179
(dp1180
g7
I22
sg8
g39
sg10
I3
sg11
VsTM
p1181
sg13
I1
sa(dp1182
g7
I78
sg8
VP07225
p1183
sg10
I9
sg11
Vprotein S
p1184
sg13
I2
sa(dp1185
g7
I64
sg8
VP02810
p1186
sg10
I9
sg11
Vprotein C
p1187
sg13
I2
sasg20
(lp1188
(dp1189
g7
I78
sg23
VC0242666
p1190
sg10
I20
sg11
Vprotein S deficiency
p1191
sg13
I3
sasa(dp1192
g2
S'Methylation of cytosine residues in DNA samples, collected before and serially after cobalamin treatment from patients with cobalamin deficiency, was studied using restriction endonucleases Hpa II and Msp I and an epsilon globin gene probe.\n'
p1193
sg4
(lp1194
(dp1195
g7
I201
sg8
VP26927
p1196
sg10
I5
sg11
VMsp I
p1197
sg13
I2
sa(dp1198
g7
I190
sg8
g39
sg10
I6
sg11
VHpa II
p1199
sg13
I2
sa(dp1200
g7
I214
sg8
VP02100
p1201
sg10
I19
sg11
Vepsilon globin gene
p1202
sg13
I3
sasg20
(lp1203
(dp1204
g7
I124
sg23
VC0042847
p1205
sg10
I20
sg11
Vcobalamin deficiency
p1206
sg13
I2
sasa(dp1207
g2
S'The most frequent germline mutations responsible for non syndromic congenital sideroblastic anemia are identified in ALAS2 and SLC25A38 genes.\n'
p1208
sg4
(lp1209
(dp1210
g7
I117
sg8
VP22557
p1211
sg10
I5
sg11
VALAS2
p1212
sg13
I1
sa(dp1213
g7
I127
sg8
g39
sg10
I14
sg11
VSLC25A38 genes
p1214
sg13
I2
sasg20
(lp1215
(dp1216
g7
I67
sg23
VC0221018
p1217
sg10
I31
sg11
Vcongenital sideroblastic anemia
p1218
sg13
I3
sasa(dp1219
g2
S'Our multicentre retrospective descriptive study compared the strategies for diagnosis and management of congenital sideroblastic anemia during the follow-up of six patients with an ALAS2 mutation and seven patients with an SLC25A38 mutation.\n'
p1220
sg4
(lp1221
(dp1222
g7
I181
sg8
VP22557
p1223
sg10
I5
sg11
VALAS2
p1224
sg13
I1
sa(dp1225
g7
I223
sg8
g39
sg10
I8
sg11
VSLC25A38
p1226
sg13
I1
sasg20
(lp1227
(dp1228
g7
I104
sg23
VC0221018
p1229
sg10
I31
sg11
Vcongenital sideroblastic anemia
p1230
sg13
I3
sasa(dp1231
g2
S'In the current paper, a case of X-linked sideroblastic anemia caused by a novel homozygous deletional mutation in exon 10 of ALAS2 gene is presented.\n'
p1232
sg4
(lp1233
(dp1234
g7
I125
sg8
VP22557
p1235
sg10
I10
sg11
VALAS2 gene
p1236
sg13
I2
sasg20
(lp1237
(dp1238
g7
I32
sg23
VC0221018
p1239
sg10
I29
sg11
VX-linked sideroblastic anemia
p1240
sg13
I3
sasa(dp1241
g2
S'The first intronic mutations in the intron 1 GATA site (int-1-GATA) of 5-aminolevulinate synthase 2 (ALAS2) have been identified in X-linked sideroblastic anemia (XLSA) pedigrees, strongly suggesting it could be causal mutations of XLSA.\n'
p1242
sg4
(lp1243
(dp1244
g7
I101
sg8
VP22557
p1245
sg10
I5
sg11
VALAS2
p1246
sg13
I1
sa(dp1247
g7
I56
sg8
g39
sg10
I10
sg11
Vint-1-GATA
p1248
sg13
I1
sa(dp1249
g7
I71
sg8
VP22557
p1250
sg10
I28
sg11
V5-aminolevulinate synthase 2
p1251
sg13
I3
sa(dp1252
g7
I132
sg8
VP22557
p1253
sg10
I29
sg11
VX-linked sideroblastic anemia
p1254
sg13
I3
sa(dp1255
g7
I163
sg8
VP22557
p1256
sg10
I4
sg11
VXLSA
p1257
sg13
I1
sa(dp1258
g7
I36
sg8
g39
sg10
I18
sg11
Vintron 1 GATA site
p1259
sg13
I4
sasg20
(lp1260
(dp1261
g7
I132
sg23
VC0221018
p1262
sg10
I29
sg11
VX-linked sideroblastic anemia
p1263
sg13
I3
sa(dp1264
g7
I163
sg23
VC0221018
p1265
sg10
I4
sg11
VXLSA
p1266
sg13
I1
sa(dp1267
g7
I163
sg23
VC0221018
p1268
sg10
I4
sg11
VXLSA
p1269
sg13
I1
sasa(dp1270
g2
S"Mutations in the C-terminus of human erythroid 5-aminolevulinate synthase (hALAS2), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are associated with two different blood disorders, X-linked sideroblastic anemia (XLSA) and X-linked protoporphyria (XLPP).\n"
p1271
sg4
(lp1272
(dp1273
g7
I31
sg8
VP22557
p1274
sg10
I42
sg11
Vhuman erythroid 5-aminolevulinate synthase
p1275
sg13
I4
sasg20
(lp1276
(dp1277
g7
I215
sg23
VC0221018
p1278
sg10
I4
sg11
VXLSA
p1279
sg13
I1
sa(dp1280
g7
I234
sg23
VC0162568
p1281
sg10
I14
sg11
Vprotoporphyria
p1282
sg13
I1
sa(dp1283
g7
I167
sg23
VC0018939
p1284
sg10
I15
sg11
Vblood disorders
p1285
sg13
I2
sa(dp1286
g7
I184
sg23
VC0221018
p1287
sg10
I29
sg11
VX-linked sideroblastic anemia
p1288
sg13
I3
sasa(dp1289
g2
S'XLSA-causing mutations yield hALAS2 variants with decreased activity, while XLPP-causing mutations result in a gain-of-function of hALAS2.\n'
p1290
sg4
(lp1291
(dp1292
g7
I29
sg8
VP26640
p1293
sg10
I15
sg11
VhALAS2 variants
p1294
sg13
I2
sasg20
(lp1295
(dp1296
g7
I0
sg23
VC0221018
p1297
sg10
I4
sg11
VXLSA
p1298
sg13
I1
sa(dp1299
g7
I50
sg23
VC0086439
p1300
sg10
I18
sg11
Vdecreased activity
p1301
sg13
I2
sasa(dp1302
g2
S'Isonicotinic acid hydrazide (isoniazid, INH), an antituberculosis agent, can cause sideroblastic anemia as a side-effect, by limiting PLP availability to hALAS2, via inhibition of pyridoxal kinase or reaction with pyridoxal to form pyridoxal isonicotinoyl hydrazone.\n'
p1303
sg4
(lp1304
sg20
(lp1305
(dp1306
g7
I83
sg23
VC0002896
p1307
sg10
I20
sg11
Vsideroblastic anemia
p1308
sg13
I2
sasa(dp1309
g2
S'Mendelian mutations in ALAS2 are a cause of sideroblastic anemia and erythropoietic protoporphyria.\n'
p1310
sg4
(lp1311
(dp1312
g7
I23
sg8
VP22557
p1313
sg10
I5
sg11
VALAS2
p1314
sg13
I1
sasg20
(lp1315
(dp1316
g7
I69
sg23
VC0162568
p1317
sg10
I29
sg11
Verythropoietic protoporphyria
p1318
sg13
I2
sa(dp1319
g7
I44
sg23
VC0002896
p1320
sg10
I20
sg11
Vsideroblastic anemia
p1321
sg13
I2
sasa(dp1322
g2
S'XLSA is caused by mutations in the erythroid-specific gene coding 5-aminolevulinate synthase (ALAS2).\n'
p1323
sg4
(lp1324
(dp1325
g7
I94
sg8
VP22557
p1326
sg10
I5
sg11
VALAS2
p1327
sg13
I1
sa(dp1328
g7
I35
sg8
VP22557
p1329
sg10
I57
sg11
Verythroid-specific gene coding 5-aminolevulinate synthase
p1330
sg13
I5
sa(dp1331
g7
I0
sg8
VP22557
p1332
sg10
I4
sg11
VXLSA
p1333
sg13
I1
sasg20
(lp1334
(dp1335
g7
I0
sg23
VC0221018
p1336
sg10
I4
sg11
VXLSA
p1337
sg13
I1
sasa(dp1338
g2
S'We report four patients with XLSA and three mutations in ALAS2: c.611G&gt;A (p.Arg204Gln), c.1218G&gt;T (p.Leu406Phe) and c.1499A&gt;G (p.Tyr500Cys).\n'
p1339
sg4
(lp1340
(dp1341
g7
I57
sg8
VP22557
p1342
sg10
I5
sg11
VALAS2
p1343
sg13
I1
sasg20
(lp1344
(dp1345
g7
I29
sg23
VC0221018
p1346
sg10
I4
sg11
VXLSA
p1347
sg13
I1
sasa(dp1348
g2
S'Delta-aminolevulinic acid synthase 2 (ALAS2 ) polymorphism is used as a marker for X-linked sideroblastic anemia.\n'
p1349
sg4
(lp1350
(dp1351
g7
I0
sg8
VP28072
p1352
sg10
I36
sg11
VDelta-aminolevulinic acid synthase 2
p1353
sg13
I4
sa(dp1354
g7
I38
sg8
VP22557
p1355
sg10
I5
sg11
VALAS2
p1356
sg13
I1
sasg20
(lp1357
(dp1358
g7
I83
sg23
VC0221018
p1359
sg10
I29
sg11
VX-linked sideroblastic anemia
p1360
sg13
I3
sasa(dp1361
g2
S'POMT1 mutations cause a wide spectrum of clinical conditions from Walker-Warburg syndrome (WWS), which involves muscle, eye and brain abnormalities, to mild forms of limb-girdle muscular dystrophy with mental retardation.\n'
p1362
sg4
(lp1363
sg20
(lp1364
(dp1365
g7
I66
sg23
VC0265221
p1366
sg10
I23
sg11
VWalker-Warburg syndrome
p1367
sg13
I2
sa(dp1368
g7
I166
sg23
VC0686353
p1369
sg10
I30
sg11
Vlimb-girdle muscular dystrophy
p1370
sg13
I3
sa(dp1371
g7
I202
sg23
VC0025362
p1372
sg10
I18
sg11
Vmental retardation
p1373
sg13
I2
sa(dp1374
g7
I91
sg23
VC0265221
p1375
sg10
I3
sg11
VWWS
p1376
sg13
I1
sasa(dp1377
g2
S'We report five Chinese patients with POMT1 mutations: one had a typical clinical manifestation of WWS, and the other four were diagnosed with congenital muscular dystrophy with mental retardation of varying severity.\n'
p1378
sg4
(lp1379
sg20
(lp1380
(dp1381
g7
I142
sg23
VC0699743
p1382
sg10
I29
sg11
Vcongenital muscular dystrophy
p1383
sg13
I3
sa(dp1384
g7
I177
sg23
VC0025362
p1385
sg10
I18
sg11
Vmental retardation
p1386
sg13
I2
sasa(dp1387
g2
S'We report two siblings of Croatian consanguineous healthy parents with a novel homozygous missense mutation in the POMT1 gene, presenting with intellectual disability and psychotic, in particular hallucinatory symptoms and abnormal brain MRIs, preceding classical symptoms of limb-girdle muscular dystrophy by several years.\n'
p1388
sg4
(lp1389
sg20
(lp1390
(dp1391
g7
I171
sg23
VC0033975
p1392
sg10
I9
sg11
Vpsychotic
p1393
sg13
I1
sa(dp1394
g7
I143
sg23
VC0025362
p1395
sg10
I23
sg11
Vintellectual disability
p1396
sg13
I2
sa(dp1397
g7
I276
sg23
VC0686353
p1398
sg10
I30
sg11
Vlimb-girdle muscular dystrophy
p1399
sg13
I3
sasa(dp1400
g2
S'Within this group mutations in the protein O-mannosyltransferase genes (POMT1 and POMT2) are known to cause a spectrum of CMD disorders including the Walker-Warburg Syndrome with severe brain and ocular malformations, and the limb girdle muscular dystrophy with and without mental retardation.\n'
p1401
sg4
(lp1402
(dp1403
g7
I82
sg8
g39
sg10
I5
sg11
VPOMT2
p1404
sg13
I1
sa(dp1405
g7
I35
sg8
g39
sg10
I35
sg11
Vprotein O-mannosyltransferase genes
p1406
sg13
I3
sasg20
(lp1407
(dp1408
g7
I274
sg23
VC0025362
p1409
sg10
I18
sg11
Vmental retardation
p1410
sg13
I2
sa(dp1411
g7
I122
sg23
VC1852502
p1412
sg10
I3
sg11
VCMD
p1413
sg13
I1
sa(dp1414
g7
I150
sg23
VC0265221
p1415
sg10
I23
sg11
VWalker-Warburg Syndrome
p1416
sg13
I2
sa(dp1417
g7
I226
sg23
VC0686353
p1418
sg10
I30
sg11
Vlimb girdle muscular dystrophy
p1419
sg13
I4
sa(dp1420
g7
I203
sg23
VC0000768
p1421
sg10
I13
sg11
Vmalformations
p1422
sg13
I1
sasa(dp1423
g2
S'Clinical phenotype in POMT1-mutated patients ranges from congenital muscular dystrophy (CMD) with structural brain abnormalities, to limb-girdle muscular dystrophy (LGMD) with microcephaly and mental retardation, to mild LGMD.\n'
p1424
sg4
(lp1425
sg20
(lp1426
(dp1427
g7
I165
sg23
VC0026850
p1428
sg10
I4
sg11
VLGMD
p1429
sg13
I1
sa(dp1430
g7
I88
sg23
VC1852502
p1431
sg10
I3
sg11
VCMD
p1432
sg13
I1
sa(dp1433
g7
I133
sg23
VC0686353
p1434
sg10
I30
sg11
Vlimb-girdle muscular dystrophy
p1435
sg13
I3
sa(dp1436
g7
I57
sg23
VC0699743
p1437
sg10
I29
sg11
Vcongenital muscular dystrophy
p1438
sg13
I3
sa(dp1439
g7
I176
sg23
VC0025958
p1440
sg10
I12
sg11
Vmicrocephaly
p1441
sg13
I1
sa(dp1442
g7
I193
sg23
VC0025362
p1443
sg10
I18
sg11
Vmental retardation
p1444
sg13
I2
sa(dp1445
g7
I165
sg23
VC0026850
p1446
sg10
I4
sg11
VLGMD
p1447
sg13
I1
sasa(dp1448
g2
S'We report three patients who harbored compound heterozygous POMT1 mutations and showed left ventricular (LV) dilation and/or decrease in myocardial contractile force: two had a LGMD phenotype with a normal or close-to-normal cognitive profile and one had CMD with mental retardation and normal brain MRI.\n'
p1449
sg4
(lp1450
sg20
(lp1451
(dp1452
g7
I264
sg23
VC0025362
p1453
sg10
I18
sg11
Vmental retardation
p1454
sg13
I2
sa(dp1455
g7
I109
sg23
VC0012359
p1456
sg10
I8
sg11
Vdilation
p1457
sg13
I1
sa(dp1458
g7
I255
sg23
VC1852502
p1459
sg10
I3
sg11
VCMD
p1460
sg13
I1
sasa(dp1461
g2
S'SLIT2 is a candidate tumor suppressor gene and recent studies have shown that SLIT2 expression is suppressed or reduced by hypermethylation in the promoter region in various cancers.\n'
p1462
sg4
(lp1463
(dp1464
g7
I0
sg8
g39
sg10
I5
sg11
VSLIT2
p1465
sg13
I1
sa(dp1466
g7
I0
sg8
g39
sg10
I5
sg11
VSLIT2
p1467
sg13
I1
sasg20
(lp1468
(dp1469
g7
I21
sg23
VC0027651
p1470
sg10
I5
sg11
Vtumor
p1471
sg13
I1
sa(dp1472
g7
I174
sg23
VC0006826
p1473
sg10
I7
sg11
Vcancers
p1474
sg13
I1
sasa(dp1475
g2
S'The aim of this study was to investigate the association between SLIT2 promoter methylation and nasopharyngeal carcinoma (NPC) and its relative diagnostic ability for NPC.\n'
p1476
sg4
(lp1477
(dp1478
g7
I65
sg8
g39
sg10
I14
sg11
VSLIT2 promoter
p1479
sg13
I2
sasg20
(lp1480
(dp1481
g7
I122
sg23
VC2931822
p1482
sg10
I3
sg11
VNPC
p1483
sg13
I1
sa(dp1484
g7
I122
sg23
VC2931822
p1485
sg10
I3
sg11
VNPC
p1486
sg13
I1
sa(dp1487
g7
I96
sg23
VC2931822
p1488
sg10
I24
sg11
Vnasopharyngeal carcinoma
p1489
sg13
I2
sasa(dp1490
g2
S'This study is to investigate the methylation status of multiple tumor suppressor 1 (p16), secreted glycoprotein 2 (SLIT2), scavenger receptor class A, member 5 putative (SCARA5), and human runt-related transcription factor 3 (Runx3) genes in the peripheral blood of hepatocellular carcinoma (HCC).This is a case-control study.\n'
p1491
sg4
(lp1492
(dp1493
g7
I84
sg8
VP42771
p1494
sg10
I3
sg11
Vp16
p1495
sg13
I1
sa(dp1496
g7
I170
sg8
g39
sg10
I6
sg11
VSCARA5
p1497
sg13
I1
sa(dp1498
g7
I99
sg8
VP55259
p1499
sg10
I14
sg11
Vglycoprotein 2
p1500
sg13
I2
sa(dp1501
g7
I123
sg8
g39
sg10
I45
sg11
Vscavenger receptor class A, member 5 putative
p1502
sg13
I7
sa(dp1503
g7
I226
sg8
g39
sg10
I5
sg11
VRunx3
p1504
sg13
I1
sa(dp1505
g7
I115
sg8
g39
sg10
I5
sg11
VSLIT2
p1506
sg13
I1
sa(dp1507
g7
I183
sg8
g39
sg10
I41
sg11
Vhuman runt-related transcription factor 3
p1508
sg13
I5
sa(dp1509
g7
I64
sg8
VP25054
p1510
sg10
I18
sg11
Vtumor suppressor 1
p1511
sg13
I3
sasg20
(lp1512
(dp1513
g7
I64
sg23
VC0027651
p1514
sg10
I5
sg11
Vtumor
p1515
sg13
I1
sa(dp1516
g7
I266
sg23
VC2239176
p1517
sg10
I24
sg11
Vhepatocellular carcinoma
p1518
sg13
I2
sa(dp1519
g7
I292
sg23
VC2239176
p1520
sg10
I3
sg11
VHCC
p1521
sg13
I1
sa(dp1522
g7
I189
sg23
VC0013336
p1523
sg10
I4
sg11
Vrunt
p1524
sg13
I1
sasa(dp1525
g2
S'Publicly-available data from The Cancer Genome Atlas (TCGA) was mined to compare the levels of miR-218 and its host gene SLIT2/3 between lung cancer tissues and normal lung tissues.\n'
p1526
sg4
(lp1527
(dp1528
g7
I95
sg8
g39
sg10
I7
sg11
VmiR-218
p1529
sg13
I1
sa(dp1530
g7
I116
sg8
g39
sg10
I12
sg11
Vgene SLIT2/3
p1531
sg13
I2
sasg20
(lp1532
(dp1533
g7
I137
sg23
VC0684249
p1534
sg10
I11
sg11
Vlung cancer
p1535
sg13
I2
sa(dp1536
g7
I33
sg23
VC0006826
p1537
sg10
I6
sg11
VCancer
p1538
sg13
I1
sasa(dp1539
g2
S'Finally, a PML/SLIT1 axis regulates sensitivity to the PML-targeting drug arsenic trioxide in primary GBM cells.\n'
p1540
sg4
(lp1541
(dp1542
g7
I11
sg8
g39
sg10
I3
sg11
VPML
p1543
sg13
I1
sa(dp1544
g7
I11
sg8
g39
sg10
I3
sg11
VPML
p1545
sg13
I1
sa(dp1546
g7
I15
sg8
g39
sg10
I5
sg11
VSLIT1
p1547
sg13
I1
sasg20
(lp1548
(dp1549
g7
I102
sg23
VC0017636
p1550
sg10
I3
sg11
VGBM
p1551
sg13
I1
sa(dp1552
g7
I11
sg23
VC0023524
p1553
sg10
I3
sg11
VPML
p1554
sg13
I1
sa(dp1555
g7
I11
sg23
VC0023524
p1556
sg10
I3
sg11
VPML
p1557
sg13
I1
sasa(dp1558
g2
S'We previously showed that Slit2-Robo1 inhibit cell migration in colorectal cancer (CRC).\n'
p1559
sg4
(lp1560
(dp1561
g7
I26
sg8
g39
sg10
I11
sg11
VSlit2-Robo1
p1562
sg13
I1
sasg20
(lp1563
(dp1564
g7
I64
sg23
VC1527249
p1565
sg10
I17
sg11
Vcolorectal cancer
p1566
sg13
I2
sa(dp1567
g7
I83
sg23
VC1527249
p1568
sg10
I3
sg11
VCRC
p1569
sg13
I1
sasa(dp1570
g2
S'Reduced NO release and/or nNOS expression are suspicious in a subset of patients with functional dyspepsia.\n'
p1571
sg4
(lp1572
sg20
(lp1573
(dp1574
g7
I97
sg23
VC0013395
p1575
sg10
I9
sg11
Vdyspepsia
p1576
sg13
I1
sasa(dp1577
g2
S'Disturbances of the allele-specific CTCF binding are causative for imprinting disorders like the Silver-Russell syndrome (SRS) or the Beckwith-Wiedemann syndrome (BWS), the latter one being associated with a dramatically increased risk to develop nephroblastomas.\n'
p1578
sg4
(lp1579
(dp1580
g7
I20
sg8
VP49711
p1581
sg10
I20
sg11
Vallele-specific CTCF
p1582
sg13
I2
sasg20
(lp1583
(dp1584
g7
I122
sg23
VC0175693
p1585
sg10
I3
sg11
VSRS
p1586
sg13
I1
sa(dp1587
g7
I247
sg23
VC0027708
p1588
sg10
I15
sg11
Vnephroblastomas
p1589
sg13
I1
sa(dp1590
g7
I97
sg23
VC0175693
p1591
sg10
I23
sg11
VSilver-Russell syndrome
p1592
sg13
I2
sa(dp1593
g7
I134
sg23
VC0004903
p1594
sg10
I27
sg11
VBeckwith-Wiedemann syndrome
p1595
sg13
I2
sa(dp1596
g7
I163
sg23
VC0004903
p1597
sg10
I3
sg11
VBWS
p1598
sg13
I1
sasa(dp1599
g2
S'Imprinting of the IGF2/H19 locus and the CDKN1C/KCNQ1 locus on chromosome 11p15.5 is mediated by CTCF, and this regulation is lost in BWS, leading to aberrant overexpression of growth-promoting genes.\n'
p1600
sg4
(lp1601
(dp1602
g7
I41
sg8
VP49918
p1603
sg10
I6
sg11
VCDKN1C
p1604
sg13
I1
sa(dp1605
g7
I18
sg8
VP01344
p1606
sg10
I4
sg11
VIGF2
p1607
sg13
I1
sa(dp1608
g7
I97
sg8
VP49711
p1609
sg10
I4
sg11
VCTCF
p1610
sg13
I1
sa(dp1611
g7
I48
sg8
VP51787
p1612
sg10
I5
sg11
VKCNQ1
p1613
sg13
I1
sasg20
(lp1614
(dp1615
g7
I134
sg23
VC0004903
p1616
sg10
I3
sg11
VBWS
p1617
sg13
I1
sasa(dp1618
g2
S'Therefore, we propose that loss of CTCF-dependent imprinting of tumor-promoting genes, such as IGF2 and TERT, results from a defective TGF-Beta pathway and is responsible at least in part for BWS-associated tumorigenesis as well as sporadic human cancers that are frequently associated with SPTBN1 and SMAD3 mutations.\n'
p1619
sg4
(lp1620
(dp1621
g7
I95
sg8
VP01344
p1622
sg10
I4
sg11
VIGF2
p1623
sg13
I1
sa(dp1624
g7
I291
sg8
g39
sg10
I6
sg11
VSPTBN1
p1625
sg13
I1
sa(dp1626
g7
I35
sg8
VP49711
p1627
sg10
I4
sg11
VCTCF
p1628
sg13
I1
sa(dp1629
g7
I104
sg8
g39
sg10
I4
sg11
VTERT
p1630
sg13
I1
sa(dp1631
g7
I135
sg8
VP18075
p1632
sg10
I8
sg11
VTGF-Beta
p1633
sg13
I1
sasg20
(lp1634
(dp1635
g7
I64
sg23
VC0027651
p1636
sg10
I5
sg11
Vtumor
p1637
sg13
I1
sa(dp1638
g7
I207
sg23
VC0007621
p1639
sg10
I13
sg11
Vtumorigenesis
p1640
sg13
I1
sa(dp1641
g7
I247
sg23
VC0006826
p1642
sg10
I7
sg11
Vcancers
p1643
sg13
I1
sa(dp1644
g7
I192
sg23
VC0004903
p1645
sg10
I3
sg11
VBWS
p1646
sg13
I1
sasa(dp1647
g2
S'By analyzing data from various libraries, like miRbase and ENCODE, we show a prevalence of various cancer-related genes, miRNAs, and regulatory binding sites, such as CTCF within CFSs.\n'
p1648
sg4
(lp1649
(dp1650
g7
I179
sg8
VP04141
p1651
sg10
I4
sg11
VCFSs
p1652
sg13
I1
sa(dp1653
g7
I167
sg8
VP49711
p1654
sg10
I4
sg11
VCTCF
p1655
sg13
I1
sasg20
(lp1656
(dp1657
g7
I99
sg23
VC0006826
p1658
sg10
I6
sg11
Vcancer
p1659
sg13
I1
sasa(dp1660
g2
S'Not only ICR1 microdeletions involving the CTCF-binding site, but also point mutations and a small deletion of the OCT-binding site have been shown to trigger methylation defects in BWS.\n'
p1661
sg4
(lp1662
(dp1663
g7
I115
sg8
VP00480
p1664
sg10
I16
sg11
VOCT-binding site
p1665
sg13
I2
sa(dp1666
g7
I43
sg8
VP49711
p1667
sg10
I17
sg11
VCTCF-binding site
p1668
sg13
I2
sasg20
(lp1669
(dp1670
g7
I182
sg23
VC0004903
p1671
sg10
I3
sg11
VBWS
p1672
sg13
I1
sasa(dp1673
g2
S'We highlight the networks of interactions between AR, Ca2+ and ATP2B1, where the extracellular proteins thrombospondin-1, gelsolin and integrinBeta1 were previously reported as regulators for cancer progression and metastasis, indicating the potential role of EV-derived proteins in mediating calcium homoeostasis under AR inhibition by enzalutamide.\n'
p1674
sg4
(lp1675
(dp1676
g7
I260
sg8
VP02649
p1677
sg10
I19
sg11
VEV-derived proteins
p1678
sg13
I2
sa(dp1679
g7
I104
sg8
VP07996
p1680
sg10
I16
sg11
Vthrombospondin-1
p1681
sg13
I1
sa(dp1682
g7
I122
sg8
VP06396
p1683
sg10
I8
sg11
Vgelsolin
p1684
sg13
I1
sasg20
(lp1685
(dp1686
g7
I215
sg23
VC0027627
p1687
sg10
I10
sg11
Vmetastasis
p1688
sg13
I1
sa(dp1689
g7
I192
sg23
VC0178874
p1690
sg10
I18
sg11
Vcancer progression
p1691
sg13
I2
sasa(dp1692
g2
S'Here, we demonstrate that gelsolin, a constituent of ejaculate, induces apoptosis of activated lymphocytes in prostate cancer.\n'
p1693
sg4
(lp1694
(dp1695
g7
I26
sg8
VP06396
p1696
sg10
I8
sg11
Vgelsolin
p1697
sg13
I1
sasg20
(lp1698
(dp1699
g7
I110
sg23
VC0600139
p1700
sg10
I15
sg11
Vprostate cancer
p1701
sg13
I2
sasa(dp1702
g2
S'Gelsolin was highly expressed in prostate cancer cells, and was associated with tumor progression, recurrence, metastasis, and poor prognosis.\n'
p1703
sg4
(lp1704
(dp1705
g7
I0
sg8
VP06396
p1706
sg10
I8
sg11
VGelsolin
p1707
sg13
I1
sasg20
(lp1708
(dp1709
g7
I33
sg23
VC0600139
p1710
sg10
I15
sg11
Vprostate cancer
p1711
sg13
I2
sa(dp1712
g7
I80
sg23
VC0178874
p1713
sg10
I17
sg11
Vtumor progression
p1714
sg13
I2
sa(dp1715
g7
I111
sg23
VC0027627
p1716
sg10
I10
sg11
Vmetastasis
p1717
sg13
I1
sa(dp1718
g7
I99
sg23
VC1458156
p1719
sg10
I10
sg11
Vrecurrence
p1720
sg13
I1
sasa(dp1721
g2
S'Epigenetic repression of the tumor suppressor gelsolin (GSN) is frequently observed in cancers.\n'
p1722
sg4
(lp1723
sg20
(lp1724
(dp1725
g7
I29
sg23
VC0027651
p1726
sg10
I5
sg11
Vtumor
p1727
sg13
I1
sa(dp1728
g7
I87
sg23
VC0006826
p1729
sg10
I7
sg11
Vcancers
p1730
sg13
I1
sasa(dp1731
g2
S'In this study, we investigated the role of tumor-associated macrophages (TAMs) in DNA methylation of the GSN gene during gastric cancer progression.\n'
p1732
sg4
(lp1733
(dp1734
g7
I105
sg8
VP06396
p1735
sg10
I8
sg11
VGSN gene
p1736
sg13
I2
sasg20
(lp1737
(dp1738
g7
I129
sg23
VC0178874
p1739
sg10
I18
sg11
Vcancer progression
p1740
sg13
I2
sa(dp1741
g7
I43
sg23
VC0027651
p1742
sg10
I5
sg11
Vtumor
p1743
sg13
I1
sasa(dp1744
g2
S'Immunofluorescence staining of 121 gastric cancer tissues showed aberrant localization of GSN and DNA methyltransferase 1 (DNMT1) and juxtaposition of DNMT1 and M2 TAMs.\n'
p1745
sg4
(lp1746
(dp1747
g7
I98
sg8
VP26358
p1748
sg10
I23
sg11
VDNA methyltransferase 1
p1749
sg13
I3
sa(dp1750
g7
I123
sg8
VP26358
p1751
sg10
I5
sg11
VDNMT1
p1752
sg13
I1
sa(dp1753
g7
I123
sg8
VP26358
p1754
sg10
I5
sg11
VDNMT1
p1755
sg13
I1
sa(dp1756
g7
I90
sg8
VP06396
p1757
sg10
I3
sg11
VGSN
p1758
sg13
I1
sasg20
(lp1759
(dp1760
g7
I35
sg23
VC0024623
p1761
sg10
I14
sg11
Vgastric cancer
p1762
sg13
I2
sasa(dp1763
g2
S'Decreased GSN protein and mRNA expression and increased DNA methylation in the GSN promoter were observed in gastric cancer cell lines and clinical specimens.\n'
p1764
sg4
(lp1765
(dp1766
g7
I10
sg8
VP06396
p1767
sg10
I11
sg11
VGSN protein
p1768
sg13
I2
sa(dp1769
g7
I79
sg8
VP06396
p1770
sg10
I12
sg11
VGSN promoter
p1771
sg13
I2
sasg20
(lp1772
(dp1773
g7
I109
sg23
VC0024623
p1774
sg10
I14
sg11
Vgastric cancer
p1775
sg13
I2
sasa(dp1776
g2
S'To examine the effect of TAMs on DNA methylation in gastric cancer cells, we performed in vitro coculture assays and found increased DNMT1 expression but decreased GSN expression in gastric cancer cells after coculture with U937 cells.\n'
p1777
sg4
(lp1778
(dp1779
g7
I133
sg8
VP26358
p1780
sg10
I5
sg11
VDNMT1
p1781
sg13
I1
sasg20
(lp1782
(dp1783
g7
I52
sg23
VC0024623
p1784
sg10
I14
sg11
Vgastric cancer
p1785
sg13
I2
sa(dp1786
g7
I52
sg23
VC0024623
p1787
sg10
I14
sg11
Vgastric cancer
p1788
sg13
I2
sasa(dp1789
g2
S'Knockdown of DNMT1 expression in gastric cancer cells could abort U937 coculture-mediated GSN downregulation.\n'
p1790
sg4
(lp1791
(dp1792
g7
I13
sg8
VP26358
p1793
sg10
I5
sg11
VDNMT1
p1794
sg13
I1
sasg20
(lp1795
(dp1796
g7
I33
sg23
VC0024623
p1797
sg10
I14
sg11
Vgastric cancer
p1798
sg13
I2
sasa(dp1799
g2
S'Inhibiting DNMT1 activity with procainamide, inhibiting DNA methylation with 5-AZA, or inhibiting CCL5/CCR5 signaling with maraviroc reduced tumor growth in vivo In conclusion, upregulation of DNMT1 by CCL5/CCR5/STAT3 signaling is critical for TAM-mediated GSN silencing in gastric cancer.\n'
p1800
sg4
(lp1801
(dp1802
g7
I11
sg8
VP26358
p1803
sg10
I5
sg11
VDNMT1
p1804
sg13
I1
sa(dp1805
g7
I98
sg8
VP13501
p1806
sg10
I4
sg11
VCCL5
p1807
sg13
I1
sa(dp1808
g7
I212
sg8
VP40763
p1809
sg10
I5
sg11
VSTAT3
p1810
sg13
I1
sa(dp1811
g7
I103
sg8
VP32302
p1812
sg10
I4
sg11
VCCR5
p1813
sg13
I1
sa(dp1814
g7
I103
sg8
VP32302
p1815
sg10
I4
sg11
VCCR5
p1816
sg13
I1
sa(dp1817
g7
I11
sg8
VP26358
p1818
sg10
I5
sg11
VDNMT1
p1819
sg13
I1
sa(dp1820
g7
I98
sg8
VP13501
p1821
sg10
I4
sg11
VCCL5
p1822
sg13
I1
sasg20
(lp1823
(dp1824
g7
I141
sg23
VC0598934
p1825
sg10
I12
sg11
Vtumor growth
p1826
sg13
I2
sa(dp1827
g7
I244
sg23
VC1834582
p1828
sg10
I3
sg11
VTAM
p1829
sg13
I1
sa(dp1830
g7
I274
sg23
VC0024623
p1831
sg10
I14
sg11
Vgastric cancer
p1832
sg13
I2
sasa(dp1833
g2
S'Basal cell cancers (BCCs) are characterized by up-regulation of Hedgehog pathway through loss of Patched1 or activation of Smoothened, and smoothened-inhibitors such as vismodegib are effective therapies for advanced BCCs.\n'
p1834
sg4
(lp1835
sg20
(lp1836
(dp1837
g7
I20
sg23
VC0751676
p1838
sg10
I4
sg11
VBCCs
p1839
sg13
I1
sa(dp1840
g7
I0
sg23
VC0751676
p1841
sg10
I18
sg11
VBasal cell cancers
p1842
sg13
I3
sa(dp1843
g7
I20
sg23
VC0751676
p1844
sg10
I4
sg11
VBCCs
p1845
sg13
I1
sasa(dp1846
g2
S'Furthermore, the cancer risks for Cd, Cr and Ni over a lifetime of exposure were higher in all treatments than the tolerable limit (1.00E-4 to 1.00E-6), however BCNs addition significantly suppressed cancer risk compared to control.\n'
p1847
sg4
(lp1848
sg20
(lp1849
(dp1850
g7
I17
sg23
VC0006826
p1851
sg10
I6
sg11
Vcancer
p1852
sg13
I1
sa(dp1853
g7
I161
sg23
VC0004779
p1854
sg10
I4
sg11
VBCNs
p1855
sg13
I1
sa(dp1856
g7
I17
sg23
VC0006826
p1857
sg10
I6
sg11
Vcancer
p1858
sg13
I1
sasa(dp1859
g2
S'Nevoid basal cell carcinoma syndrome (NBCCS) is a rare autosomal dominant disease with a complex genetic etiology.\n'
p1860
sg4
(lp1861
sg20
(lp1862
(dp1863
g7
I0
sg23
VC0004779
p1864
sg10
I36
sg11
VNevoid basal cell carcinoma syndrome
p1865
sg13
I5
sa(dp1866
g7
I38
sg23
VC0004779
p1867
sg10
I5
sg11
VNBCCS
p1868
sg13
I1
sasa(dp1869
g2
S'Among them ZFHX4 had been already identified as a new basal cell carcinoma susceptibility loci through a genome-wide association study (GWAS) and was considered the most likely pathogenic gene for this NBCCS family.\n'
p1870
sg4
(lp1871
(dp1872
g7
I11
sg8
g39
sg10
I5
sg11
VZFHX4
p1873
sg13
I1
sasg20
(lp1874
(dp1875
g7
I202
sg23
VC0004779
p1876
sg10
I5
sg11
VNBCCS
p1877
sg13
I1
sa(dp1878
g7
I54
sg23
VC0007117
p1879
sg10
I20
sg11
Vbasal cell carcinoma
p1880
sg13
I3
sasa(dp1881
g2
S'The autosomal recessive forms (LGMD2) are: LGMD2A (calpain 3), LGMD2B (dysferlin), LGMD2C (Gamma sarcoglycan), LGMD2D (Alfa sarcoglycan), LGMD2E (Beta sarcoglycan), LGMD2F (Delta sarcoglycan), LGMD2G (telethonin), LGMD2H (TRIM32), LGMD2I (FKRP), LGMD2J (titin), LGMD2K (POMT1), LGMD2L (anoctamin 5), LGMD2M (fukutin), LGMD2N (POMT2), LGMD2O (POMTnG1), LGMD2P (dystroglycan), LGMD2Q (plectin), LGMD2R (desmin), LGMD2S (TRAPPC11), LGMD2T (GMPPB), LGMD2U (ISPD), LGMD2V (Glucosidase, alpha ), LGMD2W (PINCH2).\n'
p1882
sg4
(lp1883
(dp1884
g7
I138
sg8
g39
sg10
I6
sg11
VLGMD2E
p1885
sg13
I1
sa(dp1886
g7
I83
sg8
g39
sg10
I6
sg11
VLGMD2C
p1887
sg13
I1
sa(dp1888
g7
I352
sg8
g39
sg10
I21
sg11
VLGMD2P (dystroglycan)
p1889
sg13
I2
sa(dp1890
g7
I401
sg8
VP98155
p1891
sg10
I6
sg11
Vdesmin
p1892
sg13
I1
sa(dp1893
g7
I410
sg8
VP20807
p1894
sg10
I6
sg11
VLGMD2S
p1895
sg13
I1
sa(dp1896
g7
I201
sg8
g39
sg10
I10
sg11
Vtelethonin
p1897
sg13
I1
sa(dp1898
g7
I51
sg8
VP20807
p1899
sg10
I9
sg11
Vcalpain 3
p1900
sg13
I2
sa(dp1901
g7
I437
sg8
g39
sg10
I5
sg11
VGMPPB
p1902
sg13
I1
sa(dp1903
g7
I308
sg8
g39
sg10
I7
sg11
Vfukutin
p1904
sg13
I1
sa(dp1905
g7
I300
sg8
g39
sg10
I6
sg11
VLGMD2M
p1906
sg13
I1
sa(dp1907
g7
I193
sg8
g39
sg10
I6
sg11
VLGMD2G
p1908
sg13
I1
sa(dp1909
g7
I278
sg8
g39
sg10
I20
sg11
VLGMD2L (anoctamin 5)
p1910
sg13
I3
sa(dp1911
g7
I43
sg8
VP20807
p1912
sg10
I6
sg11
VLGMD2A
p1913
sg13
I1
sa(dp1914
g7
I214
sg8
g39
sg10
I6
sg11
VLGMD2H
p1915
sg13
I1
sa(dp1916
g7
I31
sg8
VP20807
p1917
sg10
I5
sg11
VLGMD2
p1918
sg13
I1
sa(dp1919
g7
I453
sg8
g39
sg10
I4
sg11
VISPD
p1920
sg13
I1
sa(dp1921
g7
I498
sg8
g39
sg10
I6
sg11
VPINCH2
p1922
sg13
I1
sa(dp1923
g7
I326
sg8
g39
sg10
I5
sg11
VPOMT2
p1924
sg13
I1
sa(dp1925
g7
I231
sg8
g39
sg10
I6
sg11
VLGMD2I
p1926
sg13
I1
sa(dp1927
g7
I222
sg8
g39
sg10
I6
sg11
VTRIM32
p1928
sg13
I1
sa(dp1929
g7
I165
sg8
g39
sg10
I6
sg11
VLGMD2F
p1930
sg13
I1
sa(dp1931
g7
I239
sg8
g39
sg10
I4
sg11
VFKRP
p1932
sg13
I1
sa(dp1933
g7
I111
sg8
g39
sg10
I6
sg11
VLGMD2D
p1934
sg13
I1
sa(dp1935
g7
I254
sg8
g39
sg10
I5
sg11
Vtitin
p1936
sg13
I1
sasg20
(lp1937
(dp1938
g7
I138
sg23
VC1858593
p1939
sg10
I6
sg11
VLGMD2E
p1940
sg13
I1
sa(dp1941
g7
I214
sg23
VC0270968
p1942
sg10
I6
sg11
VLGMD2H
p1943
sg13
I1
sa(dp1944
g7
I31
sg23
VC1869123
p1945
sg10
I5
sg11
VLGMD2
p1946
sg13
I1
sa(dp1947
g7
I278
sg23
VC1969785
p1948
sg10
I6
sg11
VLGMD2L
p1949
sg13
I1
sa(dp1950
g7
I165
sg23
VC1832525
p1951
sg10
I6
sg11
VLGMD2F
p1952
sg13
I1
sa(dp1953
g7
I262
sg23
VC1836373
p1954
sg10
I6
sg11
VLGMD2K
p1955
sg13
I1
sa(dp1956
g7
I318
sg23
VC3150418
p1957
sg10
I6
sg11
VLGMD2N
p1958
sg13
I1
sa(dp1959
g7
I334
sg23
VC3150417
p1960
sg10
I6
sg11
VLGMD2O
p1961
sg13
I1
sa(dp1962
g7
I63
sg23
VC1850889
p1963
sg10
I6
sg11
VLGMD2B
p1964
sg13
I1
sa(dp1965
g7
I83
sg23
VC0410173
p1966
sg10
I6
sg11
VLGMD2C
p1967
sg13
I1
sa(dp1968
g7
I231
sg23
VC1846672
p1969
sg10
I6
sg11
VLGMD2I
p1970
sg13
I1
sa(dp1971
g7
I193
sg23
VC1866008
p1972
sg10
I6
sg11
VLGMD2G
p1973
sg13
I1
sa(dp1974
g7
I111
sg23
VC1842550
p1975
sg10
I6
sg11
VLGMD2D
p1976
sg13
I1
sa(dp1977
g7
I246
sg23
VC1837342
p1978
sg10
I6
sg11
VLGMD2J
p1979
sg13
I1
sa(dp1980
g7
I300
sg23
VC1969040
p1981
sg10
I6
sg11
VLGMD2M
p1982
sg13
I1
sa(dp1983
g7
I375
sg23
VC3150989
p1984
sg10
I6
sg11
VLGMD2Q
p1985
sg13
I1
sa(dp1986
g7
I43
sg23
VC1869123
p1987
sg10
I6
sg11
VLGMD2A
p1988
sg13
I1
sasa(dp1989
g2
S'TMAO promotes the atherosclerosis in vivo and in vitro.CD36/MAPK/JNK pathway may play a crucial role in TMAO-induced formation of foam cells.\n'
p1990
sg4
(lp1991
(dp1992
g7
I65
sg8
VP53779
p1993
sg10
I3
sg11
VJNK
p1994
sg13
I1
sa(dp1995
g7
I60
sg8
VP53779
p1996
sg10
I4
sg11
VMAPK
p1997
sg13
I1
sasg20
(lp1998
(dp1999
g7
I18
sg23
VC0004153
p2000
sg10
I15
sg11
Vatherosclerosis
p2001
sg13
I1
sasa(dp2002
g2
S'To determine whether deletion of JNK2 prevents high blood pressure and atherosclerosis known to be induced by vitamin D deficiency in mice, we generated mice with knockout of JNK2 in a background susceptible to diet-induced atherosclerosis (LDLR-/-).\n'
p2003
sg4
(lp2004
(dp2005
g7
I33
sg8
VP45984
p2006
sg10
I4
sg11
VJNK2
p2007
sg13
I1
sa(dp2008
g7
I33
sg8
VP45984
p2009
sg10
I4
sg11
VJNK2
p2010
sg13
I1
sa(dp2011
g7
I241
sg8
VP01130
p2012
sg10
I4
sg11
VLDLR
p2013
sg13
I1
sasg20
(lp2014
(dp2015
g7
I71
sg23
VC0004153
p2016
sg10
I15
sg11
Vatherosclerosis
p2017
sg13
I1
sa(dp2018
g7
I110
sg23
VC0042870
p2019
sg10
I20
sg11
Vvitamin D deficiency
p2020
sg13
I3
sa(dp2021
g7
I71
sg23
VC0004153
p2022
sg10
I15
sg11
Vatherosclerosis
p2023
sg13
I1
sa(dp2024
g7
I47
sg23
VC0020538
p2025
sg10
I19
sg11
Vhigh blood pressure
p2026
sg13
I3
sasa(dp2027
g2
S'Moreover, deletion of JNK2 reduced HFD-induced atherosclerosis by 30% in the proximal aorta when compared to control mice fed vitamin D-deficient diets.\n'
p2028
sg4
(lp2029
(dp2030
g7
I22
sg8
VP45984
p2031
sg10
I4
sg11
VJNK2
p2032
sg13
I1
sasg20
(lp2033
(dp2034
g7
I47
sg23
VC0004153
p2035
sg10
I15
sg11
Vatherosclerosis
p2036
sg13
I1
sasa(dp2037
g2
S'These data suggest that JNK2 signaling activation is necessary for the atherosclerosis and hypertension induced by vitamin D deficiency.\n'
p2038
sg4
(lp2039
(dp2040
g7
I24
sg8
VP45984
p2041
sg10
I4
sg11
VJNK2
p2042
sg13
I1
sasg20
(lp2043
(dp2044
g7
I91
sg23
VC0020538
p2045
sg10
I12
sg11
Vhypertension
p2046
sg13
I1
sa(dp2047
g7
I115
sg23
VC0042870
p2048
sg10
I20
sg11
Vvitamin D deficiency
p2049
sg13
I3
sa(dp2050
g7
I71
sg23
VC0004153
p2051
sg10
I15
sg11
Vatherosclerosis
p2052
sg13
I1
sasa(dp2053
g2
S'We developed a model of vestibular schwannoma growth that takes into account the effect of vascular endothelial growth factors and mammalian target of rapamycin complex 1 on tumor growth.\n'
p2054
sg4
(lp2055
(dp2056
g7
I91
sg8
VP19883
p2057
sg10
I35
sg11
Vvascular endothelial growth factors
p2058
sg13
I4
sasg20
(lp2059
(dp2060
g7
I174
sg23
VC0598934
p2061
sg10
I12
sg11
Vtumor growth
p2062
sg13
I2
sa(dp2063
g7
I24
sg23
VC0027859
p2064
sg10
I21
sg11
Vvestibular schwannoma
p2065
sg13
I2
sasa(dp2066
g2
S'The preponderance of mTOR activation was found in tumors of peripheral nerve sheath (malignant peripheral nerve sheath tumor and schwannoma), skeletal muscle origin (rhabdomyosarcoma), and in those exhibiting epithelial nature (chordoma and synovial sarcoma).\n'
p2067
sg4
(lp2068
(dp2069
g7
I21
sg8
VP42345
p2070
sg10
I4
sg11
VmTOR
p2071
sg13
I1
sasg20
(lp2072
(dp2073
g7
I85
sg23
VC0751690
p2074
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p2075
sg13
I5
sa(dp2076
g7
I241
sg23
VC0039101
p2077
sg10
I16
sg11
Vsynovial sarcoma
p2078
sg13
I2
sa(dp2079
g7
I228
sg23
VC0008487
p2080
sg10
I8
sg11
Vchordoma
p2081
sg13
I1
sa(dp2082
g7
I166
sg23
VC0035412
p2083
sg10
I16
sg11
Vrhabdomyosarcoma
p2084
sg13
I1
sa(dp2085
g7
I50
sg23
VC0027651
p2086
sg10
I6
sg11
Vtumors
p2087
sg13
I1
sa(dp2088
g7
I129
sg23
VC0027809
p2089
sg10
I10
sg11
Vschwannoma
p2090
sg13
I1
sasa(dp2091
g2
S'A random sample of 149 probands with unilateral cleft lip +/- palate was ascertained from 2 Los Angeles area hospitals.\n'
p2092
sg4
(lp2093
sg20
(lp2094
(dp2095
g7
I37
sg23
VC0392006
p2096
sg10
I20
sg11
Vunilateral cleft lip
p2097
sg13
I3
sasa(dp2098
g2
S'Accordingly, CXCL10 could not fully rescue CD27 deficiency in mice infected with influenza virus.\n'
p2099
sg4
(lp2100
(dp2101
g7
I43
sg8
VP26842
p2102
sg10
I4
sg11
VCD27
p2103
sg13
I1
sa(dp2104
g7
I13
sg8
VP02778
p2105
sg10
I6
sg11
VCXCL10
p2106
sg13
I1
sasg20
(lp2107
(dp2108
g7
I81
sg23
VC0021400
p2109
sg10
I9
sg11
Vinfluenza
p2110
sg13
I1
sasa(dp2111
g2
S'Mice defective in spermiogenesis (Tnp1(-/-), Gmcl1(-/-), Asm(-/-)) showed wild-type mid-preleptotene and bouquet frequencies.\n'
p2112
sg4
(lp2113
(dp2114
g7
I45
sg8
g39
sg10
I5
sg11
VGmcl1
p2115
sg13
I1
sa(dp2116
g7
I34
sg8
VP09430
p2117
sg10
I4
sg11
VTnp1
p2118
sg13
I1
sasg20
(lp2119
sa(dp2120
g2
S"The noncoding miRNA-34a (miR-34a) is involved in Alzheimer's disease (AD) pathologenesis and shows potential for application as a biomarker for early diagnosis and intervention.\n"
p2121
sg4
(lp2122
(dp2123
g7
I25
sg8
g39
sg10
I7
sg11
VmiR-34a
p2124
sg13
I1
sa(dp2125
g7
I14
sg8
g39
sg10
I9
sg11
VmiRNA-34a
p2126
sg13
I1
sasg20
(lp2127
(dp2128
g7
I49
sg23
VC1521724
p2129
sg10
I19
sg11
VAlzheimer's disease
p2130
sg13
I2
sa(dp2131
g7
I70
sg23
VC1521724
p2132
sg10
I2
sg11
VAD
p2133
sg13
I1
sasa(dp2134
g2
S"To explore the regulatory role of miR-34a in aging-related diseases such as Alzheimer's disease (AD) during exercise intervention, we constructed a rat model with d-galactose (d-gal)-induced oxidative stress and cognitive impairment coupled with dysfunctional autophagy and abnormal mitochondrial dynamics, determined the mitigation of cognitive impairment of d-gal-induced aging rats during swimming intervention, and evaluated miR-34a-mediated functional status of autophagy and abnormal mitochondrial dynamics.\n"
p2135
sg4
(lp2136
(dp2137
g7
I163
sg8
VP16278
p2138
sg10
I5
sg11
Vd-gal
p2139
sg13
I1
sa(dp2140
g7
I34
sg8
g39
sg10
I7
sg11
VmiR-34a
p2141
sg13
I1
sa(dp2142
g7
I163
sg8
g39
sg10
I11
sg11
Vd-galactose
p2143
sg13
I1
sa(dp2144
g7
I34
sg8
g39
sg10
I7
sg11
VmiR-34a
p2145
sg13
I1
sa(dp2146
g7
I163
sg8
g39
sg10
I5
sg11
Vd-gal
p2147
sg13
I1
sasg20
(lp2148
(dp2149
g7
I191
sg23
VC0242606
p2150
sg10
I16
sg11
Voxidative stress
p2151
sg13
I2
sa(dp2152
g7
I76
sg23
VC1521724
p2153
sg10
I19
sg11
VAlzheimer's disease
p2154
sg13
I2
sa(dp2155
g7
I212
sg23
VC0338656
p2156
sg10
I20
sg11
Vcognitive impairment
p2157
sg13
I2
sa(dp2158
g7
I97
sg23
VC1521724
p2159
sg10
I2
sg11
VAD
p2160
sg13
I1
sa(dp2161
g7
I212
sg23
VC0338656
p2162
sg10
I20
sg11
Vcognitive impairment
p2163
sg13
I2
sasa(dp2164
g2
S"In this study, we showed that presenilin (PS)-2, a major gene associated with familial Alzheimer's disease (AD) could trigger the apoptosis through the p53/miR-34a axis in PC12 cells.\n"
p2165
sg4
(lp2166
(dp2167
g7
I156
sg8
g39
sg10
I3
sg11
VmiR
p2168
sg13
I1
sa(dp2169
g7
I152
sg8
VP42771
p2170
sg10
I3
sg11
Vp53
p2171
sg13
I1
sasg20
(lp2172
(dp2173
g7
I108
sg23
VC1521724
p2174
sg10
I2
sg11
VAD
p2175
sg13
I1
sa(dp2176
g7
I78
sg23
VC0276496
p2177
sg10
I28
sg11
Vfamilial Alzheimer's disease
p2178
sg13
I3
sasa(dp2179
g2
S'A major protein constituent of a rat islet cell tumour that exhibited Ca2+-dependent changes in electrophoretic mobility has been purified to homogeneity and compared in its physicochemical and biological properties with bovine brain and rat brain calmodulin (synonymous with phosphodiesterase activator protein, calcium-dependent regulator, troponin C-like protein and modulator protein).\n'
p2180
sg4
(lp2181
(dp2182
g7
I342
sg8
VP63316
p2183
sg10
I23
sg11
Vtroponin C-like protein
p2184
sg13
I3
sa(dp2185
g7
I276
sg8
VP22413
p2186
sg10
I35
sg11
Vphosphodiesterase activator protein
p2187
sg13
I3
sa(dp2188
g7
I221
sg8
g39
sg10
I37
sg11
Vbovine brain and rat brain calmodulin
p2189
sg13
I6
sasg20
(lp2190
(dp2191
g7
I37
sg23
VC0242363
p2192
sg10
I17
sg11
Vislet cell tumour
p2193
sg13
I3
sasa(dp2194
g2
S'The top 3 reasons for choosing contralateral prophylactic mastectomy were (1) decreasing the risk of contralateral breast disease (97%), (2) peace of mind (96%), and (3) improved survival (93%).\n'
p2195
sg4
(lp2196
sg20
(lp2197
(dp2198
g7
I115
sg23
VC0006145
p2199
sg10
I14
sg11
Vbreast disease
p2200
sg13
I2
sasa(dp2201
g2
S'The top 3 causes of death from 2009 to 2013 were cancer, cerebrovascular disease, and cardiopathy, with the role of cardiopathy increasing over time (P&lt;0.01).\n'
p2202
sg4
(lp2203
sg20
(lp2204
(dp2205
g7
I49
sg23
VC0006826
p2206
sg10
I6
sg11
Vcancer
p2207
sg13
I1
sa(dp2208
g7
I86
sg23
VC0018799
p2209
sg10
I11
sg11
Vcardiopathy
p2210
sg13
I1
sa(dp2211
g7
I57
sg23
VC0007820
p2212
sg10
I23
sg11
Vcerebrovascular disease
p2213
sg13
I2
sa(dp2214
g7
I86
sg23
VC0018799
p2215
sg10
I11
sg11
Vcardiopathy
p2216
sg13
I1
sasa(dp2217
g2
S'The top 3 causes of DALY were skin and subcutaneous diseases, iron-deficiency anemia and road injuries, resulting in DALY (constituent ratio) of 1 411 (10.5%), 1 094 (8.1%) and 1 029 (7.6%) thousand years respectively.\n'
p2218
sg4
(lp2219
sg20
(lp2220
(dp2221
g7
I62
sg23
VC0162316
p2222
sg10
I22
sg11
Viron-deficiency anemia
p2223
sg13
I2
sasa(dp2224
g2
S'The adult group had results of Dermatophagoides pteryonysinus (71%), Dermatophagoides farina (72%), and Blomia tropicalis (59%); the adult food allergy category, the top 3 allergens were egg white (13%), milk (6%) and soya bean (5%).\n'
p2225
sg4
(lp2226
sg20
(lp2227
(dp2228
g7
I139
sg23
VC0016470
p2229
sg10
I12
sg11
Vfood allergy
p2230
sg13
I2
sasa(dp2231
g2
S'Also good results could be respected by cisplatin and 5-fluorouracil based neoadjuvant chemotherapy before radiotherapy plus interferon beta as a maintenance therapy in childhood aggressive nasopharyngeal carcinoma.\n'
p2232
sg4
(lp2233
(dp2234
g7
I125
sg8
VP01574
p2235
sg10
I15
sg11
Vinterferon beta
p2236
sg13
I2
sasg20
(lp2237
(dp2238
g7
I190
sg23
VC2931822
p2239
sg10
I24
sg11
Vnasopharyngeal carcinoma
p2240
sg13
I2
sa(dp2241
g7
I179
sg23
VC0001807
p2242
sg10
I10
sg11
Vaggressive
p2243
sg13
I1
sasa(dp2244
g2
S'Treating pediatric nasopharyngeal carcinoma patients with the Al-Sarraf protocol could be a feasible modality, as observed in this clinical case, despite the elevated cost of using interferon-beta in low-income countries when using more advanced radiotherapy techniques such as conformal radiotherapy and now, modulated intensity radiotherapy.\n'
p2245
sg4
(lp2246
(dp2247
g7
I181
sg8
VP01563
p2248
sg10
I15
sg11
Vinterferon-beta
p2249
sg13
I1
sasg20
(lp2250
(dp2251
g7
I19
sg23
VC2931822
p2252
sg10
I24
sg11
Vnasopharyngeal carcinoma
p2253
sg13
I2
sasa(dp2254
g2
S'Preliminary results of combined neoadjuvant chemotherapy, radiotherapy, and postradiation interferon beta (IFN-beta) in children and adolescents with nasopharyngeal carcinoma, especially in high-risk patients, have been promising.\n'
p2255
sg4
(lp2256
(dp2257
g7
I90
sg8
VP01574
p2258
sg10
I15
sg11
Vinterferon beta
p2259
sg13
I2
sa(dp2260
g7
I107
sg8
VP01574
p2261
sg10
I8
sg11
VIFN-beta
p2262
sg13
I1
sasg20
(lp2263
(dp2264
g7
I150
sg23
VC2931822
p2265
sg10
I24
sg11
Vnasopharyngeal carcinoma
p2266
sg13
I2
sasa(dp2267
g2
S'Here, we report that CAB39 was frequently up-regulated in hepatocellular carcinoma (HCC), which was significantly associated with tumor metastasis (P = 0.000), poorer disease-free survival rate (P = 0.027), and poor prognosis (P = 0.000).\n'
p2268
sg4
(lp2269
sg20
(lp2270
(dp2271
g7
I84
sg23
VC2239176
p2272
sg10
I3
sg11
VHCC
p2273
sg13
I1
sa(dp2274
g7
I58
sg23
VC2239176
p2275
sg10
I24
sg11
Vhepatocellular carcinoma
p2276
sg13
I2
sa(dp2277
g7
I130
sg23
VC0027627
p2278
sg10
I16
sg11
Vtumor metastasis
p2279
sg13
I2
sasa(dp2280
g2
S'In glioma cell lines, we found that decreased miR-451 expression suppressed tumor cell proliferation but enhanced migration with a concomitant low level of CAB39/AMPK/mTOR pathway activation and high level of Rac1/cofilin pathway activation, respectively.\n'
p2281
sg4
(lp2282
(dp2283
g7
I162
sg8
VP54646
p2284
sg10
I4
sg11
VAMPK
p2285
sg13
I1
sa(dp2286
g7
I209
sg8
VP63000
p2287
sg10
I4
sg11
VRac1
p2288
sg13
I1
sa(dp2289
g7
I214
sg8
VP23528
p2290
sg10
I7
sg11
Vcofilin
p2291
sg13
I1
sa(dp2292
g7
I156
sg8
g39
sg10
I5
sg11
VCAB39
p2293
sg13
I1
sa(dp2294
g7
I167
sg8
VP42345
p2295
sg10
I4
sg11
VmTOR
p2296
sg13
I1
sasg20
(lp2297
(dp2298
g7
I76
sg23
VC0027651
p2299
sg10
I5
sg11
Vtumor
p2300
sg13
I1
sa(dp2301
g7
I3
sg23
VC0017638
p2302
sg10
I6
sg11
Vglioma
p2303
sg13
I1
sa(dp2304
g7
I87
sg23
VC0334094
p2305
sg10
I13
sg11
Vproliferation
p2306
sg13
I1
sasa(dp2307
g2
S'By targeting CAB 39, miRNA-451 likely triggers the LKB1/AMPK/PI3K/AKT pathway, which regulates GLUT1, to inhibit the glucose metabolism of, reduce the energy supply to, and inhibit the proliferation and invasion of glioma cells.\n'
p2308
sg4
(lp2309
(dp2310
g7
I51
sg8
g39
sg10
I4
sg11
VLKB1
p2311
sg13
I1
sa(dp2312
g7
I66
sg8
g39
sg10
I3
sg11
VAKT
p2313
sg13
I1
sa(dp2314
g7
I95
sg8
VP11166
p2315
sg10
I5
sg11
VGLUT1
p2316
sg13
I1
sa(dp2317
g7
I56
sg8
VP54646
p2318
sg10
I4
sg11
VAMPK
p2319
sg13
I1
sa(dp2320
g7
I61
sg8
VP42336
p2321
sg10
I4
sg11
VPI3K
p2322
sg13
I1
sasg20
(lp2323
(dp2324
g7
I203
sg23
VC2699153
p2325
sg10
I8
sg11
Vinvasion
p2326
sg13
I1
sa(dp2327
g7
I215
sg23
VC0017638
p2328
sg10
I6
sg11
Vglioma
p2329
sg13
I1
sa(dp2330
g7
I185
sg23
VC0334094
p2331
sg10
I13
sg11
Vproliferation
p2332
sg13
I1
sasa(dp2333
g2
S'Our recent work revealed the activation mechanism of GCKIIIs by MO25, as well as how GCKIIIs heterodimerize with CCM3, a molecular bridge between GCKIII and striatins.\n'
p2334
sg4
(lp2335
(dp2336
g7
I157
sg8
g39
sg10
I9
sg11
Vstriatins
p2337
sg13
I1
sa(dp2338
g7
I113
sg8
g39
sg10
I4
sg11
VCCM3
p2339
sg13
I1
sasg20
(lp2340
(dp2341
g7
I113
sg23
VC1864040
p2342
sg10
I4
sg11
VCCM3
p2343
sg13
I1
sasa(dp2344
g2
S"We evaluated transglutaminase 5 expression in comparison with proliferating (keratin 14) and differentiating (transglutaminase 3) markers in different diseases, such as psoriasis, ichthyosis vulgaris, lamellar ichthyosis, and Darier's disease.\n"
p2345
sg4
(lp2346
sg20
(lp2347
(dp2348
g7
I201
sg23
VC0020758
p2349
sg10
I19
sg11
Vlamellar ichthyosis
p2350
sg13
I2
sa(dp2351
g7
I169
sg23
VC0033860
p2352
sg10
I9
sg11
Vpsoriasis
p2353
sg13
I1
sa(dp2354
g7
I180
sg23
VC0079584
p2355
sg10
I19
sg11
Vichthyosis vulgaris
p2356
sg13
I2
sa(dp2357
g7
I226
sg23
VC0022595
p2358
sg10
I16
sg11
VDarier's disease
p2359
sg13
I2
sasa(dp2360
g2
S'Here we investigated the cutaneous CD32A and CD89 expression in relation to the neutrophil elastase (NE) expression and serum level of anti-desmoglein 1 and 3 (DSG1/DSG3) IgG in pemphigus, anti-BP180/BP230 IgG in bullous pemphigoid (BP), anti-gliadin nonapeptides (npG), tissue (tTG), and epidermal transglutaminases (eTG) IgA in dermatitis herpetiformis (DH).\n'
p2361
sg4
(lp2362
(dp2363
g7
I323
sg8
VP11912
p2364
sg10
I3
sg11
VIgA
p2365
sg13
I1
sa(dp2366
g7
I318
sg8
VP22735
p2367
sg10
I3
sg11
VeTG
p2368
sg13
I1
sa(dp2369
g7
I289
sg8
VP22735
p2370
sg10
I27
sg11
Vepidermal transglutaminases
p2371
sg13
I2
sa(dp2372
g7
I165
sg8
VP32926
p2373
sg10
I4
sg11
VDSG3
p2374
sg13
I1
sa(dp2375
g7
I35
sg8
VP12318
p2376
sg10
I5
sg11
VCD32A
p2377
sg13
I1
sa(dp2378
g7
I80
sg8
VP08246
p2379
sg10
I19
sg11
Vneutrophil elastase
p2380
sg13
I2
sa(dp2381
g7
I101
sg8
VP08246
p2382
sg10
I2
sg11
VNE
p2383
sg13
I1
sa(dp2384
g7
I189
sg8
g39
sg10
I20
sg11
Vanti-BP180/BP230 IgG
p2385
sg13
I2
sa(dp2386
g7
I160
sg8
g39
sg10
I4
sg11
VDSG1
p2387
sg13
I1
sa(dp2388
g7
I135
sg8
g39
sg10
I23
sg11
Vanti-desmoglein 1 and 3
p2389
sg13
I4
sasg20
(lp2390
(dp2391
g7
I213
sg23
VC0030805
p2392
sg10
I18
sg11
Vbullous pemphigoid
p2393
sg13
I2
sa(dp2394
g7
I330
sg23
VC0011608
p2395
sg10
I24
sg11
Vdermatitis herpetiformis
p2396
sg13
I2
sa(dp2397
g7
I178
sg23
VC0030807
p2398
sg10
I9
sg11
Vpemphigus
p2399
sg13
I1
sa(dp2400
g7
I194
sg23
VC0030805
p2401
sg10
I2
sg11
VBP
p2402
sg13
I1
sa(dp2403
g7
I356
sg23
VC0011608
p2404
sg10
I2
sg11
VDH
p2405
sg13
I1
sasa(dp2406
g2
S'Pemphigus and bullous pemphigoid (BP) are identified by autoantibodies (abs) against desmoglein 1, 3 (DSG1/3) and BP180/BP230, respectively.\n'
p2407
sg4
(lp2408
(dp2409
g7
I102
sg8
g39
sg10
I6
sg11
VDSG1/3
p2410
sg13
I1
sa(dp2411
g7
I114
sg8
g39
sg10
I5
sg11
VBP180
p2412
sg13
I1
sa(dp2413
g7
I85
sg8
g39
sg10
I15
sg11
Vdesmoglein 1, 3
p2414
sg13
I3
sasg20
(lp2415
(dp2416
g7
I34
sg23
VC0030805
p2417
sg10
I2
sg11
VBP
p2418
sg13
I1
sa(dp2419
g7
I14
sg23
VC0030805
p2420
sg10
I18
sg11
Vbullous pemphigoid
p2421
sg13
I2
sa(dp2422
g7
I0
sg23
VC0030807
p2423
sg10
I9
sg11
VPemphigus
p2424
sg13
I1
sasa(dp2425
g2
S'To define cut-off values for Dsg1, Dsg3, and BP180, we evaluated 47 serum samples from patients with pemphigus foliaceus (PF), 59 from those with pemphigus vulgaris (PV), 52 from those with bullous pemphigoid (BP), and 995 from healthy individuals.\n'
p2426
sg4
(lp2427
(dp2428
g7
I35
sg8
VP32926
p2429
sg10
I4
sg11
VDsg3
p2430
sg13
I1
sa(dp2431
g7
I29
sg8
g39
sg10
I4
sg11
VDsg1
p2432
sg13
I1
sasg20
(lp2433
(dp2434
g7
I166
sg23
VC0030809
p2435
sg10
I2
sg11
VPV
p2436
sg13
I1
sa(dp2437
g7
I146
sg23
VC0030809
p2438
sg10
I18
sg11
Vpemphigus vulgaris
p2439
sg13
I2
sa(dp2440
g7
I101
sg23
VC0263313
p2441
sg10
I19
sg11
Vpemphigus foliaceus
p2442
sg13
I2
sa(dp2443
g7
I45
sg23
VC0030805
p2444
sg10
I2
sg11
VBP
p2445
sg13
I1
sa(dp2446
g7
I122
sg23
VC0263313
p2447
sg10
I2
sg11
VPF
p2448
sg13
I1
sa(dp2449
g7
I190
sg23
VC0030805
p2450
sg10
I18
sg11
Vbullous pemphigoid
p2451
sg13
I2
sasa(dp2452
g2
S'Serum anti-skin antibodies were significantly higher in the patients than in the controls (p = 0.008, p &lt; 0.001, p &lt; 0.001, p &lt; 0.001 and p &lt; 0.001 for desmoglein 1 (DSG1) desmoglein 3 (DSG3), bullous pemphigoid 180 (BP180), BP230 and type VII collagen (COL7), respectively).\n'
p2453
sg4
(lp2454
(dp2455
g7
I184
sg8
VP32926
p2456
sg10
I12
sg11
Vdesmoglein 3
p2457
sg13
I2
sa(dp2458
g7
I198
sg8
VP32926
p2459
sg10
I4
sg11
VDSG3
p2460
sg13
I1
sa(dp2461
g7
I247
sg8
g39
sg10
I17
sg11
Vtype VII collagen
p2462
sg13
I3
sa(dp2463
g7
I178
sg8
g39
sg10
I4
sg11
VDSG1
p2464
sg13
I1
sa(dp2465
g7
I164
sg8
g39
sg10
I12
sg11
Vdesmoglein 1
p2466
sg13
I2
sasg20
(lp2467
(dp2468
g7
I205
sg23
VC0030805
p2469
sg10
I18
sg11
Vbullous pemphigoid
p2470
sg13
I2
sasa(dp2471
g2
S'BRIP1 is a BRCA1 associated protein that is mutated in a fraction of familial breast cancer and Fanconi anemia cases.\n'
p2472
sg4
(lp2473
(dp2474
g7
I11
sg8
g39
sg10
I24
sg11
VBRCA1 associated protein
p2475
sg13
I3
sa(dp2476
g7
I0
sg8
g39
sg10
I5
sg11
VBRIP1
p2477
sg13
I1
sasg20
(lp2478
(dp2479
g7
I69
sg23
VC0346153
p2480
sg10
I22
sg11
Vfamilial breast cancer
p2481
sg13
I3
sa(dp2482
g7
I96
sg23
VC3469521
p2483
sg10
I14
sg11
VFanconi anemia
p2484
sg13
I2
sasa(dp2485
g2
S'Our previous studies of intraperitoneal ovarian carcinoma in a mouse model demonstrated that bikunin gene transfection could prevent ascites formation and intraperitoneal disseminated metastasis.\n'
p2486
sg4
(lp2487
(dp2488
g7
I93
sg8
VP02760
p2489
sg10
I12
sg11
Vbikunin gene
p2490
sg13
I2
sasg20
(lp2491
(dp2492
g7
I184
sg23
VC0027627
p2493
sg10
I10
sg11
Vmetastasis
p2494
sg13
I1
sa(dp2495
g7
I40
sg23
VC0029925
p2496
sg10
I17
sg11
Vovarian carcinoma
p2497
sg13
I2
sasa(dp2498
g2
S'The authors initially evaluated the therapeutic efficacy of once-daily oral administration of different doses of bikunin against human ovarian carcinoma HRA cells growing in the peritonea of nude mice.\n'
p2499
sg4
(lp2500
(dp2501
g7
I113
sg8
VP02760
p2502
sg10
I7
sg11
Vbikunin
p2503
sg13
I1
sasg20
(lp2504
(dp2505
g7
I135
sg23
VC0029925
p2506
sg10
I17
sg11
Vovarian carcinoma
p2507
sg13
I2
sa(dp2508
g7
I153
sg23
VC1619700
p2509
sg10
I3
sg11
VHRA
p2510
sg13
I1
sasa(dp2511
g2
S'The current study was the first to report the potent activity of once-daily oral administration of bikunin against ovarian carcinoma.\n'
p2512
sg4
(lp2513
sg20
(lp2514
(dp2515
g7
I115
sg23
VC0029925
p2516
sg10
I17
sg11
Vovarian carcinoma
p2517
sg13
I2
sasa(dp2518
g2
S'In previous studies, the authors showed that various types of cultured tumor cells treated with exogenous bikunin protein or ovarian carcinoma cells transfected with bikunin cDNA have low invasiveness and diminished metastatic potential.\n'
p2519
sg4
(lp2520
(dp2521
g7
I166
sg8
VP02760
p2522
sg10
I12
sg11
Vbikunin cDNA
p2523
sg13
I2
sa(dp2524
g7
I106
sg8
VP02760
p2525
sg10
I15
sg11
Vbikunin protein
p2526
sg13
I2
sasg20
(lp2527
(dp2528
g7
I125
sg23
VC0029925
p2529
sg10
I17
sg11
Vovarian carcinoma
p2530
sg13
I2
sa(dp2531
g7
I71
sg23
VC0027651
p2532
sg10
I5
sg11
Vtumor
p2533
sg13
I1
sasa(dp2534
g2
S'The data suggest that low bikunin mRNA expression by ovarian carcinoma cells may be associated with poor prognosis.\n'
p2535
sg4
(lp2536
(dp2537
g7
I26
sg8
VP02760
p2538
sg10
I12
sg11
Vbikunin mRNA
p2539
sg13
I2
sasg20
(lp2540
(dp2541
g7
I53
sg23
VC0029925
p2542
sg10
I17
sg11
Vovarian carcinoma
p2543
sg13
I2
sasa(dp2544
g2
S'It is conceivable that testing for bikunin mRNA may identify patients with ovarian carcinoma who are at high risk for early disease recurrence and a poor prognosis.\n'
p2545
sg4
(lp2546
(dp2547
g7
I35
sg8
VP02760
p2548
sg10
I12
sg11
Vbikunin mRNA
p2549
sg13
I2
sasg20
(lp2550
(dp2551
g7
I75
sg23
VC0029925
p2552
sg10
I17
sg11
Vovarian carcinoma
p2553
sg13
I2
sa(dp2554
g7
I132
sg23
VC1458156
p2555
sg10
I10
sg11
Vrecurrence
p2556
sg13
I1
sasa(dp2557
g2
S'Infiltration of inflammatory cells into the lungs was significantly increased; NK1R-/- animals also exhibited increased pulmonary edema, hemorrhage, and bronchoalveolar lavage fluid protein levels.\n'
p2558
sg4
(lp2559
(dp2560
g7
I79
sg8
VP25103
p2561
sg10
I4
sg11
VNK1R
p2562
sg13
I1
sasg20
(lp2563
(dp2564
g7
I0
sg23
VC0332448
p2565
sg10
I12
sg11
VInfiltration
p2566
sg13
I1
sa(dp2567
g7
I137
sg23
VC0019080
p2568
sg10
I10
sg11
Vhemorrhage
p2569
sg13
I1
sa(dp2570
g7
I120
sg23
VC0034063
p2571
sg10
I15
sg11
Vpulmonary edema
p2572
sg13
I2
sasa(dp2573
g2
S'Finally, treatment (10 mg/kg im) with SR-140333B, an NK-1R antagonist, significantly prevented 20-min FS-induced hypoxemia and pulmonary edema 24 h after insult.\n'
p2574
sg4
(lp2575
(dp2576
g7
I53
sg8
VP25103
p2577
sg10
I5
sg11
VNK-1R
p2578
sg13
I1
sasg20
(lp2579
(dp2580
g7
I127
sg23
VC0034063
p2581
sg10
I15
sg11
Vpulmonary edema
p2582
sg13
I2
sasa(dp2583
g2
S'Our data suggested that BMP4, MGP, TGFBI, and SPHK1 may be important in CAFs-associated NSCLC, and the abnormal expression and high LOH frequency of them may be used as the diagnosis targets of CAFs in NSCLC.\n'
p2584
sg4
(lp2585
(dp2586
g7
I24
sg8
VP12644
p2587
sg10
I4
sg11
VBMP4
p2588
sg13
I1
sa(dp2589
g7
I46
sg8
g39
sg10
I5
sg11
VSPHK1
p2590
sg13
I1
sa(dp2591
g7
I30
sg8
VP08493
p2592
sg10
I3
sg11
VMGP
p2593
sg13
I1
sasg20
(lp2594
(dp2595
g7
I72
sg23
VC0795907
p2596
sg10
I4
sg11
VCAFs
p2597
sg13
I1
sa(dp2598
g7
I88
sg23
VC0007131
p2599
sg10
I5
sg11
VNSCLC
p2600
sg13
I1
sa(dp2601
g7
I88
sg23
VC0007131
p2602
sg10
I5
sg11
VNSCLC
p2603
sg13
I1
sa(dp2604
g7
I72
sg23
VC0795907
p2605
sg10
I4
sg11
VCAFs
p2606
sg13
I1
sasa(dp2607
g2
S'Moreover, increased expression of p21, transforming growth factor (TGF)-Beta inducible early gene-1 (TIEG1) and TGF beta-induced (TGFBI) was observed in lung cancer cells after Cul4A knockdown, which may be partially related to increased chemosensitivity to gemcitabine.\n'
p2608
sg4
(lp2609
(dp2610
g7
I112
sg8
VP18075
p2611
sg10
I8
sg11
VTGF beta
p2612
sg13
I2
sa(dp2613
g7
I67
sg8
g39
sg10
I3
sg11
VTGF
p2614
sg13
I1
sa(dp2615
g7
I101
sg8
g39
sg10
I5
sg11
VTIEG1
p2616
sg13
I1
sa(dp2617
g7
I39
sg8
g39
sg10
I26
sg11
Vtransforming growth factor
p2618
sg13
I3
sa(dp2619
g7
I177
sg8
g39
sg10
I5
sg11
VCul4A
p2620
sg13
I1
sa(dp2621
g7
I34
sg8
VP42857
p2622
sg10
I3
sg11
Vp21
p2623
sg13
I1
sasg20
(lp2624
(dp2625
g7
I153
sg23
VC0684249
p2626
sg10
I11
sg11
Vlung cancer
p2627
sg13
I2
sasa(dp2628
g2
S'Transforming growth factor Beta-induced (TGFBI) has been implicated as a tumor suppressor, which enhances gemcitabine chemosensitivity in lung cancer cells.\n'
p2629
sg4
(lp2630
(dp2631
g7
I0
sg8
VP18075
p2632
sg10
I31
sg11
VTransforming growth factor Beta
p2633
sg13
I4
sasg20
(lp2634
(dp2635
g7
I73
sg23
VC0027651
p2636
sg10
I5
sg11
Vtumor
p2637
sg13
I1
sa(dp2638
g7
I138
sg23
VC0684249
p2639
sg10
I11
sg11
Vlung cancer
p2640
sg13
I2
sasa(dp2641
g2
S'We observed that knockdown of Cul4A was associated with increased sensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells.\n'
p2642
sg4
(lp2643
(dp2644
g7
I30
sg8
g39
sg10
I5
sg11
VCul4A
p2645
sg13
I1
sasg20
(lp2646
(dp2647
g7
I126
sg23
VC0684249
p2648
sg10
I11
sg11
Vlung cancer
p2649
sg13
I2
sasa(dp2650
g2
S'EGFR, KDR, FN1, TGFBI and PCNA may interact with VEGFA to play important roles in NSCLC tumorigenesis.\n'
p2651
sg4
(lp2652
(dp2653
g7
I6
sg8
VP35968
p2654
sg10
I3
sg11
VKDR
p2655
sg13
I1
sa(dp2656
g7
I26
sg8
VP12004
p2657
sg10
I4
sg11
VPCNA
p2658
sg13
I1
sasg20
(lp2659
(dp2660
g7
I88
sg23
VC0007621
p2661
sg10
I13
sg11
Vtumorigenesis
p2662
sg13
I1
sa(dp2663
g7
I82
sg23
VC0007131
p2664
sg10
I5
sg11
VNSCLC
p2665
sg13
I1
sasa(dp2666
g2
S'Using a small series of stage IV non-small cell lung cancer (NSCLC) patients, we previously suggested the usefulness of TGFBI as a prognostic and predictive factor in chemotherapy-treated late-stage NSCLC.\n'
p2667
sg4
(lp2668
sg20
(lp2669
(dp2670
g7
I24
sg23
VC0278987
p2671
sg10
I35
sg11
Vstage IV non-small cell lung cancer
p2672
sg13
I6
sa(dp2673
g7
I61
sg23
VC0007131
p2674
sg10
I5
sg11
VNSCLC
p2675
sg13
I1
sa(dp2676
g7
I61
sg23
VC0007131
p2677
sg10
I5
sg11
VNSCLC
p2678
sg13
I1
sasa(dp2679
g2
S'In order to validate and extend these results, we broaden the analysis and studied TGFBI expression in a large series of samples obtained from stage I-IV NSCLC patients.\n'
p2680
sg4
(lp2681
sg20
(lp2682
(dp2683
g7
I154
sg23
VC0007131
p2684
sg10
I5
sg11
VNSCLC
p2685
sg13
I1
sasa(dp2686
g2
S'TGFBI expression was assessed by immunohistochemistry in 364 completely resected primary NSCLC samples: 242 adenocarcinomas (ADCs) and 122 squamous cell carcinomas (SCCs).\n'
p2687
sg4
(lp2688
sg20
(lp2689
(dp2690
g7
I89
sg23
VC0007131
p2691
sg10
I5
sg11
VNSCLC
p2692
sg13
I1
sa(dp2693
g7
I139
sg23
VC0007137
p2694
sg10
I24
sg11
Vsquamous cell carcinomas
p2695
sg13
I3
sa(dp2696
g7
I108
sg23
VC0001418
p2697
sg10
I15
sg11
Vadenocarcinomas
p2698
sg13
I1
sa(dp2699
g7
I165
sg23
VC0007137
p2700
sg10
I4
sg11
VSCCs
p2701
sg13
I1
sa(dp2702
g7
I125
sg23
VC0001418
p2703
sg10
I4
sg11
VADCs
p2704
sg13
I1
sasa(dp2705
g2
S'TGFBI may be useful for the identification of a subset of NSCLC who may benefit from adjuvant therapy.\n'
p2706
sg4
(lp2707
sg20
(lp2708
(dp2709
g7
I58
sg23
VC0007131
p2710
sg10
I5
sg11
VNSCLC
p2711
sg13
I1
sasa(dp2712
g2
S'Loss of TGFBI expression has been described in several cancers including lung carcinoma, and it has been suggested to act as a tumor suppressor gene.\n'
p2713
sg4
(lp2714
sg20
(lp2715
(dp2716
g7
I73
sg23
VC0684249
p2717
sg10
I14
sg11
Vlung carcinoma
p2718
sg13
I2
sa(dp2719
g7
I55
sg23
VC0006826
p2720
sg10
I7
sg11
Vcancers
p2721
sg13
I1
sa(dp2722
g7
I127
sg23
VC0027651
p2723
sg10
I5
sg11
Vtumor
p2724
sg13
I1
sasa(dp2725
g2
S'To address the importance of TGFBI expression in cancer progression, we determined its expression in NSCLC clinical samples using immunohistochemistry.\n'
p2726
sg4
(lp2727
sg20
(lp2728
(dp2729
g7
I101
sg23
VC0007131
p2730
sg10
I5
sg11
VNSCLC
p2731
sg13
I1
sa(dp2732
g7
I49
sg23
VC0178874
p2733
sg10
I18
sg11
Vcancer progression
p2734
sg13
I2
sasa(dp2735
g2
S'Furthermore, we transiently over-expressed and silenced TGFBI in human NSCLC cell lines.\n'
p2736
sg4
(lp2737
sg20
(lp2738
(dp2739
g7
I71
sg23
VC0007131
p2740
sg10
I5
sg11
VNSCLC
p2741
sg13
I1
sasa(dp2742
g2
S'Among 50 lung cancer samples, 44.0% (22/50) harbored methylated CpG sites in the TGFBI promoter.\n'
p2743
sg4
(lp2744
sg20
(lp2745
(dp2746
g7
I9
sg23
VC0684249
p2747
sg10
I11
sg11
Vlung cancer
p2748
sg13
I2
sasa(dp2749
g2
S'An analysis correlating gene methylation status with clinicopathological cancer features revealed that dense methylation of the TGFBI promoter was associated with a metastatic phenotype, with 42.9% (6/14) of metastatic lung cancer samples demonstrating dense methylation vs. only 5.6% (2/36) of primary lung cancer samples (p &lt; 0.05).\n'
p2750
sg4
(lp2751
sg20
(lp2752
(dp2753
g7
I219
sg23
VC0684249
p2754
sg10
I11
sg11
Vlung cancer
p2755
sg13
I2
sa(dp2756
g7
I208
sg23
VC0153676
p2757
sg10
I22
sg11
Vmetastatic lung cancer
p2758
sg13
I3
sa(dp2759
g7
I73
sg23
VC0006826
p2760
sg10
I6
sg11
Vcancer
p2761
sg13
I1
sasa(dp2762
g2
S'Similar to these lung cancer results, 82.0% (41/50) of prostate cancer samples harbored methylated CpG sites in the TGFBI promoter, and dense methylation of the promoter was present in 38.9% (7/18) of prostate cancer samples with the feature of locoregional invasiveness vs. only 19.4% (6/31) of prostate cancer samples without locoregional invasiveness (p &lt; 0.05).\n'
p2763
sg4
(lp2764
sg20
(lp2765
(dp2766
g7
I55
sg23
VC0600139
p2767
sg10
I15
sg11
Vprostate cancer
p2768
sg13
I2
sa(dp2769
g7
I55
sg23
VC0600139
p2770
sg10
I15
sg11
Vprostate cancer
p2771
sg13
I2
sa(dp2772
g7
I55
sg23
VC0600139
p2773
sg10
I15
sg11
Vprostate cancer
p2774
sg13
I2
sa(dp2775
g7
I17
sg23
VC0684249
p2776
sg10
I11
sg11
Vlung cancer
p2777
sg13
I2
sasa(dp2778
g2
S'Dense methylation of the TGFBI promoter correlated with the extent of TGFBI gene silencing in tumor cell lines and was related to invasiveness of prostate tumors and metastatic status of lung cancer tumors.\n'
p2779
sg4
(lp2780
sg20
(lp2781
(dp2782
g7
I146
sg23
VC0033578
p2783
sg10
I15
sg11
Vprostate tumors
p2784
sg13
I2
sa(dp2785
g7
I94
sg23
VC0027651
p2786
sg10
I5
sg11
Vtumor
p2787
sg13
I1
sa(dp2788
g7
I187
sg23
VC0684249
p2789
sg10
I11
sg11
Vlung cancer
p2790
sg13
I2
sa(dp2791
g7
I155
sg23
VC0027651
p2792
sg10
I6
sg11
Vtumors
p2793
sg13
I1
sasa(dp2794
g2
S'Thus, TGFBI promoter methylation can be used as a potential prognostic marker for invasiveness and metastasis in prostate and lung cancer patients, respectively.\n'
p2795
sg4
(lp2796
sg20
(lp2797
(dp2798
g7
I99
sg23
VC0027627
p2799
sg10
I10
sg11
Vmetastasis
p2800
sg13
I1
sa(dp2801
g7
I126
sg23
VC0684249
p2802
sg10
I11
sg11
Vlung cancer
p2803
sg13
I2
sasa(dp2804
g2
S'Subunits B and C and 3-ketoacyl-CoA thiolase were detected in fibroblasts of controls and X-linked adrenoleukodystrophy patients, but not of Zellweger patients.\n'
p2805
sg4
(lp2806
(dp2807
g7
I0
sg8
VP42765
p2808
sg10
I44
sg11
VSubunits B and C and 3-ketoacyl-CoA thiolase
p2809
sg13
I7
sasg20
(lp2810
(dp2811
g7
I32
sg23
VC2678439
p2812
sg10
I3
sg11
VCoA
p2813
sg13
I1
sa(dp2814
g7
I90
sg23
VC0162309
p2815
sg10
I29
sg11
VX-linked adrenoleukodystrophy
p2816
sg13
I2
sasa(dp2817
g2
S'The CA4+ CECT attenuation obtained from imaging ex vivo human hip cartilage correlates with the glycosaminoglycan content, equilibrium modulus, and coefficient of friction, which are key indicators of cartilage functional performance and osteoarthritis stage.\n'
p2818
sg4
(lp2819
sg20
(lp2820
(dp2821
g7
I238
sg23
VC0029408
p2822
sg10
I14
sg11
Vosteoarthritis
p2823
sg13
I1
sasa(dp2824
g2
S'This study describes the regulation of EMT in RPE cells by TGF-Beta1/miR-124/RHOG signaling and suggests that the supplement of miR-124 exogenously would be a valuable therapeutic approach for the prevention or treatment of proliferative vitreoretinopathy.\n'
p2825
sg4
(lp2826
(dp2827
g7
I39
sg8
g39
sg10
I3
sg11
VEMT
p2828
sg13
I1
sa(dp2829
g7
I69
sg8
g39
sg10
I7
sg11
VmiR-124
p2830
sg13
I1
sa(dp2831
g7
I59
sg8
VP01137
p2832
sg10
I9
sg11
VTGF-Beta1
p2833
sg13
I1
sa(dp2834
g7
I69
sg8
g39
sg10
I7
sg11
VmiR-124
p2835
sg13
I1
sa(dp2836
g7
I77
sg8
VP84095
p2837
sg10
I4
sg11
VRHOG
p2838
sg13
I1
sasg20
(lp2839
(dp2840
g7
I224
sg23
VC0242852
p2841
sg10
I31
sg11
Vproliferative vitreoretinopathy
p2842
sg13
I2
sasa(dp2843
g2
S'The aim of this study was to investigate the effect of limb ischemic preconditioning (LIPC) on myocardial apoptosis in myocardial ischemia-reperfusion injury (MIRI), as well as the regulation of caspase-3 and the B cell lymphoma 2 (Bcl-2) gene in LIPC.\n'
p2844
sg4
(lp2845
(dp2846
g7
I232
sg8
VP10415
p2847
sg10
I5
sg11
VBcl-2
p2848
sg13
I1
sa(dp2849
g7
I86
sg8
VP11150
p2850
sg10
I4
sg11
VLIPC
p2851
sg13
I1
sa(dp2852
g7
I86
sg8
VP11150
p2853
sg10
I4
sg11
VLIPC
p2854
sg13
I1
sa(dp2855
g7
I195
sg8
VP42574
p2856
sg10
I9
sg11
Vcaspase-3
p2857
sg13
I1
sa(dp2858
g7
I55
sg8
VP11150
p2859
sg10
I29
sg11
Vlimb ischemic preconditioning
p2860
sg13
I3
sa(dp2861
g7
I213
sg8
VP10415
p2862
sg10
I17
sg11
VB cell lymphoma 2
p2863
sg13
I4
sasg20
(lp2864
(dp2865
g7
I119
sg23
VC0151744
p2866
sg10
I19
sg11
Vmyocardial ischemia
p2867
sg13
I2
sa(dp2868
g7
I213
sg23
VC0079731
p2869
sg10
I15
sg11
VB cell lymphoma
p2870
sg13
I3
sasa(dp2871
g2
S'Together with PDXK, 84 additional factors were identified that influence the response of NSCLC cells to cisplatin, in vitro including the hepatic lipase LIPC.\n'
p2872
sg4
(lp2873
(dp2874
g7
I146
sg8
VP04118
p2875
sg10
I11
sg11
Vlipase LIPC
p2876
sg13
I2
sasg20
(lp2877
(dp2878
g7
I89
sg23
VC0007131
p2879
sg10
I5
sg11
VNSCLC
p2880
sg13
I1
sasa(dp2881
g2
S'Here, we report that the intratumoral levels of LIPC, as assessed by immunohistochemistry in two independent cohorts of NSCLC patients, positively correlate with disease outcome.\n'
p2882
sg4
(lp2883
sg20
(lp2884
(dp2885
g7
I120
sg23
VC0007131
p2886
sg10
I5
sg11
VNSCLC
p2887
sg13
I1
sasa(dp2888
g2
S'In one out of two cohorts studied, the overall survival of NSCLC patients bearing LIPChigh lesions was unaffected, if not slightly worsened, by cisplatin-based adjuvant therapy.\n'
p2889
sg4
(lp2890
sg20
(lp2891
(dp2892
g7
I59
sg23
VC0007131
p2893
sg10
I5
sg11
VNSCLC
p2894
sg13
I1
sasa(dp2895
g2
S'Pending validation in appropriate clinical series, these results suggest that LIPClow NSCLC patients would be those who mainly benefit from adjuvant cisplatin therapy.\n'
p2896
sg4
(lp2897
sg20
(lp2898
(dp2899
g7
I86
sg23
VC0007131
p2900
sg10
I5
sg11
VNSCLC
p2901
sg13
I1
sasa(dp2902
g2
S'Thus, the expression levels of LIPC appear to have an independent prognostic value (and perhaps a predictive potential) in the setting of NSCLC.\n'
p2903
sg4
(lp2904
(dp2905
g7
I31
sg8
VP11150
p2906
sg10
I4
sg11
VLIPC
p2907
sg13
I1
sasg20
(lp2908
(dp2909
g7
I138
sg23
VC0007131
p2910
sg10
I5
sg11
VNSCLC
p2911
sg13
I1
sasa(dp2912
g2
S'If these findings were confirmed by additional studies, LIPC expression levels might allow not only for NSCLC patient stratification, but also for the implementation of personalized therapeutic approaches.\n'
p2913
sg4
(lp2914
(dp2915
g7
I56
sg8
VP11150
p2916
sg10
I4
sg11
VLIPC
p2917
sg13
I1
sasg20
(lp2918
(dp2919
g7
I104
sg23
VC0007131
p2920
sg10
I5
sg11
VNSCLC
p2921
sg13
I1
sasa(dp2922
g2
S'Here, extensive immunohistochemical analysis was performed on a tissue microarray, containing 135 ovarian cancer cases obtained during tumor debulking detecting 15 key lymphocyte markers such as CD3, CD4, and CD20, as well as activation and immunomodulatory molecules such as TIA-1 and PD-L1.\n'
p2923
sg4
(lp2924
(dp2925
g7
I209
sg8
VP35900
p2926
sg10
I4
sg11
VCD20
p2927
sg13
I1
sa(dp2928
g7
I200
sg8
VP01730
p2929
sg10
I3
sg11
VCD4
p2930
sg13
I1
sa(dp2931
g7
I276
sg8
VP31483
p2932
sg10
I5
sg11
VTIA-1
p2933
sg13
I1
sasg20
(lp2934
(dp2935
g7
I98
sg23
VC1140680
p2936
sg10
I14
sg11
Vovarian cancer
p2937
sg13
I2
sa(dp2938
g7
I276
sg23
VC0917805
p2939
sg10
I3
sg11
VTIA
p2940
sg13
I1
sa(dp2941
g7
I135
sg23
VC0027651
p2942
sg10
I5
sg11
Vtumor
p2943
sg13
I1
sasa(dp2944
g2
S'The observed total improvement in the survival rate of the second time period is followed by an increase in conservative surgery in stage TIA1, a reduction in the use of adjuvant radiotherapy among operable stages Tlbl, Tlb2 and T2A, while the treatment of locally advanced cervical cancer did not differ significantly.\n'
p2945
sg4
(lp2946
(dp2947
g7
I138
sg8
VP31483
p2948
sg10
I4
sg11
VTIA1
p2949
sg13
I1
sasg20
(lp2950
(dp2951
g7
I274
sg23
VC0302592
p2952
sg10
I15
sg11
Vcervical cancer
p2953
sg13
I2
sasa(dp2954
g2
S'Meckel syndrome (MKS) is an inherited autosomal recessive hepatorenal fibrocystic syndrome, caused by mutations in TMEM67, characterized by occipital encephalocoele, renal cysts, hepatic fibrosis, and polydactyly.\n'
p2955
sg4
(lp2956
(dp2957
g7
I115
sg8
g39
sg10
I6
sg11
VTMEM67
p2958
sg13
I1
sasg20
(lp2959
(dp2960
g7
I179
sg23
VC0239946
p2961
sg10
I16
sg11
Vhepatic fibrosis
p2962
sg13
I2
sa(dp2963
g7
I7
sg23
VC0039082
p2964
sg10
I8
sg11
Vsyndrome
p2965
sg13
I1
sa(dp2966
g7
I166
sg23
VC0268800
p2967
sg10
I11
sg11
Vrenal cysts
p2968
sg13
I2
sa(dp2969
g7
I201
sg23
VC0152427
p2970
sg10
I11
sg11
Vpolydactyly
p2971
sg13
I1
sa(dp2972
g7
I0
sg23
VC0265215
p2973
sg10
I15
sg11
VMeckel syndrome
p2974
sg13
I2
sa(dp2975
g7
I17
sg23
VC0265215
p2976
sg10
I3
sg11
VMKS
p2977
sg13
I1
sasa(dp2978
g2
S'Electroencephalographic study showed that TonEBP (+/-) mice reduced seizure frequency and severity compared with wild type during KA-induced status epilepticus.\n'
p2979
sg4
(lp2980
(dp2981
g7
I42
sg8
g39
sg10
I6
sg11
VTonEBP
p2982
sg13
I1
sasg20
(lp2983
(dp2984
g7
I68
sg23
VC0036572
p2985
sg10
I7
sg11
Vseizure
p2986
sg13
I1
sa(dp2987
g7
I141
sg23
VC0038220
p2988
sg10
I18
sg11
Vstatus epilepticus
p2989
sg13
I2
sasa(dp2990
g2
S'Among frequently-used tumor markers in lung cancer, carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125), cytokeratin 19 (CYFRA21-1) and squamous carcinoma antigen (SCC), neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP) are respectively expressed highly in lung adenocarcinoma, lung squamous carcinoma and small cell lung cancer.\n'
p2991
sg4
(lp2992
(dp2993
g7
I113
sg8
g39
sg10
I5
sg11
VCA125
p2994
sg13
I1
sa(dp2995
g7
I87
sg8
VP14209
p2996
sg10
I24
sg11
Vcarbohydrate antigen 125
p2997
sg13
I3
sa(dp2998
g7
I52
sg8
VP40198
p2999
sg10
I24
sg11
Vcarcinoembryonic antigen
p3000
sg13
I2
sa(dp3001
g7
I161
sg8
VP14209
p3002
sg10
I17
sg11
Vcarcinoma antigen
p3003
sg13
I2
sa(dp3004
g7
I211
sg8
VP09104
p3005
sg10
I3
sg11
VNSE
p3006
sg13
I1
sa(dp3007
g7
I251
sg8
VP07492
p3008
sg10
I6
sg11
VProGRP
p3009
sg13
I1
sa(dp3010
g7
I78
sg8
VP40198
p3011
sg10
I3
sg11
VCEA
p3012
sg13
I1
sa(dp3013
g7
I186
sg8
VP13929
p3014
sg10
I23
sg11
Vneuron specific enolase
p3015
sg13
I3
sa(dp3016
g7
I220
sg8
VP07492
p3017
sg10
I29
sg11
Vpro-gastrin-releasing peptide
p3018
sg13
I2
sasg20
(lp3019
(dp3020
g7
I152
sg23
VC0007137
p3021
sg10
I18
sg11
Vsquamous carcinoma
p3022
sg13
I2
sa(dp3023
g7
I22
sg23
VC0027651
p3024
sg10
I5
sg11
Vtumor
p3025
sg13
I1
sa(dp3026
g7
I152
sg23
VC0007137
p3027
sg10
I18
sg11
Vsquamous carcinoma
p3028
sg13
I2
sa(dp3029
g7
I39
sg23
VC0684249
p3030
sg10
I11
sg11
Vlung cancer
p3031
sg13
I2
sa(dp3032
g7
I296
sg23
VC0152013
p3033
sg10
I19
sg11
Vlung adenocarcinoma
p3034
sg13
I2
sa(dp3035
g7
I345
sg23
VC0149925
p3036
sg10
I22
sg11
Vsmall cell lung cancer
p3037
sg13
I4
sasa(dp3038
g2
S'##### ###########, #### (carcinoembryonic antigen, CEA) #####125 (carbohydrate antigen 125, CA125) ######19## (cytokeratin 19, CYFRA21-1) ######## (squamous carcinoma antigen, SCC) ########### (neuron specific enolase, NSE) ######### (pro-gastrin-releasing peptide, ProGRP) ############################################ (A#) ##CEA#/#CA125## (B#) ##########, ############################# ##############IV########, ##########, ################################# #CEA#CA125#, A##############CYFRA21-1 (93%) , ###NSE (36%) #SCC (13%) #ProGRP (12%) ######################## (P&lt;0.001) , ############ (####5.3## vs 7.3##, P=0.016) ############################# (P#&lt;0.001) ### ################, ############.\n'
p3039
sg4
(lp3040
(dp3041
g7
I25
sg8
VP40198
p3042
sg10
I24
sg11
Vcarcinoembryonic antigen
p3043
sg13
I2
sa(dp3044
g7
I210
sg8
VP13929
p3045
sg10
I7
sg11
Venolase
p3046
sg13
I1
sa(dp3047
g7
I235
sg8
VP07492
p3048
sg10
I29
sg11
Vpro-gastrin-releasing peptide
p3049
sg13
I2
sa(dp3050
g7
I111
sg8
g39
sg10
I25
sg11
Vcytokeratin 19, CYFRA21-1
p3051
sg13
I3
sa(dp3052
g7
I51
sg8
VP40198
p3053
sg10
I3
sg11
VCEA
p3054
sg13
I1
sa(dp3055
g7
I266
sg8
VP07492
p3056
sg10
I6
sg11
VProGRP
p3057
sg13
I1
sa(dp3058
g7
I157
sg8
VP14209
p3059
sg10
I17
sg11
Vcarcinoma antigen
p3060
sg13
I2
sa(dp3061
g7
I266
sg8
VP07492
p3062
sg10
I6
sg11
VProGRP
p3063
sg13
I1
sa(dp3064
g7
I219
sg8
VP09104
p3065
sg10
I3
sg11
VNSE
p3066
sg13
I1
sasg20
(lp3067
(dp3068
g7
I148
sg23
VC0007137
p3069
sg10
I18
sg11
Vsquamous carcinoma
p3070
sg13
I2
sasa(dp3071
g2
S'The authors built a model for lung cancer diagnosis previously based on the blood biomarkers progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYFRA21-1).\n'
p3072
sg4
(lp3073
(dp3074
g7
I93
sg8
VP07492
p3075
sg10
I28
sg11
Vprogastrin-releasing peptide
p3076
sg13
I2
sa(dp3077
g7
I158
sg8
VP40198
p3078
sg10
I3
sg11
VCEA
p3079
sg13
I1
sa(dp3080
g7
I123
sg8
VP07492
p3081
sg10
I6
sg11
VProGRP
p3082
sg13
I1
sa(dp3083
g7
I132
sg8
VP40198
p3084
sg10
I24
sg11
Vcarcinoembryonic antigen
p3085
sg13
I2
sasg20
(lp3086
(dp3087
g7
I30
sg23
VC0684249
p3088
sg10
I11
sg11
Vlung cancer
p3089
sg13
I2
sa(dp3090
g7
I164
sg23
VC0007137
p3091
sg10
I23
sg11
Vsquamous cell carcinoma
p3092
sg13
I3
sasa(dp3093
g2
S'We aimed to explore whether squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (Cyfra21-1), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA) are elevated in diabetic nephropathy (DN) and the association between urinary albumin-to-creatinine ratio (UACR) and tumor markers in diabetic patients.\n'
p3094
sg4
(lp3095
(dp3096
g7
I139
sg8
VP40198
p3097
sg10
I24
sg11
Vcarcinoembryonic antigen
p3098
sg13
I2
sa(dp3099
g7
I104
sg8
VP09104
p3100
sg10
I23
sg11
Vneuron-specific enolase
p3101
sg13
I2
sa(dp3102
g7
I248
sg8
VP00441
p3103
sg10
I7
sg11
Valbumin
p3104
sg13
I1
sa(dp3105
g7
I67
sg8
g39
sg10
I23
sg11
Vcytokeratin 19 fragment
p3106
sg13
I3
sa(dp3107
g7
I165
sg8
VP40198
p3108
sg10
I3
sg11
VCEA
p3109
sg13
I1
sa(dp3110
g7
I129
sg8
VP09104
p3111
sg10
I3
sg11
VNSE
p3112
sg13
I1
sasg20
(lp3113
(dp3114
g7
I186
sg23
VC0011881
p3115
sg10
I20
sg11
Vdiabetic nephropathy
p3116
sg13
I2
sa(dp3117
g7
I28
sg23
VC0007137
p3118
sg10
I23
sg11
Vsquamous cell carcinoma
p3119
sg13
I3
sa(dp3120
g7
I208
sg23
VC0011881
p3121
sg10
I2
sg11
VDN
p3122
sg13
I1
sa(dp3123
g7
I287
sg23
VC0027651
p3124
sg10
I5
sg11
Vtumor
p3125
sg13
I1
sasa(dp3126
g2
S'CK19 fragment Cyfra 21-1 is useful tumor marker for squamous cell carcinoma, but its clinical value in OSCC has not been confirmed.\n'
p3127
sg4
(lp3128
sg20
(lp3129
(dp3130
g7
I52
sg23
VC0007137
p3131
sg10
I23
sg11
Vsquamous cell carcinoma
p3132
sg13
I3
sa(dp3133
g7
I35
sg23
VC0027651
p3134
sg10
I5
sg11
Vtumor
p3135
sg13
I1
sasa(dp3136
g2
S'The objective of this study was to assess the value of human squamous cell carcinoma-associated antigen (SCC-Ag) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) in evaluation of patients with nonbulky early-stage squamous cell carcinoma of the cervix to determine if radiotherapy is warranted after radical surgery.\n'
p3137
sg4
(lp3138
(dp3139
g7
I75
sg8
VP14209
p3140
sg10
I28
sg11
Vcarcinoma-associated antigen
p3141
sg13
I2
sa(dp3142
g7
I155
sg8
g39
sg10
I9
sg11
VCYFRA21-1
p3143
sg13
I1
sa(dp3144
g7
I117
sg8
g39
sg10
I36
sg11
Vcytokeratin 19 fragment antigen 21-1
p3145
sg13
I5
sasg20
(lp3146
(dp3147
g7
I61
sg23
VC0007137
p3148
sg10
I23
sg11
Vsquamous cell carcinoma
p3149
sg13
I3
sa(dp3150
g7
I218
sg23
VC0279671
p3151
sg10
I37
sg11
Vsquamous cell carcinoma of the cervix
p3152
sg13
I6
sasa(dp3153
g2
S'In this review, we discuss the molecular features, functions, and clinical relevance of the conventional serum biomarkers for lung cancer, including carcinoembryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA 21-1), tissue polypeptide antigen (TPA), carbohydrate antigen 19-9 (CA19-9), sialyl Lewisx (sLex), carbohydrate antigen 125 (CA-125), squamous cell carcinoma-related antigen (SCC-Ag), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (proGRP), aiming to provide a snapshot of the current landscape and their potential combined utility in the diagnosis and prognosis of lung cancer.\n'
p3154
sg4
(lp3155
(dp3156
g7
I294
sg8
VP14209
p3157
sg10
I46
sg11
Vsialyl Lewisx (sLex), carbohydrate antigen 125
p3158
sg13
I6
sa(dp3159
g7
I401
sg8
VP09104
p3160
sg10
I23
sg11
Vneuron-specific enolase
p3161
sg13
I2
sa(dp3162
g7
I426
sg8
VP09104
p3163
sg10
I3
sg11
VNSE
p3164
sg13
I1
sa(dp3165
g7
I224
sg8
VP23468
p3166
sg10
I26
sg11
Vtissue polypeptide antigen
p3167
sg13
I3
sa(dp3168
g7
I252
sg8
VP23468
p3169
sg10
I3
sg11
VTPA
p3170
sg13
I1
sa(dp3171
g7
I436
sg8
VP07492
p3172
sg10
I29
sg11
Vpro-gastrin-releasing peptide
p3173
sg13
I2
sa(dp3174
g7
I467
sg8
VP07492
p3175
sg10
I6
sg11
VproGRP
p3176
sg13
I1
sa(dp3177
g7
I149
sg8
VP40198
p3178
sg10
I24
sg11
Vcarcinoembryonic antigen
p3179
sg13
I2
sa(dp3180
g7
I365
sg8
VP14209
p3181
sg10
I25
sg11
Vcarcinoma-related antigen
p3182
sg13
I2
sa(dp3183
g7
I342
sg8
g39
sg10
I6
sg11
VCA-125
p3184
sg13
I1
sa(dp3185
g7
I175
sg8
VP40198
p3186
sg10
I3
sg11
VCEA
p3187
sg13
I1
sasg20
(lp3188
(dp3189
g7
I126
sg23
VC0684249
p3190
sg10
I11
sg11
Vlung cancer
p3191
sg13
I2
sa(dp3192
g7
I351
sg23
VC0007137
p3193
sg10
I23
sg11
Vsquamous cell carcinoma
p3194
sg13
I3
sa(dp3195
g7
I126
sg23
VC0684249
p3196
sg10
I11
sg11
Vlung cancer
p3197
sg13
I2
sasa(dp3198
g2
S'We detected three FBN1 mutations in two patients (aged 24 and 25 years) displaying aortic root aneurysm &gt;=50 mm and moderate aortic regurgitation.\n'
p3199
sg4
(lp3200
(dp3201
g7
I18
sg8
VP35555
p3202
sg10
I14
sg11
VFBN1 mutations
p3203
sg13
I2
sasg20
(lp3204
(dp3205
g7
I128
sg23
VC0003504
p3206
sg10
I20
sg11
Vaortic regurgitation
p3207
sg13
I2
sa(dp3208
g7
I83
sg23
VC1298820
p3209
sg10
I20
sg11
Vaortic root aneurysm
p3210
sg13
I3
sasa(dp3211
g2
S'Severe heritable elastic fibre diseases are caused by mutations in elastic fibre components; for example, mutations in elastin cause supravalvular aortic stenosis and autosomal dominant cutis laxa, mutations in fibrillin-1 cause Marfan syndrome and Weill-Marchesani syndrome, and mutations in fibulins-4 and -5 cause autosomal recessive cutis laxa.\n'
p3212
sg4
(lp3213
(dp3214
g7
I211
sg8
VP35555
p3215
sg10
I11
sg11
Vfibrillin-1
p3216
sg13
I1
sa(dp3217
g7
I119
sg8
VP49918
p3218
sg10
I7
sg11
Velastin
p3219
sg13
I1
sasg20
(lp3220
(dp3221
g7
I186
sg23
VC0010495
p3222
sg10
I10
sg11
Vcutis laxa
p3223
sg13
I2
sa(dp3224
g7
I249
sg23
VC0265313
p3225
sg10
I25
sg11
VWeill-Marchesani syndrome
p3226
sg13
I2
sa(dp3227
g7
I229
sg23
VC0024796
p3228
sg10
I15
sg11
VMarfan syndrome
p3229
sg13
I2
sa(dp3230
g7
I133
sg23
VC0003499
p3231
sg10
I29
sg11
Vsupravalvular aortic stenosis
p3232
sg13
I3
sa(dp3233
g7
I186
sg23
VC0010495
p3234
sg10
I10
sg11
Vcutis laxa
p3235
sg13
I2
sasa(dp3236
g2
S'An alteration of the elastin (Eln) or fibrillin (Fbn) gene products leads to severe genetic pathologies of the cardiovascular system, such as supravalvular aortic stenosis, or Williams Beuren syndrome--in which elastin deficiency induces aortic stenoses--or Marfan syndrome, in which on the contrary fibrillin-1 deficiency promotes the appearance of aortic aneurysms.\n'
p3237
sg4
(lp3238
(dp3239
g7
I21
sg8
VP49918
p3240
sg10
I7
sg11
Velastin
p3241
sg13
I1
sa(dp3242
g7
I38
sg8
VP35555
p3243
sg10
I9
sg11
Vfibrillin
p3244
sg13
I1
sa(dp3245
g7
I49
sg8
VP35555
p3246
sg10
I3
sg11
VFbn
p3247
sg13
I1
sa(dp3248
g7
I30
sg8
g39
sg10
I3
sg11
VEln
p3249
sg13
I1
sa(dp3250
g7
I21
sg8
VP49918
p3251
sg10
I7
sg11
Velastin
p3252
sg13
I1
sa(dp3253
g7
I300
sg8
VP35555
p3254
sg10
I11
sg11
Vfibrillin-1
p3255
sg13
I1
sasg20
(lp3256
(dp3257
g7
I258
sg23
VC0024796
p3258
sg10
I15
sg11
VMarfan syndrome
p3259
sg13
I2
sa(dp3260
g7
I142
sg23
VC0003499
p3261
sg10
I29
sg11
Vsupravalvular aortic stenosis
p3262
sg13
I3
sa(dp3263
g7
I176
sg23
VC0175702
p3264
sg10
I24
sg11
VWilliams Beuren syndrome
p3265
sg13
I3
sa(dp3266
g7
I245
sg23
VC1261287
p3267
sg10
I8
sg11
Vstenoses
p3268
sg13
I1
sa(dp3269
g7
I350
sg23
VC0003486
p3270
sg10
I16
sg11
Vaortic aneurysms
p3271
sg13
I2
sasa(dp3272
g2
S'Even though elastin and fibrillin-1 are the major structural components of elastic fibers, mutations in elastin and fibrillin-1 lead to narrowing of large arteries in supravalvular aortic stenosis and dilation of the ascending aorta in Marfan syndrome, respectively.\n'
p3273
sg4
(lp3274
(dp3275
g7
I24
sg8
VP35555
p3276
sg10
I11
sg11
Vfibrillin-1
p3277
sg13
I1
sa(dp3278
g7
I12
sg8
VP49918
p3279
sg10
I7
sg11
Velastin
p3280
sg13
I1
sa(dp3281
g7
I24
sg8
VP35555
p3282
sg10
I11
sg11
Vfibrillin-1
p3283
sg13
I1
sa(dp3284
g7
I12
sg8
VP49918
p3285
sg10
I7
sg11
Velastin
p3286
sg13
I1
sasg20
(lp3287
(dp3288
g7
I236
sg23
VC0024796
p3289
sg10
I15
sg11
VMarfan syndrome
p3290
sg13
I2
sa(dp3291
g7
I167
sg23
VC0003499
p3292
sg10
I29
sg11
Vsupravalvular aortic stenosis
p3293
sg13
I3
sa(dp3294
g7
I201
sg23
VC0012359
p3295
sg10
I8
sg11
Vdilation
p3296
sg13
I1
sasa(dp3297
g2
S'Immunoperoxidase examination of the skin biopsy specimens from patients with atopic dermatitis and psoriasis revealed enhanced expression of amphiregulin, NGF, and PGP9.5, appearance of positively stained epidermal nerve fibers, and decreased expression of the nerve reduction factor semaphorin 3A in all cases.\n'
p3298
sg4
(lp3299
(dp3300
g7
I155
sg8
VP01138
p3301
sg10
I3
sg11
VNGF
p3302
sg13
I1
sa(dp3303
g7
I261
sg8
g39
sg10
I36
sg11
Vnerve reduction factor semaphorin 3A
p3304
sg13
I5
sa(dp3305
g7
I141
sg8
VP15514
p3306
sg10
I12
sg11
Vamphiregulin
p3307
sg13
I1
sa(dp3308
g7
I0
sg8
g39
sg10
I16
sg11
VImmunoperoxidase
p3309
sg13
I1
sasg20
(lp3310
(dp3311
g7
I99
sg23
VC0033860
p3312
sg10
I9
sg11
Vpsoriasis
p3313
sg13
I1
sa(dp3314
g7
I77
sg23
VC0011615
p3315
sg10
I17
sg11
Vatopic dermatitis
p3316
sg13
I2
sasa(dp3317
g2
S'Expression of neural marker PGP9.5, amphiregulin, semaphorin-3A, calcitonin gene-related peptide and its receptor, nerve growth factor and its receptor, substance P and its receptor, and expression frequency were analyzed in biopsy specimens from patients with atopic dermatitis and psoriasis and healthy volunteers by immunohistochemical method.\n'
p3318
sg4
(lp3319
(dp3320
g7
I50
sg8
g39
sg10
I13
sg11
Vsemaphorin-3A
p3321
sg13
I1
sa(dp3322
g7
I115
sg8
VP01138
p3323
sg10
I19
sg11
Vnerve growth factor
p3324
sg13
I3
sa(dp3325
g7
I28
sg8
VP09936
p3326
sg10
I6
sg11
VPGP9.5
p3327
sg13
I1
sa(dp3328
g7
I65
sg8
VP06881
p3329
sg10
I31
sg11
Vcalcitonin gene-related peptide
p3330
sg13
I3
sa(dp3331
g7
I36
sg8
VP15514
p3332
sg10
I12
sg11
Vamphiregulin
p3333
sg13
I1
sasg20
(lp3334
(dp3335
g7
I261
sg23
VC0011615
p3336
sg10
I17
sg11
Vatopic dermatitis
p3337
sg13
I2
sa(dp3338
g7
I283
sg23
VC0033860
p3339
sg10
I9
sg11
Vpsoriasis
p3340
sg13
I1
sasa(dp3341
g2
S'Expression of semaphorin-3A in patients with atopic dermatitis was less frequent than in the control.\n'
p3342
sg4
(lp3343
(dp3344
g7
I14
sg8
g39
sg10
I13
sg11
Vsemaphorin-3A
p3345
sg13
I1
sasg20
(lp3346
(dp3347
g7
I45
sg23
VC0011615
p3348
sg10
I17
sg11
Vatopic dermatitis
p3349
sg13
I2
sasa(dp3350
g2
S'We also show how sema3A plays a role in the pathogenesis of allergic rhinitis and atopic dermatitis.\n'
p3351
sg4
(lp3352
(dp3353
g7
I17
sg8
g39
sg10
I6
sg11
Vsema3A
p3354
sg13
I1
sasg20
(lp3355
(dp3356
g7
I60
sg23
VC2607914
p3357
sg10
I17
sg11
Vallergic rhinitis
p3358
sg13
I2
sa(dp3359
g7
I82
sg23
VC0011615
p3360
sg10
I17
sg11
Vatopic dermatitis
p3361
sg13
I2
sa(dp3362
g7
I44
sg23
VC0699748
p3363
sg10
I12
sg11
Vpathogenesis
p3364
sg13
I1
sasa(dp3365
g2
S'Thus, the mechanism by which high levels of km23-1 suppress ovarian carcinoma growth in vitro and inhibit ovary tumor formation in vivo appears to involve a BubR1-related mitotic delay.\n'
p3366
sg4
(lp3367
sg20
(lp3368
(dp3369
g7
I106
sg23
VC0919267
p3370
sg10
I11
sg11
Vovary tumor
p3371
sg13
I2
sa(dp3372
g7
I60
sg23
VC0029925
p3373
sg10
I17
sg11
Vovarian carcinoma
p3374
sg13
I2
sasa(dp3375
g2
S'This study was designed to create an experimental varicocele model by a simple surgical procedure in dog with minimum invasion and to investigate the effect of varicocele-induced infertility on the expression of six related genes (HSP90, HSP70, IL- 4, TNF, KITLG and KIT receptor).\n'
p3376
sg4
(lp3377
(dp3378
g7
I252
sg8
VP01375
p3379
sg10
I3
sg11
VTNF
p3380
sg13
I1
sa(dp3381
g7
I231
sg8
VP07900
p3382
sg10
I5
sg11
VHSP90
p3383
sg13
I1
sa(dp3384
g7
I267
sg8
VP10721
p3385
sg10
I12
sg11
VKIT receptor
p3386
sg13
I2
sa(dp3387
g7
I257
sg8
VP21583
p3388
sg10
I5
sg11
VKITLG
p3389
sg13
I1
sa(dp3390
g7
I238
sg8
VP34932
p3391
sg10
I5
sg11
VHSP70
p3392
sg13
I1
sasg20
(lp3393
(dp3394
g7
I179
sg23
VC0021359
p3395
sg10
I11
sg11
Vinfertility
p3396
sg13
I1
sa(dp3397
g7
I118
sg23
VC2699153
p3398
sg10
I8
sg11
Vinvasion
p3399
sg13
I1
sa(dp3400
g7
I50
sg23
VC0042341
p3401
sg10
I10
sg11
Vvaricocele
p3402
sg13
I1
sa(dp3403
g7
I50
sg23
VC0042341
p3404
sg10
I10
sg11
Vvaricocele
p3405
sg13
I1
sasa(dp3406
g2
S'Expressions of HSP90, TNF, KITLG and the KIT-receptor gene were significantly downregulated (P=0.029, 0.047, 0.004 and 0.035 respectively) in varicocele-induced testes while HSP70 was upregulated (P=0.018).\n'
p3407
sg4
(lp3408
(dp3409
g7
I27
sg8
VP21583
p3410
sg10
I5
sg11
VKITLG
p3411
sg13
I1
sa(dp3412
g7
I15
sg8
VP07900
p3413
sg10
I5
sg11
VHSP90
p3414
sg13
I1
sa(dp3415
g7
I174
sg8
VP34932
p3416
sg10
I5
sg11
VHSP70
p3417
sg13
I1
sa(dp3418
g7
I22
sg8
VP01375
p3419
sg10
I3
sg11
VTNF
p3420
sg13
I1
sa(dp3421
g7
I41
sg8
VP10721
p3422
sg10
I17
sg11
VKIT-receptor gene
p3423
sg13
I2
sasg20
(lp3424
(dp3425
g7
I142
sg23
VC0042341
p3426
sg10
I10
sg11
Vvaricocele
p3427
sg13
I1
sasa(dp3428
g2
S'Subjects with high baseline levels of SCF had lower cardiovascular (n = 340) and all-cause mortality (n = 1159) as well as a lower risk of heart failure (n = 177), stroke (n = 318) and myocardial infarction (n = 452).\n'
p3429
sg4
(lp3430
(dp3431
g7
I38
sg8
VP21583
p3432
sg10
I3
sg11
VSCF
p3433
sg13
I1
sasg20
(lp3434
(dp3435
g7
I164
sg23
VC0038454
p3436
sg10
I6
sg11
Vstroke
p3437
sg13
I1
sa(dp3438
g7
I139
sg23
VC0018802
p3439
sg10
I13
sg11
Vheart failure
p3440
sg13
I2
sa(dp3441
g7
I185
sg23
VC0027051
p3442
sg10
I21
sg11
Vmyocardial infarction
p3443
sg13
I2
sasa(dp3444
g2
S'The highest SCF quartile remained independently associated with a lower risk of a lower risk of cardiovascular [hazard ratio and 95% confidence interval 0.59 (0.43-0.81)] and all-cause mortality [0.68 (0.57-0.81)], heart failure [0.50 (0.31-0.80)] and stroke [0.66 (0.47-0.92)], but not with MI [0.96 (0.72-1.27)] as compared with the lowest quartile when adjusting for traditional cardiovascular risk factors in Cox proportional hazard regression models.\n'
p3445
sg4
(lp3446
(dp3447
g7
I12
sg8
VP21583
p3448
sg10
I3
sg11
VSCF
p3449
sg13
I1
sasg20
(lp3450
(dp3451
g7
I252
sg23
VC0038454
p3452
sg10
I6
sg11
Vstroke
p3453
sg13
I1
sa(dp3454
g7
I215
sg23
VC0018802
p3455
sg10
I13
sg11
Vheart failure
p3456
sg13
I2
sasa(dp3457
g2
S'These data suggest that a stroke-damaged brain is repairable by SCF + G-CSF even 6 months after the lesion occurs.\n'
p3458
sg4
(lp3459
(dp3460
g7
I70
sg8
VP09919
p3461
sg10
I5
sg11
VG-CSF
p3462
sg13
I1
sa(dp3463
g7
I64
sg8
VP21583
p3464
sg10
I3
sg11
VSCF
p3465
sg13
I1
sasg20
(lp3466
(dp3467
g7
I26
sg23
VC0038454
p3468
sg10
I6
sg11
Vstroke
p3469
sg13
I1
sasa(dp3470
g2
S'Preload-recruitable stroke work was significantly higher in pigs after SCF treatment (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.Beta-gal, 31.6+/-12.6 mm Hg, P=0.005), indicating enhanced cardiac function.\n'
p3471
sg4
(lp3472
(dp3473
g7
I122
sg8
VP16278
p3474
sg10
I8
sg11
VBeta-gal
p3475
sg13
I1
sasg20
(lp3476
(dp3477
g7
I20
sg23
VC0038454
p3478
sg10
I6
sg11
Vstroke
p3479
sg13
I1
sasa(dp3480
g2
S'In the chronic stages, SCF gene transfer was associated with improved cardiac function in a preclinical model of ischemic cardiomyopathy.\n'
p3481
sg4
(lp3482
(dp3483
g7
I23
sg8
VP21583
p3484
sg10
I8
sg11
VSCF gene
p3485
sg13
I2
sasg20
(lp3486
(dp3487
g7
I113
sg23
VC0349782
p3488
sg10
I23
sg11
Vischemic cardiomyopathy
p3489
sg13
I2
sasa(dp3490
g2
S'Five proteins were found to be significantly upregulated in patients with allergic rhinitis (apolipoprotein A-2 [APOA2], 9.7-fold; Alfa2-macroglobulin [A2M], 4.5-fold; apolipoprotein A-1 [APOA1], 3.2-fold; Alfa1-antitrypsin [SERPINA1], 2.5-fold; and complement C3 [C3], 2.3-fold) and 5 were found to be downregulated (antileukoproteinase [SLPI], 0.6-fold; WAP 4-disulfide core domain protein [WFDC2], 0.5-fold; haptoglobin [HP], 0.7-fold; IgJ chain [IGJ], 0.7-fold; and Ig hc V-III region BRO, 0.8-fold) compared with levels seen in healthy control subjects.\n'
p3491
sg4
(lp3492
(dp3493
g7
I152
sg8
VP01023
p3494
sg10
I3
sg11
VA2M
p3495
sg13
I1
sa(dp3496
g7
I206
sg8
g39
sg10
I17
sg11
VAlfa1-antitrypsin
p3497
sg13
I1
sa(dp3498
g7
I113
sg8
VP02652
p3499
sg10
I5
sg11
VAPOA2
p3500
sg13
I1
sa(dp3501
g7
I93
sg8
VP08519
p3502
sg10
I18
sg11
Vapolipoprotein A-2
p3503
sg13
I2
sa(dp3504
g7
I250
sg8
VP01024
p3505
sg10
I13
sg11
Vcomplement C3
p3506
sg13
I2
sa(dp3507
g7
I188
sg8
VP02647
p3508
sg10
I5
sg11
VAPOA1
p3509
sg13
I1
sa(dp3510
g7
I439
sg8
VP01591
p3511
sg10
I3
sg11
VIgJ
p3512
sg13
I1
sa(dp3513
g7
I168
sg8
VP08519
p3514
sg10
I18
sg11
Vapolipoprotein A-1
p3515
sg13
I2
sa(dp3516
g7
I411
sg8
VP00738
p3517
sg10
I11
sg11
Vhaptoglobin
p3518
sg13
I1
sa(dp3519
g7
I470
sg8
VP01766
p3520
sg10
I22
sg11
VIg hc V-III region BRO
p3521
sg13
I5
sasg20
(lp3522
(dp3523
g7
I74
sg23
VC2607914
p3524
sg10
I17
sg11
Vallergic rhinitis
p3525
sg13
I2
sasa(dp3526
g2
S'The concentrations of C-reactive protein (CRP), serum amyloid A, haptoglobin (Hp) and Alfa(1)-acid glycoprotein were measured in dogs with clinical signs of nasal disease and compared with those of healthy dogs in order to determine the expression of these proteins in cases of canine nasal disease.\n'
p3527
sg4
(lp3528
(dp3529
g7
I48
sg8
VP35542
p3530
sg10
I15
sg11
Vserum amyloid A
p3531
sg13
I3
sa(dp3532
g7
I78
sg8
VP00738
p3533
sg10
I2
sg11
VHp
p3534
sg13
I1
sa(dp3535
g7
I65
sg8
VP00738
p3536
sg10
I11
sg11
Vhaptoglobin
p3537
sg13
I1
sa(dp3538
g7
I22
sg8
VP02741
p3539
sg10
I18
sg11
VC-reactive protein
p3540
sg13
I2
sa(dp3541
g7
I42
sg8
VP02741
p3542
sg10
I3
sg11
VCRP
p3543
sg13
I1
sasg20
(lp3544
(dp3545
g7
I157
sg23
VC0028432
p3546
sg10
I13
sg11
Vnasal disease
p3547
sg13
I2
sa(dp3548
g7
I157
sg23
VC0028432
p3549
sg10
I13
sg11
Vnasal disease
p3550
sg13
I2
sa(dp3551
g7
I54
sg23
VC0011560
p3552
sg10
I7
sg11
Vamyloid
p3553
sg13
I1
sasa(dp3554
g2
S'The acute phase reaction, in association with progressive atrophic rhinitis (AR), was monitored for 3 wk using serum haptoglobin (HPT) quantification in thirty-six, 15 kg swine after intranasal challenge with varying doses of Pasteurella multocida type D (toxigenic strain) and Bordetella bronchiseptica.\n'
p3555
sg4
(lp3556
(dp3557
g7
I111
sg8
VP00738
p3558
sg10
I17
sg11
Vserum haptoglobin
p3559
sg13
I2
sa(dp3560
g7
I130
sg8
VP00738
p3561
sg10
I3
sg11
VHPT
p3562
sg13
I1
sasg20
(lp3563
(dp3564
g7
I58
sg23
VC0035459
p3565
sg10
I17
sg11
Vatrophic rhinitis
p3566
sg13
I2
sa(dp3567
g7
I4
sg23
VC0001349
p3568
sg10
I20
sg11
Vacute phase reaction
p3569
sg13
I3
sa(dp3570
g7
I77
sg23
VC0035459
p3571
sg10
I2
sg11
VAR
p3572
sg13
I1
sasa(dp3573
g2
S'Recent reports on altered distribution amongst individuals with heparin-induced thrombocytopenia (HIT) prompted us to examine the Fc gammaRIIA polymorphism in a cohort of patients with refractory idiopathic (immune) thrombocytopenic purpura (ITP), in whom severe disease had required them to undergo splenectomy.\n'
p3574
sg4
(lp3575
sg20
(lp3576
(dp3577
g7
I64
sg23
VC0272285
p3578
sg10
I32
sg11
Vheparin-induced thrombocytopenia
p3579
sg13
I2
sa(dp3580
g7
I98
sg23
VC0272285
p3581
sg10
I3
sg11
VHIT
p3582
sg13
I1
sa(dp3583
g7
I242
sg23
VC0043117
p3584
sg10
I3
sg11
VITP
p3585
sg13
I1
sa(dp3586
g7
I216
sg23
VC0857305
p3587
sg10
I24
sg11
Vthrombocytopenic purpura
p3588
sg13
I2
sasa(dp3589
g2
S'Fluorine- 18-FDG PET/CT can be used for treatment response evaluation of angiomyolipoma treated with mTOR-inhibitors.\n'
p3590
sg4
(lp3591
(dp3592
g7
I101
sg8
VP42345
p3593
sg10
I4
sg11
VmTOR
p3594
sg13
I1
sasg20
(lp3595
(dp3596
g7
I73
sg23
VC0206633
p3597
sg10
I14
sg11
Vangiomyolipoma
p3598
sg13
I1
sasa(dp3599
g2
S'International TSC guidelines recommend mammalian target of rapamycin (mTOR) inhibitors as first-line therapy for management of asymptomatic, growing angiomyolipomas &gt;3 cm in diameter.\n'
p3600
sg4
(lp3601
(dp3602
g7
I70
sg8
VP42345
p3603
sg10
I4
sg11
VmTOR
p3604
sg13
I1
sa(dp3605
g7
I39
sg8
VP42345
p3606
sg10
I29
sg11
Vmammalian target of rapamycin
p3607
sg13
I4
sasg20
(lp3608
(dp3609
g7
I14
sg23
VC0041341
p3610
sg10
I3
sg11
VTSC
p3611
sg13
I1
sa(dp3612
g7
I149
sg23
VC0206633
p3613
sg10
I15
sg11
Vangiomyolipomas
p3614
sg13
I1
sasa(dp3615
g2
S'This review discusses data regarding patient outcomes that were used to develop current guidelines for embolization of renal angiomyolipomas and presents recent data on 2 available mTOR inhibitors - sirolimus and everolimus - in the treatment of angiomyolipoma.\n'
p3616
sg4
(lp3617
(dp3618
g7
I181
sg8
VP42345
p3619
sg10
I4
sg11
VmTOR
p3620
sg13
I1
sasg20
(lp3621
(dp3622
g7
I125
sg23
VC0206633
p3623
sg10
I14
sg11
Vangiomyolipoma
p3624
sg13
I1
sa(dp3625
g7
I125
sg23
VC0206633
p3626
sg10
I15
sg11
Vangiomyolipomas
p3627
sg13
I1
sasa(dp3628
g2
S'The authors propose a hypothesis for mTORC1 haploinsufficiency as an additional mechanism for CKD and propose that preventive therapy with mTOR inhibitors might have a role in reducing the number of angiomyolipoma-related deaths.\n'
p3629
sg4
(lp3630
(dp3631
g7
I37
sg8
VP42345
p3632
sg10
I4
sg11
VmTOR
p3633
sg13
I1
sa(dp3634
g7
I199
sg8
VP41212
p3635
sg10
I29
sg11
Vangiomyolipoma-related deaths
p3636
sg13
I2
sasg20
(lp3637
(dp3638
g7
I199
sg23
VC0206633
p3639
sg10
I14
sg11
Vangiomyolipoma
p3640
sg13
I1
sasa(dp3641
g2
S'Based on recent evidence, new guidelines should be considered that support the earlier initiation of mTOR inhibitor therapy for the management of renal angiomyolipomas to prevent future serious complications, rather than try to rescue patients after the complications have occurred.\n'
p3642
sg4
(lp3643
(dp3644
g7
I101
sg8
VP42345
p3645
sg10
I4
sg11
VmTOR
p3646
sg13
I1
sasg20
(lp3647
(dp3648
g7
I152
sg23
VC0206633
p3649
sg10
I15
sg11
Vangiomyolipomas
p3650
sg13
I1
sasa(dp3651
g2
S'The exosome-mediated mechanisms may also operate in the cells of angiomyolipoma (AML), which develops as a result of mutations in TSC1/TSC2 genes in TSC patients, because we observed the reactivation of mammalian target of rapamycin and Notch pathways, driven by the delivery of Rheb and Notch1 esRNA, in AML cells depleted of Rheb that were treated with the exosomes purified from AML cells with the constitutively high Rheb levels.\n'
p3652
sg4
(lp3653
(dp3654
g7
I288
sg8
VP46531
p3655
sg10
I12
sg11
VNotch1 esRNA
p3656
sg13
I2
sa(dp3657
g7
I65
sg8
VP41212
p3658
sg10
I20
sg11
Vangiomyolipoma (AML)
p3659
sg13
I2
sa(dp3660
g7
I130
sg8
g39
sg10
I4
sg11
VTSC1
p3661
sg13
I1
sa(dp3662
g7
I135
sg8
VP49815
p3663
sg10
I10
sg11
VTSC2 genes
p3664
sg13
I2
sa(dp3665
g7
I279
sg8
g39
sg10
I4
sg11
VRheb
p3666
sg13
I1
sa(dp3667
g7
I279
sg8
g39
sg10
I4
sg11
VRheb
p3668
sg13
I1
sa(dp3669
g7
I279
sg8
g39
sg10
I4
sg11
VRheb
p3670
sg13
I1
sasg20
(lp3671
(dp3672
g7
I135
sg23
VC1860707
p3673
sg10
I4
sg11
VTSC2
p3674
sg13
I1
sa(dp3675
g7
I81
sg23
VC0023467
p3676
sg10
I3
sg11
VAML
p3677
sg13
I1
sa(dp3678
g7
I81
sg23
VC0023467
p3679
sg10
I3
sg11
VAML
p3680
sg13
I1
sa(dp3681
g7
I65
sg23
VC0206633
p3682
sg10
I14
sg11
Vangiomyolipoma
p3683
sg13
I1
sa(dp3684
g7
I130
sg23
VC1854465
p3685
sg10
I4
sg11
VTSC1
p3686
sg13
I1
sa(dp3687
g7
I81
sg23
VC0023467
p3688
sg10
I3
sg11
VAML
p3689
sg13
I1
sa(dp3690
g7
I130
sg23
VC0041341
p3691
sg10
I3
sg11
VTSC
p3692
sg13
I1
sasa(dp3693
g2
S'Mammalian target of rapamycin (mTOR) inhibitors are recommended as first-line treatment of renal angiomyolipoma associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sporadic LAM), but follow-up is limited.\n'
p3694
sg4
(lp3695
(dp3696
g7
I31
sg8
VP42345
p3697
sg10
I4
sg11
VmTOR
p3698
sg13
I1
sa(dp3699
g7
I0
sg8
VP42345
p3700
sg10
I29
sg11
VMammalian target of rapamycin
p3701
sg13
I4
sasg20
(lp3702
(dp3703
g7
I208
sg23
VC0751674
p3704
sg10
I3
sg11
VLAM
p3705
sg13
I1
sa(dp3706
g7
I173
sg23
VC0751674
p3707
sg10
I24
sg11
Vlymphangioleiomyomatosis
p3708
sg13
I1
sa(dp3709
g7
I128
sg23
VC0041341
p3710
sg10
I26
sg11
Vtuberous sclerosis complex
p3711
sg13
I3
sa(dp3712
g7
I156
sg23
VC0041341
p3713
sg10
I3
sg11
VTSC
p3714
sg13
I1
sa(dp3715
g7
I91
sg23
VC0241961
p3716
sg10
I20
sg11
Vrenal angiomyolipoma
p3717
sg13
I2
sasa(dp3718
g2
S"These data indicate that the GluN2B and GluN2D NMDA receptor subunits contribute to synaptic activity in the STN and may represent potential therapeutic targets for modulating subthalamic neuron activity in neurological disorders such as Parkinson's disease.\n"
p3719
sg4
(lp3720
(dp3721
g7
I40
sg8
g39
sg10
I29
sg11
VGluN2D NMDA receptor subunits
p3722
sg13
I4
sasg20
(lp3723
(dp3724
g7
I207
sg23
VC0027765
p3725
sg10
I22
sg11
Vneurological disorders
p3726
sg13
I2
sa(dp3727
g7
I238
sg23
VC0030567
p3728
sg10
I19
sg11
VParkinson's disease
p3729
sg13
I2
sasa(dp3730
g2
S"We have also examined whether this function of GluN2D-containing NMDARs is altered in a mouse model of Parkinson's disease.\n"
p3731
sg4
(lp3732
sg20
(lp3733
(dp3734
g7
I103
sg23
VC0030567
p3735
sg10
I19
sg11
VParkinson's disease
p3736
sg13
I2
sasa(dp3737
g2
S"GluN2D might constitute an attractive target for the development of novel pharmacological tools for therapeutic intervention in Parkinson's disease.\n"
p3738
sg4
(lp3739
sg20
(lp3740
(dp3741
g7
I128
sg23
VC0030567
p3742
sg10
I19
sg11
VParkinson's disease
p3743
sg13
I2
sasa(dp3744
g2
S'A stratification by results of the DRE (1 = normal, 2 = benign prostatic hyperplasia, 3 = prostate cancer suspected) yielded the following values: DRE 1: 2.40 versus 2.47; DRE 2: 2.99 versus 2.75; DRE 3: 3.64 versus 3.81; the difference was not significant for all three groups.\n'
p3745
sg4
(lp3746
sg20
(lp3747
(dp3748
g7
I90
sg23
VC0600139
p3749
sg10
I15
sg11
Vprostate cancer
p3750
sg13
I2
sa(dp3751
g7
I56
sg23
VC0005001
p3752
sg10
I28
sg11
Vbenign prostatic hyperplasia
p3753
sg13
I3
sasa(dp3754
g2
S'In a previous study, we showed by gene knockdown using siRNA and gene overexpression experiments that Dnaj (Hsp40) homolog, subfamily B, member 8 (DNAJB8), a role in the maintenance, of renal cell carcinoma CSCs/CICs.\n'
p3755
sg4
(lp3756
(dp3757
g7
I102
sg8
g39
sg10
I4
sg11
VDnaj
p3758
sg13
I1
sa(dp3759
g7
I108
sg8
VP25685
p3760
sg10
I5
sg11
VHsp40
p3761
sg13
I1
sa(dp3762
g7
I124
sg8
g39
sg10
I30
sg11
Vsubfamily B, member 8 (DNAJB8)
p3763
sg13
I5
sasg20
(lp3764
(dp3765
g7
I186
sg23
VC0007134
p3766
sg10
I20
sg11
Vrenal cell carcinoma
p3767
sg13
I3
sasa(dp3768
g2
S'In the present study, we established Dnajb8 knockout (KO) renal cell carcinoma (RCC) line cells (RenCa cells) and analyzed the cells to confirm the function of Dnajb8 in RCC CSCs/CICs.\n'
p3769
sg4
(lp3770
(dp3771
g7
I37
sg8
g39
sg10
I6
sg11
VDnajb8
p3772
sg13
I1
sa(dp3773
g7
I37
sg8
g39
sg10
I6
sg11
VDnajb8
p3774
sg13
I1
sasg20
(lp3775
(dp3776
g7
I80
sg23
VC0007134
p3777
sg10
I3
sg11
VRCC
p3778
sg13
I1
sa(dp3779
g7
I80
sg23
VC0007134
p3780
sg10
I3
sg11
VRCC
p3781
sg13
I1
sa(dp3782
g7
I58
sg23
VC0007134
p3783
sg10
I20
sg11
Vrenal cell carcinoma
p3784
sg13
I3
sasa(dp3785
g2
S'In this study, we show that the cancer-testis antigen and HSP40 family member DNAJB8 contributes to the CSC phenotype in renal cell carcinoma (RCC).\n'
p3786
sg4
(lp3787
(dp3788
g7
I58
sg8
VP25685
p3789
sg10
I19
sg11
VHSP40 family member
p3790
sg13
I3
sa(dp3791
g7
I32
sg8
VP15735
p3792
sg10
I21
sg11
Vcancer-testis antigen
p3793
sg13
I2
sa(dp3794
g7
I78
sg8
g39
sg10
I6
sg11
VDNAJB8
p3795
sg13
I1
sasg20
(lp3796
(dp3797
g7
I143
sg23
VC0007134
p3798
sg10
I3
sg11
VRCC
p3799
sg13
I1
sa(dp3800
g7
I121
sg23
VC0007134
p3801
sg10
I20
sg11
Vrenal cell carcinoma
p3802
sg13
I3
sa(dp3803
g7
I32
sg23
VC0006826
p3804
sg10
I6
sg11
Vcancer
p3805
sg13
I1
sasa(dp3806
g2
S'To study the effects of suppressed alpha-mannosidase Man2c1 gene expression on EC9706 human esophageal carcinoma cells, the cells were treated with short interfering RNA.\n'
p3807
sg4
(lp3808
(dp3809
g7
I35
sg8
g39
sg10
I29
sg11
Valpha-mannosidase Man2c1 gene
p3810
sg13
I3
sasg20
(lp3811
(dp3812
g7
I92
sg23
VC0152018
p3813
sg10
I20
sg11
Vesophageal carcinoma
p3814
sg13
I2
sasa(dp3815
g2
S'The data imply that induction of mitotic arrest and consequent apoptosis resulted from microtubule disorganization, which appears to be one of the major cellular mechanisms by which suppressed expression of the Man2c1 gene causes growth inhibition of EC9706 esophageal carcinoma cells.\n'
p3816
sg4
(lp3817
(dp3818
g7
I211
sg8
g39
sg10
I11
sg11
VMan2c1 gene
p3819
sg13
I2
sasg20
(lp3820
(dp3821
g7
I258
sg23
VC0152018
p3822
sg10
I20
sg11
Vesophageal carcinoma
p3823
sg13
I2
sasa(dp3824
g2
S'The result showed that the number of cases of esophageal epithelial papilloma, the average number of tumor and the incidence of esophageal cancer in the experimental group were lower than those in the control group (MANA only), though no statistical significant difference was found.\n'
p3825
sg4
(lp3826
(dp3827
g7
I216
sg8
g39
sg10
I4
sg11
VMANA
p3828
sg13
I1
sasg20
(lp3829
(dp3830
g7
I101
sg23
VC0027651
p3831
sg10
I5
sg11
Vtumor
p3832
sg13
I1
sa(dp3833
g7
I128
sg23
VC0014859
p3834
sg10
I17
sg11
Vesophageal cancer
p3835
sg13
I2
sa(dp3836
g7
I68
sg23
VC0030354
p3837
sg10
I9
sg11
Vpapilloma
p3838
sg13
I1
sasa(dp3839
g2
S'The extent of both the decrease in peroxisomal VLCS activity and the very long-chain fatty acid accumulation in the yeast FAT1 deletion model resembles that observed in cells from X-linked adrenoleukodystrophy patients.\n'
p3840
sg4
(lp3841
sg20
(lp3842
(dp3843
g7
I180
sg23
VC0162309
p3844
sg10
I29
sg11
VX-linked adrenoleukodystrophy
p3845
sg13
I2
sasa(dp3846
g2
S'PSG9 was reported as a potential predictive biomarker of pre-eclampsia, a serious complication of pregnancy that has been related to immunological dysfunction at the fetal-maternal interface.\n'
p3847
sg4
(lp3848
(dp3849
g7
I0
sg8
g39
sg10
I4
sg11
VPSG9
p3850
sg13
I1
sasg20
(lp3851
(dp3852
g7
I57
sg23
VC0032914
p3853
sg10
I13
sg11
Vpre-eclampsia
p3854
sg13
I1
sa(dp3855
g7
I82
sg23
VC0032962
p3856
sg10
I25
sg11
Vcomplication of pregnancy
p3857
sg13
I3
sasa(dp3858
g2
S'The study was designed as retrospective, and vimentin, Ki67, and CD44 expressions were evaluated by immunohistochemistry in 53 pancreatic ductal adenocarcinoma cases.\n'
p3859
sg4
(lp3860
(dp3861
g7
I55
sg8
VP46013
p3862
sg10
I4
sg11
VKi67
p3863
sg13
I1
sasg20
(lp3864
(dp3865
g7
I127
sg23
VC1335302
p3866
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p3867
sg13
I3
sasa(dp3868
g2
S'This study was purposed to analyze the methylation status of death-associated protein kinase (dapk) gene promoter in Chinese patients with acute myeloid leukemia (AML) and its relationship with clinical features.\n'
p3869
sg4
(lp3870
sg20
(lp3871
(dp3872
g7
I163
sg23
VC0023467
p3873
sg10
I3
sg11
VAML
p3874
sg13
I1
sa(dp3875
g7
I139
sg23
VC0023467
p3876
sg10
I22
sg11
Vacute myeloid leukemia
p3877
sg13
I3
sasa(dp3878
g2
S'We recently reported that both Survivin and its binding protein Borealin in the CPC complex are essential for the development of hepatocellular carcinoma, suggesting that disrupting the interaction between Survivin and Borealin would be a promising strategy.\n'
p3879
sg4
(lp3880
(dp3881
g7
I64
sg8
g39
sg10
I8
sg11
VBorealin
p3882
sg13
I1
sasg20
(lp3883
(dp3884
g7
I129
sg23
VC1512411
p3885
sg10
I24
sg11
Vhepatocellular carcinoma
p3886
sg13
I2
sasa(dp3887
g2
S'The expression levels of four CPC proteins - aurora B kinase (AURKB), borealin, inner centromere protein (INCENP), and survivin - were evaluated using immunohistochemistry in an independent cohort of NSCLC specimens.\n'
p3888
sg4
(lp3889
(dp3890
g7
I62
sg8
g39
sg10
I5
sg11
VAURKB
p3891
sg13
I1
sa(dp3892
g7
I80
sg8
g39
sg10
I24
sg11
Vinner centromere protein
p3893
sg13
I3
sa(dp3894
g7
I30
sg8
VP33981
p3895
sg10
I30
sg11
VCPC proteins - aurora B kinase
p3896
sg13
I6
sa(dp3897
g7
I106
sg8
g39
sg10
I6
sg11
VINCENP
p3898
sg13
I1
sasg20
(lp3899
(dp3900
g7
I200
sg23
VC0007131
p3901
sg10
I5
sg11
VNSCLC
p3902
sg13
I1
sasa(dp3903
g2
S'High expressions of AURKB, INCENP, and survivin, but not borealin, were associated with shorter survival in patients with NSCLC.\n'
p3904
sg4
(lp3905
(dp3906
g7
I27
sg8
g39
sg10
I6
sg11
VINCENP
p3907
sg13
I1
sa(dp3908
g7
I20
sg8
g39
sg10
I5
sg11
VAURKB
p3909
sg13
I1
sasg20
(lp3910
(dp3911
g7
I122
sg23
VC0007131
p3912
sg10
I5
sg11
VNSCLC
p3913
sg13
I1
sasa(dp3914
g2
S'In silico analysis further indicated that CDCA8 overexpressed in breast cancer tissues compared with the normal controls is significantly associated with the triple-negative phenotype.\n'
p3915
sg4
(lp3916
(dp3917
g7
I42
sg8
g39
sg10
I5
sg11
VCDCA8
p3918
sg13
I1
sasg20
(lp3919
(dp3920
g7
I65
sg23
VC0678222
p3921
sg10
I13
sg11
Vbreast cancer
p3922
sg13
I2
sasa(dp3923
g2
S'Experimentally, we performed a immunohistochemical study to detect the expression of CDCA8 in 112 breast cancer samples, and evaluated its clinicopathological and prognostic significance.\n'
p3924
sg4
(lp3925
(dp3926
g7
I85
sg8
g39
sg10
I5
sg11
VCDCA8
p3927
sg13
I1
sasg20
(lp3928
(dp3929
g7
I98
sg23
VC0678222
p3930
sg10
I13
sg11
Vbreast cancer
p3931
sg13
I2
sasa(dp3932
g2
S'We found that CDCA8 was frequently over-expressed in breast cancer tissues, and increased expression of CDCA8 was positively associated with FOXM1 expression, triple-negative phenotype and shorter overall survival.\n'
p3933
sg4
(lp3934
(dp3935
g7
I141
sg8
g39
sg10
I5
sg11
VFOXM1
p3936
sg13
I1
sa(dp3937
g7
I14
sg8
g39
sg10
I5
sg11
VCDCA8
p3938
sg13
I1
sa(dp3939
g7
I14
sg8
g39
sg10
I5
sg11
VCDCA8
p3940
sg13
I1
sasg20
(lp3941
(dp3942
g7
I53
sg23
VC0678222
p3943
sg10
I13
sg11
Vbreast cancer
p3944
sg13
I2
sasa(dp3945
g2
S'Our results suggest that FOXM1-CDCA8 signature might be involved in breast cancer progression, and serves as a potential prognostic factor and a promising therapeutical target.\n'
p3946
sg4
(lp3947
(dp3948
g7
I25
sg8
g39
sg10
I5
sg11
VFOXM1
p3949
sg13
I1
sa(dp3950
g7
I31
sg8
g39
sg10
I5
sg11
VCDCA8
p3951
sg13
I1
sasg20
(lp3952
(dp3953
g7
I75
sg23
VC0178874
p3954
sg10
I18
sg11
Vcancer progression
p3955
sg13
I2
sasa(dp3956
g2
S'The major forms of primary liver cancer are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA).\n'
p3957
sg4
(lp3958
sg20
(lp3959
(dp3960
g7
I112
sg23
VC1865926
p3961
sg10
I4
sg11
ViCCA
p3962
sg13
I1
sa(dp3963
g7
I44
sg23
VC2239176
p3964
sg10
I24
sg11
Vhepatocellular carcinoma
p3965
sg13
I2
sa(dp3966
g7
I70
sg23
VC2239176
p3967
sg10
I3
sg11
VHCC
p3968
sg13
I1
sa(dp3969
g7
I79
sg23
VC0345905
p3970
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p3971
sg13
I2
sa(dp3972
g7
I19
sg23
VC0024620
p3973
sg10
I20
sg11
Vprimary liver cancer
p3974
sg13
I3
sasa(dp3975
g2
S'Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare tumors, notably fibrolamellar carcinoma and hepatoblastoma.\n'
p3976
sg4
(lp3977
(dp3978
g7
I76
sg8
g39
sg10
I25
sg11
Vcholangiocarcinoma (iCCA)
p3979
sg13
I2
sasg20
(lp3980
(dp3981
g7
I63
sg23
VC0345905
p3982
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p3983
sg13
I2
sa(dp3984
g7
I0
sg23
VC0024620
p3985
sg10
I20
sg11
VPrimary liver cancer
p3986
sg13
I3
sa(dp3987
g7
I57
sg23
VC2239176
p3988
sg10
I3
sg11
VHCC
p3989
sg13
I1
sa(dp3990
g7
I96
sg23
VC1865926
p3991
sg10
I4
sg11
ViCCA
p3992
sg13
I1
sa(dp3993
g7
I162
sg23
VC0206624
p3994
sg10
I14
sg11
Vhepatoblastoma
p3995
sg13
I1
sa(dp3996
g7
I134
sg23
VC0334287
p3997
sg10
I23
sg11
Vfibrolamellar carcinoma
p3998
sg13
I2
sa(dp3999
g7
I31
sg23
VC2239176
p4000
sg10
I24
sg11
Vhepatocellular carcinoma
p4001
sg13
I2
sa(dp4002
g7
I118
sg23
VC0027651
p4003
sg10
I6
sg11
Vtumors
p4004
sg13
I1
sasa(dp4005
g2
S'The study group was composed of those patients who were transplanted for hepatocellular carcinoma or decompensated cirrhosis and found to have an iCCA at explant pathology.\n'
p4006
sg4
(lp4007
sg20
(lp4008
(dp4009
g7
I162
sg23
VC0677042
p4010
sg10
I9
sg11
Vpathology
p4011
sg13
I1
sa(dp4012
g7
I146
sg23
VC1865926
p4013
sg10
I4
sg11
ViCCA
p4014
sg13
I1
sa(dp4015
g7
I73
sg23
VC1512411
p4016
sg10
I24
sg11
Vhepatocellular carcinoma
p4017
sg13
I2
sa(dp4018
g7
I101
sg23
VC1619727
p4019
sg10
I23
sg11
Vdecompensated cirrhosis
p4020
sg13
I2
sasa(dp4021
g2
S'Between January 2000 and December 2013, 81 patients were found to have an iCCA at explant; 33 had separate nodules of iCCA and hepatocellular carcinoma, and 48 had only iCCA (study group).\n'
p4022
sg4
(lp4023
sg20
(lp4024
(dp4025
g7
I74
sg23
VC1865926
p4026
sg10
I4
sg11
ViCCA
p4027
sg13
I1
sa(dp4028
g7
I127
sg23
VC1512411
p4029
sg10
I24
sg11
Vhepatocellular carcinoma
p4030
sg13
I2
sa(dp4031
g7
I74
sg23
VC1865926
p4032
sg10
I4
sg11
ViCCA
p4033
sg13
I1
sa(dp4034
g7
I107
sg23
VC0028259
p4035
sg10
I7
sg11
Vnodules
p4036
sg13
I1
sa(dp4037
g7
I74
sg23
VC1865926
p4038
sg10
I4
sg11
ViCCA
p4039
sg13
I1
sasa(dp4040
g2
S'Intrahepatic cholangiocarcinoma (iCCA) is a treatment-refractory primary liver cancer with an increasing incidence and mortality worldwide in recent years.\n'
p4041
sg4
(lp4042
(dp4043
g7
I13
sg8
g39
sg10
I25
sg11
Vcholangiocarcinoma (iCCA)
p4044
sg13
I2
sasg20
(lp4045
(dp4046
g7
I33
sg23
VC1865926
p4047
sg10
I4
sg11
ViCCA
p4048
sg13
I1
sa(dp4049
g7
I0
sg23
VC0345905
p4050
sg10
I31
sg11
VIntrahepatic cholangiocarcinoma
p4051
sg13
I2
sa(dp4052
g7
I65
sg23
VC0024620
p4053
sg10
I20
sg11
Vprimary liver cancer
p4054
sg13
I3
sasa(dp4055
g2
S'In a newly diagnosed patient with acute myeloid leukemia (AML) and complex cytogenetics and negative for gene mutations associated with myeloid neoplasms, RNA sequencing by next-generation sequencing (NGS) through a large cancer-related gene panel showed ETV6-LYN leukemic fusion transcript.\n'
p4056
sg4
(lp4057
(dp4058
g7
I255
sg8
VP41212
p4059
sg10
I4
sg11
VETV6
p4060
sg13
I1
sa(dp4061
g7
I260
sg8
VP07948
p4062
sg10
I3
sg11
VLYN
p4063
sg13
I1
sasg20
(lp4064
(dp4065
g7
I222
sg23
VC0006826
p4066
sg10
I6
sg11
Vcancer
p4067
sg13
I1
sa(dp4068
g7
I144
sg23
VC0027651
p4069
sg10
I9
sg11
Vneoplasms
p4070
sg13
I1
sa(dp4071
g7
I58
sg23
VC0023467
p4072
sg10
I3
sg11
VAML
p4073
sg13
I1
sa(dp4074
g7
I34
sg23
VC0023467
p4075
sg10
I22
sg11
Vacute myeloid leukemia
p4076
sg13
I3
sasa(dp4077
g2
S'The upregulation of the Lyn/Syk-mediated PI3K p110Delta isoform in SW480 cells and the Lyn-dependent PI3K p110Alfa isoform in SW620 cells triggered fatty acid production and cell motility in IGF-1-activated colon cancer cells.\n'
p4078
sg4
(lp4079
(dp4080
g7
I28
sg8
VP43405
p4081
sg10
I3
sg11
VSyk
p4082
sg13
I1
sa(dp4083
g7
I41
sg8
g39
sg10
I22
sg11
VPI3K p110Delta isoform
p4084
sg13
I3
sa(dp4085
g7
I191
sg8
VP01343
p4086
sg10
I5
sg11
VIGF-1
p4087
sg13
I1
sa(dp4088
g7
I87
sg8
VP07948
p4089
sg10
I35
sg11
VLyn-dependent PI3K p110Alfa isoform
p4090
sg13
I4
sa(dp4091
g7
I24
sg8
VP07948
p4092
sg10
I3
sg11
VLyn
p4093
sg13
I1
sasg20
(lp4094
(dp4095
g7
I207
sg23
VC0699790
p4096
sg10
I12
sg11
Vcolon cancer
p4097
sg13
I2
sasa(dp4098
g2
S'We report here that Btk negatively regulates, through its tyrosine kinase activity, the FasL-mediated cell death in epithelial cell lines from colon cancer origin.\n'
p4099
sg4
(lp4100
(dp4101
g7
I58
sg8
VP29401
p4102
sg10
I15
sg11
Vtyrosine kinase
p4103
sg13
I2
sa(dp4104
g7
I88
sg8
VP48023
p4105
sg10
I4
sg11
VFasL
p4106
sg13
I1
sa(dp4107
g7
I20
sg8
g39
sg10
I3
sg11
VBtk
p4108
sg13
I1
sasg20
(lp4109
(dp4110
g7
I143
sg23
VC0699790
p4111
sg10
I12
sg11
Vcolon cancer
p4112
sg13
I2
sasa(dp4113
g2
S'We used a series of patient-derived three-dimensional colon cancer cultures and studied their response to stimulation with CD95 ligand (CD95L).\n'
p4114
sg4
(lp4115
(dp4116
g7
I123
sg8
VP48023
p4117
sg10
I11
sg11
VCD95 ligand
p4118
sg13
I2
sa(dp4119
g7
I136
sg8
VP48023
p4120
sg10
I5
sg11
VCD95L
p4121
sg13
I1
sasg20
(lp4122
(dp4123
g7
I54
sg23
VC0699790
p4124
sg10
I12
sg11
Vcolon cancer
p4125
sg13
I2
sasa(dp4126
g2
S'Multiple TLRs such as TLR2, TLR3, TLR4, and TLR9, as well as other receptors, can be expressed in cirrhosis and hepatocellular carcinoma.\n'
p4127
sg4
(lp4128
(dp4129
g7
I22
sg8
g39
sg10
I4
sg11
VTLR2
p4130
sg13
I1
sa(dp4131
g7
I44
sg8
g39
sg10
I4
sg11
VTLR9
p4132
sg13
I1
sa(dp4133
g7
I28
sg8
g39
sg10
I4
sg11
VTLR3
p4134
sg13
I1
sasg20
(lp4135
(dp4136
g7
I112
sg23
VC1512411
p4137
sg10
I24
sg11
Vhepatocellular carcinoma
p4138
sg13
I2
sa(dp4139
g7
I98
sg23
VC0023890
p4140
sg10
I9
sg11
Vcirrhosis
p4141
sg13
I1
sasa(dp4142
g2
S'About 53 and 85% of hepatocellular carcinoma patients frequently express TLR3 and TLR9, respectively.\n'
p4143
sg4
(lp4144
(dp4145
g7
I82
sg8
g39
sg10
I4
sg11
VTLR9
p4146
sg13
I1
sa(dp4147
g7
I73
sg8
g39
sg10
I4
sg11
VTLR3
p4148
sg13
I1
sasg20
(lp4149
(dp4150
g7
I20
sg23
VC1512411
p4151
sg10
I24
sg11
Vhepatocellular carcinoma
p4152
sg13
I2
sasa(dp4153
g2
S'Only this combination prevented subsequent tumour spread and resulted in a significantly improved survival, justifying the need for further exploration of the combination of ablative therapies and TLR9 agonists in liver cancer.\n'
p4154
sg4
(lp4155
(dp4156
g7
I197
sg8
g39
sg10
I4
sg11
VTLR9
p4157
sg13
I1
sasg20
(lp4158
(dp4159
g7
I214
sg23
VC0345904
p4160
sg10
I12
sg11
Vliver cancer
p4161
sg13
I2
sa(dp4162
g7
I43
sg23
VC0027651
p4163
sg10
I6
sg11
Vtumour
p4164
sg13
I1
sasa(dp4165
g2
S"In Myelodysplastic Syndromes (MDS) PI-PLCBeta1 has a genetic and epigenetic relevance and it is related to MDS patients' risk of Acute Myeloid Leukemia (AML) evolution.\n"
p4166
sg4
(lp4167
sg20
(lp4168
(dp4169
g7
I3
sg23
VC0033027
p4170
sg10
I25
sg11
VMyelodysplastic Syndromes
p4171
sg13
I2
sa(dp4172
g7
I30
sg23
VC0265219
p4173
sg10
I3
sg11
VMDS
p4174
sg13
I1
sa(dp4175
g7
I129
sg23
VC0023467
p4176
sg10
I22
sg11
VAcute Myeloid Leukemia
p4177
sg13
I3
sa(dp4178
g7
I153
sg23
VC0023467
p4179
sg10
I3
sg11
VAML
p4180
sg13
I1
sa(dp4181
g7
I30
sg23
VC0265219
p4182
sg10
I3
sg11
VMDS
p4183
sg13
I1
sasa(dp4184
g2
S'Investigation of the interplay between ROS, PI-PLCBeta1, and their signaling mediators in leukemia might therefore reveal innovative targets of pharmacological therapy in the treatment for leukemia.\n'
p4185
sg4
(lp4186
(dp4187
g7
I39
sg8
VP08922
p4188
sg10
I3
sg11
VROS
p4189
sg13
I1
sasg20
(lp4190
(dp4191
g7
I90
sg23
VC0023418
p4192
sg10
I8
sg11
Vleukemia
p4193
sg13
I1
sa(dp4194
g7
I90
sg23
VC0023418
p4195
sg10
I8
sg11
Vleukemia
p4196
sg13
I1
sasa(dp4197
g2
S'Phosphoinositide-phospholipase C (PI-PLC) Beta1 is involved in both genetic and epigenetic mechanisms of MDS progression to acute myeloid leukemia.\n'
p4198
sg4
(lp4199
(dp4200
g7
I34
sg8
VP51178
p4201
sg10
I6
sg11
VPI-PLC
p4202
sg13
I1
sa(dp4203
g7
I0
sg8
g39
sg10
I32
sg11
VPhosphoinositide-phospholipase C
p4204
sg13
I2
sasg20
(lp4205
(dp4206
g7
I105
sg23
VC0265219
p4207
sg10
I3
sg11
VMDS
p4208
sg13
I1
sa(dp4209
g7
I124
sg23
VC0023467
p4210
sg10
I22
sg11
Vacute myeloid leukemia
p4211
sg13
I3
sasa(dp4212
g2
S'The evidence, in a number of patients with myelodysplastic syndromes, that the mono-allelic deletion of PLCBeta1 is associated with an increased risk of developing acute myeloid leukemia paves the way for an entirely new field of investigation.\n'
p4213
sg4
(lp4214
sg20
(lp4215
(dp4216
g7
I164
sg23
VC0023467
p4217
sg10
I22
sg11
Vacute myeloid leukemia
p4218
sg13
I3
sa(dp4219
g7
I43
sg23
VC0033027
p4220
sg10
I25
sg11
Vmyelodysplastic syndromes
p4221
sg13
I2
sa(dp4222
g7
I79
sg23
VC0021345
p4223
sg10
I4
sg11
Vmono
p4224
sg13
I1
sasa(dp4225
g2
S'Indeed, the recent discovery of a possible involvement of the interstitial deletion of PLCbeta1 gene in the progression of myelodysplastic syndrome (MDS) to acute myeloid leukemia in humans (AML) strengthens this contention.\n'
p4226
sg4
(lp4227
sg20
(lp4228
(dp4229
g7
I123
sg23
VC3463824
p4230
sg10
I24
sg11
Vmyelodysplastic syndrome
p4231
sg13
I2
sa(dp4232
g7
I157
sg23
VC0023467
p4233
sg10
I32
sg11
Vacute myeloid leukemia in humans
p4234
sg13
I5
sa(dp4235
g7
I149
sg23
VC0265219
p4236
sg10
I3
sg11
VMDS
p4237
sg13
I1
sa(dp4238
g7
I191
sg23
VC0023467
p4239
sg10
I3
sg11
VAML
p4240
sg13
I1
sasa(dp4241
g2
S"The current study aims at investigating the role of functional polymorphisms in the 5'UTR (c.-52G&gt;A, c.-44G&gt;C and c.-20G&gt;A) of DEFB1 gene, encoding for the antimicrobial peptide human beta-defensin 1, in the predisposition to recurrent tonsillitis in children from North Eastern Italy.\n"
p4242
sg4
(lp4243
(dp4244
g7
I165
sg8
VP60022
p4245
sg10
I43
sg11
Vantimicrobial peptide human beta-defensin 1
p4246
sg13
I5
sa(dp4247
g7
I136
sg8
VP60022
p4248
sg10
I10
sg11
VDEFB1 gene
p4249
sg13
I2
sasg20
(lp4250
(dp4251
g7
I245
sg23
VC0040425
p4252
sg10
I11
sg11
Vtonsillitis
p4253
sg13
I1
sasa(dp4254
g2
S'No significant correlation was found between DEFB1 allele, genotype and haplotype frequencies and recurrent tonsillitis susceptibility with the exception of an increased risk to disease development in patients carrying DEFB1 rare haplotypes.\n'
p4255
sg4
(lp4256
(dp4257
g7
I45
sg8
VP60022
p4258
sg10
I12
sg11
VDEFB1 allele
p4259
sg13
I2
sa(dp4260
g7
I45
sg8
VP60022
p4261
sg10
I5
sg11
VDEFB1
p4262
sg13
I1
sasg20
(lp4263
(dp4264
g7
I108
sg23
VC0040425
p4265
sg10
I11
sg11
Vtonsillitis
p4266
sg13
I1
sasa(dp4267
g2
S'Our results may suggest that DEFB1 polymorphisms alone may not influence pathology susceptibility, however they could possibly concur, together with other factors involved in the genetic control of innate immune system, in the predisposition towards recurrent tonsillitis.\n'
p4268
sg4
(lp4269
(dp4270
g7
I29
sg8
VP60022
p4271
sg10
I5
sg11
VDEFB1
p4272
sg13
I1
sasg20
(lp4273
(dp4274
g7
I260
sg23
VC0040425
p4275
sg10
I11
sg11
Vtonsillitis
p4276
sg13
I1
sa(dp4277
g7
I73
sg23
VC0677042
p4278
sg10
I9
sg11
Vpathology
p4279
sg13
I1
sasa(dp4280
g2
S'The aim of this study was to investigate the association between beta defensin 1 gene single nucleotide polymorphisms and chronic tonsillitis.\n'
p4281
sg4
(lp4282
(dp4283
g7
I65
sg8
VP60022
p4284
sg10
I20
sg11
Vbeta defensin 1 gene
p4285
sg13
I4
sasg20
(lp4286
(dp4287
g7
I122
sg23
VC0149517
p4288
sg10
I19
sg11
Vchronic tonsillitis
p4289
sg13
I2
sasa(dp4290
g2
S'In this study, we found that DEFB1 gene -20G/A, -44C/G and -52G/A single nucleotide polymorphisms were not associated with chronic tonsillitis.\n'
p4291
sg4
(lp4292
(dp4293
g7
I29
sg8
VP60022
p4294
sg10
I15
sg11
VDEFB1 gene -20G
p4295
sg13
I3
sasg20
(lp4296
(dp4297
g7
I123
sg23
VC0149517
p4298
sg10
I19
sg11
Vchronic tonsillitis
p4299
sg13
I2
sasa(dp4300
g2
S'Studies, which analyse other polymorphism of the beta defensin 1 gene in large case series, should be conducted to understand the role of DEFB1 gene on chronic tonsillitis.\n'
p4301
sg4
(lp4302
(dp4303
g7
I49
sg8
VP60022
p4304
sg10
I20
sg11
Vbeta defensin 1 gene
p4305
sg13
I4
sa(dp4306
g7
I138
sg8
VP60022
p4307
sg10
I10
sg11
VDEFB1 gene
p4308
sg13
I2
sasg20
(lp4309
(dp4310
g7
I152
sg23
VC0149517
p4311
sg10
I19
sg11
Vchronic tonsillitis
p4312
sg13
I2
sasa(dp4313
g2
S'Microarray analyses of sinus mucosa in pediatric patients with chronic rhinosinusitis (CRS) have recently demonstrated increased messenger RNA expression of the inflammatory chemokines CXCL5 and CXCL13 and of the innate immune mediators Beta-defensin 1 (DEFB1), serum amyloid A2 (SAA2), and serpin B4.\n'
p4314
sg4
(lp4315
(dp4316
g7
I291
sg8
VP48594
p4317
sg10
I9
sg11
Vserpin B4
p4318
sg13
I2
sa(dp4319
g7
I185
sg8
VP42830
p4320
sg10
I5
sg11
VCXCL5
p4321
sg13
I1
sa(dp4322
g7
I262
sg8
g39
sg10
I16
sg11
Vserum amyloid A2
p4323
sg13
I3
sa(dp4324
g7
I237
sg8
VP60022
p4325
sg10
I15
sg11
VBeta-defensin 1
p4326
sg13
I2
sa(dp4327
g7
I254
sg8
VP60022
p4328
sg10
I5
sg11
VDEFB1
p4329
sg13
I1
sa(dp4330
g7
I195
sg8
g39
sg10
I6
sg11
VCXCL13
p4331
sg13
I1
sa(dp4332
g7
I280
sg8
g39
sg10
I4
sg11
VSAA2
p4333
sg13
I1
sasg20
(lp4334
(dp4335
g7
I87
sg23
VC0010278
p4336
sg10
I3
sg11
VCRS
p4337
sg13
I1
sa(dp4338
g7
I23
sg23
VC0016169
p4339
sg10
I5
sg11
Vsinus
p4340
sg13
I1
sa(dp4341
g7
I268
sg23
VC0011560
p4342
sg10
I7
sg11
Vamyloid
p4343
sg13
I1
sa(dp4344
g7
I63
sg23
VC0149516
p4345
sg10
I22
sg11
Vchronic rhinosinusitis
p4346
sg13
I2
sasa(dp4347
g2
S'Our aim was to investigate HBD1-3 in tonsillar tissue and their potential role in allergic rhinitis (AR).\n'
p4348
sg4
(lp4349
(dp4350
g7
I27
sg8
VP60022
p4351
sg10
I6
sg11
VHBD1-3
p4352
sg13
I1
sasg20
(lp4353
(dp4354
g7
I101
sg23
VC2607914
p4355
sg10
I2
sg11
VAR
p4356
sg13
I1
sa(dp4357
g7
I82
sg23
VC2607914
p4358
sg10
I17
sg11
Vallergic rhinitis
p4359
sg13
I2
sasa(dp4360
g2
S'hBD-1 and hBD-2 were expressed in both normal and chronic sinusitis mucosa, but the expression levels varied significantly between the individuals.\n'
p4361
sg4
(lp4362
(dp4363
g7
I10
sg8
g39
sg10
I5
sg11
VhBD-2
p4364
sg13
I1
sa(dp4365
g7
I0
sg8
VP60022
p4366
sg10
I5
sg11
VhBD-1
p4367
sg13
I1
sasg20
(lp4368
(dp4369
g7
I0
sg23
VC1840321
p4370
sg10
I3
sg11
VhBD
p4371
sg13
I1
sa(dp4372
g7
I50
sg23
VC0149516
p4373
sg10
I17
sg11
Vchronic sinusitis
p4374
sg13
I2
sa(dp4375
g7
I0
sg23
VC1840321
p4376
sg10
I3
sg11
VhBD
p4377
sg13
I1
sasa(dp4378
g2
S'To determine the frequency of mitochondrial DNA depletion syndrome (MDS) in infants with cholestasis and liver failure and to further clarify the clinical, biochemical, radiologic, histopathologic, and molecular features associated with MDS due to deoxyguanosine kinase (DGUOK) and MPV17 gene mutations.\n'
p4379
sg4
(lp4380
(dp4381
g7
I271
sg8
g39
sg10
I5
sg11
VDGUOK
p4382
sg13
I1
sa(dp4383
g7
I248
sg8
g39
sg10
I21
sg11
Vdeoxyguanosine kinase
p4384
sg13
I2
sa(dp4385
g7
I282
sg8
VP39210
p4386
sg10
I10
sg11
VMPV17 gene
p4387
sg13
I2
sasg20
(lp4388
(dp4389
g7
I105
sg23
VC0085605
p4390
sg10
I13
sg11
Vliver failure
p4391
sg13
I2
sa(dp4392
g7
I30
sg23
VC0265219
p4393
sg10
I36
sg11
Vmitochondrial DNA depletion syndrome
p4394
sg13
I4
sa(dp4395
g7
I68
sg23
VC0265219
p4396
sg10
I3
sg11
VMDS
p4397
sg13
I1
sa(dp4398
g7
I68
sg23
VC0265219
p4399
sg10
I3
sg11
VMDS
p4400
sg13
I1
sa(dp4401
g7
I89
sg23
VC0008370
p4402
sg10
I11
sg11
Vcholestasis
p4403
sg13
I1
sasa(dp4404
g2
S'We identified pathogenic MPV17 and DGUOK mutations in 11 infants (6 females) representing 2.5% of the 450 cases of infantile cholestasis and 22% of the 50 cases of infantile liver failure referred to our center during the study period.\n'
p4405
sg4
(lp4406
(dp4407
g7
I35
sg8
g39
sg10
I5
sg11
VDGUOK
p4408
sg13
I1
sa(dp4409
g7
I14
sg8
VP39210
p4410
sg10
I16
sg11
Vpathogenic MPV17
p4411
sg13
I2
sasg20
(lp4412
(dp4413
g7
I125
sg23
VC0008370
p4414
sg10
I11
sg11
Vcholestasis
p4415
sg13
I1
sa(dp4416
g7
I174
sg23
VC0085605
p4417
sg10
I13
sg11
Vliver failure
p4418
sg13
I2
sasa(dp4419
g2
S'Mitochondrial DNA depletion seen in Navajo neurohepatopathy and in respiratory chain disorders of infancy was associated with cholestasis and cirrhosis in the former and microvesicular steatosis and oncocytic transformation (mitochondrial hyperplasia) in the latter.\n'
p4420
sg4
(lp4421
sg20
(lp4422
(dp4423
g7
I36
sg23
VC1850406
p4424
sg10
I23
sg11
VNavajo neurohepatopathy
p4425
sg13
I2
sa(dp4426
g7
I0
sg23
VC0342782
p4427
sg10
I27
sg11
VMitochondrial DNA depletion
p4428
sg13
I3
sa(dp4429
g7
I225
sg23
VC0544933
p4430
sg10
I25
sg11
Vmitochondrial hyperplasia
p4431
sg13
I2
sa(dp4432
g7
I126
sg23
VC0008370
p4433
sg10
I11
sg11
Vcholestasis
p4434
sg13
I1
sa(dp4435
g7
I142
sg23
VC0023890
p4436
sg10
I9
sg11
Vcirrhosis
p4437
sg13
I1
sa(dp4438
g7
I185
sg23
VC0152254
p4439
sg10
I9
sg11
Vsteatosis
p4440
sg13
I1
sa(dp4441
g7
I209
sg23
VC1510411
p4442
sg10
I14
sg11
Vtransformation
p4443
sg13
I1
sasa(dp4444
g2
S'The results revealed the panels of immunohistochemical markers for the differential diagnosis of rectal adenocarcinoma, in which [+] designates positivity in rectal adenocarcinoma and [-] designates negativity in rectal adenocarcinoma: from bladder adenocarcinoma, CDX2[+], VIL1[+], KRT7[-], THBD[-] and UPK3A[-]; from prostate adenocarcinoma, CDX2[+], VIL1[+], CEACAM5[+], KLK3(PSA)[-], ACPP(PAP)[-] and SLC45A3(prostein)[-]; and from ovarian mucinous adenocarcinoma, CEACAM5[+], VIL1[+], CDX2[+], KRT7[-] and MUC5AC[-].\n'
p4445
sg4
(lp4446
(dp4447
g7
I379
sg8
VP55786
p4448
sg10
I3
sg11
VPSA
p4449
sg13
I1
sa(dp4450
g7
I374
sg8
VP03952
p4451
sg10
I4
sg11
VKLK3
p4452
sg13
I1
sa(dp4453
g7
I393
sg8
g39
sg10
I3
sg11
VPAP
p4454
sg13
I1
sa(dp4455
g7
I405
sg8
g39
sg10
I7
sg11
VSLC45A3
p4456
sg13
I1
sa(dp4457
g7
I490
sg8
g39
sg10
I16
sg11
VCDX2[+], KRT7[-]
p4458
sg13
I2
sa(dp4459
g7
I344
sg8
g39
sg10
I28
sg11
VCDX2[+], VIL1[+], CEACAM5[+]
p4460
sg13
I3
sa(dp4461
g7
I265
sg8
g39
sg10
I47
sg11
VCDX2[+], VIL1[+], KRT7[-], THBD[-] and UPK3A[-]
p4462
sg13
I6
sa(dp4463
g7
I453
sg8
g39
sg10
I35
sg11
Vadenocarcinoma, CEACAM5[+], VIL1[+]
p4464
sg13
I3
sa(dp4465
g7
I388
sg8
VP15309
p4466
sg10
I4
sg11
VACPP
p4467
sg13
I1
sasg20
(lp4468
(dp4469
g7
I379
sg23
VC1519176
p4470
sg10
I3
sg11
VPSA
p4471
sg13
I1
sa(dp4472
g7
I393
sg23
VC1863340
p4473
sg10
I3
sg11
VPAP
p4474
sg13
I1
sa(dp4475
g7
I319
sg23
VC0007112
p4476
sg10
I23
sg11
Vprostate adenocarcinoma
p4477
sg13
I2
sa(dp4478
g7
I97
sg23
VC0149978
p4479
sg10
I21
sg11
Vrectal adenocarcinoma
p4480
sg13
I2
sa(dp4481
g7
I436
sg23
VC1335167
p4482
sg10
I31
sg11
Vovarian mucinous adenocarcinoma
p4483
sg13
I3
sa(dp4484
g7
I97
sg23
VC0149978
p4485
sg10
I21
sg11
Vrectal adenocarcinoma
p4486
sg13
I2
sa(dp4487
g7
I97
sg23
VC0149978
p4488
sg10
I21
sg11
Vrectal adenocarcinoma
p4489
sg13
I2
sa(dp4490
g7
I241
sg23
VC0279682
p4491
sg10
I22
sg11
Vbladder adenocarcinoma
p4492
sg13
I2
sasa(dp4493
g2
S'Long-term survival estimated by log-rank test was negatively impacted by anemia (hemoglobin &lt;10 mg/dl), low serum albumin, emergent/urgent operation, and infective endocarditis.\n'
p4494
sg4
(lp4495
(dp4496
g7
I117
sg8
VP00441
p4497
sg10
I7
sg11
Valbumin
p4498
sg13
I1
sa(dp4499
g7
I81
sg8
g39
sg10
I10
sg11
Vhemoglobin
p4500
sg13
I1
sasg20
(lp4501
(dp4502
g7
I61
sg23
VC0040456
p4503
sg10
I8
sg11
Vimpacted
p4504
sg13
I1
sa(dp4505
g7
I73
sg23
VC0002871
p4506
sg10
I6
sg11
Vanemia
p4507
sg13
I1
sa(dp4508
g7
I157
sg23
VC0014121
p4509
sg10
I22
sg11
Vinfective endocarditis
p4510
sg13
I2
sasa(dp4511
g2
S'Less common syndromes that are associated with ST are; Fabry Disease, Ellis-van Creveld syndrome, Nance-Horan syndrome, Rubinstein-Taybi Syndrome and Trico-Rhino-Phalangeal syndrome.\n'
p4512
sg4
(lp4513
sg20
(lp4514
(dp4515
g7
I137
sg23
VC0039082
p4516
sg10
I8
sg11
VSyndrome
p4517
sg13
I1
sa(dp4518
g7
I55
sg23
VC0002986
p4519
sg10
I13
sg11
VFabry Disease
p4520
sg13
I2
sa(dp4521
g7
I12
sg23
VC0039082
p4522
sg10
I9
sg11
Vsyndromes
p4523
sg13
I1
sa(dp4524
g7
I110
sg23
VC0035934
p4525
sg10
I26
sg11
Vsyndrome, Rubinstein-Taybi
p4526
sg13
I2
sa(dp4527
g7
I70
sg23
VC0013903
p4528
sg10
I26
sg11
VEllis-van Creveld syndrome
p4529
sg13
I3
sa(dp4530
g7
I12
sg23
VC0039082
p4531
sg10
I8
sg11
Vsyndrome
p4532
sg13
I1
sasa(dp4533
g2
S'The occurrence of multiple supernumerary teeth is often found in association with syndromes such as Gardner syndrome, Anderson-Fabry disease, Ellis-van Creveld syndrome, Ehlers-Danlos syndrome, incontinentia pigmenti, and Tricho-rhino-phalangeal syndrome.\n'
p4534
sg4
(lp4535
sg20
(lp4536
(dp4537
g7
I100
sg23
VC0017097
p4538
sg10
I16
sg11
VGardner syndrome
p4539
sg13
I2
sa(dp4540
g7
I160
sg23
VC0013720
p4541
sg10
I23
sg11
Vsyndrome, Ehlers-Danlos
p4542
sg13
I2
sa(dp4543
g7
I194
sg23
VC2930820
p4544
sg10
I22
sg11
Vincontinentia pigmenti
p4545
sg13
I2
sa(dp4546
g7
I82
sg23
VC0039082
p4547
sg10
I8
sg11
Vsyndrome
p4548
sg13
I1
sa(dp4549
g7
I170
sg23
VC0013720
p4550
sg10
I22
sg11
VEhlers-Danlos syndrome
p4551
sg13
I2
sa(dp4552
g7
I82
sg23
VC0039082
p4553
sg10
I9
sg11
Vsyndromes
p4554
sg13
I1
sa(dp4555
g7
I142
sg23
VC0013903
p4556
sg10
I26
sg11
VEllis-van Creveld syndrome
p4557
sg13
I3
sa(dp4558
g7
I118
sg23
VC0002986
p4559
sg10
I22
sg11
VAnderson-Fabry disease
p4560
sg13
I2
sa(dp4561
g7
I27
sg23
VC0040457
p4562
sg10
I19
sg11
Vsupernumerary teeth
p4563
sg13
I2
sasa(dp4564
g2
S"Multiple hyperodontia can be associated with several syndromes such as Gardner's, cleidocranial dysplasia, tricho-rhino phalangic syndrome or in patients with cleft lip and palate.\n"
p4565
sg4
(lp4566
sg20
(lp4567
(dp4568
g7
I53
sg23
VC0039082
p4569
sg10
I9
sg11
Vsyndromes
p4570
sg13
I1
sa(dp4571
g7
I82
sg23
VC0008928
p4572
sg10
I23
sg11
Vcleidocranial dysplasia
p4573
sg13
I2
sa(dp4574
g7
I53
sg23
VC0039082
p4575
sg10
I8
sg11
Vsyndrome
p4576
sg13
I1
sa(dp4577
g7
I159
sg23
VC0158646
p4578
sg10
I20
sg11
Vcleft lip and palate
p4579
sg13
I4
sasa(dp4580
g2
S'The manifestations of branchio-oto-renal syndrome (BOR), Treacher Collins syndrome, tricho-rhino-phalangeal syndrome, van der Woude syndrome, and Langer-Giedion syndrome are well-defined; these conditions represent clinically and genetically separate syndromes.\n'
p4581
sg4
(lp4582
sg20
(lp4583
(dp4584
g7
I146
sg23
VC0023003
p4585
sg10
I23
sg11
VLanger-Giedion syndrome
p4586
sg13
I2
sa(dp4587
g7
I41
sg23
VC0039082
p4588
sg10
I8
sg11
Vsyndrome
p4589
sg13
I1
sa(dp4590
g7
I118
sg23
VC0175697
p4591
sg10
I22
sg11
Vvan der Woude syndrome
p4592
sg13
I4
sa(dp4593
g7
I57
sg23
VC0242387
p4594
sg10
I25
sg11
VTreacher Collins syndrome
p4595
sg13
I3
sa(dp4596
g7
I51
sg23
VC0265234
p4597
sg10
I3
sg11
VBOR
p4598
sg13
I1
sa(dp4599
g7
I251
sg23
VC0039082
p4600
sg10
I9
sg11
Vsyndromes
p4601
sg13
I1
sa(dp4602
g7
I22
sg23
VC0265234
p4603
sg10
I27
sg11
Vbranchio-oto-renal syndrome
p4604
sg13
I2
sasa(dp4605
g2
S'We found that ROR1 associates with hematopoietic-lineage-cell-specific protein 1 (HS1) in freshly isolated CLL cells or in CLL cells cultured with exogenous Wnt5a.\n'
p4606
sg4
(lp4607
(dp4608
g7
I82
sg8
VP27348
p4609
sg10
I3
sg11
VHS1
p4610
sg13
I1
sa(dp4611
g7
I35
sg8
VP14222
p4612
sg10
I45
sg11
Vhematopoietic-lineage-cell-specific protein 1
p4613
sg13
I3
sa(dp4614
g7
I14
sg8
VP35398
p4615
sg10
I4
sg11
VROR1
p4616
sg13
I1
sa(dp4617
g7
I157
sg8
VP41221
p4618
sg10
I5
sg11
VWnt5a
p4619
sg13
I1
sasg20
(lp4620
(dp4621
g7
I82
sg23
VC2674218
p4622
sg10
I3
sg11
VHS1
p4623
sg13
I1
sa(dp4624
g7
I35
sg23
VC2674218
p4625
sg10
I45
sg11
Vhematopoietic-lineage-cell-specific protein 1
p4626
sg13
I3
sa(dp4627
g7
I107
sg23
VC0023434
p4628
sg10
I3
sg11
VCLL
p4629
sg13
I1
sa(dp4630
g7
I107
sg23
VC0023434
p4631
sg10
I3
sg11
VCLL
p4632
sg13
I1
sasa(dp4633
g2
S'Hematopoietic cell-specific lyn substrate 1 (HS1) is a cortactin-related and leukocyte-specific actin-binding protein (ABP) that regulates several processes in various immune cells.\n'
p4634
sg4
(lp4635
(dp4636
g7
I0
sg8
VP14317
p4637
sg10
I43
sg11
VHematopoietic cell-specific lyn substrate 1
p4638
sg13
I5
sa(dp4639
g7
I45
sg8
VP27348
p4640
sg10
I3
sg11
VHS1
p4641
sg13
I1
sa(dp4642
g7
I77
sg8
g39
sg10
I40
sg11
Vleukocyte-specific actin-binding protein
p4643
sg13
I3
sa(dp4644
g7
I119
sg8
VP19801
p4645
sg10
I3
sg11
VABP
p4646
sg13
I1
sa(dp4647
g7
I55
sg8
g39
sg10
I17
sg11
Vcortactin-related
p4648
sg13
I1
sasg20
(lp4649
(dp4650
g7
I0
sg23
VC2674218
p4651
sg10
I43
sg11
VHematopoietic cell-specific lyn substrate 1
p4652
sg13
I5
sa(dp4653
g7
I45
sg23
VC2674218
p4654
sg10
I3
sg11
VHS1
p4655
sg13
I1
sasa(dp4656
g2
S'From this group, we validated the HSP90 cochaperone P23 that was demonstrated to exhibit cytosolic prostaglandin E2 synthase 3 (PTGES3) activity, and the hematopoietic cell-specific LYN substrate 1 (HCLS1 or HS1), a hematopoietic cell-specific adapter molecule, as novel macrophage RBPs.\n'
p4657
sg4
(lp4658
(dp4659
g7
I52
sg8
VP10301
p4660
sg10
I3
sg11
VP23
p4661
sg13
I1
sa(dp4662
g7
I208
sg8
VP27348
p4663
sg10
I3
sg11
VHS1
p4664
sg13
I1
sa(dp4665
g7
I199
sg8
VP14317
p4666
sg10
I5
sg11
VHCLS1
p4667
sg13
I1
sa(dp4668
g7
I34
sg8
VP07900
p4669
sg10
I5
sg11
VHSP90
p4670
sg13
I1
sa(dp4671
g7
I271
sg8
VP09603
p4672
sg10
I15
sg11
Vmacrophage RBPs
p4673
sg13
I2
sa(dp4674
g7
I128
sg8
g39
sg10
I6
sg11
VPTGES3
p4675
sg13
I1
sa(dp4676
g7
I154
sg8
VP14317
p4677
sg10
I43
sg11
Vhematopoietic cell-specific LYN substrate 1
p4678
sg13
I5
sa(dp4679
g7
I89
sg8
g39
sg10
I37
sg11
Vcytosolic prostaglandin E2 synthase 3
p4680
sg13
I5
sasg20
(lp4681
(dp4682
g7
I208
sg23
VC2674218
p4683
sg10
I3
sg11
VHS1
p4684
sg13
I1
sasa(dp4685
g2
S'Both fascin and cortactin are known constituents but the role of fascin actin bundling is still unclear and cortactin research rather focuses on its homologue hematopoietic lineage cell-specific protein-1 (HS1).\n'
p4686
sg4
(lp4687
(dp4688
g7
I159
sg8
VP14317
p4689
sg10
I45
sg11
Vhematopoietic lineage cell-specific protein-1
p4690
sg13
I4
sa(dp4691
g7
I206
sg8
VP27348
p4692
sg10
I3
sg11
VHS1
p4693
sg13
I1
sa(dp4694
g7
I16
sg8
g39
sg10
I9
sg11
Vcortactin
p4695
sg13
I1
sa(dp4696
g7
I65
sg8
g39
sg10
I12
sg11
Vfascin actin
p4697
sg13
I2
sa(dp4698
g7
I16
sg8
g39
sg10
I9
sg11
Vcortactin
p4699
sg13
I1
sa(dp4700
g7
I5
sg8
g39
sg10
I6
sg11
Vfascin
p4701
sg13
I1
sasg20
(lp4702
(dp4703
g7
I159
sg23
VC2674218
p4704
sg10
I45
sg11
Vhematopoietic lineage cell-specific protein-1
p4705
sg13
I4
sa(dp4706
g7
I206
sg23
VC2674218
p4707
sg10
I3
sg11
VHS1
p4708
sg13
I1
sasa(dp4709
g2
S'HS-1-associated protein X-1 (HAX1) is a multi-functional protein which was first identified as a Hematopoietic cell specific Lyn Substrate 1 (HS1)-binding protein.\n'
p4710
sg4
(lp4711
(dp4712
g7
I97
sg8
VP07948
p4713
sg10
I65
sg11
VHematopoietic cell specific Lyn Substrate 1 (HS1)-binding protein
p4714
sg13
I8
sa(dp4715
g7
I29
sg8
g39
sg10
I4
sg11
VHAX1
p4716
sg13
I1
sa(dp4717
g7
I0
sg8
g39
sg10
I27
sg11
VHS-1-associated protein X-1
p4718
sg13
I3
sasg20
(lp4719
(dp4720
g7
I97
sg23
VC2674218
p4721
sg10
I43
sg11
VHematopoietic cell specific Lyn Substrate 1
p4722
sg13
I6
sa(dp4723
g7
I142
sg23
VC2674218
p4724
sg10
I3
sg11
VHS1
p4725
sg13
I1
sasa(dp4726
g2
S'Proteins that drive actin polymerization such as WASp (Wiskott-Aldrich syndrome protein) and HS1 (hematopoietic lineage cell-specific protein 1) promote signaling through PLCGamma1 (phospholipase CGamma1) and release of Ca(2+) from endoplasmic reticulum stores.\n'
p4727
sg4
(lp4728
(dp4729
g7
I182
sg8
VP04054
p4730
sg10
I21
sg11
Vphospholipase CGamma1
p4731
sg13
I2
sa(dp4732
g7
I93
sg8
VP27348
p4733
sg10
I3
sg11
VHS1
p4734
sg13
I1
sa(dp4735
g7
I171
sg8
VP19174
p4736
sg10
I9
sg11
VPLCGamma1
p4737
sg13
I1
sa(dp4738
g7
I98
sg8
VP14317
p4739
sg10
I45
sg11
Vhematopoietic lineage cell-specific protein 1
p4740
sg13
I5
sasg20
(lp4741
(dp4742
g7
I93
sg23
VC2674218
p4743
sg10
I3
sg11
VHS1
p4744
sg13
I1
sa(dp4745
g7
I55
sg23
VC0043194
p4746
sg10
I24
sg11
VWiskott-Aldrich syndrome
p4747
sg13
I2
sa(dp4748
g7
I98
sg23
VC2674218
p4749
sg10
I45
sg11
Vhematopoietic lineage cell-specific protein 1
p4750
sg13
I5
sasa(dp4751
g2
S'HS1 (hematopoietic cell-specific Lyn substrate-1) is a cytoskeletal interactor in the B-cell receptor (BCR) signaling pathway whose phosphorylation correlates with prognosis in Chronic Lymphocytic Leukemia (CLL).\n'
p4752
sg4
(lp4753
(dp4754
g7
I103
sg8
VP11274
p4755
sg10
I3
sg11
VBCR
p4756
sg13
I1
sa(dp4757
g7
I0
sg8
VP27348
p4758
sg10
I3
sg11
VHS1
p4759
sg13
I1
sa(dp4760
g7
I86
sg8
g39
sg10
I15
sg11
VB-cell receptor
p4761
sg13
I2
sa(dp4762
g7
I5
sg8
g39
sg10
I43
sg11
Vhematopoietic cell-specific Lyn substrate-1
p4763
sg13
I4
sasg20
(lp4764
(dp4765
g7
I0
sg23
VC2674218
p4766
sg10
I3
sg11
VHS1
p4767
sg13
I1
sa(dp4768
g7
I5
sg23
VC2674218
p4769
sg10
I43
sg11
Vhematopoietic cell-specific Lyn substrate-1
p4770
sg13
I4
sa(dp4771
g7
I177
sg23
VC0023434
p4772
sg10
I28
sg11
VChronic Lymphocytic Leukemia
p4773
sg13
I3
sa(dp4774
g7
I207
sg23
VC0023434
p4775
sg10
I3
sg11
VCLL
p4776
sg13
I1
sasa(dp4777
g2
S'We found that hematopoietic cell-specific Lyn substrate 1 (HCLS1 or HS1) is highly expressed in human myeloid cells and that stimulation with granulocyte colony-stimulating factor (G-CSF) leads to HCLS1 phosphorylation.\n'
p4778
sg4
(lp4779
(dp4780
g7
I59
sg8
VP14317
p4781
sg10
I5
sg11
VHCLS1
p4782
sg13
I1
sa(dp4783
g7
I68
sg8
VP27348
p4784
sg10
I3
sg11
VHS1
p4785
sg13
I1
sa(dp4786
g7
I181
sg8
VP09919
p4787
sg10
I5
sg11
VG-CSF
p4788
sg13
I1
sa(dp4789
g7
I142
sg8
VP09919
p4790
sg10
I37
sg11
Vgranulocyte colony-stimulating factor
p4791
sg13
I3
sa(dp4792
g7
I59
sg8
VP14317
p4793
sg10
I5
sg11
VHCLS1
p4794
sg13
I1
sa(dp4795
g7
I42
sg8
VP07948
p4796
sg10
I15
sg11
VLyn substrate 1
p4797
sg13
I3
sasg20
(lp4798
(dp4799
g7
I68
sg23
VC2674218
p4800
sg10
I3
sg11
VHS1
p4801
sg13
I1
sasa(dp4802
g2
S'In patients with severe congenital neutropenia, inherited mutations in the gene encoding HCLS1-associated protein X-1 (HAX1) lead to profound defects in G-CSF-triggered phosphorylation of HCLS1 and subsequently to reduced autoregulation and expression of LEF-1.\n'
p4803
sg4
(lp4804
(dp4805
g7
I89
sg8
VP14317
p4806
sg10
I5
sg11
VHCLS1
p4807
sg13
I1
sa(dp4808
g7
I119
sg8
g39
sg10
I4
sg11
VHAX1
p4809
sg13
I1
sa(dp4810
g7
I153
sg8
VP09919
p4811
sg10
I5
sg11
VG-CSF
p4812
sg13
I1
sa(dp4813
g7
I255
sg8
g39
sg10
I5
sg11
VLEF-1
p4814
sg13
I1
sa(dp4815
g7
I89
sg8
g39
sg10
I28
sg11
VHCLS1-associated protein X-1
p4816
sg13
I3
sasg20
(lp4817
(dp4818
g7
I17
sg23
VC1853118
p4819
sg10
I29
sg11
Vsevere congenital neutropenia
p4820
sg13
I3
sasa(dp4821
g2
S'In bone marrow biopsies of the majority of tested patients with acute myeloid leukemia, HCLS1 protein expression is substantially elevated, associated with high levels of G-CSF synthesis and, in some individuals, a four-residue insertion in a proline-rich region of HCLS1 protein known to accelerate intracellular signaling.\n'
p4822
sg4
(lp4823
(dp4824
g7
I171
sg8
VP09919
p4825
sg10
I5
sg11
VG-CSF
p4826
sg13
I1
sa(dp4827
g7
I88
sg8
VP14317
p4828
sg10
I13
sg11
VHCLS1 protein
p4829
sg13
I2
sa(dp4830
g7
I88
sg8
VP14317
p4831
sg10
I13
sg11
VHCLS1 protein
p4832
sg13
I2
sasg20
(lp4833
(dp4834
g7
I64
sg23
VC0023467
p4835
sg10
I22
sg11
Vacute myeloid leukemia
p4836
sg13
I3
sasa(dp4837
g2
S'In B-Chronic Lymphocytic Leukemia (B-CLL) kinase Lyn is overexpressed, active, abnormally distributed, and part of a cytosolic complex involving hematopoietic lineage cell-specific protein 1 (HS1).\n'
p4838
sg4
(lp4839
(dp4840
g7
I145
sg8
VP14317
p4841
sg10
I45
sg11
Vhematopoietic lineage cell-specific protein 1
p4842
sg13
I5
sa(dp4843
g7
I49
sg8
VP07948
p4844
sg10
I3
sg11
VLyn
p4845
sg13
I1
sa(dp4846
g7
I192
sg8
VP27348
p4847
sg10
I3
sg11
VHS1
p4848
sg13
I1
sasg20
(lp4849
(dp4850
g7
I5
sg23
VC0023434
p4851
sg10
I28
sg11
VChronic Lymphocytic Leukemia
p4852
sg13
I3
sa(dp4853
g7
I145
sg23
VC2674218
p4854
sg10
I45
sg11
Vhematopoietic lineage cell-specific protein 1
p4855
sg13
I5
sa(dp4856
g7
I37
sg23
VC0023434
p4857
sg10
I3
sg11
VCLL
p4858
sg13
I1
sa(dp4859
g7
I192
sg23
VC2674218
p4860
sg10
I3
sg11
VHS1
p4861
sg13
I1
sasa(dp4862
g2
S'Using immunohistochemistry, MMP-9, VEGF-C and the level of lymphatic microvessel density (LMVD) were analyzed in 106 cases of breast invasive ductal carcinoma and 20 cases of breast proliferative lesions.\n'
p4863
sg4
(lp4864
(dp4865
g7
I35
sg8
VP49767
p4866
sg10
I6
sg11
VVEGF-C
p4867
sg13
I1
sa(dp4868
g7
I28
sg8
VP14780
p4869
sg10
I5
sg11
VMMP-9
p4870
sg13
I1
sasg20
(lp4871
(dp4872
g7
I182
sg23
VC0334094
p4873
sg10
I13
sg11
Vproliferative
p4874
sg13
I1
sa(dp4875
g7
I133
sg23
VC1134719
p4876
sg10
I25
sg11
Vinvasive ductal carcinoma
p4877
sg13
I3
sasa(dp4878
g2
S'Key words used in the research included \'VEGF-C", "breast cancer", "immunohistochemistry", "breast neoplasma(s)", "breast carcinoma", "metastasis", and "prognosis".\n'
p4879
sg4
(lp4880
(dp4881
g7
I40
sg8
VP49767
p4882
sg10
I7
sg11
V'VEGF-C
p4883
sg13
I1
sasg20
(lp4884
(dp4885
g7
I51
sg23
VC0678222
p4886
sg10
I13
sg11
Vbreast cancer
p4887
sg13
I2
sa(dp4888
g7
I135
sg23
VC0027627
p4889
sg10
I10
sg11
Vmetastasis
p4890
sg13
I1
sa(dp4891
g7
I115
sg23
VC0678222
p4892
sg10
I16
sg11
Vbreast carcinoma
p4893
sg13
I2
sasa(dp4894
g2
S'Pathology revealed an invasive lobular carcinoma (2.5 x 2 mm in size) with extensive lymphatic involvement, which strongly expressed both vascular endothelial growth factor-C (VEGF-C) and VEGF-D. Riportiamo il caso di metastasi ascellare sinistra da carcinoma occulto della mammella in donna di 63 anni.\n'
p4895
sg4
(lp4896
(dp4897
g7
I138
sg8
VP49767
p4898
sg10
I36
sg11
Vvascular endothelial growth factor-C
p4899
sg13
I4
sa(dp4900
g7
I176
sg8
VP49767
p4901
sg10
I6
sg11
VVEGF-C
p4902
sg13
I1
sa(dp4903
g7
I188
sg8
g39
sg10
I6
sg11
VVEGF-D
p4904
sg13
I1
sasg20
(lp4905
(dp4906
g7
I39
sg23
VC0007097
p4907
sg10
I9
sg11
Vcarcinoma
p4908
sg13
I1
sa(dp4909
g7
I0
sg23
VC0677042
p4910
sg10
I9
sg11
VPathology
p4911
sg13
I1
sa(dp4912
g7
I22
sg23
VC0279565
p4913
sg10
I26
sg11
Vinvasive lobular carcinoma
p4914
sg13
I3
sasa(dp4915
g2
S'Related to these dissemination and metastatic features, we aimed to study the immunohistochemical expression of D2-40, VEGF-C and VEGFR-3 in 25 cases of ILCs stratified according to the histopathological and molecular classification.\n'
p4916
sg4
(lp4917
(dp4918
g7
I130
sg8
VP35916
p4919
sg10
I7
sg11
VVEGFR-3
p4920
sg13
I1
sa(dp4921
g7
I119
sg8
VP49767
p4922
sg10
I6
sg11
VVEGF-C
p4923
sg13
I1
sasg20
(lp4924
sa(dp4925
g2
S'We found hypomethylation of the CRIPTO promoter in undifferentiated fetal germ cells, embryonal carcinoma and seminomas, but hypermethylation in differentiated fetal germ cells and the differentiated types of non-seminomas.\n'
p4926
sg4
(lp4927
(dp4928
g7
I32
sg8
VP13385
p4929
sg10
I15
sg11
VCRIPTO promoter
p4930
sg13
I2
sasg20
(lp4931
(dp4932
g7
I110
sg23
VC0036631
p4933
sg10
I9
sg11
Vseminomas
p4934
sg13
I1
sa(dp4935
g7
I86
sg23
VC0206659
p4936
sg10
I19
sg11
Vembryonal carcinoma
p4937
sg13
I2
sa(dp4938
g7
I110
sg23
VC0036631
p4939
sg10
I9
sg11
Vseminomas
p4940
sg13
I1
sasa(dp4941
g2
S'CRIPTO protein was strongly expressed in germ cell neoplasia in situ along with embryonal carcinoma, yolk sac tumor and seminomas.\n'
p4942
sg4
(lp4943
(dp4944
g7
I0
sg8
VP13385
p4945
sg10
I14
sg11
VCRIPTO protein
p4946
sg13
I2
sasg20
(lp4947
(dp4948
g7
I80
sg23
VC0206659
p4949
sg10
I19
sg11
Vembryonal carcinoma
p4950
sg13
I2
sa(dp4951
g7
I51
sg23
VC0027651
p4952
sg10
I9
sg11
Vneoplasia
p4953
sg13
I1
sa(dp4954
g7
I101
sg23
VC0014145
p4955
sg10
I14
sg11
Vyolk sac tumor
p4956
sg13
I3
sa(dp4957
g7
I120
sg23
VC0036631
p4958
sg10
I9
sg11
Vseminomas
p4959
sg13
I1
sasa(dp4960
g2
S'Further, cleaved CRIPTO was detected in media from seminoma and embryonal carcinoma cell lines, suggesting that cleaved CRIPTO may provide diagnostic indication of germ cell cancer.\n'
p4961
sg4
(lp4962
(dp4963
g7
I17
sg8
VP13385
p4964
sg10
I6
sg11
VCRIPTO
p4965
sg13
I1
sasg20
(lp4966
(dp4967
g7
I164
sg23
VC0740345
p4968
sg10
I16
sg11
Vgerm cell cancer
p4969
sg13
I3
sa(dp4970
g7
I51
sg23
VC0036631
p4971
sg10
I8
sg11
Vseminoma
p4972
sg13
I1
sa(dp4973
g7
I64
sg23
VC0206659
p4974
sg10
I19
sg11
Vembryonal carcinoma
p4975
sg13
I2
sasa(dp4976
g2
S'Accordingly, CRIPTO was detectable in serum from 6/15 patients with embryonal carcinoma, 5/15 patients with seminoma, 4/5 patients with germ cell neoplasia in situ cells only and in 1/15 control patients.\n'
p4977
sg4
(lp4978
sg20
(lp4979
(dp4980
g7
I108
sg23
VC0036631
p4981
sg10
I8
sg11
Vseminoma
p4982
sg13
I1
sa(dp4983
g7
I68
sg23
VC0206659
p4984
sg10
I19
sg11
Vembryonal carcinoma
p4985
sg13
I2
sa(dp4986
g7
I146
sg23
VC0027651
p4987
sg10
I9
sg11
Vneoplasia
p4988
sg13
I1
sasa(dp4989
g2
S'In addition, knockdown of Cripto-1 expression in human and mouse embryonal carcinoma cells desensitized the ligand-induced Notch signaling activation.\n'
p4990
sg4
(lp4991
(dp4992
g7
I26
sg8
VP13385
p4993
sg10
I8
sg11
VCripto-1
p4994
sg13
I1
sasg20
(lp4995
(dp4996
g7
I65
sg23
VC0206659
p4997
sg10
I19
sg11
Vembryonal carcinoma
p4998
sg13
I2
sasa(dp4999
g2
S'In the present study, we investigated the effect of low levels of oxygen, which occurs naturally in rapidly growing tissues, on Cripto-1 expression in mouse embryonic stem (mES) cells and in human embryonal carcinoma cells.\n'
p5000
sg4
(lp5001
(dp5002
g7
I128
sg8
VP13385
p5003
sg10
I8
sg11
VCripto-1
p5004
sg13
I1
sasg20
(lp5005
(dp5006
g7
I197
sg23
VC0206659
p5007
sg10
I19
sg11
Vembryonal carcinoma
p5008
sg13
I2
sa(dp5009
g7
I173
sg23
VC0265215
p5010
sg10
I3
sg11
VmES
p5011
sg13
I1
sa(dp5012
g7
I151
sg23
VC0265215
p5013
sg10
I20
sg11
Vmouse embryonic stem
p5014
sg13
I3
sasa(dp5015
g2
S'During hypoxia, Cripto-1 expression levels were significantly elevated in mES cells and in Ntera-2 or NCCIT human embryonal carcinoma cells, as compared with cells growing with normal oxygen levels.\n'
p5016
sg4
(lp5017
(dp5018
g7
I16
sg8
VP13385
p5019
sg10
I8
sg11
VCripto-1
p5020
sg13
I1
sasg20
(lp5021
(dp5022
g7
I74
sg23
VC0265215
p5023
sg10
I3
sg11
VmES
p5024
sg13
I1
sa(dp5025
g7
I114
sg23
VC0206659
p5026
sg10
I19
sg11
Vembryonal carcinoma
p5027
sg13
I2
sa(dp5028
g7
I7
sg23
VC0242184
p5029
sg10
I7
sg11
Vhypoxia
p5030
sg13
I1
sasa(dp5031
g2
S'The typical malformative pattern of MMF embryopathy includes external ear anomalies ranging from hypoplastic pinna (microtia) to complete absence of pinna (anotia); cleft lip, with or without cleft palate, and ocular anomalies as iris or chorioretinal coloboma and anophthalmia/microphthalmia.\n'
p5032
sg4
(lp5033
sg20
(lp5034
(dp5035
g7
I238
sg23
VC0240896
p5036
sg10
I22
sg11
Vchorioretinal coloboma
p5037
sg13
I2
sa(dp5038
g7
I165
sg23
VC0008924
p5039
sg10
I9
sg11
Vcleft lip
p5040
sg13
I2
sa(dp5041
g7
I36
sg23
VC0152423
p5042
sg10
I78
sg11
VMMF embryopathy includes external ear anomalies ranging from hypoplastic pinna
p5043
sg13
I10
sa(dp5044
g7
I116
sg23
VC0152423
p5045
sg10
I8
sg11
Vmicrotia
p5046
sg13
I1
sa(dp5047
g7
I156
sg23
VC0702139
p5048
sg10
I6
sg11
Vanotia
p5049
sg13
I1
sa(dp5050
g7
I278
sg23
VC0026010
p5051
sg10
I14
sg11
Vmicrophthalmia
p5052
sg13
I1
sa(dp5053
g7
I192
sg23
VC0008925
p5054
sg10
I12
sg11
Vcleft palate
p5055
sg13
I2
sa(dp5056
g7
I265
sg23
VC0003119
p5057
sg10
I12
sg11
Vanophthalmia
p5058
sg13
I1
sasa(dp5059
g2
S'HOXA2 biallelic mutations were also described in an inbreed family with autosomal recessive microtia, hearing impairment and incomplete cleft palate.\n'
p5060
sg4
(lp5061
(dp5062
g7
I0
sg8
g39
sg10
I5
sg11
VHOXA2
p5063
sg13
I1
sasg20
(lp5064
(dp5065
g7
I136
sg23
VC0008925
p5066
sg10
I12
sg11
Vcleft palate
p5067
sg13
I2
sa(dp5068
g7
I92
sg23
VC0152423
p5069
sg10
I8
sg11
Vmicrotia
p5070
sg13
I1
sa(dp5071
g7
I110
sg23
VC0684336
p5072
sg10
I10
sg11
Vimpairment
p5073
sg13
I1
sasa(dp5074
g2
S'We observed significant odds ratios (ORs) for isolated hydrocephaly (adjusted OR [AOR], 2.1; 95% confidence interval [CI], 1.1-4.2), isolated anotia/microtia (AOR, 2.0; 95% CI, 1.0-4.0), isolated colonic atresia (crude OR, 7.5; 95% CI, 2.5-22.3), isolated omphalocele (AOR, 2.3; 95% CI, 1.1-4.6) and isolated anencephaly (crude OR, 0.23; 95% CI, 0.06-0.94).\n'
p5075
sg4
(lp5076
sg20
(lp5077
(dp5078
g7
I55
sg23
VC0020255
p5079
sg10
I12
sg11
Vhydrocephaly
p5080
sg13
I1
sa(dp5081
g7
I309
sg23
VC0002902
p5082
sg10
I11
sg11
Vanencephaly
p5083
sg13
I1
sa(dp5084
g7
I142
sg23
VC0702139
p5085
sg10
I6
sg11
Vanotia
p5086
sg13
I1
sa(dp5087
g7
I196
sg23
VC0266190
p5088
sg10
I15
sg11
Vcolonic atresia
p5089
sg13
I2
sa(dp5090
g7
I256
sg23
VC0795690
p5091
sg10
I11
sg11
Vomphalocele
p5092
sg13
I1
sa(dp5093
g7
I149
sg23
VC0152423
p5094
sg10
I8
sg11
Vmicrotia
p5095
sg13
I1
sasa(dp5096
g2
S'However the prevalence of some malformations such as Down syndrome, Polydactyly, anotia-microtia, syndactyly and cleft palate have increased.\n'
p5097
sg4
(lp5098
sg20
(lp5099
(dp5100
g7
I88
sg23
VC0152423
p5101
sg10
I8
sg11
Vmicrotia
p5102
sg13
I1
sa(dp5103
g7
I53
sg23
VC0013080
p5104
sg10
I13
sg11
VDown syndrome
p5105
sg13
I2
sa(dp5106
g7
I81
sg23
VC0702139
p5107
sg10
I6
sg11
Vanotia
p5108
sg13
I1
sa(dp5109
g7
I68
sg23
VC0152427
p5110
sg10
I11
sg11
VPolydactyly
p5111
sg13
I1
sa(dp5112
g7
I98
sg23
VC0039075
p5113
sg10
I10
sg11
Vsyndactyly
p5114
sg13
I1
sa(dp5115
g7
I113
sg23
VC0008925
p5116
sg10
I12
sg11
Vcleft palate
p5117
sg13
I2
sa(dp5118
g7
I31
sg23
VC0000768
p5119
sg10
I13
sg11
Vmalformations
p5120
sg13
I1
sasa(dp5121
g2
S'American Indians/Alaska Natives had a significantly higher and 50% or greater prevalence for 7 conditions (aPR = 3.97; 95% confidence interval [CI] = 2.89, 5.44 for anotia or microtia); aPRs of 1.5 to 2.1 for cleft lip, trisomy 18, and encephalocele, and lower, upper, and any limb deficiency).\n'
p5122
sg4
(lp5123
sg20
(lp5124
(dp5125
g7
I220
sg23
VC0152096
p5126
sg10
I10
sg11
Vtrisomy 18
p5127
sg13
I2
sa(dp5128
g7
I209
sg23
VC0008924
p5129
sg10
I9
sg11
Vcleft lip
p5130
sg13
I2
sa(dp5131
g7
I165
sg23
VC0702139
p5132
sg10
I6
sg11
Vanotia
p5133
sg13
I1
sa(dp5134
g7
I236
sg23
VC0014065
p5135
sg10
I13
sg11
Vencephalocele
p5136
sg13
I1
sa(dp5137
g7
I175
sg23
VC0152423
p5138
sg10
I8
sg11
Vmicrotia
p5139
sg13
I1
sasa(dp5140
g2
S'However, trends were observed for coarctation, pyloric stenosis, and shaft or penoscrotal hypospadias in OS twins; microcephaly, anotia/microtia, conotruncal defects, membranous ventricular septal defects, pyloric stenosis, all hypospadias, and craniosynostosis in SS twins; and tetralogy of Fallot, right ventricular outflow tract obstructions, renal agenesis/hypoplasia, and craniosynostosis in all twins.\n'
p5141
sg4
(lp5142
sg20
(lp5143
(dp5144
g7
I136
sg23
VC0152423
p5145
sg10
I8
sg11
Vmicrotia
p5146
sg13
I1
sa(dp5147
g7
I115
sg23
VC0025958
p5148
sg10
I12
sg11
Vmicrocephaly
p5149
sg13
I1
sa(dp5150
g7
I55
sg23
VC0947637
p5151
sg10
I8
sg11
Vstenosis
p5152
sg13
I1
sa(dp5153
g7
I279
sg23
VC0039685
p5154
sg10
I19
sg11
Vtetralogy of Fallot
p5155
sg13
I3
sa(dp5156
g7
I245
sg23
VC0010278
p5157
sg10
I16
sg11
Vcraniosynostosis
p5158
sg13
I1
sa(dp5159
g7
I332
sg23
VC0028778
p5160
sg10
I12
sg11
Vobstructions
p5161
sg13
I1
sa(dp5162
g7
I78
sg23
VC0452147
p5163
sg10
I23
sg11
Vpenoscrotal hypospadias
p5164
sg13
I2
sa(dp5165
g7
I361
sg23
VC0243069
p5166
sg10
I10
sg11
Vhypoplasia
p5167
sg13
I1
sa(dp5168
g7
I178
sg23
VC0018818
p5169
sg10
I26
sg11
Vventricular septal defects
p5170
sg13
I3
sa(dp5171
g7
I346
sg23
VC0542519
p5172
sg10
I14
sg11
Vrenal agenesis
p5173
sg13
I2
sa(dp5174
g7
I245
sg23
VC0010278
p5175
sg10
I16
sg11
Vcraniosynostosis
p5176
sg13
I1
sa(dp5177
g7
I129
sg23
VC0702139
p5178
sg10
I6
sg11
Vanotia
p5179
sg13
I1
sa(dp5180
g7
I34
sg23
VC0332886
p5181
sg10
I11
sg11
Vcoarctation
p5182
sg13
I1
sa(dp5183
g7
I90
sg23
VC1691215
p5184
sg10
I11
sg11
Vhypospadias
p5185
sg13
I1
sa(dp5186
g7
I55
sg23
VC0947637
p5187
sg10
I8
sg11
Vstenosis
p5188
sg13
I1
sasa(dp5189
g2
S'CMs most frequently found were: spina bifida, limb reduction defects, cleft lip palate, microcephaly, anotia/microtia, hypospadias, polydactyly, cleft palate, anophthalmia/ microphthalmia and omphalocele.\n'
p5190
sg4
(lp5191
sg20
(lp5192
(dp5193
g7
I109
sg23
VC0152423
p5194
sg10
I8
sg11
Vmicrotia
p5195
sg13
I1
sa(dp5196
g7
I159
sg23
VC0003119
p5197
sg10
I12
sg11
Vanophthalmia
p5198
sg13
I1
sa(dp5199
g7
I132
sg23
VC0152427
p5200
sg10
I11
sg11
Vpolydactyly
p5201
sg13
I1
sa(dp5202
g7
I32
sg23
VC0080178
p5203
sg10
I12
sg11
Vspina bifida
p5204
sg13
I2
sa(dp5205
g7
I173
sg23
VC0026010
p5206
sg10
I14
sg11
Vmicrophthalmia
p5207
sg13
I1
sa(dp5208
g7
I145
sg23
VC0008925
p5209
sg10
I12
sg11
Vcleft palate
p5210
sg13
I2
sa(dp5211
g7
I119
sg23
VC1691215
p5212
sg10
I11
sg11
Vhypospadias
p5213
sg13
I1
sa(dp5214
g7
I102
sg23
VC0702139
p5215
sg10
I6
sg11
Vanotia
p5216
sg13
I1
sa(dp5217
g7
I192
sg23
VC0795690
p5218
sg10
I11
sg11
Vomphalocele
p5219
sg13
I1
sa(dp5220
g7
I70
sg23
VC0158646
p5221
sg10
I16
sg11
Vcleft lip palate
p5222
sg13
I3
sa(dp5223
g7
I88
sg23
VC0025958
p5224
sg10
I12
sg11
Vmicrocephaly
p5225
sg13
I1
sasa(dp5226
g2
S'The patient had been treated with vitamin B12 1,000 micrograms/day injection and, in Sep. 1984, he recovered from megaloblastic anemia (Hb 13.4 g/dl, RBC 440 X 10(4)/mm3, MCV 90.7 fl, MCH 30.4 pg).\n'
p5227
sg4
(lp5228
sg20
(lp5229
(dp5230
g7
I114
sg23
VC0002888
p5231
sg10
I20
sg11
Vmegaloblastic anemia
p5232
sg13
I2
sasa(dp5233
g2
S'The large cluster has additionally been covered by a sequence ready PAC contig and three probably unrelated genes (TRMI2, BTN and SSADH) have been accurately localized within the 6p22.2-p22.1 region.\n'
p5234
sg4
(lp5235
(dp5236
g7
I122
sg8
g39
sg10
I3
sg11
VBTN
p5237
sg13
I1
sa(dp5238
g7
I130
sg8
VP51649
p5239
sg10
I5
sg11
VSSADH
p5240
sg13
I1
sasg20
(lp5241
(dp5242
g7
I68
sg23
VC0033036
p5243
sg10
I3
sg11
VPAC
p5244
sg13
I1
sasa(dp5245
g2
S'Twenty-two Japanese patients with glaucomatocyclitic crisis were typed for HLA-A, HLA-B, and HLA-C antigens to detect the immunogenetic factors in this disease.\n'
p5246
sg4
(lp5247
(dp5248
g7
I75
sg8
VP30447
p5249
sg10
I5
sg11
VHLA-A
p5250
sg13
I1
sa(dp5251
g7
I82
sg8
VP30461
p5252
sg10
I5
sg11
VHLA-B
p5253
sg13
I1
sa(dp5254
g7
I93
sg8
VP30499
p5255
sg10
I14
sg11
VHLA-C antigens
p5256
sg13
I2
sasg20
(lp5257
(dp5258
g7
I34
sg23
VC0152138
p5259
sg10
I25
sg11
Vglaucomatocyclitic crisis
p5260
sg13
I2
sasa(dp5261
g2
S'Integrin Alfa3 (ITGA3) gene mutations are associated with Interstitial Lung disease, Nephrotic syndrome and Epidermolysis bullosa (ILNEB syndrome).\n'
p5262
sg4
(lp5263
(dp5264
g7
I0
sg8
VP26006
p5265
sg10
I14
sg11
VIntegrin Alfa3
p5266
sg13
I2
sa(dp5267
g7
I16
sg8
VP26006
p5268
sg10
I5
sg11
VITGA3
p5269
sg13
I1
sasg20
(lp5270
(dp5271
g7
I85
sg23
VC0027726
p5272
sg10
I18
sg11
VNephrotic syndrome
p5273
sg13
I2
sa(dp5274
g7
I95
sg23
VC0039082
p5275
sg10
I8
sg11
Vsyndrome
p5276
sg13
I1
sa(dp5277
g7
I108
sg23
VC0014527
p5278
sg10
I21
sg11
VEpidermolysis bullosa
p5279
sg13
I2
sa(dp5280
g7
I58
sg23
VC0206062
p5281
sg10
I25
sg11
VInterstitial Lung disease
p5282
sg13
I3
sasa(dp5283
g2
S'To date only six patients are reported: all carried homozygous ITGA3 mutations and presented a dramatically severe phenotype leading to death before age 2 years, from multi-organ failure due to interstitial lung disease and congenital nephrotic syndrome.\n'
p5284
sg4
(lp5285
(dp5286
g7
I63
sg8
VP26006
p5287
sg10
I15
sg11
VITGA3 mutations
p5288
sg13
I2
sasg20
(lp5289
(dp5290
g7
I194
sg23
VC0206062
p5291
sg10
I25
sg11
Vinterstitial lung disease
p5292
sg13
I3
sa(dp5293
g7
I224
sg23
VC0268713
p5294
sg10
I29
sg11
Vcongenital nephrotic syndrome
p5295
sg13
I3
sa(dp5296
g7
I167
sg23
VC0026766
p5297
sg10
I19
sg11
Vmulti-organ failure
p5298
sg13
I2
sasa(dp5299
g2
S'Interstitial lung disease, nephrotic syndrome and junctional epidermolysis bullosa is an autosomal recessive multiorgan disorder caused by mutations in the gene for the integrin Alfa3 subunit (ITGA3).\n'
p5300
sg4
(lp5301
(dp5302
g7
I193
sg8
VP26006
p5303
sg10
I5
sg11
VITGA3
p5304
sg13
I1
sa(dp5305
g7
I169
sg8
VP26006
p5306
sg10
I22
sg11
Vintegrin Alfa3 subunit
p5307
sg13
I3
sasg20
(lp5308
(dp5309
g7
I27
sg23
VC0027726
p5310
sg10
I18
sg11
Vnephrotic syndrome
p5311
sg13
I2
sa(dp5312
g7
I50
sg23
VC0079301
p5313
sg10
I32
sg11
Vjunctional epidermolysis bullosa
p5314
sg13
I3
sa(dp5315
g7
I0
sg23
VC0206062
p5316
sg10
I25
sg11
VInterstitial lung disease
p5317
sg13
I3
sasa(dp5318
g2
S'Recently, mutations in the human ITGA3 were shown to cause congenital nephrotic syndrome, epidermolysis bullosa and interstitial lung disease, otherwise termed NEP syndrome (Nephrotic syndrome, Epidermolysis bullosa and Pulmonary disease).\n'
p5319
sg4
(lp5320
(dp5321
g7
I27
sg8
VP26006
p5322
sg10
I11
sg11
Vhuman ITGA3
p5323
sg13
I2
sasg20
(lp5324
(dp5325
g7
I174
sg23
VC0027726
p5326
sg10
I18
sg11
VNephrotic syndrome
p5327
sg13
I2
sa(dp5328
g7
I194
sg23
VC0014527
p5329
sg10
I21
sg11
VEpidermolysis bullosa
p5330
sg13
I2
sa(dp5331
g7
I220
sg23
VC0024115
p5332
sg10
I17
sg11
VPulmonary disease
p5333
sg13
I2
sa(dp5334
g7
I116
sg23
VC0206062
p5335
sg10
I25
sg11
Vinterstitial lung disease
p5336
sg13
I3
sa(dp5337
g7
I59
sg23
VC0268713
p5338
sg10
I29
sg11
Vcongenital nephrotic syndrome
p5339
sg13
I3
sa(dp5340
g7
I80
sg23
VC0039082
p5341
sg10
I8
sg11
Vsyndrome
p5342
sg13
I1
sa(dp5343
g7
I90
sg23
VC0014527
p5344
sg10
I21
sg11
Vepidermolysis bullosa
p5345
sg13
I2
sasa(dp5346
g2
S'Here, we report on a patient homozygous for a novel missense mutation in the human ITGA3 gene, causing fatal interstitial lung disease and congenital nephrotic syndrome.\n'
p5347
sg4
(lp5348
(dp5349
g7
I77
sg8
VP26006
p5350
sg10
I16
sg11
Vhuman ITGA3 gene
p5351
sg13
I3
sasg20
(lp5352
(dp5353
g7
I109
sg23
VC0206062
p5354
sg10
I25
sg11
Vinterstitial lung disease
p5355
sg13
I3
sa(dp5356
g7
I139
sg23
VC0268713
p5357
sg10
I29
sg11
Vcongenital nephrotic syndrome
p5358
sg13
I3
sasa(dp5359
g2
S'H-2a/b fetuses had a cleft palate frequency of 29%; 11% of the H-2b/b fetuses had cleft palate (P less than .01), demonstrating that the higher susceptibility to cleft palate segregates with the H-2a halotype.\n'
p5360
sg4
(lp5361
(dp5362
g7
I63
sg8
VP14207
p5363
sg10
I14
sg11
VH-2b/b fetuses
p5364
sg13
I2
sasg20
(lp5365
(dp5366
g7
I21
sg23
VC0008925
p5367
sg10
I12
sg11
Vcleft palate
p5368
sg13
I2
sa(dp5369
g7
I21
sg23
VC0008925
p5370
sg10
I12
sg11
Vcleft palate
p5371
sg13
I2
sa(dp5372
g7
I21
sg23
VC0008925
p5373
sg10
I12
sg11
Vcleft palate
p5374
sg13
I2
sasa(dp5375
g2
S'The estimated mean arcsine % cleft palate at 160 mg/kg was different for each strain: B10.A-H-2a, 53.1 +/- 2.19; B10.BR-H-2k, 33.1 +/- 2.27; B10.D2-H-2d, 25.0 +/- 2.75.\n'
p5376
sg4
(lp5377
(dp5378
g7
I86
sg8
g39
sg10
I3
sg11
VB10
p5379
sg13
I1
sa(dp5380
g7
I86
sg8
g39
sg10
I3
sg11
VB10
p5381
sg13
I1
sasg20
(lp5382
(dp5383
g7
I29
sg23
VC0008925
p5384
sg10
I12
sg11
Vcleft palate
p5385
sg13
I2
sasa(dp5386
g2
S'The frequency of cleft palate (CP) and corticosterone levels in maternal plasma and amniotic fluid were determined in pregnant C57BL/10 (H-2b) and congenic B10.A (H-2a) mice after the ip injection of repository ACTH, corticosterone acetate, or desoxycorticosterone acetate (DOCA) on the 11th through 14th day of gestation.\n'
p5387
sg4
(lp5388
(dp5389
g7
I211
sg8
VP01189
p5390
sg10
I4
sg11
VACTH
p5391
sg13
I1
sa(dp5392
g7
I156
sg8
g39
sg10
I5
sg11
VB10.A
p5393
sg13
I1
sasg20
(lp5394
(dp5395
g7
I17
sg23
VC0008925
p5396
sg10
I12
sg11
Vcleft palate
p5397
sg13
I2
sa(dp5398
g7
I31
sg23
VC0008925
p5399
sg10
I2
sg11
VCP
p5400
sg13
I1
sasa(dp5401
g2
S'In conclusion, it appears extremely useful to combine IHC analysis of SATB2 and CD99 with molecular analysis of Ewing sarcoma-associated genetic aberrations, to differentiate small cell osteosarcoma from other small round cell malignancies of bone.\n'
p5402
sg4
(lp5403
(dp5404
g7
I70
sg8
g39
sg10
I5
sg11
VSATB2
p5405
sg13
I1
sa(dp5406
g7
I80
sg8
VP14209
p5407
sg10
I4
sg11
VCD99
p5408
sg13
I1
sasg20
(lp5409
(dp5410
g7
I227
sg23
VC0006826
p5411
sg10
I12
sg11
Vmalignancies
p5412
sg13
I1
sa(dp5413
g7
I112
sg23
VC0553580
p5414
sg10
I13
sg11
VEwing sarcoma
p5415
sg13
I2
sa(dp5416
g7
I175
sg23
VC0279622
p5417
sg10
I23
sg11
Vsmall cell osteosarcoma
p5418
sg13
I3
sasa(dp5419
g2
S'The strong IHC expression of SATB2 associated with CD99 immunonegativity and the absence of EWSR1 and FUS gene rearrangements in small cell osteosarcoma argues against the existence of a morphologic/genetic continuum with Ewing sarcoma.\n'
p5420
sg4
(lp5421
(dp5422
g7
I51
sg8
VP14209
p5423
sg10
I4
sg11
VCD99
p5424
sg13
I1
sa(dp5425
g7
I102
sg8
VP35637
p5426
sg10
I8
sg11
VFUS gene
p5427
sg13
I2
sa(dp5428
g7
I29
sg8
g39
sg10
I5
sg11
VSATB2
p5429
sg13
I1
sa(dp5430
g7
I92
sg8
g39
sg10
I5
sg11
VEWSR1
p5431
sg13
I1
sasg20
(lp5432
(dp5433
g7
I129
sg23
VC0279622
p5434
sg10
I23
sg11
Vsmall cell osteosarcoma
p5435
sg13
I3
sa(dp5436
g7
I222
sg23
VC0553580
p5437
sg10
I13
sg11
VEwing sarcoma
p5438
sg13
I2
sasa(dp5439
g2
S"Reduced orexin immunoreactivity has been reported in various neurologic conditions such as narcolepsy, Alzheimer's disease, Lewy body disease and multiple system atrophy (MSA); however, there has been no report investigating orexin in Perry syndrome, a rare hereditary neurodegenerative disease characterized by four clinical cardinal signs (parkinsonism, depression/apathy, weight loss, and central hypoventilation).\n"
p5440
sg4
(lp5441
(dp5442
g7
I8
sg8
g39
sg10
I6
sg11
Vorexin
p5443
sg13
I1
sasg20
(lp5444
(dp5445
g7
I146
sg23
VC0393571
p5446
sg10
I23
sg11
Vmultiple system atrophy
p5447
sg13
I3
sa(dp5448
g7
I400
sg23
VC0398353
p5449
sg10
I15
sg11
Vhypoventilation
p5450
sg13
I1
sa(dp5451
g7
I171
sg23
VC0393571
p5452
sg10
I3
sg11
VMSA
p5453
sg13
I1
sa(dp5454
g7
I91
sg23
VC0027404
p5455
sg10
I10
sg11
Vnarcolepsy
p5456
sg13
I1
sa(dp5457
g7
I258
sg23
VC0751870
p5458
sg10
I36
sg11
Vhereditary neurodegenerative disease
p5459
sg13
I3
sa(dp5460
g7
I367
sg23
VC0085632
p5461
sg10
I6
sg11
Vapathy
p5462
sg13
I1
sa(dp5463
g7
I235
sg23
VC1868594
p5464
sg10
I14
sg11
VPerry syndrome
p5465
sg13
I2
sa(dp5466
g7
I124
sg23
VC0752347
p5467
sg10
I17
sg11
VLewy body disease
p5468
sg13
I3
sa(dp5469
g7
I103
sg23
VC1521724
p5470
sg10
I19
sg11
VAlzheimer's disease
p5471
sg13
I2
sa(dp5472
g7
I342
sg23
VC0242422
p5473
sg10
I12
sg11
Vparkinsonism
p5474
sg13
I1
sa(dp5475
g7
I356
sg23
VC0011581
p5476
sg10
I10
sg11
Vdepression
p5477
sg13
I1
sasa(dp5478
g2
S'We evaluated CSF hypocretin-1 levels in 15 patients with moderately severe multiple system atrophy (MSA), another synucleinopathy where sleep disorders occur frequently and EDS has been reported, performing additional electrophysiological studies in 5 of them to assess the presence of EDS and sleep onset REM (SOREM) periods.\n'
p5479
sg4
(lp5480
(dp5481
g7
I13
sg8
VP04141
p5482
sg10
I16
sg11
VCSF hypocretin-1
p5483
sg13
I2
sasg20
(lp5484
(dp5485
g7
I173
sg23
VC0013720
p5486
sg10
I3
sg11
VEDS
p5487
sg13
I1
sa(dp5488
g7
I75
sg23
VC0393571
p5489
sg10
I23
sg11
Vmultiple system atrophy
p5490
sg13
I3
sa(dp5491
g7
I136
sg23
VC0851578
p5492
sg10
I15
sg11
Vsleep disorders
p5493
sg13
I2
sa(dp5494
g7
I173
sg23
VC0013720
p5495
sg10
I3
sg11
VEDS
p5496
sg13
I1
sa(dp5497
g7
I100
sg23
VC0393571
p5498
sg10
I3
sg11
VMSA
p5499
sg13
I1
sasa(dp5500
g2
S'The combined adjuvant acts via MyD88 in both bone marrow-derived and non-bone marrow-derived radioresistant cells to induce hemagglutinin-specific antibodies and protect mice against influenza virus challenge.\n'
p5501
sg4
(lp5502
(dp5503
g7
I31
sg8
g39
sg10
I5
sg11
VMyD88
p5504
sg13
I1
sasg20
(lp5505
(dp5506
g7
I183
sg23
VC0021400
p5507
sg10
I9
sg11
Vinfluenza
p5508
sg13
I1
sasa(dp5509
g2
S'After acid-loading for 7 days, CD-Rhbg/Rhcg-KO mice developed significantly more severe metabolic acidosis than did C mice.\n'
p5510
sg4
(lp5511
(dp5512
g7
I34
sg8
g39
sg10
I4
sg11
VRhbg
p5513
sg13
I1
sa(dp5514
g7
I39
sg8
g39
sg10
I4
sg11
VRhcg
p5515
sg13
I1
sasg20
(lp5516
(dp5517
g7
I88
sg23
VC0220981
p5518
sg10
I18
sg11
Vmetabolic acidosis
p5519
sg13
I2
sasa(dp5520
g2
S'Metabolic acidosis increased phosphenolpyruvate carboxykinase (PEPCK) and Na(+)/H(+) exchanger NHE-3 and decreased glutamine synthetase (GS) expression in both genotypes, and these changes were significantly greater in CD-Rhbg/Rhcg-KO than in C mice.\n'
p5521
sg4
(lp5522
(dp5523
g7
I115
sg8
VP15104
p5524
sg10
I20
sg11
Vglutamine synthetase
p5525
sg13
I2
sa(dp5526
g7
I222
sg8
g39
sg10
I4
sg11
VRhbg
p5527
sg13
I1
sa(dp5528
g7
I227
sg8
g39
sg10
I4
sg11
VRhcg
p5529
sg13
I1
sa(dp5530
g7
I29
sg8
VP35558
p5531
sg10
I32
sg11
Vphosphenolpyruvate carboxykinase
p5532
sg13
I2
sa(dp5533
g7
I95
sg8
VP48764
p5534
sg10
I5
sg11
VNHE-3
p5535
sg13
I1
sa(dp5536
g7
I137
sg8
VP15104
p5537
sg10
I2
sg11
VGS
p5538
sg13
I1
sa(dp5539
g7
I63
sg8
VP35558
p5540
sg10
I5
sg11
VPEPCK
p5541
sg13
I1
sasg20
(lp5542
(dp5543
g7
I0
sg23
VC0220981
p5544
sg10
I18
sg11
VMetabolic acidosis
p5545
sg13
I2
sasa(dp5546
g2
S'We conclude that 1) Rhbg and Rhcg are critically important in the renal response to metabolic acidosis; 2) the significantly greater changes in PEPCK, NHE-3, and GS expression in acid-loaded CD-Rhbg/Rhcg-KO compared with acid-loaded C mice cause the role of Rhbg and Rhcg to be underestimated quantitatively; and 3) in mice with intact Rhbg and Rhcg expression, metabolic acidosis does not induce maximal changes in PEPCK, NHE-3, and GS expression despite the presence of persistent metabolic acidosis.\n'
p5547
sg4
(lp5548
(dp5549
g7
I20
sg8
g39
sg10
I4
sg11
VRhbg
p5550
sg13
I1
sa(dp5551
g7
I29
sg8
g39
sg10
I4
sg11
VRhcg
p5552
sg13
I1
sa(dp5553
g7
I29
sg8
g39
sg10
I4
sg11
VRhcg
p5554
sg13
I1
sa(dp5555
g7
I20
sg8
g39
sg10
I4
sg11
VRhbg
p5556
sg13
I1
sa(dp5557
g7
I144
sg8
VP35558
p5558
sg10
I5
sg11
VPEPCK
p5559
sg13
I1
sa(dp5560
g7
I144
sg8
VP35558
p5561
sg10
I5
sg11
VPEPCK
p5562
sg13
I1
sa(dp5563
g7
I29
sg8
g39
sg10
I4
sg11
VRhcg
p5564
sg13
I1
sa(dp5565
g7
I151
sg8
VP48764
p5566
sg10
I5
sg11
VNHE-3
p5567
sg13
I1
sa(dp5568
g7
I20
sg8
g39
sg10
I4
sg11
VRhbg
p5569
sg13
I1
sa(dp5570
g7
I20
sg8
g39
sg10
I4
sg11
VRhbg
p5571
sg13
I1
sa(dp5572
g7
I29
sg8
g39
sg10
I4
sg11
VRhcg
p5573
sg13
I1
sa(dp5574
g7
I151
sg8
VP48764
p5575
sg10
I5
sg11
VNHE-3
p5576
sg13
I1
sasg20
(lp5577
(dp5578
g7
I84
sg23
VC0220981
p5579
sg10
I18
sg11
Vmetabolic acidosis
p5580
sg13
I2
sa(dp5581
g7
I84
sg23
VC0220981
p5582
sg10
I18
sg11
Vmetabolic acidosis
p5583
sg13
I2
sa(dp5584
g7
I84
sg23
VC0220981
p5585
sg10
I18
sg11
Vmetabolic acidosis
p5586
sg13
I2
sasa(dp5587
g2
S'HsRhCG(R202C) may confer susceptibility to disorders leading to metabolic acidosis for instance.\n'
p5588
sg4
(lp5589
sg20
(lp5590
(dp5591
g7
I64
sg23
VC0220981
p5592
sg10
I18
sg11
Vmetabolic acidosis
p5593
sg13
I2
sasa(dp5594
g2
S'The Rhesus factor protein, Rh C glycoprotein (Rhcg), is an ammonia transporter whose expression in the collecting duct is necessary for normal ammonia excretion both in basal conditions and in response to metabolic acidosis.\n'
p5595
sg4
(lp5596
(dp5597
g7
I27
sg8
VP36222
p5598
sg10
I17
sg11
VRh C glycoprotein
p5599
sg13
I3
sa(dp5600
g7
I4
sg8
g39
sg10
I21
sg11
VRhesus factor protein
p5601
sg13
I3
sa(dp5602
g7
I46
sg8
g39
sg10
I4
sg11
VRhcg
p5603
sg13
I1
sasg20
(lp5604
(dp5605
g7
I205
sg23
VC0220981
p5606
sg10
I18
sg11
Vmetabolic acidosis
p5607
sg13
I2
sasa(dp5608
g2
S'Lack of the renal isoform RhCG in mice causes reduced ammonium excretion and metabolic acidosis.\n'
p5609
sg4
(lp5610
(dp5611
g7
I26
sg8
g39
sg10
I4
sg11
VRhCG
p5612
sg13
I1
sasg20
(lp5613
(dp5614
g7
I77
sg23
VC0220981
p5615
sg10
I18
sg11
Vmetabolic acidosis
p5616
sg13
I2
sasa(dp5617
g2
S'Deletion of RhBG in mice had no effect on renal ammonium excretion, whereas RhCG deficiency reduces renal ammonium secretion strongly, causes metabolic acidosis in acid-challenged mice, and impairs restoration of normal acid-base status.\n'
p5618
sg4
(lp5619
(dp5620
g7
I12
sg8
g39
sg10
I4
sg11
VRhBG
p5621
sg13
I1
sa(dp5622
g7
I76
sg8
g39
sg10
I4
sg11
VRhCG
p5623
sg13
I1
sasg20
(lp5624
(dp5625
g7
I142
sg23
VC0220981
p5626
sg10
I18
sg11
Vmetabolic acidosis
p5627
sg13
I2
sasa(dp5628
g2
S'The purpose of the current studies was to better understand the specific role of Rhcg expression in intercalated cells in basal and metabolic acidosis-stimulated renal ammonia excretion.\n'
p5629
sg4
(lp5630
(dp5631
g7
I81
sg8
g39
sg10
I4
sg11
VRhcg
p5632
sg13
I1
sasg20
(lp5633
(dp5634
g7
I132
sg23
VC0220981
p5635
sg10
I18
sg11
Vmetabolic acidosis
p5636
sg13
I2
sasa(dp5637
g2
S'We conclude that 1) Rhcg expression in intercalated cells is necessary for the normal renal response to metabolic acidosis; 2) principal cell Rhcg contributes to both basal and acidosis-stimulated ammonia excretion; and 3) adaptations in Rhbg expression occur in response to acid-loading.\n'
p5638
sg4
(lp5639
(dp5640
g7
I238
sg8
g39
sg10
I4
sg11
VRhbg
p5641
sg13
I1
sa(dp5642
g7
I20
sg8
g39
sg10
I4
sg11
VRhcg
p5643
sg13
I1
sasg20
(lp5644
(dp5645
g7
I114
sg23
VC0001122
p5646
sg10
I8
sg11
Vacidosis
p5647
sg13
I1
sa(dp5648
g7
I104
sg23
VC0220981
p5649
sg10
I18
sg11
Vmetabolic acidosis
p5650
sg13
I2
sasa(dp5651
g2
S'Early onset ataxia with ocular motor apraxia and hypoalbuminemia (EAOH)/ataxia with oculomotor apraxia 1 (AOA1) is an autosomal recessive disorder caused by mutations in the APTX gene.\n'
p5652
sg4
(lp5653
(dp5654
g7
I84
sg8
VP0CE72
p5655
sg10
I20
sg11
Voculomotor apraxia 1
p5656
sg13
I3
sasg20
(lp5657
(dp5658
g7
I106
sg23
VC1859598
p5659
sg10
I4
sg11
VAOA1
p5660
sg13
I1
sa(dp5661
g7
I12
sg23
VC0004134
p5662
sg10
I6
sg11
Vataxia
p5663
sg13
I1
sa(dp5664
g7
I24
sg23
VC3489733
p5665
sg10
I20
sg11
Vocular motor apraxia
p5666
sg13
I3
sa(dp5667
g7
I66
sg23
VC1859598
p5668
sg10
I4
sg11
VEAOH
p5669
sg13
I1
sa(dp5670
g7
I71
sg23
VC1859598
p5671
sg10
I33
sg11
V/ataxia with oculomotor apraxia 1
p5672
sg13
I5
sasa(dp5673
g2
S'Ataxia with ocular motor apraxia type 1 (AOA1) is another autosomal recessive cerebellar ataxia which is associated with oculomotor apraxia, hypoalbuminaemia, and hypercholesterolemia.\n'
p5674
sg4
(lp5675
sg20
(lp5676
(dp5677
g7
I163
sg23
VC0020443
p5678
sg10
I20
sg11
Vhypercholesterolemia
p5679
sg13
I1
sa(dp5680
g7
I121
sg23
VC3489733
p5681
sg10
I18
sg11
Voculomotor apraxia
p5682
sg13
I2
sa(dp5683
g7
I41
sg23
VC1859598
p5684
sg10
I4
sg11
VAOA1
p5685
sg13
I1
sa(dp5686
g7
I0
sg23
VC1859598
p5687
sg10
I39
sg11
VAtaxia with ocular motor apraxia type 1
p5688
sg13
I7
sa(dp5689
g7
I78
sg23
VC0007758
p5690
sg10
I17
sg11
Vcerebellar ataxia
p5691
sg13
I2
sasa(dp5692
g2
S'Mutations in TDP1 and APTX have been linked to Spinocerebellar ataxia with axonal neuropathy (SCAN1) and Ataxia-ocular motor apraxia 1 (AOA1), respectively, while mutations in PNKP are considered to be responsible for Microcephaly with seizures (MCSZ) and Ataxia-ocular motor apraxia 4 (AOA4).\n'
p5693
sg4
(lp5694
(dp5695
g7
I13
sg8
g39
sg10
I4
sg11
VTDP1
p5696
sg13
I1
sa(dp5697
g7
I176
sg8
g39
sg10
I4
sg11
VPNKP
p5698
sg13
I1
sa(dp5699
g7
I287
sg8
VP01720
p5700
sg10
I4
sg11
VAOA4
p5701
sg13
I1
sa(dp5702
g7
I256
sg8
VP01720
p5703
sg10
I29
sg11
VAtaxia-ocular motor apraxia 4
p5704
sg13
I4
sa(dp5705
g7
I136
sg8
VP01720
p5706
sg10
I4
sg11
VAOA1
p5707
sg13
I1
sa(dp5708
g7
I94
sg8
g39
sg10
I5
sg11
VSCAN1
p5709
sg13
I1
sa(dp5710
g7
I105
sg8
VP01720
p5711
sg10
I29
sg11
VAtaxia-ocular motor apraxia 1
p5712
sg13
I4
sasg20
(lp5713
(dp5714
g7
I105
sg23
VC0004134
p5715
sg10
I6
sg11
VAtaxia
p5716
sg13
I1
sa(dp5717
g7
I246
sg23
VC3150667
p5718
sg10
I4
sg11
VMCSZ
p5719
sg13
I1
sa(dp5720
g7
I75
sg23
VC0270921
p5721
sg10
I17
sg11
Vaxonal neuropathy
p5722
sg13
I2
sa(dp5723
g7
I218
sg23
VC3150667
p5724
sg10
I26
sg11
VMicrocephaly with seizures
p5725
sg13
I3
sa(dp5726
g7
I136
sg23
VC1859598
p5727
sg10
I4
sg11
VAOA1
p5728
sg13
I1
sa(dp5729
g7
I94
sg23
VC1846574
p5730
sg10
I5
sg11
VSCAN1
p5731
sg13
I1
sa(dp5732
g7
I105
sg23
VC1859598
p5733
sg10
I29
sg11
VAtaxia-ocular motor apraxia 1
p5734
sg13
I4
sa(dp5735
g7
I47
sg23
VC0087012
p5736
sg10
I22
sg11
VSpinocerebellar ataxia
p5737
sg13
I2
sa(dp5738
g7
I112
sg23
VC3489733
p5739
sg10
I20
sg11
Vocular motor apraxia
p5740
sg13
I3
sasa(dp5741
g2
S'Mutations in APTX cause an inherited human disease syndrome characterized by early-onset progressive ataxia with ocular motor apraxia (AOA1).\n'
p5742
sg4
(lp5743
sg20
(lp5744
(dp5745
g7
I101
sg23
VC0004134
p5746
sg10
I6
sg11
Vataxia
p5747
sg13
I1
sa(dp5748
g7
I113
sg23
VC3489733
p5749
sg10
I20
sg11
Vocular motor apraxia
p5750
sg13
I3
sa(dp5751
g7
I135
sg23
VC1859598
p5752
sg10
I4
sg11
VAOA1
p5753
sg13
I1
sa(dp5754
g7
I51
sg23
VC0039082
p5755
sg10
I8
sg11
Vsyndrome
p5756
sg13
I1
sasa(dp5757
g2
S'Ataxia oculomotor apraxia type 1 (AOA1), an autosomal recessive ataxia, results from a mutation on the aprataxin gene (APTX).\n'
p5758
sg4
(lp5759
(dp5760
g7
I34
sg8
VP0CE72
p5761
sg10
I4
sg11
VAOA1
p5762
sg13
I1
sa(dp5763
g7
I0
sg8
VP0CE72
p5764
sg10
I32
sg11
VAtaxia oculomotor apraxia type 1
p5765
sg13
I5
sasg20
(lp5766
(dp5767
g7
I34
sg23
VC1859598
p5768
sg10
I4
sg11
VAOA1
p5769
sg13
I1
sa(dp5770
g7
I64
sg23
VC0004134
p5771
sg10
I6
sg11
Vataxia
p5772
sg13
I1
sa(dp5773
g7
I0
sg23
VC1859598
p5774
sg10
I32
sg11
VAtaxia oculomotor apraxia type 1
p5775
sg13
I5
sasa(dp5776
g2
S'Early onset ataxia with ocular motor apraxia and hypoalbuminaemia/ataxia-oculomotor apraxia 1 is a recessively inherited ataxia caused by mutations in the aprataxin gene.\n'
p5777
sg4
(lp5778
sg20
(lp5779
(dp5780
g7
I12
sg23
VC0004134
p5781
sg10
I6
sg11
Vataxia
p5782
sg13
I1
sa(dp5783
g7
I12
sg23
VC0004134
p5784
sg10
I6
sg11
Vataxia
p5785
sg13
I1
sa(dp5786
g7
I66
sg23
VC1859598
p5787
sg10
I27
sg11
Vataxia-oculomotor apraxia 1
p5788
sg13
I3
sa(dp5789
g7
I24
sg23
VC3489733
p5790
sg10
I20
sg11
Vocular motor apraxia
p5791
sg13
I3
sasa(dp5792
g2
S'Significant attention has been given on the DNA SSB repair (SSBR) system in neurons, because the impairment of the SSBR causes human neurodegenerative disorders, including early-onset ataxia with ocular motor apraxia and hypoalbuminemia (EAOH), also known as ataxia-oculomotor apraxia Type 1 (AOA1).\n'
p5793
sg4
(lp5794
(dp5795
g7
I293
sg8
VP0CE72
p5796
sg10
I4
sg11
VAOA1
p5797
sg13
I1
sa(dp5798
g7
I259
sg8
VP0CE72
p5799
sg10
I32
sg11
Vataxia-oculomotor apraxia Type 1
p5800
sg13
I4
sasg20
(lp5801
(dp5802
g7
I238
sg23
VC1859598
p5803
sg10
I4
sg11
VEAOH
p5804
sg13
I1
sa(dp5805
g7
I184
sg23
VC0004134
p5806
sg10
I6
sg11
Vataxia
p5807
sg13
I1
sa(dp5808
g7
I293
sg23
VC1859598
p5809
sg10
I4
sg11
VAOA1
p5810
sg13
I1
sa(dp5811
g7
I97
sg23
VC0684336
p5812
sg10
I10
sg11
Vimpairment
p5813
sg13
I1
sa(dp5814
g7
I133
sg23
VC0524851
p5815
sg10
I27
sg11
Vneurodegenerative disorders
p5816
sg13
I2
sa(dp5817
g7
I196
sg23
VC3489733
p5818
sg10
I20
sg11
Vocular motor apraxia
p5819
sg13
I3
sa(dp5820
g7
I259
sg23
VC1859598
p5821
sg10
I32
sg11
Vataxia-oculomotor apraxia Type 1
p5822
sg13
I4
sasa(dp5823
g2
S'EAOH/AOA1 is characterized by early-onset slowly progressive ataxia, ocular motor apraxia, peripheral neuropathy and hypoalbuminemia.\n'
p5824
sg4
(lp5825
sg20
(lp5826
(dp5827
g7
I5
sg23
VC1859598
p5828
sg10
I4
sg11
VAOA1
p5829
sg13
I1
sa(dp5830
g7
I69
sg23
VC3489733
p5831
sg10
I20
sg11
Vocular motor apraxia
p5832
sg13
I3
sa(dp5833
g7
I61
sg23
VC0004134
p5834
sg10
I6
sg11
Vataxia
p5835
sg13
I1
sa(dp5836
g7
I0
sg23
VC1859598
p5837
sg10
I4
sg11
VEAOH
p5838
sg13
I1
sa(dp5839
g7
I91
sg23
VC0031117
p5840
sg10
I21
sg11
Vperipheral neuropathy
p5841
sg13
I2
sasa(dp5842
g2
S"We have demonstrated by in vitro assay that aprataxin, the causative gene product for early-onset ataxia with ocular motor apraxia and hypoalbuminemia/ ataxia with oculomotor apraxia type 1 (EAOH/AOA1), specifically removes 3'-phosphoglycolate and 3'-phosphate ends at DNA 3'-ends, but not 3'-alpha, beta-unsaturated aldehyde ends.\n"
p5843
sg4
(lp5844
sg20
(lp5845
(dp5846
g7
I110
sg23
VC3489733
p5847
sg10
I20
sg11
Vocular motor apraxia
p5848
sg13
I3
sa(dp5849
g7
I164
sg23
VC3489733
p5850
sg10
I18
sg11
Voculomotor apraxia
p5851
sg13
I2
sa(dp5852
g7
I191
sg23
VC1859598
p5853
sg10
I4
sg11
VEAOH
p5854
sg13
I1
sa(dp5855
g7
I98
sg23
VC0004134
p5856
sg10
I6
sg11
Vataxia
p5857
sg13
I1
sa(dp5858
g7
I196
sg23
VC1859598
p5859
sg10
I4
sg11
VAOA1
p5860
sg13
I1
sa(dp5861
g7
I98
sg23
VC0004134
p5862
sg10
I6
sg11
Vataxia
p5863
sg13
I1
sasa(dp5864
g2
S"We have demonstrated by in vitro assay that aprataxin, the causative gene product for early-onset ataxia with ocular motor apraxia and hypoalbuminemia/ataxia with oculomotor apraxia type 1 (EAOH/AOA1), specifically removes 3'-phosphoglycolate and 3'-phosphate ends at DNA 3'-ends, but not 3'-alpha, beta-unsaturated aldehyde ends.\n"
p5865
sg4
(lp5866
sg20
(lp5867
(dp5868
g7
I98
sg23
VC0004134
p5869
sg10
I6
sg11
Vataxia
p5870
sg13
I1
sa(dp5871
g7
I110
sg23
VC3489733
p5872
sg10
I20
sg11
Vocular motor apraxia
p5873
sg13
I3
sa(dp5874
g7
I195
sg23
VC1859598
p5875
sg10
I4
sg11
VAOA1
p5876
sg13
I1
sa(dp5877
g7
I163
sg23
VC3489733
p5878
sg10
I18
sg11
Voculomotor apraxia
p5879
sg13
I2
sa(dp5880
g7
I98
sg23
VC0004134
p5881
sg10
I6
sg11
Vataxia
p5882
sg13
I1
sa(dp5883
g7
I190
sg23
VC1859598
p5884
sg10
I4
sg11
VEAOH
p5885
sg13
I1
sasa(dp5886
g2
S'This study was designed to evaluate the protective effects of vitamin E (VitE) and testosterone on varicocele (VCL)-induced damage in testis and sperm parameters and their effects on Hsp70-2 chaperone expression and on antioxidant status.\n'
p5887
sg4
(lp5888
(dp5889
g7
I183
sg8
VP54652
p5890
sg10
I7
sg11
VHsp70-2
p5891
sg13
I1
sasg20
(lp5892
(dp5893
g7
I99
sg23
VC0042341
p5894
sg10
I10
sg11
Vvaricocele
p5895
sg13
I1
sa(dp5896
g7
I111
sg23
VC0042341
p5897
sg10
I3
sg11
VVCL
p5898
sg13
I1
sasa(dp5899
g2
S'Previous studies have reported that oxidored-nitro domain containing protein 1 (NOR1) is a novel tumor suppressor gene identified in various types of cancer, such as nasopharyngeal carcinoma and cervical cancer.\n'
p5900
sg4
(lp5901
(dp5902
g7
I36
sg8
g39
sg10
I42
sg11
Voxidored-nitro domain containing protein 1
p5903
sg13
I5
sa(dp5904
g7
I80
sg8
g39
sg10
I4
sg11
VNOR1
p5905
sg13
I1
sasg20
(lp5906
(dp5907
g7
I195
sg23
VC0302592
p5908
sg10
I15
sg11
Vcervical cancer
p5909
sg13
I2
sa(dp5910
g7
I150
sg23
VC0006826
p5911
sg10
I6
sg11
Vcancer
p5912
sg13
I1
sa(dp5913
g7
I166
sg23
VC2931822
p5914
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5915
sg13
I2
sa(dp5916
g7
I97
sg23
VC0027651
p5917
sg10
I5
sg11
Vtumor
p5918
sg13
I1
sasa(dp5919
g2
S'The recombinant             expression vector pCDNA3.1-myc-his-NOR1 was constructed and transfected into human             NPC 6-10B nasopharyngeal cancer and HeLa cervical cancer (CCA) cells.\n'
p5920
sg4
(lp5921
(dp5922
g7
I46
sg8
VP12524
p5923
sg10
I21
sg11
VpCDNA3.1-myc-his-NOR1
p5924
sg13
I1
sasg20
(lp5925
(dp5926
g7
I181
sg23
VC0220668
p5927
sg10
I3
sg11
VCCA
p5928
sg13
I1
sa(dp5929
g7
I164
sg23
VC0302592
p5930
sg10
I15
sg11
Vcervical cancer
p5931
sg13
I2
sa(dp5932
g7
I123
sg23
VC2931822
p5933
sg10
I3
sg11
VNPC
p5934
sg13
I1
sa(dp5935
g7
I133
sg23
VC2931822
p5936
sg10
I21
sg11
Vnasopharyngeal cancer
p5937
sg13
I2
sasa(dp5938
g2
S'PTI-1 was detected by cotransfecting human prostate carcinoma DNA into CREF-Trans 6 cells, inducing tumors in nude mice, and isolating genes displaying increased expression in tumor-derived cells by using differential RNA display (DD).\n'
p5939
sg4
(lp5940
(dp5941
g7
I0
sg8
VP68104
p5942
sg10
I5
sg11
VPTI-1
p5943
sg13
I1
sasg20
(lp5944
(dp5945
g7
I100
sg23
VC0027651
p5946
sg10
I5
sg11
Vtumor
p5947
sg13
I1
sa(dp5948
g7
I100
sg23
VC0027651
p5949
sg10
I6
sg11
Vtumors
p5950
sg13
I1
sa(dp5951
g7
I43
sg23
VC0600139
p5952
sg10
I18
sg11
Vprostate carcinoma
p5953
sg13
I2
sasa(dp5954
g2
S'This study demonstrates that GBMs acquire resistance to radiation via upregulation of acid ceramidase (ASAH1) and sphingosine-1-phosphate (Sph-1P).\n'
p5955
sg4
(lp5956
(dp5957
g7
I114
sg8
VP08247
p5958
sg10
I23
sg11
Vsphingosine-1-phosphate
p5959
sg13
I1
sa(dp5960
g7
I86
sg8
g39
sg10
I15
sg11
Vacid ceramidase
p5961
sg13
I2
sa(dp5962
g7
I139
sg8
VP08247
p5963
sg10
I6
sg11
VSph-1P
p5964
sg13
I1
sa(dp5965
g7
I103
sg8
g39
sg10
I5
sg11
VASAH1
p5966
sg13
I1
sasg20
(lp5967
(dp5968
g7
I139
sg23
VC2674218
p5969
sg10
I3
sg11
VSph
p5970
sg13
I1
sasa(dp5971
g2
S'These results suggest that ASAH1 and Sph-1P may be excellent targets for the treatment of new GBMs and recurrent GBMs, especially since the latter overexpresses ASAH1.\n'
p5972
sg4
(lp5973
(dp5974
g7
I27
sg8
g39
sg10
I5
sg11
VASAH1
p5975
sg13
I1
sa(dp5976
g7
I27
sg8
g39
sg10
I5
sg11
VASAH1
p5977
sg13
I1
sa(dp5978
g7
I37
sg8
VP08247
p5979
sg10
I6
sg11
VSph-1P
p5980
sg13
I1
sasg20
(lp5981
(dp5982
g7
I37
sg23
VC2674218
p5983
sg10
I3
sg11
VSph
p5984
sg13
I1
sasa(dp5985
g2
S'Real-time reverse transcriptase PCR analyses of 26 cancer-related genes revealed that seven genes (NPPB, ATF3, DDIT4, CDH10, TSPAN14, TXNIP, and AXL) were significantly upregulated and nine genes (PAGE4, LRP8, SNCAIP, IGFBP5, SLCO2A1, CLDN2, ESRRG, D2HGDH, and PDGFRA) were significantly downregulated.\n'
p5986
sg4
(lp5987
(dp5988
g7
I10
sg8
VP63136
p5989
sg10
I21
sg11
Vreverse transcriptase
p5990
sg13
I2
sa(dp5991
g7
I261
sg8
VP16234
p5992
sg10
I6
sg11
VPDGFRA
p5993
sg13
I1
sa(dp5994
g7
I249
sg8
g39
sg10
I6
sg11
VD2HGDH
p5995
sg13
I1
sa(dp5996
g7
I118
sg8
g39
sg10
I5
sg11
VCDH10
p5997
sg13
I1
sa(dp5998
g7
I226
sg8
g39
sg10
I7
sg11
VSLCO2A1
p5999
sg13
I1
sa(dp6000
g7
I235
sg8
VP57739
p6001
sg10
I5
sg11
VCLDN2
p6002
sg13
I1
sa(dp6003
g7
I111
sg8
g39
sg10
I5
sg11
VDDIT4
p6004
sg13
I1
sa(dp6005
g7
I99
sg8
VP16860
p6006
sg10
I4
sg11
VNPPB
p6007
sg13
I1
sa(dp6008
g7
I105
sg8
VP18847
p6009
sg10
I4
sg11
VATF3
p6010
sg13
I1
sa(dp6011
g7
I197
sg8
g39
sg10
I5
sg11
VPAGE4
p6012
sg13
I1
sa(dp6013
g7
I134
sg8
g39
sg10
I5
sg11
VTXNIP
p6014
sg13
I1
sa(dp6015
g7
I218
sg8
VP24593
p6016
sg10
I6
sg11
VIGFBP5
p6017
sg13
I1
sa(dp6018
g7
I204
sg8
g39
sg10
I4
sg11
VLRP8
p6019
sg13
I1
sa(dp6020
g7
I125
sg8
g39
sg10
I7
sg11
VTSPAN14
p6021
sg13
I1
sasg20
(lp6022
(dp6023
g7
I51
sg23
VC0006826
p6024
sg10
I6
sg11
Vcancer
p6025
sg13
I1
sasa(dp6026
g2
S'We found that patients with essential thrombocythemia exhibited higher serum Sph-1-P and DHSph-1-P concentrations.\n'
p6027
sg4
(lp6028
(dp6029
g7
I77
sg8
VP08247
p6030
sg10
I7
sg11
VSph-1-P
p6031
sg13
I1
sasg20
(lp6032
(dp6033
g7
I77
sg23
VC2674218
p6034
sg10
I3
sg11
VSph
p6035
sg13
I1
sa(dp6036
g7
I28
sg23
VC0040028
p6037
sg10
I25
sg11
Vessential thrombocythemia
p6038
sg13
I2
sasa(dp6039
g2
S'In addition, synphilin-1A blocks the ubiquitylation and degradation of the SIAH substrates synphilin-1 and deleted in colon cancer protein.\n'
p6040
sg4
(lp6041
(dp6042
g7
I75
sg8
g39
sg10
I63
sg11
VSIAH substrates synphilin-1 and deleted in colon cancer protein
p6043
sg13
I9
sasg20
(lp6044
(dp6045
g7
I118
sg23
VC0699790
p6046
sg10
I12
sg11
Vcolon cancer
p6047
sg13
I2
sasa(dp6048
g2
S'KA B. bovis parasites are currently in use as a live attenuated vaccine for bovine babesiosis in Australia.\n'
p6049
sg4
(lp6050
sg20
(lp6051
(dp6052
g7
I76
sg23
VC0276852
p6053
sg10
I17
sg11
Vbovine babesiosis
p6054
sg13
I2
sasa(dp6055
g2
S'PurposeIn 2012 we reported in six individuals a clinical condition almost indistinguishable from PLOD1-kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS), caused by biallelic mutations in FKBP14, and characterized by progressive kyphoscoliosis, myopathy, and hearing loss in addition to connective tissue abnormalities such as joint hypermobility and hyperelastic skin.\n'
p6056
sg4
(lp6057
(dp6058
g7
I188
sg8
g39
sg10
I6
sg11
VFKBP14
p6059
sg13
I1
sasg20
(lp6060
(dp6061
g7
I57
sg23
VC0012634
p6062
sg10
I9
sg11
Vcondition
p6063
sg13
I1
sa(dp6064
g7
I245
sg23
VC0026848
p6065
sg10
I8
sg11
Vmyopathy
p6066
sg13
I1
sa(dp6067
g7
I118
sg23
VC0013720
p6068
sg10
I22
sg11
VEhlers-Danlos syndrome
p6069
sg13
I2
sa(dp6070
g7
I229
sg23
VC0600033
p6071
sg10
I14
sg11
Vkyphoscoliosis
p6072
sg13
I1
sa(dp6073
g7
I259
sg23
VC0011053
p6074
sg10
I12
sg11
Vhearing loss
p6075
sg13
I2
sa(dp6076
g7
I327
sg23
VC0086437
p6077
sg10
I19
sg11
Vjoint hypermobility
p6078
sg13
I2
sasa(dp6079
g2
S'Molecular analysis of the PLOD1 gene revealed that she had a novel homozygous p.Pro622Argfs*3 (c. 1863_1864dupCG) mutation in exon 17 that is expected to cause complete loss of the enzyme lysyl hydroxylase 1 and to cause kyphoscoliotic type of the Ehlers-Danlos syndrome.\n'
p6080
sg4
(lp6081
(dp6082
g7
I181
sg8
g39
sg10
I26
sg11
Venzyme lysyl hydroxylase 1
p6083
sg13
I4
sa(dp6084
g7
I26
sg8
g39
sg10
I10
sg11
VPLOD1 gene
p6085
sg13
I2
sasg20
(lp6086
(dp6087
g7
I248
sg23
VC0013720
p6088
sg10
I22
sg11
VEhlers-Danlos syndrome
p6089
sg13
I2
sasa(dp6090
g2
S'We describe a child with the kyphoscoliotic type of the Ehlers-Danlos syndrome with a novel mutation of the PLOD1 gene.\n'
p6091
sg4
(lp6092
(dp6093
g7
I108
sg8
g39
sg10
I10
sg11
VPLOD1 gene
p6094
sg13
I2
sasg20
(lp6095
(dp6096
g7
I86
sg23
VC2985438
p6097
sg10
I14
sg11
Vnovel mutation
p6098
sg13
I2
sa(dp6099
g7
I56
sg23
VC0013720
p6100
sg10
I22
sg11
VEhlers-Danlos syndrome
p6101
sg13
I2
sasa(dp6102
g2
S'The absence of FKBP22 leads to a kyphoscoliotic type of Ehlers-Danlos syndrome (EDS), and this type of EDS is classified as EDS type VI, which can also be caused by a deficiency in lysyl-hydroxylase 1.\n'
p6103
sg4
(lp6104
(dp6105
g7
I15
sg8
g39
sg10
I6
sg11
VFKBP22
p6106
sg13
I1
sasg20
(lp6107
(dp6108
g7
I80
sg23
VC0013720
p6109
sg10
I3
sg11
VEDS
p6110
sg13
I1
sa(dp6111
g7
I80
sg23
VC0013720
p6112
sg10
I3
sg11
VEDS
p6113
sg13
I1
sa(dp6114
g7
I80
sg23
VC0013720
p6115
sg10
I3
sg11
VEDS
p6116
sg13
I1
sa(dp6117
g7
I56
sg23
VC0013720
p6118
sg10
I22
sg11
VEhlers-Danlos syndrome
p6119
sg13
I2
sasa(dp6120
g2
S'The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA) (OMIM 225400) is a rare inheritable connective tissue disorder characterized by a deficiency of collagen lysyl hydroxylase 1 (LH1; EC 1.14.11.4) due to mutations in PLOD1.\n'
p6121
sg4
(lp6122
(dp6123
g7
I186
sg8
g39
sg10
I3
sg11
VLH1
p6124
sg13
I1
sa(dp6125
g7
I225
sg8
g39
sg10
I5
sg11
VPLOD1
p6126
sg13
I1
sa(dp6127
g7
I156
sg8
g39
sg10
I28
sg11
Vcollagen lysyl hydroxylase 1
p6128
sg13
I4
sasg20
(lp6129
(dp6130
g7
I27
sg23
VC0013720
p6131
sg10
I22
sg11
VEhlers-Danlos syndrome
p6132
sg13
I2
sa(dp6133
g7
I96
sg23
VC0009782
p6134
sg10
I26
sg11
Vconnective tissue disorder
p6135
sg13
I3
sa(dp6136
g7
I51
sg23
VC0013720
p6137
sg10
I3
sg11
VEDS
p6138
sg13
I1
sasa(dp6139
g2
S'PLAN syndrome encompasses a group of phenotypes with a different age of onset: classic infantile neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy of childhood-onset (atypical NAD) and adult-onset PLA2G6-related dystonia-parkinsonism (PARK14).\n'
p6140
sg4
(lp6141
(dp6142
g7
I246
sg8
g39
sg10
I6
sg11
VPARK14
p6143
sg13
I1
sasg20
(lp6144
(dp6145
g7
I97
sg23
VC0338473
p6146
sg10
I21
sg11
Vneuroaxonal dystrophy
p6147
sg13
I2
sa(dp6148
g7
I120
sg23
VC0270724
p6149
sg10
I4
sg11
VINAD
p6150
sg13
I1
sa(dp6151
g7
I87
sg23
VC0270724
p6152
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6153
sg13
I3
sa(dp6154
g7
I5
sg23
VC0039082
p6155
sg10
I8
sg11
Vsyndrome
p6156
sg13
I1
sa(dp6157
g7
I121
sg23
VC1850380
p6158
sg10
I3
sg11
VNAD
p6159
sg13
I1
sa(dp6160
g7
I223
sg23
VC0393593
p6161
sg10
I8
sg11
Vdystonia
p6162
sg13
I1
sa(dp6163
g7
I232
sg23
VC0242422
p6164
sg10
I12
sg11
Vparkinsonism
p6165
sg13
I1
sa(dp6166
g7
I246
sg23
VC2751842
p6167
sg10
I6
sg11
VPARK14
p6168
sg13
I1
sa(dp6169
g7
I0
sg23
VC0270724
p6170
sg10
I4
sg11
VPLAN
p6171
sg13
I1
sasa(dp6172
g2
S'A recessive mutation in PLA2G6, which is known to cause infantile neuroaxonal dystrophy (INAD) and neurodegeneration associated with brain iron accumulation (NBIA), has recently been shown to be responsible for PARK14-linked dystonia-parkinsonism.\n'
p6173
sg4
(lp6174
(dp6175
g7
I24
sg8
g39
sg10
I6
sg11
VPLA2G6
p6176
sg13
I1
sa(dp6177
g7
I211
sg8
g39
sg10
I6
sg11
VPARK14
p6178
sg13
I1
sasg20
(lp6179
(dp6180
g7
I89
sg23
VC0270724
p6181
sg10
I4
sg11
VINAD
p6182
sg13
I1
sa(dp6183
g7
I211
sg23
VC2751842
p6184
sg10
I6
sg11
VPARK14
p6185
sg13
I1
sa(dp6186
g7
I234
sg23
VC0242422
p6187
sg10
I12
sg11
Vparkinsonism
p6188
sg13
I1
sa(dp6189
g7
I225
sg23
VC0393593
p6190
sg10
I8
sg11
Vdystonia
p6191
sg13
I1
sa(dp6192
g7
I99
sg23
VC0027746
p6193
sg10
I17
sg11
Vneurodegeneration
p6194
sg13
I1
sa(dp6195
g7
I56
sg23
VC0270724
p6196
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6197
sg13
I3
sasa(dp6198
g2
S'Recessively inherited mutations of the PLA2G6 gene are causative of infantile neuroaxonal dystrophy and other PLA2G6-associated neurodegeneration, which includes conditions known as atypical neuroaxonal dystrophy, Karak syndrome and early-onset dystonia-parkinsonism with cognitive impairment.\n'
p6199
sg4
(lp6200
(dp6201
g7
I39
sg8
g39
sg10
I6
sg11
VPLA2G6
p6202
sg13
I1
sa(dp6203
g7
I39
sg8
g39
sg10
I11
sg11
VPLA2G6 gene
p6204
sg13
I2
sasg20
(lp6205
(dp6206
g7
I78
sg23
VC0338473
p6207
sg10
I21
sg11
Vneuroaxonal dystrophy
p6208
sg13
I2
sa(dp6209
g7
I272
sg23
VC0338656
p6210
sg10
I20
sg11
Vcognitive impairment
p6211
sg13
I2
sa(dp6212
g7
I110
sg23
VC0270724
p6213
sg10
I35
sg11
VPLA2G6-associated neurodegeneration
p6214
sg13
I2
sa(dp6215
g7
I68
sg23
VC0270724
p6216
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6217
sg13
I3
sa(dp6218
g7
I245
sg23
VC0393593
p6219
sg10
I8
sg11
Vdystonia
p6220
sg13
I1
sa(dp6221
g7
I214
sg23
VC2750220
p6222
sg10
I14
sg11
VKarak syndrome
p6223
sg13
I2
sa(dp6224
g7
I254
sg23
VC0242422
p6225
sg10
I12
sg11
Vparkinsonism
p6226
sg13
I1
sasa(dp6227
g2
S'Recessive mutations in PLA2G6 have been associated with different neurodegenerative disorders, including infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation and more recently, early-onset dystonia parkinsonism.\n'
p6228
sg4
(lp6229
(dp6230
g7
I23
sg8
g39
sg10
I6
sg11
VPLA2G6
p6231
sg13
I1
sasg20
(lp6232
(dp6233
g7
I138
sg23
VC0027746
p6234
sg10
I17
sg11
Vneurodegeneration
p6235
sg13
I1
sa(dp6236
g7
I225
sg23
VC0242422
p6237
sg10
I12
sg11
Vparkinsonism
p6238
sg13
I1
sa(dp6239
g7
I66
sg23
VC0524851
p6240
sg10
I27
sg11
Vneurodegenerative disorders
p6241
sg13
I2
sa(dp6242
g7
I216
sg23
VC0393593
p6243
sg10
I8
sg11
Vdystonia
p6244
sg13
I1
sa(dp6245
g7
I105
sg23
VC0270724
p6246
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6247
sg13
I3
sasa(dp6248
g2
S'Mutations in PLA2G6 were identified in patients with a spectrum of neurodegenerative conditions, such as infantile neuroaxonal dystrophy (INAD), atypical late-onset neuroaxonal dystrophy (ANAD) and dystonia parkinsonism complex (DPC).\n'
p6249
sg4
(lp6250
(dp6251
g7
I13
sg8
g39
sg10
I6
sg11
VPLA2G6
p6252
sg13
I1
sasg20
(lp6253
(dp6254
g7
I207
sg23
VC0242422
p6255
sg10
I12
sg11
Vparkinsonism
p6256
sg13
I1
sa(dp6257
g7
I115
sg23
VC0338473
p6258
sg10
I21
sg11
Vneuroaxonal dystrophy
p6259
sg13
I2
sa(dp6260
g7
I198
sg23
VC0393593
p6261
sg10
I8
sg11
Vdystonia
p6262
sg13
I1
sa(dp6263
g7
I138
sg23
VC0270724
p6264
sg10
I4
sg11
VINAD
p6265
sg13
I1
sa(dp6266
g7
I105
sg23
VC0270724
p6267
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6268
sg13
I3
sasa(dp6269
g2
S'Mutations in PLA2G6 are associated with a number of neurodegenerative disorders including neurodegeneration with brain iron accumulation (NBIA), infantile neuroaxonal dystrophy (INAD), and dystonia parkinsonism, collectively known as PLA2G6-associated neurodegeneration (PLAN).\n'
p6270
sg4
(lp6271
(dp6272
g7
I13
sg8
g39
sg10
I6
sg11
VPLA2G6
p6273
sg13
I1
sa(dp6274
g7
I13
sg8
g39
sg10
I6
sg11
VPLA2G6
p6275
sg13
I1
sasg20
(lp6276
(dp6277
g7
I52
sg23
VC0524851
p6278
sg10
I27
sg11
Vneurodegenerative disorders
p6279
sg13
I2
sa(dp6280
g7
I189
sg23
VC0393593
p6281
sg10
I8
sg11
Vdystonia
p6282
sg13
I1
sa(dp6283
g7
I178
sg23
VC0270724
p6284
sg10
I4
sg11
VINAD
p6285
sg13
I1
sa(dp6286
g7
I271
sg23
VC0270724
p6287
sg10
I4
sg11
VPLAN
p6288
sg13
I1
sa(dp6289
g7
I234
sg23
VC0270724
p6290
sg10
I35
sg11
VPLA2G6-associated neurodegeneration
p6291
sg13
I2
sa(dp6292
g7
I90
sg23
VC0027746
p6293
sg10
I17
sg11
Vneurodegeneration
p6294
sg13
I1
sa(dp6295
g7
I198
sg23
VC0242422
p6296
sg10
I12
sg11
Vparkinsonism
p6297
sg13
I1
sa(dp6298
g7
I145
sg23
VC0270724
p6299
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6300
sg13
I3
sasa(dp6301
g2
S'PLA2G6-associated neurodegeneration (PLAN) is a recessive neurodegenerative disorder characterized by three distinct phenotypes: infantile neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (atypical NAD), and PLA2G6-related dystonia-parkinsonism.\n'
p6302
sg4
(lp6303
(dp6304
g7
I0
sg8
g39
sg10
I6
sg11
VPLA2G6
p6305
sg13
I1
sa(dp6306
g7
I0
sg8
g39
sg10
I6
sg11
VPLA2G6
p6307
sg13
I1
sasg20
(lp6308
(dp6309
g7
I139
sg23
VC0338473
p6310
sg10
I21
sg11
Vneuroaxonal dystrophy
p6311
sg13
I2
sa(dp6312
g7
I162
sg23
VC0270724
p6313
sg10
I4
sg11
VINAD
p6314
sg13
I1
sa(dp6315
g7
I129
sg23
VC0270724
p6316
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6317
sg13
I3
sa(dp6318
g7
I0
sg23
VC0270724
p6319
sg10
I35
sg11
VPLA2G6-associated neurodegeneration
p6320
sg13
I2
sa(dp6321
g7
I163
sg23
VC1850380
p6322
sg10
I3
sg11
VNAD
p6323
sg13
I1
sa(dp6324
g7
I235
sg23
VC0393593
p6325
sg10
I8
sg11
Vdystonia
p6326
sg13
I1
sa(dp6327
g7
I58
sg23
VC0524851
p6328
sg10
I26
sg11
Vneurodegenerative disorder
p6329
sg13
I2
sa(dp6330
g7
I37
sg23
VC0270724
p6331
sg10
I4
sg11
VPLAN
p6332
sg13
I1
sa(dp6333
g7
I244
sg23
VC0242422
p6334
sg10
I12
sg11
Vparkinsonism
p6335
sg13
I1
sasa(dp6336
g2
S'Three patients presented with PLA2G6-associated neurodegeneration (PLAN); two had infantile neuroaxonal dystrophy (INAD) and one had adult-onset dystonia-parkinsonism.\n'
p6337
sg4
(lp6338
sg20
(lp6339
(dp6340
g7
I67
sg23
VC0270724
p6341
sg10
I4
sg11
VPLAN
p6342
sg13
I1
sa(dp6343
g7
I133
sg23
VC0752197
p6344
sg10
I20
sg11
Vadult-onset dystonia
p6345
sg13
I2
sa(dp6346
g7
I82
sg23
VC0270724
p6347
sg10
I31
sg11
Vinfantile neuroaxonal dystrophy
p6348
sg13
I3
sa(dp6349
g7
I154
sg23
VC0242422
p6350
sg10
I12
sg11
Vparkinsonism
p6351
sg13
I1
sa(dp6352
g7
I30
sg23
VC0270724
p6353
sg10
I35
sg11
VPLA2G6-associated neurodegeneration
p6354
sg13
I2
sa(dp6355
g7
I115
sg23
VC0270724
p6356
sg10
I4
sg11
VINAD
p6357
sg13
I1
sasa(dp6358
g2
S'The incidence of abdominal pain (X(2) = 6.588, P = 0.010), acute cholecystitis (X(2) = 29.176, P = 0.000), acute cholangitis (X(2) = 6.349, P = 0.012), choledocholithiasis (X(2) = 16.744, P = 0.000), carcinoembryonic antigen test (P = 0.007), CA125 (P = 0.001), and diffuse gallbladder wall thickening (X(2) = 6.031, P = 0.014), continued mucosal line (X(2) = 15.745, P = 0.000), homogeneous enhancement of mucosal line (X(2) = 19.947, P = 0.000), submucosal hypoattenuated nodules or band (X(2) = 18.607, P = 0.000) in computed tomography demonstrated statistically significant differences between cases of xanthogranulomatous cholecystitis and gallbladder cancer.\n'
p6359
sg4
(lp6360
(dp6361
g7
I200
sg8
VP40198
p6362
sg10
I24
sg11
Vcarcinoembryonic antigen
p6363
sg13
I2
sasg20
(lp6364
(dp6365
g7
I646
sg23
VC0153452
p6366
sg10
I18
sg11
Vgallbladder cancer
p6367
sg13
I2
sa(dp6368
g7
I59
sg23
VC0149520
p6369
sg10
I19
sg11
Vacute cholecystitis
p6370
sg13
I2
sa(dp6371
g7
I608
sg23
VC1337035
p6372
sg10
I33
sg11
Vxanthogranulomatous cholecystitis
p6373
sg13
I2
sa(dp6374
g7
I474
sg23
VC0028259
p6375
sg10
I7
sg11
Vnodules
p6376
sg13
I1
sa(dp6377
g7
I152
sg23
VC0701818
p6378
sg10
I19
sg11
Vcholedocholithiasis
p6379
sg13
I1
sa(dp6380
g7
I17
sg23
VC0000737
p6381
sg10
I14
sg11
Vabdominal pain
p6382
sg13
I2
sa(dp6383
g7
I107
sg23
VC0267917
p6384
sg10
I17
sg11
Vacute cholangitis
p6385
sg13
I2
sasa(dp6386
g2
S'Radioimmunoassay for serum CA19-9, CA125 and carcinoembryonic antigen (CEA) was obtained from 86 patients with hyperbilirubinemia, including 50 patients with malignant jaundice (pancreatic carcinoma 20, biliary tract carcinoma 30) and 36 patients with benign jaundice (choledocholithiasis 33, acute cholangitis 3).\n'
p6387
sg4
(lp6388
(dp6389
g7
I71
sg8
VP40198
p6390
sg10
I3
sg11
VCEA
p6391
sg13
I1
sa(dp6392
g7
I35
sg8
g39
sg10
I5
sg11
VCA125
p6393
sg13
I1
sa(dp6394
g7
I45
sg8
VP40198
p6395
sg10
I24
sg11
Vcarcinoembryonic antigen
p6396
sg13
I2
sasg20
(lp6397
(dp6398
g7
I189
sg23
VC0007097
p6399
sg10
I9
sg11
Vcarcinoma
p6400
sg13
I1
sa(dp6401
g7
I293
sg23
VC0267917
p6402
sg10
I17
sg11
Vacute cholangitis
p6403
sg13
I2
sa(dp6404
g7
I178
sg23
VC0235974
p6405
sg10
I20
sg11
Vpancreatic carcinoma
p6406
sg13
I2
sa(dp6407
g7
I269
sg23
VC0701818
p6408
sg10
I19
sg11
Vcholedocholithiasis
p6409
sg13
I1
sa(dp6410
g7
I168
sg23
VC0022346
p6411
sg10
I8
sg11
Vjaundice
p6412
sg13
I1
sa(dp6413
g7
I168
sg23
VC0022346
p6414
sg10
I8
sg11
Vjaundice
p6415
sg13
I1
sa(dp6416
g7
I111
sg23
VC0020433
p6417
sg10
I18
sg11
Vhyperbilirubinemia
p6418
sg13
I1
sasa(dp6419
g2
S'Furthermore, an increased risk of non-astrocytoma subtype associated with EGFRrs9642393, EME1rs12450550, ATMrs170548, and GLTSCRrs1035938 as well as a decreased risk of this subtype associated with XRCC4rs7721416 and XRCC4rs2662242 were detected.This study indicates SNPs in EGFR, ERCC1, CHAF1A, XRCC1, EME1, ATM, GLTSCR1, and XRCC4 may be associated with the risk of PBTs.\n'
p6420
sg4
(lp6421
(dp6422
g7
I198
sg8
g39
sg10
I5
sg11
VXRCC4
p6423
sg13
I1
sa(dp6424
g7
I288
sg8
g39
sg10
I6
sg11
VCHAF1A
p6425
sg13
I1
sa(dp6426
g7
I89
sg8
g39
sg10
I4
sg11
VEME1
p6427
sg13
I1
sa(dp6428
g7
I314
sg8
g39
sg10
I7
sg11
VGLTSCR1
p6429
sg13
I1
sa(dp6430
g7
I105
sg8
g39
sg10
I3
sg11
VATM
p6431
sg13
I1
sa(dp6432
g7
I281
sg8
VP07992
p6433
sg10
I5
sg11
VERCC1
p6434
sg13
I1
sa(dp6435
g7
I296
sg8
VP18887
p6436
sg10
I5
sg11
VXRCC1
p6437
sg13
I1
sasg20
(lp6438
(dp6439
g7
I38
sg23
VC0004114
p6440
sg10
I11
sg11
Vastrocytoma
p6441
sg13
I1
sasa(dp6442
g2
S'We observed significantly increased risk of meningioma with the T variant of GLTSCR1 rs1035938 (OR(CT/TT) = 3.5; 95% confidence interval: 1.8-6.9; P(trend) .0006), which persisted after controlling for multiple comparisons (P = .019).\n'
p6443
sg4
(lp6444
(dp6445
g7
I77
sg8
g39
sg10
I17
sg11
VGLTSCR1 rs1035938
p6446
sg13
I2
sa(dp6447
g7
I64
sg8
VP26640
p6448
sg10
I9
sg11
VT variant
p6449
sg13
I2
sasg20
(lp6450
(dp6451
g7
I44
sg23
VC0025286
p6452
sg10
I10
sg11
Vmeningioma
p6453
sg13
I1
sasa(dp6454
g2
S'However, the results might warrant clarification in additional series in conjunction with the nearby putative glioma suppressor genes (GLTSCR1 and GLTSCR2).\n'
p6455
sg4
(lp6456
(dp6457
g7
I147
sg8
g39
sg10
I7
sg11
VGLTSCR2
p6458
sg13
I1
sa(dp6459
g7
I135
sg8
g39
sg10
I7
sg11
VGLTSCR1
p6460
sg13
I1
sasg20
(lp6461
(dp6462
g7
I110
sg23
VC0017638
p6463
sg10
I6
sg11
Vglioma
p6464
sg13
I1
sasa(dp6465
g2
S'The authors have previously described a 150-kilobase minimal deletion region in gliomas that maps to 19q13.33 and contains 3 novel candidate genes (GLTSCR1, EHD2, and GLTSCR2).\n'
p6466
sg4
(lp6467
(dp6468
g7
I148
sg8
g39
sg10
I7
sg11
VGLTSCR1
p6469
sg13
I1
sa(dp6470
g7
I167
sg8
g39
sg10
I7
sg11
VGLTSCR2
p6471
sg13
I1
sa(dp6472
g7
I157
sg8
g39
sg10
I4
sg11
VEHD2
p6473
sg13
I1
sasg20
(lp6474
(dp6475
g7
I80
sg23
VC0017638
p6476
sg10
I7
sg11
Vgliomas
p6477
sg13
I1
sasa(dp6478
g2
S'The prevalence of a germline GLTSCR1-exon-1 T allele (SNP rs1035938) was 40% in cases with oligodendrogliomas compared with 27% in controls (P = 0.029), and the prevalence of an ERCC2-exon-22 T allele (SNP rs1052555) was 35% in cases with oligodendrogliomas compared with 18% in controls (P = 0.043).\n'
p6479
sg4
(lp6480
(dp6481
g7
I29
sg8
g39
sg10
I23
sg11
VGLTSCR1-exon-1 T allele
p6482
sg13
I3
sa(dp6483
g7
I54
sg8
g39
sg10
I13
sg11
VSNP rs1035938
p6484
sg13
I2
sa(dp6485
g7
I202
sg8
g39
sg10
I13
sg11
VSNP rs1052555
p6486
sg13
I2
sa(dp6487
g7
I178
sg8
VP18074
p6488
sg10
I22
sg11
VERCC2-exon-22 T allele
p6489
sg13
I3
sasg20
(lp6490
(dp6491
g7
I91
sg23
VC0028945
p6492
sg10
I18
sg11
Voligodendrogliomas
p6493
sg13
I1
sa(dp6494
g7
I91
sg23
VC0028945
p6495
sg10
I18
sg11
Voligodendrogliomas
p6496
sg13
I1
sasa(dp6497
g2
S'Cases with oligodendrogliomas with the 19q deletion had a significantly higher frequency of the GLTSCR1-exon-1 T allele compared with cases without the 19q deletion (P = 0.01).\n'
p6498
sg4
(lp6499
(dp6500
g7
I96
sg8
g39
sg10
I23
sg11
VGLTSCR1-exon-1 T allele
p6501
sg13
I3
sasg20
(lp6502
(dp6503
g7
I11
sg23
VC0028945
p6504
sg10
I18
sg11
Voligodendrogliomas
p6505
sg13
I1
sasa(dp6506
g2
S'It was noteworthy that cases with gliomas who were homozygous for the GLTSCR1-exon-1 T allele had a significantly better survival: 77% and 68% survival at 2 and 5 years compared with 56% and 34% for other genotypes (P = 0.02, log-rank test).\n'
p6507
sg4
(lp6508
(dp6509
g7
I70
sg8
g39
sg10
I23
sg11
VGLTSCR1-exon-1 T allele
p6510
sg13
I3
sasg20
(lp6511
(dp6512
g7
I34
sg23
VC0017638
p6513
sg10
I7
sg11
Vgliomas
p6514
sg13
I1
sasa(dp6515
g2
S'These results suggested that alterations in GLTSCR1 (or a closely linked gene) were associated with the development and progression of oligodendroglioma.\n'
p6516
sg4
(lp6517
(dp6518
g7
I44
sg8
g39
sg10
I7
sg11
VGLTSCR1
p6519
sg13
I1
sasg20
(lp6520
(dp6521
g7
I135
sg23
VC0028945
p6522
sg10
I17
sg11
Voligodendroglioma
p6523
sg13
I1
sasa(dp6524
g2
S'These data suggest that PDLSCs promote osteoclast differentiation via Runx2 upregulating RANKL and downregulating OPG, leading to enhanced root resorption that results in physiological exfoliation of primary teeth.\n'
p6525
sg4
(lp6526
(dp6527
g7
I70
sg8
g39
sg10
I5
sg11
VRunx2
p6528
sg13
I1
sa(dp6529
g7
I89
sg8
g39
sg10
I5
sg11
VRANKL
p6530
sg13
I1
sasg20
(lp6531
(dp6532
g7
I139
sg23
VC0035851
p6533
sg10
I15
sg11
Vroot resorption
p6534
sg13
I2
sasa(dp6535
g2
S'E-selectin overexpression in association with BRAF mutation status could promote a more aggressive phenotype in papillary thyroid carcinoma.\n'
p6536
sg4
(lp6537
(dp6538
g7
I46
sg8
VP15056
p6539
sg10
I4
sg11
VBRAF
p6540
sg13
I1
sa(dp6541
g7
I0
sg8
VP16581
p6542
sg10
I10
sg11
VE-selectin
p6543
sg13
I1
sasg20
(lp6544
(dp6545
g7
I88
sg23
VC0001807
p6546
sg10
I10
sg11
Vaggressive
p6547
sg13
I1
sa(dp6548
g7
I112
sg23
VC0238463
p6549
sg10
I27
sg11
Vpapillary thyroid carcinoma
p6550
sg13
I3
sasa(dp6551
g2
S'Se le ha relacionado principalmente con aneurismas y otros padecimientos, pero no con paraganglioma.\n'
p6552
sg4
(lp6553
sg20
(lp6554
(dp6555
g7
I86
sg23
VC0030421
p6556
sg10
I13
sg11
Vparaganglioma
p6557
sg13
I1
sasa(dp6558
g2
S'Se le coloco un marcapasos temporal en el preoperatorio y despues de la reseccion del paraganglioma carotideo, de acuerdo con los estudios de electrofisiologia cardiaca, se le dio de alta de manera definitiva, sin necesidad de emplear electroestimulacion definitiva.\n'
p6559
sg4
(lp6560
(dp6561
g7
I210
sg8
g39
sg10
I3
sg11
Vsin
p6562
sg13
I1
sa(dp6563
g7
I0
sg8
g39
sg10
I57
sg11
VSe le coloco un marcapasos temporal en el preoperatorio y
p6564
sg13
I10
sasg20
(lp6565
(dp6566
g7
I86
sg23
VC0030421
p6567
sg10
I13
sg11
Vparaganglioma
p6568
sg13
I1
sasa(dp6569
g2
S'We             investigated the liver colonization of pancreatic cancer cells under hepatic ischemia-reperfusion             and examined the involvement of E-selectin and its ligands.\n'
p6570
sg4
(lp6571
(dp6572
g7
I157
sg8
VP16581
p6573
sg10
I10
sg11
VE-selectin
p6574
sg13
I1
sasg20
(lp6575
(dp6576
g7
I54
sg23
VC0235974
p6577
sg10
I17
sg11
Vpancreatic cancer
p6578
sg13
I2
sa(dp6579
g7
I84
sg23
VC0920569
p6580
sg10
I16
sg11
Vhepatic ischemia
p6581
sg13
I2
sasa(dp6582
g2
S'Hepatic ischemia-reperfusion increases             liver metastases and E-selectin expression in pancreatic cancer.\n'
p6583
sg4
(lp6584
(dp6585
g7
I72
sg8
VP16581
p6586
sg10
I10
sg11
VE-selectin
p6587
sg13
I1
sasg20
(lp6588
(dp6589
g7
I51
sg23
VC0494165
p6590
sg10
I16
sg11
Vliver metastases
p6591
sg13
I2
sa(dp6592
g7
I0
sg23
VC0920569
p6593
sg10
I16
sg11
VHepatic ischemia
p6594
sg13
I2
sa(dp6595
g7
I97
sg23
VC0235974
p6596
sg10
I17
sg11
Vpancreatic cancer
p6597
sg13
I2
sasa(dp6598
g2
S'To evaluate the possibility that L. donovani utilize LFA-3 mediated evasion pathway in human visceral leishmaniasis; in vitro experiments were performed for measurement of pathogenic cytokine IL-10 and Foxp3 mRNA expression.\n'
p6599
sg4
(lp6600
(dp6601
g7
I183
sg8
VP13236
p6602
sg10
I14
sg11
Vcytokine IL-10
p6603
sg13
I2
sa(dp6604
g7
I202
sg8
g39
sg10
I10
sg11
VFoxp3 mRNA
p6605
sg13
I2
sa(dp6606
g7
I53
sg8
VP19256
p6607
sg10
I5
sg11
VLFA-3
p6608
sg13
I1
sasg20
(lp6609
(dp6610
g7
I93
sg23
VC0023290
p6611
sg10
I22
sg11
Vvisceral leishmaniasis
p6612
sg13
I2
sasa(dp6613
g2
S'This study recommends further investigations to strengthen the pathogenic and prognostic significance of LFA-3 in visceral leishmaniasis.\n'
p6614
sg4
(lp6615
(dp6616
g7
I105
sg8
VP19256
p6617
sg10
I5
sg11
VLFA-3
p6618
sg13
I1
sasg20
(lp6619
(dp6620
g7
I114
sg23
VC0023290
p6621
sg10
I22
sg11
Vvisceral leishmaniasis
p6622
sg13
I2
sasa(dp6623
g2
S'The expression products of Mr 69,000 GST-4BX/CD58 and Mr 41,000 GST-4BX were present mainly in the form of inclusion bodies and soluble substance respectively, and both were recognized by sera of cysticercosis patients.\n'
p6624
sg4
(lp6625
(dp6626
g7
I45
sg8
VP19256
p6627
sg10
I4
sg11
VCD58
p6628
sg13
I1
sa(dp6629
g7
I37
sg8
g39
sg10
I3
sg11
VGST
p6630
sg13
I1
sa(dp6631
g7
I54
sg8
VP08235
p6632
sg10
I17
sg11
VMr 41,000 GST-4BX
p6633
sg13
I3
sasg20
(lp6634
(dp6635
g7
I196
sg23
VC0010678
p6636
sg10
I13
sg11
Vcysticercosis
p6637
sg13
I1
sasa(dp6638
g2
S'25 children at risk of developing dyslexia were trained with Hoeren, Lauschen, Lernen 1 und 2 (Kuspert &amp; Schneider, 2008; Plume &amp; Schneider, 2004) by their kindergarten teachers and were compared with 60 untrained at-risk children.\n'
p6639
sg4
(lp6640
sg20
(lp6641
(dp6642
g7
I34
sg23
VC0476254
p6643
sg10
I8
sg11
Vdyslexia
p6644
sg13
I1
sasa(dp6645
g2
S'Using Sprague-Dawley rats and rat renal proximal tubular cells (NRK52E), we determined the potential involvement of Fgf10, Fgfr2 and AR in DBP-induced renal fibrosis.\n'
p6646
sg4
(lp6647
(dp6648
g7
I116
sg8
g39
sg10
I5
sg11
VFgf10
p6649
sg13
I1
sasg20
(lp6650
(dp6651
g7
I151
sg23
VC0151650
p6652
sg10
I14
sg11
Vrenal fibrosis
p6653
sg13
I2
sasa(dp6654
g2
S'Our findings suggest the potential involvement of Fgf10/Fgfr2 and AR in renal fibrosis of adult male rat offspring induced by prenatal exposure to DBP.\n'
p6655
sg4
(lp6656
(dp6657
g7
I50
sg8
g39
sg10
I5
sg11
VFgf10
p6658
sg13
I1
sasg20
(lp6659
(dp6660
g7
I72
sg23
VC0151650
p6661
sg10
I14
sg11
Vrenal fibrosis
p6662
sg13
I2
sasa(dp6663
g2
S'MTLE hippocampi of subjects without psychiatric history, MTLE + major depression, MTLE + interictal psychosis derived from epilepsy surgery, and control necropsies were investigated for p75(NTR), TrkB, TrkA, and TrkC immunohistochemistry.\n'
p6664
sg4
(lp6665
(dp6666
g7
I196
sg8
g39
sg10
I4
sg11
VTrkB
p6667
sg13
I1
sa(dp6668
g7
I212
sg8
g39
sg10
I4
sg11
VTrkC
p6669
sg13
I1
sa(dp6670
g7
I186
sg8
VP20333
p6671
sg10
I3
sg11
Vp75
p6672
sg13
I1
sa(dp6673
g7
I190
sg8
VP30989
p6674
sg10
I3
sg11
VNTR
p6675
sg13
I1
sa(dp6676
g7
I202
sg8
VP06753
p6677
sg10
I4
sg11
VTrkA
p6678
sg13
I1
sasg20
(lp6679
(dp6680
g7
I64
sg23
VC1269683
p6681
sg10
I16
sg11
Vmajor depression
p6682
sg13
I2
sa(dp6683
g7
I123
sg23
VC0014544
p6684
sg10
I8
sg11
Vepilepsy
p6685
sg13
I1
sa(dp6686
g7
I100
sg23
VC0349204
p6687
sg10
I9
sg11
Vpsychosis
p6688
sg13
I1
sasa(dp6689
g2
S"Tyrosine kinase receptors TrkB and TrkC mediate neuroprotective effects of the brain-derived neurotrophic factor (BDNF) and neurotrophins in the dopaminergic nigro-striatal system, but it is obscure about their responses or expression changes in the injured substantia nigra under Parkinson's disease.\n"
p6690
sg4
(lp6691
(dp6692
g7
I35
sg8
g39
sg10
I4
sg11
VTrkC
p6693
sg13
I1
sa(dp6694
g7
I124
sg8
VP30990
p6695
sg10
I13
sg11
Vneurotrophins
p6696
sg13
I1
sa(dp6697
g7
I114
sg8
g39
sg10
I4
sg11
VBDNF
p6698
sg13
I1
sa(dp6699
g7
I0
sg8
VP29401
p6700
sg10
I15
sg11
VTyrosine kinase
p6701
sg13
I2
sa(dp6702
g7
I26
sg8
g39
sg10
I4
sg11
VTrkB
p6703
sg13
I1
sa(dp6704
g7
I79
sg8
g39
sg10
I33
sg11
Vbrain-derived neurotrophic factor
p6705
sg13
I3
sasg20
(lp6706
(dp6707
g7
I281
sg23
VC0030567
p6708
sg10
I19
sg11
VParkinson's disease
p6709
sg13
I2
sasa(dp6710
g2
S'ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%-2% of non-small cell lung carcinoma (NSCLC) and in a variety of other tumours including cholangiocarcinoma, gastric carcinoma, colorectal carcinoma and in spitzoid neoplasms, glioblastoma and inflammatory myofibroblastic tumours.\n'
p6711
sg4
(lp6712
(dp6713
g7
I10
sg8
VP29401
p6714
sg10
I24
sg11
Vreceptor tyrosine kinase
p6715
sg13
I3
sa(dp6716
g7
I0
sg8
VP08922
p6717
sg10
I4
sg11
VROS1
p6718
sg13
I1
sasg20
(lp6719
(dp6720
g7
I189
sg23
VC0206698
p6721
sg10
I18
sg11
Vcholangiocarcinoma
p6722
sg13
I1
sa(dp6723
g7
I127
sg23
VC0007097
p6724
sg10
I9
sg11
Vcarcinoma
p6725
sg13
I1
sa(dp6726
g7
I217
sg23
VC0009402
p6727
sg10
I21
sg11
Vcarcinoma, colorectal
p6728
sg13
I2
sa(dp6729
g7
I276
sg23
VC0017636
p6730
sg10
I12
sg11
Vglioblastoma
p6731
sg13
I1
sa(dp6732
g7
I265
sg23
VC0027651
p6733
sg10
I9
sg11
Vneoplasms
p6734
sg13
I1
sa(dp6735
g7
I107
sg23
VC0007131
p6736
sg10
I29
sg11
Vnon-small cell lung carcinoma
p6737
sg13
I4
sa(dp6738
g7
I171
sg23
VC0027651
p6739
sg10
I7
sg11
Vtumours
p6740
sg13
I1
sa(dp6741
g7
I138
sg23
VC0007131
p6742
sg10
I5
sg11
VNSCLC
p6743
sg13
I1
sa(dp6744
g7
I171
sg23
VC0027651
p6745
sg10
I7
sg11
Vtumours
p6746
sg13
I1
sasa(dp6747
g2
S'Moreover, several of the ROS1 fusion proteins are implicated in the pathogenesis of a very small proportion of other cancers including glioblastoma, angiosarcoma, and cholangiocarcinoma as well as ovarian, gastric, and colorectal carcinomas.\n'
p6748
sg4
(lp6749
(dp6750
g7
I25
sg8
VP08922
p6751
sg10
I20
sg11
VROS1 fusion proteins
p6752
sg13
I3
sasg20
(lp6753
(dp6754
g7
I149
sg23
VC0018923
p6755
sg10
I12
sg11
Vangiosarcoma
p6756
sg13
I1
sa(dp6757
g7
I135
sg23
VC0017636
p6758
sg10
I12
sg11
Vglioblastoma
p6759
sg13
I1
sa(dp6760
g7
I219
sg23
VC0009402
p6761
sg10
I21
sg11
Vcolorectal carcinomas
p6762
sg13
I2
sa(dp6763
g7
I68
sg23
VC0699748
p6764
sg10
I12
sg11
Vpathogenesis
p6765
sg13
I1
sa(dp6766
g7
I117
sg23
VC0006826
p6767
sg10
I7
sg11
Vcancers
p6768
sg13
I1
sa(dp6769
g7
I167
sg23
VC0206698
p6770
sg10
I18
sg11
Vcholangiocarcinoma
p6771
sg13
I1
sasa(dp6772
g2
S'The aim of this study was to determine frequency and clinicopathological features associated with ROS1 rearrangement in patients with cholangiocarcinoma (CCA).\n'
p6773
sg4
(lp6774
(dp6775
g7
I98
sg8
VP08922
p6776
sg10
I4
sg11
VROS1
p6777
sg13
I1
sasg20
(lp6778
(dp6779
g7
I154
sg23
VC0220668
p6780
sg10
I3
sg11
VCCA
p6781
sg13
I1
sa(dp6782
g7
I134
sg23
VC0206698
p6783
sg10
I18
sg11
Vcholangiocarcinoma
p6784
sg13
I1
sasa(dp6785
g2
S'We investigated the clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma.\n'
p6786
sg4
(lp6787
(dp6788
g7
I62
sg8
VP08922
p6789
sg10
I4
sg11
VROS1
p6790
sg13
I1
sasg20
(lp6791
(dp6792
g7
I81
sg23
VC0345905
p6793
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p6794
sg13
I2
sasa(dp6795
g2
S'ROS1 protein expression was significantly correlated with well differentiated tumors, papillary or mucinous histology, oncocytic/hepatoid or intestinal type tumors, and periductal infiltrating or intraductal growing tumors (vs. mass-forming cholangiocarcinoma).\n'
p6796
sg4
(lp6797
(dp6798
g7
I0
sg8
VP08922
p6799
sg10
I4
sg11
VROS1
p6800
sg13
I1
sasg20
(lp6801
(dp6802
g7
I180
sg23
VC0332448
p6803
sg10
I12
sg11
Vinfiltrating
p6804
sg13
I1
sa(dp6805
g7
I78
sg23
VC0027651
p6806
sg10
I6
sg11
Vtumors
p6807
sg13
I1
sa(dp6808
g7
I78
sg23
VC0027651
p6809
sg10
I6
sg11
Vtumors
p6810
sg13
I1
sa(dp6811
g7
I241
sg23
VC0206698
p6812
sg10
I18
sg11
Vcholangiocarcinoma
p6813
sg13
I1
sa(dp6814
g7
I78
sg23
VC0027651
p6815
sg10
I6
sg11
Vtumors
p6816
sg13
I1
sasa(dp6817
g2
S'ROS1 protein expression was associated with well-differentiated histology and better survival in our patients with resected intrahepatic cholangiocarcinoma.\n'
p6818
sg4
(lp6819
(dp6820
g7
I0
sg8
VP08922
p6821
sg10
I4
sg11
VROS1
p6822
sg13
I1
sasg20
(lp6823
(dp6824
g7
I124
sg23
VC0345905
p6825
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p6826
sg13
I2
sasa(dp6827
g2
S'On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.\n'
p6828
sg4
(lp6829
(dp6830
g7
I283
sg8
g39
sg10
I3
sg11
VMSN
p6831
sg13
I1
sa(dp6832
g7
I293
sg8
g39
sg10
I5
sg11
VTRIM4
p6833
sg13
I1
sa(dp6834
g7
I287
sg8
VP08922
p6835
sg10
I4
sg11
VROS1
p6836
sg13
I1
sa(dp6837
g7
I236
sg8
g39
sg10
I7
sg11
VARHGEF2
p6838
sg13
I1
sa(dp6839
g7
I305
sg8
VP63027
p6840
sg10
I5
sg11
VVAMP2
p6841
sg13
I1
sa(dp6842
g7
I373
sg8
g39
sg10
I32
sg11
Vcholangiocarcinoma and PPL-NTRK1
p6843
sg13
I3
sa(dp6844
g7
I332
sg8
g39
sg10
I9
sg11
VRUFY2-RET
p6845
sg13
I1
sa(dp6846
g7
I358
sg8
g39
sg10
I11
sg11
VFGFR2-CREB5
p6847
sg13
I1
sa(dp6848
g7
I317
sg8
VP06753
p6849
sg10
I4
sg11
VTPM3
p6850
sg13
I1
sa(dp6851
g7
I299
sg8
VP15056
p6852
sg10
I4
sg11
VBRAF
p6853
sg13
I1
sa(dp6854
g7
I222
sg8
VP35637
p6855
sg10
I12
sg11
Vgene fusions
p6856
sg13
I2
sasg20
(lp6857
(dp6858
g7
I345
sg23
VC0684249
p6859
sg10
I11
sg11
Vlung cancer
p6860
sg13
I2
sa(dp6861
g7
I373
sg23
VC0206698
p6862
sg10
I18
sg11
Vcholangiocarcinoma
p6863
sg13
I1
sa(dp6864
g7
I409
sg23
VC0549473
p6865
sg10
I17
sg11
Vthyroid carcinoma
p6866
sg13
I2
sa(dp6867
g7
I269
sg23
VC0017636
p6868
sg10
I12
sg11
Vglioblastoma
p6869
sg13
I1
sasa(dp6870
g2
S'We developed a new, quick, specific, and sensitive PCR test to screen for the FIG-ROS1 fusion and applied it to a series of Italian patients with bile duct carcinoma (BTC).\n'
p6871
sg4
(lp6872
(dp6873
g7
I78
sg8
g39
sg10
I3
sg11
VFIG
p6874
sg13
I1
sa(dp6875
g7
I82
sg8
VP08922
p6876
sg10
I4
sg11
VROS1
p6877
sg13
I1
sasg20
(lp6878
(dp6879
g7
I167
sg23
VC0740277
p6880
sg10
I3
sg11
VBTC
p6881
sg13
I1
sa(dp6882
g7
I146
sg23
VC0740277
p6883
sg10
I19
sg11
Vbile duct carcinoma
p6884
sg13
I3
sasa(dp6885
g2
S'We found that six out of 65 (9%) BTC patients were positive for the FIG-ROS1 fusion, comprising two out of 14 (14%) gallbladder carcinoma (GBC) patients and four out of 25 (16%) extrahepatic cholangiocarcinoma (ECC) patients.\n'
p6886
sg4
(lp6887
(dp6888
g7
I68
sg8
g39
sg10
I3
sg11
VFIG
p6889
sg13
I1
sa(dp6890
g7
I72
sg8
VP08922
p6891
sg10
I4
sg11
VROS1
p6892
sg13
I1
sasg20
(lp6893
(dp6894
g7
I139
sg23
VC0235782
p6895
sg10
I3
sg11
VGBC
p6896
sg13
I1
sa(dp6897
g7
I191
sg23
VC0206698
p6898
sg10
I18
sg11
Vcholangiocarcinoma
p6899
sg13
I1
sa(dp6900
g7
I116
sg23
VC0235782
p6901
sg10
I21
sg11
Vgallbladder carcinoma
p6902
sg13
I2
sasa(dp6903
g2
S'None of the 26 intrahepatic cholangiocarcinoma cases harbored the FIG-ROS1 fusion.\n'
p6904
sg4
(lp6905
(dp6906
g7
I70
sg8
VP08922
p6907
sg10
I4
sg11
VROS1
p6908
sg13
I1
sa(dp6909
g7
I66
sg8
g39
sg10
I3
sg11
VFIG
p6910
sg13
I1
sasg20
(lp6911
(dp6912
g7
I15
sg23
VC0345905
p6913
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p6914
sg13
I2
sasa(dp6915
g2
S'Recently inhibition of ROS1 kinase has proven to be a promising strategy for several indications such as glioblastoma, non-small cell lung cancer (NSCLC), and cholangiocarcinoma.\n'
p6916
sg4
(lp6917
(dp6918
g7
I23
sg8
VP08922
p6919
sg10
I11
sg11
VROS1 kinase
p6920
sg13
I2
sasg20
(lp6921
(dp6922
g7
I119
sg23
VC0007131
p6923
sg10
I26
sg11
Vnon-small cell lung cancer
p6924
sg13
I4
sa(dp6925
g7
I147
sg23
VC0007131
p6926
sg10
I5
sg11
VNSCLC
p6927
sg13
I1
sa(dp6928
g7
I105
sg23
VC0017636
p6929
sg10
I12
sg11
Vglioblastoma
p6930
sg13
I1
sa(dp6931
g7
I159
sg23
VC0206698
p6932
sg10
I18
sg11
Vcholangiocarcinoma
p6933
sg13
I1
sasa(dp6934
g2
S'Thrombospondin-1 was an independent predictive factor for all endpoints and plasma thrombospondin-1 concentrations were highly associated with injury severity reflected by hematoma volume and National Institutes of Health Stroke Scale score.\n'
p6935
sg4
(lp6936
sg20
(lp6937
(dp6938
g7
I172
sg23
VC0018944
p6939
sg10
I8
sg11
Vhematoma
p6940
sg13
I1
sa(dp6941
g7
I222
sg23
VC0038454
p6942
sg10
I6
sg11
VStroke
p6943
sg13
I1
sasa(dp6944
g2
S'Under receiver operating characteristic curves, plasma thrombospondin-1 concentrations had similar predictive values compared with hematoma volume and National Institutes of Health Stroke Scale score.\n'
p6945
sg4
(lp6946
sg20
(lp6947
(dp6948
g7
I181
sg23
VC0038454
p6949
sg10
I6
sg11
VStroke
p6950
sg13
I1
sa(dp6951
g7
I131
sg23
VC0018944
p6952
sg10
I8
sg11
Vhematoma
p6953
sg13
I1
sasa(dp6954
g2
S'The current study was designed to investigate the change of plasma thrombospondin-1 concentrations and assess the prognostic value of plasma thrombospondin-1 concentrations for long-term mortality and functional outcome of ischemic stroke patients.\n'
p6955
sg4
(lp6956
sg20
(lp6957
(dp6958
g7
I223
sg23
VC3272363
p6959
sg10
I15
sg11
Vischemic stroke
p6960
sg13
I2
sasa(dp6961
g2
S'Plasma thrombospondin-1 concentrations are elevated obviously and are highly associated with long-term outcome of ischemic stroke.\n'
p6962
sg4
(lp6963
(dp6964
g7
I7
sg8
VP07996
p6965
sg10
I16
sg11
Vthrombospondin-1
p6966
sg13
I1
sasg20
(lp6967
(dp6968
g7
I114
sg23
VC3272363
p6969
sg10
I15
sg11
Vischemic stroke
p6970
sg13
I2
sasa(dp6971
g2
S'These results demonstrate that miR-487b regulates angiogenesis by directly targeting THBS1 in HUVECs, indicating that miR-487b may contribute to angiogenesis and the functional recovery from ischemic stroke.\n'
p6972
sg4
(lp6973
(dp6974
g7
I31
sg8
g39
sg10
I8
sg11
VmiR-487b
p6975
sg13
I1
sa(dp6976
g7
I31
sg8
g39
sg10
I8
sg11
VmiR-487b
p6977
sg13
I1
sa(dp6978
g7
I85
sg8
VP07996
p6979
sg10
I5
sg11
VTHBS1
p6980
sg13
I1
sasg20
(lp6981
(dp6982
g7
I191
sg23
VC3272363
p6983
sg10
I15
sg11
Vischemic stroke
p6984
sg13
I2
sa(dp6985
g7
I166
sg23
VC0599766
p6986
sg10
I19
sg11
Vfunctional recovery
p6987
sg13
I2
sasa(dp6988
g2
S'Compared with those without left ventricular hypertrophy (n=51) and left ventricular hypertrophy without ECG strain (n=30), patients with ECG strain (n=21) had more severe aortic stenosis, increased left ventricular mass index, more myocardial injury (high-sensitivity plasma cardiac troponin I concentration, 4.3 ng/L [interquartile range, 2.5-7.3 ng/L] versus 7.3 ng/L [interquartile range, 3.2-20.8 ng/L] versus 18.6 ng/L [interquartile range, 9.0-45.2 ng/L], respectively; P&lt;0.001) and increased diffuse fibrosis (extracellular volume fraction, 27.4+/-2.2% versus 27.2+/-2.9% versus 30.9+/-1.9%, respectively; P&lt;0.001).\n'
p6989
sg4
(lp6990
(dp6991
g7
I284
sg8
VP24821
p6992
sg10
I10
sg11
Vtroponin I
p6993
sg13
I2
sasg20
(lp6994
(dp6995
g7
I28
sg23
VC0149721
p6996
sg10
I28
sg11
Vleft ventricular hypertrophy
p6997
sg13
I3
sa(dp6998
g7
I28
sg23
VC0149721
p6999
sg10
I28
sg11
Vleft ventricular hypertrophy
p7000
sg13
I3
sa(dp7001
g7
I503
sg23
VC1265984
p7002
sg10
I16
sg11
Vdiffuse fibrosis
p7003
sg13
I2
sa(dp7004
g7
I172
sg23
VC0003507
p7005
sg10
I15
sg11
Vaortic stenosis
p7006
sg13
I2
sasa(dp7007
g2
S'Cardiac troponin I and T provide may provide clinically useful prognostic information both concerning the future risk of developing heart failure in asymptomatic subjects and the risk of fatal events and hospital admissions in those with already established heart failure This review summarizes current literature on the clinical performance and utility of cardiac troponin measurements as diagnostic and prognostic tools in patients with symptomatic heart failure, as well as in those with asymptomatic left ventricular dysfunction, and clinical phenotypes at high risk for developing heart failure, including stable coronary artery disease, left ventricular hypertrophy, and aortic stenosis.\n'
p7008
sg4
(lp7009
(dp7010
g7
I8
sg8
VP24821
p7011
sg10
I8
sg11
Vtroponin
p7012
sg13
I1
sa(dp7013
g7
I0
sg8
VP24821
p7014
sg10
I18
sg11
VCardiac troponin I
p7015
sg13
I3
sasg20
(lp7016
(dp7017
g7
I132
sg23
VC0018802
p7018
sg10
I13
sg11
Vheart failure
p7019
sg13
I2
sa(dp7020
g7
I618
sg23
VC1956346
p7021
sg10
I23
sg11
Vcoronary artery disease
p7022
sg13
I3
sa(dp7023
g7
I132
sg23
VC0018802
p7024
sg10
I13
sg11
Vheart failure
p7025
sg13
I2
sa(dp7026
g7
I504
sg23
VC0242698
p7027
sg10
I28
sg11
Vleft ventricular dysfunction
p7028
sg13
I3
sa(dp7029
g7
I677
sg23
VC0003507
p7030
sg10
I15
sg11
Vaortic stenosis
p7031
sg13
I2
sa(dp7032
g7
I643
sg23
VC0149721
p7033
sg10
I28
sg11
Vleft ventricular hypertrophy
p7034
sg13
I3
sa(dp7035
g7
I132
sg23
VC0018802
p7036
sg10
I13
sg11
Vheart failure
p7037
sg13
I2
sa(dp7038
g7
I132
sg23
VC0018802
p7039
sg10
I13
sg11
Vheart failure
p7040
sg13
I2
sasa(dp7041
g2
S'High-sensitivity cardiac troponin I (cTnI) assays hold promise in detecting the transition from hypertrophy to heart failure in aortic stenosis.\n'
p7042
sg4
(lp7043
(dp7044
g7
I17
sg8
VP19429
p7045
sg10
I18
sg11
Vcardiac troponin I
p7046
sg13
I3
sa(dp7047
g7
I37
sg8
VP19429
p7048
sg10
I4
sg11
VcTnI
p7049
sg13
I1
sasg20
(lp7050
(dp7051
g7
I128
sg23
VC0003507
p7052
sg10
I15
sg11
Vaortic stenosis
p7053
sg13
I2
sa(dp7054
g7
I80
sg23
VC0599156
p7055
sg10
I10
sg11
Vtransition
p7056
sg13
I1
sa(dp7057
g7
I96
sg23
VC0020564
p7058
sg10
I11
sg11
Vhypertrophy
p7059
sg13
I1
sa(dp7060
g7
I111
sg23
VC0018802
p7061
sg10
I13
sg11
Vheart failure
p7062
sg13
I2
sasa(dp7063
g2
S'We sought to investigate the mechanism for troponin release in patients with aortic stenosis and whether plasma cTnI concentrations are associated with long-term outcome.\n'
p7064
sg4
(lp7065
(dp7066
g7
I43
sg8
VP24821
p7067
sg10
I16
sg11
Vtroponin release
p7068
sg13
I2
sa(dp7069
g7
I105
sg8
VP19429
p7070
sg10
I11
sg11
Vplasma cTnI
p7071
sg13
I2
sasg20
(lp7072
(dp7073
g7
I77
sg23
VC0003507
p7074
sg10
I15
sg11
Vaortic stenosis
p7075
sg13
I2
sasa(dp7076
g2
S'The indexed LV mass and measures of replacement fibrosis (late gadolinium enhancement) were associated with cTnI concentrations independent of age, sex, coronary artery disease, aortic stenosis severity, and diastolic function.\n'
p7077
sg4
(lp7078
(dp7079
g7
I108
sg8
VP19429
p7080
sg10
I4
sg11
VcTnI
p7081
sg13
I1
sasg20
(lp7082
(dp7083
g7
I153
sg23
VC1956346
p7084
sg10
I23
sg11
Vcoronary artery disease
p7085
sg13
I3
sa(dp7086
g7
I48
sg23
VC0016059
p7087
sg10
I8
sg11
Vfibrosis
p7088
sg13
I1
sa(dp7089
g7
I178
sg23
VC0003507
p7090
sg10
I15
sg11
Vaortic stenosis
p7091
sg13
I2
sasa(dp7092
g2
S'Plasma cTnI concentrations were associated with AVR or cardiovascular death HR 1.77 (95% CI, 1.22 to 2.55) independent of age, sex, systolic ejection fraction, and aortic stenosis severity.\n'
p7093
sg4
(lp7094
(dp7095
g7
I7
sg8
VP19429
p7096
sg10
I4
sg11
VcTnI
p7097
sg13
I1
sasg20
(lp7098
(dp7099
g7
I164
sg23
VC0003507
p7100
sg10
I15
sg11
Vaortic stenosis
p7101
sg13
I2
sasa(dp7102
g2
S'In patients with aortic stenosis, plasma cTnI concentration is associated with advanced hypertrophy and replacement myocardial fibrosis as well as AVR or cardiovascular death.\n'
p7103
sg4
(lp7104
(dp7105
g7
I41
sg8
VP19429
p7106
sg10
I4
sg11
VcTnI
p7107
sg13
I1
sasg20
(lp7108
(dp7109
g7
I88
sg23
VC0020564
p7110
sg10
I11
sg11
Vhypertrophy
p7111
sg13
I1
sa(dp7112
g7
I17
sg23
VC0003507
p7113
sg10
I15
sg11
Vaortic stenosis
p7114
sg13
I2
sa(dp7115
g7
I116
sg23
VC0151654
p7116
sg10
I19
sg11
Vmyocardial fibrosis
p7117
sg13
I2
sasa(dp7118
g2
S'Cardiac samples from 43 sarcomere mutation-positive patients (HCMmut: mutations in thick (MYBPC3, MYH7) and thin (TPM1, TNNI3, TNNT2) myofilament genes) were compared with 14 sarcomere mutation-negative patients (HCMsmn), eight patients with secondary LV hypertrophy due to aortic stenosis (LVHao) and 13 donors.\n'
p7119
sg4
(lp7120
(dp7121
g7
I114
sg8
VP07951
p7122
sg10
I4
sg11
VTPM1
p7123
sg13
I1
sa(dp7124
g7
I90
sg8
g39
sg10
I6
sg11
VMYBPC3
p7125
sg13
I1
sa(dp7126
g7
I120
sg8
VP19429
p7127
sg10
I5
sg11
VTNNI3
p7128
sg13
I1
sa(dp7129
g7
I127
sg8
VP45379
p7130
sg10
I5
sg11
VTNNT2
p7131
sg13
I1
sasg20
(lp7132
(dp7133
g7
I252
sg23
VC0149721
p7134
sg10
I14
sg11
VLV hypertrophy
p7135
sg13
I2
sa(dp7136
g7
I274
sg23
VC0003507
p7137
sg10
I15
sg11
Vaortic stenosis
p7138
sg13
I2
sasa(dp7139
g2
S'We discover three additional pathways viz., Glycerophospholipid metablism, h-Efp pathway and CARM1 and Regulation of Estrogen Receptor, which can be related to the metastasis phase of breast cancer.\n'
p7140
sg4
(lp7141
(dp7142
g7
I77
sg8
g39
sg10
I3
sg11
VEfp
p7143
sg13
I1
sa(dp7144
g7
I93
sg8
g39
sg10
I5
sg11
VCARM1
p7145
sg13
I1
sa(dp7146
g7
I117
sg8
VP03372
p7147
sg10
I17
sg11
VEstrogen Receptor
p7148
sg13
I2
sasg20
(lp7149
(dp7150
g7
I184
sg23
VC0678222
p7151
sg10
I13
sg11
Vbreast cancer
p7152
sg13
I2
sa(dp7153
g7
I164
sg23
VC0027627
p7154
sg10
I10
sg11
Vmetastasis
p7155
sg13
I1
sasa(dp7156
g2
S'Not only are the expression levels of CARM1 and MED12 positively correlated, but their high expression also predicts better prognosis in human breast cancers after chemotherapy.\n'
p7157
sg4
(lp7158
(dp7159
g7
I38
sg8
g39
sg10
I5
sg11
VCARM1
p7160
sg13
I1
sa(dp7161
g7
I48
sg8
g39
sg10
I5
sg11
VMED12
p7162
sg13
I1
sasg20
(lp7163
(dp7164
g7
I143
sg23
VC0006142
p7165
sg10
I14
sg11
Vbreast cancers
p7166
sg13
I2
sasa(dp7167
g2
S'To investigate the functional roles and the prognosis potential of CARM1 alternative spliced isoforms in breast cancer, we used recently developed antibodies to detect differential CARM1 isoform expression in subcellular compartments and among malignant and benign breast tumors.\n'
p7168
sg4
(lp7169
(dp7170
g7
I181
sg8
g39
sg10
I13
sg11
VCARM1 isoform
p7171
sg13
I2
sa(dp7172
g7
I67
sg8
g39
sg10
I5
sg11
VCARM1
p7173
sg13
I1
sasg20
(lp7174
(dp7175
g7
I105
sg23
VC0678222
p7176
sg10
I13
sg11
Vbreast cancer
p7177
sg13
I2
sa(dp7178
g7
I258
sg23
VC0346156
p7179
sg10
I20
sg11
Vbenign breast tumors
p7180
sg13
I3
sasa(dp7181
g2
S'Furthermore neither CARM1FL nor CARM1DeltaE15 expression correlated with breast cancer molecular subtypes, tumor size, or lymph node involvement.\n'
p7182
sg4
(lp7183
sg20
(lp7184
(dp7185
g7
I73
sg23
VC0678222
p7186
sg10
I13
sg11
Vbreast cancer
p7187
sg13
I2
sa(dp7188
g7
I107
sg23
VC0027651
p7189
sg10
I5
sg11
Vtumor
p7190
sg13
I1
sasa(dp7191
g2
S'This study also demonstrates no obvious association of CARM1 isoform expression and clinical correlates in breast cancer.\n'
p7192
sg4
(lp7193
(dp7194
g7
I55
sg8
g39
sg10
I13
sg11
VCARM1 isoform
p7195
sg13
I2
sasg20
(lp7196
(dp7197
g7
I107
sg23
VC0678222
p7198
sg10
I13
sg11
Vbreast cancer
p7199
sg13
I2
sasa(dp7200
g2
S'Recent studies, however, have shown that CARM1 expression correlates with poor prognosis, indicating a need for further studies of both CARM1 isoforms in a large cohort of breast cancer specimens.\n'
p7201
sg4
(lp7202
(dp7203
g7
I41
sg8
g39
sg10
I5
sg11
VCARM1
p7204
sg13
I1
sa(dp7205
g7
I136
sg8
g39
sg10
I14
sg11
VCARM1 isoforms
p7206
sg13
I2
sasg20
(lp7207
(dp7208
g7
I172
sg23
VC0678222
p7209
sg10
I13
sg11
Vbreast cancer
p7210
sg13
I2
sasa(dp7211
g2
S'Coactivator-associated arginine methyltransferase 1 (CARM1), a coactivator for various cancer-relevant transcription factors, is overexpressed in breast cancer.\n'
p7212
sg4
(lp7213
(dp7214
g7
I53
sg8
g39
sg10
I5
sg11
VCARM1
p7215
sg13
I1
sa(dp7216
g7
I0
sg8
g39
sg10
I51
sg11
VCoactivator-associated arginine methyltransferase 1
p7217
sg13
I4
sasg20
(lp7218
(dp7219
g7
I87
sg23
VC0006826
p7220
sg10
I6
sg11
Vcancer
p7221
sg13
I1
sa(dp7222
g7
I146
sg23
VC0678222
p7223
sg10
I13
sg11
Vbreast cancer
p7224
sg13
I2
sasa(dp7225
g2
S'To elucidate the functions of CARM1 in tumorigenesis, we knocked out CARM1 from several breast cancer cell lines using Zinc-Finger Nuclease technology, which resulted in drastic phenotypic and biochemical changes.\n'
p7226
sg4
(lp7227
(dp7228
g7
I119
sg8
g39
sg10
I20
sg11
VZinc-Finger Nuclease
p7229
sg13
I2
sa(dp7230
g7
I30
sg8
g39
sg10
I5
sg11
VCARM1
p7231
sg13
I1
sa(dp7232
g7
I30
sg8
g39
sg10
I5
sg11
VCARM1
p7233
sg13
I1
sasg20
(lp7234
(dp7235
g7
I39
sg23
VC0007621
p7236
sg10
I13
sg11
Vtumorigenesis
p7237
sg13
I1
sa(dp7238
g7
I88
sg23
VC0678222
p7239
sg10
I13
sg11
Vbreast cancer
p7240
sg13
I2
sasa(dp7241
g2
S'CARM1 has been reported to be associated with high grade tumors in breast cancer.\n'
p7242
sg4
(lp7243
(dp7244
g7
I0
sg8
g39
sg10
I5
sg11
VCARM1
p7245
sg13
I1
sasg20
(lp7246
(dp7247
g7
I57
sg23
VC0027651
p7248
sg10
I6
sg11
Vtumors
p7249
sg13
I1
sa(dp7250
g7
I67
sg23
VC0678222
p7251
sg10
I13
sg11
Vbreast cancer
p7252
sg13
I2
sasa(dp7253
g2
S'It still remains unknown the expression pattern of CARM1 in breast cancer and its relationships with clinicopathological characteristics and molecular subtypes.\n'
p7254
sg4
(lp7255
(dp7256
g7
I51
sg8
g39
sg10
I5
sg11
VCARM1
p7257
sg13
I1
sasg20
(lp7258
(dp7259
g7
I60
sg23
VC0678222
p7260
sg10
I13
sg11
Vbreast cancer
p7261
sg13
I2
sasa(dp7262
g2
S'CARM1 expression was increased in invasive breast cancer.\n'
p7263
sg4
(lp7264
(dp7265
g7
I0
sg8
g39
sg10
I5
sg11
VCARM1
p7266
sg13
I1
sasg20
(lp7267
(dp7268
g7
I34
sg23
VC0853879
p7269
sg10
I22
sg11
Vinvasive breast cancer
p7270
sg13
I3
sasa(dp7271
g2
S'Our results support the value of using CARM1 in prognostic stratification of breast cancer patients and its potential therapeutic implications in targeting treatment.\n'
p7272
sg4
(lp7273
(dp7274
g7
I39
sg8
g39
sg10
I5
sg11
VCARM1
p7275
sg13
I1
sasg20
(lp7276
(dp7277
g7
I77
sg23
VC0678222
p7278
sg10
I13
sg11
Vbreast cancer
p7279
sg13
I2
sasa(dp7280
g2
S'It plays an important role in breast cancer growth by regulating the E2F1 expression suggesting that CARM1 could be a target in the subclassification of oestrogen-dependent breast cancer.\n'
p7281
sg4
(lp7282
(dp7283
g7
I101
sg8
g39
sg10
I5
sg11
VCARM1
p7284
sg13
I1
sa(dp7285
g7
I69
sg8
g39
sg10
I4
sg11
VE2F1
p7286
sg13
I1
sasg20
(lp7287
(dp7288
g7
I30
sg23
VC0678222
p7289
sg10
I13
sg11
Vbreast cancer
p7290
sg13
I2
sa(dp7291
g7
I30
sg23
VC0678222
p7292
sg10
I13
sg11
Vbreast cancer
p7293
sg13
I2
sasa(dp7294
g2
S'This study aims to investigate the clinical and biological importance of CARM1 protein expression in a large (1,130 patients), well-characterised and annotated series of invasive breast cancers using tissue microarrays and immunohistochemistry.\n'
p7295
sg4
(lp7296
(dp7297
g7
I73
sg8
g39
sg10
I13
sg11
VCARM1 protein
p7298
sg13
I2
sasg20
(lp7299
(dp7300
g7
I179
sg23
VC0006142
p7301
sg10
I14
sg11
Vbreast cancers
p7302
sg13
I2
sasa(dp7303
g2
S'Outcome analyses indicate that CARM1 expression is an independent predictor of shorter breast cancer-specific survival and disease-free interval in the whole series and in the ER-positive subgroup.\n'
p7304
sg4
(lp7305
(dp7306
g7
I31
sg8
g39
sg10
I5
sg11
VCARM1
p7307
sg13
I1
sasg20
(lp7308
(dp7309
g7
I87
sg23
VC0678222
p7310
sg10
I13
sg11
Vbreast cancer
p7311
sg13
I2
sasa(dp7312
g2
S'CARM1 shows an oncogenic effect in breast cancer and its expression is associated with poor prognosis.\n'
p7313
sg4
(lp7314
(dp7315
g7
I0
sg8
g39
sg10
I5
sg11
VCARM1
p7316
sg13
I1
sasg20
(lp7317
(dp7318
g7
I35
sg23
VC0678222
p7319
sg10
I13
sg11
Vbreast cancer
p7320
sg13
I2
sasa(dp7321
g2
S'We investigated CARM1 levels and localization across breast cancer tumors in a cohort of patients of either European or African ancestry.\n'
p7322
sg4
(lp7323
(dp7324
g7
I16
sg8
g39
sg10
I5
sg11
VCARM1
p7325
sg13
I1
sasg20
(lp7326
(dp7327
g7
I53
sg23
VC0678222
p7328
sg10
I13
sg11
Vbreast cancer
p7329
sg13
I2
sa(dp7330
g7
I67
sg23
VC0027651
p7331
sg10
I6
sg11
Vtumors
p7332
sg13
I1
sasa(dp7333
g2
S'Although it is known to be an ER cofactor in breast cancer, CARM1 expression levels are independent of ER.\n'
p7334
sg4
(lp7335
(dp7336
g7
I60
sg8
g39
sg10
I5
sg11
VCARM1
p7337
sg13
I1
sasg20
(lp7338
(dp7339
g7
I45
sg23
VC0678222
p7340
sg10
I13
sg11
Vbreast cancer
p7341
sg13
I2
sasa(dp7342
g2
S'Mutations in the genes ENG, ACVRL1 and SMAD4 that are part of the transforming growth factor-beta signalling pathway cause hereditary haemorrhagic telangiectasia (HHT).\n'
p7343
sg4
(lp7344
(dp7345
g7
I28
sg8
VP37023
p7346
sg10
I6
sg11
VACVRL1
p7347
sg13
I1
sa(dp7348
g7
I66
sg8
VP18075
p7349
sg10
I31
sg11
Vtransforming growth factor-beta
p7350
sg13
I3
sa(dp7351
g7
I23
sg8
VP17813
p7352
sg10
I3
sg11
VENG
p7353
sg13
I1
sa(dp7354
g7
I39
sg8
g39
sg10
I5
sg11
VSMAD4
p7355
sg13
I1
sasg20
(lp7356
(dp7357
g7
I123
sg23
VC0039445
p7358
sg10
I38
sg11
Vhereditary haemorrhagic telangiectasia
p7359
sg13
I3
sa(dp7360
g7
I163
sg23
VC0039445
p7361
sg10
I3
sg11
VHHT
p7362
sg13
I1
sasa(dp7363
g2
S'However, the genetic effects of SMAD4 in the pathogenesis of thoracic aortic aneurysm and dissection (TAAD) are still largely unknown.\n'
p7364
sg4
(lp7365
(dp7366
g7
I32
sg8
g39
sg10
I5
sg11
VSMAD4
p7367
sg13
I1
sasg20
(lp7368
(dp7369
g7
I45
sg23
VC0699748
p7370
sg10
I12
sg11
Vpathogenesis
p7371
sg13
I1
sa(dp7372
g7
I70
sg23
VC1812607
p7373
sg10
I30
sg11
Vaortic aneurysm and dissection
p7374
sg13
I4
sasa(dp7375
g2
S'However, the exact role of Smad4 in smooth muscle cells (SMCs) leading to the pathogenesis of aortic aneurysms is largely unknown.\n'
p7376
sg4
(lp7377
(dp7378
g7
I27
sg8
g39
sg10
I5
sg11
VSmad4
p7379
sg13
I1
sasg20
(lp7380
(dp7381
g7
I94
sg23
VC0003486
p7382
sg10
I16
sg11
Vaortic aneurysms
p7383
sg13
I2
sa(dp7384
g7
I78
sg23
VC0699748
p7385
sg10
I12
sg11
Vpathogenesis
p7386
sg13
I1
sasa(dp7387
g2
S'To determine the role of smooth muscle Smad4 in the pathogenesis of aortic aneurysms.\n'
p7388
sg4
(lp7389
(dp7390
g7
I39
sg8
g39
sg10
I5
sg11
VSmad4
p7391
sg13
I1
sasg20
(lp7392
(dp7393
g7
I68
sg23
VC0003486
p7394
sg10
I16
sg11
Vaortic aneurysms
p7395
sg13
I2
sa(dp7396
g7
I52
sg23
VC0699748
p7397
sg10
I12
sg11
Vpathogenesis
p7398
sg13
I1
sasa(dp7399
g2
S'Conditional gene knockout strategy combined with histology and expression analysis showed that Smad4 or TGF-Beta receptor type II deficiency in SMCs led to the occurrence of aortic aneurysms along with an upregulation of cathepsin S and matrix metallopeptidase-12, which are proteases essential for elastin degradation.\n'
p7400
sg4
(lp7401
(dp7402
g7
I237
sg8
g39
sg10
I26
sg11
Vmatrix metallopeptidase-12
p7403
sg13
I2
sa(dp7404
g7
I104
sg8
VP37173
p7405
sg10
I25
sg11
VTGF-Beta receptor type II
p7406
sg13
I4
sa(dp7407
g7
I95
sg8
g39
sg10
I5
sg11
VSmad4
p7408
sg13
I1
sa(dp7409
g7
I221
sg8
VP25774
p7410
sg10
I11
sg11
Vcathepsin S
p7411
sg13
I2
sa(dp7412
g7
I299
sg8
VP49918
p7413
sg10
I7
sg11
Velastin
p7414
sg13
I1
sasg20
(lp7415
(dp7416
g7
I174
sg23
VC0003486
p7417
sg10
I16
sg11
Vaortic aneurysms
p7418
sg13
I2
sasa(dp7419
g2
S'Monocyte/macrophage depletion or blocking selective chemokine axis largely abrogated the progression of aortic aneurysm caused by Smad4 deficiency in SMCs.\n'
p7420
sg4
(lp7421
(dp7422
g7
I130
sg8
g39
sg10
I5
sg11
VSmad4
p7423
sg13
I1
sasg20
(lp7424
(dp7425
g7
I104
sg23
VC0003486
p7426
sg10
I15
sg11
Vaortic aneurysm
p7427
sg13
I2
sa(dp7428
g7
I33
sg23
VC0233660
p7429
sg10
I8
sg11
Vblocking
p7430
sg13
I1
sasa(dp7431
g2
S'The findings reveal that Smad4-dependent TGF-Beta signaling in SMCs protects against aortic aneurysm formation and dissection.\n'
p7432
sg4
(lp7433
(dp7434
g7
I25
sg8
g39
sg10
I24
sg11
VSmad4-dependent TGF-Beta
p7435
sg13
I2
sasg20
(lp7436
(dp7437
g7
I85
sg23
VC0003486
p7438
sg10
I15
sg11
Vaortic aneurysm
p7439
sg13
I2
sasa(dp7440
g2
S'Patients with a SMAD4 mutation should be followed up both for JPS and haemorrhagic hereditary telangiectasia and may develop protein loosing enteropathy and immunodeficiency.\n'
p7441
sg4
(lp7442
(dp7443
g7
I16
sg8
g39
sg10
I14
sg11
VSMAD4 mutation
p7444
sg13
I2
sasg20
(lp7445
(dp7446
g7
I94
sg23
VC0039446
p7447
sg10
I14
sg11
Vtelangiectasia
p7448
sg13
I1
sa(dp7449
g7
I157
sg23
VC0021051
p7450
sg10
I16
sg11
Vimmunodeficiency
p7451
sg13
I1
sa(dp7452
g7
I62
sg23
VC0345893
p7453
sg10
I3
sg11
VJPS
p7454
sg13
I1
sa(dp7455
g7
I141
sg23
VC0021831
p7456
sg10
I11
sg11
Venteropathy
p7457
sg13
I1
sasa(dp7458
g2
S'These changes may participate in pathophysiology of cardiac dysfunction in renovascular hypertension that is associated with subnormal level of serum apelin.\n'
p7459
sg4
(lp7460
(dp7461
g7
I144
sg8
g39
sg10
I12
sg11
Vserum apelin
p7462
sg13
I2
sasg20
(lp7463
(dp7464
g7
I75
sg23
VC0020545
p7465
sg10
I25
sg11
Vrenovascular hypertension
p7466
sg13
I2
sasa(dp7467
g2
S'The aim of this study was to analyze the interaction of apelin and the opioid system with respect to vascular responses to apelin in rats with renovascular hypertension (two-kidney, one clip (2K1C)).\n'
p7468
sg4
(lp7469
(dp7470
g7
I56
sg8
g39
sg10
I6
sg11
Vapelin
p7471
sg13
I1
sasg20
(lp7472
(dp7473
g7
I143
sg23
VC0020545
p7474
sg10
I25
sg11
Vrenovascular hypertension
p7475
sg13
I2
sasa(dp7476
g2
S'Down regulation of apelin receptor in nonischemic kidney of hypertensive rats may play a role in pathophysiology of renovascular hypertension.\n'
p7477
sg4
(lp7478
(dp7479
g7
I19
sg8
VP35414
p7480
sg10
I15
sg11
Vapelin receptor
p7481
sg13
I2
sasg20
(lp7482
(dp7483
g7
I116
sg23
VC0020545
p7484
sg10
I25
sg11
Vrenovascular hypertension
p7485
sg13
I2
sasa(dp7486
g2
S'The data obtained with four independently derived transgenic embryos and with one transgenic line demonstrate that deregulated Pax-2 expression results in histologically abnormal and dysfunctional renal epithelium with properties similar to congenital nephrotic syndrome.\n'
p7487
sg4
(lp7488
(dp7489
g7
I127
sg8
g39
sg10
I5
sg11
VPax-2
p7490
sg13
I1
sasg20
(lp7491
(dp7492
g7
I241
sg23
VC0268713
p7493
sg10
I29
sg11
Vcongenital nephrotic syndrome
p7494
sg13
I3
sasa(dp7495
g2
S'In a recent report, deregulation of expression of the gene coding for the Pax-2 DNA-binding protein was shown to generate severe kidney abnormalities in transgenic mice resembling the clinical and pathological findings in congenital nephrotic syndrome, making it a candidate gene for CNF.\n'
p7496
sg4
(lp7497
(dp7498
g7
I74
sg8
g39
sg10
I25
sg11
VPax-2 DNA-binding protein
p7499
sg13
I3
sa(dp7500
g7
I284
sg8
g39
sg10
I3
sg11
VCNF
p7501
sg13
I1
sasg20
(lp7502
(dp7503
g7
I222
sg23
VC0268713
p7504
sg10
I29
sg11
Vcongenital nephrotic syndrome
p7505
sg13
I3
sa(dp7506
g7
I284
sg23
VC0403399
p7507
sg10
I3
sg11
VCNF
p7508
sg13
I1
sasa(dp7509
g2
S'However, in this study, we have unequivocally excluded the Pax-2 gene locus as a causative for congenital nephrotic syndrome of the Finnish type.\n'
p7510
sg4
(lp7511
(dp7512
g7
I59
sg8
g39
sg10
I16
sg11
VPax-2 gene locus
p7513
sg13
I3
sasg20
(lp7514
(dp7515
g7
I95
sg23
VC0268713
p7516
sg10
I29
sg11
Vcongenital nephrotic syndrome
p7517
sg13
I3
sasa(dp7518
g2
S'Evaluation of 29 SNPs (P &lt; 1 x 10(-5)) in an additional 971 severely obese children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and RMST).\n'
p7519
sg4
(lp7520
(dp7521
g7
I160
sg8
VP48357
p7522
sg10
I4
sg11
VLEPR
p7523
sg13
I1
sa(dp7524
g7
I166
sg8
VP24723
p7525
sg10
I5
sg11
VPRKCH
p7526
sg13
I1
sasg20
(lp7527
(dp7528
g7
I144
sg23
VC0028756
p7529
sg10
I14
sg11
Vsevere obesity
p7530
sg13
I2
sa(dp7531
g7
I72
sg23
VC0028754
p7532
sg10
I5
sg11
Vobese
p7533
sg13
I1
sasa(dp7534
g2
S'Spondyloepiphyseal dysplasia tarda (SEDT) is an X-linked recessive osteochondrodysplasia characterized by disproportionately short stature and degenerative joint disease.\n'
p7535
sg4
(lp7536
sg20
(lp7537
(dp7538
g7
I0
sg23
VC0220776
p7539
sg10
I34
sg11
VSpondyloepiphyseal dysplasia tarda
p7540
sg13
I3
sa(dp7541
g7
I36
sg23
VC0220776
p7542
sg10
I4
sg11
VSEDT
p7543
sg13
I1
sa(dp7544
g7
I67
sg23
VC0026707
p7545
sg10
I21
sg11
Vosteochondrodysplasia
p7546
sg13
I1
sa(dp7547
g7
I125
sg23
VC0013336
p7548
sg10
I13
sg11
Vshort stature
p7549
sg13
I2
sa(dp7550
g7
I143
sg23
VC0029408
p7551
sg10
I26
sg11
Vdegenerative joint disease
p7552
sg13
I3
sasa(dp7553
g2
S'Spondyloepiphyseal dysplasia tarda (SEDT) is a genetically heterogeneous disorder often associated with the early onset of osteoarthrosis.\n'
p7554
sg4
(lp7555
sg20
(lp7556
(dp7557
g7
I0
sg23
VC0220776
p7558
sg10
I34
sg11
VSpondyloepiphyseal dysplasia tarda
p7559
sg13
I3
sa(dp7560
g7
I36
sg23
VC0220776
p7561
sg10
I4
sg11
VSEDT
p7562
sg13
I1
sa(dp7563
g7
I123
sg23
VC0029408
p7564
sg10
I14
sg11
Vosteoarthrosis
p7565
sg13
I1
sasa(dp7566
g2
S'SEDT should be kept in mind as a differential diagnosis in men with early "primary" bilateral osteoarthrosis.\n'
p7567
sg4
(lp7568
sg20
(lp7569
(dp7570
g7
I94
sg23
VC0029408
p7571
sg10
I14
sg11
Vosteoarthrosis
p7572
sg13
I1
sa(dp7573
g7
I0
sg23
VC0220776
p7574
sg10
I4
sg11
VSEDT
p7575
sg13
I1
sasa(dp7576
g2
S'Until now, four disease genes for Warburg micro syndrome, RAB3GAP1, RAB3GAP2, RAB18 and TBC1D20, have been identified.\n'
p7577
sg4
(lp7578
(dp7579
g7
I58
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7580
sg13
I1
sa(dp7581
g7
I88
sg8
g39
sg10
I7
sg11
VTBC1D20
p7582
sg13
I1
sa(dp7583
g7
I78
sg8
g39
sg10
I5
sg11
VRAB18
p7584
sg13
I1
sa(dp7585
g7
I68
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7586
sg13
I1
sasg20
(lp7587
(dp7588
g7
I34
sg23
VC1838625
p7589
sg10
I22
sg11
VWarburg micro syndrome
p7590
sg13
I3
sasa(dp7591
g2
S'RAB18, RAB3GAP1, RAB3GAP2 and TBC1D20 are each mutated in Warburg Micro syndrome, a rare autosomal recessive multisystem disorder.\n'
p7592
sg4
(lp7593
(dp7594
g7
I30
sg8
g39
sg10
I7
sg11
VTBC1D20
p7595
sg13
I1
sa(dp7596
g7
I17
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7597
sg13
I1
sa(dp7598
g7
I7
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7599
sg13
I1
sa(dp7600
g7
I0
sg8
g39
sg10
I5
sg11
VRAB18
p7601
sg13
I1
sasg20
(lp7602
(dp7603
g7
I58
sg23
VC1838625
p7604
sg10
I22
sg11
VWarburg Micro syndrome
p7605
sg13
I3
sa(dp7606
g7
I109
sg23
VC0559758
p7607
sg10
I20
sg11
Vmultisystem disorder
p7608
sg13
I2
sasa(dp7609
g2
S'In addition to TBC1D20, mutations in RAB3GAP1, RAB3GAP2 and RAB18 cause WARBM1-3 respectively.\n'
p7610
sg4
(lp7611
(dp7612
g7
I47
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7613
sg13
I1
sa(dp7614
g7
I37
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7615
sg13
I1
sa(dp7616
g7
I60
sg8
g39
sg10
I5
sg11
VRAB18
p7617
sg13
I1
sa(dp7618
g7
I15
sg8
g39
sg10
I7
sg11
VTBC1D20
p7619
sg13
I1
sa(dp7620
g7
I72
sg8
g39
sg10
I8
sg11
VWARBM1-3
p7621
sg13
I1
sasg20
(lp7622
(dp7623
g7
I72
sg23
VC1838625
p7624
sg10
I6
sg11
VWARBM1
p7625
sg13
I1
sasa(dp7626
g2
S'WARBM1-4 can be caused by biallelic mutations of the RAB3GAP1 (RAB3 GTPase-activating protein 1), RAB3GAP2, RAB18 (RAS-associated protein RAB18), or TBC1D20 (TBC1 domain protein, member 20) gene, respectively.\n'
p7627
sg4
(lp7628
(dp7629
g7
I98
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7630
sg13
I1
sa(dp7631
g7
I149
sg8
g39
sg10
I7
sg11
VTBC1D20
p7632
sg13
I1
sa(dp7633
g7
I53
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7634
sg13
I1
sa(dp7635
g7
I115
sg8
g39
sg10
I28
sg11
VRAS-associated protein RAB18
p7636
sg13
I3
sa(dp7637
g7
I63
sg8
VP14222
p7638
sg10
I32
sg11
VRAB3 GTPase-activating protein 1
p7639
sg13
I4
sa(dp7640
g7
I0
sg8
g39
sg10
I8
sg11
VWARBM1-4
p7641
sg13
I1
sa(dp7642
g7
I108
sg8
g39
sg10
I5
sg11
VRAB18
p7643
sg13
I1
sa(dp7644
g7
I158
sg8
g39
sg10
I19
sg11
VTBC1 domain protein
p7645
sg13
I3
sasg20
(lp7646
(dp7647
g7
I0
sg23
VC1838625
p7648
sg10
I6
sg11
VWARBM1
p7649
sg13
I1
sasa(dp7650
g2
S'Based on the function of TBC1D20 as a RABGAP and the bs cataract and testicular phenotypes, we hypothesized that mutations in TBC1D20 may contribute to Warburg micro syndrome (WARBM); WARBM constitutes a spectrum of disorders characterized by eye, brain, and endocrine abnormalities caused by mutations in RAB3GAP1, RAB3GAP2, and RAB18.\n'
p7651
sg4
(lp7652
(dp7653
g7
I330
sg8
g39
sg10
I5
sg11
VRAB18
p7654
sg13
I1
sa(dp7655
g7
I25
sg8
g39
sg10
I7
sg11
VTBC1D20
p7656
sg13
I1
sa(dp7657
g7
I306
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7658
sg13
I1
sa(dp7659
g7
I152
sg8
g39
sg10
I22
sg11
VWarburg micro syndrome
p7660
sg13
I3
sa(dp7661
g7
I316
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7662
sg13
I1
sa(dp7663
g7
I176
sg8
g39
sg10
I5
sg11
VWARBM
p7664
sg13
I1
sa(dp7665
g7
I25
sg8
g39
sg10
I7
sg11
VTBC1D20
p7666
sg13
I1
sasg20
(lp7667
(dp7668
g7
I176
sg23
VC1838625
p7669
sg10
I5
sg11
VWARBM
p7670
sg13
I1
sa(dp7671
g7
I152
sg23
VC1838625
p7672
sg10
I22
sg11
VWarburg micro syndrome
p7673
sg13
I3
sa(dp7674
g7
I176
sg23
VC1838625
p7675
sg10
I5
sg11
VWARBM
p7676
sg13
I1
sa(dp7677
g7
I56
sg23
VC0086543
p7678
sg10
I8
sg11
Vcataract
p7679
sg13
I1
sasa(dp7680
g2
S'Micro syndrome has been associated with causative mutations in three disease genes: RAB3GAP1, RAB3GAP2 and RAB18.\n'
p7681
sg4
(lp7682
(dp7683
g7
I94
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7684
sg13
I1
sa(dp7685
g7
I84
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7686
sg13
I1
sa(dp7687
g7
I107
sg8
g39
sg10
I5
sg11
VRAB18
p7688
sg13
I1
sasg20
(lp7689
(dp7690
g7
I0
sg23
VC1838625
p7691
sg10
I14
sg11
VMicro syndrome
p7692
sg13
I2
sasa(dp7693
g2
S'While biallelic loss-of-function mutations in RAB3GAP1 are present in the majority of patients with Warburg Micro syndrome; a hypomorphic homozygous splicing mutation of RAB3GAP2 has been reported in a single family with Martsolf syndrome.\n'
p7694
sg4
(lp7695
(dp7696
g7
I46
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7697
sg13
I1
sa(dp7698
g7
I170
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7699
sg13
I1
sasg20
(lp7700
(dp7701
g7
I221
sg23
VC0796037
p7702
sg10
I17
sg11
VMartsolf syndrome
p7703
sg13
I2
sa(dp7704
g7
I100
sg23
VC1838625
p7705
sg10
I22
sg11
VWarburg Micro syndrome
p7706
sg13
I3
sasa(dp7707
g2
S'Here, we report a novel homozygous RAB3GAP2 small in-frame deletion, c.499_507delTTCTACACT (p.Phe167_Thr169del) that causes Warburg Micro syndrome in a girl from a consanguineous Turkish family presenting with congenital cataracts, microphthalmia, absent visually evoked potentials, microcephaly, polymicrogyria, hypoplasia of the corpus callosum, and severe developmental delay.\n'
p7708
sg4
(lp7709
(dp7710
g7
I35
sg8
g39
sg10
I32
sg11
VRAB3GAP2 small in-frame deletion
p7711
sg13
I4
sasg20
(lp7712
(dp7713
g7
I124
sg23
VC1838625
p7714
sg10
I22
sg11
VWarburg Micro syndrome
p7715
sg13
I3
sa(dp7716
g7
I232
sg23
VC0026010
p7717
sg10
I14
sg11
Vmicrophthalmia
p7718
sg13
I1
sa(dp7719
g7
I283
sg23
VC0025958
p7720
sg10
I12
sg11
Vmicrocephaly
p7721
sg13
I1
sa(dp7722
g7
I313
sg23
VC0344482
p7723
sg10
I33
sg11
Vhypoplasia of the corpus callosum
p7724
sg13
I5
sa(dp7725
g7
I210
sg23
VC0009691
p7726
sg10
I20
sg11
Vcongenital cataracts
p7727
sg13
I2
sa(dp7728
g7
I297
sg23
VC0266464
p7729
sg10
I14
sg11
Vpolymicrogyria
p7730
sg13
I1
sa(dp7731
g7
I359
sg23
VC0424605
p7732
sg10
I19
sg11
Vdevelopmental delay
p7733
sg13
I2
sasa(dp7734
g2
S'No RAB3GAP2 mutations were detected in ten additional unrelated patients with RAB3GAP1-negative Warburg Micro syndrome, consistent with further genetic heterogeneity.\n'
p7735
sg4
(lp7736
(dp7737
g7
I3
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7738
sg13
I1
sa(dp7739
g7
I78
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7740
sg13
I1
sasg20
(lp7741
(dp7742
g7
I96
sg23
VC1838625
p7743
sg10
I22
sg11
VWarburg Micro syndrome
p7744
sg13
I3
sasa(dp7745
g2
S'Rather, our findings suggest that loss-of-function mutations of RAB3GAP1 as well as functionally severe RAB3GAP2 mutations cause Warburg Micro syndrome while hypomorphic RAB3GAP2 mutations can result in the milder Martsolf phenotype.\n'
p7746
sg4
(lp7747
(dp7748
g7
I64
sg8
g39
sg10
I8
sg11
VRAB3GAP1
p7749
sg13
I1
sa(dp7750
g7
I104
sg8
g39
sg10
I8
sg11
VRAB3GAP2
p7751
sg13
I1
sa(dp7752
g7
I104
sg8
g39
sg10
I18
sg11
VRAB3GAP2 mutations
p7753
sg13
I2
sasg20
(lp7754
(dp7755
g7
I129
sg23
VC1838625
p7756
sg10
I22
sg11
VWarburg Micro syndrome
p7757
sg13
I3
sasa(dp7758
g2
S"Studying a panel of human B-cell lines derived from patients with Burkitt's lymphoma (BL) and AIDS-associated Burkitt's lymphoma (AIDS-BL) we had described constitutive expression and secretion of large amounts of Interleukin-16 (IL-16), Macrophage Inflammatory Protein-1alpha (MIP-1alpha), Macrophage Inflammatory Protein-1beta (MIP-1beta), Interleukin-12 (IL-12), Interleukin-10 (IL-10), and Interleukin-7 (IL-7).\n"
p7759
sg4
(lp7760
(dp7761
g7
I358
sg8
VP60568
p7762
sg10
I5
sg11
VIL-12
p7763
sg13
I1
sa(dp7764
g7
I278
sg8
g39
sg10
I10
sg11
VMIP-1alpha
p7765
sg13
I1
sa(dp7766
g7
I382
sg8
VP22301
p7767
sg10
I5
sg11
VIL-10
p7768
sg13
I1
sa(dp7769
g7
I214
sg8
g39
sg10
I14
sg11
VInterleukin-16
p7770
sg13
I1
sa(dp7771
g7
I394
sg8
VP13232
p7772
sg10
I13
sg11
VInterleukin-7
p7773
sg13
I1
sa(dp7774
g7
I342
sg8
VP60568
p7775
sg10
I14
sg11
VInterleukin-12
p7776
sg13
I1
sa(dp7777
g7
I238
sg8
VP09603
p7778
sg10
I38
sg11
VMacrophage Inflammatory Protein-1alpha
p7779
sg13
I3
sa(dp7780
g7
I230
sg8
g39
sg10
I5
sg11
VIL-16
p7781
sg13
I1
sa(dp7782
g7
I291
sg8
VP09603
p7783
sg10
I37
sg11
VMacrophage Inflammatory Protein-1beta
p7784
sg13
I3
sa(dp7785
g7
I366
sg8
VP22301
p7786
sg10
I14
sg11
VInterleukin-10
p7787
sg13
I1
sa(dp7788
g7
I330
sg8
g39
sg10
I9
sg11
VMIP-1beta
p7789
sg13
I1
sa(dp7790
g7
I409
sg8
VP13232
p7791
sg10
I4
sg11
VIL-7
p7792
sg13
I1
sasg20
(lp7793
(dp7794
g7
I278
sg23
VC1851100
p7795
sg10
I3
sg11
VMIP
p7796
sg13
I1
sa(dp7797
g7
I66
sg23
VC0006413
p7798
sg10
I18
sg11
VBurkitt's lymphoma
p7799
sg13
I2
sa(dp7800
g7
I278
sg23
VC1851100
p7801
sg10
I3
sg11
VMIP
p7802
sg13
I1
sa(dp7803
g7
I94
sg23
VC1720008
p7804
sg10
I34
sg11
VAIDS-associated Burkitt's lymphoma
p7805
sg13
I3
sa(dp7806
g7
I130
sg23
VC1720008
p7807
sg10
I7
sg11
VAIDS-BL
p7808
sg13
I1
sa(dp7809
g7
I86
sg23
VC0006413
p7810
sg10
I2
sg11
VBL
p7811
sg13
I1
sasa(dp7812
g2
S"In Northern blot analysis we detected 2.4 kb IL-7 mRNA and by quantitative PCR we demonstrated IL-7 expression in 5 of 6 B CLS derived from patients with AIDS-associated Burkitt's lymphoma (AABCL), 3 of 3 CLS derived from patients with American Burkitt's lymphoma and 5 of 6 normal lymphoblastoid CLS.\n"
p7813
sg4
(lp7814
(dp7815
g7
I45
sg8
VP13232
p7816
sg10
I4
sg11
VIL-7
p7817
sg13
I1
sa(dp7818
g7
I38
sg8
VP13232
p7819
sg10
I16
sg11
V2.4 kb IL-7 mRNA
p7820
sg13
I4
sasg20
(lp7821
(dp7822
g7
I154
sg23
VC1720008
p7823
sg10
I34
sg11
VAIDS-associated Burkitt's lymphoma
p7824
sg13
I3
sa(dp7825
g7
I123
sg23
VC0265252
p7826
sg10
I3
sg11
VCLS
p7827
sg13
I1
sa(dp7828
g7
I123
sg23
VC0265252
p7829
sg10
I3
sg11
VCLS
p7830
sg13
I1
sa(dp7831
g7
I170
sg23
VC0006413
p7832
sg10
I18
sg11
VBurkitt's lymphoma
p7833
sg13
I2
sa(dp7834
g7
I123
sg23
VC0265252
p7835
sg10
I3
sg11
VCLS
p7836
sg13
I1
sasa(dp7837
g2
S"Only 1 of 5 African Burkitt's lymphoma CLS and 2 of 7 EBV- CLS expressed IL-7.\n"
p7838
sg4
(lp7839
(dp7840
g7
I39
sg8
VP51812
p7841
sg10
I3
sg11
VCLS
p7842
sg13
I1
sa(dp7843
g7
I73
sg8
VP13232
p7844
sg10
I4
sg11
VIL-7
p7845
sg13
I1
sasg20
(lp7846
(dp7847
g7
I39
sg23
VC0265252
p7848
sg10
I3
sg11
VCLS
p7849
sg13
I1
sa(dp7850
g7
I12
sg23
VC0343640
p7851
sg10
I26
sg11
VAfrican Burkitt's lymphoma
p7852
sg13
I3
sa(dp7853
g7
I39
sg23
VC0265252
p7854
sg10
I3
sg11
VCLS
p7855
sg13
I1
sasa(dp7856
g2
S'Overall, our study provides the first evidence that CAC1, associated with LSD1, functions as an ERAlfa corepressor, implicating a potential antitumor target in ERAlfa-positive breast cancer.\n'
p7857
sg4
(lp7858
(dp7859
g7
I52
sg8
g39
sg10
I4
sg11
VCAC1
p7860
sg13
I1
sasg20
(lp7861
(dp7862
g7
I176
sg23
VC0678222
p7863
sg10
I13
sg11
Vbreast cancer
p7864
sg13
I2
sasa(dp7865
g2
S'Patients with a larger or complete cleft of the secondary hard palate (HSCP) and patients with unilateral (UCLP) or bilateral (BCLP) cleft lip and palate undergo two surgical stages for palate closure: a supra-periosteal retropositioning is performed around 12 months of age, and a modified Langenbeck closure of the hard palate around 60 months of age.\n'
p7866
sg4
(lp7867
sg20
(lp7868
(dp7869
g7
I133
sg23
VC0158646
p7870
sg10
I20
sg11
Vcleft lip and palate
p7871
sg13
I4
sasa(dp7872
g2
S'The all-cleft group consisted of 25 patients with hard palate cleft comprising 15 patients with unilateral cleft palate and lip (UCLP); 2 with CP but no cleft lip (UCLP subgroup) and 8 patients with bilateral cleft lip and palate (BCLP subgroup).\n'
p7873
sg4
(lp7874
sg20
(lp7875
(dp7876
g7
I199
sg23
VC0392005
p7877
sg10
I19
sg11
Vbilateral cleft lip
p7878
sg13
I3
sa(dp7879
g7
I209
sg23
VC0158646
p7880
sg10
I20
sg11
Vcleft lip and palate
p7881
sg13
I4
sa(dp7882
g7
I55
sg23
VC0008925
p7883
sg10
I12
sg11
Vpalate cleft
p7884
sg13
I2
sa(dp7885
g7
I129
sg23
VC0158646
p7886
sg10
I4
sg11
VUCLP
p7887
sg13
I1
sa(dp7888
g7
I129
sg23
VC0158646
p7889
sg10
I4
sg11
VUCLP
p7890
sg13
I1
sa(dp7891
g7
I153
sg23
VC0008924
p7892
sg10
I9
sg11
Vcleft lip
p7893
sg13
I2
sa(dp7894
g7
I96
sg23
VC0158646
p7895
sg10
I31
sg11
Vunilateral cleft palate and lip
p7896
sg13
I5
sasa(dp7897
g2
S'We evaluated with a certain assessment protocol hearing and speech abilities of 42 patients between 5 and 15 years of age: 9 with CP (cleft of the soft and hard palate), 19 with unilateral cleft lip and palate (UCLP), 14 with bilateral cleft lip and palate (BCLP), surgically treated by a team of surgeons using two different surgical techniques between 18 and 24 months of age.\n'
p7898
sg4
(lp7899
sg20
(lp7900
(dp7901
g7
I178
sg23
VC0392006
p7902
sg10
I20
sg11
Vunilateral cleft lip
p7903
sg13
I3
sa(dp7904
g7
I226
sg23
VC0392005
p7905
sg10
I19
sg11
Vbilateral cleft lip
p7906
sg13
I3
sa(dp7907
g7
I189
sg23
VC0158646
p7908
sg10
I20
sg11
Vcleft lip and palate
p7909
sg13
I4
sa(dp7910
g7
I189
sg23
VC0158646
p7911
sg10
I20
sg11
Vcleft lip and palate
p7912
sg13
I4
sasa(dp7913
g2
S'Haplotypes generated with intragenic SNPs indicated the C-C-G-G-T-A to be a risk haplotype associated with CYP1B1 mutations in POAG (P = 0.006) and PACG (P = 0.043), similar to that observed in cases of primary congenital glaucoma worldwide.\n'
p7914
sg4
(lp7915
(dp7916
g7
I107
sg8
g39
sg10
I6
sg11
VCYP1B1
p7917
sg13
I1
sasg20
(lp7918
(dp7919
g7
I203
sg23
VC1533041
p7920
sg10
I27
sg11
Vprimary congenital glaucoma
p7921
sg13
I3
sa(dp7922
g7
I127
sg23
VC0339573
p7923
sg10
I4
sg11
VPOAG
p7924
sg13
I1
sasa(dp7925
g2
S'To compare pepsin, carbonic anhydrase III (CAIII), cyclooxygenase-2 (COX-2) and mucin 5AC (MUC5AC) expression in children with adenoid hypertrophy and normal controls.\n'
p7926
sg4
(lp7927
(dp7928
g7
I19
sg8
VP07451
p7929
sg10
I22
sg11
Vcarbonic anhydrase III
p7930
sg13
I3
sa(dp7931
g7
I69
sg8
VP35354
p7932
sg10
I5
sg11
VCOX-2
p7933
sg13
I1
sa(dp7934
g7
I43
sg8
VP07451
p7935
sg10
I5
sg11
VCAIII
p7936
sg13
I1
sa(dp7937
g7
I11
sg8
VP00790
p7938
sg10
I6
sg11
Vpepsin
p7939
sg13
I1
sa(dp7940
g7
I51
sg8
VP35354
p7941
sg10
I16
sg11
Vcyclooxygenase-2
p7942
sg13
I1
sasg20
(lp7943
(dp7944
g7
I127
sg23
VC0149825
p7945
sg10
I19
sg11
Vadenoid hypertrophy
p7946
sg13
I2
sasa(dp7947
g2
S'Immunodeficient Rag2(-/-)Gammac(-/-) mice, bearing various human multiple myeloma tumors, were treated with human peripheral blood mononuclear cell (PBMC) alone or together with autologous ex vivo cultured Tregs.\n'
p7948
sg4
(lp7949
(dp7950
g7
I16
sg8
VP55895
p7951
sg10
I4
sg11
VRag2
p7952
sg13
I1
sasg20
(lp7953
(dp7954
g7
I65
sg23
VC0026764
p7955
sg10
I16
sg11
Vmultiple myeloma
p7956
sg13
I2
sa(dp7957
g7
I82
sg23
VC0027651
p7958
sg10
I6
sg11
Vtumors
p7959
sg13
I1
sa(dp7960
g7
I0
sg23
VC0021051
p7961
sg10
I15
sg11
VImmunodeficient
p7962
sg13
I1
sasa(dp7963
g2
S'In macrophage-depleted Rag2(-/-)Gammac(-/-) mice, which were also devoid of T, B, and natural killer cells, mHag-specific native T cells or tetanus toxoid (TT)-specific T cells transduced with the mHag-specific T-cell receptor (TCR) were injected to treat full-blown mHag(+) human multiple myeloma tumors.\n'
p7964
sg4
(lp7965
(dp7966
g7
I23
sg8
VP55895
p7967
sg10
I4
sg11
VRag2
p7968
sg13
I1
sa(dp7969
g7
I197
sg8
g39
sg10
I29
sg11
VmHag-specific T-cell receptor
p7970
sg13
I3
sasg20
(lp7971
(dp7972
g7
I140
sg23
VC0039614
p7973
sg10
I7
sg11
Vtetanus
p7974
sg13
I1
sa(dp7975
g7
I281
sg23
VC0026764
p7976
sg10
I16
sg11
Vmultiple myeloma
p7977
sg13
I2
sa(dp7978
g7
I298
sg23
VC0027651
p7979
sg10
I6
sg11
Vtumors
p7980
sg13
I1
sasa(dp7981
g2
S'Here we have explored the feasibility of establishing such a model in immunodeficient RAG2(-/-)gammac(-/-) mice, by utilizing non-invasive bioluminescent imaging for real-time monitoring of multiple myeloma cell growth.\n'
p7982
sg4
(lp7983
sg20
(lp7984
(dp7985
g7
I70
sg23
VC0021051
p7986
sg10
I15
sg11
Vimmunodeficient
p7987
sg13
I1
sa(dp7988
g7
I190
sg23
VC0026764
p7989
sg10
I16
sg11
Vmultiple myeloma
p7990
sg13
I2
sasa(dp7991
g2
S'Seven multiple myeloma cell lines, marked with a green fluorescent protein firefly luciferase fusion gene, were intravenously injected into RAG2(-/-)gammac(-/-) mice.\n'
p7992
sg4
(lp7993
(dp7994
g7
I49
sg8
g39
sg10
I25
sg11
Vgreen fluorescent protein
p7995
sg13
I3
sa(dp7996
g7
I140
sg8
VP55895
p7997
sg10
I4
sg11
VRAG2
p7998
sg13
I1
sasg20
(lp7999
(dp8000
g7
I6
sg23
VC0026764
p8001
sg10
I16
sg11
Vmultiple myeloma
p8002
sg13
I2
sasa(dp8003
g2
S'Obesity stimulates cancer progression through chronic, low-grade inflammation in white adipose tissue, leading to accumulation of adipose tissue macrophages (ATMs), in particular, the pro-inflammatory M1 phenotype macrophage.\n'
p8004
sg4
(lp8005
sg20
(lp8006
(dp8007
g7
I0
sg23
VC0028754
p8008
sg10
I7
sg11
VObesity
p8009
sg13
I1
sa(dp8010
g7
I65
sg23
VC0021368
p8011
sg10
I12
sg11
Vinflammation
p8012
sg13
I1
sa(dp8013
g7
I19
sg23
VC0178874
p8014
sg10
I18
sg11
Vcancer progression
p8015
sg13
I2
sasa(dp8016
g2
S'Alternative activation (M2) of adipose tissue resident macrophage (ATM) inhibits obesity-induced metabolic inflammation.\n'
p8017
sg4
(lp8018
(dp8019
g7
I31
sg8
g39
sg10
I40
sg11
Vadipose tissue resident macrophage (ATM)
p8020
sg13
I5
sasg20
(lp8021
(dp8022
g7
I81
sg23
VC0028754
p8023
sg10
I7
sg11
Vobesity
p8024
sg13
I1
sa(dp8025
g7
I107
sg23
VC0021368
p8026
sg10
I12
sg11
Vinflammation
p8027
sg13
I1
sasa(dp8028
g2
S'Visceral white adipose tissue (WAT) has been closely associated with obesity-induced inflammation and adipose tissue macrophages (ATMs) are responsible for obesity-induced inflammation by releasing inflammatory cytokines such as tumor necrosis factor-Alfa (TNF-Alfa) and interleukin-6.\n'
p8029
sg4
(lp8030
(dp8031
g7
I229
sg8
VP01375
p8032
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p8033
sg13
I3
sa(dp8034
g7
I271
sg8
VP05231
p8035
sg10
I13
sg11
Vinterleukin-6
p8036
sg13
I1
sa(dp8037
g7
I257
sg8
VP01375
p8038
sg10
I8
sg11
VTNF-Alfa
p8039
sg13
I1
sasg20
(lp8040
(dp8041
g7
I229
sg23
VC0333516
p8042
sg10
I14
sg11
Vtumor necrosis
p8043
sg13
I2
sa(dp8044
g7
I69
sg23
VC0028754
p8045
sg10
I7
sg11
Vobesity
p8046
sg13
I1
sa(dp8047
g7
I85
sg23
VC0021368
p8048
sg10
I12
sg11
Vinflammation
p8049
sg13
I1
sa(dp8050
g7
I85
sg23
VC0021368
p8051
sg10
I12
sg11
Vinflammation
p8052
sg13
I1
sa(dp8053
g7
I69
sg23
VC0028754
p8054
sg10
I7
sg11
Vobesity
p8055
sg13
I1
sasa(dp8056
g2
S'During obesity, adipose tissue macrophages (ATMs) adopt a metabolically activated (MMe) phenotype.\n'
p8057
sg4
(lp8058
sg20
(lp8059
(dp8060
g7
I7
sg23
VC0028754
p8061
sg10
I7
sg11
Vobesity
p8062
sg13
I1
sasa(dp8063
g2
S'The quantity and activation state of adipose tissue macrophages (ATMs) impact the development of obesity-induced metabolic diseases.\n'
p8064
sg4
(lp8065
sg20
(lp8066
(dp8067
g7
I113
sg23
VC0025517
p8068
sg10
I18
sg11
Vmetabolic diseases
p8069
sg13
I2
sa(dp8070
g7
I97
sg23
VC0028754
p8071
sg10
I7
sg11
Vobesity
p8072
sg13
I1
sasa(dp8073
g2
S'Appetite-controlling hormones play key roles in obesity; however, our understanding of their effects on ATMs is limited.\n'
p8074
sg4
(lp8075
sg20
(lp8076
(dp8077
g7
I48
sg23
VC0028754
p8078
sg10
I7
sg11
Vobesity
p8079
sg13
I1
sasa(dp8080
g2
S'Therefore, ATM activation is a therapeutic target for IR in obesity.\n'
p8081
sg4
(lp8082
(dp8083
g7
I11
sg8
g39
sg10
I3
sg11
VATM
p8084
sg13
I1
sa(dp8085
g7
I54
sg8
VP06213
p8086
sg10
I2
sg11
VIR
p8087
sg13
I1
sasg20
(lp8088
(dp8089
g7
I60
sg23
VC0028754
p8090
sg10
I7
sg11
Vobesity
p8091
sg13
I1
sasa(dp8092
g2
S'The function of RUNDC3B has yet to be determined, although its dysregulated expression has been associated with malignant potential of both breast and lung carcinoma.\n'
p8093
sg4
(lp8094
(dp8095
g7
I16
sg8
g39
sg10
I7
sg11
VRUNDC3B
p8096
sg13
I1
sasg20
(lp8097
(dp8098
g7
I151
sg23
VC0684249
p8099
sg10
I14
sg11
Vlung carcinoma
p8100
sg13
I2
sasa(dp8101
g2
S'We developed sensitive methods for detecting and quantifying RPIP9 mRNA and used it to identify these transcripts in normal human tissues, 60 biopsies of primary breast carcinoma, in isolated epithelial cells both from the primary tumor and from associated lymph nodes, and from bone marrow biopsies of 74 breast cancer patients.\n'
p8102
sg4
(lp8103
(dp8104
g7
I61
sg8
g39
sg10
I10
sg11
VRPIP9 mRNA
p8105
sg13
I2
sasg20
(lp8106
(dp8107
g7
I223
sg23
VC0677930
p8108
sg10
I13
sg11
Vprimary tumor
p8109
sg13
I2
sa(dp8110
g7
I162
sg23
VC0678222
p8111
sg10
I16
sg11
Vbreast carcinoma
p8112
sg13
I2
sa(dp8113
g7
I306
sg23
VC0678222
p8114
sg10
I13
sg11
Vbreast cancer
p8115
sg13
I2
sasa(dp8116
g2
S'Tumorigenic breast carcinoma cell lines expressed RPIP9, whereas MCF-10A and HBL-100 that do not form tumors in nude mice had undetectable levels of RPIP9 mRNA.\n'
p8117
sg4
(lp8118
(dp8119
g7
I50
sg8
g39
sg10
I5
sg11
VRPIP9
p8120
sg13
I1
sa(dp8121
g7
I77
sg8
VP09382
p8122
sg10
I7
sg11
VHBL-100
p8123
sg13
I1
sa(dp8124
g7
I149
sg8
g39
sg10
I10
sg11
VRPIP9 mRNA
p8125
sg13
I2
sasg20
(lp8126
(dp8127
g7
I12
sg23
VC0678222
p8128
sg10
I16
sg11
Vbreast carcinoma
p8129
sg13
I2
sa(dp8130
g7
I102
sg23
VC0027651
p8131
sg10
I6
sg11
Vtumors
p8132
sg13
I1
sasa(dp8133
g2
S'RPIP9 was activated in a high proportion of breast carcinomas (61.6%; n = 60) and a significant correlation with metastatic lymph node invasion (N = 0-3 vs. N &gt; 3, where N = number of lymph nodes invaded; p = 0.031) was found.\n'
p8134
sg4
(lp8135
(dp8136
g7
I0
sg8
g39
sg10
I5
sg11
VRPIP9
p8137
sg13
I1
sasg20
(lp8138
(dp8139
g7
I44
sg23
VC0678222
p8140
sg10
I17
sg11
Vbreast carcinomas
p8141
sg13
I2
sa(dp8142
g7
I135
sg23
VC2699153
p8143
sg10
I8
sg11
Vinvasion
p8144
sg13
I1
sasa(dp8145
g2
S'In this study, we provide genetic and pharmacological evidence that inhibiting the N-myristoyltransferase NMT1 suppresses cell cycle progression, proliferation and malignant growth of prostate cancer cells.\n'
p8146
sg4
(lp8147
(dp8148
g7
I83
sg8
VP30419
p8149
sg10
I27
sg11
VN-myristoyltransferase NMT1
p8150
sg13
I2
sasg20
(lp8151
(dp8152
g7
I146
sg23
VC0334094
p8153
sg10
I13
sg11
Vproliferation
p8154
sg13
I1
sa(dp8155
g7
I184
sg23
VC0600139
p8156
sg10
I15
sg11
Vprostate cancer
p8157
sg13
I2
sasa(dp8158
g2
S'The feature selection procedure extracted several cancer-related and lymph node metastasis-related genes, such as TP73, PDX1, FUT8, HOXD1, NMT1, and SEMA3E.\n'
p8159
sg4
(lp8160
(dp8161
g7
I149
sg8
g39
sg10
I6
sg11
VSEMA3E
p8162
sg13
I1
sa(dp8163
g7
I139
sg8
VP30419
p8164
sg10
I4
sg11
VNMT1
p8165
sg13
I1
sa(dp8166
g7
I126
sg8
g39
sg10
I4
sg11
VFUT8
p8167
sg13
I1
sa(dp8168
g7
I120
sg8
VP52945
p8169
sg10
I4
sg11
VPDX1
p8170
sg13
I1
sa(dp8171
g7
I132
sg8
g39
sg10
I5
sg11
VHOXD1
p8172
sg13
I1
sasg20
(lp8173
(dp8174
g7
I50
sg23
VC0006826
p8175
sg10
I6
sg11
Vcancer
p8176
sg13
I1
sa(dp8177
g7
I69
sg23
VC0686619
p8178
sg10
I21
sg11
Vlymph node metastasis
p8179
sg13
I3
sasa(dp8180
g2
S'This study examined recombinant wild-type human phosphoribosylpyrophosphate synthetase 1 (wt-PRS1, EC 2.7.6.1) and the point mutant Asn114Ser PRS1 (N114S-Mutant) in cells of a patient with primary gout.\n'
p8181
sg4
(lp8182
(dp8183
g7
I20
sg8
g39
sg10
I68
sg11
Vrecombinant wild-type human phosphoribosylpyrophosphate synthetase 1
p8184
sg13
I6
sasg20
(lp8185
(dp8186
g7
I125
sg23
VC0596988
p8187
sg10
I6
sg11
Vmutant
p8188
sg13
I1
sa(dp8189
g7
I189
sg23
VC0149896
p8190
sg10
I12
sg11
Vprimary gout
p8191
sg13
I2
sa(dp8192
g7
I154
sg23
VC0596988
p8193
sg10
I6
sg11
VMutant
p8194
sg13
I1
sasa(dp8195
g2
S'The enzymic activities of erythrocyte phosphoribosyl pyrophosphate synthetase (EC 2.7.6.1) and glutathione reductase (EC 1.6.4.2) have been measured in 54 primary gout patients, 35 individuals having hyperuricaemia and 51 healthy controls.\n'
p8196
sg4
(lp8197
(dp8198
g7
I26
sg8
VP11908
p8199
sg10
I51
sg11
Verythrocyte phosphoribosyl pyrophosphate synthetase
p8200
sg13
I4
sa(dp8201
g7
I95
sg8
VP00390
p8202
sg10
I21
sg11
Vglutathione reductase
p8203
sg13
I2
sasg20
(lp8204
(dp8205
g7
I155
sg23
VC0149896
p8206
sg10
I12
sg11
Vprimary gout
p8207
sg13
I2
sa(dp8208
g7
I200
sg23
VC0740394
p8209
sg10
I14
sg11
Vhyperuricaemia
p8210
sg13
I1
sasa(dp8211
g2
S'Among affected members of a family (B. family) with excessive purine production and gout, activity of phosphoribosylpyrophosphate synthetase (EC 2.7.6.1) is 2.5- to 3.0-fold higher than among normal people.\n'
p8212
sg4
(lp8213
(dp8214
g7
I102
sg8
VP11908
p8215
sg10
I38
sg11
Vphosphoribosylpyrophosphate synthetase
p8216
sg13
I2
sasg20
(lp8217
(dp8218
g7
I84
sg23
VC0018099
p8219
sg10
I4
sg11
Vgout
p8220
sg13
I1
sasa(dp8221
g2
S'Clinical manifestations of PP-Rib-P synthetase superactivity are mainly limited to gout in early adulthood.\n'
p8222
sg4
(lp8223
sg20
(lp8224
(dp8225
g7
I83
sg23
VC0018099
p8226
sg10
I4
sg11
Vgout
p8227
sg13
I1
sasa(dp8228
g2
S'We herein document the association of PP-Rib-P synthetase superactivity, gout with excessive uric acid synthesis, and sensorineural deafness in an additional family.\n'
p8229
sg4
(lp8230
sg20
(lp8231
(dp8232
g7
I73
sg23
VC0018099
p8233
sg10
I4
sg11
Vgout
p8234
sg13
I1
sa(dp8235
g7
I118
sg23
VC0018784
p8236
sg10
I22
sg11
Vsensorineural deafness
p8237
sg13
I2
sasa(dp8238
g2
S'The management of acute aortic aneurysm rupture or dissection (AARD) requires specific medical expertise, diagnostic techniques, and therapeutic options, not always available in all hospitals through the entire week.\n'
p8239
sg4
(lp8240
sg20
(lp8241
(dp8242
g7
I24
sg23
VC0741160
p8243
sg10
I23
sg11
Vaortic aneurysm rupture
p8244
sg13
I3
sasa(dp8245
g2
S'The aim of this study was to investigate single nucleotide polymorphisms (SNPs) in the adenosine deaminase, RNA-specific, B1 (ADARB1) and adenosine deaminase, RNA specific, B2 (ADARB2) genes in an Australian case-control Caucasian population for association with migraine.\n'
p8246
sg4
(lp8247
(dp8248
g7
I87
sg8
VP00813
p8249
sg10
I19
sg11
Vadenosine deaminase
p8250
sg13
I2
sa(dp8251
g7
I177
sg8
g39
sg10
I6
sg11
VADARB2
p8252
sg13
I1
sa(dp8253
g7
I87
sg8
VP00813
p8254
sg10
I19
sg11
Vadenosine deaminase
p8255
sg13
I2
sasg20
(lp8256
(dp8257
g7
I263
sg23
VC0149931
p8258
sg10
I8
sg11
Vmigraine
p8259
sg13
I1
sasa(dp8260
g2
S'SNPs in the ADARB2 gene were previously found to be positively associated with migraine in a pedigree-based genome wide association study using the genetic isolate of Norfolk Island, Australia.\n'
p8261
sg4
(lp8262
(dp8263
g7
I12
sg8
g39
sg10
I11
sg11
VADARB2 gene
p8264
sg13
I2
sasg20
(lp8265
(dp8266
g7
I79
sg23
VC0149931
p8267
sg10
I8
sg11
Vmigraine
p8268
sg13
I1
sasa(dp8269
g2
S'Chi-square analysis found no significant association between any of the SNPs tested in the ADARB1 and ADARB2 genes in this study and the occurrence of migraine.\n'
p8270
sg4
(lp8271
(dp8272
g7
I102
sg8
g39
sg10
I12
sg11
VADARB2 genes
p8273
sg13
I2
sasg20
(lp8274
(dp8275
g7
I151
sg23
VC0149931
p8276
sg10
I8
sg11
Vmigraine
p8277
sg13
I1
sasa(dp8278
g2
S'In contrast to findings that SNPs in the ADARB2 gene were positively associated with migraine in the Norfolk Island population, we find no evidence to support the involvement of RNA editing genes in migraine susceptibility in an Australian Caucasian population.\n'
p8279
sg4
(lp8280
(dp8281
g7
I41
sg8
g39
sg10
I11
sg11
VADARB2 gene
p8282
sg13
I2
sasg20
(lp8283
(dp8284
g7
I85
sg23
VC0149931
p8285
sg10
I8
sg11
Vmigraine
p8286
sg13
I1
sa(dp8287
g7
I85
sg23
VC0149931
p8288
sg10
I8
sg11
Vmigraine
p8289
sg13
I1
sasa(dp8290
g2
S'We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion.\n'
p8291
sg4
(lp8292
(dp8293
g7
I22
sg8
g39
sg10
I7
sg11
Vdrebrin
p8294
sg13
I1
sa(dp8295
g7
I30
sg8
g39
sg10
I3
sg11
VEB3
p8296
sg13
I1
sasg20
(lp8297
(dp8298
g7
I202
sg23
VC2699153
p8299
sg10
I13
sg11
Vcell invasion
p8300
sg13
I2
sa(dp8301
g7
I186
sg23
VC0600139
p8302
sg10
I15
sg11
Vprostate cancer
p8303
sg13
I2
sasa(dp8304
g2
S'Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays.\n'
p8305
sg4
(lp8306
(dp8307
g7
I18
sg8
g39
sg10
I7
sg11
Vdrebrin
p8308
sg13
I1
sa(dp8309
g7
I26
sg8
g39
sg10
I3
sg11
VEB3
p8310
sg13
I1
sa(dp8311
g7
I18
sg8
g39
sg10
I7
sg11
Vdrebrin
p8312
sg13
I1
sasg20
(lp8313
(dp8314
g7
I140
sg23
VC0600139
p8315
sg10
I15
sg11
Vprostate cancer
p8316
sg13
I2
sa(dp8317
g7
I128
sg23
VC2699153
p8318
sg10
I8
sg11
Vinvasion
p8319
sg13
I1
sasa(dp8320
g2
S'Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively.\n'
p8321
sg4
(lp8322
(dp8323
g7
I53
sg8
g39
sg10
I3
sg11
VEB3
p8324
sg13
I1
sa(dp8325
g7
I42
sg8
g39
sg10
I7
sg11
Vdrebrin
p8326
sg13
I1
sasg20
(lp8327
(dp8328
g7
I127
sg23
VC2699153
p8329
sg10
I8
sg11
Vinvasion
p8330
sg13
I1
sa(dp8331
g7
I139
sg23
VC0600139
p8332
sg10
I15
sg11
Vprostate cancer
p8333
sg13
I2
sasa(dp8334
g2
S'Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays.\n'
p8335
sg4
(lp8336
(dp8337
g7
I72
sg8
g39
sg10
I3
sg11
VEB3
p8338
sg13
I1
sa(dp8339
g7
I87
sg8
g39
sg10
I7
sg11
Vdrebrin
p8340
sg13
I1
sasg20
(lp8341
(dp8342
g7
I111
sg23
VC2699153
p8343
sg10
I8
sg11
Vinvasion
p8344
sg13
I1
sa(dp8345
g7
I123
sg23
VC0600139
p8346
sg10
I15
sg11
Vprostate cancer
p8347
sg13
I2
sasa(dp8348
g2
S'Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression.\n'
p8349
sg4
(lp8350
(dp8351
g7
I88
sg8
g39
sg10
I7
sg11
Vdrebrin
p8352
sg13
I1
sa(dp8353
g7
I96
sg8
g39
sg10
I3
sg11
VEB3
p8354
sg13
I1
sasg20
(lp8355
(dp8356
g7
I115
sg23
VC0600139
p8357
sg10
I15
sg11
Vprostate cancer
p8358
sg13
I2
sa(dp8359
g7
I131
sg23
VC2699153
p8360
sg10
I13
sg11
Vcell invasion
p8361
sg13
I2
sa(dp8362
g7
I176
sg23
VC0242656
p8363
sg10
I19
sg11
Vdisease progression
p8364
sg13
I2
sasa(dp8365
g2
S'The colonic adenocarcinoma cell line LS180, its more motile sublines (EB3, 3LNLN, 5W) and Beta-catenin-knockdown LS180 cells were used to investigate the expression levels and subcellular localization of Beta-catenin and gelsolin.\n'
p8366
sg4
(lp8367
(dp8368
g7
I221
sg8
VP06396
p8369
sg10
I8
sg11
Vgelsolin
p8370
sg13
I1
sa(dp8371
g7
I90
sg8
VP35222
p8372
sg10
I12
sg11
VBeta-catenin
p8373
sg13
I1
sa(dp8374
g7
I90
sg8
VP35222
p8375
sg10
I12
sg11
VBeta-catenin
p8376
sg13
I1
sasg20
(lp8377
(dp8378
g7
I4
sg23
VC0338106
p8379
sg10
I22
sg11
Vcolonic adenocarcinoma
p8380
sg13
I2
sasa(dp8381
g2
S'IL-10, IL-12 and IL-17F as inflammatory cytokines might be an important functional candidate genes for autoimmune diseases including MCTD.\n'
p8382
sg4
(lp8383
sg20
(lp8384
(dp8385
g7
I103
sg23
VC0004364
p8386
sg10
I19
sg11
Vautoimmune diseases
p8387
sg13
I2
sa(dp8388
g7
I133
sg23
VC0026272
p8389
sg10
I4
sg11
VMCTD
p8390
sg13
I1
sasa(dp8391
g2
S'The frequency of the IL-10-592A and -1082A allele was higher in MCTD patients than in control groups (both p = 0,0000).\n'
p8392
sg4
(lp8393
sg20
(lp8394
(dp8395
g7
I64
sg23
VC0026272
p8396
sg10
I4
sg11
VMCTD
p8397
sg13
I1
sasa(dp8398
g2
S'Present findings indicate that IL-10 gene variants may be considered as genetic risk factors for MCTD susceptibility.\n'
p8399
sg4
(lp8400
(dp8401
g7
I31
sg8
VP26640
p8402
sg10
I19
sg11
VIL-10 gene variants
p8403
sg13
I3
sasg20
(lp8404
(dp8405
g7
I97
sg23
VC0026272
p8406
sg10
I4
sg11
VMCTD
p8407
sg13
I1
sasa(dp8408
g2
S'There was an increase in the percentage and absolute number of CD4+IL-10+ Treg cells in patients with MCTD compared to the healthy controls (p&lt;0.02).\n'
p8409
sg4
(lp8410
(dp8411
g7
I63
sg8
VP01730
p8412
sg10
I6
sg11
VCD4+IL
p8413
sg13
I1
sasg20
(lp8414
(dp8415
g7
I102
sg23
VC0026272
p8416
sg10
I4
sg11
VMCTD
p8417
sg13
I1
sasa(dp8418
g2
S'The percentage of CD4+IL-10+ Treg cells was higher in the active stage of MCTD than in the inactive stage of the disease (p&lt;0.005).\n'
p8419
sg4
(lp8420
(dp8421
g7
I18
sg8
VP01730
p8422
sg10
I6
sg11
VCD4+IL
p8423
sg13
I1
sasg20
(lp8424
(dp8425
g7
I74
sg23
VC0026272
p8426
sg10
I4
sg11
VMCTD
p8427
sg13
I1
sasa(dp8428
g2
S'However, we did not find any significant difference in the absolute number of CD4+IL-10+ Treg cells between the patients in the active and inactive stages of MCTD.\n'
p8429
sg4
(lp8430
(dp8431
g7
I78
sg8
VP01730
p8432
sg10
I6
sg11
VCD4+IL
p8433
sg13
I1
sasg20
(lp8434
(dp8435
g7
I158
sg23
VC0026272
p8436
sg10
I4
sg11
VMCTD
p8437
sg13
I1
sasa(dp8438
g2
S'We suggest that the increase in the number of CD4+IL-10+ Treg cells is a compensatory mechanism aiming to restore the balance between type 1 and type 2 cytokines in MCTD.\n'
p8439
sg4
(lp8440
(dp8441
g7
I46
sg8
VP01730
p8442
sg10
I6
sg11
VCD4+IL
p8443
sg13
I1
sasg20
(lp8444
(dp8445
g7
I165
sg23
VC0026272
p8446
sg10
I4
sg11
VMCTD
p8447
sg13
I1
sasa(dp8448
g2
S'Again, CD4+ and CD8+ T cells from patients with active MCTD produced significantly more IL-10 than cells in patients with inactive disease or in controls (p &lt; 0.05).\n'
p8449
sg4
(lp8450
(dp8451
g7
I16
sg8
VP01732
p8452
sg10
I4
sg11
VCD8+
p8453
sg13
I1
sa(dp8454
g7
I7
sg8
VP01730
p8455
sg10
I4
sg11
VCD4+
p8456
sg13
I1
sasg20
(lp8457
(dp8458
g7
I55
sg23
VC0026272
p8459
sg10
I4
sg11
VMCTD
p8460
sg13
I1
sasa(dp8461
g2
S'Our results suggest that MCTD is associated with increased production of both type 1 (IFN-gamma) and type 2 cytokines (IL-4, IL-10).\n'
p8462
sg4
(lp8463
(dp8464
g7
I119
sg8
VP05112
p8465
sg10
I4
sg11
VIL-4
p8466
sg13
I1
sa(dp8467
g7
I86
sg8
VP01579
p8468
sg10
I9
sg11
VIFN-gamma
p8469
sg13
I1
sa(dp8470
g7
I101
sg8
VP01374
p8471
sg10
I16
sg11
Vtype 2 cytokines
p8472
sg13
I3
sasg20
(lp8473
(dp8474
g7
I25
sg23
VC0026272
p8475
sg10
I4
sg11
VMCTD
p8476
sg13
I1
sasa(dp8477
g2
S'Patients with active disease have more IL-4-expressing Tc2 cells and IL-10-expressing Th2 and Tc2 cells than patients with inactive MCTD or controls.\n'
p8478
sg4
(lp8479
(dp8480
g7
I39
sg8
VP05112
p8481
sg10
I4
sg11
VIL-4
p8482
sg13
I1
sasg20
(lp8483
(dp8484
g7
I132
sg23
VC0026272
p8485
sg10
I4
sg11
VMCTD
p8486
sg13
I1
sasa(dp8487
g2
S'In MCTD, increased IL-10 production by Th2 and Tc2 cells may be an attempt by the immune system to downregulate the inflammatory reaction, although this effect may not be sufficient to restore the physiological Th1/Th2 balance in MCTD.\n'
p8488
sg4
(lp8489
sg20
(lp8490
(dp8491
g7
I116
sg23
VC0021368
p8492
sg10
I21
sg11
Vinflammatory reaction
p8493
sg13
I2
sa(dp8494
g7
I3
sg23
VC0026272
p8495
sg10
I4
sg11
VMCTD
p8496
sg13
I1
sa(dp8497
g7
I3
sg23
VC0026272
p8498
sg10
I4
sg11
VMCTD
p8499
sg13
I1
sasa(dp8500
g2
S'To investigate the levels and relationship between IL-10, TNF-alpha, anti-U1snRNP antibodies and disease activity in longitudinally collected serum samples from patients with mixed connective tissue disease (MCTD).\n'
p8501
sg4
(lp8502
(dp8503
g7
I58
sg8
VP01375
p8504
sg10
I9
sg11
VTNF-alpha
p8505
sg13
I1
sasg20
(lp8506
(dp8507
g7
I208
sg23
VC0026272
p8508
sg10
I4
sg11
VMCTD
p8509
sg13
I1
sa(dp8510
g7
I175
sg23
VC0026272
p8511
sg10
I31
sg11
Vmixed connective tissue disease
p8512
sg13
I4
sasa(dp8513
g2
S'Increased and fluctuating levels of IL-10 or TNF-alpha without correlation to disease activity were observed in MCTD patients.\n'
p8514
sg4
(lp8515
(dp8516
g7
I45
sg8
VP01375
p8517
sg10
I9
sg11
VTNF-alpha
p8518
sg13
I1
sasg20
(lp8519
(dp8520
g7
I112
sg23
VC0026272
p8521
sg10
I4
sg11
VMCTD
p8522
sg13
I1
sasa(dp8523
g2
S'The MCTD patients had the highest serum levels of IL-10, but also had elevated IFN-gamma and TNF-alpha levels similar to the RA patients.\n'
p8524
sg4
(lp8525
(dp8526
g7
I79
sg8
VP01579
p8527
sg10
I9
sg11
VIFN-gamma
p8528
sg13
I1
sa(dp8529
g7
I93
sg8
VP01375
p8530
sg10
I9
sg11
VTNF-alpha
p8531
sg13
I1
sasg20
(lp8532
(dp8533
g7
I4
sg23
VC0026272
p8534
sg10
I4
sg11
VMCTD
p8535
sg13
I1
sasa(dp8536
g2
S'Although the EZH2 expression in OSCC is highly correlated with tumorigenesis, it has not been determined if specific EZH2 genetic variants are associated with OSCC risk.\n'
p8537
sg4
(lp8538
(dp8539
g7
I13
sg8
g39
sg10
I4
sg11
VEZH2
p8540
sg13
I1
sa(dp8541
g7
I13
sg8
g39
sg10
I4
sg11
VEZH2
p8542
sg13
I1
sasg20
(lp8543
(dp8544
g7
I63
sg23
VC0007621
p8545
sg10
I13
sg11
Vtumorigenesis
p8546
sg13
I1
sasa(dp8547
g2
S'The aim of this study was to investigate the relationship between genetic polymorphisms of EZH2 and susceptibility to OSCC in Taiwan.\n'
p8548
sg4
(lp8549
(dp8550
g7
I91
sg8
g39
sg10
I23
sg11
VEZH2 and susceptibility
p8551
sg13
I3
sasg20
(lp8552
sa(dp8553
g2
S'After adjusting for other co-variants, we found that carrying CC genotype at EZH2 rs6950683 and rs3757441 had a lower risk of developing OSCC than did wild-type carriers.\n'
p8554
sg4
(lp8555
sg20
(lp8556
sa(dp8557
g2
S'The CCCA or CCTA haplotype among the four EZH2 sites was also associated with a reduced risk of OSCC.\n'
p8558
sg4
(lp8559
(dp8560
g7
I4
sg8
g39
sg10
I4
sg11
VCCCA
p8561
sg13
I1
sa(dp8562
g7
I42
sg8
g39
sg10
I10
sg11
VEZH2 sites
p8563
sg13
I2
sa(dp8564
g7
I12
sg8
VP49585
p8565
sg10
I14
sg11
VCCTA haplotype
p8566
sg13
I2
sasg20
(lp8567
sa(dp8568
g2
S'Furthermore, OSCC patients who carried CC genotype at EZH2 rs6950683 had a higher methylation than TC genotype.\n'
p8569
sg4
(lp8570
(dp8571
g7
I54
sg8
g39
sg10
I14
sg11
VEZH2 rs6950683
p8572
sg13
I2
sasg20
(lp8573
sa(dp8574
g2
S'Our results suggest that the two SNPs of EZH2 (rs6950683 and rs3757441) might contribute to the prediction of OSCC susceptibility.\n'
p8575
sg4
(lp8576
(dp8577
g7
I41
sg8
g39
sg10
I4
sg11
VEZH2
p8578
sg13
I1
sasg20
(lp8579
sa(dp8580
g2
S'This is the first study to provide insight into risk factors associated with EZH2 variants and epigenetic changes in carcinogenesis of OSCC in Taiwan.\n'
p8581
sg4
(lp8582
(dp8583
g7
I77
sg8
g39
sg10
I13
sg11
VEZH2 variants
p8584
sg13
I2
sasg20
(lp8585
(dp8586
g7
I117
sg23
VC0596263
p8587
sg10
I14
sg11
Vcarcinogenesis
p8588
sg13
I1
sasa(dp8589
g2
S'We found that DZNep reduced the cellular levels of polycomb group proteins (EZH2, SUZ12, BMI1, and RING1A) and the associated trimethylation of Lys27 on histone H3 and monoubiquitination of Lys119 on histone H2A in the poorly differentiated OSCC cell line SAS.\n'
p8590
sg4
(lp8591
(dp8592
g7
I76
sg8
g39
sg10
I4
sg11
VEZH2
p8593
sg13
I1
sa(dp8594
g7
I51
sg8
VP00390
p8595
sg10
I23
sg11
Vpolycomb group proteins
p8596
sg13
I3
sa(dp8597
g7
I153
sg8
g39
sg10
I10
sg11
Vhistone H3
p8598
sg13
I2
sa(dp8599
g7
I200
sg8
VP04908
p8600
sg10
I11
sg11
Vhistone H2A
p8601
sg13
I2
sa(dp8602
g7
I99
sg8
g39
sg10
I6
sg11
VRING1A
p8603
sg13
I1
sa(dp8604
g7
I89
sg8
VP35226
p8605
sg10
I4
sg11
VBMI1
p8606
sg13
I1
sa(dp8607
g7
I82
sg8
g39
sg10
I5
sg11
VSUZ12
p8608
sg13
I1
sasg20
(lp8609
sa(dp8610
g2
S'Furthermore, significant negative correlation between HOTAIR levels and E-cadherin levels was found in OSCC tissues and cell lines, and HOTAIR contributed to the regulation of E-cadherin through binding to EZH2 and H3K27me3 with the E-cadherin promoter.\n'
p8611
sg4
(lp8612
(dp8613
g7
I72
sg8
VP12830
p8614
sg10
I10
sg11
VE-cadherin
p8615
sg13
I1
sa(dp8616
g7
I72
sg8
VP12830
p8617
sg10
I10
sg11
VE-cadherin
p8618
sg13
I1
sa(dp8619
g7
I233
sg8
VP12830
p8620
sg10
I19
sg11
VE-cadherin promoter
p8621
sg13
I2
sa(dp8622
g7
I206
sg8
g39
sg10
I4
sg11
VEZH2
p8623
sg13
I1
sasg20
(lp8624
sa(dp8625
g2
S'Although the polycomb group protein enhancer of zeste homolog 2 (EZH2) plays a crucial role in cell proliferation and differentiation during the occurrence and development progress of several kinds of malignant tumors, the impact of EZH2 on the development and progression of OSCC is unclear.\n'
p8626
sg4
(lp8627
(dp8628
g7
I36
sg8
g39
sg10
I27
sg11
Venhancer of zeste homolog 2
p8629
sg13
I5
sa(dp8630
g7
I65
sg8
g39
sg10
I4
sg11
VEZH2
p8631
sg13
I1
sa(dp8632
g7
I65
sg8
g39
sg10
I4
sg11
VEZH2
p8633
sg13
I1
sa(dp8634
g7
I13
sg8
VP00390
p8635
sg10
I31
sg11
Vpolycomb group protein enhancer
p8636
sg13
I4
sasg20
(lp8637
(dp8638
g7
I100
sg23
VC0334094
p8639
sg10
I13
sg11
Vproliferation
p8640
sg13
I1
sa(dp8641
g7
I201
sg23
VC0006826
p8642
sg10
I16
sg11
Vmalignant tumors
p8643
sg13
I2
sasa(dp8644
g2
S'In this study, we demonstrate that EZH2 is overexpressed in OSCC cells and clinical tissue.\n'
p8645
sg4
(lp8646
(dp8647
g7
I35
sg8
g39
sg10
I4
sg11
VEZH2
p8648
sg13
I1
sasg20
(lp8649
sa(dp8650
g2
S'With in vitro RNAi analysis, we generated stable EZH2 knocking down cell lines from two OSCC cell lines, with two sh-RNAs targeting to EZH2, respectively.\n'
p8651
sg4
(lp8652
(dp8653
g7
I49
sg8
g39
sg10
I4
sg11
VEZH2
p8654
sg13
I1
sa(dp8655
g7
I49
sg8
g39
sg10
I4
sg11
VEZH2
p8656
sg13
I1
sasg20
(lp8657
sa(dp8658
g2
S'We found that knocking down of EZH2 could decrease the proliferation ability and induce apoptosis of OSCC cells.\n'
p8659
sg4
(lp8660
(dp8661
g7
I31
sg8
g39
sg10
I4
sg11
VEZH2
p8662
sg13
I1
sasg20
(lp8663
(dp8664
g7
I55
sg23
VC0334094
p8665
sg10
I13
sg11
Vproliferation
p8666
sg13
I1
sasa(dp8667
g2
S'Moreover, we demonstrated that of EZH2 inhibition decreased the migration and metastasis of OSCC cells.\n'
p8668
sg4
(lp8669
(dp8670
g7
I34
sg8
g39
sg10
I4
sg11
VEZH2
p8671
sg13
I1
sasg20
(lp8672
(dp8673
g7
I78
sg23
VC0027627
p8674
sg10
I10
sg11
Vmetastasis
p8675
sg13
I1
sasa(dp8676
g2
S'In conclusion, the results of the current study demonstrated an association between EZH2 expression and OSCC cell development.\n'
p8677
sg4
(lp8678
(dp8679
g7
I84
sg8
g39
sg10
I4
sg11
VEZH2
p8680
sg13
I1
sasg20
(lp8681
sa(dp8682
g2
S'We recommend that EZH2 acts as an oncogene and plays an important role in OSCC carcinogenesis.\n'
p8683
sg4
(lp8684
(dp8685
g7
I18
sg8
g39
sg10
I4
sg11
VEZH2
p8686
sg13
I1
sasg20
(lp8687
(dp8688
g7
I79
sg23
VC0596263
p8689
sg10
I14
sg11
Vcarcinogenesis
p8690
sg13
I1
sasa(dp8691
g2
S'Here, we examined the relationship between P53 and EZH2 in oral squamous cell carcinoma (OSCC).\n'
p8692
sg4
(lp8693
(dp8694
g7
I43
sg8
VP42771
p8695
sg10
I3
sg11
VP53
p8696
sg13
I1
sa(dp8697
g7
I51
sg8
g39
sg10
I4
sg11
VEZH2
p8698
sg13
I1
sasg20
(lp8699
(dp8700
g7
I64
sg23
VC0007137
p8701
sg10
I23
sg11
Vsquamous cell carcinoma
p8702
sg13
I3
sasa(dp8703
g2
S'Using immunohistochemistry, we investigated the expression of EZH2 and BMI1 in 99 surgically-resected OSCC and 34 epithelial dysplasia samples.\n'
p8704
sg4
(lp8705
(dp8706
g7
I71
sg8
VP35226
p8707
sg10
I4
sg11
VBMI1
p8708
sg13
I1
sa(dp8709
g7
I62
sg8
g39
sg10
I4
sg11
VEZH2
p8710
sg13
I1
sasg20
(lp8711
(dp8712
g7
I114
sg23
VC0878500
p8713
sg10
I20
sg11
Vepithelial dysplasia
p8714
sg13
I2
sasa(dp8715
g2
S'EZH2 and BMI1 protein were up-regulated in OSCC tissues compared with epithelial dysplasia and normal epithelium.\n'
p8716
sg4
(lp8717
(dp8718
g7
I0
sg8
g39
sg10
I4
sg11
VEZH2
p8719
sg13
I1
sa(dp8720
g7
I9
sg8
VP35226
p8721
sg10
I12
sg11
VBMI1 protein
p8722
sg13
I2
sasg20
(lp8723
(dp8724
g7
I70
sg23
VC0878500
p8725
sg10
I20
sg11
Vepithelial dysplasia
p8726
sg13
I2
sasa(dp8727
g2
S'Aberrant EZH2 and BMI1 protein expression was observed in 32 and 59 of the 99 OSCC samples, respectively.\n'
p8728
sg4
(lp8729
(dp8730
g7
I18
sg8
VP35226
p8731
sg10
I12
sg11
VBMI1 protein
p8732
sg13
I2
sa(dp8733
g7
I9
sg8
g39
sg10
I4
sg11
VEZH2
p8734
sg13
I1
sasg20
(lp8735
sa(dp8736
g2
S'Aberrant EZH2 expression was associated with P53 alteration in OSCC tissue.\n'
p8737
sg4
(lp8738
(dp8739
g7
I9
sg8
g39
sg10
I4
sg11
VEZH2
p8740
sg13
I1
sasg20
(lp8741
sa(dp8742
g2
S'P53 alteration may be involved in dysregulated EZH2 expression, and aberrant expression of EZH2 may play a role in carcinogenesis of OSCC.\n'
p8743
sg4
(lp8744
(dp8745
g7
I47
sg8
g39
sg10
I4
sg11
VEZH2
p8746
sg13
I1
sa(dp8747
g7
I0
sg8
VP42771
p8748
sg10
I3
sg11
VP53
p8749
sg13
I1
sa(dp8750
g7
I47
sg8
g39
sg10
I4
sg11
VEZH2
p8751
sg13
I1
sasg20
(lp8752
(dp8753
g7
I115
sg23
VC0596263
p8754
sg10
I14
sg11
Vcarcinogenesis
p8755
sg13
I1
sasa(dp8756
g2
S'Our result suggests that overexpressions of histone modification-related proteins-ARK2, G9a, EZH2, and SUV39H1 but not SUV39H2 are associated with prognosis of OSCC in the male population of Taiwan.\n'
p8757
sg4
(lp8758
(dp8759
g7
I93
sg8
g39
sg10
I4
sg11
VEZH2
p8760
sg13
I1
sa(dp8761
g7
I119
sg8
g39
sg10
I7
sg11
VSUV39H2
p8762
sg13
I1
sa(dp8763
g7
I103
sg8
g39
sg10
I7
sg11
VSUV39H1
p8764
sg13
I1
sa(dp8765
g7
I44
sg8
VP62805
p8766
sg10
I7
sg11
Vhistone
p8767
sg13
I1
sa(dp8768
g7
I82
sg8
g39
sg10
I4
sg11
VARK2
p8769
sg13
I1
sasg20
(lp8770
sa(dp8771
g2
S'To assess OSCC risk of OLs, we investigated the role of the transcriptional repressor enhancer of zeste homolog 2 (EZH2) in oral tumorigenesis and its clinical implication as an OSCC risk predictor.\n'
p8772
sg4
(lp8773
(dp8774
g7
I115
sg8
g39
sg10
I4
sg11
VEZH2
p8775
sg13
I1
sa(dp8776
g7
I86
sg8
g39
sg10
I27
sg11
Venhancer of zeste homolog 2
p8777
sg13
I5
sasg20
(lp8778
(dp8779
g7
I129
sg23
VC0007621
p8780
sg10
I13
sg11
Vtumorigenesis
p8781
sg13
I1
sasa(dp8782
g2
S'Immunohistochemistry was used to measure EZH2 expression in OLs from 76 patients, including 37 who later developed OSCC and 39 who did not.\n'
p8783
sg4
(lp8784
(dp8785
g7
I41
sg8
g39
sg10
I4
sg11
VEZH2
p8786
sg13
I1
sasg20
(lp8787
sa(dp8788
g2
S'The higher EZH2 levels were strongly associated with dysplasia (P &lt; 0.001) and OSCC development (P &lt; 0.0001).\n'
p8789
sg4
(lp8790
(dp8791
g7
I11
sg8
g39
sg10
I4
sg11
VEZH2
p8792
sg13
I1
sasg20
(lp8793
(dp8794
g7
I53
sg23
VC0334044
p8795
sg10
I9
sg11
Vdysplasia
p8796
sg13
I1
sasa(dp8797
g2
S'Multivariate analysis indicated that EZH2 expression was the only independent factor for OSCC development (P &lt; 0.0001).\n'
p8798
sg4
(lp8799
(dp8800
g7
I37
sg8
g39
sg10
I4
sg11
VEZH2
p8801
sg13
I1
sasg20
(lp8802
sa(dp8803
g2
S'At 5 years after diagnosis, 80% of patients whose OLs expressed strong EZH2 developed OSCC whereas only 24% patients with moderate and none with weak/no EZH2 expression did so (P &lt; 0.0001).\n'
p8804
sg4
(lp8805
(dp8806
g7
I71
sg8
g39
sg10
I4
sg11
VEZH2
p8807
sg13
I1
sasg20
(lp8808
sa(dp8809
g2
S'Our data suggest that EZH2 plays an important role in OL malignant transformation and may be a biomarker in predicting OSCC development in patients with OLs.\n'
p8810
sg4
(lp8811
(dp8812
g7
I22
sg8
g39
sg10
I4
sg11
VEZH2
p8813
sg13
I1
sasg20
(lp8814
(dp8815
g7
I57
sg23
VC1608408
p8816
sg10
I24
sg11
Vmalignant transformation
p8817
sg13
I2
sasa(dp8818
g2
S'The aim of the present study was to evaluate the expression of EZH2 protein in human oral normal mucosa, dysplasia and oral squamous cell carcinoma (OSCC) with clinicopathological profiles.\n'
p8819
sg4
(lp8820
(dp8821
g7
I63
sg8
g39
sg10
I12
sg11
VEZH2 protein
p8822
sg13
I2
sasg20
(lp8823
(dp8824
g7
I124
sg23
VC0007137
p8825
sg10
I23
sg11
Vsquamous cell carcinoma
p8826
sg13
I3
sa(dp8827
g7
I105
sg23
VC0334044
p8828
sg10
I9
sg11
Vdysplasia
p8829
sg13
I1
sasa(dp8830
g2
S'EZH2 expression was assessed by Western blotting and immunohistochemistry in 3 OSCC cell lines, 10 normal mucosae, 50 dysplasias and 102 OSCCs.\n'
p8831
sg4
(lp8832
(dp8833
g7
I0
sg8
g39
sg10
I4
sg11
VEZH2
p8834
sg13
I1
sasg20
(lp8835
(dp8836
g7
I118
sg23
VC0334044
p8837
sg10
I10
sg11
Vdysplasias
p8838
sg13
I1
sasa(dp8839
g2
S'Western blot analysis detected EZH2 protein as a single band at 91kDa in the 3 OSCC cell lines, but it was almost absent in non-tumoral oral mucosae.\n'
p8840
sg4
(lp8841
(dp8842
g7
I31
sg8
g39
sg10
I12
sg11
VEZH2 protein
p8843
sg13
I2
sasg20
(lp8844
sa(dp8845
g2
S'The LI of EZH2 was highest in the OSCCs, followed by the dysplasias (p&lt;0.05) and normal mucosae (p&lt;0.05) with significant difference.\n'
p8846
sg4
(lp8847
(dp8848
g7
I10
sg8
g39
sg10
I4
sg11
VEZH2
p8849
sg13
I1
sasg20
(lp8850
(dp8851
g7
I57
sg23
VC0334044
p8852
sg10
I10
sg11
Vdysplasias
p8853
sg13
I1
sasa(dp8854
g2
S'The LI of EZH2 correlated with the clinical stage, tumor size, lymph node metastasis and LIs of Ki-67 and P53, but not with the AI in OSCCs, and inversely correlated with the histological differentiation of OSCCs.\n'
p8855
sg4
(lp8856
(dp8857
g7
I106
sg8
VP42771
p8858
sg10
I3
sg11
VP53
p8859
sg13
I1
sa(dp8860
g7
I96
sg8
VP46013
p8861
sg10
I5
sg11
VKi-67
p8862
sg13
I1
sasg20
(lp8863
(dp8864
g7
I51
sg23
VC0027651
p8865
sg10
I5
sg11
Vtumor
p8866
sg13
I1
sa(dp8867
g7
I63
sg23
VC0686619
p8868
sg10
I21
sg11
Vlymph node metastasis
p8869
sg13
I3
sasa(dp8870
g2
S'The survival rate calculated by the Kaplan-Meier method revealed that OSCC patients with higher EZH2 expression showed poorer prognosis than those with a lower EZH2 expression (p&lt;0.01).\n'
p8871
sg4
(lp8872
(dp8873
g7
I96
sg8
g39
sg10
I4
sg11
VEZH2
p8874
sg13
I1
sa(dp8875
g7
I96
sg8
g39
sg10
I4
sg11
VEZH2
p8876
sg13
I1
sasg20
(lp8877
sa(dp8878
g2
S'These results suggest that overexpression of EZH2 is correlated with malignant potential and poor prognosis in OSCCs.\n'
p8879
sg4
(lp8880
(dp8881
g7
I45
sg8
g39
sg10
I4
sg11
VEZH2
p8882
sg13
I1
sasg20
(lp8883
sa(dp8884
g2
S'EZH2 might serve as a novel biomarker for predicting prognosis in patients with OSCCs.\n'
p8885
sg4
(lp8886
(dp8887
g7
I0
sg8
g39
sg10
I4
sg11
VEZH2
p8888
sg13
I1
sasg20
(lp8889
sa(dp8890
g2
S'We therefore examined the association between 14-3-3Sigma expression determined by immunohistochemistry and clinical outcomes of 51 patients with UPSC.\n'
p8891
sg4
(lp8892
sg20
(lp8893
sa(dp8894
g2
S'UPSC was considered positive for 14-3-3Sigma when &gt; 30% of tumor cells were stained with a specific antibody.\n'
p8895
sg4
(lp8896
sg20
(lp8897
(dp8898
g7
I62
sg23
VC0027651
p8899
sg10
I5
sg11
Vtumor
p8900
sg13
I1
sasa(dp8901
g2
S'These CpG islands were hypermethylated in 30% of 14-3-3Sigma-positive UPSC and 80% of 14-3-3Sigma-negative UPSC, although the difference was not statistically significant.\n'
p8902
sg4
(lp8903
sg20
(lp8904
sa(dp8905
g2
S'These findings suggest that decreased expression of immunoreactive 14-3-3Sigma may be a predictor of poor prognosis in patients with UPSC.\n'
p8906
sg4
(lp8907
(dp8908
g7
I52
sg8
VP41252
p8909
sg10
I26
sg11
Vimmunoreactive 14-3-3Sigma
p8910
sg13
I2
sasg20
(lp8911
sa(dp8912
g2
S'Aberrant fusion proteins involving the MLL histone methyltransferase (HMT) lead to recruitment of DOT1L, to a multi-protein complex resulting in aberrant methylation of histone H3 lysine 79 at MLL target genes, and ultimately enhanced expression of critical genes for hematopoietic differentiation, including HOXA9 and MEIS1, and as such defines the established mechanism for leukemogenesis in MLL-rearrangement (MLL-r) leukemias.\n'
p8913
sg4
(lp8914
(dp8915
g7
I319
sg8
g39
sg10
I5
sg11
VMEIS1
p8916
sg13
I1
sa(dp8917
g7
I39
sg8
VP50135
p8918
sg10
I29
sg11
VMLL histone methyltransferase
p8919
sg13
I3
sa(dp8920
g7
I98
sg8
g39
sg10
I5
sg11
VDOT1L
p8921
sg13
I1
sa(dp8922
g7
I169
sg8
g39
sg10
I20
sg11
Vhistone H3 lysine 79
p8923
sg13
I4
sa(dp8924
g7
I309
sg8
VP31269
p8925
sg10
I5
sg11
VHOXA9
p8926
sg13
I1
sa(dp8927
g7
I70
sg8
VP50135
p8928
sg10
I3
sg11
VHMT
p8929
sg13
I1
sa(dp8930
g7
I39
sg8
g39
sg10
I3
sg11
VMLL
p8931
sg13
I1
sasg20
(lp8932
(dp8933
g7
I376
sg23
VC0598766
p8934
sg10
I14
sg11
Vleukemogenesis
p8935
sg13
I1
sa(dp8936
g7
I420
sg23
VC0023418
p8937
sg10
I9
sg11
Vleukemias
p8938
sg13
I1
sa(dp8939
g7
I83
sg23
VC0271510
p8940
sg10
I11
sg11
Vrecruitment
p8941
sg13
I1
sasa(dp8942
g2
S'Pinometostat is a first-in-class, small molecule inhibitor of DOT1L with sub-nanomolar affinity and &gt;37,000 fold selectivity against non-MLL HMTs, and was the first member of the novel HMT inhibitor class to enter Phase 1 clinical trials in both adult and pediatric MLL-r leukemia patients.\n'
p8943
sg4
(lp8944
(dp8945
g7
I144
sg8
VP50135
p8946
sg10
I3
sg11
VHMT
p8947
sg13
I1
sa(dp8948
g7
I136
sg8
VP50135
p8949
sg10
I12
sg11
Vnon-MLL HMTs
p8950
sg13
I2
sa(dp8951
g7
I62
sg8
g39
sg10
I5
sg11
VDOT1L
p8952
sg13
I1
sasg20
(lp8953
(dp8954
g7
I275
sg23
VC0023418
p8955
sg10
I8
sg11
Vleukemia
p8956
sg13
I1
sasa(dp8957
g2
S'This study aimed to analyze the use of the revised International Prognostic Scoring System (IPSS-R) assessed after hypomethylating treatment (HMT) for patients with myelodysplastic syndrome (MDS) undergoing an allogeneic stem cell transplantation (SCT).\n'
p8958
sg4
(lp8959
sg20
(lp8960
(dp8961
g7
I191
sg23
VC0265219
p8962
sg10
I3
sg11
VMDS
p8963
sg13
I1
sa(dp8964
g7
I165
sg23
VC3463824
p8965
sg10
I24
sg11
Vmyelodysplastic syndrome
p8966
sg13
I2
sa(dp8967
g7
I221
sg23
VC1848934
p8968
sg10
I25
sg11
Vstem cell transplantation
p8969
sg13
I3
sa(dp8970
g7
I248
sg23
VC1848934
p8971
sg10
I3
sg11
VSCT
p8972
sg13
I1
sasa(dp8973
g2
S'Mitochondrial (mt) DNA-associated NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) syndrome is due to mutation in the MT-ATP6 gene.\n'
p8974
sg4
(lp8975
(dp8976
g7
I34
sg8
VP47972
p8977
sg10
I4
sg11
VNARP
p8978
sg13
I1
sa(dp8979
g7
I137
sg8
VP36543
p8980
sg10
I12
sg11
VMT-ATP6 gene
p8981
sg13
I2
sasg20
(lp8982
(dp8983
g7
I80
sg23
VC0035334
p8984
sg10
I20
sg11
Vretinitis pigmentosa
p8985
sg13
I2
sa(dp8986
g7
I51
sg23
VC0030552
p8987
sg10
I15
sg11
Vmuscle weakness
p8988
sg13
I2
sa(dp8989
g7
I68
sg23
VC0004134
p8990
sg10
I6
sg11
Vataxia
p8991
sg13
I1
sa(dp8992
g7
I102
sg23
VC0039082
p8993
sg10
I8
sg11
Vsyndrome
p8994
sg13
I1
sasa(dp8995
g2
S'Pathogenic mutations in MT-ATP6 are associated with the Leigh syndrome, the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP), as well as with non-classical phenotypes, while MT-ATP8 is less frequently mutated in patients with mitochondrial disease.\n'
p8996
sg4
(lp8997
(dp8998
g7
I189
sg8
VP03928
p8999
sg10
I7
sg11
VMT-ATP8
p9000
sg13
I1
sa(dp9001
g7
I24
sg8
VP36543
p9002
sg10
I7
sg11
VMT-ATP6
p9003
sg13
I1
sasg20
(lp9004
(dp9005
g7
I241
sg23
VC0751651
p9006
sg10
I21
sg11
Vmitochondrial disease
p9007
sg13
I2
sa(dp9008
g7
I88
sg23
VC1328349
p9009
sg10
I44
sg11
Vneuropathy, ataxia, and retinitis pigmentosa
p9010
sg13
I5
sa(dp9011
g7
I56
sg23
VC0023264
p9012
sg10
I14
sg11
VLeigh syndrome
p9013
sg13
I2
sa(dp9014
g7
I62
sg23
VC0039082
p9015
sg10
I8
sg11
Vsyndrome
p9016
sg13
I1
sasa(dp9017
g2
S'Neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) is caused by m.8993T&gt;G/C mutations in the mitochondrial adenosine triphosphate synthase subunit 6 gene (MT-ATP6).\n'
p9018
sg4
(lp9019
(dp9020
g7
I113
sg8
VP56381
p9021
sg10
I60
sg11
Vmitochondrial adenosine triphosphate synthase subunit 6 gene
p9022
sg13
I7
sa(dp9023
g7
I175
sg8
VP36543
p9024
sg10
I7
sg11
VMT-ATP6
p9025
sg13
I1
sasg20
(lp9026
(dp9027
g7
I28
sg23
VC0004134
p9028
sg10
I6
sg11
Vataxia
p9029
sg13
I1
sa(dp9030
g7
I40
sg23
VC0035334
p9031
sg10
I20
sg11
Vretinitis pigmentosa
p9032
sg13
I2
sa(dp9033
g7
I11
sg23
VC0030552
p9034
sg10
I15
sg11
Vmuscle weakness
p9035
sg13
I2
sasa(dp9036
g2
S'One member of a pedigree with NARP syndrome (neurogenic weakness, ataxia, and retinitis pigmentosa), a mitochondrial disorder due to a point mutation at position 8993 in the mitochondrial genome ATPase 6 gene, was reevaluated some 20 years after first being reported in the medical literature.\n'
p9037
sg4
(lp9038
(dp9039
g7
I174
sg8
VP38606
p9040
sg10
I34
sg11
Vmitochondrial genome ATPase 6 gene
p9041
sg13
I5
sasg20
(lp9042
(dp9043
g7
I78
sg23
VC0035334
p9044
sg10
I20
sg11
Vretinitis pigmentosa
p9045
sg13
I2
sa(dp9046
g7
I103
sg23
VC0751651
p9047
sg10
I22
sg11
Vmitochondrial disorder
p9048
sg13
I2
sa(dp9049
g7
I66
sg23
VC0004134
p9050
sg10
I6
sg11
Vataxia
p9051
sg13
I1
sa(dp9052
g7
I56
sg23
VC1883552
p9053
sg10
I8
sg11
Vweakness
p9054
sg13
I1
sa(dp9055
g7
I30
sg23
VC1328349
p9056
sg10
I13
sg11
VNARP syndrome
p9057
sg13
I2
sasa(dp9058
g2
S'Mutations in the human mitochondrial ATP6 gene encoding ATP synthase subunit a/6 (referred to as Atp6p in yeast) are at the base of neurodegenerative disorders like Neurogenic Ataxia and Retinitis Pigmentosa (NARP), Leigh syndrome (LS), Charcot-Marie-Tooth (CMT), and ataxia telangiectasia.\n'
p9059
sg4
(lp9060
(dp9061
g7
I56
sg8
g39
sg10
I20
sg11
VATP synthase subunit
p9062
sg13
I3
sa(dp9063
g7
I17
sg8
VP36543
p9064
sg10
I29
sg11
Vhuman mitochondrial ATP6 gene
p9065
sg13
I4
sasg20
(lp9066
(dp9067
g7
I176
sg23
VC0004134
p9068
sg10
I6
sg11
VAtaxia
p9069
sg13
I1
sa(dp9070
g7
I232
sg23
VC0023264
p9071
sg10
I2
sg11
VLS
p9072
sg13
I1
sa(dp9073
g7
I216
sg23
VC0023264
p9074
sg10
I14
sg11
VLeigh syndrome
p9075
sg13
I2
sa(dp9076
g7
I132
sg23
VC0524851
p9077
sg10
I27
sg11
Vneurodegenerative disorders
p9078
sg13
I2
sa(dp9079
g7
I187
sg23
VC0035334
p9080
sg10
I20
sg11
VRetinitis Pigmentosa
p9081
sg13
I2
sa(dp9082
g7
I268
sg23
VC0004135
p9083
sg10
I21
sg11
Vataxia telangiectasia
p9084
sg13
I2
sasa(dp9085
g2
S'Mutations in the ATP6 gene are reported to be associated with Leber hereditary optic neuropathy, bilateral striatal necrosis, coronary atherosclerosis risk and neuropathy, ataxia and retinitis pigmentosa (NARP)/maternally inherited Leigh syndromes.\n'
p9086
sg4
(lp9087
(dp9088
g7
I17
sg8
VP36543
p9089
sg10
I9
sg11
VATP6 gene
p9090
sg13
I2
sasg20
(lp9091
(dp9092
g7
I172
sg23
VC0004134
p9093
sg10
I6
sg11
Vataxia
p9094
sg13
I1
sa(dp9095
g7
I126
sg23
VC2733225
p9096
sg10
I24
sg11
Vcoronary atherosclerosis
p9097
sg13
I2
sa(dp9098
g7
I62
sg23
VC0917796
p9099
sg10
I33
sg11
VLeber hereditary optic neuropathy
p9100
sg13
I4
sa(dp9101
g7
I183
sg23
VC0035334
p9102
sg10
I20
sg11
Vretinitis pigmentosa
p9103
sg13
I2
sa(dp9104
g7
I238
sg23
VC0039082
p9105
sg10
I9
sg11
Vsyndromes
p9106
sg13
I1
sa(dp9107
g7
I85
sg23
VC0442874
p9108
sg10
I10
sg11
Vneuropathy
p9109
sg13
I1
sasa(dp9110
g2
S'The fusion inhibition observed upon deletion of OXPHOS related genes or upon removal of the entire mtDNA was similar to that observed upon introduction of point mutations in the mitochondrial ATP6 gene that are associated to neurogenic ataxia and retinitis pigmentosa (NARP) or to maternally inherited Leigh Syndrome (MILS) in humans.\n'
p9111
sg4
(lp9112
(dp9113
g7
I48
sg8
VP12235
p9114
sg10
I20
sg11
VOXPHOS related genes
p9115
sg13
I3
sa(dp9116
g7
I178
sg8
VP36543
p9117
sg10
I23
sg11
Vmitochondrial ATP6 gene
p9118
sg13
I3
sasg20
(lp9119
(dp9120
g7
I318
sg23
VC0872216
p9121
sg10
I4
sg11
VMILS
p9122
sg13
I1
sa(dp9123
g7
I247
sg23
VC0035334
p9124
sg10
I20
sg11
Vretinitis pigmentosa
p9125
sg13
I2
sa(dp9126
g7
I236
sg23
VC0004134
p9127
sg10
I6
sg11
Vataxia
p9128
sg13
I1
sa(dp9129
g7
I281
sg23
VC2931092
p9130
sg10
I35
sg11
Vmaternally inherited Leigh Syndrome
p9131
sg13
I4
sasa(dp9132
g2
S'We hypothesized that Nrf2 modulates progression from acute tubular damage to renal fibrosis.\n'
p9133
sg4
(lp9134
(dp9135
g7
I21
sg8
g39
sg10
I4
sg11
VNrf2
p9136
sg13
I1
sasg20
(lp9137
(dp9138
g7
I77
sg23
VC0151650
p9139
sg10
I14
sg11
Vrenal fibrosis
p9140
sg13
I2
sasa(dp9141
g2
S'We asked whether Nrf2 deletion increases renal injury in mice following unilateral ureteral obstruction (UUO).\n'
p9142
sg4
(lp9143
(dp9144
g7
I17
sg8
g39
sg10
I4
sg11
VNrf2
p9145
sg13
I1
sasg20
(lp9146
(dp9147
g7
I83
sg23
VC0041956
p9148
sg10
I20
sg11
Vureteral obstruction
p9149
sg13
I2
sa(dp9150
g7
I105
sg23
VC0041956
p9151
sg10
I3
sg11
VUUO
p9152
sg13
I1
sasa(dp9153
g2
S'We studied Nrf2 in renal biopsies of patients with acute, subacute and chronic tubulointerstitial nephritis (TIN).\n'
p9154
sg4
(lp9155
sg20
(lp9156
(dp9157
g7
I71
sg23
VC0238304
p9158
sg10
I36
sg11
Vchronic tubulointerstitial nephritis
p9159
sg13
I3
sasa(dp9160
g2
S'The aim of this study was to evaluate the effects of resistance exercise programs on the expression of transcription factors Nrf2 and nuclear factor KB (NF-KB) in CKD patients on hemodialysis (HD).\n'
p9161
sg4
(lp9162
(dp9163
g7
I125
sg8
g39
sg10
I4
sg11
VNrf2
p9164
sg13
I1
sa(dp9165
g7
I134
sg8
VP01160
p9166
sg10
I17
sg11
Vnuclear factor KB
p9167
sg13
I3
sa(dp9168
g7
I153
sg8
VP01160
p9169
sg10
I5
sg11
VNF-KB
p9170
sg13
I1
sasg20
(lp9171
sa(dp9172
g2
S'In conclusion, these data suggest that resistance exercises seem to be capable of inducing Nrf2 activation in CKD patients on HD.\n'
p9173
sg4
(lp9174
(dp9175
g7
I91
sg8
g39
sg10
I4
sg11
VNrf2
p9176
sg13
I1
sasg20
(lp9177
sa(dp9178
g2
S'Activate Nrf2 could inhibit the activation of NLRP3 inflammasome in acute liver injury and severe lupus nephritis.\n'
p9179
sg4
(lp9180
(dp9181
g7
I9
sg8
g39
sg10
I4
sg11
VNrf2
p9182
sg13
I1
sasg20
(lp9183
(dp9184
g7
I98
sg23
VC0024143
p9185
sg10
I15
sg11
Vlupus nephritis
p9186
sg13
I2
sasa(dp9187
g2
S'Here, we show that the loss of Nrf2 suppresses fibrosis and inflammation in a unilateral ureter obstruction (UUO) model of CKD in mice.\n'
p9188
sg4
(lp9189
(dp9190
g7
I31
sg8
g39
sg10
I4
sg11
VNrf2
p9191
sg13
I1
sasg20
(lp9192
(dp9193
g7
I89
sg23
VC0041956
p9194
sg10
I18
sg11
Vureter obstruction
p9195
sg13
I2
sa(dp9196
g7
I109
sg23
VC0041956
p9197
sg10
I3
sg11
VUUO
p9198
sg13
I1
sa(dp9199
g7
I47
sg23
VC0016059
p9200
sg10
I8
sg11
Vfibrosis
p9201
sg13
I1
sa(dp9202
g7
I60
sg23
VC0021368
p9203
sg10
I12
sg11
Vinflammation
p9204
sg13
I1
sasa(dp9205
g2
S'These results demonstrate that Nrf2-related inflammasome activation can promote CKD symptoms via infiltration of M1 macrophages.\n'
p9206
sg4
(lp9207
(dp9208
g7
I31
sg8
g39
sg10
I4
sg11
VNrf2
p9209
sg13
I1
sasg20
(lp9210
(dp9211
g7
I97
sg23
VC0332448
p9212
sg10
I12
sg11
Vinfiltration
p9213
sg13
I1
sasa(dp9214
g2
S'Thus, we have identified the Nrf2 pathway as a promising therapeutic target for CKD.\n'
p9215
sg4
(lp9216
(dp9217
g7
I29
sg8
g39
sg10
I4
sg11
VNrf2
p9218
sg13
I1
sasg20
(lp9219
sa(dp9220
g2
S'Reduced nuclear factor erythroid 2-related factor 2 (NRF2) pathway activity was reported in models of chronic kidney disease (CKD).\n'
p9221
sg4
(lp9222
(dp9223
g7
I53
sg8
g39
sg10
I4
sg11
VNRF2
p9224
sg13
I1
sa(dp9225
g7
I8
sg8
g39
sg10
I43
sg11
Vnuclear factor erythroid 2-related factor 2
p9226
sg13
I6
sasg20
(lp9227
(dp9228
g7
I102
sg23
VC1561643
p9229
sg10
I22
sg11
Vchronic kidney disease
p9230
sg13
I3
sa(dp9231
g7
I126
sg23
VC1561643
p9232
sg10
I3
sg11
VCKD
p9233
sg13
I1
sasa(dp9234
g2
S'Mechanistically, AR signaling promoted glutamine metabolism by increasing the expression of the glutamine transporters SLC1A4 and SLC1A5, genes commonly overexpressed in prostate cancer.\n'
p9235
sg4
(lp9236
(dp9237
g7
I96
sg8
VP43007
p9238
sg10
I29
sg11
Vglutamine transporters SLC1A4
p9239
sg13
I3
sa(dp9240
g7
I130
sg8
g39
sg10
I6
sg11
VSLC1A5
p9241
sg13
I1
sasg20
(lp9242
(dp9243
g7
I170
sg23
VC0600139
p9244
sg10
I15
sg11
Vprostate cancer
p9245
sg13
I2
sasa(dp9246
g2
S'Interestingly, MYC, a canonical oncogene in prostate cancer and previously described master regulator of glutamine metabolism, was only a context-dependent regulator of SLC1A4 and SLC1A5 levels, being unable to regulate either transporter in PTEN wild-type cells.\n'
p9247
sg4
(lp9248
(dp9249
g7
I180
sg8
g39
sg10
I6
sg11
VSLC1A5
p9250
sg13
I1
sa(dp9251
g7
I242
sg8
VP60484
p9252
sg10
I4
sg11
VPTEN
p9253
sg13
I1
sa(dp9254
g7
I169
sg8
VP43007
p9255
sg10
I6
sg11
VSLC1A4
p9256
sg13
I1
sa(dp9257
g7
I15
sg8
VP12524
p9258
sg10
I3
sg11
VMYC
p9259
sg13
I1
sasg20
(lp9260
(dp9261
g7
I44
sg23
VC0600139
p9262
sg10
I15
sg11
Vprostate cancer
p9263
sg13
I2
sasa(dp9264
g2
S'In contrast, rapamycin was able to decrease the androgen-mediated expression of SLC1A4 and SLC1A5 independent of PTEN status, indicating that mTOR complex 1 (mTORC1) was needed for maximal AR-mediated glutamine uptake and prostate cancer cell growth.\n'
p9265
sg4
(lp9266
(dp9267
g7
I113
sg8
VP60484
p9268
sg10
I4
sg11
VPTEN
p9269
sg13
I1
sa(dp9270
g7
I158
sg8
VP42345
p9271
sg10
I6
sg11
VmTORC1
p9272
sg13
I1
sa(dp9273
g7
I142
sg8
VP42345
p9274
sg10
I14
sg11
VmTOR complex 1
p9275
sg13
I3
sa(dp9276
g7
I91
sg8
g39
sg10
I6
sg11
VSLC1A5
p9277
sg13
I1
sa(dp9278
g7
I80
sg8
VP43007
p9279
sg10
I6
sg11
VSLC1A4
p9280
sg13
I1
sasg20
(lp9281
(dp9282
g7
I231
sg23
VC1516170
p9283
sg10
I18
sg11
Vcancer cell growth
p9284
sg13
I3
sasa(dp9285
g2
S'SLC1A4 deficiency is a recently described neurodevelopmental disorder associated with microcephaly, global developmental delay, abnormal myelination, thin corpus callosum and seizures.\n'
p9286
sg4
(lp9287
(dp9288
g7
I0
sg8
VP43007
p9289
sg10
I6
sg11
VSLC1A4
p9290
sg13
I1
sasg20
(lp9291
(dp9292
g7
I86
sg23
VC0025958
p9293
sg10
I12
sg11
Vmicrocephaly
p9294
sg13
I1
sa(dp9295
g7
I100
sg23
VC0557874
p9296
sg10
I26
sg11
Vglobal developmental delay
p9297
sg13
I3
sa(dp9298
g7
I175
sg23
VC0036572
p9299
sg10
I8
sg11
Vseizures
p9300
sg13
I1
sa(dp9301
g7
I42
sg23
VC1535926
p9302
sg10
I27
sg11
Vneurodevelopmental disorder
p9303
sg13
I2
sasa(dp9304
g2
S'Investigation for SLC1A4 deficiency should be performed regardless of ethnicity and extend to include unexplained early-onset epileptic encephalopathy.\n'
p9305
sg4
(lp9306
(dp9307
g7
I18
sg8
VP43007
p9308
sg10
I6
sg11
VSLC1A4
p9309
sg13
I1
sasg20
(lp9310
(dp9311
g7
I126
sg23
VC0543888
p9312
sg10
I24
sg11
Vepileptic encephalopathy
p9313
sg13
I2
sasa(dp9314
g2
S'Skeletal muscle of dystrophin-null mice, an animal model for Duchenne Muscular Dystrophy, deteriorates by the lack of ADAM8, which is characterized by increased area of muscle degeneration and increased number of necrotic and calcified muscle fibers.\n'
p9315
sg4
(lp9316
(dp9317
g7
I118
sg8
VP78325
p9318
sg10
I5
sg11
VADAM8
p9319
sg13
I1
sa(dp9320
g7
I19
sg8
VP11532
p9321
sg10
I10
sg11
Vdystrophin
p9322
sg13
I1
sasg20
(lp9323
(dp9324
g7
I169
sg23
VC0234958
p9325
sg10
I19
sg11
Vmuscle degeneration
p9326
sg13
I2
sa(dp9327
g7
I61
sg23
VC0013264
p9328
sg10
I27
sg11
VDuchenne Muscular Dystrophy
p9329
sg13
I3
sasa(dp9330
g2
S'Although some studies have described the function of ADAM8 (a disintegrin and metalloprotease 8) related with rheumatoid arthritis, cancer and asthma, etc., the concrete role of ADAM8 in acute liver injury is still unknown.\n'
p9331
sg4
(lp9332
(dp9333
g7
I53
sg8
VP78325
p9334
sg10
I5
sg11
VADAM8
p9335
sg13
I1
sa(dp9336
g7
I53
sg8
VP78325
p9337
sg10
I5
sg11
VADAM8
p9338
sg13
I1
sa(dp9339
g7
I60
sg8
VP78325
p9340
sg10
I35
sg11
Va disintegrin and metalloprotease 8
p9341
sg13
I5
sasg20
(lp9342
(dp9343
g7
I143
sg23
VC0004096
p9344
sg10
I6
sg11
Vasthma
p9345
sg13
I1
sa(dp9346
g7
I132
sg23
VC0006826
p9347
sg10
I6
sg11
Vcancer
p9348
sg13
I1
sa(dp9349
g7
I110
sg23
VC0003873
p9350
sg10
I20
sg11
Vrheumatoid arthritis
p9351
sg13
I2
sasa(dp9352
g2
S'The role of ADAM-8 in cancer and inflammatory diseases such as allergy, arthritis and asthma makes it an attractive target for drug development.\n'
p9353
sg4
(lp9354
(dp9355
g7
I12
sg8
VP78325
p9356
sg10
I6
sg11
VADAM-8
p9357
sg13
I1
sasg20
(lp9358
(dp9359
g7
I22
sg23
VC0006826
p9360
sg10
I6
sg11
Vcancer
p9361
sg13
I1
sa(dp9362
g7
I63
sg23
VC0020517
p9363
sg10
I7
sg11
Vallergy
p9364
sg13
I1
sa(dp9365
g7
I72
sg23
VC0003864
p9366
sg10
I9
sg11
Varthritis
p9367
sg13
I1
sa(dp9368
g7
I86
sg23
VC0004096
p9369
sg10
I6
sg11
Vasthma
p9370
sg13
I1
sasa(dp9371
g2
S'ADAM8 expression is increased in the interface tissue around a loosened hip prosthesis and in the pannus and synovium of patients with rheumatoid arthritis, but its potential role in these processes is unclear.\n'
p9372
sg4
(lp9373
(dp9374
g7
I0
sg8
VP78325
p9375
sg10
I5
sg11
VADAM8
p9376
sg13
I1
sasg20
(lp9377
(dp9378
g7
I98
sg23
VC0155094
p9379
sg10
I6
sg11
Vpannus
p9380
sg13
I1
sa(dp9381
g7
I135
sg23
VC0003873
p9382
sg10
I20
sg11
Vrheumatoid arthritis
p9383
sg13
I2
sasa(dp9384
g2
S'A disintegrin and metalloprotease-8 (ADAM8) is thought to play a role in cancer and inflammatory diseases such as allergy, arthritis, and asthma.\n'
p9385
sg4
(lp9386
(dp9387
g7
I37
sg8
VP78325
p9388
sg10
I5
sg11
VADAM8
p9389
sg13
I1
sa(dp9390
g7
I0
sg8
VP78325
p9391
sg10
I35
sg11
VA disintegrin and metalloprotease-8
p9392
sg13
I4
sasg20
(lp9393
(dp9394
g7
I138
sg23
VC0004096
p9395
sg10
I6
sg11
Vasthma
p9396
sg13
I1
sa(dp9397
g7
I114
sg23
VC0020517
p9398
sg10
I7
sg11
Vallergy
p9399
sg13
I1
sa(dp9400
g7
I73
sg23
VC0006826
p9401
sg10
I6
sg11
Vcancer
p9402
sg13
I1
sa(dp9403
g7
I123
sg23
VC0003864
p9404
sg10
I9
sg11
Varthritis
p9405
sg13
I1
sasa(dp9406
g2
S'We therefore decided to test the role of ADAM8 in autoimmune inflammatory arthritis using transgenic mice expressing catalytically inactive ADAM8.\n'
p9407
sg4
(lp9408
(dp9409
g7
I41
sg8
VP78325
p9410
sg10
I5
sg11
VADAM8
p9411
sg13
I1
sa(dp9412
g7
I41
sg8
VP78325
p9413
sg10
I5
sg11
VADAM8
p9414
sg13
I1
sasg20
(lp9415
(dp9416
g7
I50
sg23
VC0443146
p9417
sg10
I10
sg11
Vautoimmune
p9418
sg13
I1
sa(dp9419
g7
I61
sg23
VC0003864
p9420
sg10
I22
sg11
Vinflammatory arthritis
p9421
sg13
I2
sasa(dp9422
g2
S'Transgenic DBA/1J mice expressing an inactivating point mutation in the ADAM8 gene to change Glu330 to Gln330 (ADAM8(EQ)) were generated to evaluate the proteolytic function of ADAM8 in an lipopolysaccharide-synchronized collagen-induced arthritis (LPS-CIA) model of autoimmune arthritis.\n'
p9423
sg4
(lp9424
(dp9425
g7
I72
sg8
VP78325
p9426
sg10
I5
sg11
VADAM8
p9427
sg13
I1
sa(dp9428
g7
I72
sg8
VP78325
p9429
sg10
I10
sg11
VADAM8 gene
p9430
sg13
I2
sa(dp9431
g7
I72
sg8
VP78325
p9432
sg10
I5
sg11
VADAM8
p9433
sg13
I1
sasg20
(lp9434
(dp9435
g7
I238
sg23
VC0003864
p9436
sg10
I9
sg11
Varthritis
p9437
sg13
I1
sa(dp9438
g7
I249
sg23
VC0175697
p9439
sg10
I3
sg11
VLPS
p9440
sg13
I1
sa(dp9441
g7
I11
sg23
VC0398550
p9442
sg10
I3
sg11
VDBA
p9443
sg13
I1
sa(dp9444
g7
I267
sg23
VC3160909
p9445
sg10
I20
sg11
Vautoimmune arthritis
p9446
sg13
I2
sasa(dp9447
g2
S'Expression profiling of paw joints from wild-type mice revealed that ADAM8 mRNA levels increased at the onset of clinical arthritis and correlated well with cellular macrophage markers.\n'
p9448
sg4
(lp9449
(dp9450
g7
I69
sg8
VP78325
p9451
sg10
I10
sg11
VADAM8 mRNA
p9452
sg13
I2
sasg20
(lp9453
(dp9454
g7
I122
sg23
VC0003864
p9455
sg10
I9
sg11
Varthritis
p9456
sg13
I1
sasa(dp9457
g2
S'When subjected to LPS-CIA, ADAM8(EQ) mice demonstrated decreased incidence and severity of clinical arthritis compared to wild-type mice.\n'
p9458
sg4
(lp9459
(dp9460
g7
I27
sg8
VP78325
p9461
sg10
I5
sg11
VADAM8
p9462
sg13
I1
sa(dp9463
g7
I18
sg8
VP22079
p9464
sg10
I7
sg11
VLPS-CIA
p9465
sg13
I1
sasg20
(lp9466
(dp9467
g7
I18
sg23
VC0175697
p9468
sg10
I3
sg11
VLPS
p9469
sg13
I1
sa(dp9470
g7
I100
sg23
VC0003864
p9471
sg10
I9
sg11
Varthritis
p9472
sg13
I1
sasa(dp9473
g2
S'We conclude that ADAM8 proteolytic activity plays a key role in the development of experimental arthritis and may thus be an attractive target for the treatment of arthritic disorders while minimizing risk of immunocompromise.\n'
p9474
sg4
(lp9475
(dp9476
g7
I17
sg8
VP78325
p9477
sg10
I5
sg11
VADAM8
p9478
sg13
I1
sasg20
(lp9479
(dp9480
g7
I96
sg23
VC0003864
p9481
sg10
I9
sg11
Varthritis
p9482
sg13
I1
sasa(dp9483
g2
S'Further, BCO2 is associated with the development of mitochondrial oxidative stress, macular degeneration, anemia, and hepatic steatosis.\n'
p9484
sg4
(lp9485
(dp9486
g7
I9
sg8
g39
sg10
I4
sg11
VBCO2
p9487
sg13
I1
sasg20
(lp9488
(dp9489
g7
I106
sg23
VC0002871
p9490
sg10
I6
sg11
Vanemia
p9491
sg13
I1
sa(dp9492
g7
I84
sg23
VC0242383
p9493
sg10
I20
sg11
Vmacular degeneration
p9494
sg13
I2
sa(dp9495
g7
I118
sg23
VC0015695
p9496
sg10
I17
sg11
Vhepatic steatosis
p9497
sg13
I2
sa(dp9498
g7
I66
sg23
VC0242606
p9499
sg10
I16
sg11
Voxidative stress
p9500
sg13
I2
sasa(dp9501
g2
S"However, overexpression of a mutant NOD2, 3020insC, associated with severe Crohn's disease, results in enhanced HCMV replication and decreased levels of IFN-Beta in U373 cells.\n"
p9502
sg4
(lp9503
(dp9504
g7
I153
sg8
VP01574
p9505
sg10
I8
sg11
VIFN-Beta
p9506
sg13
I1
sa(dp9507
g7
I36
sg8
VP22301
p9508
sg10
I4
sg11
VNOD2
p9509
sg13
I1
sasg20
(lp9510
(dp9511
g7
I29
sg23
VC0596988
p9512
sg10
I6
sg11
Vmutant
p9513
sg13
I1
sa(dp9514
g7
I75
sg23
VC0010346
p9515
sg10
I15
sg11
VCrohn's disease
p9516
sg13
I2
sasa(dp9517
g2
S"The patient was started on therapy with interferon-beta for multiple sclerosis, prednizolone and azathioprine for Crohn's disease and oxybutynin hydrochloride for urine incontinence.\n"
p9518
sg4
(lp9519
(dp9520
g7
I40
sg8
VP01563
p9521
sg10
I15
sg11
Vinterferon-beta
p9522
sg13
I1
sasg20
(lp9523
(dp9524
g7
I163
sg23
VC0042024
p9525
sg10
I18
sg11
Vurine incontinence
p9526
sg13
I2
sa(dp9527
g7
I60
sg23
VC0026769
p9528
sg10
I18
sg11
Vmultiple sclerosis
p9529
sg13
I2
sa(dp9530
g7
I114
sg23
VC0010346
p9531
sg10
I15
sg11
VCrohn's disease
p9532
sg13
I2
sasa(dp9533
g2
S'Overall, our findings suggest that the efficacy of nAChR agonists on enteric neurons is enhanced after long-term morphine exposure, and activation of the Alfa3Beta4 subtype of nAChR reverses chronic, but not acute, morphine-induced constipation.\n'
p9534
sg4
(lp9535
(dp9536
g7
I51
sg8
VP43681
p9537
sg10
I5
sg11
VnAChR
p9538
sg13
I1
sasg20
(lp9539
(dp9540
g7
I232
sg23
VC0009806
p9541
sg10
I12
sg11
Vconstipation
p9542
sg13
I1
sasa(dp9543
g2
S'The disruption of the nAChR-mediated positive feedback modulation by antidepressants might explain the frequent occurrence of constipation, a common side effect, attributed to these drugs.\n'
p9544
sg4
(lp9545
(dp9546
g7
I22
sg8
VP43681
p9547
sg10
I5
sg11
VnAChR
p9548
sg13
I1
sasg20
(lp9549
(dp9550
g7
I126
sg23
VC0009806
p9551
sg10
I12
sg11
Vconstipation
p9552
sg13
I1
sa(dp9553
g7
I149
sg23
VC0879626
p9554
sg10
I11
sg11
Vside effect
p9555
sg13
I2
sasa(dp9556
g2
S'Based on the results of previous studies, the ADD3 gene, located in the 10q24.2 region, may be a susceptibility gene of biliary atresia (BA).\n'
p9557
sg4
(lp9558
(dp9559
g7
I46
sg8
g39
sg10
I9
sg11
VADD3 gene
p9560
sg13
I2
sasg20
(lp9561
(dp9562
g7
I120
sg23
VC0005411
p9563
sg10
I15
sg11
Vbiliary atresia
p9564
sg13
I2
sa(dp9565
g7
I137
sg23
VC0005411
p9566
sg10
I2
sg11
VBA
p9567
sg13
I1
sasa(dp9568
g2
S'Several polymorphisms in the human gene encoding MMP have been investigated for the association with ischemic stroke (IS) in the population, of which the MMP-1 -1607 1G/2G, -519 A/G, and MMP-12 -82 A/G polymorphisms gain more and more attention; however, the results are controversial and ambiguous.\n'
p9569
sg4
(lp9570
(dp9571
g7
I154
sg8
VP03956
p9572
sg10
I17
sg11
VMMP-1 -1607 1G/2G
p9573
sg13
I3
sa(dp9574
g7
I29
sg8
g39
sg10
I23
sg11
Vhuman gene encoding MMP
p9575
sg13
I4
sasg20
(lp9576
(dp9577
g7
I101
sg23
VC3272363
p9578
sg10
I15
sg11
Vischemic stroke
p9579
sg13
I2
sa(dp9580
g7
I118
sg23
VC3272363
p9581
sg10
I2
sg11
VIS
p9582
sg13
I1
sasa(dp9583
g2
S'This review will evaluate the evidence for associations between polymorphisms in MMP-1, 2, 3, 9, and 12 with ischemic stroke incidence, pathophysiology, and clinical outcome.\n'
p9584
sg4
(lp9585
(dp9586
g7
I81
sg8
VP03956
p9587
sg10
I5
sg11
VMMP-1
p9588
sg13
I1
sasg20
(lp9589
(dp9590
g7
I109
sg23
VC3272363
p9591
sg10
I15
sg11
Vischemic stroke
p9592
sg13
I2
sasa(dp9593
g2
S'The mRNA transcripts and protein for TREM-1, MMP-1, MMP-9, collagen type I (COL1A1) and collagen type III (COL3A1) were analyzed by qPCR and immunofluorescence in both tissues and VSMCs isolated from atherosclerotic carotid plaques of symptomatic and asymptomatic patients with carotid stenosis.\n'
p9594
sg4
(lp9595
(dp9596
g7
I59
sg8
VP29475
p9597
sg10
I15
sg11
Vcollagen type I
p9598
sg13
I3
sa(dp9599
g7
I45
sg8
VP03956
p9600
sg10
I5
sg11
VMMP-1
p9601
sg13
I1
sa(dp9602
g7
I37
sg8
g39
sg10
I6
sg11
VTREM-1
p9603
sg13
I1
sa(dp9604
g7
I52
sg8
VP14780
p9605
sg10
I5
sg11
VMMP-9
p9606
sg13
I1
sasg20
(lp9607
(dp9608
g7
I224
sg23
VC0333463
p9609
sg10
I7
sg11
Vplaques
p9610
sg13
I1
sa(dp9611
g7
I278
sg23
VC0007282
p9612
sg10
I16
sg11
Vcarotid stenosis
p9613
sg13
I2
sasa(dp9614
g2
S'Expression of SGLT1, is increased in patients with end-stage cardiomyopathy secondary to type 2 diabetes.\n'
p9615
sg4
(lp9616
(dp9617
g7
I14
sg8
VP11166
p9618
sg10
I5
sg11
VSGLT1
p9619
sg13
I1
sasg20
(lp9620
(dp9621
g7
I89
sg23
VC0011860
p9622
sg10
I15
sg11
Vtype 2 diabetes
p9623
sg13
I3
sa(dp9624
g7
I61
sg23
VC0036529
p9625
sg10
I24
sg11
Vcardiomyopathy secondary
p9626
sg13
I2
sasa(dp9627
g2
S'The expression of a novel cardiac glucose transporter, SGLT1, is increased in glycogen storage cardiomyopathy secondary to mutations in PRKAG2.\n'
p9628
sg4
(lp9629
(dp9630
g7
I55
sg8
VP11166
p9631
sg10
I5
sg11
VSGLT1
p9632
sg13
I1
sa(dp9633
g7
I26
sg8
VP11166
p9634
sg10
I27
sg11
Vcardiac glucose transporter
p9635
sg13
I3
sa(dp9636
g7
I136
sg8
g39
sg10
I6
sg11
VPRKAG2
p9637
sg13
I1
sasg20
(lp9638
(dp9639
g7
I78
sg23
VC0878677
p9640
sg10
I31
sg11
Vglycogen storage cardiomyopathy
p9641
sg13
I3
sasa(dp9642
g2
S'We sought to determine the role of SGLT1 in the pathogenesis of PRKAG2 cardiomyopathy and its role in cardiac structure and function.\n'
p9643
sg4
(lp9644
(dp9645
g7
I64
sg8
g39
sg10
I6
sg11
VPRKAG2
p9646
sg13
I1
sa(dp9647
g7
I35
sg8
VP11166
p9648
sg10
I5
sg11
VSGLT1
p9649
sg13
I1
sasg20
(lp9650
(dp9651
g7
I48
sg23
VC0699748
p9652
sg10
I12
sg11
Vpathogenesis
p9653
sg13
I1
sa(dp9654
g7
I71
sg23
VC0878544
p9655
sg10
I14
sg11
Vcardiomyopathy
p9656
sg13
I1
sasa(dp9657
g2
S'Cardiac knockdown of SGLT1 in a murine model of PRKAG2 cardiomyopathy attenuates the disease phenotype, implicating SGLT1 in the pathogenesis.\n'
p9658
sg4
(lp9659
(dp9660
g7
I21
sg8
VP11166
p9661
sg10
I5
sg11
VSGLT1
p9662
sg13
I1
sa(dp9663
g7
I48
sg8
g39
sg10
I6
sg11
VPRKAG2
p9664
sg13
I1
sa(dp9665
g7
I21
sg8
VP11166
p9666
sg10
I5
sg11
VSGLT1
p9667
sg13
I1
sasg20
(lp9668
(dp9669
g7
I129
sg23
VC0699748
p9670
sg10
I12
sg11
Vpathogenesis
p9671
sg13
I1
sa(dp9672
g7
I55
sg23
VC0878544
p9673
sg10
I14
sg11
Vcardiomyopathy
p9674
sg13
I1
sasa(dp9675
g2
S'Furthermore, it has been reported that perturbation of SGLT1 is associated with cardiomyopathy and cancer.\n'
p9676
sg4
(lp9677
(dp9678
g7
I55
sg8
VP11166
p9679
sg10
I5
sg11
VSGLT1
p9680
sg13
I1
sasg20
(lp9681
(dp9682
g7
I80
sg23
VC0878544
p9683
sg10
I14
sg11
Vcardiomyopathy
p9684
sg13
I1
sa(dp9685
g7
I99
sg23
VC0006826
p9686
sg10
I6
sg11
Vcancer
p9687
sg13
I1
sasa(dp9688
g2
S'Sodium-dependent glucose cotransporters (SGLT1 and SGLT2), which have a key role in the absorption of glucose in the kidney and/or gastrointestinal tract, have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.\n'
p9689
sg4
(lp9690
(dp9691
g7
I41
sg8
VP11166
p9692
sg10
I5
sg11
VSGLT1
p9693
sg13
I1
sa(dp9694
g7
I51
sg8
VP31639
p9695
sg10
I5
sg11
VSGLT2
p9696
sg13
I1
sa(dp9697
g7
I0
sg8
VP19525
p9698
sg10
I39
sg11
VSodium-dependent glucose cotransporters
p9699
sg13
I3
sasg20
(lp9700
(dp9701
g7
I210
sg23
VC0011849
p9702
sg10
I8
sg11
Vdiabetes
p9703
sg13
I1
sa(dp9704
g7
I223
sg23
VC0878544
p9705
sg10
I14
sg11
Vcardiomyopathy
p9706
sg13
I1
sasa(dp9707
g2
S'However, the role and molecular mechanism of miR-137 and GLS in malignant melanoma has not been reported.\n'
p9708
sg4
(lp9709
sg20
(lp9710
(dp9711
g7
I64
sg23
VC0025202
p9712
sg10
I18
sg11
Vmalignant melanoma
p9713
sg13
I2
sasa(dp9714
g2
S'In this study, we showed that miR-137 was decreased in melanoma tissue, and the low miR-137 level and high GLS expression are independent risk factor in melanoma.\n'
p9715
sg4
(lp9716
(dp9717
g7
I30
sg8
g39
sg10
I7
sg11
VmiR-137
p9718
sg13
I1
sa(dp9719
g7
I107
sg8
g39
sg10
I3
sg11
VGLS
p9720
sg13
I1
sasg20
(lp9721
(dp9722
g7
I55
sg23
VC0025202
p9723
sg10
I8
sg11
Vmelanoma
p9724
sg13
I1
sa(dp9725
g7
I55
sg23
VC0025202
p9726
sg10
I8
sg11
Vmelanoma
p9727
sg13
I1
sasa(dp9728
g2
S'GLS is crucial for glutamine catabolism and growth of malignant melanoma.\n'
p9729
sg4
(lp9730
sg20
(lp9731
(dp9732
g7
I54
sg23
VC0025202
p9733
sg10
I18
sg11
Vmalignant melanoma
p9734
sg13
I2
sasa(dp9735
g2
S'We also demonstrated that miR-137 acts as a tumor suppressor in melanoma by targeting GLS.\n'
p9736
sg4
(lp9737
sg20
(lp9738
(dp9739
g7
I44
sg23
VC0027651
p9740
sg10
I5
sg11
Vtumor
p9741
sg13
I1
sa(dp9742
g7
I64
sg23
VC0025202
p9743
sg10
I8
sg11
Vmelanoma
p9744
sg13
I1
sasa(dp9745
g2
S'The effects of these enzymes on the proliferation of gastric cancer cells were examined using siRNAs, Shikonin as a PKM2 inhibitor, or BPTES as a GLS inhibitor, in vitro and in vivo.\n'
p9746
sg4
(lp9747
(dp9748
g7
I146
sg8
g39
sg10
I3
sg11
VGLS
p9749
sg13
I1
sasg20
(lp9750
(dp9751
g7
I53
sg23
VC0024623
p9752
sg10
I14
sg11
Vgastric cancer
p9753
sg13
I2
sa(dp9754
g7
I36
sg23
VC0334094
p9755
sg10
I13
sg11
Vproliferation
p9756
sg13
I1
sasa(dp9757
g2
S'These findings suggested that PKM2 and GLS might play important roles in the proliferation of hypoxic gastric cancer cells.\n'
p9758
sg4
(lp9759
(dp9760
g7
I39
sg8
g39
sg10
I3
sg11
VGLS
p9761
sg13
I1
sasg20
(lp9762
(dp9763
g7
I77
sg23
VC0334094
p9764
sg10
I13
sg11
Vproliferation
p9765
sg13
I1
sa(dp9766
g7
I102
sg23
VC0024623
p9767
sg10
I14
sg11
Vgastric cancer
p9768
sg13
I2
sa(dp9769
g7
I94
sg23
VC0242184
p9770
sg10
I7
sg11
Vhypoxic
p9771
sg13
I1
sasa(dp9772
g2
S'A combination of PKM2 and GLS inhibitors might be therapeutically promising for the treatment of gastric cancer.\n'
p9773
sg4
(lp9774
(dp9775
g7
I26
sg8
g39
sg10
I3
sg11
VGLS
p9776
sg13
I1
sasg20
(lp9777
(dp9778
g7
I97
sg23
VC0024623
p9779
sg10
I14
sg11
Vgastric cancer
p9780
sg13
I2
sasa(dp9781
g2
S'This study has identified GLS a potential therapeutic target in breast cancer, specifically in the basal subtype that exhibits a deregulated glutaminolysis pathway.\n'
p9782
sg4
(lp9783
(dp9784
g7
I26
sg8
g39
sg10
I3
sg11
VGLS
p9785
sg13
I1
sasg20
(lp9786
(dp9787
g7
I64
sg23
VC0678222
p9788
sg10
I13
sg11
Vbreast cancer
p9789
sg13
I2
sasa(dp9790
g2
S'Using inducible shRNA mediated gene knockdown, we discovered that loss of GLS function in triple-negative breast cancer (TNBC) cell lines with a deregulated glutaminolysis pathway led to profound tumor growth inhibition in vitro and in vivo.\n'
p9791
sg4
(lp9792
(dp9793
g7
I74
sg8
g39
sg10
I3
sg11
VGLS
p9794
sg13
I1
sasg20
(lp9795
(dp9796
g7
I196
sg23
VC0598934
p9797
sg10
I12
sg11
Vtumor growth
p9798
sg13
I2
sa(dp9799
g7
I106
sg23
VC0678222
p9800
sg10
I13
sg11
Vbreast cancer
p9801
sg13
I2
sasa(dp9802
g2
S'The present study revealed that the loss of GLS1 expression by RNA interference or inhibitor decreased the proliferation and viability of colorectal cancer (CRC) cells.\n'
p9803
sg4
(lp9804
(dp9805
g7
I44
sg8
g39
sg10
I4
sg11
VGLS1
p9806
sg13
I1
sasg20
(lp9807
(dp9808
g7
I157
sg23
VC1527249
p9809
sg10
I3
sg11
VCRC
p9810
sg13
I1
sa(dp9811
g7
I107
sg23
VC0334094
p9812
sg10
I13
sg11
Vproliferation
p9813
sg13
I1
sa(dp9814
g7
I138
sg23
VC1527249
p9815
sg10
I17
sg11
Vcolorectal cancer
p9816
sg13
I2
sasa(dp9817
g2
S'In conclusion, the present study defined a key role of GLS1 in coupling glutaminolysis with elevated glucose uptake and consequently the growth of colon cancer cells.\n'
p9818
sg4
(lp9819
(dp9820
g7
I55
sg8
g39
sg10
I4
sg11
VGLS1
p9821
sg13
I1
sasg20
(lp9822
(dp9823
g7
I147
sg23
VC0699790
p9824
sg10
I12
sg11
Vcolon cancer
p9825
sg13
I2
sasa(dp9826
g2
S'Due to the functional importance of GLS1 in regulating cell metabolism, it was proposed that GLS1 may serve as a target for colorectal cancer therapy.\n'
p9827
sg4
(lp9828
(dp9829
g7
I36
sg8
g39
sg10
I4
sg11
VGLS1
p9830
sg13
I1
sa(dp9831
g7
I36
sg8
g39
sg10
I4
sg11
VGLS1
p9832
sg13
I1
sasg20
(lp9833
(dp9834
g7
I124
sg23
VC1527249
p9835
sg10
I17
sg11
Vcolorectal cancer
p9836
sg13
I2
sasa(dp9837
g2
S'We demonstrate the glutaminase (GLS) is a direct target of miR-513c in human neuroblastoma cells.\n'
p9838
sg4
(lp9839
(dp9840
g7
I32
sg8
g39
sg10
I3
sg11
VGLS
p9841
sg13
I1
sa(dp9842
g7
I19
sg8
g39
sg10
I11
sg11
Vglutaminase
p9843
sg13
I1
sa(dp9844
g7
I59
sg8
g39
sg10
I8
sg11
VmiR-513c
p9845
sg13
I1
sasg20
(lp9846
(dp9847
g7
I77
sg23
VC0027819
p9848
sg10
I13
sg11
Vneuroblastoma
p9849
sg13
I1
sasa(dp9850
g2
S"In addition, we found restoration of GLS expression recovered the neuroblastoma cells' migration, invasion, and proliferation.\n"
p9851
sg4
(lp9852
sg20
(lp9853
(dp9854
g7
I112
sg23
VC0334094
p9855
sg10
I13
sg11
Vproliferation
p9856
sg13
I1
sa(dp9857
g7
I66
sg23
VC0027819
p9858
sg10
I13
sg11
Vneuroblastoma
p9859
sg13
I1
sa(dp9860
g7
I98
sg23
VC2699153
p9861
sg10
I8
sg11
Vinvasion
p9862
sg13
I1
sasa(dp9863
g2
S'To compare homocysteine and thrombophilic mutations for the methylenetetrahydrofolate reductase (MTHFR) C677T, factor V Leiden, and prothrombin G20210A between retinal vein occlusion (RVO) and healthy controls in a Turkish population.\n'
p9864
sg4
(lp9865
(dp9866
g7
I60
sg8
VP42898
p9867
sg10
I91
sg11
Vmethylenetetrahydrofolate reductase (MTHFR) C677T, factor V Leiden, and prothrombin G20210A
p9868
sg13
I10
sasg20
(lp9869
(dp9870
g7
I184
sg23
VC0035328
p9871
sg10
I3
sg11
VRVO
p9872
sg13
I1
sa(dp9873
g7
I160
sg23
VC0035328
p9874
sg10
I22
sg11
Vretinal vein occlusion
p9875
sg13
I3
sasa(dp9876
g2
S'Forty-nine subjects with RVO were compared for homocysteine status and the MTHFR C677T, prothrombin G20210A, and factor V Leiden mutations with those of 68 healthy controls.\n'
p9877
sg4
(lp9878
(dp9879
g7
I88
sg8
VP00734
p9880
sg10
I50
sg11
Vprothrombin G20210A, and factor V Leiden mutations
p9881
sg13
I7
sa(dp9882
g7
I75
sg8
VP42898
p9883
sg10
I11
sg11
VMTHFR C677T
p9884
sg13
I2
sasg20
(lp9885
sa(dp9886
g2
S'Two RVO patients (4.1%) with bilateral involvement had MTHFR C677T mutation.\n'
p9887
sg4
(lp9888
(dp9889
g7
I55
sg8
VP42898
p9890
sg10
I11
sg11
VMTHFR C677T
p9891
sg13
I2
sasg20
(lp9892
sa(dp9893
g2
S'Screening for thrombophilic mutations such as MTHFR C677T, factor V Leiden, and prothrombin G20210A in RVO patients at all ages seems to be unnecessary and not cost-effective.\n'
p9894
sg4
(lp9895
(dp9896
g7
I46
sg8
VP42898
p9897
sg10
I28
sg11
VMTHFR C677T, factor V Leiden
p9898
sg13
I5
sa(dp9899
g7
I80
sg8
VP00734
p9900
sg10
I19
sg11
Vprothrombin G20210A
p9901
sg13
I2
sasg20
(lp9902
sa(dp9903
g2
S'To evaluate the role of plasma total homocysteine (tHcy) and homozygosity for the thermolabile variant of the methylenetetrahydrofolate reductase (MTHFR) C677T genotype in the risk of retinal vein occlusion (RVO).\n'
p9904
sg4
(lp9905
(dp9906
g7
I147
sg8
VP42898
p9907
sg10
I5
sg11
VMTHFR
p9908
sg13
I1
sa(dp9909
g7
I110
sg8
VP42898
p9910
sg10
I35
sg11
Vmethylenetetrahydrofolate reductase
p9911
sg13
I2
sasg20
(lp9912
(dp9913
g7
I208
sg23
VC0035328
p9914
sg10
I3
sg11
VRVO
p9915
sg13
I1
sa(dp9916
g7
I184
sg23
VC0035328
p9917
sg10
I22
sg11
Vretinal vein occlusion
p9918
sg13
I3
sasa(dp9919
g2
S'No significant association between MTHFR C677T genotype and RVO was found under all genetic models.\n'
p9920
sg4
(lp9921
(dp9922
g7
I35
sg8
VP42898
p9923
sg10
I11
sg11
VMTHFR C677T
p9924
sg13
I2
sasg20
(lp9925
sa(dp9926
g2
S'There was no evidence to suggest an association between homozygosity for the MTHFR C677T genotype and RVO.\n'
p9927
sg4
(lp9928
(dp9929
g7
I77
sg8
VP42898
p9930
sg10
I11
sg11
VMTHFR C677T
p9931
sg13
I2
sasg20
(lp9932
sa(dp9933
g2
S'In 139 patients with CRVO (n = 88) and BRVO (n = 51) and in 40 healthy controls factor VIII, fibrinogen, antithrombin III, protein C, protein S, activated protein C resistance, anticardiolipin antibodies (ACA), homocysteine, factor V Leiden, prothrombin G20210A and methylene tetrahydrofolate reductase (MTHFR) C677T mutation were assessed retrospectively.\n'
p9934
sg4
(lp9935
(dp9936
g7
I105
sg8
VP05546
p9937
sg10
I16
sg11
Vantithrombin III
p9938
sg13
I2
sa(dp9939
g7
I80
sg8
VP00451
p9940
sg10
I11
sg11
Vfactor VIII
p9941
sg13
I2
sa(dp9942
g7
I134
sg8
VP07225
p9943
sg10
I9
sg11
Vprotein S
p9944
sg13
I2
sa(dp9945
g7
I145
sg8
VP04070
p9946
sg10
I19
sg11
Vactivated protein C
p9947
sg13
I3
sa(dp9948
g7
I93
sg8
VP22087
p9949
sg10
I10
sg11
Vfibrinogen
p9950
sg13
I1
sa(dp9951
g7
I266
sg8
VP42898
p9952
sg10
I36
sg11
Vmethylene tetrahydrofolate reductase
p9953
sg13
I3
sa(dp9954
g7
I123
sg8
VP02810
p9955
sg10
I9
sg11
Vprotein C
p9956
sg13
I2
sa(dp9957
g7
I211
sg8
VP00734
p9958
sg10
I50
sg11
Vhomocysteine, factor V Leiden, prothrombin G20210A
p9959
sg13
I6
sa(dp9960
g7
I304
sg8
VP42898
p9961
sg10
I5
sg11
VMTHFR
p9962
sg13
I1
sasg20
(lp9963
(dp9964
g7
I145
sg23
VC1861171
p9965
sg10
I30
sg11
Vactivated protein C resistance
p9966
sg13
I4
sasa(dp9967
g2
S'Elevated factor VIII activity and the homozygous MTHFR C677T mutation were significantly more often found in CRVO and BRVO cases compared to controls.\n'
p9968
sg4
(lp9969
(dp9970
g7
I49
sg8
VP42898
p9971
sg10
I11
sg11
VMTHFR C677T
p9972
sg13
I2
sa(dp9973
g7
I9
sg8
VP00451
p9974
sg10
I11
sg11
Vfactor VIII
p9975
sg13
I2
sasg20
(lp9976
sa(dp9977
g2
S'We suggest elevated fibrinogen levels, ACA and the homozygous MTHFR C677T mutation as potential risk factors for CRVO/BRVO.\n'
p9978
sg4
(lp9979
(dp9980
g7
I20
sg8
VP22087
p9981
sg10
I10
sg11
Vfibrinogen
p9982
sg13
I1
sa(dp9983
g7
I62
sg8
VP42898
p9984
sg10
I11
sg11
VMTHFR C677T
p9985
sg13
I2
sasg20
(lp9986
sa(dp9987
g2
S'In our study, the FII G20210A and the MTHFR C677T mutations resulted significantly higher in patients than in controls; in contrast, thrombophilic mutation of FV, ACE, and PAI-1 genes was not statistically correlated with RVO.\n'
p9988
sg4
(lp9989
(dp9990
g7
I38
sg8
VP42898
p9991
sg10
I11
sg11
VMTHFR C677T
p9992
sg13
I2
sa(dp9993
g7
I163
sg8
VP12821
p9994
sg10
I3
sg11
VACE
p9995
sg13
I1
sa(dp9996
g7
I172
sg8
VP05121
p9997
sg10
I11
sg11
VPAI-1 genes
p9998
sg13
I2
sasg20
(lp9999
sa(dp10000
g2
S'The present study investigated the correlation between the antitumor effect of telomelysin and mRNA expression of hTERT and coxsackievirus and adenovirus receptor (CAR) in head and neck squamous cell carcinoma (HNSCC) in vitro and whether telomelysin enhances the antitumor effect of paclitaxel or cisplatin, in vivo using a HNSCC xenograft model.\n'
p10001
sg4
(lp10002
(dp10003
g7
I114
sg8
g39
sg10
I5
sg11
VhTERT
p10004
sg13
I1
sa(dp10005
g7
I143
sg8
g39
sg10
I19
sg11
Vadenovirus receptor
p10006
sg13
I2
sasg20
(lp10007
(dp10008
g7
I211
sg23
VC1168401
p10009
sg10
I5
sg11
VHNSCC
p10010
sg13
I1
sa(dp10011
g7
I164
sg23
VC2607929
p10012
sg10
I3
sg11
VCAR
p10013
sg13
I1
sa(dp10014
g7
I124
sg23
VC2607929
p10015
sg10
I38
sg11
Vcoxsackievirus and adenovirus receptor
p10016
sg13
I4
sa(dp10017
g7
I172
sg23
VC1168401
p10018
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p10019
sg13
I6
sa(dp10020
g7
I211
sg23
VC1168401
p10021
sg10
I5
sg11
VHNSCC
p10022
sg13
I1
sasa(dp10023
g2
S'Even though adenoviral vector is widely used in gene therapy of squamous cell carcinoma of the head and neck (SCCHN), the expression level of Coxsackievirus and adenovirus receptor (CAR) in SCCNH is not clearly defined.\n'
p10024
sg4
(lp10025
(dp10026
g7
I161
sg8
g39
sg10
I19
sg11
Vadenovirus receptor
p10027
sg13
I2
sasg20
(lp10028
(dp10029
g7
I110
sg23
VC1168401
p10030
sg10
I5
sg11
VSCCHN
p10031
sg13
I1
sa(dp10032
g7
I64
sg23
VC1168401
p10033
sg10
I44
sg11
Vsquamous cell carcinoma of the head and neck
p10034
sg13
I8
sa(dp10035
g7
I142
sg23
VC2607929
p10036
sg10
I38
sg11
VCoxsackievirus and adenovirus receptor
p10037
sg13
I4
sa(dp10038
g7
I182
sg23
VC2607929
p10039
sg10
I3
sg11
VCAR
p10040
sg13
I1
sasa(dp10041
g2
S'Anti-TNF-Alfa antibody could reduce IR by inhibiting AKt/mTOR signaling pathway and the expression levels of NFKB, IKKBeta, and SOCS-3 in rats with sepsis-induced stress hyperglycemia.\n'
p10042
sg4
(lp10043
(dp10044
g7
I115
sg8
g39
sg10
I7
sg11
VIKKBeta
p10045
sg13
I1
sa(dp10046
g7
I53
sg8
g39
sg10
I3
sg11
VAKt
p10047
sg13
I1
sa(dp10048
g7
I57
sg8
VP42345
p10049
sg10
I4
sg11
VmTOR
p10050
sg13
I1
sa(dp10051
g7
I128
sg8
g39
sg10
I6
sg11
VSOCS-3
p10052
sg13
I1
sa(dp10053
g7
I109
sg8
g39
sg10
I4
sg11
VNFKB
p10054
sg13
I1
sa(dp10055
g7
I0
sg8
VP01375
p10056
sg10
I22
sg11
VAnti-TNF-Alfa antibody
p10057
sg13
I2
sasg20
(lp10058
(dp10059
g7
I148
sg23
VC0243026
p10060
sg10
I6
sg11
Vsepsis
p10061
sg13
I1
sa(dp10062
g7
I163
sg23
VC0745099
p10063
sg10
I20
sg11
Vstress hyperglycemia
p10064
sg13
I2
sasa(dp10065
g2
S'MLDSTZ treatment induced glucose intolerance in both SOCS2+/+ and SOCS2-/- mice, as shown by glucose tolerance tests, with SOCS2+/+ mice showing a more marked intolerance, compared to SOCS2-/- mice.\n'
p10066
sg4
(lp10067
(dp10068
g7
I53
sg8
g39
sg10
I5
sg11
VSOCS2
p10069
sg13
I1
sa(dp10070
g7
I53
sg8
g39
sg10
I5
sg11
VSOCS2
p10071
sg13
I1
sasg20
(lp10072
(dp10073
g7
I35
sg23
VC0020963
p10074
sg10
I9
sg11
Vtolerance
p10075
sg13
I1
sa(dp10076
g7
I25
sg23
VC0271650
p10077
sg10
I19
sg11
Vglucose intolerance
p10078
sg13
I2
sasa(dp10079
g2
S'Therapies aimed at inhibiting SOCS3 in skeletal muscle may be effective in reversing obesity-related glucose intolerance and insulin resistance.\n'
p10080
sg4
(lp10081
(dp10082
g7
I125
sg8
VP01308
p10083
sg10
I7
sg11
Vinsulin
p10084
sg13
I1
sa(dp10085
g7
I30
sg8
g39
sg10
I5
sg11
VSOCS3
p10086
sg13
I1
sasg20
(lp10087
(dp10088
g7
I101
sg23
VC0271650
p10089
sg10
I19
sg11
Vglucose intolerance
p10090
sg13
I2
sa(dp10091
g7
I85
sg23
VC0028754
p10092
sg10
I7
sg11
Vobesity
p10093
sg13
I1
sa(dp10094
g7
I125
sg23
VC0021655
p10095
sg10
I18
sg11
Vinsulin resistance
p10096
sg13
I2
sasa(dp10097
g2
S'Nonetheless, combined inactivation of SOCS-3 and PTP-1B in brain revealed additive effects on several parameters, including partial resistance to DIO and associated glucose intolerance.\n'
p10098
sg4
(lp10099
(dp10100
g7
I38
sg8
g39
sg10
I6
sg11
VSOCS-3
p10101
sg13
I1
sa(dp10102
g7
I49
sg8
g39
sg10
I6
sg11
VPTP-1B
p10103
sg13
I1
sasg20
(lp10104
(dp10105
g7
I165
sg23
VC0271650
p10106
sg10
I19
sg11
Vglucose intolerance
p10107
sg13
I2
sa(dp10108
g7
I49
sg23
VC0398648
p10109
sg10
I3
sg11
VPTP
p10110
sg13
I1
sa(dp10111
g7
I22
sg23
VC0544461
p10112
sg10
I12
sg11
Vinactivation
p10113
sg13
I1
sasa(dp10114
g2
S'Along with skeletal findings, HPP patients may present with hypercalcemia, seizures, pseudotumor cerebri, and pulmonary insufficiency.\n'
p10115
sg4
(lp10116
sg20
(lp10117
(dp10118
g7
I60
sg23
VC0020437
p10119
sg10
I13
sg11
Vhypercalcemia
p10120
sg13
I1
sa(dp10121
g7
I30
sg23
VC1840392
p10122
sg10
I3
sg11
VHPP
p10123
sg13
I1
sa(dp10124
g7
I110
sg23
VC0034088
p10125
sg10
I23
sg11
Vpulmonary insufficiency
p10126
sg13
I2
sa(dp10127
g7
I85
sg23
VC0033845
p10128
sg10
I19
sg11
Vpseudotumor cerebri
p10129
sg13
I2
sa(dp10130
g7
I75
sg23
VC0036572
p10131
sg10
I8
sg11
Vseizures
p10132
sg13
I1
sasa(dp10133
g2
S'Despite fluid resuscitation and insulin infusion of 0.1 unit/kg/h, which are the mainstays of therapy for DKA, her severe metabolic acidosis and altered mental status did not improve.\n'
p10134
sg4
(lp10135
(dp10136
g7
I32
sg8
VP01308
p10137
sg10
I7
sg11
Vinsulin
p10138
sg13
I1
sasg20
(lp10139
(dp10140
g7
I122
sg23
VC0220981
p10141
sg10
I18
sg11
Vmetabolic acidosis
p10142
sg13
I2
sa(dp10143
g7
I145
sg23
VC0278061
p10144
sg10
I21
sg11
Valtered mental status
p10145
sg13
I3
sasa(dp10146
g2
S'This metabolic acidosis can be associated with muscle wasting, development or exacerbation of bone disease, hypoalbuminemia, increased inflammation, progression of CKD, protein malnutrition, alterations in insulin, leptin, and growth hormone, and increased mortality.\n'
p10147
sg4
(lp10148
(dp10149
g7
I227
sg8
VP01242
p10150
sg10
I14
sg11
Vgrowth hormone
p10151
sg13
I2
sa(dp10152
g7
I206
sg8
VP01308
p10153
sg10
I7
sg11
Vinsulin
p10154
sg13
I1
sa(dp10155
g7
I215
sg8
VP41159
p10156
sg10
I6
sg11
Vleptin
p10157
sg13
I1
sasg20
(lp10158
(dp10159
g7
I47
sg23
VC0026846
p10160
sg10
I14
sg11
Vmuscle wasting
p10161
sg13
I2
sa(dp10162
g7
I94
sg23
VC0005940
p10163
sg10
I12
sg11
Vbone disease
p10164
sg13
I2
sa(dp10165
g7
I169
sg23
VC0022806
p10166
sg10
I20
sg11
Vprotein malnutrition
p10167
sg13
I2
sa(dp10168
g7
I135
sg23
VC0021368
p10169
sg10
I12
sg11
Vinflammation
p10170
sg13
I1
sa(dp10171
g7
I5
sg23
VC0220981
p10172
sg10
I18
sg11
Vmetabolic acidosis
p10173
sg13
I2
sasa(dp10174
g2
S'Insulin and dextrose infusions were commenced and she was managed in intensive care unit where the metabolic acidosis resolved over a 12-h period.\n'
p10175
sg4
(lp10176
(dp10177
g7
I0
sg8
VP01308
p10178
sg10
I7
sg11
VInsulin
p10179
sg13
I1
sasg20
(lp10180
(dp10181
g7
I99
sg23
VC0220981
p10182
sg10
I18
sg11
Vmetabolic acidosis
p10183
sg13
I2
sasa(dp10184
g2
S'Both of them were aggressively treated with intravenous fluids and insulin drip as per the protocol for the blood glucose levels till the anion gap normalized, and the metabolic acidosis reversed.\n'
p10185
sg4
(lp10186
(dp10187
g7
I67
sg8
VP01308
p10188
sg10
I7
sg11
Vinsulin
p10189
sg13
I1
sasg20
(lp10190
(dp10191
g7
I168
sg23
VC0220981
p10192
sg10
I18
sg11
Vmetabolic acidosis
p10193
sg13
I2
sasa(dp10194
g2
S'Recombinant antigens (rAgs) are available today which detect prepatent infections in onchocerciasis.\n'
p10195
sg4
(lp10196
(dp10197
g7
I0
sg8
VP01893
p10198
sg10
I20
sg11
VRecombinant antigens
p10199
sg13
I2
sa(dp10200
g7
I22
sg8
VP52803
p10201
sg10
I4
sg11
VrAgs
p10202
sg13
I1
sasg20
(lp10203
(dp10204
g7
I71
sg23
VC0021311
p10205
sg10
I10
sg11
Vinfections
p10206
sg13
I1
sa(dp10207
g7
I85
sg23
VC0029001
p10208
sg10
I14
sg11
Vonchocerciasis
p10209
sg13
I1
sasa(dp10210
g2
S"Therefore, inhibition of ADAMTS-3 upregulates Reelin activity and may be a potential therapeutic strategy for the prevention or treatment of neuropsychiatric and neurodegenerative disorders, such as schizophrenia and Alzheimer's disease.\n"
p10211
sg4
(lp10212
(dp10213
g7
I46
sg8
VP78509
p10214
sg10
I6
sg11
VReelin
p10215
sg13
I1
sa(dp10216
g7
I25
sg8
g39
sg10
I8
sg11
VADAMTS-3
p10217
sg13
I1
sasg20
(lp10218
(dp10219
g7
I217
sg23
VC1521724
p10220
sg10
I19
sg11
VAlzheimer's disease
p10221
sg13
I2
sa(dp10222
g7
I199
sg23
VC0036341
p10223
sg10
I13
sg11
Vschizophrenia
p10224
sg13
I1
sa(dp10225
g7
I162
sg23
VC0524851
p10226
sg10
I27
sg11
Vneurodegenerative disorders
p10227
sg13
I2
sasa(dp10228
g2
S"We conducted quantitative real-time PCR analysis of active subfamilies of LINE1 repeats (aL1) using genomic DNA extracted from brain specimens of Alzheimer's disease (AD) patients and individuals without neuropsychiatric pathologies, as well as DNA extracted from blood specimens of individuals of different ages (healthy and AD subjects).\n"
p10229
sg4
(lp10230
sg20
(lp10231
(dp10232
g7
I167
sg23
VC1521724
p10233
sg10
I2
sg11
VAD
p10234
sg13
I1
sa(dp10235
g7
I146
sg23
VC1521724
p10236
sg10
I19
sg11
VAlzheimer's disease
p10237
sg13
I2
sa(dp10238
g7
I167
sg23
VC1521724
p10239
sg10
I2
sg11
VAD
p10240
sg13
I1
sasa(dp10241
g2
S"To examine whether informant-based assessments of patients with Alzheimer's disease (AD) can be used longitudinally to track patient functioning, the authors followed AD patients (N=153) and their caregivers over 1 year with the Relative's Assessment of Global Symptomatology-Elderly (RAGS-E) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASc).\n"
p10242
sg4
(lp10243
(dp10244
g7
I285
sg8
VP52803
p10245
sg10
I6
sg11
VRAGS-E
p10246
sg13
I1
sa(dp10247
g7
I229
sg8
VP52803
p10248
sg10
I54
sg11
VRelative's Assessment of Global Symptomatology-Elderly
p10249
sg13
I5
sasg20
(lp10250
(dp10251
g7
I85
sg23
VC1521724
p10252
sg10
I2
sg11
VAD
p10253
sg13
I1
sa(dp10254
g7
I301
sg23
VC1521724
p10255
sg10
I19
sg11
VAlzheimer's Disease
p10256
sg13
I2
sa(dp10257
g7
I85
sg23
VC1521724
p10258
sg10
I2
sg11
VAD
p10259
sg13
I1
sa(dp10260
g7
I64
sg23
VC1521724
p10261
sg10
I19
sg11
VAlzheimer's disease
p10262
sg13
I2
sasa(dp10263
g2
S'Using The Cancer Genome Atlas datasets to re-analyze the effect of some previously reported metastatic genes-e.g., JAM2, PPARGC1A, SIK2, and TRAF6-on overall survival of patients with renal and liver cancers, we found that these genes are actually protective factors for patients with cancer.\n'
p10264
sg4
(lp10265
(dp10266
g7
I115
sg8
VP57087
p10267
sg10
I4
sg11
VJAM2
p10268
sg13
I1
sa(dp10269
g7
I131
sg8
g39
sg10
I4
sg11
VSIK2
p10270
sg13
I1
sa(dp10271
g7
I121
sg8
g39
sg10
I8
sg11
VPPARGC1A
p10272
sg13
I1
sa(dp10273
g7
I141
sg8
g39
sg10
I5
sg11
VTRAF6
p10274
sg13
I1
sasg20
(lp10275
(dp10276
g7
I200
sg23
VC0006826
p10277
sg10
I6
sg11
Vcancer
p10278
sg13
I1
sa(dp10279
g7
I194
sg23
VC0345904
p10280
sg10
I13
sg11
Vliver cancers
p10281
sg13
I2
sa(dp10282
g7
I10
sg23
VC0006826
p10283
sg10
I6
sg11
VCancer
p10284
sg13
I1
sasa(dp10285
g2
S'A cell wounding assay, cell spread assay and cell-matrix adhesion assay were carried out to analyze the cell movement and cell adhesion ability of colon cancer, immunoprecipitation and immunofluorescence assay was confirmed the interaction of PRL-3 and JAM2.\n'
p10286
sg4
(lp10287
(dp10288
g7
I253
sg8
VP57087
p10289
sg10
I4
sg11
VJAM2
p10290
sg13
I1
sa(dp10291
g7
I243
sg8
VP01236
p10292
sg10
I5
sg11
VPRL-3
p10293
sg13
I1
sasg20
(lp10294
(dp10295
g7
I57
sg23
VC0001511
p10296
sg10
I8
sg11
Vadhesion
p10297
sg13
I1
sa(dp10298
g7
I57
sg23
VC0001511
p10299
sg10
I8
sg11
Vadhesion
p10300
sg13
I1
sa(dp10301
g7
I147
sg23
VC0699790
p10302
sg10
I12
sg11
Vcolon cancer
p10303
sg13
I2
sasa(dp10304
g2
S'The findings of the present study revealed the roles of PRL-3 in cancer cell motility and adhesion process, and provided information on the possibility of PRL-3 increase cell-cell adhesion by associating with JAM2.\n'
p10305
sg4
(lp10306
(dp10307
g7
I56
sg8
VP01236
p10308
sg10
I3
sg11
VPRL
p10309
sg13
I1
sa(dp10310
g7
I209
sg8
VP57087
p10311
sg10
I4
sg11
VJAM2
p10312
sg13
I1
sa(dp10313
g7
I56
sg8
VP01236
p10314
sg10
I5
sg11
VPRL-3
p10315
sg13
I1
sasg20
(lp10316
(dp10317
g7
I90
sg23
VC0001511
p10318
sg10
I8
sg11
Vadhesion
p10319
sg13
I1
sa(dp10320
g7
I65
sg23
VC0006826
p10321
sg10
I6
sg11
Vcancer
p10322
sg13
I1
sa(dp10323
g7
I90
sg23
VC0001511
p10324
sg10
I8
sg11
Vadhesion
p10325
sg13
I1
sasa(dp10326
g2
S'In this review, we briefly focus on what is currently known about the structure, function, and mechanism of JAM-B, with particular emphasis on cancer.\n'
p10327
sg4
(lp10328
(dp10329
g7
I108
sg8
VP57087
p10330
sg10
I5
sg11
VJAM-B
p10331
sg13
I1
sasg20
(lp10332
(dp10333
g7
I143
sg23
VC0006826
p10334
sg10
I6
sg11
Vcancer
p10335
sg13
I1
sasa(dp10336
g2
S'Aberrant expression of JAM-2 is associated with cancer progression but little work has been carried out in discovering how this affects changes in cell behaviour.\n'
p10337
sg4
(lp10338
(dp10339
g7
I23
sg8
VP57087
p10340
sg10
I5
sg11
VJAM-2
p10341
sg13
I1
sasg20
(lp10342
(dp10343
g7
I48
sg23
VC0178874
p10344
sg10
I18
sg11
Vcancer progression
p10345
sg13
I2
sasa(dp10346
g2
S'The present study aimed to examine the expression of JAM-2 in human colon cancer specimens and cell lines and its role in the development of colon cancer.\n'
p10347
sg4
(lp10348
(dp10349
g7
I53
sg8
VP57087
p10350
sg10
I5
sg11
VJAM-2
p10351
sg13
I1
sasg20
(lp10352
(dp10353
g7
I68
sg23
VC0699790
p10354
sg10
I12
sg11
Vcolon cancer
p10355
sg13
I2
sa(dp10356
g7
I68
sg23
VC0699790
p10357
sg10
I12
sg11
Vcolon cancer
p10358
sg13
I2
sasa(dp10359
g2
S'JAM-2 expression in human colon cancer specimens (normal, n=75; cancer, n=94) and cell lines was analysed using quantitative real-time PCR and conventional RT-PCR.\n'
p10360
sg4
(lp10361
(dp10362
g7
I0
sg8
VP57087
p10363
sg10
I5
sg11
VJAM-2
p10364
sg13
I1
sasg20
(lp10365
(dp10366
g7
I32
sg23
VC0006826
p10367
sg10
I6
sg11
Vcancer
p10368
sg13
I1
sa(dp10369
g7
I26
sg23
VC0699790
p10370
sg10
I12
sg11
Vcolon cancer
p10371
sg13
I2
sasa(dp10372
g2
S'Colon cancer cells were stably transfected with a mammalian expression vector to overexpress JAM-2-Flag.\n'
p10373
sg4
(lp10374
(dp10375
g7
I93
sg8
VP57087
p10376
sg10
I10
sg11
VJAM-2-Flag
p10377
sg13
I1
sasg20
(lp10378
(dp10379
g7
I0
sg23
VC0699790
p10380
sg10
I12
sg11
VColon cancer
p10381
sg13
I2
sasa(dp10382
g2
S'JAM-2 was lowly expressed in colon cancer cells such as RKO, HT115.\n'
p10383
sg4
(lp10384
(dp10385
g7
I0
sg8
VP57087
p10386
sg10
I5
sg11
VJAM-2
p10387
sg13
I1
sasg20
(lp10388
(dp10389
g7
I29
sg23
VC0699790
p10390
sg10
I12
sg11
Vcolon cancer
p10391
sg13
I2
sasa(dp10392
g2
S'Taken together, JAM-2 may function as a putative tumour suppressor in the progression and metastasis of colorectal cancer.\n'
p10393
sg4
(lp10394
(dp10395
g7
I16
sg8
VP57087
p10396
sg10
I5
sg11
VJAM-2
p10397
sg13
I1
sasg20
(lp10398
(dp10399
g7
I104
sg23
VC1527249
p10400
sg10
I17
sg11
Vcolorectal cancer
p10401
sg13
I2
sa(dp10402
g7
I90
sg23
VC0027627
p10403
sg10
I10
sg11
Vmetastasis
p10404
sg13
I1
sa(dp10405
g7
I49
sg23
VC0027651
p10406
sg10
I6
sg11
Vtumour
p10407
sg13
I1
sasa(dp10408
g2
S'We identified 27 mutated genes, of which 19 genes are reported in COSMIC database (ZNF208, CRNN, ATXN3, DCTN1, RP1L1, PRB4, PRB1, MUC4, HS6ST3, MUC17, JAM2, ITGAD, IREB2, IQUB, CORO1B, CCDC121, AKAP2, ACAN and ACADL), and eight genes have not previously been described in gastric cancer (CCDC178, ARMC4, TUBB6, PLIN4, PKLR, PDZD2, DMBT1and DAB1).Additionally,GPX4 and MPND in 19q13.3-13.4 region, is characterized as a novel fusion-gene.\n'
p10409
sg4
(lp10410
(dp10411
g7
I194
sg8
g39
sg10
I5
sg11
VAKAP2
p10412
sg13
I1
sa(dp10413
g7
I331
sg8
g39
sg10
I13
sg11
VDMBT1and DAB1
p10414
sg13
I2
sa(dp10415
g7
I144
sg8
g39
sg10
I5
sg11
VMUC17
p10416
sg13
I1
sa(dp10417
g7
I118
sg8
VP10163
p10418
sg10
I4
sg11
VPRB4
p10419
sg13
I1
sa(dp10420
g7
I91
sg8
g39
sg10
I4
sg11
VCRNN
p10421
sg13
I1
sa(dp10422
g7
I124
sg8
VP02812
p10423
sg10
I4
sg11
VPRB1
p10424
sg13
I1
sa(dp10425
g7
I210
sg8
VP28330
p10426
sg10
I5
sg11
VACADL
p10427
sg13
I1
sa(dp10428
g7
I171
sg8
g39
sg10
I4
sg11
VIQUB
p10429
sg13
I1
sa(dp10430
g7
I111
sg8
g39
sg10
I5
sg11
VRP1L1
p10431
sg13
I1
sa(dp10432
g7
I201
sg8
VP16112
p10433
sg10
I4
sg11
VACAN
p10434
sg13
I1
sa(dp10435
g7
I311
sg8
g39
sg10
I5
sg11
VPLIN4
p10436
sg13
I1
sa(dp10437
g7
I177
sg8
g39
sg10
I6
sg11
VCORO1B
p10438
sg13
I1
sa(dp10439
g7
I151
sg8
VP57087
p10440
sg10
I4
sg11
VJAM2
p10441
sg13
I1
sa(dp10442
g7
I157
sg8
g39
sg10
I5
sg11
VITGAD
p10443
sg13
I1
sa(dp10444
g7
I83
sg8
g39
sg10
I6
sg11
VZNF208
p10445
sg13
I1
sa(dp10446
g7
I185
sg8
g39
sg10
I7
sg11
VCCDC121
p10447
sg13
I1
sa(dp10448
g7
I104
sg8
g39
sg10
I5
sg11
VDCTN1
p10449
sg13
I1
sa(dp10450
g7
I359
sg8
VP36969
p10451
sg10
I4
sg11
VGPX4
p10452
sg13
I1
sa(dp10453
g7
I297
sg8
g39
sg10
I5
sg11
VARMC4
p10454
sg13
I1
sa(dp10455
g7
I136
sg8
g39
sg10
I6
sg11
VHS6ST3
p10456
sg13
I1
sa(dp10457
g7
I97
sg8
g39
sg10
I5
sg11
VATXN3
p10458
sg13
I1
sa(dp10459
g7
I324
sg8
g39
sg10
I5
sg11
VPDZD2
p10460
sg13
I1
sa(dp10461
g7
I164
sg8
VP48200
p10462
sg10
I5
sg11
VIREB2
p10463
sg13
I1
sa(dp10464
g7
I318
sg8
VP30613
p10465
sg10
I4
sg11
VPKLR
p10466
sg13
I1
sa(dp10467
g7
I304
sg8
g39
sg10
I5
sg11
VTUBB6
p10468
sg13
I1
sasg20
(lp10469
(dp10470
g7
I272
sg23
VC0024623
p10471
sg10
I14
sg11
Vgastric cancer
p10472
sg13
I2
sasa(dp10473
g2
S'In simple AD patients and AD patients complicated by allergic rhinitis or asthma, there were no significant differences in the Th9 cell percentage, PU.1 and IL-9 expression levels between them.\n'
p10474
sg4
(lp10475
(dp10476
g7
I148
sg8
VP17947
p10477
sg10
I4
sg11
VPU.1
p10478
sg13
I1
sa(dp10479
g7
I157
sg8
VP15248
p10480
sg10
I4
sg11
VIL-9
p10481
sg13
I1
sasg20
(lp10482
(dp10483
g7
I53
sg23
VC2607914
p10484
sg10
I17
sg11
Vallergic rhinitis
p10485
sg13
I2
sa(dp10486
g7
I74
sg23
VC0004096
p10487
sg10
I6
sg11
Vasthma
p10488
sg13
I1
sasa(dp10489
g2
S'Appendicitis patients had lower level of neutrophil defensin mRNA (DEFA1,3), but higher levels of alkaline phosphatase (ALPL) and interleukin-8 receptor-Beta (CXCR2/IL8RB), which was confirmed in a larger cohort of 60 patients using droplet digital PCR (ddPCR).\n'
p10490
sg4
(lp10491
(dp10492
g7
I159
sg8
VP25025
p10493
sg10
I5
sg11
VCXCR2
p10494
sg13
I1
sa(dp10495
g7
I120
sg8
VP10696
p10496
sg10
I4
sg11
VALPL
p10497
sg13
I1
sa(dp10498
g7
I98
sg8
VP10696
p10499
sg10
I20
sg11
Valkaline phosphatase
p10500
sg13
I2
sa(dp10501
g7
I67
sg8
VP59665
p10502
sg10
I5
sg11
VDEFA1
p10503
sg13
I1
sa(dp10504
g7
I130
sg8
VP60568
p10505
sg10
I27
sg11
Vinterleukin-8 receptor-Beta
p10506
sg13
I2
sa(dp10507
g7
I41
sg8
VP28039
p10508
sg10
I24
sg11
Vneutrophil defensin mRNA
p10509
sg13
I3
sa(dp10510
g7
I165
sg8
VP25025
p10511
sg10
I5
sg11
VIL8RB
p10512
sg13
I1
sasg20
(lp10513
(dp10514
g7
I0
sg23
VC0003615
p10515
sg10
I12
sg11
VAppendicitis
p10516
sg13
I1
sasa(dp10517
g2
S'K. pneumoniae-treated mice and controls additionally underwent inferior vena cava (IVC) ligation to generate VT. Lung-contusion mice demonstrated no increase in E-selectin or P-selectin whereas mice infected with K. pneumoniae demonstrated increased circulating P-selectin, ICAM-1, VCAM-1 and thrombin-antithrombin (TAT) complexes.\n'
p10518
sg4
(lp10519
(dp10520
g7
I282
sg8
VP19320
p10521
sg10
I6
sg11
VVCAM-1
p10522
sg13
I1
sa(dp10523
g7
I274
sg8
VP05362
p10524
sg10
I6
sg11
VICAM-1
p10525
sg13
I1
sa(dp10526
g7
I316
sg8
VP17735
p10527
sg10
I3
sg11
VTAT
p10528
sg13
I1
sa(dp10529
g7
I161
sg8
VP16581
p10530
sg10
I10
sg11
VE-selectin
p10531
sg13
I1
sa(dp10532
g7
I175
sg8
VP16109
p10533
sg10
I10
sg11
VP-selectin
p10534
sg13
I1
sa(dp10535
g7
I293
sg8
VP17735
p10536
sg10
I21
sg11
Vthrombin-antithrombin
p10537
sg13
I1
sa(dp10538
g7
I175
sg8
VP16109
p10539
sg10
I10
sg11
VP-selectin
p10540
sg13
I1
sasg20
(lp10541
sa(dp10542
g2
S'To test whether autoimmunity to sperm in men with cystic fibrosis (CF) is a result of cross-reactivity between sperm and carbohydrate sequences of the abnormal CF mucins, we investigated the possible epitope sharing between sperm surface antigens and CF mucin antigens using specific monoclonal antibodies (mAbs) directed to purified CF tracheobronchial mucin-1 (HTM-1) and the expression of tracheal mucin 8 gene (MUC8) mRNA in normal male and female reproductive tract tissues by Northern blot analysis.\n'
p10543
sg4
(lp10544
(dp10545
g7
I392
sg8
g39
sg10
I21
sg11
Vtracheal mucin 8 gene
p10546
sg13
I4
sa(dp10547
g7
I251
sg8
g39
sg10
I17
sg11
VCF mucin antigens
p10548
sg13
I3
sa(dp10549
g7
I334
sg8
g39
sg10
I27
sg11
VCF tracheobronchial mucin-1
p10550
sg13
I3
sa(dp10551
g7
I160
sg8
g39
sg10
I9
sg11
VCF mucins
p10552
sg13
I2
sa(dp10553
g7
I224
sg8
VP10523
p10554
sg10
I22
sg11
Vsperm surface antigens
p10555
sg13
I3
sasg20
(lp10556
(dp10557
g7
I67
sg23
VC0016059
p10558
sg10
I2
sg11
VCF
p10559
sg13
I1
sa(dp10560
g7
I67
sg23
VC0016059
p10561
sg10
I2
sg11
VCF
p10562
sg13
I1
sa(dp10563
g7
I50
sg23
VC0010674
p10564
sg10
I15
sg11
Vcystic fibrosis
p10565
sg13
I2
sa(dp10566
g7
I67
sg23
VC0016059
p10567
sg10
I2
sg11
VCF
p10568
sg13
I1
sa(dp10569
g7
I67
sg23
VC0016059
p10570
sg10
I2
sg11
VCF
p10571
sg13
I1
sa(dp10572
g7
I16
sg23
VC0004368
p10573
sg10
I12
sg11
Vautoimmunity
p10574
sg13
I1
sasa(dp10575
g2
S'It is interesting to note that RTN1 is localized to 14q23.1 where SPG15 locus was mapped.\n'
p10576
sg4
(lp10577
(dp10578
g7
I31
sg8
g39
sg10
I4
sg11
VRTN1
p10579
sg13
I1
sa(dp10580
g7
I66
sg8
g39
sg10
I11
sg11
VSPG15 locus
p10581
sg13
I2
sasg20
(lp10582
(dp10583
g7
I66
sg23
VC1849128
p10584
sg10
I5
sg11
VSPG15
p10585
sg13
I1
sasa(dp10586
g2
S'Therefore, we considered RTN1 as a candidate gene for the SPG15 locus, but our mutational analysis possibly excludes RTN1 as causative gene.\n'
p10587
sg4
(lp10588
(dp10589
g7
I25
sg8
g39
sg10
I4
sg11
VRTN1
p10590
sg13
I1
sa(dp10591
g7
I58
sg8
g39
sg10
I11
sg11
VSPG15 locus
p10592
sg13
I2
sa(dp10593
g7
I25
sg8
g39
sg10
I4
sg11
VRTN1
p10594
sg13
I1
sasg20
(lp10595
(dp10596
g7
I58
sg23
VC1849128
p10597
sg10
I5
sg11
VSPG15
p10598
sg13
I1
sasa(dp10599
g2
S"We validated hundreds of nELAVL targets among which were important neuronal and disease-associated transcripts, including Alzheimer's disease (AD) transcripts.\n"
p10600
sg4
(lp10601
sg20
(lp10602
(dp10603
g7
I122
sg23
VC1521724
p10604
sg10
I19
sg11
VAlzheimer's disease
p10605
sg13
I2
sa(dp10606
g7
I143
sg23
VC1521724
p10607
sg10
I2
sg11
VAD
p10608
sg13
I1
sasa(dp10609
g2
S"We also examine the putative role and the observed changes of ELAV-like proteins and of their interactions with other regulatory elements in Alzheimer's disease, cancer, and inflammation.\n"
p10610
sg4
(lp10611
(dp10612
g7
I62
sg8
g39
sg10
I18
sg11
VELAV-like proteins
p10613
sg13
I2
sasg20
(lp10614
(dp10615
g7
I141
sg23
VC1521724
p10616
sg10
I19
sg11
VAlzheimer's disease
p10617
sg13
I2
sa(dp10618
g7
I162
sg23
VC0006826
p10619
sg10
I6
sg11
Vcancer
p10620
sg13
I1
sa(dp10621
g7
I174
sg23
VC0021368
p10622
sg10
I12
sg11
Vinflammation
p10623
sg13
I1
sasa(dp10624
g2
S"Neuronal ELAV (nELAV) proteins are RNA-binding proteins which play a physiological role in controlling gene expression in memory formation, and their alteration may contribute to cognitive impairment associated with neurodegenerative pathologies such as Alzheimer's disease (AD).\n"
p10625
sg4
(lp10626
(dp10627
g7
I9
sg8
g39
sg10
I4
sg11
VELAV
p10628
sg13
I1
sasg20
(lp10629
(dp10630
g7
I254
sg23
VC1521724
p10631
sg10
I19
sg11
VAlzheimer's disease
p10632
sg13
I2
sa(dp10633
g7
I275
sg23
VC1521724
p10634
sg10
I2
sg11
VAD
p10635
sg13
I1
sa(dp10636
g7
I179
sg23
VC0338656
p10637
sg10
I20
sg11
Vcognitive impairment
p10638
sg13
I2
sasa(dp10639
g2
S'Indeed, we found that the content of nELAV proteins is significantly decreased along with clinical dementia progression in the hippocampi of AD brains, where it inversely correlates with the amount of amyloid-beta (Abeta).\n'
p10640
sg4
(lp10641
(dp10642
g7
I201
sg8
g39
sg10
I12
sg11
Vamyloid-beta
p10643
sg13
I1
sa(dp10644
g7
I215
sg8
g39
sg10
I5
sg11
VAbeta
p10645
sg13
I1
sa(dp10646
g7
I37
sg8
VP02649
p10647
sg10
I14
sg11
VnELAV proteins
p10648
sg13
I2
sasg20
(lp10649
(dp10650
g7
I99
sg23
VC0497327
p10651
sg10
I8
sg11
Vdementia
p10652
sg13
I1
sa(dp10653
g7
I201
sg23
VC0011560
p10654
sg10
I7
sg11
Vamyloid
p10655
sg13
I1
sasa(dp10656
g2
S"CR was registered in 3 of 8, 5 of 8 and 10 of 17 treated patients who were affected by extra-mammary Paget's disease (EMPD), erythroplasia of Queyrat (QD), and invasive squamous cell carcinoma (SCC), respectively.\n"
p10657
sg4
(lp10658
sg20
(lp10659
(dp10660
g7
I118
sg23
VC0030186
p10661
sg10
I4
sg11
VEMPD
p10662
sg13
I1
sa(dp10663
g7
I194
sg23
VC0007137
p10664
sg10
I3
sg11
VSCC
p10665
sg13
I1
sa(dp10666
g7
I169
sg23
VC0007137
p10667
sg10
I23
sg11
Vsquamous cell carcinoma
p10668
sg13
I3
sa(dp10669
g7
I87
sg23
VC0030186
p10670
sg10
I29
sg11
Vextra-mammary Paget's disease
p10671
sg13
I3
sa(dp10672
g7
I125
sg23
VC0154089
p10673
sg10
I24
sg11
Verythroplasia of Queyrat
p10674
sg13
I3
sasa(dp10675
g2
S'Thus, in this work we aimed at i) identifying the interaction site of the Hsp27/eIF4E complex and ii) interfere with the relevant protein/protein association mechanism involved in castration-resistant progression of prostate cancer.\n'
p10676
sg4
(lp10677
(dp10678
g7
I74
sg8
g39
sg10
I5
sg11
VHsp27
p10679
sg13
I1
sa(dp10680
g7
I80
sg8
VP06730
p10681
sg10
I5
sg11
VeIF4E
p10682
sg13
I1
sasg20
(lp10683
(dp10684
g7
I201
sg23
VC1739135
p10685
sg10
I30
sg11
Vprogression of prostate cancer
p10686
sg13
I4
sasa(dp10687
g2
S'In order to find a potential inhibitor of Hsp27/eIF4E interaction, BRET assays in combination with molecular simulations identified the phenazine derivative 14 as the compound able to efficiently interfere with this protein/protein interaction, thereby inhibiting cell viability and increasing cell death in chemo- and castration-resistant prostate cancer models in vitro and in vivo.\n'
p10688
sg4
(lp10689
(dp10690
g7
I42
sg8
g39
sg10
I5
sg11
VHsp27
p10691
sg13
I1
sa(dp10692
g7
I48
sg8
VP06730
p10693
sg10
I5
sg11
VeIF4E
p10694
sg13
I1
sasg20
(lp10695
(dp10696
g7
I340
sg23
VC0600139
p10697
sg10
I15
sg11
Vprostate cancer
p10698
sg13
I2
sasa(dp10699
g2
S'Bioinformatics analysis and Luciferase reporter assays demonstrated that miR-455-3p directly targets and suppresses eIF4E, the rate-limiting factor for cap-dependent translation, which plays important roles in the initiation and progression of prostate cancers.\n'
p10700
sg4
(lp10701
(dp10702
g7
I116
sg8
VP06730
p10703
sg10
I5
sg11
VeIF4E
p10704
sg13
I1
sa(dp10705
g7
I73
sg8
g39
sg10
I10
sg11
VmiR-455-3p
p10706
sg13
I1
sasg20
(lp10707
(dp10708
g7
I152
sg23
VC1855179
p10709
sg10
I3
sg11
Vcap
p10710
sg13
I1
sa(dp10711
g7
I244
sg23
VC0376358
p10712
sg10
I16
sg11
Vprostate cancers
p10713
sg13
I2
sasa(dp10714
g2
S'Further studies demonstrated that miR-455-3p inhibits cap-dependent translation and the proliferation of prostate cancer cells through targeting eIF4E.\n'
p10715
sg4
(lp10716
(dp10717
g7
I145
sg8
VP06730
p10718
sg10
I5
sg11
VeIF4E
p10719
sg13
I1
sa(dp10720
g7
I34
sg8
g39
sg10
I10
sg11
VmiR-455-3p
p10721
sg13
I1
sasg20
(lp10722
(dp10723
g7
I54
sg23
VC1855179
p10724
sg10
I3
sg11
Vcap
p10725
sg13
I1
sa(dp10726
g7
I88
sg23
VC0334094
p10727
sg10
I13
sg11
Vproliferation
p10728
sg13
I1
sa(dp10729
g7
I105
sg23
VC0600139
p10730
sg10
I15
sg11
Vprostate cancer
p10731
sg13
I2
sasa(dp10732
g2
S'Taken together, our findings suggest that miR-455-3p functions as a tumor suppressor by directly targeting eIF4E in prostate carcinogenesis and may be used as a potential target for therapeutic intervention in prostate cancer.\n'
p10733
sg4
(lp10734
(dp10735
g7
I107
sg8
VP06730
p10736
sg10
I5
sg11
VeIF4E
p10737
sg13
I1
sa(dp10738
g7
I42
sg8
g39
sg10
I10
sg11
VmiR-455-3p
p10739
sg13
I1
sasg20
(lp10740
(dp10741
g7
I125
sg23
VC0596263
p10742
sg10
I14
sg11
Vcarcinogenesis
p10743
sg13
I1
sa(dp10744
g7
I68
sg23
VC0027651
p10745
sg10
I5
sg11
Vtumor
p10746
sg13
I1
sa(dp10747
g7
I210
sg23
VC0600139
p10748
sg10
I15
sg11
Vprostate cancer
p10749
sg13
I2
sasa(dp10750
g2
S'Translational control, mediated by the rate-limiting eukaryotic translation initiation factor 4E (eIF4E), drives selective translation of several oncogenic proteins, thereby contributing to tumor growth, metastasis, and treatment resistance in various cancers, including prostate cancer.\n'
p10751
sg4
(lp10752
(dp10753
g7
I98
sg8
VP06730
p10754
sg10
I5
sg11
VeIF4E
p10755
sg13
I1
sa(dp10756
g7
I53
sg8
VP06730
p10757
sg10
I43
sg11
Veukaryotic translation initiation factor 4E
p10758
sg13
I5
sasg20
(lp10759
(dp10760
g7
I271
sg23
VC0600139
p10761
sg10
I15
sg11
Vprostate cancer
p10762
sg13
I2
sa(dp10763
g7
I204
sg23
VC0027627
p10764
sg10
I10
sg11
Vmetastasis
p10765
sg13
I1
sa(dp10766
g7
I190
sg23
VC0598934
p10767
sg10
I12
sg11
Vtumor growth
p10768
sg13
I2
sa(dp10769
g7
I252
sg23
VC0006826
p10770
sg10
I7
sg11
Vcancers
p10771
sg13
I1
sasa(dp10772
g2
S'We report that gal and VNPT55 profoundly inhibit migration and invasion of prostate cancer cells, possibly by down-regulating protein expression of several EMT markers (Snail, Slug, N-cadherin, vimentin, and MMP-2/-9) via antagonizing the Mnk-eIF4E axis.\n'
p10773
sg4
(lp10774
(dp10775
g7
I182
sg8
VP19022
p10776
sg10
I10
sg11
VN-cadherin
p10777
sg13
I1
sa(dp10778
g7
I15
sg8
VP16278
p10779
sg10
I3
sg11
Vgal
p10780
sg13
I1
sa(dp10781
g7
I208
sg8
VP08253
p10782
sg10
I8
sg11
VMMP-2/-9
p10783
sg13
I1
sa(dp10784
g7
I239
sg8
g39
sg10
I3
sg11
VMnk
p10785
sg13
I1
sa(dp10786
g7
I243
sg8
VP06730
p10787
sg10
I5
sg11
VeIF4E
p10788
sg13
I1
sa(dp10789
g7
I176
sg8
g39
sg10
I4
sg11
VSlug
p10790
sg13
I1
sasg20
(lp10791
(dp10792
g7
I63
sg23
VC2699153
p10793
sg10
I8
sg11
Vinvasion
p10794
sg13
I1
sa(dp10795
g7
I75
sg23
VC0600139
p10796
sg10
I15
sg11
Vprostate cancer
p10797
sg13
I2
sa(dp10798
g7
I239
sg23
VC0022716
p10799
sg10
I3
sg11
VMnk
p10800
sg13
I1
sasa(dp10801
g2
S'The synthesis and in vitro and in vivo antibreast and antiprostate cancers activities of novel C-4 heteroaryl 13-cis-retinamides that modulate Mnk-eIF4E and AR signaling are discussed.\n'
p10802
sg4
(lp10803
(dp10804
g7
I147
sg8
VP06730
p10805
sg10
I5
sg11
VeIF4E
p10806
sg13
I1
sa(dp10807
g7
I143
sg8
g39
sg10
I3
sg11
VMnk
p10808
sg13
I1
sasg20
(lp10809
(dp10810
g7
I113
sg23
VC0007099
p10811
sg10
I3
sg11
Vcis
p10812
sg13
I1
sa(dp10813
g7
I67
sg23
VC0006826
p10814
sg10
I7
sg11
Vcancers
p10815
sg13
I1
sa(dp10816
g7
I143
sg23
VC0022716
p10817
sg10
I3
sg11
VMnk
p10818
sg13
I1
sasa(dp10819
g2
S'Androgen receptor (AR) and MNK activated eIF4E signaling promotes the development and progression of prostate cancer (PCa).\n'
p10820
sg4
(lp10821
(dp10822
g7
I19
sg8
VP10275
p10823
sg10
I2
sg11
VAR
p10824
sg13
I1
sa(dp10825
g7
I0
sg8
VP10275
p10826
sg10
I17
sg11
VAndrogen receptor
p10827
sg13
I2
sa(dp10828
g7
I41
sg8
VP06730
p10829
sg10
I5
sg11
VeIF4E
p10830
sg13
I1
sa(dp10831
g7
I27
sg8
g39
sg10
I3
sg11
VMNK
p10832
sg13
I1
sasg20
(lp10833
(dp10834
g7
I27
sg23
VC0022716
p10835
sg10
I3
sg11
VMNK
p10836
sg13
I1
sa(dp10837
g7
I118
sg23
VC0268398
p10838
sg10
I3
sg11
VPCa
p10839
sg13
I1
sa(dp10840
g7
I86
sg23
VC1739135
p10841
sg10
I30
sg11
Vprogression of prostate cancer
p10842
sg13
I4
sasa(dp10843
g2
S'Our findings provide the first preclinical evidence that simultaneous inhibition of AR and eIF4E activation is a novel and efficacious therapeutic approach for PCa, and that NRs hold significant promise for treatment of advanced prostate cancer.\n'
p10844
sg4
(lp10845
(dp10846
g7
I91
sg8
VP06730
p10847
sg10
I5
sg11
VeIF4E
p10848
sg13
I1
sasg20
(lp10849
(dp10850
g7
I160
sg23
VC0268398
p10851
sg10
I3
sg11
VPCa
p10852
sg13
I1
sa(dp10853
g7
I229
sg23
VC0600139
p10854
sg10
I15
sg11
Vprostate cancer
p10855
sg13
I2
sasa(dp10856
g2
S'Previously, various associations between Phe and hyperprolactinemia were revealed in studies performed in phenylketonuria (PKU) children and adolescents.\n'
p10857
sg4
(lp10858
sg20
(lp10859
(dp10860
g7
I106
sg23
VC0031485
p10861
sg10
I15
sg11
Vphenylketonuria
p10862
sg13
I1
sa(dp10863
g7
I49
sg23
VC0020514
p10864
sg10
I18
sg11
Vhyperprolactinemia
p10865
sg13
I1
sa(dp10866
g7
I123
sg23
VC0031485
p10867
sg10
I3
sg11
VPKU
p10868
sg13
I1
sasa(dp10869
g2
S'We have therefore evaluated whether increased serum Phe concentrations lead to increased prolactin (PRL) secretion in phenylketonuria.\n'
p10870
sg4
(lp10871
(dp10872
g7
I100
sg8
VP01236
p10873
sg10
I3
sg11
VPRL
p10874
sg13
I1
sa(dp10875
g7
I89
sg8
VP01236
p10876
sg10
I9
sg11
Vprolactin
p10877
sg13
I1
sasg20
(lp10878
(dp10879
g7
I118
sg23
VC0031485
p10880
sg10
I15
sg11
Vphenylketonuria
p10881
sg13
I1
sasa(dp10882
g2
S'In patients with phenylketonuria (PKU), we found normal PRL responses to phenylalanine, demonstrating that conversion of phenylalanine to tyrosine is not necessary for PRL stimulation.\n'
p10883
sg4
(lp10884
(dp10885
g7
I56
sg8
VP01236
p10886
sg10
I3
sg11
VPRL
p10887
sg13
I1
sa(dp10888
g7
I56
sg8
VP01236
p10889
sg10
I3
sg11
VPRL
p10890
sg13
I1
sasg20
(lp10891
(dp10892
g7
I34
sg23
VC0031485
p10893
sg10
I3
sg11
VPKU
p10894
sg13
I1
sa(dp10895
g7
I17
sg23
VC0031485
p10896
sg10
I15
sg11
Vphenylketonuria
p10897
sg13
I1
sasa(dp10898
g2
S'Thus, we designed and synthesized novel pyrimidinyl acyl thiourea derivatives to selectively inhibit Hsp90 alpha in human invasive ductal breast (MCF-7) and human bone osteosarcoma (Saos-2) cell lines.\n'
p10899
sg4
(lp10900
(dp10901
g7
I101
sg8
VP07900
p10902
sg10
I11
sg11
VHsp90 alpha
p10903
sg13
I2
sasg20
(lp10904
(dp10905
g7
I163
sg23
VC0585442
p10906
sg10
I17
sg11
Vbone osteosarcoma
p10907
sg13
I2
sasa(dp10908
g2
S'Inhibition of oncogenic BRAF(V600E) or MEK-attenuated activation of inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6) signaling of the UPR in melanoma cells.\n'
p10909
sg4
(lp10910
(dp10911
g7
I68
sg8
VP21399
p10912
sg10
I27
sg11
Vinositol-requiring enzyme 1
p10913
sg13
I3
sa(dp10914
g7
I107
sg8
VP18850
p10915
sg10
I33
sg11
Vactivating transcription factor 6
p10916
sg13
I4
sa(dp10917
g7
I14
sg8
VP15056
p10918
sg10
I14
sg11
Voncogenic BRAF
p10919
sg13
I2
sa(dp10920
g7
I39
sg8
VP45985
p10921
sg10
I3
sg11
VMEK
p10922
sg13
I1
sa(dp10923
g7
I97
sg8
VP21399
p10924
sg10
I4
sg11
VIRE1
p10925
sg13
I1
sa(dp10926
g7
I142
sg8
VP18850
p10927
sg10
I4
sg11
VATF6
p10928
sg13
I1
sasg20
(lp10929
(dp10930
g7
I172
sg23
VC0025202
p10931
sg10
I8
sg11
Vmelanoma
p10932
sg13
I1
sasa(dp10933
g2
S'Moreover, XBP-1, which is known to be transcriptionally regulated by ATF6 and functionally activated by IRE1 alpha, was found to play an important role in 2-DG-mediated transcriptional up-regulation of TRAIL-R2 in melanoma cells.\n'
p10934
sg4
(lp10935
(dp10936
g7
I104
sg8
VP21399
p10937
sg10
I10
sg11
VIRE1 alpha
p10938
sg13
I2
sa(dp10939
g7
I69
sg8
VP18850
p10940
sg10
I4
sg11
VATF6
p10941
sg13
I1
sa(dp10942
g7
I10
sg8
VP17861
p10943
sg10
I5
sg11
VXBP-1
p10944
sg13
I1
sa(dp10945
g7
I202
sg8
g39
sg10
I8
sg11
VTRAIL-R2
p10946
sg13
I1
sasg20
(lp10947
(dp10948
g7
I214
sg23
VC0025202
p10949
sg10
I8
sg11
Vmelanoma
p10950
sg13
I1
sasa(dp10951
g2
S'These results indicate that 2-DG sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-2 via the ATF6/IRE1 alpha/XBP-1 axis of the unfolded protein response.\n'
p10952
sg4
(lp10953
(dp10954
g7
I133
sg8
VP17861
p10955
sg10
I16
sg11
VIRE1 alpha/XBP-1
p10956
sg13
I2
sa(dp10957
g7
I68
sg8
VP50591
p10958
sg10
I5
sg11
VTRAIL
p10959
sg13
I1
sa(dp10960
g7
I128
sg8
VP18850
p10961
sg10
I4
sg11
VATF6
p10962
sg13
I1
sa(dp10963
g7
I112
sg8
VP50591
p10964
sg10
I7
sg11
VTRAIL-2
p10965
sg13
I1
sasg20
(lp10966
(dp10967
g7
I50
sg23
VC0025202
p10968
sg10
I8
sg11
Vmelanoma
p10969
sg13
I1
sasa(dp10970
g2
S'In one melanoma line, there was clear evidence of activation of the IRE1alpha pathway, and small interfering RNA (siRNA) knockdown of IRE1alpha substantially reduced the up-regulation of TRAIL-R2.\n'
p10971
sg4
(lp10972
(dp10973
g7
I68
sg8
g39
sg10
I9
sg11
VIRE1alpha
p10974
sg13
I1
sa(dp10975
g7
I68
sg8
g39
sg10
I9
sg11
VIRE1alpha
p10976
sg13
I1
sa(dp10977
g7
I187
sg8
g39
sg10
I8
sg11
VTRAIL-R2
p10978
sg13
I1
sasg20
(lp10979
(dp10980
g7
I7
sg23
VC0025202
p10981
sg10
I8
sg11
Vmelanoma
p10982
sg13
I1
sasa(dp10983
g2
S'We further examined CNV of NKG2C and HLA-E allelic distribution in 653 patients afflicted with nasopharyngeal carcinoma (NPC) in Hunan province.\n'
p10984
sg4
(lp10985
(dp10986
g7
I27
sg8
VP26717
p10987
sg10
I5
sg11
VNKG2C
p10988
sg13
I1
sa(dp10989
g7
I37
sg8
VP13747
p10990
sg10
I5
sg11
VHLA-E
p10991
sg13
I1
sasg20
(lp10992
(dp10993
g7
I121
sg23
VC2931822
p10994
sg10
I3
sg11
VNPC
p10995
sg13
I1
sa(dp10996
g7
I95
sg23
VC2931822
p10997
sg10
I24
sg11
Vnasopharyngeal carcinoma
p10998
sg13
I2
sasa(dp10999
g2
S'Genetic modulation or pharmacologic inhibition of RHAMM activity was sufficient and necessary for metastatic phenotypes induced by RB loss in prostate cancer.\n'
p11000
sg4
(lp11001
(dp11002
g7
I50
sg8
g39
sg10
I5
sg11
VRHAMM
p11003
sg13
I1
sasg20
(lp11004
(dp11005
g7
I142
sg23
VC0600139
p11006
sg10
I15
sg11
Vprostate cancer
p11007
sg13
I2
sasa(dp11008
g2
S'Collectively, our findings show how RB loss drives metastatic capacity and highlight RHAMM as a candidate therapeutic target for treating advanced prostate cancer.\n'
p11009
sg4
(lp11010
sg20
(lp11011
(dp11012
g7
I147
sg23
VC0600139
p11013
sg10
I15
sg11
Vprostate cancer
p11014
sg13
I2
sasa(dp11015
g2
S'However the role of HA receptors CD44 and Hyaluronan Mediated Motility Receptor (RHAMM) in regulating the growth of bladder cancer cells driven by loss of AGL has not been studied.\n'
p11016
sg4
(lp11017
(dp11018
g7
I23
sg8
g39
sg10
I56
sg11
Vreceptors CD44 and Hyaluronan Mediated Motility Receptor
p11019
sg13
I7
sa(dp11020
g7
I20
sg8
g39
sg10
I12
sg11
VHA receptors
p11021
sg13
I2
sa(dp11022
g7
I155
sg8
VP35573
p11023
sg10
I3
sg11
VAGL
p11024
sg13
I1
sa(dp11025
g7
I81
sg8
g39
sg10
I5
sg11
VRHAMM
p11026
sg13
I1
sasg20
(lp11027
(dp11028
g7
I116
sg23
VC0699885
p11029
sg10
I14
sg11
Vbladder cancer
p11030
sg13
I2
sasa(dp11031
g2
S'Western blot analysis and Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay was carried out to study cellular apoptosis with HAS2, CD44 and RHAMM loss in bladder cancer cells with and without AGL expression.\n'
p11032
sg4
(lp11033
(dp11034
g7
I26
sg8
VP04053
p11035
sg10
I37
sg11
VTerminal deoxynucleotidyl transferase
p11036
sg13
I3
sa(dp11037
g7
I171
sg8
g39
sg10
I5
sg11
VRHAMM
p11038
sg13
I1
sa(dp11039
g7
I223
sg8
VP35573
p11040
sg10
I3
sg11
VAGL
p11041
sg13
I1
sa(dp11042
g7
I156
sg8
g39
sg10
I4
sg11
VHAS2
p11043
sg13
I1
sa(dp11044
g7
I65
sg8
VP04053
p11045
sg10
I3
sg11
VTdT
p11046
sg13
I1
sasg20
(lp11047
(dp11048
g7
I185
sg23
VC0699885
p11049
sg10
I14
sg11
Vbladder cancer
p11050
sg13
I2
sasa(dp11051
g2
S'Higher amounts of cleaved Cas3, Cas9 and PARP was observed in AGL low bladder cancer cell with loss of HAS2, CD44 or RHAMM.\n'
p11052
sg4
(lp11053
(dp11054
g7
I103
sg8
g39
sg10
I4
sg11
VHAS2
p11055
sg13
I1
sa(dp11056
g7
I26
sg8
g39
sg10
I4
sg11
VCas3
p11057
sg13
I1
sa(dp11058
g7
I41
sg8
VP09874
p11059
sg10
I4
sg11
VPARP
p11060
sg13
I1
sasg20
(lp11061
(dp11062
g7
I70
sg23
VC0699885
p11063
sg10
I14
sg11
Vbladder cancer
p11064
sg13
I2
sasa(dp11065
g2
S'TUNEL staining showed more apoptotic cells with loss of HAS2, CD44 or RHAMM in AGL low bladder cancer cells.\n'
p11066
sg4
(lp11067
(dp11068
g7
I56
sg8
g39
sg10
I4
sg11
VHAS2
p11069
sg13
I1
sasg20
(lp11070
(dp11071
g7
I87
sg23
VC0699885
p11072
sg10
I14
sg11
Vbladder cancer
p11073
sg13
I2
sasa(dp11074
g2
S'This revealed that bladder cancer cells whose aggressive growth is mediated by loss of AGL are susceptible to apoptosis with loss of HAS2, CD44 or RHAMM.\n'
p11075
sg4
(lp11076
(dp11077
g7
I133
sg8
g39
sg10
I4
sg11
VHAS2
p11078
sg13
I1
sa(dp11079
g7
I87
sg8
VP35573
p11080
sg10
I3
sg11
VAGL
p11081
sg13
I1
sasg20
(lp11082
(dp11083
g7
I19
sg23
VC0699885
p11084
sg10
I14
sg11
Vbladder cancer
p11085
sg13
I2
sa(dp11086
g7
I46
sg23
VC0001807
p11087
sg10
I10
sg11
Vaggressive
p11088
sg13
I1
sasa(dp11089
g2
S'Interestingly loss of either CD44 or RHAMM induces apoptosis in different low AGL expressing bladder cancer cell lines.\n'
p11090
sg4
(lp11091
(dp11092
g7
I37
sg8
g39
sg10
I5
sg11
VRHAMM
p11093
sg13
I1
sasg20
(lp11094
(dp11095
g7
I93
sg23
VC0699885
p11096
sg10
I14
sg11
Vbladder cancer
p11097
sg13
I2
sasa(dp11098
g2
S'Growth assays showed that loss of CD44 and RHAMM predominantly inhibit anchorage dependent and independent growth of AGL low bladder cancer cells.\n'
p11099
sg4
(lp11100
sg20
(lp11101
(dp11102
g7
I125
sg23
VC0699885
p11103
sg10
I14
sg11
Vbladder cancer
p11104
sg13
I2
sasa(dp11105
g2
S'Clinicopathologic analysis revealed that high RHAMM mRNA expression is a marker of poor patient outcome in bladder cancer and patients with high RHAMM and low AGL tumor mRNA expression have poor survival.\n'
p11106
sg4
(lp11107
(dp11108
g7
I159
sg8
VP35573
p11109
sg10
I14
sg11
VAGL tumor mRNA
p11110
sg13
I3
sa(dp11111
g7
I46
sg8
g39
sg10
I10
sg11
VRHAMM mRNA
p11112
sg13
I2
sasg20
(lp11113
(dp11114
g7
I163
sg23
VC0027651
p11115
sg10
I5
sg11
Vtumor
p11116
sg13
I1
sa(dp11117
g7
I107
sg23
VC0699885
p11118
sg10
I14
sg11
Vbladder cancer
p11119
sg13
I2
sasa(dp11120
g2
S'Our findings strongly point to the importance of the HAS2-HA-CD44/RHAMM pathway for rapid growth of bladder cancer cells with loss of AGL and provides rational for targeting this pathway at various steps for "personalized" treatment of bladder cancer patients based of their AGL expression status.\n'
p11121
sg4
(lp11122
(dp11123
g7
I53
sg8
g39
sg10
I4
sg11
VHAS2
p11124
sg13
I1
sa(dp11125
g7
I134
sg8
VP35573
p11126
sg10
I3
sg11
VAGL
p11127
sg13
I1
sa(dp11128
g7
I66
sg8
g39
sg10
I5
sg11
VRHAMM
p11129
sg13
I1
sasg20
(lp11130
(dp11131
g7
I100
sg23
VC0699885
p11132
sg10
I14
sg11
Vbladder cancer
p11133
sg13
I2
sa(dp11134
g7
I100
sg23
VC0699885
p11135
sg10
I14
sg11
Vbladder cancer
p11136
sg13
I2
sasa(dp11137
g2
S'In vitro knock-down of RHAMM, CD44 and HAS isoenzymes was achieved by siRNA and lentiviral shRNA in J82 bladder cancer cells.\n'
p11138
sg4
(lp11139
(dp11140
g7
I23
sg8
g39
sg10
I5
sg11
VRHAMM
p11141
sg13
I1
sasg20
(lp11142
(dp11143
g7
I104
sg23
VC0699885
p11144
sg10
I14
sg11
Vbladder cancer
p11145
sg13
I2
sasa(dp11146
g2
S'Subsequently, Kaplan-Meier analysis revealed reduced bladder cancer specific survival in patients with high RHAMM mRNA and low HAS3v1 expression.\n'
p11147
sg4
(lp11148
(dp11149
g7
I108
sg8
g39
sg10
I10
sg11
VRHAMM mRNA
p11150
sg13
I2
sasg20
(lp11151
(dp11152
g7
I53
sg23
VC0699885
p11153
sg10
I14
sg11
Vbladder cancer
p11154
sg13
I2
sasa(dp11155
g2
S'The data suggest that RHAMM plays a crucial role in mediating progression of muscle-invasive bladder cancer and recommends RHAMM for further evaluation as a prognostic marker or therapeutic target in bladder cancer therapy.\n'
p11156
sg4
(lp11157
(dp11158
g7
I22
sg8
g39
sg10
I5
sg11
VRHAMM
p11159
sg13
I1
sasg20
(lp11160
(dp11161
g7
I93
sg23
VC0699885
p11162
sg10
I14
sg11
Vbladder cancer
p11163
sg13
I2
sa(dp11164
g7
I84
sg23
VC0859917
p11165
sg10
I23
sg11
Vinvasive bladder cancer
p11166
sg13
I3
sasa(dp11167
g2
S'Clinical and oncological data from men with localised prostate adenocarcinoma were also assessed and compared with RHAMM expression data.\n'
p11168
sg4
(lp11169
sg20
(lp11170
(dp11171
g7
I54
sg23
VC0007112
p11172
sg10
I23
sg11
Vprostate adenocarcinoma
p11173
sg13
I2
sasa(dp11174
g2
S'There was no RHAMM expression in any tissue from normal patients or those with BPH or prostate cancer without ADT.\n'
p11175
sg4
(lp11176
sg20
(lp11177
(dp11178
g7
I86
sg23
VC0600139
p11179
sg10
I15
sg11
Vprostate cancer
p11180
sg13
I2
sa(dp11181
g7
I79
sg23
VC0005001
p11182
sg10
I3
sg11
VBPH
p11183
sg13
I1
sasa(dp11184
g2
S'There was RHAMM expression in 39.4% of prostate cancer tissues treated with ADT and in 46.2% of CRPC samples (P = 0.001).\n'
p11185
sg4
(lp11186
sg20
(lp11187
(dp11188
g7
I39
sg23
VC0600139
p11189
sg10
I15
sg11
Vprostate cancer
p11190
sg13
I2
sasa(dp11191
g2
S'No prognostic or clinical factors related to prostate cancer were associated with RHAMM expression.\n'
p11192
sg4
(lp11193
(dp11194
g7
I82
sg8
g39
sg10
I5
sg11
VRHAMM
p11195
sg13
I1
sasg20
(lp11196
(dp11197
g7
I45
sg23
VC0600139
p11198
sg10
I15
sg11
Vprostate cancer
p11199
sg13
I2
sasa(dp11200
g2
S'RHAMM expression in prostate cancer is directly associated with ADT.\n'
p11201
sg4
(lp11202
(dp11203
g7
I0
sg8
g39
sg10
I5
sg11
VRHAMM
p11204
sg13
I1
sasg20
(lp11205
(dp11206
g7
I20
sg23
VC0600139
p11207
sg10
I15
sg11
Vprostate cancer
p11208
sg13
I2
sasa(dp11209
g2
S'When prostate cancer becomes CRPC, RHAMM expression is higher.\n'
p11210
sg4
(lp11211
sg20
(lp11212
(dp11213
g7
I5
sg23
VC0600139
p11214
sg10
I15
sg11
Vprostate cancer
p11215
sg13
I2
sasa(dp11216
g2
S'RHAMM expression was not associated with prostate cancer prognostic factors.\n'
p11217
sg4
(lp11218
(dp11219
g7
I0
sg8
g39
sg10
I5
sg11
VRHAMM
p11220
sg13
I1
sa(dp11221
g7
I41
sg8
VP19883
p11222
sg10
I34
sg11
Vprostate cancer prognostic factors
p11223
sg13
I4
sasg20
(lp11224
(dp11225
g7
I41
sg23
VC0600139
p11226
sg10
I15
sg11
Vprostate cancer
p11227
sg13
I2
sasa(dp11228
g2
S'RHAMM overexpression may contribute to the development of hormonal resistance in prostate cancer.\n'
p11229
sg4
(lp11230
(dp11231
g7
I0
sg8
g39
sg10
I5
sg11
VRHAMM
p11232
sg13
I1
sasg20
(lp11233
(dp11234
g7
I81
sg23
VC0600139
p11235
sg10
I15
sg11
Vprostate cancer
p11236
sg13
I2
sasa(dp11237
g2
S'With regards to genodermatosis (neurofibromatosis type I, cutis laxa, pseudoxanthoma elasticum, epidermolysis bullosa, ichtyoses and pilar diseases), we found novel facts in the fields of molecular analysis, clinical aspects, pathophysiology and quality of life.\n'
p11238
sg4
(lp11239
sg20
(lp11240
(dp11241
g7
I96
sg23
VC0014527
p11242
sg10
I21
sg11
Vepidermolysis bullosa
p11243
sg13
I2
sa(dp11244
g7
I16
sg23
VC0037277
p11245
sg10
I14
sg11
Vgenodermatosis
p11246
sg13
I1
sa(dp11247
g7
I70
sg23
VC0033847
p11248
sg10
I24
sg11
Vpseudoxanthoma elasticum
p11249
sg13
I2
sa(dp11250
g7
I32
sg23
VC0027831
p11251
sg10
I24
sg11
Vneurofibromatosis type I
p11252
sg13
I3
sa(dp11253
g7
I58
sg23
VC0010495
p11254
sg10
I10
sg11
Vcutis laxa
p11255
sg13
I2
sasa(dp11256
g2
S'In IL-23p19(-/-), IL-22(-/-) and IL-18(-/-) mice viable C. jejuni were detected in MLNs, but did not translocate to spleen, liver, kidney and blood in the majority of cases.\n'
p11257
sg4
(lp11258
(dp11259
g7
I18
sg8
g39
sg10
I5
sg11
VIL-22
p11260
sg13
I1
sasg20
(lp11261
(dp11262
g7
I83
sg23
VC0026691
p11263
sg10
I4
sg11
VMLNs
p11264
sg13
I1
sasa(dp11265
g2
S'The mRNA expression levels of miR-200c and USP25 were examined in NSCLC cell lines and patient specimens using quantitative reverse transcription-PCR.\n'
p11266
sg4
(lp11267
(dp11268
g7
I30
sg8
g39
sg10
I8
sg11
VmiR-200c
p11269
sg13
I1
sa(dp11270
g7
I43
sg8
g39
sg10
I5
sg11
VUSP25
p11271
sg13
I1
sasg20
(lp11272
(dp11273
g7
I66
sg23
VC0007131
p11274
sg10
I5
sg11
VNSCLC
p11275
sg13
I1
sasa(dp11276
g2
S'The protein expression levels of USP25 were examined in NSCLC cell lines and patient specimens using western blot and immunohistochemical staining.\n'
p11277
sg4
(lp11278
(dp11279
g7
I33
sg8
g39
sg10
I5
sg11
VUSP25
p11280
sg13
I1
sasg20
(lp11281
(dp11282
g7
I56
sg23
VC0007131
p11283
sg10
I5
sg11
VNSCLC
p11284
sg13
I1
sasa(dp11285
g2
S"Further studies revealed that USP25 was a downstream target of miR-200c in NSCLC cells as miR-200c bound directly to the 3'-untranslated region of USP25, thus reducing both the messenger RNA and protein levels of USP25.\n"
p11286
sg4
(lp11287
(dp11288
g7
I30
sg8
g39
sg10
I5
sg11
VUSP25
p11289
sg13
I1
sa(dp11290
g7
I63
sg8
g39
sg10
I8
sg11
VmiR-200c
p11291
sg13
I1
sa(dp11292
g7
I63
sg8
g39
sg10
I8
sg11
VmiR-200c
p11293
sg13
I1
sa(dp11294
g7
I30
sg8
g39
sg10
I5
sg11
VUSP25
p11295
sg13
I1
sa(dp11296
g7
I30
sg8
g39
sg10
I5
sg11
VUSP25
p11297
sg13
I1
sasg20
(lp11298
(dp11299
g7
I75
sg23
VC0007131
p11300
sg10
I5
sg11
VNSCLC
p11301
sg13
I1
sasa(dp11302
g2
S'Moreover, USP25 protein and mRNA level expressions were higher in NSCLC patients, compared to healthy control, and correlated with clinical stage and lymphatic node metastasis.\n'
p11303
sg4
(lp11304
(dp11305
g7
I10
sg8
g39
sg10
I13
sg11
VUSP25 protein
p11306
sg13
I2
sasg20
(lp11307
(dp11308
g7
I66
sg23
VC0007131
p11309
sg10
I5
sg11
VNSCLC
p11310
sg13
I1
sa(dp11311
g7
I165
sg23
VC0027627
p11312
sg10
I10
sg11
Vmetastasis
p11313
sg13
I1
sasa(dp11314
g2
S'These findings indicate that miR-200c exerts tumor-suppressive effects for NSCLC through the suppression of USP25 expression and suggests a new therapeutic application of miR-200c in the treatment of NSCLC.\n'
p11315
sg4
(lp11316
(dp11317
g7
I29
sg8
g39
sg10
I8
sg11
VmiR-200c
p11318
sg13
I1
sa(dp11319
g7
I108
sg8
g39
sg10
I5
sg11
VUSP25
p11320
sg13
I1
sa(dp11321
g7
I29
sg8
g39
sg10
I8
sg11
VmiR-200c
p11322
sg13
I1
sasg20
(lp11323
(dp11324
g7
I75
sg23
VC0007131
p11325
sg10
I5
sg11
VNSCLC
p11326
sg13
I1
sa(dp11327
g7
I75
sg23
VC0007131
p11328
sg10
I5
sg11
VNSCLC
p11329
sg13
I1
sa(dp11330
g7
I45
sg23
VC0027651
p11331
sg10
I5
sg11
Vtumor
p11332
sg13
I1
sa(dp11333
g7
I93
sg23
VC0221103
p11334
sg10
I11
sg11
Vsuppression
p11335
sg13
I1
sasa(dp11336
g2
S'Based on own current research results, this viewpoint essay provides important insights that Hsp90 is also involved as a notable pathophysiological factor in autoimmune blistering dermatoses including epidermolysis bullosa acquisita, bullous pemphigoid and possibly dermatitis herpetiformis.\n'
p11337
sg4
(lp11338
(dp11339
g7
I93
sg8
VP07900
p11340
sg10
I5
sg11
VHsp90
p11341
sg13
I1
sasg20
(lp11342
(dp11343
g7
I180
sg23
VC0037274
p11344
sg10
I10
sg11
Vdermatoses
p11345
sg13
I1
sa(dp11346
g7
I266
sg23
VC0011608
p11347
sg10
I24
sg11
Vdermatitis herpetiformis
p11348
sg13
I2
sa(dp11349
g7
I158
sg23
VC0443146
p11350
sg10
I10
sg11
Vautoimmune
p11351
sg13
I1
sa(dp11352
g7
I201
sg23
VC0079293
p11353
sg10
I31
sg11
Vepidermolysis bullosa acquisita
p11354
sg13
I3
sa(dp11355
g7
I234
sg23
VC0030805
p11356
sg10
I18
sg11
Vbullous pemphigoid
p11357
sg13
I2
sa(dp11358
g7
I169
sg23
VC0005758
p11359
sg10
I10
sg11
Vblistering
p11360
sg13
I1
sasa(dp11361
g2
S'To further study the role of Hsp in autoimmune bullous diseases, we have investigated for the first time the humoral autoimmune response to Hsp40, Hsp60, Hsp70, and Hsp90 in patients with dermatitis herpetiformis (DH; n = 26), bullous pemphigoid (BP; n = 23), and pemphigus vulgaris (PV; n = 16), the first representing a cutaneous manifestation of celiac disease.\n'
p11362
sg4
(lp11363
(dp11364
g7
I147
sg8
VP10809
p11365
sg10
I5
sg11
VHsp60
p11366
sg13
I1
sa(dp11367
g7
I29
sg8
g39
sg10
I3
sg11
VHsp
p11368
sg13
I1
sa(dp11369
g7
I154
sg8
VP34932
p11370
sg10
I16
sg11
VHsp70, and Hsp90
p11371
sg13
I3
sa(dp11372
g7
I140
sg8
VP25685
p11373
sg10
I5
sg11
VHsp40
p11374
sg13
I1
sasg20
(lp11375
(dp11376
g7
I284
sg23
VC0030809
p11377
sg10
I2
sg11
VPV
p11378
sg13
I1
sa(dp11379
g7
I29
sg23
VC0034152
p11380
sg10
I3
sg11
VHsp
p11381
sg13
I1
sa(dp11382
g7
I188
sg23
VC0011608
p11383
sg10
I24
sg11
Vdermatitis herpetiformis
p11384
sg13
I2
sa(dp11385
g7
I349
sg23
VC0007570
p11386
sg10
I14
sg11
Vceliac disease
p11387
sg13
I2
sa(dp11388
g7
I36
sg23
VC0443146
p11389
sg10
I10
sg11
Vautoimmune
p11390
sg13
I1
sa(dp11391
g7
I117
sg23
VC0004366
p11392
sg10
I19
sg11
Vautoimmune response
p11393
sg13
I2
sa(dp11394
g7
I264
sg23
VC0030809
p11395
sg10
I18
sg11
Vpemphigus vulgaris
p11396
sg13
I2
sa(dp11397
g7
I227
sg23
VC0030805
p11398
sg10
I18
sg11
Vbullous pemphigoid
p11399
sg13
I2
sa(dp11400
g7
I214
sg23
VC0011608
p11401
sg10
I2
sg11
VDH
p11402
sg13
I1
sa(dp11403
g7
I247
sg23
VC0030805
p11404
sg10
I2
sg11
VBP
p11405
sg13
I1
sasa(dp11406
g2
S'The general classes of disorders covered in this complex review are: peroxisomal disorders (adrenoleukodystrophy), lysosomal storage disorders (including metachromatic leukodystrophy, Krabbe or globoid cell leukodystrophy, Fabry, Niemann-Pick, GM1, GM2, Gaucher, mucopolysaccharidoses, and Salla diseases), mitochondrial disorders (including mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes, myoclonic epilepsy with ragged red fibers, Leigh disease, and Kearns-Sayre syndrome), urea cycle disorders, several organic acidemias (including phenylketonuria, maple syrup urine disease, 3-hydroxy-3-methylglutaryl colyase deficiency, glutaric acidurias, methylmalonic academia, proprionic academia, 3-methylglucatonic aciduria, and 2-hydroxyglutaric acidurias), cytoskeletal or transporter molecule defects (including Alexander or fibrinoid leukodystrophy, proteolipid protein-1 defect or Pelizaeus Merzbacher, Wilson, and Huntington diseases), and several neurodegenerative disorders of brain iron accumulation.\n'
p11407
sg4
(lp11408
sg20
(lp11409
(dp11410
g7
I482
sg23
VC0022541
p11411
sg10
I21
sg11
VKearns-Sayre syndrome
p11412
sg13
I2
sa(dp11413
g7
I582
sg23
VC0024776
p11414
sg10
I25
sg11
Vmaple syrup urine disease
p11415
sg13
I4
sa(dp11416
g7
I379
sg23
VC0001125
p11417
sg10
I15
sg11
Vlactic acidosis
p11418
sg13
I2
sa(dp11419
g7
I665
sg23
VC0278026
p11420
sg10
I8
sg11
Vaciduria
p11421
sg13
I1
sa(dp11422
g7
I342
sg23
VC0162666
p11423
sg10
I31
sg11
Vmitochondrial encephalomyopathy
p11424
sg13
I2
sa(dp11425
g7
I463
sg23
VC0023264
p11426
sg10
I13
sg11
VLeigh disease
p11427
sg13
I2
sa(dp11428
g7
I979
sg23
VC0524851
p11429
sg10
I27
sg11
Vneurodegenerative disorders
p11430
sg13
I2
sa(dp11431
g7
I307
sg23
VC0751651
p11432
sg10
I23
sg11
Vmitochondrial disorders
p11433
sg13
I2
sa(dp11434
g7
I420
sg23
VC0162672
p11435
sg10
I41
sg11
Vmyoclonic epilepsy with ragged red fibers
p11436
sg13
I6
sa(dp11437
g7
I853
sg23
VC0270726
p11438
sg10
I24
sg11
Vfibrinoid leukodystrophy
p11439
sg13
I2
sa(dp11440
g7
I194
sg23
VC0023521
p11441
sg10
I27
sg11
Vgloboid cell leukodystrophy
p11442
sg13
I3
sa(dp11443
g7
I506
sg23
VC0154246
p11444
sg10
I20
sg11
Vurea cycle disorders
p11445
sg13
I3
sa(dp11446
g7
I665
sg23
VC0278026
p11447
sg10
I9
sg11
Vacidurias
p11448
sg13
I1
sa(dp11449
g7
I665
sg23
VC0278026
p11450
sg10
I9
sg11
Vacidurias
p11451
sg13
I1
sa(dp11452
g7
I69
sg23
VC0282528
p11453
sg10
I21
sg11
Vperoxisomal disorders
p11454
sg13
I2
sa(dp11455
g7
I115
sg23
VC0085078
p11456
sg10
I27
sg11
Vlysosomal storage disorders
p11457
sg13
I3
sa(dp11458
g7
I263
sg23
VC0026703
p11459
sg10
I21
sg11
Vmucopolysaccharidoses
p11460
sg13
I1
sa(dp11461
g7
I565
sg23
VC0031485
p11462
sg10
I15
sg11
Vphenylketonuria
p11463
sg13
I1
sa(dp11464
g7
I154
sg23
VC0023522
p11465
sg10
I28
sg11
Vmetachromatic leukodystrophy
p11466
sg13
I2
sa(dp11467
g7
I544
sg23
VC0268030
p11468
sg10
I9
sg11
Vacidemias
p11469
sg13
I1
sa(dp11470
g7
I92
sg23
VC0162309
p11471
sg10
I20
sg11
Vadrenoleukodystrophy
p11472
sg13
I1
sasa(dp11473
g2
S'Inborn errors of purine metabolism, either deficiencies of synthesis or catabolism pathways, lead to a wide spectrum of clinical presentations: urolithiasis (adenine phosphoribosyltransferase), primary immune deficiency (adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency), severe intellectual disability, and other neurological symptoms (Lesch-Nyhan disease, adenylosuccinase deficiency, and molybdenum cofactor deficiency).\n'
p11474
sg4
(lp11475
(dp11476
g7
I221
sg8
VP00813
p11477
sg10
I19
sg11
Vadenosine deaminase
p11478
sg13
I2
sa(dp11479
g7
I387
sg8
VP30566
p11480
sg10
I16
sg11
Vadenylosuccinase
p11481
sg13
I1
sa(dp11482
g7
I256
sg8
VP00491
p11483
sg10
I31
sg11
Vpurine nucleoside phosphorylase
p11484
sg13
I3
sa(dp11485
g7
I158
sg8
VP07741
p11486
sg10
I33
sg11
Vadenine phosphoribosyltransferase
p11487
sg13
I2
sasg20
(lp11488
(dp11489
g7
I256
sg23
VC0268125
p11490
sg10
I42
sg11
Vpurine nucleoside phosphorylase deficiency
p11491
sg13
I4
sa(dp11492
g7
I387
sg23
VC0268126
p11493
sg10
I27
sg11
Vadenylosuccinase deficiency
p11494
sg13
I2
sa(dp11495
g7
I420
sg23
VC0268119
p11496
sg10
I30
sg11
Vmolybdenum cofactor deficiency
p11497
sg13
I3
sa(dp11498
g7
I202
sg23
VC0850497
p11499
sg10
I17
sg11
Vimmune deficiency
p11500
sg13
I2
sa(dp11501
g7
I308
sg23
VC0025362
p11502
sg10
I23
sg11
Vintellectual disability
p11503
sg13
I2
sa(dp11504
g7
I343
sg23
VC0235031
p11505
sg10
I21
sg11
Vneurological symptoms
p11506
sg13
I2
sa(dp11507
g7
I144
sg23
VC0451641
p11508
sg10
I12
sg11
Vurolithiasis
p11509
sg13
I1
sa(dp11510
g7
I366
sg23
VC0023374
p11511
sg10
I19
sg11
VLesch-Nyhan disease
p11512
sg13
I2
sa(dp11513
g7
I221
sg23
VC0268124
p11514
sg10
I30
sg11
Vadenosine deaminase deficiency
p11515
sg13
I3
sasa(dp11516
g2
S'The phenotypical suppression of the purine nucleoside phosphorylase deficiency is the result of the mutations (called pnd), which are mapped on the chromosome of E. coli beyond the region of the structural pup-gene location and have phenotypic manifestation distinct from that of pup+ allele: a) pnd mutants divide into some groups for the ability of utilizing several purine nucleosides, including xantosine that cannot be metabolized by pnd+ strains of E. coli; b) pnd mutations do not restore the ability of purine auxotrophs (pur) defective in purine nucleoside phosphorylase (pup) and adenine phosphoribosyltransferase (apt) to grow on the medium with adenine as the sole source of purines.\n'
p11517
sg4
(lp11518
(dp11519
g7
I625
sg8
g39
sg10
I3
sg11
Vapt
p11520
sg13
I1
sa(dp11521
g7
I36
sg8
VP00491
p11522
sg10
I31
sg11
Vpurine nucleoside phosphorylase
p11523
sg13
I3
sa(dp11524
g7
I206
sg8
VP00491
p11525
sg10
I3
sg11
Vpup
p11526
sg13
I1
sa(dp11527
g7
I206
sg8
VP00491
p11528
sg10
I3
sg11
Vpup
p11529
sg13
I1
sa(dp11530
g7
I36
sg8
VP00491
p11531
sg10
I31
sg11
Vpurine nucleoside phosphorylase
p11532
sg13
I3
sa(dp11533
g7
I590
sg8
VP07741
p11534
sg10
I33
sg11
Vadenine phosphoribosyltransferase
p11535
sg13
I2
sasg20
(lp11536
(dp11537
g7
I17
sg23
VC0221103
p11538
sg10
I11
sg11
Vsuppression
p11539
sg13
I1
sa(dp11540
g7
I118
sg23
VC0013405
p11541
sg10
I3
sg11
Vpnd
p11542
sg13
I1
sa(dp11543
g7
I118
sg23
VC0013405
p11544
sg10
I3
sg11
Vpnd
p11545
sg13
I1
sa(dp11546
g7
I36
sg23
VC0268125
p11547
sg10
I42
sg11
Vpurine nucleoside phosphorylase deficiency
p11548
sg13
I4
sa(dp11549
g7
I118
sg23
VC0013405
p11550
sg10
I3
sg11
Vpnd
p11551
sg13
I1
sasa(dp11552
g2
S'Mutations of SLC9A6 may cause an X-linked clinical syndrome first described by Christianson in 1999 in which affected males exhibited profound intellectual disability, autism, drug-resistant epilepsy, ophthalmoplegia, mild craniofacial dysmorphism, microcephaly, and ataxia.\n'
p11553
sg4
(lp11554
(dp11555
g7
I13
sg8
g39
sg10
I6
sg11
VSLC9A6
p11556
sg13
I1
sasg20
(lp11557
(dp11558
g7
I191
sg23
VC0014544
p11559
sg10
I8
sg11
Vepilepsy
p11560
sg13
I1
sa(dp11561
g7
I143
sg23
VC0025362
p11562
sg10
I23
sg11
Vintellectual disability
p11563
sg13
I2
sa(dp11564
g7
I236
sg23
VC1737329
p11565
sg10
I11
sg11
Vdysmorphism
p11566
sg13
I1
sa(dp11567
g7
I168
sg23
VC0004352
p11568
sg10
I6
sg11
Vautism
p11569
sg13
I1
sa(dp11570
g7
I249
sg23
VC0025958
p11571
sg10
I12
sg11
Vmicrocephaly
p11572
sg13
I1
sa(dp11573
g7
I201
sg23
VC0029089
p11574
sg10
I15
sg11
Vophthalmoplegia
p11575
sg13
I1
sa(dp11576
g7
I51
sg23
VC0039082
p11577
sg10
I8
sg11
Vsyndrome
p11578
sg13
I1
sa(dp11579
g7
I267
sg23
VC0004134
p11580
sg10
I6
sg11
Vataxia
p11581
sg13
I1
sasa(dp11582
g2
S'Coagulation factor IX (recombinant), albumin fusion protein (Idelvion) for hemophilia B; captisol-enabled melphalan hydrochloride (Evomela) for multiple myeloma; and antihemophilic factor (recombinant) (Kovaltry) for hemophilia A.\n'
p11583
sg4
(lp11584
(dp11585
g7
I0
sg8
VP00740
p11586
sg10
I21
sg11
VCoagulation factor IX
p11587
sg13
I3
sa(dp11588
g7
I37
sg8
VP00441
p11589
sg10
I7
sg11
Valbumin
p11590
sg13
I1
sasg20
(lp11591
(dp11592
g7
I217
sg23
VC0019069
p11593
sg10
I12
sg11
Vhemophilia A
p11594
sg13
I2
sa(dp11595
g7
I75
sg23
VC0008533
p11596
sg10
I12
sg11
Vhemophilia B
p11597
sg13
I2
sa(dp11598
g7
I144
sg23
VC0026764
p11599
sg10
I16
sg11
Vmultiple myeloma
p11600
sg13
I2
sasa(dp11601
g2
S'An initial presentation of hematological malignancies associated with autoantibodies is not common, and there is only one documented case of multiple myeloma presenting with acquired FVIII inhibitor for multiple myeloma.\n'
p11602
sg4
(lp11603
(dp11604
g7
I183
sg8
VP00451
p11605
sg10
I5
sg11
VFVIII
p11606
sg13
I1
sasg20
(lp11607
(dp11608
g7
I27
sg23
VC0376545
p11609
sg10
I26
sg11
Vhematological malignancies
p11610
sg13
I2
sa(dp11611
g7
I141
sg23
VC0026764
p11612
sg10
I16
sg11
Vmultiple myeloma
p11613
sg13
I2
sa(dp11614
g7
I141
sg23
VC0026764
p11615
sg10
I16
sg11
Vmultiple myeloma
p11616
sg13
I2
sasa(dp11617
g2
S'In this paper, we describe a second case of multiple myeloma who presented with acquired FVIII inhibitor.\n'
p11618
sg4
(lp11619
(dp11620
g7
I89
sg8
VP00451
p11621
sg10
I5
sg11
VFVIII
p11622
sg13
I1
sasg20
(lp11623
(dp11624
g7
I44
sg23
VC0026764
p11625
sg10
I16
sg11
Vmultiple myeloma
p11626
sg13
I2
sasa(dp11627
g2
S'The patient was diagnosed with the IgG kappa type of multiple myeloma associated with acquired FVIII inhibitor.\n'
p11628
sg4
(lp11629
(dp11630
g7
I95
sg8
VP00451
p11631
sg10
I5
sg11
VFVIII
p11632
sg13
I1
sasg20
(lp11633
(dp11634
g7
I53
sg23
VC0026764
p11635
sg10
I16
sg11
Vmultiple myeloma
p11636
sg13
I2
sasa(dp11637
g2
S'Clinicians should be alert to the presence of rare underlying neoplastic diseases such as multiple myeloma, in patients with acquired FVIII inhibitor.\n'
p11638
sg4
(lp11639
(dp11640
g7
I134
sg8
VP00451
p11641
sg10
I5
sg11
VFVIII
p11642
sg13
I1
sasg20
(lp11643
(dp11644
g7
I90
sg23
VC0026764
p11645
sg10
I16
sg11
Vmultiple myeloma
p11646
sg13
I2
sasa(dp11647
g2
S"In order to measure the levels of Dynamin1, we isolated cortical white matter from a total of 34 post-mortem brains derived from controls (N=11), mixed Alzheimer's disease (AD) and VaD (N=8), VaD (N=7), and stroke no dementia (SND, N=8) subjects.\n"
p11648
sg4
(lp11649
(dp11650
g7
I34
sg8
g39
sg10
I8
sg11
VDynamin1
p11651
sg13
I1
sasg20
(lp11652
(dp11653
g7
I217
sg23
VC0497327
p11654
sg10
I8
sg11
Vdementia
p11655
sg13
I1
sa(dp11656
g7
I152
sg23
VC1521724
p11657
sg10
I19
sg11
VAlzheimer's disease
p11658
sg13
I2
sa(dp11659
g7
I173
sg23
VC1521724
p11660
sg10
I2
sg11
VAD
p11661
sg13
I1
sa(dp11662
g7
I207
sg23
VC0038454
p11663
sg10
I6
sg11
Vstroke
p11664
sg13
I1
sasa(dp11665
g2
S'We performed a retrospective analysis of 531 paired liver stiffness measurements made by Fibroscan when the study began (LSM1) and at follow-up (LSM2), more than 1 day and less than 1 year apart, from 432 stable (for body mass index, waist circumference, and alcohol consumption), untreated, immunocompetent patients with chronic liver disease (from January 2006 through March 2009).\n'
p11666
sg4
(lp11667
(dp11668
g7
I121
sg8
g39
sg10
I4
sg11
VLSM1
p11669
sg13
I1
sa(dp11670
g7
I145
sg8
g39
sg10
I4
sg11
VLSM2
p11671
sg13
I1
sasg20
(lp11672
(dp11673
g7
I322
sg23
VC0341439
p11674
sg10
I21
sg11
Vchronic liver disease
p11675
sg13
I3
sa(dp11676
g7
I58
sg23
VC0427008
p11677
sg10
I9
sg11
Vstiffness
p11678
sg13
I1
sasa(dp11679
g2
S'Patient 1 was hypotonic and dysmorphic at birth, with aplasia of the posterior corpus callosum, bilateral ptosis, oculomotor paralysis, down-slanting palpebral fissures, facial asymmetry, submucosal cleft palate, micrognathia, wide-spaced nipples, right-sided aortic arch, hypospadias, bilateral inguinal hernias, double toenail of the left second toe, partial 2-3 toe syndactyly, kyphoscoliosis and colonic atony.\n'
p11680
sg4
(lp11681
sg20
(lp11682
(dp11683
g7
I273
sg23
VC1691215
p11684
sg10
I11
sg11
Vhypospadias
p11685
sg13
I1
sa(dp11686
g7
I54
sg23
VC0243065
p11687
sg10
I7
sg11
Vaplasia
p11688
sg13
I1
sa(dp11689
g7
I361
sg23
VC0432040
p11690
sg10
I18
sg11
V2-3 toe syndactyly
p11691
sg13
I3
sa(dp11692
g7
I170
sg23
VC1306710
p11693
sg10
I16
sg11
Vfacial asymmetry
p11694
sg13
I2
sa(dp11695
g7
I114
sg23
VC0029089
p11696
sg10
I20
sg11
Voculomotor paralysis
p11697
sg13
I2
sa(dp11698
g7
I14
sg23
VC0241938
p11699
sg10
I9
sg11
Vhypotonic
p11700
sg13
I1
sa(dp11701
g7
I296
sg23
VC0019294
p11702
sg10
I16
sg11
Vinguinal hernias
p11703
sg13
I2
sa(dp11704
g7
I400
sg23
VC0267516
p11705
sg10
I13
sg11
Vcolonic atony
p11706
sg13
I2
sa(dp11707
g7
I381
sg23
VC0600033
p11708
sg10
I14
sg11
Vkyphoscoliosis
p11709
sg13
I1
sa(dp11710
g7
I213
sg23
VC0025990
p11711
sg10
I12
sg11
Vmicrognathia
p11712
sg13
I1
sa(dp11713
g7
I199
sg23
VC0008925
p11714
sg10
I12
sg11
Vcleft palate
p11715
sg13
I2
sa(dp11716
g7
I106
sg23
VC0005745
p11717
sg10
I6
sg11
Vptosis
p11718
sg13
I1
sasa(dp11719
g2
S'mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line.\n'
p11720
sg4
(lp11721
(dp11722
g7
I180
sg8
g39
sg10
I7
sg11
VmiR 550
p11723
sg13
I2
sa(dp11724
g7
I18
sg8
g39
sg10
I5
sg11
VPRP-1
p11725
sg13
I1
sasg20
(lp11726
(dp11727
g7
I197
sg23
VC0008479
p11728
sg10
I14
sg11
Vchondrosarcoma
p11729
sg13
I1
sa(dp11730
g7
I59
sg23
VC0027651
p11731
sg10
I5
sg11
Vtumor
p11732
sg13
I1
sasa(dp11733
g2
S'As described in the literature, hereditary angioedema (HAE) is an autosomal dominant disease that presents with recurrent events of angioedema caused by a) deficiency or b) functional alteration of the plasma protein C1 inhibitor (C1-inh); this enzyme is involved in the regulation of the complement, kallikrein-kinin, fibrinolytic, and coagulation systems.\n'
p11734
sg4
(lp11735
(dp11736
g7
I301
sg8
VP06870
p11737
sg10
I16
sg11
Vkallikrein-kinin
p11738
sg13
I1
sasg20
(lp11739
(dp11740
g7
I32
sg23
VC0019243
p11741
sg10
I21
sg11
Vhereditary angioedema
p11742
sg13
I2
sa(dp11743
g7
I43
sg23
VC0002994
p11744
sg10
I10
sg11
Vangioedema
p11745
sg13
I1
sa(dp11746
g7
I55
sg23
VC0019243
p11747
sg10
I3
sg11
VHAE
p11748
sg13
I1
sasa(dp11749
g2
S'Hereditary angioedema (HAE) is an autosomal dominant disease characterized by recurrent angioedema episodes caused by a quantitative or functional defect of the plasma protein C1 esterase inhibitor (C1-INH).\n'
p11750
sg4
(lp11751
(dp11752
g7
I161
sg8
VP22760
p11753
sg10
I36
sg11
Vplasma protein C1 esterase inhibitor
p11754
sg13
I5
sa(dp11755
g7
I199
sg8
VP05111
p11756
sg10
I6
sg11
VC1-INH
p11757
sg13
I1
sasg20
(lp11758
(dp11759
g7
I0
sg23
VC0019243
p11760
sg10
I21
sg11
VHereditary angioedema
p11761
sg13
I2
sa(dp11762
g7
I11
sg23
VC0002994
p11763
sg10
I10
sg11
Vangioedema
p11764
sg13
I1
sa(dp11765
g7
I23
sg23
VC0019243
p11766
sg10
I3
sg11
VHAE
p11767
sg13
I1
sasa(dp11768
g2
S'Hereditary angioedema (HAE) is a rare, life-threatening, autosomal dominant disease characterized by recurrent episodes of angioedema, and caused by a deficiency of the plasma protein C1-esterase inhibitor (C1-INH).\n'
p11769
sg4
(lp11770
(dp11771
g7
I169
sg8
VP22760
p11772
sg10
I36
sg11
Vplasma protein C1-esterase inhibitor
p11773
sg13
I4
sa(dp11774
g7
I207
sg8
VP05111
p11775
sg10
I6
sg11
VC1-INH
p11776
sg13
I1
sasg20
(lp11777
(dp11778
g7
I0
sg23
VC0019243
p11779
sg10
I21
sg11
VHereditary angioedema
p11780
sg13
I2
sa(dp11781
g7
I11
sg23
VC0002994
p11782
sg10
I10
sg11
Vangioedema
p11783
sg13
I1
sa(dp11784
g7
I23
sg23
VC0019243
p11785
sg10
I3
sg11
VHAE
p11786
sg13
I1
sasa(dp11787
g2
S'Hereditary angioedema (HAE) is an autosomal dominant disease characterized by recurrent episodes of angioedema, and caused by a deficiency of the plasma protein C1 inhibitor.\n'
p11788
sg4
(lp11789
sg20
(lp11790
(dp11791
g7
I0
sg23
VC0019243
p11792
sg10
I21
sg11
VHereditary angioedema
p11793
sg13
I2
sa(dp11794
g7
I23
sg23
VC0019243
p11795
sg10
I3
sg11
VHAE
p11796
sg13
I1
sa(dp11797
g7
I11
sg23
VC0002994
p11798
sg10
I10
sg11
Vangioedema
p11799
sg13
I1
sasa(dp11800
g2
S'To assess the use of serum levels of angiopoietin-1 (Ang1), Ang2 and tumor necrosis factor-Alfa (TNFAlfa) as predictive factors for small bowel angiodysplasia (SBA).\n'
p11801
sg4
(lp11802
(dp11803
g7
I69
sg8
VP01375
p11804
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p11805
sg13
I3
sa(dp11806
g7
I97
sg8
VP01375
p11807
sg10
I7
sg11
VTNFAlfa
p11808
sg13
I1
sa(dp11809
g7
I60
sg8
g39
sg10
I4
sg11
VAng2
p11810
sg13
I1
sa(dp11811
g7
I53
sg8
g39
sg10
I4
sg11
VAng1
p11812
sg13
I1
sa(dp11813
g7
I37
sg8
g39
sg10
I14
sg11
Vangiopoietin-1
p11814
sg13
I1
sasg20
(lp11815
(dp11816
g7
I69
sg23
VC0333516
p11817
sg10
I14
sg11
Vtumor necrosis
p11818
sg13
I2
sa(dp11819
g7
I144
sg23
VC0085411
p11820
sg10
I14
sg11
Vangiodysplasia
p11821
sg13
I1
sasa(dp11822
g2
S'Gene expression levels of Ang-1, Ang-2, and their receptor Tie2 were all significantly higher in biopsies from areas of angiodysplasia compared with normal small bowel.\n'
p11823
sg4
(lp11824
(dp11825
g7
I59
sg8
g39
sg10
I4
sg11
VTie2
p11826
sg13
I1
sa(dp11827
g7
I33
sg8
VP03950
p11828
sg10
I5
sg11
VAng-2
p11829
sg13
I1
sa(dp11830
g7
I26
sg8
VP03950
p11831
sg10
I5
sg11
VAng-1
p11832
sg13
I1
sasg20
(lp11833
(dp11834
g7
I120
sg23
VC0085411
p11835
sg10
I14
sg11
Vangiodysplasia
p11836
sg13
I1
sasa(dp11837
g2
S'We undertook this study to find new members of the cancer-testis gene family appropriate for cancer immunotherapy We analyzed the expression of six testis-specific genes called ODF1, ODF2, ODF3, ODF4, LEMD1 and SPATA19 in 30 prostate cancer and 25 benign prostate hyperplasia (BPH) samples by RT-PCR and restriction fragment length polymorphism (RFLP).\n'
p11838
sg4
(lp11839
(dp11840
g7
I189
sg8
g39
sg10
I4
sg11
VODF3
p11841
sg13
I1
sa(dp11842
g7
I195
sg8
g39
sg10
I4
sg11
VODF4
p11843
sg13
I1
sa(dp11844
g7
I177
sg8
g39
sg10
I4
sg11
VODF1
p11845
sg13
I1
sa(dp11846
g7
I211
sg8
g39
sg10
I7
sg11
VSPATA19
p11847
sg13
I1
sa(dp11848
g7
I201
sg8
g39
sg10
I5
sg11
VLEMD1
p11849
sg13
I1
sa(dp11850
g7
I183
sg8
g39
sg10
I4
sg11
VODF2
p11851
sg13
I1
sasg20
(lp11852
(dp11853
g7
I277
sg23
VC0005001
p11854
sg10
I3
sg11
VBPH
p11855
sg13
I1
sa(dp11856
g7
I225
sg23
VC0600139
p11857
sg10
I15
sg11
Vprostate cancer
p11858
sg13
I2
sa(dp11859
g7
I51
sg23
VC0006826
p11860
sg10
I6
sg11
Vcancer
p11861
sg13
I1
sa(dp11862
g7
I248
sg23
VC0005001
p11863
sg10
I27
sg11
Vbenign prostate hyperplasia
p11864
sg13
I3
sa(dp11865
g7
I51
sg23
VC0006826
p11866
sg10
I6
sg11
Vcancer
p11867
sg13
I1
sasa(dp11868
g2
S'Of the prostate cancer samples, 10, 10, 23 and 40% showed ODF1, ODF2, LEMD1 and SPATA19 specific bands, respectively, but none of the BPH samples expressed any of these genes.\n'
p11869
sg4
(lp11870
(dp11871
g7
I70
sg8
g39
sg10
I5
sg11
VLEMD1
p11872
sg13
I1
sa(dp11873
g7
I80
sg8
g39
sg10
I7
sg11
VSPATA19
p11874
sg13
I1
sa(dp11875
g7
I58
sg8
g39
sg10
I4
sg11
VODF1
p11876
sg13
I1
sa(dp11877
g7
I64
sg8
g39
sg10
I4
sg11
VODF2
p11878
sg13
I1
sasg20
(lp11879
(dp11880
g7
I134
sg23
VC0005001
p11881
sg10
I3
sg11
VBPH
p11882
sg13
I1
sa(dp11883
g7
I7
sg23
VC0600139
p11884
sg10
I15
sg11
Vprostate cancer
p11885
sg13
I2
sasa(dp11886
g2
S'ODF1, ODF2, SPATA19 and LEMD1 are members of cancer-testis gene family.\n'
p11887
sg4
(lp11888
(dp11889
g7
I12
sg8
g39
sg10
I7
sg11
VSPATA19
p11890
sg13
I1
sa(dp11891
g7
I6
sg8
g39
sg10
I4
sg11
VODF2
p11892
sg13
I1
sa(dp11893
g7
I24
sg8
g39
sg10
I5
sg11
VLEMD1
p11894
sg13
I1
sa(dp11895
g7
I0
sg8
g39
sg10
I4
sg11
VODF1
p11896
sg13
I1
sa(dp11897
g7
I45
sg8
VP15735
p11898
sg10
I25
sg11
Vcancer-testis gene family
p11899
sg13
I3
sasg20
(lp11900
(dp11901
g7
I45
sg23
VC0006826
p11902
sg10
I6
sg11
Vcancer
p11903
sg13
I1
sasa(dp11904
g2
S'To identify the miRNA signature that was specific for oral squamous cell carcinoma (OSCC), we first examined expression profiles of 148 miRNAs in a panel of 18 OSCC cell lines and the immortalized oral keratinocyte line RT7 as a control.\n'
p11905
sg4
(lp11906
sg20
(lp11907
(dp11908
g7
I54
sg23
VC0007137
p11909
sg10
I28
sg11
Voral squamous cell carcinoma
p11910
sg13
I4
sa(dp11911
g7
I84
sg23
VC0007137
p11912
sg10
I4
sg11
VOSCC
p11913
sg13
I1
sa(dp11914
g7
I84
sg23
VC0007137
p11915
sg10
I4
sg11
VOSCC
p11916
sg13
I1
sasa(dp11917
g2
S'Compared with RT7, the expression of 54 miRNAs (36.5%) was frequently down-regulated in OSCC lines (&lt;0.5-fold expression, &gt;or=66.7% of 18 lines).\n'
p11918
sg4
(lp11919
(dp11920
g7
I14
sg8
g39
sg10
I3
sg11
VRT7
p11921
sg13
I1
sasg20
(lp11922
sa(dp11923
g2
S'Pain conditions included neuropathic pain, fibromyalgia, complex regional pain syndrome (CRPS) type I and post-surgical chronic back and leg pain (CBLP).\n'
p11924
sg4
(lp11925
sg20
(lp11926
(dp11927
g7
I25
sg23
VC0027796
p11928
sg10
I16
sg11
Vneuropathic pain
p11929
sg13
I2
sa(dp11930
g7
I89
sg23
VC0458219
p11931
sg10
I4
sg11
VCRPS
p11932
sg13
I1
sa(dp11933
g7
I137
sg23
VC0023222
p11934
sg10
I8
sg11
Vleg pain
p11935
sg13
I2
sa(dp11936
g7
I43
sg23
VC0016053
p11937
sg10
I12
sg11
Vfibromyalgia
p11938
sg13
I1
sa(dp11939
g7
I57
sg23
VC0458219
p11940
sg10
I30
sg11
Vcomplex regional pain syndrome
p11941
sg13
I4
sasa(dp11942
g2
S"The following recommendations were reached: 'weak' for SCS added to conventional medical management in diabetic painful neuropathy, CBLP and CRPS, for SCS versus reoperation in CBLP, for MCS in neuropathic pain, for rTMS of M1 in neuropathic pain and fibromyalgia and for tDCS of M1 in neuropathic pain; 'inconclusive' for DBS in neuropathic pain, rTMS and tDCS of the DLPFC, and for motor cortex tDCS in fibromyalgia and spinal cord injury pain.\n"
p11943
sg4
(lp11944
sg20
(lp11945
(dp11946
g7
I120
sg23
VC0442874
p11947
sg10
I10
sg11
Vneuropathy
p11948
sg13
I1
sa(dp11949
g7
I194
sg23
VC0027796
p11950
sg10
I16
sg11
Vneuropathic pain
p11951
sg13
I2
sa(dp11952
g7
I429
sg23
VC0035334
p11953
sg10
I4
sg11
Vcord
p11954
sg13
I1
sa(dp11955
g7
I251
sg23
VC0016053
p11956
sg10
I12
sg11
Vfibromyalgia
p11957
sg13
I1
sa(dp11958
g7
I251
sg23
VC0016053
p11959
sg10
I12
sg11
Vfibromyalgia
p11960
sg13
I1
sa(dp11961
g7
I194
sg23
VC0027796
p11962
sg10
I16
sg11
Vneuropathic pain
p11963
sg13
I2
sa(dp11964
g7
I55
sg23
VC0175699
p11965
sg10
I3
sg11
VSCS
p11966
sg13
I1
sa(dp11967
g7
I194
sg23
VC0027796
p11968
sg10
I16
sg11
Vneuropathic pain
p11969
sg13
I2
sa(dp11970
g7
I141
sg23
VC0458219
p11971
sg10
I4
sg11
VCRPS
p11972
sg13
I1
sa(dp11973
g7
I55
sg23
VC0175699
p11974
sg10
I3
sg11
VSCS
p11975
sg13
I1
sa(dp11976
g7
I187
sg23
VC0036221
p11977
sg10
I3
sg11
VMCS
p11978
sg13
I1
sa(dp11979
g7
I194
sg23
VC0027796
p11980
sg10
I16
sg11
Vneuropathic pain
p11981
sg13
I2
sa(dp11982
g7
I112
sg23
VC0030193
p11983
sg10
I7
sg11
Vpainful
p11984
sg13
I1
sasa(dp11985
g2
S'The aim is to assess the ability to discriminate words, using two psychoacoustic verbal tests of central auditory processes in Spanish: Binaural Fusion Test (BFT in its Spanish version) and Filtered Word Test (FWT in its Spanish version) in children with dyslexia and controls.\n'
p11986
sg4
(lp11987
sg20
(lp11988
(dp11989
g7
I255
sg23
VC0476254
p11990
sg10
I8
sg11
Vdyslexia
p11991
sg13
I1
sasa(dp11992
g2
S'Anemia grade 2 was seen in 16.0%, neutropenia grade 3 in 8.0% and thrombocytopenia grade 3 in 24.0% of patients, respectively.\n'
p11993
sg4
(lp11994
sg20
(lp11995
(dp11996
g7
I0
sg23
VC0002871
p11997
sg10
I6
sg11
VAnemia
p11998
sg13
I1
sasa(dp11999
g2
S'Thrombocytopenia occurred in 56% of the dogs (grade 1 in 3 dogs, grade 2 in 6 dogs, grade 3 in 7 dogs, and grade 4 in 7 dogs) and neutropenia in 17% of the dogs (grade 2 in 1 dog, grade 3 in 2 dogs, and grade 4 in 4 dogs).\n'
p12000
sg4
(lp12001
sg20
(lp12002
sa(dp12003
g2
S'Hematological toxicity: leucopenia grade 3 or 4 in 21/75 courses; thrombocytopenia grade 3 in 8/75 courses; infectious episodes grade 2 or 3 in 7/75 courses.\n'
p12004
sg4
(lp12005
sg20
(lp12006
(dp12007
g7
I108
sg23
VC0009450
p12008
sg10
I10
sg11
Vinfectious
p12009
sg13
I1
sa(dp12010
g7
I24
sg23
VC0023530
p12011
sg10
I10
sg11
Vleucopenia
p12012
sg13
I1
sasa(dp12013
g2
S'Neutropenia was grade 3 in 8.6% of patients and grade 4 in 5.2% of patients, and thrombocytopenia was grade 3 in 17.2% of patients and grade 4 in 12% of patients; hepatic and pulmonary toxic effects were grade 3 in 5.2% and 8.6% of patients, respectively.\n'
p12014
sg4
(lp12015
sg20
(lp12016
sa(dp12017
g2
S'The chief toxicity was bone marrow suppression, with grade 4 granulocytopenia in 20 patients, grade 3 in 7 patients, and grade 3 and 4 thrombocytopenia in 5 patients.\n'
p12018
sg4
(lp12019
sg20
(lp12020
(dp12021
g7
I35
sg23
VC0221103
p12022
sg10
I11
sg11
Vsuppression
p12023
sg13
I1
sa(dp12024
g7
I61
sg23
VC0001824
p12025
sg10
I16
sg11
Vgranulocytopenia
p12026
sg13
I1
sasa(dp12027
g2
S'Furthermore, ephrinB1 depletion by siRNA suppresses EphB2-Fc-induced RhoA activation, and reduces motility and invasiveness of the SW480 and Hs578T human cancer cell lines.\n'
p12028
sg4
(lp12029
(dp12030
g7
I13
sg8
VP98172
p12031
sg10
I8
sg11
VephrinB1
p12032
sg13
I1
sa(dp12033
g7
I69
sg8
VP61586
p12034
sg10
I4
sg11
VRhoA
p12035
sg13
I1
sa(dp12036
g7
I52
sg8
VP52799
p12037
sg10
I5
sg11
VEphB2
p12038
sg13
I1
sasg20
(lp12039
(dp12040
g7
I154
sg23
VC0006826
p12041
sg10
I6
sg11
Vcancer
p12042
sg13
I1
sasa(dp12043
g2
S'In the current study, we investigated whether EphB2 knockdown in combination with radiation can alter invasiveness and decrease medulloblastoma tumor growth or viability in vitro.\n'
p12044
sg4
(lp12045
(dp12046
g7
I46
sg8
VP52799
p12047
sg10
I5
sg11
VEphB2
p12048
sg13
I1
sasg20
(lp12049
(dp12050
g7
I128
sg23
VC0025149
p12051
sg10
I15
sg11
Vmedulloblastoma
p12052
sg13
I1
sa(dp12053
g7
I144
sg23
VC0598934
p12054
sg10
I12
sg11
Vtumor growth
p12055
sg13
I2
sasa(dp12056
g2
S'The radiosensitization effect following EphB2 knockdown was determined by clonogenic assay in human medulloblastoma cells.\n'
p12057
sg4
(lp12058
(dp12059
g7
I40
sg8
VP52799
p12060
sg10
I5
sg11
VEphB2
p12061
sg13
I1
sasg20
(lp12062
(dp12063
g7
I100
sg23
VC0025149
p12064
sg10
I15
sg11
Vmedulloblastoma
p12065
sg13
I1
sasa(dp12066
g2
S'We observed that EphB2 is expressed in both medulloblastoma cell lines and patient samples and its downregulation sensitized these cells to radiation as evident by decreased clonogenic survival fractions.\n'
p12067
sg4
(lp12068
(dp12069
g7
I17
sg8
VP52799
p12070
sg10
I5
sg11
VEphB2
p12071
sg13
I1
sasg20
(lp12072
(dp12073
g7
I44
sg23
VC0025149
p12074
sg10
I15
sg11
Vmedulloblastoma
p12075
sg13
I1
sasa(dp12076
g2
S'EphB2 expression was also high across different medulloblastoma subgroups compared to normal cerebellum.\n'
p12077
sg4
(lp12078
(dp12079
g7
I0
sg8
VP52799
p12080
sg10
I5
sg11
VEphB2
p12081
sg13
I1
sasg20
(lp12082
(dp12083
g7
I48
sg23
VC0025149
p12084
sg10
I15
sg11
Vmedulloblastoma
p12085
sg13
I1
sasa(dp12086
g2
S'We also found that the combined approach of EphB2 knockdown and radiation exposure significantly reduced overall cell viability in medulloblastoma cells compared to control groups.\n'
p12087
sg4
(lp12088
(dp12089
g7
I44
sg8
VP52799
p12090
sg10
I5
sg11
VEphB2
p12091
sg13
I1
sasg20
(lp12092
(dp12093
g7
I131
sg23
VC0025149
p12094
sg10
I15
sg11
Vmedulloblastoma
p12095
sg13
I1
sasa(dp12096
g2
S'Overall, our findings indicate that specific targeting of EphB2 receptor in combination with radiation may serve as an effective therapeutic strategy in medulloblastoma.\n'
p12097
sg4
(lp12098
(dp12099
g7
I58
sg8
VP52799
p12100
sg10
I14
sg11
VEphB2 receptor
p12101
sg13
I2
sasg20
(lp12102
(dp12103
g7
I153
sg23
VC0025149
p12104
sg10
I15
sg11
Vmedulloblastoma
p12105
sg13
I1
sasa(dp12106
g2
S'However, the expression levels and clinical significances of junctional adhesion molecule-A, a member of junctional adhesion molecules, and EphB2, a member of Eph/ephrin family, in lung adenocarcinoma patients are unclear.\n'
p12107
sg4
(lp12108
(dp12109
g7
I140
sg8
VP21709
p12110
sg10
I3
sg11
VEph
p12111
sg13
I1
sa(dp12112
g7
I140
sg8
VP52799
p12113
sg10
I5
sg11
VEphB2
p12114
sg13
I1
sasg20
(lp12115
(dp12116
g7
I181
sg23
VC0152013
p12117
sg10
I19
sg11
Vlung adenocarcinoma
p12118
sg13
I2
sa(dp12119
g7
I72
sg23
VC0001511
p12120
sg10
I8
sg11
Vadhesion
p12121
sg13
I1
sa(dp12122
g7
I72
sg23
VC0001511
p12123
sg10
I8
sg11
Vadhesion
p12124
sg13
I1
sasa(dp12125
g2
S"Therefore, in this study, we aimed to identify the expression and prognostic values of junctional adhesion molecule-A and EphB2 in lung adenocarcinoma patients' cohort.\n"
p12126
sg4
(lp12127
(dp12128
g7
I122
sg8
VP52799
p12129
sg10
I5
sg11
VEphB2
p12130
sg13
I1
sasg20
(lp12131
(dp12132
g7
I131
sg23
VC0152013
p12133
sg10
I19
sg11
Vlung adenocarcinoma
p12134
sg13
I2
sa(dp12135
g7
I98
sg23
VC0001511
p12136
sg10
I8
sg11
Vadhesion
p12137
sg13
I1
sasa(dp12138
g2
S'In our study, 70 (55.6%) showed high expression of junctional adhesion molecule-A protein and 51 (40.5%) showed high expression of EphB2 protein in 126 lung adenocarcinoma tissues.\n'
p12139
sg4
(lp12140
(dp12141
g7
I131
sg8
VP52799
p12142
sg10
I13
sg11
VEphB2 protein
p12143
sg13
I2
sasg20
(lp12144
(dp12145
g7
I62
sg23
VC0001511
p12146
sg10
I8
sg11
Vadhesion
p12147
sg13
I1
sa(dp12148
g7
I152
sg23
VC0152013
p12149
sg10
I19
sg11
Vlung adenocarcinoma
p12150
sg13
I2
sasa(dp12151
g2
S'Junctional adhesion molecule-A and EphB2 expressions were both significantly increased in tumor tissues compared with noncancerous lung tissues.\n'
p12152
sg4
(lp12153
(dp12154
g7
I0
sg8
g39
sg10
I30
sg11
VJunctional adhesion molecule-A
p12155
sg13
I3
sa(dp12156
g7
I35
sg8
VP52799
p12157
sg10
I5
sg11
VEphB2
p12158
sg13
I1
sasg20
(lp12159
(dp12160
g7
I90
sg23
VC0027651
p12161
sg10
I5
sg11
Vtumor
p12162
sg13
I1
sa(dp12163
g7
I11
sg23
VC0001511
p12164
sg10
I8
sg11
Vadhesion
p12165
sg13
I1
sasa(dp12166
g2
S'Kaplan-Meier analysis and log-rank test indicated that low expression of junctional adhesion molecule-A and EphB2 proteins can predict better survival and low mortality rate of lung adenocarcinomas.\n'
p12167
sg4
(lp12168
(dp12169
g7
I108
sg8
VP52799
p12170
sg10
I14
sg11
VEphB2 proteins
p12171
sg13
I2
sa(dp12172
g7
I73
sg8
g39
sg10
I30
sg11
Vjunctional adhesion molecule-A
p12173
sg13
I3
sasg20
(lp12174
(dp12175
g7
I84
sg23
VC0001511
p12176
sg10
I8
sg11
Vadhesion
p12177
sg13
I1
sa(dp12178
g7
I182
sg23
VC0001418
p12179
sg10
I15
sg11
Vadenocarcinomas
p12180
sg13
I1
sasa(dp12181
g2
S'In univariate analysis, high expression levels of junctional adhesion molecule-A and EphB2 were both found to be significantly correlated with poor overall survival of lung adenocarcinoma patients (hazard ratio = 1.791, 95% confidence interval = 1.041-3.084, p = 0.035; hazard ratio = 1.762, 95% confidence interval = 1.038-2.992, p = 0.036, respectively).\n'
p12182
sg4
(lp12183
(dp12184
g7
I50
sg8
g39
sg10
I30
sg11
Vjunctional adhesion molecule-A
p12185
sg13
I3
sa(dp12186
g7
I85
sg8
VP52799
p12187
sg10
I5
sg11
VEphB2
p12188
sg13
I1
sasg20
(lp12189
(dp12190
g7
I61
sg23
VC0001511
p12191
sg10
I8
sg11
Vadhesion
p12192
sg13
I1
sa(dp12193
g7
I168
sg23
VC0152013
p12194
sg10
I19
sg11
Vlung adenocarcinoma
p12195
sg13
I2
sasa(dp12196
g2
S'The multivariate Cox proportional hazard model demonstrated that EphB2 expression is an independent prognosis parameter in lung adenocarcinoma patients (hazard ratio = 1.738, 95% confidence interval = 1.023-2.952, p = 0.016).\n'
p12197
sg4
(lp12198
(dp12199
g7
I65
sg8
VP52799
p12200
sg10
I5
sg11
VEphB2
p12201
sg13
I1
sasg20
(lp12202
(dp12203
g7
I123
sg23
VC0152013
p12204
sg10
I19
sg11
Vlung adenocarcinoma
p12205
sg13
I2
sasa(dp12206
g2
S'Taken together, high expression of junctional adhesion molecule-A and EphB2 can predict poor overall survival and high mortality rate, and EphB2 is an independent prognostic biomarker in lung adenocarcinoma patients.\n'
p12207
sg4
(lp12208
(dp12209
g7
I70
sg8
VP52799
p12210
sg10
I5
sg11
VEphB2
p12211
sg13
I1
sa(dp12212
g7
I70
sg8
VP52799
p12213
sg10
I5
sg11
VEphB2
p12214
sg13
I1
sa(dp12215
g7
I35
sg8
g39
sg10
I30
sg11
Vjunctional adhesion molecule-A
p12216
sg13
I3
sasg20
(lp12217
(dp12218
g7
I46
sg23
VC0001511
p12219
sg10
I8
sg11
Vadhesion
p12220
sg13
I1
sa(dp12221
g7
I187
sg23
VC0152013
p12222
sg10
I19
sg11
Vlung adenocarcinoma
p12223
sg13
I2
sasa(dp12224
g2
S'Four of the six patients with aNTs underwent Kausch-Whipple procedure, one patient ampullectomy (gangliocytic paraganglioma) and one patient palliative chemotherapy.\n'
p12225
sg4
(lp12226
sg20
(lp12227
(dp12228
g7
I97
sg23
VC0030421
p12229
sg10
I26
sg11
Vgangliocytic paraganglioma
p12230
sg13
I2
sasa(dp12231
g2
S'Toll-like receptors (TLR), especially TLR3, 7 and 9, play an important role in the pathogenesis of systemic lupus erythematosus (SLE).\n'
p12232
sg4
(lp12233
(dp12234
g7
I38
sg8
g39
sg10
I4
sg11
VTLR3
p12235
sg13
I1
sa(dp12236
g7
I21
sg8
g39
sg10
I3
sg11
VTLR
p12237
sg13
I1
sa(dp12238
g7
I0
sg8
g39
sg10
I19
sg11
VToll-like receptors
p12239
sg13
I2
sasg20
(lp12240
(dp12241
g7
I129
sg23
VC0024141
p12242
sg10
I3
sg11
VSLE
p12243
sg13
I1
sa(dp12244
g7
I99
sg23
VC0024141
p12245
sg10
I28
sg11
Vsystemic lupus erythematosus
p12246
sg13
I3
sa(dp12247
g7
I83
sg23
VC0699748
p12248
sg10
I12
sg11
Vpathogenesis
p12249
sg13
I1
sasa(dp12250
g2
S'Alstroem syndrome is an autosomal recessive disorder characterized by hearing loss, blindness, obesity, non-insulin dependent diabetes, and others.\n'
p12251
sg4
(lp12252
(dp12253
g7
I108
sg8
VP01308
p12254
sg10
I7
sg11
Vinsulin
p12255
sg13
I1
sasg20
(lp12256
(dp12257
g7
I0
sg23
VC0268425
p12258
sg10
I17
sg11
VAlstroem syndrome
p12259
sg13
I2
sa(dp12260
g7
I104
sg23
VC0011860
p12261
sg10
I30
sg11
Vnon-insulin dependent diabetes
p12262
sg13
I3
sa(dp12263
g7
I84
sg23
VC0456909
p12264
sg10
I9
sg11
Vblindness
p12265
sg13
I1
sa(dp12266
g7
I70
sg23
VC0011053
p12267
sg10
I12
sg11
Vhearing loss
p12268
sg13
I2
sa(dp12269
g7
I95
sg23
VC0028754
p12270
sg10
I7
sg11
Vobesity
p12271
sg13
I1
sasa(dp12272
g2
S'A number of known inherited syndromes, such as ataxia telangiectasia, ataxia-telangiectasia like-disorder, radiosensitive severe combined immunodeficiency, Nijmegen breakage syndrome, and LIG4 deficiency are associated with increased radiosensitivity and/or cancer risk.\n'
p12273
sg4
(lp12274
(dp12275
g7
I188
sg8
VP49917
p12276
sg10
I4
sg11
VLIG4
p12277
sg13
I1
sasg20
(lp12278
(dp12279
g7
I122
sg23
VC0085110
p12280
sg10
I32
sg11
Vsevere combined immunodeficiency
p12281
sg13
I3
sa(dp12282
g7
I28
sg23
VC0039082
p12283
sg10
I9
sg11
Vsyndromes
p12284
sg13
I1
sa(dp12285
g7
I70
sg23
VC0004135
p12286
sg10
I21
sg11
Vataxia-telangiectasia
p12287
sg13
I1
sa(dp12288
g7
I258
sg23
VC0006826
p12289
sg10
I6
sg11
Vcancer
p12290
sg13
I1
sa(dp12291
g7
I156
sg23
VC0398791
p12292
sg10
I26
sg11
VNijmegen breakage syndrome
p12293
sg13
I3
sa(dp12294
g7
I47
sg23
VC0004135
p12295
sg10
I21
sg11
Vataxia telangiectasia
p12296
sg13
I2
sasa(dp12297
g2
S'Cellular radiosensitivity in the absence of clinical manifestations of Ataxia telangiectasia lead to the diagnosis of DNA ligase IV (LIG4) deficiency syndrome, confirmed by compound heterozygous mutations in the LIG4 gene.\n'
p12298
sg4
(lp12299
(dp12300
g7
I118
sg8
VP49917
p12301
sg10
I13
sg11
VDNA ligase IV
p12302
sg13
I3
sa(dp12303
g7
I133
sg8
VP49917
p12304
sg10
I4
sg11
VLIG4
p12305
sg13
I1
sa(dp12306
g7
I212
sg8
VP49917
p12307
sg10
I9
sg11
VLIG4 gene
p12308
sg13
I2
sasg20
(lp12309
(dp12310
g7
I71
sg23
VC0004135
p12311
sg10
I21
sg11
VAtaxia telangiectasia
p12312
sg13
I2
sa(dp12313
g7
I150
sg23
VC0039082
p12314
sg10
I8
sg11
Vsyndrome
p12315
sg13
I1
sasa(dp12316
g2
S'Cellular hypersensitivity was confirmed in vitro and attributed to the ataxia-telangiectasia (A-T) gene in cases I and II, a newly described defect in the DNA ligase 4 gene in case III, and a novel and as yet incompletely defined, molecular defect in case IV who presented with xeroderma pigmentosum (XP).\n'
p12317
sg4
(lp12318
(dp12319
g7
I155
sg8
VP49917
p12320
sg10
I17
sg11
VDNA ligase 4 gene
p12321
sg13
I4
sasg20
(lp12322
(dp12323
g7
I301
sg23
VC0043346
p12324
sg10
I2
sg11
VXP
p12325
sg13
I1
sa(dp12326
g7
I278
sg23
VC0043346
p12327
sg10
I21
sg11
Vxeroderma pigmentosum
p12328
sg13
I2
sa(dp12329
g7
I94
sg23
VC0004135
p12330
sg10
I3
sg11
VA-T
p12331
sg13
I1
sa(dp12332
g7
I9
sg23
VC0020517
p12333
sg10
I16
sg11
Vhypersensitivity
p12334
sg13
I1
sa(dp12335
g7
I71
sg23
VC0004135
p12336
sg10
I21
sg11
Vataxia-telangiectasia
p12337
sg13
I1
sasa(dp12338
g2
S'To detect new predictive markers from the prostate cancer tissue, to study the expression by cultured cancer-associated fibroblasts (CAFs) of stromal factors implicated in prostate carcinogenesis, and to compare their expressions in localized, metastatic, castration-sensitive (CSCP), castration-resistant prostate tumors (CRCP) as well as in fibroblasts from benign prostatic hyperplasia (BPH).\n'
p12339
sg4
(lp12340
sg20
(lp12341
(dp12342
g7
I390
sg23
VC0005001
p12343
sg10
I3
sg11
VBPH
p12344
sg13
I1
sa(dp12345
g7
I133
sg23
VC0795907
p12346
sg10
I4
sg11
VCAFs
p12347
sg13
I1
sa(dp12348
g7
I181
sg23
VC0596263
p12349
sg10
I14
sg11
Vcarcinogenesis
p12350
sg13
I1
sa(dp12351
g7
I306
sg23
VC0033578
p12352
sg10
I15
sg11
Vprostate tumors
p12353
sg13
I2
sa(dp12354
g7
I42
sg23
VC0600139
p12355
sg10
I15
sg11
Vprostate cancer
p12356
sg13
I2
sa(dp12357
g7
I102
sg23
VC0795907
p12358
sg10
I29
sg11
Vcancer-associated fibroblasts
p12359
sg13
I2
sa(dp12360
g7
I360
sg23
VC0005001
p12361
sg10
I28
sg11
Vbenign prostatic hyperplasia
p12362
sg13
I3
sasa(dp12363
g2
S'The goal of this study was to determine the risk of special adverse events related to CYP- 17 inhibitor in patients with metastatic castration-resistant prostate cancer (CRCP).\n'
p12364
sg4
(lp12365
(dp12366
g7
I86
sg8
g39
sg10
I7
sg11
VCYP- 17
p12367
sg13
I2
sasg20
(lp12368
(dp12369
g7
I153
sg23
VC0600139
p12370
sg10
I15
sg11
Vprostate cancer
p12371
sg13
I2
sasa(dp12372
g2
S'Despite the initial response, patients typically relapse with a more aggressive form described as castration-resistant prostate cancer (CRCP), driven by continued androgen receptor (AR) signaling.\n'
p12373
sg4
(lp12374
(dp12375
g7
I182
sg8
VP10275
p12376
sg10
I2
sg11
VAR
p12377
sg13
I1
sa(dp12378
g7
I163
sg8
VP10275
p12379
sg10
I17
sg11
Vandrogen receptor
p12380
sg13
I2
sasg20
(lp12381
(dp12382
g7
I69
sg23
VC0001807
p12383
sg10
I10
sg11
Vaggressive
p12384
sg13
I1
sa(dp12385
g7
I119
sg23
VC0600139
p12386
sg10
I15
sg11
Vprostate cancer
p12387
sg13
I2
sa(dp12388
g7
I49
sg23
VC0277556
p12389
sg10
I7
sg11
Vrelapse
p12390
sg13
I1
sasa(dp12391
g2
S'In CRCP, prostate cancer cells still rely on intracellular androgens and, to a greater extent, on active AR for growth and survival.\n'
p12392
sg4
(lp12393
(dp12394
g7
I3
sg8
g39
sg10
I4
sg11
VCRCP
p12395
sg13
I1
sasg20
(lp12396
(dp12397
g7
I9
sg23
VC0600139
p12398
sg10
I15
sg11
Vprostate cancer
p12399
sg13
I2
sasa(dp12400
g2
S'We previously reported that the intronic tagSNP +357G/C in the metastasis suppressor HTPAP is associated with metastasis and prognosis of hepatocellular carcinoma (HCC).\n'
p12401
sg4
(lp12402
sg20
(lp12403
(dp12404
g7
I63
sg23
VC0027627
p12405
sg10
I10
sg11
Vmetastasis
p12406
sg13
I1
sa(dp12407
g7
I138
sg23
VC2239176
p12408
sg10
I24
sg11
Vhepatocellular carcinoma
p12409
sg13
I2
sa(dp12410
g7
I164
sg23
VC2239176
p12411
sg10
I3
sg11
VHCC
p12412
sg13
I1
sa(dp12413
g7
I63
sg23
VC0027627
p12414
sg10
I10
sg11
Vmetastasis
p12415
sg13
I1
sasa(dp12416
g2
S'By using publicly available genomic data from a panel of 883 cell lines derived from different cancers, we identified the cell lines presenting amplification of both WHSC1L1 and PPAPDC1B.\n'
p12417
sg4
(lp12418
(dp12419
g7
I178
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12420
sg13
I1
sa(dp12421
g7
I166
sg8
g39
sg10
I7
sg11
VWHSC1L1
p12422
sg13
I1
sasg20
(lp12423
(dp12424
g7
I144
sg23
VC1705759
p12425
sg10
I13
sg11
Vamplification
p12426
sg13
I1
sa(dp12427
g7
I95
sg23
VC0006826
p12428
sg10
I7
sg11
Vcancers
p12429
sg13
I1
sasa(dp12430
g2
S'In particular, we focused on cell lines derived from lung cancer and pancreatic adenocarcinoma and found a correlation between the amplification of PPAPDC1B and WHSC1L1 with their overexpression.\n'
p12431
sg4
(lp12432
(dp12433
g7
I148
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12434
sg13
I1
sa(dp12435
g7
I161
sg8
g39
sg10
I7
sg11
VWHSC1L1
p12436
sg13
I1
sasg20
(lp12437
(dp12438
g7
I69
sg23
VC0281361
p12439
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12440
sg13
I2
sa(dp12441
g7
I53
sg23
VC0684249
p12442
sg10
I11
sg11
Vlung cancer
p12443
sg13
I2
sa(dp12444
g7
I131
sg23
VC1705759
p12445
sg10
I13
sg11
Vamplification
p12446
sg13
I1
sasa(dp12447
g2
S'Loss-of-function studies based on the use of siRNA and shRNA demonstrated that PPAPDC1B and WHSC1L1 played a major role in regulating the survival of pancreatic adenocarcinoma and small-cell lung cancer-derived cell lines, both in anchorage-dependent and anchorage-independent conditions, displaying amplification and overexpression of these genes.\n'
p12448
sg4
(lp12449
(dp12450
g7
I79
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12451
sg13
I1
sa(dp12452
g7
I92
sg8
g39
sg10
I7
sg11
VWHSC1L1
p12453
sg13
I1
sasg20
(lp12454
(dp12455
g7
I300
sg23
VC1705759
p12456
sg10
I13
sg11
Vamplification
p12457
sg13
I1
sa(dp12458
g7
I191
sg23
VC0684249
p12459
sg10
I11
sg11
Vlung cancer
p12460
sg13
I2
sa(dp12461
g7
I150
sg23
VC0281361
p12462
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12463
sg13
I2
sasa(dp12464
g2
S'Finally, quantitative RT-PCR experiments after PPAPDC1B and WHSC1L1 knockdown revealed exclusive PPAPDC1B and WHSC1L1 gene targets in small-cell lung cancer and pancreatic adenocarcinoma-derived cell lines compared with breast cancer.\n'
p12465
sg4
(lp12466
(dp12467
g7
I60
sg8
g39
sg10
I7
sg11
VWHSC1L1
p12468
sg13
I1
sa(dp12469
g7
I47
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12470
sg13
I1
sa(dp12471
g7
I47
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12472
sg13
I1
sa(dp12473
g7
I110
sg8
g39
sg10
I12
sg11
VWHSC1L1 gene
p12474
sg13
I2
sasg20
(lp12475
(dp12476
g7
I145
sg23
VC0684249
p12477
sg10
I11
sg11
Vlung cancer
p12478
sg13
I2
sa(dp12479
g7
I220
sg23
VC0678222
p12480
sg10
I13
sg11
Vbreast cancer
p12481
sg13
I2
sa(dp12482
g7
I161
sg23
VC0281361
p12483
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12484
sg13
I2
sasa(dp12485
g2
S'The phosphatidic acid phosphatase HTPAP has been defined as a metastatic suppressor of hepatocellular carcinoma (HCC), but little is known about its function or potential applications as a prognostic marker.\n'
p12486
sg4
(lp12487
(dp12488
g7
I4
sg8
g39
sg10
I35
sg11
Vphosphatidic acid phosphatase HTPAP
p12489
sg13
I4
sasg20
(lp12490
(dp12491
g7
I113
sg23
VC2239176
p12492
sg10
I3
sg11
VHCC
p12493
sg13
I1
sa(dp12494
g7
I87
sg23
VC2239176
p12495
sg10
I24
sg11
Vhepatocellular carcinoma
p12496
sg13
I2
sasa(dp12497
g2
S'An analysis of comparative genomic hybridization array and expression profiling data for a series of 152 ductal breast carcinomas and 21 cell lines identified five genes (LSM1, BAG4, DDHD2, PPAPDC1B, and WHSC1L1) within the amplified region as consistently overexpressed due to an increased gene copy number.\n'
p12498
sg4
(lp12499
(dp12500
g7
I171
sg8
g39
sg10
I4
sg11
VLSM1
p12501
sg13
I1
sa(dp12502
g7
I177
sg8
g39
sg10
I4
sg11
VBAG4
p12503
sg13
I1
sa(dp12504
g7
I190
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12505
sg13
I1
sa(dp12506
g7
I204
sg8
g39
sg10
I7
sg11
VWHSC1L1
p12507
sg13
I1
sa(dp12508
g7
I183
sg8
g39
sg10
I5
sg11
VDDHD2
p12509
sg13
I1
sasg20
(lp12510
(dp12511
g7
I112
sg23
VC0678222
p12512
sg10
I17
sg11
Vbreast carcinomas
p12513
sg13
I2
sasa(dp12514
g2
S'The potential of PPAPDC1B, which encodes a transmembrane phosphatase, as a therapeutic target was further shown by the strong inhibition of growth of breast tumor xenografts displaying 8p11-12 amplification induced by the silencing of PPAPDC1B.\n'
p12515
sg4
(lp12516
(dp12517
g7
I17
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12518
sg13
I1
sa(dp12519
g7
I17
sg8
g39
sg10
I8
sg11
VPPAPDC1B
p12520
sg13
I1
sasg20
(lp12521
(dp12522
g7
I150
sg23
VC1458155
p12523
sg10
I12
sg11
Vbreast tumor
p12524
sg13
I2
sa(dp12525
g7
I193
sg23
VC1705759
p12526
sg10
I13
sg11
Vamplification
p12527
sg13
I1
sasa(dp12528
g2
S'The increased vulnerability to AF in FKBP12.6-/- mice substantiates the notion that defective SR Ca(2+) release caused by abnormal RyR2 and FKBP12.6 interactions may contribute to the initiation or maintenance of atrial fibrillation.\n'
p12529
sg4
(lp12530
(dp12531
g7
I37
sg8
VP62942
p12532
sg10
I6
sg11
VFKBP12
p12533
sg13
I1
sa(dp12534
g7
I131
sg8
g39
sg10
I4
sg11
VRyR2
p12535
sg13
I1
sa(dp12536
g7
I37
sg8
VP62942
p12537
sg10
I6
sg11
VFKBP12
p12538
sg13
I1
sasg20
(lp12539
(dp12540
g7
I213
sg23
VC0004238
p12541
sg10
I19
sg11
Vatrial fibrillation
p12542
sg13
I2
sasa(dp12543
g2
S'So, it is hypothesized that genetic alterations of SEPT12 may be concerned in male infertility.\n'
p12544
sg4
(lp12545
(dp12546
g7
I51
sg8
g39
sg10
I6
sg11
VSEPT12
p12547
sg13
I1
sasg20
(lp12548
(dp12549
g7
I78
sg23
VC0021364
p12550
sg10
I16
sg11
Vmale infertility
p12551
sg13
I2
sasa(dp12552
g2
S'The objective of this research is exploration of new single nucleotide polymorphism G5508A in the SEPT12 gene association with idiopathic male infertility in Iranian men.\n'
p12553
sg4
(lp12554
(dp12555
g7
I98
sg8
g39
sg10
I11
sg11
VSEPT12 gene
p12556
sg13
I2
sasg20
(lp12557
(dp12558
g7
I138
sg23
VC0021364
p12559
sg10
I16
sg11
Vmale infertility
p12560
sg13
I2
sasa(dp12561
g2
S'Taken together, our results demonstrate the molecular architecture of SEPT12 filaments at the sperm annulus, their mechanical support of sperm motility, and their correlation with male infertility.\n'
p12562
sg4
(lp12563
(dp12564
g7
I70
sg8
g39
sg10
I16
sg11
VSEPT12 filaments
p12565
sg13
I2
sasg20
(lp12566
(dp12567
g7
I180
sg23
VC0021364
p12568
sg10
I16
sg11
Vmale infertility
p12569
sg13
I2
sasa(dp12570
g2
S'This study provides the first causal link between SEPTIN12 genetic variant and male infertility with distinctive sperm pathology.\n'
p12571
sg4
(lp12572
sg20
(lp12573
(dp12574
g7
I79
sg23
VC0021364
p12575
sg10
I16
sg11
Vmale infertility
p12576
sg13
I2
sa(dp12577
g7
I119
sg23
VC0677042
p12578
sg10
I9
sg11
Vpathology
p12579
sg13
I1
sasa(dp12580
g2
S'To investigate the association between SEPTIN12 gene variants and the risk of azoospermia caused by meiotic arrest.\n'
p12581
sg4
(lp12582
sg20
(lp12583
(dp12584
g7
I78
sg23
VC1321542
p12585
sg10
I11
sg11
Vazoospermia
p12586
sg13
I1
sasa(dp12587
g2
S'Mutational analysis of the SEPTIN12 gene was performed using DNA from 30 Japanese patients with azoospermia by meiotic arrest and 140 fertile male controls.\n'
p12588
sg4
(lp12589
sg20
(lp12590
(dp12591
g7
I96
sg23
VC1321542
p12592
sg10
I11
sg11
Vazoospermia
p12593
sg13
I1
sasa(dp12594
g2
S'The c.204G&gt;C (Gln38His) variant in the SEPTIN12 gene was associated with increased susceptibility to azoospermia caused by meiotic arrest.\n'
p12595
sg4
(lp12596
(dp12597
g7
I14
sg8
VP26640
p12598
sg10
I20
sg11
VC (Gln38His) variant
p12599
sg13
I3
sasg20
(lp12600
(dp12601
g7
I104
sg23
VC1321542
p12602
sg10
I11
sg11
Vazoospermia
p12603
sg13
I1
sasa(dp12604
g2
S'Therefore, we hypothesized that mutation or polymorphisms of SEPTIN12  participate in male infertility, especially Sertoli cell-only syndrome  (SCOS).\n'
p12605
sg4
(lp12606
sg20
(lp12607
(dp12608
g7
I86
sg23
VC0021364
p12609
sg10
I16
sg11
Vmale infertility
p12610
sg13
I2
sa(dp12611
g7
I115
sg23
VC1384583
p12612
sg10
I26
sg11
VSertoli cell-only syndrome
p12613
sg13
I3
sa(dp12614
g7
I144
sg23
VC1384583
p12615
sg10
I4
sg11
VSCOS
p12616
sg13
I1
sasa(dp12617
g2
S'To investigate whether SEPTIN12 gene defects are associated  with azoospermia caused by SCOS, mutational analysis was performed in 100  Japanese patients by direct sequencing of coding regions.\n'
p12618
sg4
(lp12619
sg20
(lp12620
(dp12621
g7
I66
sg23
VC1321542
p12622
sg10
I11
sg11
Vazoospermia
p12623
sg13
I1
sasa(dp12624
g2
S'No  mutations were found in SEPTIN12 ; however, 8 coding  single-nucleotide polymorphisms (SNP1-SNP8) could be detected in the  patients with SCOS.\n'
p12625
sg4
(lp12626
sg20
(lp12627
sa(dp12628
g2
S'Here we describe a new and highly efficient antipneumococcal vaccine design based on synthetic conjugation of S. pneumoniae capsule polysaccharides to the potent lipid antigen Alfa-galactosylceramide, which stimulates invariant natural killer T (iNKT) cells when presented by the nonpolymorphic antigen-presenting molecule CD1d.\n'
p12629
sg4
(lp12630
(dp12631
g7
I323
sg8
VP15813
p12632
sg10
I4
sg11
VCD1d
p12633
sg13
I1
sasg20
(lp12634
sa(dp12635
g2
S'Our findings indicate that p38Gamma and p38Delta are potential therapeutic targets in complex diseases, such as rheumatoid arthritis, that involve innate and adaptive immune responses.\n'
p12636
sg4
(lp12637
(dp12638
g7
I40
sg8
g39
sg10
I8
sg11
Vp38Delta
p12639
sg13
I1
sa(dp12640
g7
I27
sg8
VP53778
p12641
sg10
I8
sg11
Vp38Gamma
p12642
sg13
I1
sasg20
(lp12643
(dp12644
g7
I112
sg23
VC0003873
p12645
sg10
I20
sg11
Vrheumatoid arthritis
p12646
sg13
I2
sasa(dp12647
g2
S'Among them, compound 4a, (S)-2-(4-fluorophenyl)-4-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole (R-132811), achieved the most promising results in various in vitro and in vivo tests including several rheumatoid arthritis models ((i) inhibition of p38alpha, p38beta, p38gamma, and p38delta MAP kinases: IC(50)=0.034, 0.572, &gt;10, and &gt;10 microM, respectively; (ii) inhibition of TNFalpha, IL-1beta, IL-6, and IL-8 production in human whole blood: IC(50)=0.026, 0.020, 0.88, and 0.016 microM, respectively; (iii) inhibition of LPS induced TNFalpha, IL-1beta and IL-6 production in mice: ID(50)=0.93, 8.63, and 0.11 mg/kg, p.o., respectively; (iv) inhibition of anti-collagen antibody-induced arthritis in mice: ID(50)=2.22 mg/kg, p.o.\n'
p12648
sg4
(lp12649
(dp12650
g7
I268
sg8
g39
sg10
I8
sg11
Vp38alpha
p12651
sg13
I1
sa(dp12652
g7
I424
sg8
VP05231
p12653
sg10
I4
sg11
VIL-6
p12654
sg13
I1
sa(dp12655
g7
I424
sg8
VP05231
p12656
sg10
I4
sg11
VIL-6
p12657
sg13
I1
sa(dp12658
g7
I301
sg8
g39
sg10
I20
sg11
Vp38delta MAP kinases
p12659
sg13
I3
sa(dp12660
g7
I404
sg8
VP01375
p12661
sg10
I8
sg11
VTNFalpha
p12662
sg13
I1
sa(dp12663
g7
I414
sg8
VP01584
p12664
sg10
I8
sg11
VIL-1beta
p12665
sg13
I1
sa(dp12666
g7
I278
sg8
g39
sg10
I7
sg11
Vp38beta
p12667
sg13
I1
sa(dp12668
g7
I404
sg8
VP01375
p12669
sg10
I8
sg11
VTNFalpha
p12670
sg13
I1
sa(dp12671
g7
I414
sg8
VP01584
p12672
sg10
I8
sg11
VIL-1beta
p12673
sg13
I1
sa(dp12674
g7
I287
sg8
VP53778
p12675
sg10
I8
sg11
Vp38gamma
p12676
sg13
I1
sasg20
(lp12677
(dp12678
g7
I551
sg23
VC0175697
p12679
sg10
I3
sg11
VLPS
p12680
sg13
I1
sa(dp12681
g7
I232
sg23
VC0003864
p12682
sg10
I9
sg11
Varthritis
p12683
sg13
I1
sa(dp12684
g7
I221
sg23
VC0003873
p12685
sg10
I20
sg11
Vrheumatoid arthritis
p12686
sg13
I2
sasa(dp12687
g2
S'To study was to study the expression of CD40/CD40L in colon cancer and investigate the effects of CD40/CD40L overexpression on the proliferation and apoptosis of SW48 colon cancer cell line.\n'
p12688
sg4
(lp12689
(dp12690
g7
I45
sg8
VP29965
p12691
sg10
I5
sg11
VCD40L
p12692
sg13
I1
sa(dp12693
g7
I45
sg8
VP29965
p12694
sg10
I5
sg11
VCD40L
p12695
sg13
I1
sa(dp12696
g7
I40
sg8
VP25942
p12697
sg10
I4
sg11
VCD40
p12698
sg13
I1
sa(dp12699
g7
I40
sg8
VP25942
p12700
sg10
I4
sg11
VCD40
p12701
sg13
I1
sasg20
(lp12702
(dp12703
g7
I54
sg23
VC0699790
p12704
sg10
I12
sg11
Vcolon cancer
p12705
sg13
I2
sa(dp12706
g7
I54
sg23
VC0699790
p12707
sg10
I12
sg11
Vcolon cancer
p12708
sg13
I2
sa(dp12709
g7
I131
sg23
VC0334094
p12710
sg10
I13
sg11
Vproliferation
p12711
sg13
I1
sasa(dp12712
g2
S'Immunohistochemistry was used to detect the expression of CD40 protein in colon cancer tissue samples from 70 patients, and 10 adjacent normal tissue samples.\n'
p12713
sg4
(lp12714
(dp12715
g7
I58
sg8
VP25942
p12716
sg10
I12
sg11
VCD40 protein
p12717
sg13
I2
sasg20
(lp12718
(dp12719
g7
I74
sg23
VC0699790
p12720
sg10
I12
sg11
Vcolon cancer
p12721
sg13
I2
sasa(dp12722
g2
S'A CD40L gene-containing plasmid was transfected into SW48 colon cancer cells using lipofectamine 2000.\n'
p12723
sg4
(lp12724
(dp12725
g7
I2
sg8
VP29965
p12726
sg10
I10
sg11
VCD40L gene
p12727
sg13
I2
sasg20
(lp12728
(dp12729
g7
I58
sg23
VC0699790
p12730
sg10
I12
sg11
Vcolon cancer
p12731
sg13
I2
sasa(dp12732
g2
S'The expression of CD40 in colorectal cancer tissue was significantly higher than in normal adjacent tissue.\n'
p12733
sg4
(lp12734
(dp12735
g7
I18
sg8
VP25942
p12736
sg10
I4
sg11
VCD40
p12737
sg13
I1
sasg20
(lp12738
(dp12739
g7
I26
sg23
VC1527249
p12740
sg10
I17
sg11
Vcolorectal cancer
p12741
sg13
I2
sasa(dp12742
g2
S'In conclusion, CD40 protein expression was significantly higher in colon cancer tissue compared with normal tissue, and the apoptosis of SW48 colon cancer cells can be induced by CD40L gene transfection.\n'
p12743
sg4
(lp12744
(dp12745
g7
I15
sg8
VP25942
p12746
sg10
I12
sg11
VCD40 protein
p12747
sg13
I2
sa(dp12748
g7
I179
sg8
VP29965
p12749
sg10
I10
sg11
VCD40L gene
p12750
sg13
I2
sasg20
(lp12751
(dp12752
g7
I67
sg23
VC0699790
p12753
sg10
I12
sg11
Vcolon cancer
p12754
sg13
I2
sa(dp12755
g7
I67
sg23
VC0699790
p12756
sg10
I12
sg11
Vcolon cancer
p12757
sg13
I2
sasa(dp12758
g2
S'We also uncovered a strong correlation between survival of colorectal cancer patients and NOS2, CD40, and TNF expression in their tumors.\n'
p12759
sg4
(lp12760
(dp12761
g7
I106
sg8
VP01375
p12762
sg10
I3
sg11
VTNF
p12763
sg13
I1
sa(dp12764
g7
I96
sg8
VP25942
p12765
sg10
I4
sg11
VCD40
p12766
sg13
I1
sa(dp12767
g7
I90
sg8
VP60321
p12768
sg10
I4
sg11
VNOS2
p12769
sg13
I1
sasg20
(lp12770
(dp12771
g7
I59
sg23
VC1527249
p12772
sg10
I17
sg11
Vcolorectal cancer
p12773
sg13
I2
sa(dp12774
g7
I130
sg23
VC0027651
p12775
sg10
I6
sg11
Vtumors
p12776
sg13
I1
sasa(dp12777
g2
S'We reveal here a correlation between CD40 expression and colon cancer differentiation.\n'
p12778
sg4
(lp12779
(dp12780
g7
I37
sg8
VP25942
p12781
sg10
I4
sg11
VCD40
p12782
sg13
I1
sasg20
(lp12783
(dp12784
g7
I57
sg23
VC0699790
p12785
sg10
I12
sg11
Vcolon cancer
p12786
sg13
I2
sasa(dp12787
g2
S'Upon CD40 ligand (CD40L) binding, CD40/CD40L signaling inhibited colon cancer proliferation, induced apoptosis, stalled cells at G0/G1, and influenced cell adhesion and metastasis.\n'
p12788
sg4
(lp12789
(dp12790
g7
I5
sg8
VP25942
p12791
sg10
I4
sg11
VCD40
p12792
sg13
I1
sa(dp12793
g7
I5
sg8
VP29965
p12794
sg10
I11
sg11
VCD40 ligand
p12795
sg13
I2
sa(dp12796
g7
I18
sg8
VP29965
p12797
sg10
I5
sg11
VCD40L
p12798
sg13
I1
sa(dp12799
g7
I18
sg8
VP29965
p12800
sg10
I5
sg11
VCD40L
p12801
sg13
I1
sasg20
(lp12802
(dp12803
g7
I65
sg23
VC0699790
p12804
sg10
I12
sg11
Vcolon cancer
p12805
sg13
I2
sa(dp12806
g7
I169
sg23
VC0027627
p12807
sg10
I10
sg11
Vmetastasis
p12808
sg13
I1
sa(dp12809
g7
I156
sg23
VC0001511
p12810
sg10
I8
sg11
Vadhesion
p12811
sg13
I1
sa(dp12812
g7
I78
sg23
VC0334094
p12813
sg10
I13
sg11
Vproliferation
p12814
sg13
I1
sasa(dp12815
g2
S'Real-time PCR and western blotting analysis showed that AHRR expression in colon cancer cells was up-regulated by CD40L binding.\n'
p12816
sg4
(lp12817
(dp12818
g7
I114
sg8
VP29965
p12819
sg10
I5
sg11
VCD40L
p12820
sg13
I1
sa(dp12821
g7
I56
sg8
VP04798
p12822
sg10
I4
sg11
VAHRR
p12823
sg13
I1
sasg20
(lp12824
(dp12825
g7
I75
sg23
VC0699790
p12826
sg10
I12
sg11
Vcolon cancer
p12827
sg13
I2
sasa(dp12828
g2
S'First, insulin-like growth factor-1 receptor antibody therapy resulted in hyperglycemia and metabolic syndrome most likely due to disruption of insulin-like growth factor-1 homeostasis and subsequent growth hormone elevation.\n'
p12829
sg4
(lp12830
(dp12831
g7
I7
sg8
VP01308
p12832
sg10
I46
sg11
Vinsulin-like growth factor-1 receptor antibody
p12833
sg13
I5
sa(dp12834
g7
I7
sg8
VP01308
p12835
sg10
I28
sg11
Vinsulin-like growth factor-1
p12836
sg13
I3
sasg20
(lp12837
(dp12838
g7
I74
sg23
VC0020456
p12839
sg10
I13
sg11
Vhyperglycemia
p12840
sg13
I1
sa(dp12841
g7
I92
sg23
VC0524620
p12842
sg10
I18
sg11
Vmetabolic syndrome
p12843
sg13
I2
sasa(dp12844
g2
S'More specifically, it has been shown that the miR-194 can target the insulin-like growth factor receptor 1 (IGF1R) and silence its protein expression resulting in hyperglycemia.\n'
p12845
sg4
(lp12846
(dp12847
g7
I108
sg8
VP08069
p12848
sg10
I5
sg11
VIGF1R
p12849
sg13
I1
sa(dp12850
g7
I69
sg8
VP01308
p12851
sg10
I37
sg11
Vinsulin-like growth factor receptor 1
p12852
sg13
I5
sasg20
(lp12853
(dp12854
g7
I163
sg23
VC0020456
p12855
sg10
I13
sg11
Vhyperglycemia
p12856
sg13
I1
sa(dp12857
g7
I119
sg23
VC0858952
p12858
sg10
I7
sg11
Vsilence
p12859
sg13
I1
sasa(dp12860
g2
S'Using the 30% total body surface area (TBSA) model of burn injury in rats we found that the miRNA let-7b can target IGF1R and downregulate its protein expression, in turn attenuating PI3K/Akt and Gsk3Beta activation leading to hyperglycemia.\n'
p12861
sg4
(lp12862
(dp12863
g7
I116
sg8
VP08069
p12864
sg10
I5
sg11
VIGF1R
p12865
sg13
I1
sa(dp12866
g7
I183
sg8
VP42336
p12867
sg10
I4
sg11
VPI3K
p12868
sg13
I1
sa(dp12869
g7
I188
sg8
g39
sg10
I3
sg11
VAkt
p12870
sg13
I1
sasg20
(lp12871
(dp12872
g7
I227
sg23
VC0020456
p12873
sg10
I13
sg11
Vhyperglycemia
p12874
sg13
I1
sasa(dp12875
g2
S'In vivo targeting of let-7b by antagomir mitigated the effect of increased let-7b expression on IGF1R protein expression and hyperglycemia.\n'
p12876
sg4
(lp12877
(dp12878
g7
I96
sg8
VP08069
p12879
sg10
I13
sg11
VIGF1R protein
p12880
sg13
I2
sasg20
(lp12881
(dp12882
g7
I125
sg23
VC0020456
p12883
sg10
I13
sg11
Vhyperglycemia
p12884
sg13
I1
sasa(dp12885
g2
S'The findings are of significant importance as they demonstrate for the first time the contribution of IGF-1 receptors (IGF-1R) and Akt signaling in cardiac hypertrophy but not in cardiac autophagy regulation in obesity and T2DM.\n'
p12886
sg4
(lp12887
(dp12888
g7
I102
sg8
VP01343
p12889
sg10
I15
sg11
VIGF-1 receptors
p12890
sg13
I2
sa(dp12891
g7
I131
sg8
g39
sg10
I3
sg11
VAkt
p12892
sg13
I1
sa(dp12893
g7
I119
sg8
VP08069
p12894
sg10
I6
sg11
VIGF-1R
p12895
sg13
I1
sasg20
(lp12896
(dp12897
g7
I148
sg23
VC1383860
p12898
sg10
I19
sg11
Vcardiac hypertrophy
p12899
sg13
I2
sa(dp12900
g7
I211
sg23
VC0028754
p12901
sg10
I7
sg11
Vobesity
p12902
sg13
I1
sasa(dp12903
g2
S'Together, our results suggest a mechanism by which coxsackieviral infection induces CryAB degradation and loss-of-function, resulting in desmin aggregation, ultimately contributing to compromised cytoskeletal integrity and viral cardiomyopathy.\n'
p12904
sg4
(lp12905
(dp12906
g7
I84
sg8
VP02511
p12907
sg10
I5
sg11
VCryAB
p12908
sg13
I1
sa(dp12909
g7
I137
sg8
VP98155
p12910
sg10
I6
sg11
Vdesmin
p12911
sg13
I1
sasg20
(lp12912
(dp12913
g7
I223
sg23
VC0264797
p12914
sg10
I20
sg11
Vviral cardiomyopathy
p12915
sg13
I2
sa(dp12916
g7
I66
sg23
VC0009450
p12917
sg10
I9
sg11
Vinfection
p12918
sg13
I1
sasa(dp12919
g2
S'We identified by a next-generation sequencing panel the novel CRYAB missense mutation c.326A&gt;G, p.D109G in a small family with RCM in combination with skeletal myopathy with an early onset of the disease.\n'
p12920
sg4
(lp12921
(dp12922
g7
I62
sg8
VP02511
p12923
sg10
I5
sg11
VCRYAB
p12924
sg13
I1
sa(dp12925
g7
I130
sg8
VP19429
p12926
sg10
I3
sg11
VRCM
p12927
sg13
I1
sasg20
(lp12928
(dp12929
g7
I163
sg23
VC0026848
p12930
sg10
I8
sg11
Vmyopathy
p12931
sg13
I1
sa(dp12932
g7
I130
sg23
VC1861861
p12933
sg10
I3
sg11
VRCM
p12934
sg13
I1
sasa(dp12935
g2
S'Mutations of HSPB5 (also known as CRYAB or AlfaB-crystallin), a bona fide heat shock protein and molecular chaperone encoded by the HSPB5 (crystallin, alpha B) gene, are linked to multisystem disorders featuring variable combinations of cataracts, cardiomyopathy, and skeletal myopathy.\n'
p12936
sg4
(lp12937
(dp12938
g7
I43
sg8
VP22914
p12939
sg10
I16
sg11
VAlfaB-crystallin
p12940
sg13
I1
sa(dp12941
g7
I49
sg8
VP22914
p12942
sg10
I10
sg11
Vcrystallin
p12943
sg13
I1
sa(dp12944
g7
I13
sg8
VP02511
p12945
sg10
I5
sg11
VHSPB5
p12946
sg13
I1
sa(dp12947
g7
I13
sg8
VP02511
p12948
sg10
I5
sg11
VHSPB5
p12949
sg13
I1
sa(dp12950
g7
I34
sg8
VP02511
p12951
sg10
I5
sg11
VCRYAB
p12952
sg13
I1
sasg20
(lp12953
(dp12954
g7
I237
sg23
VC0521707
p12955
sg10
I9
sg11
Vcataracts
p12956
sg13
I1
sa(dp12957
g7
I248
sg23
VC0878544
p12958
sg10
I14
sg11
Vcardiomyopathy
p12959
sg13
I1
sa(dp12960
g7
I254
sg23
VC0026848
p12961
sg10
I8
sg11
Vmyopathy
p12962
sg13
I1
sa(dp12963
g7
I180
sg23
VC0559758
p12964
sg10
I21
sg11
Vmultisystem disorders
p12965
sg13
I2
sasa(dp12966
g2
S'This study aimed to investigate the pathological mechanisms involved in an early-onset myofibrillar myopathy manifesting in a child harboring a homozygous recessive mutation in HSPB5, 343delT.\n'
p12967
sg4
(lp12968
(dp12969
g7
I177
sg8
VP02511
p12970
sg10
I5
sg11
VHSPB5
p12971
sg13
I1
sasg20
(lp12972
(dp12973
g7
I87
sg23
VC2678065
p12974
sg10
I21
sg11
Vmyofibrillar myopathy
p12975
sg13
I2
sasa(dp12976
g2
S'These data support a loss-of-function model for the myopathy observed in the patient because the insoluble mutant would be unavailable to perform normal functions of HSPB5, although additional gain-of-function effects of the mutant protein cannot be excluded.\n'
p12977
sg4
(lp12978
(dp12979
g7
I166
sg8
VP02511
p12980
sg10
I5
sg11
VHSPB5
p12981
sg13
I1
sasg20
(lp12982
(dp12983
g7
I52
sg23
VC0026848
p12984
sg10
I8
sg11
Vmyopathy
p12985
sg13
I1
sa(dp12986
g7
I107
sg23
VC0596988
p12987
sg10
I6
sg11
Vmutant
p12988
sg13
I1
sa(dp12989
g7
I107
sg23
VC0596988
p12990
sg10
I6
sg11
Vmutant
p12991
sg13
I1
sasa(dp12992
g2
S'Here we report that NFKB transcription factor is activated by misincorporation of amino acid analogues into proteins, inhibition of proteasomal activity, expression of the R120G mutated form of HspB5 (associated with myofibrillar myopathy), or expression of the G985R and G93A mutated forms of superoxide dismutase 1 (linked to familial amyotrophic lateral sclerosis).\n'
p12993
sg4
(lp12994
(dp12995
g7
I20
sg8
VP35398
p12996
sg10
I25
sg11
VNFKB transcription factor
p12997
sg13
I3
sa(dp12998
g7
I194
sg8
VP02511
p12999
sg10
I5
sg11
VHspB5
p13000
sg13
I1
sa(dp13001
g7
I294
sg8
VP00441
p13002
sg10
I22
sg11
Vsuperoxide dismutase 1
p13003
sg13
I3
sasg20
(lp13004
(dp13005
g7
I217
sg23
VC2678065
p13006
sg10
I21
sg11
Vmyofibrillar myopathy
p13007
sg13
I2
sa(dp13008
g7
I337
sg23
VC0002736
p13009
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p13010
sg13
I3
sasa(dp13011
g2
S'The boundaries of this concept are still uncertain, and whereas six genes (DES, CRYAB, LDB3/ZASP, MYOT, FLNC and BAG3) are now classically considered as responsible for MFM, other entities such as FHL1 myopathy or Hereditary Myopathy with Early Respiratory Failure linked to mutations of titin can now as well be included in this group.\n'
p13012
sg4
(lp13013
(dp13014
g7
I113
sg8
g39
sg10
I4
sg11
VBAG3
p13015
sg13
I1
sa(dp13016
g7
I75
sg8
VP98155
p13017
sg10
I3
sg11
VDES
p13018
sg13
I1
sa(dp13019
g7
I104
sg8
g39
sg10
I4
sg11
VFLNC
p13020
sg13
I1
sa(dp13021
g7
I288
sg8
g39
sg10
I5
sg11
Vtitin
p13022
sg13
I1
sa(dp13023
g7
I98
sg8
g39
sg10
I4
sg11
VMYOT
p13024
sg13
I1
sa(dp13025
g7
I80
sg8
VP02511
p13026
sg10
I5
sg11
VCRYAB
p13027
sg13
I1
sasg20
(lp13028
(dp13029
g7
I202
sg23
VC0026848
p13030
sg10
I8
sg11
Vmyopathy
p13031
sg13
I1
sa(dp13032
g7
I75
sg23
VC0394006
p13033
sg10
I3
sg11
VDES
p13034
sg13
I1
sa(dp13035
g7
I197
sg23
VC0272199
p13036
sg10
I4
sg11
VFHL1
p13037
sg13
I1
sa(dp13038
g7
I214
sg23
VC1863599
p13039
sg10
I50
sg11
VHereditary Myopathy with Early Respiratory Failure
p13040
sg13
I6
sasa(dp13041
g2
S'In the present study, we demonstrate that lncRNA TRERNA1 acts like an enhancer of SNAI1 to promote cell invasion and migration and to contribute to metastasis of gastric cancer (GC).\n'
p13042
sg4
(lp13043
(dp13044
g7
I82
sg8
g39
sg10
I5
sg11
VSNAI1
p13045
sg13
I1
sasg20
(lp13046
(dp13047
g7
I162
sg23
VC0024623
p13048
sg10
I14
sg11
Vgastric cancer
p13049
sg13
I2
sa(dp13050
g7
I99
sg23
VC2699153
p13051
sg10
I13
sg11
Vcell invasion
p13052
sg13
I2
sa(dp13053
g7
I178
sg23
VC0024623
p13054
sg10
I2
sg11
VGC
p13055
sg13
I1
sa(dp13056
g7
I148
sg23
VC0027627
p13057
sg10
I10
sg11
Vmetastasis
p13058
sg13
I1
sasa(dp13059
g2
S'treRNA is a long non-coding RNA (lncRNA) involved in cancer progression.\n'
p13060
sg4
(lp13061
sg20
(lp13062
(dp13063
g7
I53
sg23
VC0178874
p13064
sg10
I18
sg11
Vcancer progression
p13065
sg13
I2
sasa(dp13066
g2
S'Suppression of treRNA by miR-190a led to significant changes of mesenchymal-epithelial transition markers and impaired migration and invasion capability of hepatoma cells.\n'
p13067
sg4
(lp13068
sg20
(lp13069
(dp13070
g7
I156
sg23
VC0023903
p13071
sg10
I8
sg11
Vhepatoma
p13072
sg13
I1
sa(dp13073
g7
I133
sg23
VC2699153
p13074
sg10
I8
sg11
Vinvasion
p13075
sg13
I1
sa(dp13076
g7
I110
sg23
VC0684336
p13077
sg10
I8
sg11
Vimpaired
p13078
sg13
I1
sa(dp13079
g7
I0
sg23
VC0221103
p13080
sg10
I11
sg11
VSuppression
p13081
sg13
I1
sa(dp13082
g7
I87
sg23
VC0599156
p13083
sg10
I10
sg11
Vtransition
p13084
sg13
I1
sasa(dp13085
g2
S'Our results reveal the involvement of miR-190a-treRNA axis in hepatoma progression and shed light on lncRNA-based cancer therapies for hepatoma patients at high risk of metastasis.\n'
p13086
sg4
(lp13087
(dp13088
g7
I38
sg8
g39
sg10
I15
sg11
VmiR-190a-treRNA
p13089
sg13
I1
sasg20
(lp13090
(dp13091
g7
I62
sg23
VC0023903
p13092
sg10
I8
sg11
Vhepatoma
p13093
sg13
I1
sa(dp13094
g7
I62
sg23
VC0023903
p13095
sg10
I8
sg11
Vhepatoma
p13096
sg13
I1
sa(dp13097
g7
I169
sg23
VC0027627
p13098
sg10
I10
sg11
Vmetastasis
p13099
sg13
I1
sa(dp13100
g7
I114
sg23
VC0006826
p13101
sg10
I6
sg11
Vcancer
p13102
sg13
I1
sasa(dp13103
g2
S'We found that treRNA is upregulated in paired clinical breast cancer primary and lymph-node metastasis samples, and that its expression stimulates tumour invasion in vitro and metastasis in vivo.\n'
p13104
sg4
(lp13105
sg20
(lp13106
(dp13107
g7
I147
sg23
VC0027651
p13108
sg10
I6
sg11
Vtumour
p13109
sg13
I1
sa(dp13110
g7
I92
sg23
VC0027627
p13111
sg10
I10
sg11
Vmetastasis
p13112
sg13
I1
sa(dp13113
g7
I154
sg23
VC2699153
p13114
sg10
I8
sg11
Vinvasion
p13115
sg13
I1
sa(dp13116
g7
I55
sg23
VC0678222
p13117
sg10
I13
sg11
Vbreast cancer
p13118
sg13
I2
sa(dp13119
g7
I92
sg23
VC0027627
p13120
sg10
I10
sg11
Vmetastasis
p13121
sg13
I1
sasa(dp13122
g2
S'The aim of this study was to determine the expression levels of EP300, TP53 and BAX genes and their respective proteins in clear cell renal cell carcinoma (ccRCC) and evaluate the value of these factors as prognostic factors.\n'
p13123
sg4
(lp13124
(dp13125
g7
I64
sg8
g39
sg10
I5
sg11
VEP300
p13126
sg13
I1
sa(dp13127
g7
I80
sg8
VP01893
p13128
sg10
I9
sg11
VBAX genes
p13129
sg13
I2
sasg20
(lp13130
(dp13131
g7
I123
sg23
VC0279702
p13132
sg10
I31
sg11
Vclear cell renal cell carcinoma
p13133
sg13
I5
sa(dp13134
g7
I156
sg23
VC0279702
p13135
sg10
I5
sg11
VccRCC
p13136
sg13
I1
sasa(dp13137
g2
S'Bioinformatics assessment revealed a correlation between p300, EGR1 and MAML1 copy number and mRNA alterations in renal clear cell carcinoma and p300, EGR1 and MAML1 gene alterations were associated with increased overall survival.\n'
p13138
sg4
(lp13139
(dp13140
g7
I63
sg8
VP18146
p13141
sg10
I4
sg11
VEGR1
p13142
sg13
I1
sa(dp13143
g7
I57
sg8
g39
sg10
I4
sg11
Vp300
p13144
sg13
I1
sa(dp13145
g7
I72
sg8
g39
sg10
I5
sg11
VMAML1
p13146
sg13
I1
sa(dp13147
g7
I160
sg8
g39
sg10
I10
sg11
VMAML1 gene
p13148
sg13
I2
sa(dp13149
g7
I63
sg8
VP18146
p13150
sg10
I4
sg11
VEGR1
p13151
sg13
I1
sa(dp13152
g7
I57
sg8
g39
sg10
I4
sg11
Vp300
p13153
sg13
I1
sasg20
(lp13154
(dp13155
g7
I114
sg23
VC0279702
p13156
sg10
I26
sg11
Vrenal clear cell carcinoma
p13157
sg13
I4
sasa(dp13158
g2
S'We propose that activation of TRPV1 and TRPA1 receptors by H2S during neuro-inflammation conditions contributes to the nociceptive firing in primary afferents underlying migraine pain.\n'
p13159
sg4
(lp13160
(dp13161
g7
I30
sg8
g39
sg10
I5
sg11
VTRPV1
p13162
sg13
I1
sa(dp13163
g7
I40
sg8
g39
sg10
I15
sg11
VTRPA1 receptors
p13164
sg13
I2
sasg20
(lp13165
(dp13166
g7
I170
sg23
VC0149931
p13167
sg10
I8
sg11
Vmigraine
p13168
sg13
I1
sa(dp13169
g7
I76
sg23
VC0021368
p13170
sg10
I12
sg11
Vinflammation
p13171
sg13
I1
sasa(dp13172
g2
S'Methods We investigated the functional roles of TRPM8 and TRPV1 in a meningeal inflammation-based migraine model by measuring the effects of facial TRPM8 activation on thermal allodynia and assessing receptor coexpression changes in TG neurons.\n'
p13173
sg4
(lp13174
(dp13175
g7
I58
sg8
g39
sg10
I5
sg11
VTRPV1
p13176
sg13
I1
sa(dp13177
g7
I48
sg8
g39
sg10
I5
sg11
VTRPM8
p13178
sg13
I1
sa(dp13179
g7
I48
sg8
g39
sg10
I5
sg11
VTRPM8
p13180
sg13
I1
sasg20
(lp13181
(dp13182
g7
I79
sg23
VC0021368
p13183
sg10
I12
sg11
Vinflammation
p13184
sg13
I1
sa(dp13185
g7
I168
sg23
VC0751214
p13186
sg10
I17
sg11
Vthermal allodynia
p13187
sg13
I2
sa(dp13188
g7
I98
sg23
VC0149931
p13189
sg10
I8
sg11
Vmigraine
p13190
sg13
I1
sasa(dp13191
g2
S'Conclusions Our findings provide a plausible mechanism to explain how facial TRPM8 activation can relieve migraine by suppressing TRPV1 activity.\n'
p13192
sg4
(lp13193
(dp13194
g7
I77
sg8
g39
sg10
I5
sg11
VTRPM8
p13195
sg13
I1
sa(dp13196
g7
I130
sg8
g39
sg10
I5
sg11
VTRPV1
p13197
sg13
I1
sasg20
(lp13198
(dp13199
g7
I106
sg23
VC0149931
p13200
sg10
I8
sg11
Vmigraine
p13201
sg13
I1
sasa(dp13202
g2
S'Using case-control comparisons, we analyzed eight single nucleotide polymorphisms (SNPs) in genes definitively associated with interindividual variation in leukocyte telomere length (LTL) in prior genome-wide association studies: ACYP2, TERC, NAF1, TERT, OBFC1, CTC1, ZNF208 and RTEL1 Six of these SNPs were associated (P &lt; 0.05) with neuroblastoma risk, one with leukemia risk and one with osteosarcoma risk.\n'
p13203
sg4
(lp13204
(dp13205
g7
I249
sg8
g39
sg10
I4
sg11
VTERT
p13206
sg13
I1
sa(dp13207
g7
I230
sg8
VP14621
p13208
sg10
I5
sg11
VACYP2
p13209
sg13
I1
sa(dp13210
g7
I255
sg8
g39
sg10
I5
sg11
VOBFC1
p13211
sg13
I1
sa(dp13212
g7
I262
sg8
g39
sg10
I4
sg11
VCTC1
p13213
sg13
I1
sa(dp13214
g7
I243
sg8
g39
sg10
I4
sg11
VNAF1
p13215
sg13
I1
sa(dp13216
g7
I268
sg8
g39
sg10
I6
sg11
VZNF208
p13217
sg13
I1
sa(dp13218
g7
I279
sg8
g39
sg10
I9
sg11
VRTEL1 Six
p13219
sg13
I2
sasg20
(lp13220
(dp13221
g7
I338
sg23
VC0027819
p13222
sg10
I13
sg11
Vneuroblastoma
p13223
sg13
I1
sa(dp13224
g7
I367
sg23
VC0023418
p13225
sg10
I8
sg11
Vleukemia
p13226
sg13
I1
sa(dp13227
g7
I394
sg23
VC0029463
p13228
sg10
I12
sg11
Vosteosarcoma
p13229
sg13
I1
sasa(dp13230
g2
S"Three polypeptides, primarily positioned 5' to the damage, are in close physical proximity to the psoralen lesion and thus are cross-linked to the damaged DNA: these proteins are RPA70, RPA32, and the XPD subunit of TFIIH.\n"
p13231
sg4
(lp13232
(dp13233
g7
I216
sg8
VP32780
p13234
sg10
I5
sg11
VTFIIH
p13235
sg13
I1
sa(dp13236
g7
I186
sg8
VP15927
p13237
sg10
I5
sg11
VRPA32
p13238
sg13
I1
sa(dp13239
g7
I179
sg8
VP27694
p13240
sg10
I5
sg11
VRPA70
p13241
sg13
I1
sasg20
(lp13242
(dp13243
g7
I201
sg23
VC0268138
p13244
sg10
I3
sg11
VXPD
p13245
sg13
I1
sasa(dp13246
g2
S'Based on these results, we propose that RPA70 makes the initial contact with psoralen-damaged DNA but that within preincision complexes, it is RPA32 and XPD that are in close contact with the lesion.\n'
p13247
sg4
(lp13248
(dp13249
g7
I153
sg8
VP18074
p13250
sg10
I3
sg11
VXPD
p13251
sg13
I1
sa(dp13252
g7
I40
sg8
VP27694
p13253
sg10
I5
sg11
VRPA70
p13254
sg13
I1
sa(dp13255
g7
I143
sg8
VP15927
p13256
sg10
I5
sg11
VRPA32
p13257
sg13
I1
sasg20
(lp13258
(dp13259
g7
I153
sg23
VC0268138
p13260
sg10
I3
sg11
VXPD
p13261
sg13
I1
sasa(dp13262
g2
S'It has potential use as an antagonist in the treatment of CCR9-overexpressed carcinoma.\n'
p13263
sg4
(lp13264
(dp13265
g7
I58
sg8
VP51686
p13266
sg10
I4
sg11
VCCR9
p13267
sg13
I1
sasg20
(lp13268
(dp13269
g7
I77
sg23
VC0007097
p13270
sg10
I9
sg11
Vcarcinoma
p13271
sg13
I1
sasa(dp13272
g2
S'Taken together, these results indicate that ATC cells down-regulate D6/ACKR2 expression through miR-146a activity to sustain leukocyte trafficking inside tumor microenvironment and shed light on a novel mechanism by which NF-KB indirectly inhibits the expression and the function of anti-tumorigenic gene in thyroid cancer.\n'
p13273
sg4
(lp13274
(dp13275
g7
I96
sg8
g39
sg10
I8
sg11
VmiR-146a
p13276
sg13
I1
sasg20
(lp13277
(dp13278
g7
I308
sg23
VC0007115
p13279
sg10
I14
sg11
Vthyroid cancer
p13280
sg13
I2
sa(dp13281
g7
I154
sg23
VC0027651
p13282
sg10
I5
sg11
Vtumor
p13283
sg13
I1
sasa(dp13284
g2
S'Here, we provide a summary of the data on the role of ACKR2 expressed by lymphatics, indicating an essential role for this ACKRs in the regulation of the inflammation and the immune response in different pathological conditions, including infection, allergy, and cancer.\n'
p13285
sg4
(lp13286
sg20
(lp13287
(dp13288
g7
I250
sg23
VC0020517
p13289
sg10
I7
sg11
Vallergy
p13290
sg13
I1
sa(dp13291
g7
I239
sg23
VC0009450
p13292
sg10
I9
sg11
Vinfection
p13293
sg13
I1
sa(dp13294
g7
I263
sg23
VC0006826
p13295
sg10
I6
sg11
Vcancer
p13296
sg13
I1
sa(dp13297
g7
I154
sg23
VC0021368
p13298
sg10
I12
sg11
Vinflammation
p13299
sg13
I1
sasa(dp13300
g2
S'Using a computational approach, we deconvoluted expression data from a mixed physical co-culture of GBM cells and ECs and identified a previously undescribed upregulation of the cAMP specific phosphodiesterase PDE7B in GBM cells in response to direct contact with ECs.\n'
p13301
sg4
(lp13302
(dp13303
g7
I178
sg8
VP49913
p13304
sg10
I37
sg11
VcAMP specific phosphodiesterase PDE7B
p13305
sg13
I4
sasg20
(lp13306
(dp13307
g7
I100
sg23
VC0017636
p13308
sg10
I3
sg11
VGBM
p13309
sg13
I1
sa(dp13310
g7
I100
sg23
VC0017636
p13311
sg10
I3
sg11
VGBM
p13312
sg13
I1
sasa(dp13313
g2
S'We further found that elevated PDE7B expression occurs in most GBM cases and has a negative effect on survival.\n'
p13314
sg4
(lp13315
(dp13316
g7
I31
sg8
g39
sg10
I5
sg11
VPDE7B
p13317
sg13
I1
sasg20
(lp13318
(dp13319
g7
I63
sg23
VC0017636
p13320
sg10
I3
sg11
VGBM
p13321
sg13
I1
sasa(dp13322
g2
S'PDE7B overexpression resulted in the expansion of a stem-like cell subpopulation in vitro and increased tumor growth and aggressiveness in an in vivo intracranial GBM model.\n'
p13323
sg4
(lp13324
(dp13325
g7
I0
sg8
g39
sg10
I5
sg11
VPDE7B
p13326
sg13
I1
sasg20
(lp13327
(dp13328
g7
I121
sg23
VC0001807
p13329
sg10
I14
sg11
Vaggressiveness
p13330
sg13
I1
sa(dp13331
g7
I104
sg23
VC0598934
p13332
sg10
I12
sg11
Vtumor growth
p13333
sg13
I2
sa(dp13334
g7
I163
sg23
VC0017636
p13335
sg10
I3
sg11
VGBM
p13336
sg13
I1
sasa(dp13337
g2
S'Collectively these studies illustrate a novel approach for studying cell-cell interactions and identifying new therapeutic targets like PDE7B in GBM.\n'
p13338
sg4
(lp13339
(dp13340
g7
I136
sg8
g39
sg10
I5
sg11
VPDE7B
p13341
sg13
I1
sasg20
(lp13342
(dp13343
g7
I145
sg23
VC0017636
p13344
sg10
I3
sg11
VGBM
p13345
sg13
I1
sasa(dp13346
g2
S'In order to determine the relationship between expression of cyclic nucleotide phosphodiesterase isoform 7B (PDE7B) and mantle cell lymphoma (MCL) progression, PDE7B mRNA expression was measured by qRT-PCR in 21 untreated MCL patients with bone marrow involvement and 20 healthy donors.\n'
p13347
sg4
(lp13348
(dp13349
g7
I160
sg8
g39
sg10
I10
sg11
VPDE7B mRNA
p13350
sg13
I2
sa(dp13351
g7
I109
sg8
g39
sg10
I5
sg11
VPDE7B
p13352
sg13
I1
sa(dp13353
g7
I61
sg8
VP09543
p13354
sg10
I46
sg11
Vcyclic nucleotide phosphodiesterase isoform 7B
p13355
sg13
I5
sasg20
(lp13356
(dp13357
g7
I142
sg23
VC1708350
p13358
sg10
I3
sg11
VMCL
p13359
sg13
I1
sa(dp13360
g7
I120
sg23
VC0334634
p13361
sg10
I20
sg11
Vmantle cell lymphoma
p13362
sg13
I3
sa(dp13363
g7
I142
sg23
VC1708350
p13364
sg10
I3
sg11
VMCL
p13365
sg13
I1
sasa(dp13366
g2
S'Expression of cyclic adenosine monophosphate-specific phosphodiesterase 7B (PDE7B) mRNA is increased in patients with chronic lymphocytic leukemia (CLL), thus suggesting that variation may occur in the PDE7B gene in CLL.\n'
p13367
sg4
(lp13368
(dp13369
g7
I14
sg8
g39
sg10
I60
sg11
Vcyclic adenosine monophosphate-specific phosphodiesterase 7B
p13370
sg13
I5
sa(dp13371
g7
I76
sg8
g39
sg10
I5
sg11
VPDE7B
p13372
sg13
I1
sa(dp13373
g7
I202
sg8
g39
sg10
I10
sg11
VPDE7B gene
p13374
sg13
I2
sasg20
(lp13375
(dp13376
g7
I118
sg23
VC0023434
p13377
sg10
I28
sg11
Vchronic lymphocytic leukemia
p13378
sg13
I3
sa(dp13379
g7
I148
sg23
VC0023434
p13380
sg10
I3
sg11
VCLL
p13381
sg13
I1
sa(dp13382
g7
I148
sg23
VC0023434
p13383
sg10
I3
sg11
VCLL
p13384
sg13
I1
sasa(dp13385
g2
S'To investigate the expression level of cyclic nucleotide phosphodiesterase (PDE) 7B mRNA and its prognostic value in mantle cell lymphoma (MCL), the real-time quantitative RT-PCR (QPCR) was used to detect pde7b expression levels of bone marrow mononuclear cells from 20 newly diagnosed MCL patients with bone marrow involvement and peripheral blood mononuclear cells from 20 normal persons, the association of pde7b expression levels with prognostic indexes was analyzed by statistical software.\n'
p13386
sg4
(lp13387
(dp13388
g7
I205
sg8
g39
sg10
I5
sg11
Vpde7b
p13389
sg13
I1
sa(dp13390
g7
I39
sg8
VP09543
p13391
sg10
I35
sg11
Vcyclic nucleotide phosphodiesterase
p13392
sg13
I3
sa(dp13393
g7
I205
sg8
g39
sg10
I5
sg11
Vpde7b
p13394
sg13
I1
sa(dp13395
g7
I76
sg8
VP49419
p13396
sg10
I3
sg11
VPDE
p13397
sg13
I1
sasg20
(lp13398
(dp13399
g7
I139
sg23
VC1708350
p13400
sg10
I3
sg11
VMCL
p13401
sg13
I1
sa(dp13402
g7
I117
sg23
VC0334634
p13403
sg10
I20
sg11
Vmantle cell lymphoma
p13404
sg13
I3
sa(dp13405
g7
I76
sg23
VC1849508
p13406
sg10
I3
sg11
VPDE
p13407
sg13
I1
sa(dp13408
g7
I57
sg23
VC1849508
p13409
sg10
I17
sg11
Vphosphodiesterase
p13410
sg13
I1
sa(dp13411
g7
I139
sg23
VC1708350
p13412
sg10
I3
sg11
VMCL
p13413
sg13
I1
sasa(dp13414
g2
S'Pitx1 transcripts increased significantly in control mice with induced hypothyroidism, but they remained unchanged in Pitx2(flox/-);Tg(Tshb-cre) mice, possibly because Pitx1 levels were already maximally elevated in untreated mutants.\n'
p13415
sg4
(lp13416
(dp13417
g7
I0
sg8
VP78337
p13418
sg10
I17
sg11
VPitx1 transcripts
p13419
sg13
I2
sa(dp13420
g7
I0
sg8
VP78337
p13421
sg10
I5
sg11
VPitx1
p13422
sg13
I1
sa(dp13423
g7
I118
sg8
g39
sg10
I13
sg11
VPitx2(flox/-)
p13424
sg13
I1
sasg20
(lp13425
(dp13426
g7
I71
sg23
VC0020676
p13427
sg10
I14
sg11
Vhypothyroidism
p13428
sg13
I1
sasa(dp13429
g2
S'These results suggest that PITX2 and PITX1 have overlapping roles in thyrotroph function and response to hypothyroidism.\n'
p13430
sg4
(lp13431
(dp13432
g7
I37
sg8
VP78337
p13433
sg10
I5
sg11
VPITX1
p13434
sg13
I1
sa(dp13435
g7
I27
sg8
g39
sg10
I5
sg11
VPITX2
p13436
sg13
I1
sasg20
(lp13437
(dp13438
g7
I105
sg23
VC0020676
p13439
sg10
I14
sg11
Vhypothyroidism
p13440
sg13
I1
sasa(dp13441
g2
S'We excluded germline mutations in PHEX, FGF23, DMP1, and ENPP1 (genes for hereditary hypophosphatemic rickets) and somatic mutations in the GNAS and HRAS/KRAS (the disease-causing genes for McCune-Albright syndrome and linear nevus sebaceous syndrome, respectively).\n'
p13442
sg4
(lp13443
(dp13444
g7
I40
sg8
g39
sg10
I5
sg11
VFGF23
p13445
sg13
I1
sa(dp13446
g7
I140
sg8
VP84996
p13447
sg10
I4
sg11
VGNAS
p13448
sg13
I1
sa(dp13449
g7
I34
sg8
VP78562
p13450
sg10
I4
sg11
VPHEX
p13451
sg13
I1
sa(dp13452
g7
I57
sg8
VP22413
p13453
sg10
I5
sg11
VENPP1
p13454
sg13
I1
sa(dp13455
g7
I149
sg8
VP01112
p13456
sg10
I4
sg11
VHRAS
p13457
sg13
I1
sa(dp13458
g7
I47
sg8
g39
sg10
I4
sg11
VDMP1
p13459
sg13
I1
sa(dp13460
g7
I154
sg8
VP01116
p13461
sg10
I4
sg11
VKRAS
p13462
sg13
I1
sasg20
(lp13463
(dp13464
g7
I219
sg23
VC0265329
p13465
sg10
I31
sg11
Vlinear nevus sebaceous syndrome
p13466
sg13
I4
sa(dp13467
g7
I85
sg23
VC1704375
p13468
sg10
I24
sg11
Vhypophosphatemic rickets
p13469
sg13
I2
sa(dp13470
g7
I190
sg23
VC0242292
p13471
sg10
I24
sg11
VMcCune-Albright syndrome
p13472
sg13
I2
sa(dp13473
g7
I115
sg23
VC0544886
p13474
sg10
I17
sg11
Vsomatic mutations
p13475
sg13
I2
sasa(dp13476
g2
S'Fibrous dysplasia of bone (FD) is associated with increased total FGF23 levels (cFGF23 + iFGF23); however, classic hypophosphatemic rickets is uncommon.\n'
p13477
sg4
(lp13478
(dp13479
g7
I66
sg8
g39
sg10
I5
sg11
VFGF23
p13480
sg13
I1
sasg20
(lp13481
(dp13482
g7
I27
sg23
VC0259779
p13483
sg10
I2
sg11
VFD
p13484
sg13
I1
sa(dp13485
g7
I115
sg23
VC1704375
p13486
sg10
I24
sg11
Vhypophosphatemic rickets
p13487
sg13
I2
sa(dp13488
g7
I0
sg23
VC0259779
p13489
sg10
I25
sg11
VFibrous dysplasia of bone
p13490
sg13
I4
sasa(dp13491
g2
S'There were two confirmed partial responses in patients with triple-negative breast cancer (TP53-mutated) and melanoma (n = 1 each) and one unconfirmed partial response in a patient with cancer of unknown primary origin.Conclusions: Chk1 inhibition with GDC-0425 in combination with gemcitabine was tolerated with manageable bone marrow suppression.\n'
p13492
sg4
(lp13493
(dp13494
g7
I232
sg8
g39
sg10
I4
sg11
VChk1
p13495
sg13
I1
sa(dp13496
g7
I253
sg8
VP16260
p13497
sg10
I8
sg11
VGDC-0425
p13498
sg13
I1
sasg20
(lp13499
(dp13500
g7
I76
sg23
VC0678222
p13501
sg10
I13
sg11
Vbreast cancer
p13502
sg13
I2
sa(dp13503
g7
I186
sg23
VC0027667
p13504
sg10
I32
sg11
Vcancer of unknown primary origin
p13505
sg13
I5
sa(dp13506
g7
I109
sg23
VC0025202
p13507
sg10
I8
sg11
Vmelanoma
p13508
sg13
I1
sa(dp13509
g7
I336
sg23
VC0221103
p13510
sg10
I11
sg11
Vsuppression
p13511
sg13
I1
sasa(dp13512
g2
S'The goals of our studies were to characterize the brain distribution, pharmacodynamic (PD) effect, and efficacy of GDC-0084 in orthotopic xenograft models of GBM.\n'
p13513
sg4
(lp13514
sg20
(lp13515
(dp13516
g7
I158
sg23
VC0017636
p13517
sg10
I3
sg11
VGBM
p13518
sg13
I1
sasa(dp13519
g2
S'Mice bearing U87 or GS2 intracranial tumors were treated with GDC-0084 to assess its brain distribution by matrix-assisted laser desorption ionization (MALDI) imaging and measure its PD effects and efficacy in GBM orthotopic models.\n'
p13520
sg4
(lp13521
sg20
(lp13522
(dp13523
g7
I24
sg23
VC1527390
p13524
sg10
I19
sg11
Vintracranial tumors
p13525
sg13
I2
sa(dp13526
g7
I20
sg23
VC1868679
p13527
sg10
I3
sg11
VGS2
p13528
sg13
I1
sa(dp13529
g7
I210
sg23
VC0017636
p13530
sg10
I3
sg11
VGBM
p13531
sg13
I1
sasa(dp13532
g2
S'Pigmented lesion clinics (PLCs) that use technology such as digital dermoscopy and total-body photography are thought to confer a clinical advantage for patients at high risk of developing melanoma over general dermatology clinics (GDCs) with regular dermoscopy.\n'
p13533
sg4
(lp13534
sg20
(lp13535
(dp13536
g7
I189
sg23
VC0025202
p13537
sg10
I8
sg11
Vmelanoma
p13538
sg13
I1
sasa(dp13539
g2
S'To examine the difference between depths of melanomas diagnosed in a PLC and a GDC.\n'
p13540
sg4
(lp13541
sg20
(lp13542
(dp13543
g7
I44
sg23
VC0025202
p13544
sg10
I9
sg11
Vmelanomas
p13545
sg13
I1
sasa(dp13546
g2
S'The average Breslow depth for melanomas at the PLC was also smaller compared with the GDC (0.0371 vs 0.3450 mm; P = .02).\n'
p13547
sg4
(lp13548
sg20
(lp13549
(dp13550
g7
I30
sg23
VC0025202
p13551
sg10
I9
sg11
Vmelanomas
p13552
sg13
I1
sasa(dp13553
g2
S'Inhibitors currently in clinical trials, INCB024360, GDC-0919, indoximod, and an IDO1 peptide-based vaccine, are being evaluated for their efficacy against a wide range of cancers including melanoma, glioblastoma, non-small cell lung, pancreatic, and/or breast cancer, as well as metastatic disease.\n'
p13554
sg4
(lp13555
(dp13556
g7
I53
sg8
VP16260
p13557
sg10
I8
sg11
VGDC-0919
p13558
sg13
I1
sasg20
(lp13559
(dp13560
g7
I190
sg23
VC0025202
p13561
sg10
I8
sg11
Vmelanoma
p13562
sg13
I1
sa(dp13563
g7
I280
sg23
VC2939420
p13564
sg10
I18
sg11
Vmetastatic disease
p13565
sg13
I2
sa(dp13566
g7
I200
sg23
VC0017636
p13567
sg10
I12
sg11
Vglioblastoma
p13568
sg13
I1
sa(dp13569
g7
I254
sg23
VC0678222
p13570
sg10
I13
sg11
Vbreast cancer
p13571
sg13
I2
sa(dp13572
g7
I172
sg23
VC0006826
p13573
sg10
I7
sg11
Vcancers
p13574
sg13
I1
sasa(dp13575
g2
S'From 2001 to 2006, 11 patients with MVAC-treated metastatic urothelial carcinoma received as a second-line therapy GDC therapy consisting of gemcitabine (1,000 mg/m2) on day land 8, docetaxel (80 mg/m2) on day 1 and carboplatin (AUC 5) on day 1 in each 21-day cycle.\n'
p13576
sg4
(lp13577
sg20
(lp13578
(dp13579
g7
I60
sg23
VC0007138
p13580
sg10
I20
sg11
Vurothelial carcinoma
p13581
sg13
I2
sasa(dp13582
g2
S'GDC regimen as a second-line chemotherapy was effective in 54% of patients with MVAC-treated metastatic urothelial carcinoma, although the high incidence of hematologic toxicities and short period of progression-free survival remain to be major problems.\n'
p13583
sg4
(lp13584
(dp13585
g7
I0
sg8
VP16260
p13586
sg10
I3
sg11
VGDC
p13587
sg13
I1
sasg20
(lp13588
(dp13589
g7
I104
sg23
VC0007138
p13590
sg10
I20
sg11
Vurothelial carcinoma
p13591
sg13
I2
sasa(dp13592
g2
S'The number of Foxp3+ T cells and the expression of IL-10, TGF-Beta1 and FOXP3 in infected patients with gastritis were significantly higher than the ones in infected patients with peptic ulcer.\n'
p13593
sg4
(lp13594
(dp13595
g7
I58
sg8
VP01137
p13596
sg10
I9
sg11
VTGF-Beta1
p13597
sg13
I1
sa(dp13598
g7
I72
sg8
g39
sg10
I5
sg11
VFOXP3
p13599
sg13
I1
sasg20
(lp13600
(dp13601
g7
I104
sg23
VC0017152
p13602
sg10
I9
sg11
Vgastritis
p13603
sg13
I1
sa(dp13604
g7
I180
sg23
VC0030920
p13605
sg10
I12
sg11
Vpeptic ulcer
p13606
sg13
I2
sasa(dp13607
g2
S'These results indicate that the percentage of CD4(+) Foxp3(+) Treg cells are increased in H. pylori-infected mice, suggesting a role of Treg cells in H. pylori-induced pathologies, even at the early stages of chronic gastritis and gastric tumorigenesis.\n'
p13608
sg4
(lp13609
(dp13610
g7
I46
sg8
VP01730
p13611
sg10
I3
sg11
VCD4
p13612
sg13
I1
sasg20
(lp13613
(dp13614
g7
I209
sg23
VC0085695
p13615
sg10
I17
sg11
Vchronic gastritis
p13616
sg13
I2
sa(dp13617
g7
I239
sg23
VC0007621
p13618
sg10
I13
sg11
Vtumorigenesis
p13619
sg13
I1
sasa(dp13620
g2
S'We found a significant association between autism and a coding variant in the seizure-related gene SEZ6L2 (12/1106 autism vs. 3/1161 controls; p = 0.018).\n'
p13621
sg4
(lp13622
(dp13623
g7
I99
sg8
g39
sg10
I6
sg11
VSEZ6L2
p13624
sg13
I1
sasg20
(lp13625
(dp13626
g7
I43
sg23
VC0004352
p13627
sg10
I6
sg11
Vautism
p13628
sg13
I1
sa(dp13629
g7
I78
sg23
VC0036572
p13630
sg10
I7
sg11
Vseizure
p13631
sg13
I1
sa(dp13632
g7
I43
sg23
VC0004352
p13633
sg10
I6
sg11
Vautism
p13634
sg13
I1
sasa(dp13635
g2
S'Blockade of ET receptors unraveled the major vasoconstrictive role of ET-1 in the pathophysiology of VOC, stressing the pivotal role of abnormal endothelial phenotype in this hemoglobinopathy and opening potential new therapeutic options.\n'
p13636
sg4
(lp13637
(dp13638
g7
I12
sg8
g39
sg10
I12
sg11
VET receptors
p13639
sg13
I2
sa(dp13640
g7
I70
sg8
VP05305
p13641
sg10
I4
sg11
VET-1
p13642
sg13
I1
sasg20
(lp13643
(dp13644
g7
I175
sg23
VC0019045
p13645
sg10
I16
sg11
Vhemoglobinopathy
p13646
sg13
I1
sasa(dp13647
g2
S'We used immunohistochemical analysis with anti-endothelin-1 and anti-von Willebrand factor antibodies in comparing kidney biopsies from patients with systemic sclerosis and scleroderma renal crisis (n = 14); from normal kidneys (n = 5); and from patients with typical hemolytic uremic syndrome and thrombotic microangiopathy (n = 5), antiphospholipid syndrome (n = 6), diabetic nephropathy (n = 5), minimal change disease with cyclosporine toxicity (n = 5), or nephroangiosclerosis (n = 5).\n'
p13648
sg4
(lp13649
(dp13650
g7
I64
sg8
VP04275
p13651
sg10
I37
sg11
Vanti-von Willebrand factor antibodies
p13652
sg13
I4
sa(dp13653
g7
I42
sg8
VP20800
p13654
sg10
I17
sg11
Vanti-endothelin-1
p13655
sg13
I1
sasg20
(lp13656
(dp13657
g7
I461
sg23
VC0948347
p13658
sg10
I20
sg11
Vnephroangiosclerosis
p13659
sg13
I1
sa(dp13660
g7
I150
sg23
VC0036421
p13661
sg10
I18
sg11
Vsystemic sclerosis
p13662
sg13
I2
sa(dp13663
g7
I399
sg23
VC1704320
p13664
sg10
I22
sg11
Vminimal change disease
p13665
sg13
I3
sa(dp13666
g7
I298
sg23
VC2717961
p13667
sg10
I26
sg11
Vthrombotic microangiopathy
p13668
sg13
I2
sa(dp13669
g7
I268
sg23
VC0019061
p13670
sg10
I25
sg11
Vhemolytic uremic syndrome
p13671
sg13
I3
sa(dp13672
g7
I173
sg23
VC1262147
p13673
sg10
I24
sg11
Vscleroderma renal crisis
p13674
sg13
I3
sa(dp13675
g7
I334
sg23
VC0085278
p13676
sg10
I25
sg11
Vantiphospholipid syndrome
p13677
sg13
I2
sa(dp13678
g7
I369
sg23
VC0011881
p13679
sg10
I20
sg11
Vdiabetic nephropathy
p13680
sg13
I2
sasa(dp13681
g2
S'Glomerular endothelin-1 staining without arteriolar staining was seen in hemolytic uremic syndrome; and isolated arteriolar staining (without glomerular staining) was seen in a number of conditions including antiphospholipid nephropathy, cyclosporine toxicity, and diabetic nephropathy.\n'
p13682
sg4
(lp13683
(dp13684
g7
I11
sg8
VP20800
p13685
sg10
I12
sg11
Vendothelin-1
p13686
sg13
I1
sasg20
(lp13687
(dp13688
g7
I265
sg23
VC0011881
p13689
sg10
I20
sg11
Vdiabetic nephropathy
p13690
sg13
I2
sa(dp13691
g7
I225
sg23
VC0022658
p13692
sg10
I11
sg11
Vnephropathy
p13693
sg13
I1
sa(dp13694
g7
I73
sg23
VC0019061
p13695
sg10
I25
sg11
Vhemolytic uremic syndrome
p13696
sg13
I3
sasa(dp13697
g2
S'A second course of antiviral therapy using peginterferon alpha-2b and ribavirin achieved normalization of serum transaminases and HCV-RNA, but also caused interstitial pneumonia.\n'
p13698
sg4
(lp13699
(dp13700
g7
I106
sg8
g39
sg10
I19
sg11
Vserum transaminases
p13701
sg13
I2
sasg20
(lp13702
(dp13703
g7
I155
sg23
VC0206061
p13704
sg10
I22
sg11
Vinterstitial pneumonia
p13705
sg13
I2
sasa(dp13706
g2
S'We found that certain miRNAs, such as miR-196a and miR-1246, are highly enriched in pancreatic cancer exosomes.\n'
p13707
sg4
(lp13708
(dp13709
g7
I38
sg8
g39
sg10
I8
sg11
VmiR-196a
p13710
sg13
I1
sa(dp13711
g7
I51
sg8
g39
sg10
I8
sg11
VmiR-1246
p13712
sg13
I1
sasg20
(lp13713
(dp13714
g7
I84
sg23
VC0235974
p13715
sg10
I17
sg11
Vpancreatic cancer
p13716
sg13
I2
sasa(dp13717
g2
S'Consistently, plasma exosome miR-196a and miR-1246 levels were significantly elevated in pancreatic cancer patients as compared to healthy subjects.\n'
p13718
sg4
(lp13719
(dp13720
g7
I14
sg8
g39
sg10
I23
sg11
Vplasma exosome miR-196a
p13721
sg13
I3
sa(dp13722
g7
I42
sg8
g39
sg10
I8
sg11
VmiR-1246
p13723
sg13
I1
sasg20
(lp13724
(dp13725
g7
I89
sg23
VC0235974
p13726
sg10
I17
sg11
Vpancreatic cancer
p13727
sg13
I2
sasa(dp13728
g2
S'An analysis of the cancer subtypes indicated that plasma exosome miR-196a is a better indicator of pancreatic ductal adenocarcinoma (PDAC), whereas plasma exosome miR-1246 is significantly elevated in patients with intraductal papillary mucinous neoplasms (IPMN).\n'
p13729
sg4
(lp13730
(dp13731
g7
I148
sg8
g39
sg10
I23
sg11
Vplasma exosome miR-1246
p13732
sg13
I3
sa(dp13733
g7
I50
sg8
g39
sg10
I23
sg11
Vplasma exosome miR-196a
p13734
sg13
I3
sasg20
(lp13735
(dp13736
g7
I246
sg23
VC0027651
p13737
sg10
I9
sg11
Vneoplasms
p13738
sg13
I1
sa(dp13739
g7
I133
sg23
VC1335302
p13740
sg10
I4
sg11
VPDAC
p13741
sg13
I1
sa(dp13742
g7
I99
sg23
VC1335302
p13743
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p13744
sg13
I3
sa(dp13745
g7
I19
sg23
VC0006826
p13746
sg10
I6
sg11
Vcancer
p13747
sg13
I1
sasa(dp13748
g2
S'In conclusion, we demonstrate that certain miRNA species, such as miR-196a and miR-1246, are highly enriched in pancreatic cancer exosomes and elevated in plasma exosomes of patients with localized pancreatic cancer.\n'
p13749
sg4
(lp13750
(dp13751
g7
I79
sg8
g39
sg10
I8
sg11
VmiR-1246
p13752
sg13
I1
sa(dp13753
g7
I66
sg8
g39
sg10
I8
sg11
VmiR-196a
p13754
sg13
I1
sasg20
(lp13755
(dp13756
g7
I112
sg23
VC0235974
p13757
sg10
I17
sg11
Vpancreatic cancer
p13758
sg13
I2
sa(dp13759
g7
I112
sg23
VC0235974
p13760
sg10
I17
sg11
Vpancreatic cancer
p13761
sg13
I2
sasa(dp13762
g2
S'A study demonstrated that expression levels of miR-1246, miR-3976, miR-4306, and miR-4644 in serum exosomes were higher in pancreatic cancer patients than these levels in healthy control participants.\n'
p13763
sg4
(lp13764
(dp13765
g7
I57
sg8
g39
sg10
I8
sg11
VmiR-3976
p13766
sg13
I1
sa(dp13767
g7
I47
sg8
g39
sg10
I8
sg11
VmiR-1246
p13768
sg13
I1
sa(dp13769
g7
I67
sg8
g39
sg10
I8
sg11
VmiR-4306
p13770
sg13
I1
sasg20
(lp13771
(dp13772
g7
I123
sg23
VC0235974
p13773
sg10
I17
sg11
Vpancreatic cancer
p13774
sg13
I2
sasa(dp13775
g2
S'The in vitro drug sensitivity of pancreatic cancer cells was altered according to the miR-1246 expression via CCNG2.\n'
p13776
sg4
(lp13777
(dp13778
g7
I110
sg8
g39
sg10
I5
sg11
VCCNG2
p13779
sg13
I1
sa(dp13780
g7
I86
sg8
g39
sg10
I8
sg11
VmiR-1246
p13781
sg13
I1
sasg20
(lp13782
(dp13783
g7
I33
sg23
VC0235974
p13784
sg10
I17
sg11
Vpancreatic cancer
p13785
sg13
I2
sasa(dp13786
g2
S'miR-1246 expression was associated with chemoresistance and CSC-like properties via CCNG2, and could predict worse prognosis in pancreatic cancer patients.\n'
p13787
sg4
(lp13788
(dp13789
g7
I84
sg8
g39
sg10
I5
sg11
VCCNG2
p13790
sg13
I1
sasg20
(lp13791
(dp13792
g7
I128
sg23
VC0235974
p13793
sg10
I17
sg11
Vpancreatic cancer
p13794
sg13
I2
sasa(dp13795
g2
S'Similarly in PLP1CreER:tdT mice, PLP1 cells that co-express S100b but not RET also give rise to neurons following colitis.\n'
p13796
sg4
(lp13797
(dp13798
g7
I60
sg8
VP04271
p13799
sg10
I5
sg11
VS100b
p13800
sg13
I1
sa(dp13801
g7
I74
sg8
VP07949
p13802
sg10
I3
sg11
VRET
p13803
sg13
I1
sa(dp13804
g7
I13
sg8
VP60201
p13805
sg10
I4
sg11
VPLP1
p13806
sg13
I1
sa(dp13807
g7
I23
sg8
VP04053
p13808
sg10
I8
sg11
VtdT mice
p13809
sg13
I2
sasg20
(lp13810
(dp13811
g7
I114
sg23
VC0009319
p13812
sg10
I7
sg11
Vcolitis
p13813
sg13
I1
sasa(dp13814
g2
S'The colocalization of the P2X7 receptor-immunoreactive (IR) cells was observed in the myenteric plexus with nitric oxide synthase (NOS)-, ChAT-,calbindin-, calretinin- and HuC/D-IR neurons and S100Beta-IR cells in the control, sham and colitis groups.\n'
p13815
sg4
(lp13816
(dp13817
g7
I172
sg8
VP06213
p13818
sg10
I16
sg11
VHuC/D-IR neurons
p13819
sg13
I2
sa(dp13820
g7
I138
sg8
VP28329
p13821
sg10
I4
sg11
VChAT
p13822
sg13
I1
sa(dp13823
g7
I131
sg8
VP29475
p13824
sg10
I3
sg11
VNOS
p13825
sg13
I1
sa(dp13826
g7
I193
sg8
VP04271
p13827
sg10
I8
sg11
VS100Beta
p13828
sg13
I1
sa(dp13829
g7
I108
sg8
VP29475
p13830
sg10
I21
sg11
Vnitric oxide synthase
p13831
sg13
I3
sa(dp13832
g7
I156
sg8
VP22676
p13833
sg10
I10
sg11
Vcalretinin
p13834
sg13
I1
sa(dp13835
g7
I26
sg8
g39
sg10
I13
sg11
VP2X7 receptor
p13836
sg13
I2
sasg20
(lp13837
(dp13838
g7
I236
sg23
VC0009319
p13839
sg10
I7
sg11
Vcolitis
p13840
sg13
I1
sasa(dp13841
g2
S'Ulcerative colitis patients had significantly lower serum S100B levels, while GFAP was of no diagnostic value in UC patients.\n'
p13842
sg4
(lp13843
(dp13844
g7
I52
sg8
VP04271
p13845
sg10
I11
sg11
Vserum S100B
p13846
sg13
I2
sasg20
(lp13847
(dp13848
g7
I0
sg23
VC0009324
p13849
sg10
I18
sg11
VUlcerative colitis
p13850
sg13
I2
sasa(dp13851
g2
S'Molecules inhibiting S100B-driven enteric activation might mitigate the course of ulcerative colitis (UC).\n'
p13852
sg4
(lp13853
(dp13854
g7
I21
sg8
VP04271
p13855
sg10
I5
sg11
VS100B
p13856
sg13
I1
sasg20
(lp13857
(dp13858
g7
I82
sg23
VC0009324
p13859
sg10
I18
sg11
Vulcerative colitis
p13860
sg13
I2
sa(dp13861
g7
I102
sg23
VC0009324
p13862
sg10
I2
sg11
VUC
p13863
sg13
I1
sasa(dp13864
g2
S'Pentamidine exerts a marked anti-inflammatory effect in a mice model of acute colitis, likely targeting S100B activity.\n'
p13865
sg4
(lp13866
(dp13867
g7
I104
sg8
VP04271
p13868
sg10
I5
sg11
VS100B
p13869
sg13
I1
sasg20
(lp13870
(dp13871
g7
I78
sg23
VC0009319
p13872
sg10
I7
sg11
Vcolitis
p13873
sg13
I1
sasa(dp13874
g2
S'We hypothesized that polymorphisms in PLIN1 and PLIN4 would be associated with bone measures in adult Caucasian participants of the Framingham Osteoporosis Study (FOS).\n'
p13875
sg4
(lp13876
(dp13877
g7
I48
sg8
g39
sg10
I5
sg11
VPLIN4
p13878
sg13
I1
sa(dp13879
g7
I38
sg8
g39
sg10
I5
sg11
VPLIN1
p13880
sg13
I1
sasg20
(lp13881
(dp13882
g7
I143
sg23
VC0029456
p13883
sg10
I12
sg11
VOsteoporosis
p13884
sg13
I1
sasa(dp13885
g2
S'A complete prevention of intestinal tumors in BD6 rats was also produced not only by the DSF metabolite carbon disulfide (250 mg/kg) but also by the hepatotoxic agent carbon tetrachloride (1.5 ml/kg), which suggests that the block of DMH metabolism in rat liver is not an exclusive property of thiono-sulfur compounds.\n'
p13886
sg4
(lp13887
sg20
(lp13888
(dp13889
g7
I25
sg23
VC0021841
p13890
sg10
I17
sg11
Vintestinal tumors
p13891
sg13
I2
sasa(dp13892
g2
S"Drp1 (Dynamin-related protein 1), a regulator of mitochondrial fission, shows neuroprotective effects on Parkinson's disease.\n"
p13893
sg4
(lp13894
(dp13895
g7
I0
sg8
VP46939
p13896
sg10
I4
sg11
VDrp1
p13897
sg13
I1
sa(dp13898
g7
I6
sg8
VP14222
p13899
sg10
I25
sg11
VDynamin-related protein 1
p13900
sg13
I3
sasg20
(lp13901
(dp13902
g7
I105
sg23
VC0030567
p13903
sg10
I19
sg11
VParkinson's disease
p13904
sg13
I2
sasa(dp13905
g2
S"The role of a Parkinson's disease-associated protein-parkin, which biochemically and genetically interacts with Drp1-in mitochondrial connectivity also remains poorly understood.\n"
p13906
sg4
(lp13907
(dp13908
g7
I112
sg8
VP46939
p13909
sg10
I4
sg11
VDrp1
p13910
sg13
I1
sasg20
(lp13911
(dp13912
g7
I14
sg23
VC0030567
p13913
sg10
I19
sg11
VParkinson's disease
p13914
sg13
I2
sasa(dp13915
g2
S'These results clearly indicate that bombesin exerts morphological, adhesive, and proliferative effects on Isreco1 cells, suggesting that expression of the bombesin/GRP-R may contribute to the malignant properties of colon carcinoma cells.\n'
p13916
sg4
(lp13917
(dp13918
g7
I164
sg8
VP07492
p13919
sg10
I3
sg11
VGRP
p13920
sg13
I1
sa(dp13921
g7
I36
sg8
VP07492
p13922
sg10
I8
sg11
Vbombesin
p13923
sg13
I1
sasg20
(lp13924
(dp13925
g7
I216
sg23
VC0699790
p13926
sg10
I15
sg11
Vcolon carcinoma
p13927
sg13
I2
sa(dp13928
g7
I81
sg23
VC0334094
p13929
sg10
I13
sg11
Vproliferative
p13930
sg13
I1
sasa(dp13931
g2
S'Specific deletion of suppressor of cytokine signaling 3 (Socs3) in keratinocytes can cause severe skin inflammation with infiltration of immune cells.\n'
p13932
sg4
(lp13933
(dp13934
g7
I57
sg8
g39
sg10
I5
sg11
VSocs3
p13935
sg13
I1
sa(dp13936
g7
I21
sg8
g39
sg10
I34
sg11
Vsuppressor of cytokine signaling 3
p13937
sg13
I5
sasg20
(lp13938
(dp13939
g7
I121
sg23
VC0332448
p13940
sg10
I12
sg11
Vinfiltration
p13941
sg13
I1
sa(dp13942
g7
I98
sg23
VC0011603
p13943
sg10
I17
sg11
Vskin inflammation
p13944
sg13
I2
sasa(dp13945
g2
S'We found that SOCS3 and SOCS1 expression was reduced in vivo, in tumor lesions of BCC and SCC, as compared to other skin inflammatory conditions such as psoriasis, despite the high number of IL-22-secreting TILs.\n'
p13946
sg4
(lp13947
(dp13948
g7
I24
sg8
g39
sg10
I5
sg11
VSOCS1
p13949
sg13
I1
sa(dp13950
g7
I191
sg8
g39
sg10
I20
sg11
VIL-22-secreting TILs
p13951
sg13
I2
sa(dp13952
g7
I14
sg8
g39
sg10
I5
sg11
VSOCS3
p13953
sg13
I1
sasg20
(lp13954
(dp13955
g7
I65
sg23
VC0027651
p13956
sg10
I5
sg11
Vtumor
p13957
sg13
I1
sa(dp13958
g7
I153
sg23
VC0033860
p13959
sg10
I9
sg11
Vpsoriasis
p13960
sg13
I1
sasa(dp13961
g2
S'In the present study, we identified that suppressor of cytokine signaling-3 (SOCS3), a classical inhibitor of cytokine signaling, significantly inhibits CD8+T cell maturation, interferon-Gamma (IFN-Gamma) production and alopecia areata.\n'
p13962
sg4
(lp13963
(dp13964
g7
I41
sg8
g39
sg10
I34
sg11
Vsuppressor of cytokine signaling-3
p13965
sg13
I4
sa(dp13966
g7
I176
sg8
VP01579
p13967
sg10
I16
sg11
Vinterferon-Gamma
p13968
sg13
I1
sa(dp13969
g7
I194
sg8
VP01579
p13970
sg10
I9
sg11
VIFN-Gamma
p13971
sg13
I1
sa(dp13972
g7
I153
sg8
VP01732
p13973
sg10
I5
sg11
VCD8+T
p13974
sg13
I1
sa(dp13975
g7
I77
sg8
g39
sg10
I5
sg11
VSOCS3
p13976
sg13
I1
sasg20
(lp13977
(dp13978
g7
I220
sg23
VC0002171
p13979
sg10
I15
sg11
Valopecia areata
p13980
sg13
I2
sasa(dp13981
g2
S'SOCS3 is downregulated in the skin of alopecia areata patients and murine autoimmune alopecia model.\n'
p13982
sg4
(lp13983
(dp13984
g7
I0
sg8
g39
sg10
I5
sg11
VSOCS3
p13985
sg13
I1
sasg20
(lp13986
(dp13987
g7
I38
sg23
VC0002171
p13988
sg10
I15
sg11
Valopecia areata
p13989
sg13
I2
sa(dp13990
g7
I74
sg23
VC0443146
p13991
sg10
I10
sg11
Vautoimmune
p13992
sg13
I1
sasa(dp13993
g2
S'Furthermore, SOCS3 treatment prevents the development of alopecia areata in the graft model.\n'
p13994
sg4
(lp13995
(dp13996
g7
I13
sg8
g39
sg10
I5
sg11
VSOCS3
p13997
sg13
I1
sasg20
(lp13998
(dp13999
g7
I57
sg23
VC0002171
p14000
sg10
I15
sg11
Valopecia areata
p14001
sg13
I2
sasa(dp14002
g2
S'The expression of Fas and major histocompatibility complex-1 (MHC I) is upregulated in skin from C3H/HeJ alopecia areata mice, and this increase is suppressed by SOCS3.\n'
p14003
sg4
(lp14004
(dp14005
g7
I26
sg8
VP18464
p14006
sg10
I34
sg11
Vmajor histocompatibility complex-1
p14007
sg13
I3
sa(dp14008
g7
I18
sg8
VP48023
p14009
sg10
I3
sg11
VFas
p14010
sg13
I1
sa(dp14011
g7
I62
sg8
VP13747
p14012
sg10
I5
sg11
VMHC I
p14013
sg13
I2
sa(dp14014
g7
I162
sg8
g39
sg10
I5
sg11
VSOCS3
p14015
sg13
I1
sasg20
(lp14016
(dp14017
g7
I18
sg23
VC0015923
p14018
sg10
I3
sg11
VFas
p14019
sg13
I1
sa(dp14020
g7
I105
sg23
VC0002171
p14021
sg10
I15
sg11
Valopecia areata
p14022
sg13
I2
sasa(dp14023
g2
S'The SOCS3 level is negative correlation with the Fas and MHC I level in patients with alopecia areata.\n'
p14024
sg4
(lp14025
(dp14026
g7
I49
sg8
VP48023
p14027
sg10
I3
sg11
VFas
p14028
sg13
I1
sa(dp14029
g7
I4
sg8
g39
sg10
I5
sg11
VSOCS3
p14030
sg13
I1
sa(dp14031
g7
I57
sg8
VP13747
p14032
sg10
I5
sg11
VMHC I
p14033
sg13
I2
sasg20
(lp14034
(dp14035
g7
I49
sg23
VC0015923
p14036
sg10
I3
sg11
VFas
p14037
sg13
I1
sa(dp14038
g7
I86
sg23
VC0002171
p14039
sg10
I15
sg11
Valopecia areata
p14040
sg13
I2
sasa(dp14041
g2
S'These results suggest that SOCS3 treatment may be an effective strategy to treat autoimmune alopecia as well as to more generally prevent cytokine-dependent tissue destruction in inflammatory diseases.\n'
p14042
sg4
(lp14043
(dp14044
g7
I27
sg8
g39
sg10
I5
sg11
VSOCS3
p14045
sg13
I1
sasg20
(lp14046
(dp14047
g7
I81
sg23
VC0443146
p14048
sg10
I10
sg11
Vautoimmune
p14049
sg13
I1
sasa(dp14050
g2
S'Signal transducer and activator of transcription 1 (STAT1) and STAT3, and the downstream proteins suppressor of cytokine signaling 1 (SOCS1) and SOCS3, have been implicated in psoriasis disease progression.\n'
p14051
sg4
(lp14052
(dp14053
g7
I52
sg8
VP42224
p14054
sg10
I5
sg11
VSTAT1
p14055
sg13
I1
sa(dp14056
g7
I0
sg8
VP42224
p14057
sg10
I50
sg11
VSignal transducer and activator of transcription 1
p14058
sg13
I7
sa(dp14059
g7
I145
sg8
g39
sg10
I5
sg11
VSOCS3
p14060
sg13
I1
sa(dp14061
g7
I134
sg8
g39
sg10
I5
sg11
VSOCS1
p14062
sg13
I1
sa(dp14063
g7
I98
sg8
g39
sg10
I34
sg11
Vsuppressor of cytokine signaling 1
p14064
sg13
I5
sa(dp14065
g7
I63
sg8
VP40763
p14066
sg10
I5
sg11
VSTAT3
p14067
sg13
I1
sasg20
(lp14068
(dp14069
g7
I176
sg23
VC0033860
p14070
sg10
I9
sg11
Vpsoriasis
p14071
sg13
I1
sa(dp14072
g7
I186
sg23
VC0242656
p14073
sg10
I19
sg11
Vdisease progression
p14074
sg13
I2
sasa(dp14075
g2
S'After the identification of thyroid H2O2 generation system (DUOX) and of its maturation factors (DUOXA), defects in DUOX2 and/or DUOXA2 were rapidly recognized as the possible cause of congenital hypothyroidism (CH) due to thyroid dyshormonogenesis.\n'
p14076
sg4
(lp14077
(dp14078
g7
I116
sg8
g39
sg10
I5
sg11
VDUOX2
p14079
sg13
I1
sasg20
(lp14080
(dp14081
g7
I212
sg23
VC0342200
p14082
sg10
I2
sg11
VCH
p14083
sg13
I1
sa(dp14084
g7
I185
sg23
VC0342200
p14085
sg10
I25
sg11
Vcongenital hypothyroidism
p14086
sg13
I2
sasa(dp14087
g2
S'DUOX2 mutations result in dyshormonogenetic congenital hypothyroidism (CH) that may be phenotypically heterogeneous, leading to the hypothesis that CH severity may be influenced by environmental factors (e.g., dietary iodine) and oligogenic modifiers (e.g., variants in the homologous reduced form of NAD phosphate-oxidase DUOX1).\n'
p14088
sg4
(lp14089
(dp14090
g7
I0
sg8
g39
sg10
I15
sg11
VDUOX2 mutations
p14091
sg13
I2
sa(dp14092
g7
I301
sg8
VP51649
p14093
sg10
I27
sg11
VNAD phosphate-oxidase DUOX1
p14094
sg13
I3
sasg20
(lp14095
(dp14096
g7
I44
sg23
VC0342200
p14097
sg10
I25
sg11
Vcongenital hypothyroidism
p14098
sg13
I2
sa(dp14099
g7
I71
sg23
VC0342200
p14100
sg10
I2
sg11
VCH
p14101
sg13
I1
sa(dp14102
g7
I301
sg23
VC1850380
p14103
sg10
I3
sg11
VNAD
p14104
sg13
I1
sa(dp14105
g7
I71
sg23
VC0342200
p14106
sg10
I2
sg11
VCH
p14107
sg13
I1
sasa(dp14108
g2
S'The mutations in the dual oxidase 2 (DUOX2) and dual oxidase maturation factor 2 (DUOXA2) genes can cause congenital hypothyroidism (CH).\n'
p14109
sg4
(lp14110
(dp14111
g7
I82
sg8
g39
sg10
I6
sg11
VDUOXA2
p14112
sg13
I1
sa(dp14113
g7
I21
sg8
g39
sg10
I14
sg11
Vdual oxidase 2
p14114
sg13
I3
sa(dp14115
g7
I37
sg8
g39
sg10
I5
sg11
VDUOX2
p14116
sg13
I1
sa(dp14117
g7
I48
sg8
g39
sg10
I32
sg11
Vdual oxidase maturation factor 2
p14118
sg13
I5
sasg20
(lp14119
(dp14120
g7
I133
sg23
VC0342200
p14121
sg10
I2
sg11
VCH
p14122
sg13
I1
sa(dp14123
g7
I106
sg23
VC0342200
p14124
sg10
I25
sg11
Vcongenital hypothyroidism
p14125
sg13
I2
sasa(dp14126
g2
S'This study reports the pedigree with goitrous congenital hypothyroidism (GCH) due to the coexistence of heterozygous mutations in the DUOX2 and DUOXA2 genes.\n'
p14127
sg4
(lp14128
(dp14129
g7
I134
sg8
g39
sg10
I5
sg11
VDUOX2
p14130
sg13
I1
sa(dp14131
g7
I144
sg8
g39
sg10
I12
sg11
VDUOXA2 genes
p14132
sg13
I2
sasg20
(lp14133
(dp14134
g7
I46
sg23
VC0342200
p14135
sg10
I25
sg11
Vcongenital hypothyroidism
p14136
sg13
I2
sasa(dp14137
g2
S'Dos casos clinicos Transient congenital hypothyroidism due to biallelic defects of DUOX2 gene.\n'
p14138
sg4
(lp14139
(dp14140
g7
I83
sg8
g39
sg10
I10
sg11
VDUOX2 gene
p14141
sg13
I2
sa(dp14142
g7
I0
sg8
g39
sg10
I3
sg11
VDos
p14143
sg13
I1
sasg20
(lp14144
(dp14145
g7
I29
sg23
VC0342200
p14146
sg10
I25
sg11
Vcongenital hypothyroidism
p14147
sg13
I2
sasa(dp14148
g2
S'Two clinical cases Mutations in the DUOX2 gene have been described in transient and permanent congenital hypothyroidism.\n'
p14149
sg4
(lp14150
(dp14151
g7
I36
sg8
g39
sg10
I10
sg11
VDUOX2 gene
p14152
sg13
I2
sasg20
(lp14153
(dp14154
g7
I94
sg23
VC0342200
p14155
sg10
I25
sg11
Vcongenital hypothyroidism
p14156
sg13
I2
sasa(dp14157
g2
S'Objective: To explore the TPO, DUOX2 and DUOXA2 genotypes and phenotypes of children with permanent congenital hypothyroidism(PCH) suspected dyshormonogenesis in Guangzhou, identified and treated at Guangzhou Newborn Screening Center.\n'
p14158
sg4
(lp14159
(dp14160
g7
I31
sg8
g39
sg10
I5
sg11
VDUOX2
p14161
sg13
I1
sa(dp14162
g7
I41
sg8
g39
sg10
I16
sg11
VDUOXA2 genotypes
p14163
sg13
I2
sa(dp14164
g7
I26
sg8
VP40225
p14165
sg10
I3
sg11
VTPO
p14166
sg13
I1
sasg20
(lp14167
(dp14168
g7
I100
sg23
VC0342200
p14169
sg10
I25
sg11
Vcongenital hypothyroidism
p14170
sg13
I2
sasa(dp14171
g2
S'##############################(congenital hypothyroidism, CH)##TPO#DUOX2#DUOXA2################# ######################9#(#2011-2012######6#)##############CH######, ##Sanger#####TPO#DUOX2#DUOXA2##################, ############## ### 9####, 4###TPO####(##3#########, 1#########), 4###DUOX2##########, 1##DUOXA2########c.738C&gt;G(p.Y246X)####TPO#####c.1784G&gt;C(p.R595T)#SIFT#PolyPhen#2##############2#TPO###################CH##, ###########6#TPO#DUOX2#DUOXA2########################2011-2012####433 578####CH####156#CH, 6###############CH, ##1####TPO#######, ####TPO#DUOX2#DUOXA2###### ### TPO#DUOX2#######################CH############, TPO#DUOX2#DUOXA2########CH####, #################TPO#########CH##, ###p.R595T########.\n'
p14172
sg4
(lp14173
(dp14174
g7
I67
sg8
g39
sg10
I5
sg11
VDUOX2
p14175
sg13
I1
sa(dp14176
g7
I63
sg8
VP40225
p14177
sg10
I3
sg11
VTPO
p14178
sg13
I1
sa(dp14179
g7
I73
sg8
g39
sg10
I6
sg11
VDUOXA2
p14180
sg13
I1
sa(dp14181
g7
I63
sg8
VP40225
p14182
sg10
I3
sg11
VTPO
p14183
sg13
I1
sa(dp14184
g7
I73
sg8
g39
sg10
I6
sg11
VDUOXA2
p14185
sg13
I1
sa(dp14186
g7
I63
sg8
VP40225
p14187
sg10
I3
sg11
VTPO
p14188
sg13
I1
sa(dp14189
g7
I67
sg8
g39
sg10
I5
sg11
VDUOX2
p14190
sg13
I1
sa(dp14191
g7
I73
sg8
g39
sg10
I6
sg11
VDUOXA2
p14192
sg13
I1
sa(dp14193
g7
I63
sg8
VP40225
p14194
sg10
I3
sg11
VTPO
p14195
sg13
I1
sa(dp14196
g7
I67
sg8
g39
sg10
I5
sg11
VDUOX2
p14197
sg13
I1
sa(dp14198
g7
I63
sg8
VP40225
p14199
sg10
I3
sg11
VTPO
p14200
sg13
I1
sa(dp14201
g7
I63
sg8
VP40225
p14202
sg10
I3
sg11
VTPO
p14203
sg13
I1
sa(dp14204
g7
I73
sg8
g39
sg10
I6
sg11
VDUOXA2
p14205
sg13
I1
sa(dp14206
g7
I63
sg8
VP40225
p14207
sg10
I3
sg11
VTPO
p14208
sg13
I1
sa(dp14209
g7
I67
sg8
g39
sg10
I5
sg11
VDUOX2
p14210
sg13
I1
sa(dp14211
g7
I73
sg8
g39
sg10
I6
sg11
VDUOXA2
p14212
sg13
I1
sa(dp14213
g7
I63
sg8
VP40225
p14214
sg10
I3
sg11
VTPO
p14215
sg13
I1
sa(dp14216
g7
I73
sg8
g39
sg10
I6
sg11
VDUOXA2
p14217
sg13
I1
sa(dp14218
g7
I67
sg8
g39
sg10
I5
sg11
VDUOX2
p14219
sg13
I1
sa(dp14220
g7
I63
sg8
VP40225
p14221
sg10
I3
sg11
VTPO
p14222
sg13
I1
sa(dp14223
g7
I63
sg8
VP40225
p14224
sg10
I3
sg11
VTPO
p14225
sg13
I1
sa(dp14226
g7
I67
sg8
g39
sg10
I5
sg11
VDUOX2
p14227
sg13
I1
sa(dp14228
g7
I67
sg8
g39
sg10
I5
sg11
VDUOX2
p14229
sg13
I1
sasg20
(lp14230
(dp14231
g7
I31
sg23
VC0342200
p14232
sg10
I25
sg11
Vcongenital hypothyroidism
p14233
sg13
I2
sasa(dp14234
g2
S'Gene variants have been reported to be associated with congenital hypothyroidism (CH), the purpose of this study was to analyze the mutation spectrum and prevalence of 12 known causative genes (TSHR, PAX8, NKX2.1, NKX2.5, FOXE1, DUOX2, TG, TPO, GLIS3, NIS, SLC26A4 and DEHAL1) in CH in China.\n'
p14235
sg4
(lp14236
(dp14237
g7
I240
sg8
VP40225
p14238
sg10
I3
sg11
VTPO
p14239
sg13
I1
sa(dp14240
g7
I200
sg8
g39
sg10
I4
sg11
VPAX8
p14241
sg13
I1
sa(dp14242
g7
I194
sg8
VP16473
p14243
sg10
I4
sg11
VTSHR
p14244
sg13
I1
sa(dp14245
g7
I222
sg8
g39
sg10
I5
sg11
VFOXE1
p14246
sg13
I1
sa(dp14247
g7
I245
sg8
g39
sg10
I5
sg11
VGLIS3
p14248
sg13
I1
sa(dp14249
g7
I252
sg8
g39
sg10
I3
sg11
VNIS
p14250
sg13
I1
sa(dp14251
g7
I229
sg8
g39
sg10
I5
sg11
VDUOX2
p14252
sg13
I1
sa(dp14253
g7
I214
sg8
VP52952
p14254
sg10
I6
sg11
VNKX2.5
p14255
sg13
I1
sa(dp14256
g7
I257
sg8
g39
sg10
I7
sg11
VSLC26A4
p14257
sg13
I1
sa(dp14258
g7
I206
sg8
VP43699
p14259
sg10
I6
sg11
VNKX2.1
p14260
sg13
I1
sasg20
(lp14261
(dp14262
g7
I82
sg23
VC0342200
p14263
sg10
I2
sg11
VCH
p14264
sg13
I1
sa(dp14265
g7
I82
sg23
VC0342200
p14266
sg10
I2
sg11
VCH
p14267
sg13
I1
sa(dp14268
g7
I55
sg23
VC0342200
p14269
sg10
I25
sg11
Vcongenital hypothyroidism
p14270
sg13
I2
sasa(dp14271
g2
S'In the present study, we demonstrated that lncRNA-XIST was overexpressed in NSCLC tumor samples, and knockdown of lncRNA-XIST significantly decreased autophagy by regulation of ATG7 as determined by qPCR and by western blotting.\n'
p14272
sg4
(lp14273
(dp14274
g7
I177
sg8
g39
sg10
I4
sg11
VATG7
p14275
sg13
I1
sasg20
(lp14276
(dp14277
g7
I82
sg23
VC0027651
p14278
sg10
I5
sg11
Vtumor
p14279
sg13
I1
sa(dp14280
g7
I76
sg23
VC0007131
p14281
sg10
I5
sg11
VNSCLC
p14282
sg13
I1
sasa(dp14283
g2
S'Taken together, our results show that HULC may promote ovarian carcinoma tumorigenesis by inhibiting ATG7 and inducing progression by regulating ITGB1.\n'
p14284
sg4
(lp14285
(dp14286
g7
I101
sg8
g39
sg10
I4
sg11
VATG7
p14287
sg13
I1
sasg20
(lp14288
(dp14289
g7
I73
sg23
VC0007621
p14290
sg10
I13
sg11
Vtumorigenesis
p14291
sg13
I1
sa(dp14292
g7
I55
sg23
VC0029925
p14293
sg10
I17
sg11
Vovarian carcinoma
p14294
sg13
I2
sasa(dp14295
g2
S'Inhibition of CK2 in gp91 KO mice subjected to ischemia reperfusion did not increase brain infarction compared with TBCA-treated WT mice.\n'
p14296
sg4
(lp14297
(dp14298
g7
I14
sg8
VP68400
p14299
sg10
I3
sg11
VCK2
p14300
sg13
I1
sasg20
(lp14301
(dp14302
g7
I85
sg23
VC0751955
p14303
sg10
I16
sg11
Vbrain infarction
p14304
sg13
I2
sa(dp14305
g7
I47
sg23
VC0022116
p14306
sg10
I8
sg11
Vischemia
p14307
sg13
I1
sasa(dp14308
g2
S'Suspected cases of mitochondrial neurogastrointestinal encephalopathy (MNGIE), myofibrillar myopathy (MFM) and distal myopathy with rimmed vacuoles (DMRV) were confirmed by molecular genetic studies examining thymidine phosphorylase, GNE, ZASP myotilin, desmin, abeta-crystalline and filamin C genes.\n'
p14309
sg4
(lp14310
(dp14311
g7
I239
sg8
g39
sg10
I13
sg11
VZASP myotilin
p14312
sg13
I2
sa(dp14313
g7
I262
sg8
g39
sg10
I37
sg11
Vabeta-crystalline and filamin C genes
p14314
sg13
I5
sa(dp14315
g7
I234
sg8
g39
sg10
I3
sg11
VGNE
p14316
sg13
I1
sa(dp14317
g7
I209
sg8
VP19971
p14318
sg10
I23
sg11
Vthymidine phosphorylase
p14319
sg13
I2
sa(dp14320
g7
I254
sg8
VP98155
p14321
sg10
I6
sg11
Vdesmin
p14322
sg13
I1
sasg20
(lp14323
(dp14324
g7
I71
sg23
VC0872218
p14325
sg10
I5
sg11
VMNGIE
p14326
sg13
I1
sa(dp14327
g7
I19
sg23
VC1697449
p14328
sg10
I50
sg11
Vmitochondrial neurogastrointestinal encephalopathy
p14329
sg13
I3
sa(dp14330
g7
I79
sg23
VC2678065
p14331
sg10
I21
sg11
Vmyofibrillar myopathy
p14332
sg13
I2
sa(dp14333
g7
I102
sg23
VC2678065
p14334
sg10
I3
sg11
VMFM
p14335
sg13
I1
sa(dp14336
g7
I111
sg23
VC1853926
p14337
sg10
I36
sg11
Vdistal myopathy with rimmed vacuoles
p14338
sg13
I5
sa(dp14339
g7
I149
sg23
VC1853926
p14340
sg10
I4
sg11
VDMRV
p14341
sg13
I1
sasa(dp14342
g2
S'TDP-43-immunoreactive intracytoplasmic inclusions were seen in all cases examined of myotilinopathy, desminopathy, and sIBM, and in 1 case of inclusion body myositis with Paget disease of bone and frontotemporal degeneration (IBMPFD).\n'
p14343
sg4
(lp14344
sg20
(lp14345
(dp14346
g7
I226
sg23
VC1833662
p14347
sg10
I6
sg11
VIBMPFD
p14348
sg13
I1
sa(dp14349
g7
I142
sg23
VC1833662
p14350
sg10
I82
sg11
Vinclusion body myositis with Paget disease of bone and frontotemporal degeneration
p14351
sg13
I11
sa(dp14352
g7
I85
sg23
VC1836607
p14353
sg10
I14
sg11
Vmyotilinopathy
p14354
sg13
I1
sasa(dp14355
g2
S'In desmin myopathy but not hereditary inclusion-body myopathy (hIBM), there is accumulation of myofibrillar proteins including desmin, myotilin, dystrophin, gelsolin, actin, and CDC kinase.\n'
p14356
sg4
(lp14357
(dp14358
g7
I145
sg8
VP11532
p14359
sg10
I10
sg11
Vdystrophin
p14360
sg13
I1
sa(dp14361
g7
I157
sg8
VP06396
p14362
sg10
I8
sg11
Vgelsolin
p14363
sg13
I1
sa(dp14364
g7
I135
sg8
g39
sg10
I8
sg11
Vmyotilin
p14365
sg13
I1
sa(dp14366
g7
I3
sg8
VP98155
p14367
sg10
I6
sg11
Vdesmin
p14368
sg13
I1
sa(dp14369
g7
I3
sg8
VP98155
p14370
sg10
I6
sg11
Vdesmin
p14371
sg13
I1
sa(dp14372
g7
I178
sg8
VP33981
p14373
sg10
I10
sg11
VCDC kinase
p14374
sg13
I2
sasg20
(lp14375
(dp14376
g7
I10
sg23
VC0026848
p14377
sg10
I8
sg11
Vmyopathy
p14378
sg13
I1
sa(dp14379
g7
I10
sg23
VC0026848
p14380
sg10
I8
sg11
Vmyopathy
p14381
sg13
I1
sasa(dp14382
g2
S'Recent findings include: the beginnings of an understanding of the role of the sarcomere in controlling muscle gene expression; the theoretical analysis of the increasing number of mutations identified in the skeletal muscle actin gene; the identification of mutations in myosin causing hereditary inclusion body myopathy and hyaline body myopathy and the identification of mutations in myotilin in myofibrillar myopathy.\n'
p14383
sg4
(lp14384
(dp14385
g7
I209
sg8
VP21817
p14386
sg10
I26
sg11
Vskeletal muscle actin gene
p14387
sg13
I4
sa(dp14388
g7
I387
sg8
g39
sg10
I8
sg11
Vmyotilin
p14389
sg13
I1
sa(dp14390
g7
I272
sg8
VP13535
p14391
sg10
I6
sg11
Vmyosin
p14392
sg13
I1
sasg20
(lp14393
(dp14394
g7
I326
sg23
VC0333440
p14395
sg10
I12
sg11
Vhyaline body
p14396
sg13
I2
sa(dp14397
g7
I313
sg23
VC0026848
p14398
sg10
I8
sg11
Vmyopathy
p14399
sg13
I1
sa(dp14400
g7
I313
sg23
VC0026848
p14401
sg10
I8
sg11
Vmyopathy
p14402
sg13
I1
sa(dp14403
g7
I399
sg23
VC2678065
p14404
sg10
I21
sg11
Vmyofibrillar myopathy
p14405
sg13
I2
sasa(dp14406
g2
S'We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for atopic dermatitis.\n'
p14407
sg4
(lp14408
(dp14409
g7
I66
sg8
g39
sg10
I8
sg11
VSLC25A46
p14410
sg13
I1
sa(dp14411
g7
I109
sg8
VP35225
p14412
sg10
I15
sg11
VKIF3A-IL13 loci
p14413
sg13
I2
sa(dp14414
g7
I76
sg8
g39
sg10
I8
sg11
VTNFRSF6B
p14415
sg13
I1
sa(dp14416
g7
I58
sg8
g39
sg10
I7
sg11
VTMEM232
p14417
sg13
I1
sa(dp14418
g7
I43
sg8
VP20930
p14419
sg10
I3
sg11
VFLG
p14420
sg13
I1
sa(dp14421
g7
I48
sg8
g39
sg10
I8
sg11
VC11orf30
p14422
sg13
I1
sa(dp14423
g7
I99
sg8
g39
sg10
I5
sg11
VACTL9
p14424
sg13
I1
sa(dp14425
g7
I92
sg8
g39
sg10
I5
sg11
VOVOL1
p14426
sg13
I1
sasg20
(lp14427
(dp14428
g7
I231
sg23
VC0011615
p14429
sg10
I17
sg11
Vatopic dermatitis
p14430
sg13
I2
sasa(dp14431
g2
S'The tachykinins, a family of proinflammatory neuropeptides, have been implicated in the pathogenesis of pulmonary edema in some settings, including the pulmonary vascular leak associated with exposure to hypoxia.\n'
p14432
sg4
(lp14433
(dp14434
g7
I4
sg8
VP29401
p14435
sg10
I11
sg11
Vtachykinins
p14436
sg13
I1
sasg20
(lp14437
(dp14438
g7
I104
sg23
VC0034063
p14439
sg10
I15
sg11
Vpulmonary edema
p14440
sg13
I2
sa(dp14441
g7
I88
sg23
VC0699748
p14442
sg10
I12
sg11
Vpathogenesis
p14443
sg13
I1
sa(dp14444
g7
I204
sg23
VC0242184
p14445
sg10
I7
sg11
Vhypoxia
p14446
sg13
I1
sasa(dp14447
g2
S'Because CGRP potentiated the pulmonary edema induced in capsaicin and ACh, but decreased the effects of SP, we hypothesize that CGRP exerts a positive retro-control on the release of neuropeptides by these fibers but can attenuate their effects on the target cells.\n'
p14448
sg4
(lp14449
(dp14450
g7
I8
sg8
VP80511
p14451
sg10
I4
sg11
VCGRP
p14452
sg13
I1
sa(dp14453
g7
I8
sg8
VP80511
p14454
sg10
I4
sg11
VCGRP
p14455
sg13
I1
sasg20
(lp14456
(dp14457
g7
I29
sg23
VC0034063
p14458
sg10
I15
sg11
Vpulmonary edema
p14459
sg13
I2
sa(dp14460
g7
I70
sg23
VC0234238
p14461
sg10
I3
sg11
VACh
p14462
sg13
I1
sasa(dp14463
g2
S'On the other hand, intravenous administration of some neuropeptides that may be released from the capsaicin-sensitive nerves (e.g., substance P or calcitonin gene-related peptide) inhibited the development of pulmonary edema in vagotomized rats.\n'
p14464
sg4
(lp14465
(dp14466
g7
I147
sg8
VP06881
p14467
sg10
I31
sg11
Vcalcitonin gene-related peptide
p14468
sg13
I3
sasg20
(lp14469
(dp14470
g7
I209
sg23
VC0034063
p14471
sg10
I15
sg11
Vpulmonary edema
p14472
sg13
I2
sasa(dp14473
g2
S'Finally, miR-1271 rescued the function of circ-ABCB10 on breast cancer cells, confirming the sponge effect of circ-ABCB10 on miR-1271.\n'
p14474
sg4
(lp14475
(dp14476
g7
I9
sg8
g39
sg10
I8
sg11
VmiR-1271
p14477
sg13
I1
sa(dp14478
g7
I47
sg8
g39
sg10
I6
sg11
VABCB10
p14479
sg13
I1
sasg20
(lp14480
(dp14481
g7
I57
sg23
VC0678222
p14482
sg10
I13
sg11
Vbreast cancer
p14483
sg13
I2
sasa(dp14484
g2
S'Overall, results identified a new functional circ-ABCB10 in breast cancer tumorigenesis, and reveal the important regulatory role of circ-ABCB10 through sponging miR-1271, providing a novel insight for breast cancer pathogenesis.\n'
p14485
sg4
(lp14486
sg20
(lp14487
(dp14488
g7
I216
sg23
VC0699748
p14489
sg10
I12
sg11
Vpathogenesis
p14490
sg13
I1
sa(dp14491
g7
I60
sg23
VC0678222
p14492
sg10
I13
sg11
Vbreast cancer
p14493
sg13
I2
sa(dp14494
g7
I60
sg23
VC0678222
p14495
sg10
I13
sg11
Vbreast cancer
p14496
sg13
I2
sa(dp14497
g7
I74
sg23
VC0007621
p14498
sg10
I13
sg11
Vtumorigenesis
p14499
sg13
I1
sasa(dp14500
g2
S'Significantly higher level of miR-21 and lower level of miR-1271 expression were found in cancer tissues.\n'
p14501
sg4
(lp14502
sg20
(lp14503
(dp14504
g7
I90
sg23
VC0006826
p14505
sg10
I6
sg11
Vcancer
p14506
sg13
I1
sasa(dp14507
g2
S'Our results suggested that reduced expression of miR-1271 may be involved in the ERG expression and that miR-1271 could be a therapeutic target for ERG-positive prostate cancer patients.\n'
p14508
sg4
(lp14509
(dp14510
g7
I49
sg8
g39
sg10
I8
sg11
VmiR-1271
p14511
sg13
I1
sa(dp14512
g7
I81
sg8
VP11308
p14513
sg10
I3
sg11
VERG
p14514
sg13
I1
sa(dp14515
g7
I81
sg8
VP11308
p14516
sg10
I3
sg11
VERG
p14517
sg13
I1
sa(dp14518
g7
I49
sg8
g39
sg10
I8
sg11
VmiR-1271
p14519
sg13
I1
sasg20
(lp14520
(dp14521
g7
I161
sg23
VC0600139
p14522
sg10
I15
sg11
Vprostate cancer
p14523
sg13
I2
sasa(dp14524
g2
S'miR-1271 is a multifunctional post-translational modulator, which is involved in several diseases.\n'
p14525
sg4
(lp14526
(dp14527
g7
I0
sg8
g39
sg10
I8
sg11
VmiR-1271
p14528
sg13
I1
sasg20
(lp14529
sa(dp14530
g2
S'In the present study, it was hypothesized that a post-translational mechanism of miR-1271 regulates the expression of FN1 in the progression of neuroglioma.\n'
p14531
sg4
(lp14532
(dp14533
g7
I81
sg8
g39
sg10
I8
sg11
VmiR-1271
p14534
sg13
I1
sasg20
(lp14535
sa(dp14536
g2
S'The miR-1271 levels in glioma tissues and cell lines were assessed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).\n'
p14537
sg4
(lp14538
(dp14539
g7
I4
sg8
g39
sg10
I8
sg11
VmiR-1271
p14540
sg13
I1
sasg20
(lp14541
(dp14542
g7
I23
sg23
VC0017638
p14543
sg10
I6
sg11
Vglioma
p14544
sg13
I1
sasa(dp14545
g2
S'The results showed that miR-1271 was downregulated in glioma tumor tissues and cell lines.\n'
p14546
sg4
(lp14547
(dp14548
g7
I24
sg8
g39
sg10
I8
sg11
VmiR-1271
p14549
sg13
I1
sasg20
(lp14550
(dp14551
g7
I54
sg23
VC0017638
p14552
sg10
I6
sg11
Vglioma
p14553
sg13
I1
sa(dp14554
g7
I61
sg23
VC0027651
p14555
sg10
I5
sg11
Vtumor
p14556
sg13
I1
sasa(dp14557
g2
S'In addition, it was demonstrated that low levels of miR-1271 in patients with glioma were correlated with low survival rate.\n'
p14558
sg4
(lp14559
sg20
(lp14560
(dp14561
g7
I78
sg23
VC0017638
p14562
sg10
I6
sg11
Vglioma
p14563
sg13
I1
sasa(dp14564
g2
S'Therefore, it was concluded that miR-1271 inhibited glioma cell growth by targeting FN1, and a low level of miR-1271 in glioma tumor tissues was associated with lower survival rates in patients with glioma.\n'
p14565
sg4
(lp14566
sg20
(lp14567
(dp14568
g7
I127
sg23
VC0027651
p14569
sg10
I5
sg11
Vtumor
p14570
sg13
I1
sa(dp14571
g7
I52
sg23
VC0017638
p14572
sg10
I6
sg11
Vglioma
p14573
sg13
I1
sa(dp14574
g7
I52
sg23
VC0017638
p14575
sg10
I6
sg11
Vglioma
p14576
sg13
I1
sa(dp14577
g7
I52
sg23
VC0017638
p14578
sg10
I6
sg11
Vglioma
p14579
sg13
I1
sasa(dp14580
g2
S'The expression of Foxk2 may be regulated by miR-1271, which could serve as a promising therapeutic target for NSCLC.\n'
p14581
sg4
(lp14582
(dp14583
g7
I18
sg8
g39
sg10
I5
sg11
VFoxk2
p14584
sg13
I1
sasg20
(lp14585
(dp14586
g7
I110
sg23
VC0007131
p14587
sg10
I5
sg11
VNSCLC
p14588
sg13
I1
sasa(dp14589
g2
S'Furthermore, DIXDC1 expression was inversely correlated with miR-1271 expression in prostate cancer tissues.\n'
p14590
sg4
(lp14591
(dp14592
g7
I13
sg8
g39
sg10
I6
sg11
VDIXDC1
p14593
sg13
I1
sasg20
(lp14594
(dp14595
g7
I84
sg23
VC0600139
p14596
sg10
I15
sg11
Vprostate cancer
p14597
sg13
I2
sasa(dp14598
g2
S'The overexpression of miR-1271 significantly inhibited proliferation, invasion and Wnt signaling in prostate cancer cells.\n'
p14599
sg4
(lp14600
sg20
(lp14601
(dp14602
g7
I55
sg23
VC0334094
p14603
sg10
I13
sg11
Vproliferation
p14604
sg13
I1
sa(dp14605
g7
I100
sg23
VC0600139
p14606
sg10
I15
sg11
Vprostate cancer
p14607
sg13
I2
sa(dp14608
g7
I70
sg23
VC2699153
p14609
sg10
I8
sg11
Vinvasion
p14610
sg13
I1
sasa(dp14611
g2
S'Targeting DIXDC1 by miR-1271 may be a promising therapeutic strategy for prostate cancer.\n'
p14612
sg4
(lp14613
(dp14614
g7
I10
sg8
g39
sg10
I6
sg11
VDIXDC1
p14615
sg13
I1
sa(dp14616
g7
I20
sg8
g39
sg10
I8
sg11
VmiR-1271
p14617
sg13
I1
sasg20
(lp14618
(dp14619
g7
I73
sg23
VC0600139
p14620
sg10
I15
sg11
Vprostate cancer
p14621
sg13
I2
sasa(dp14622
g2
S'Since this damage is repaired by O6 -methylguanine-DNA methyltransferase (MGMT), the repair enzyme represents the most important factor of drug resistance, limiting the therapy of malignant high-grade gliomas.\n'
p14623
sg4
(lp14624
(dp14625
g7
I74
sg8
VP16455
p14626
sg10
I4
sg11
VMGMT
p14627
sg13
I1
sa(dp14628
g7
I33
sg8
VP16455
p14629
sg10
I39
sg11
VO6 -methylguanine-DNA methyltransferase
p14630
sg13
I3
sasg20
(lp14631
(dp14632
g7
I201
sg23
VC0017638
p14633
sg10
I7
sg11
Vgliomas
p14634
sg13
I1
sasa(dp14635
g2
S'Here, we addressed the question whether MGMT in glioma cells is enhanced following alkylating drugs or ionizing radiation, using promoter assays.\n'
p14636
sg4
(lp14637
(dp14638
g7
I40
sg8
VP16455
p14639
sg10
I4
sg11
VMGMT
p14640
sg13
I1
sasg20
(lp14641
(dp14642
g7
I48
sg23
VC0017638
p14643
sg10
I6
sg11
Vglioma
p14644
sg13
I1
sasa(dp14645
g2
S'This enhanced the immunogenicity of glioma cells in a NGK2D-dependent manner, was independent from cytotoxic or growth inhibitory effects, attenuated by O6-methylguanine-DNA-methyltransferase (MGMT) and required the DNA damage response.\n'
p14646
sg4
(lp14647
(dp14648
g7
I193
sg8
VP16455
p14649
sg10
I4
sg11
VMGMT
p14650
sg13
I1
sa(dp14651
g7
I153
sg8
g39
sg10
I38
sg11
VO6-methylguanine-DNA-methyltransferase
p14652
sg13
I1
sasg20
(lp14653
(dp14654
g7
I36
sg23
VC0017638
p14655
sg10
I6
sg11
Vglioma
p14656
sg13
I1
sa(dp14657
g7
I216
sg23
VC0012860
p14658
sg10
I10
sg11
VDNA damage
p14659
sg13
I2
sasa(dp14660
g2
S'Among patients affected by advanced glioblastoma or melanoma and treated with TEM, loss of tumoral O6-methylguanine DNA methyltransferase (MGMT) is correlated with improved survival.\n'
p14661
sg4
(lp14662
(dp14663
g7
I139
sg8
VP16455
p14664
sg10
I4
sg11
VMGMT
p14665
sg13
I1
sa(dp14666
g7
I99
sg8
VP26358
p14667
sg10
I38
sg11
VO6-methylguanine DNA methyltransferase
p14668
sg13
I3
sasg20
(lp14669
(dp14670
g7
I78
sg23
VC0276640
p14671
sg10
I3
sg11
VTEM
p14672
sg13
I1
sa(dp14673
g7
I52
sg23
VC0025202
p14674
sg10
I8
sg11
Vmelanoma
p14675
sg13
I1
sa(dp14676
g7
I36
sg23
VC0017636
p14677
sg10
I12
sg11
Vglioblastoma
p14678
sg13
I1
sasa(dp14679
g2
S"In this study, we stimulated cervical cancer cells with 5-aza-2'-deoxycytidine (5-Aza-dC) and found that this treatment inhibited cell proliferation and induced apoptosis; additionally, methylation of p16 and O-6-methylguanine-DNA methyltransferase (MGMT) was reversed, although their expression was suppressed.\n"
p14680
sg4
(lp14681
(dp14682
g7
I209
sg8
VP16455
p14683
sg10
I39
sg11
VO-6-methylguanine-DNA methyltransferase
p14684
sg13
I2
sa(dp14685
g7
I201
sg8
VP42771
p14686
sg10
I3
sg11
Vp16
p14687
sg13
I1
sa(dp14688
g7
I250
sg8
VP16455
p14689
sg10
I4
sg11
VMGMT
p14690
sg13
I1
sasg20
(lp14691
(dp14692
g7
I135
sg23
VC0334094
p14693
sg10
I13
sg11
Vproliferation
p14694
sg13
I1
sa(dp14695
g7
I29
sg23
VC0302592
p14696
sg10
I15
sg11
Vcervical cancer
p14697
sg13
I2
sasa(dp14698
g2
S'In a multivariate Cox regression analyses, adjusted for inherited thrombophilia, age, sex and BMI, low levels of TGF-Beta1 [hazard ratio (HR) = 2.2, 95% confidence interval (CI) 1.1-4.3; p = 0.02] and TGF-Beta2 (HR = 2.4, 95% CI 1.2-4.7; p = 0.01) were independently associated with a higher risk of recurrent VTE.\n'
p14699
sg4
(lp14700
(dp14701
g7
I201
sg8
VP61812
p14702
sg10
I9
sg11
VTGF-Beta2
p14703
sg13
I1
sa(dp14704
g7
I113
sg8
VP01137
p14705
sg10
I9
sg11
VTGF-Beta1
p14706
sg13
I1
sasg20
(lp14707
(dp14708
g7
I66
sg23
VC2827470
p14709
sg10
I13
sg11
Vthrombophilia
p14710
sg13
I1
sasa(dp14711
g2
S'The increased osteoclastic activity in preeclampsia may be attributed to increased RANKL induced by increased interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor beta2 (TGF-beta2) production.\n'
p14712
sg4
(lp14713
(dp14714
g7
I132
sg8
VP01375
p14715
sg10
I27
sg11
Vtumor necrosis factor-alpha
p14716
sg13
I3
sa(dp14717
g7
I177
sg8
VP61812
p14718
sg10
I32
sg11
Vtransforming growth factor beta2
p14719
sg13
I4
sa(dp14720
g7
I83
sg8
g39
sg10
I5
sg11
VRANKL
p14721
sg13
I1
sa(dp14722
g7
I161
sg8
VP01375
p14723
sg10
I9
sg11
VTNF-alpha
p14724
sg13
I1
sa(dp14725
g7
I110
sg8
VP05231
p14726
sg10
I13
sg11
Vinterleukin-6
p14727
sg13
I1
sa(dp14728
g7
I125
sg8
VP05231
p14729
sg10
I4
sg11
VIL-6
p14730
sg13
I1
sa(dp14731
g7
I211
sg8
VP61812
p14732
sg10
I9
sg11
VTGF-beta2
p14733
sg13
I1
sasg20
(lp14734
(dp14735
g7
I39
sg23
VC0032914
p14736
sg10
I12
sg11
Vpreeclampsia
p14737
sg13
I1
sa(dp14738
g7
I132
sg23
VC0333516
p14739
sg10
I14
sg11
Vtumor necrosis
p14740
sg13
I2
sasa(dp14741
g2
S'Both the enhancement of I(K,slow) and the negative inotropic effect of palmitate:BSA were reduced in the presence of the Kv1.5 selective channel blocker, diphenyl phosphine oxide-1 (DPO-1).Taken together, these results suggest that elevations in circulating saturated free fatty acids, as occurs in diabetes, can directly augment repolarizing myocardial Kv currents and impair excitation-contraction coupling.\n'
p14742
sg4
(lp14743
(dp14744
g7
I81
sg8
VP49639
p14745
sg10
I3
sg11
VBSA
p14746
sg13
I1
sa(dp14747
g7
I121
sg8
VP22460
p14748
sg10
I23
sg11
VKv1.5 selective channel
p14749
sg13
I3
sasg20
(lp14750
(dp14751
g7
I299
sg23
VC0011849
p14752
sg10
I8
sg11
Vdiabetes
p14753
sg13
I1
sa(dp14754
g7
I388
sg23
VC1140999
p14755
sg10
I11
sg11
Vcontraction
p14756
sg13
I1
sasa(dp14757
g2
S'We have previously reported that the level of leucine-rich alpha-2-glycoprotein (LRG) expression is specifically increased in cerebrospinal fluid (CSF) of idiopathic normal pressure hydrocephalus (INPH).\n'
p14758
sg4
(lp14759
(dp14760
g7
I81
sg8
VP02750
p14761
sg10
I3
sg11
VLRG
p14762
sg13
I1
sa(dp14763
g7
I46
sg8
VP02750
p14764
sg10
I33
sg11
Vleucine-rich alpha-2-glycoprotein
p14765
sg13
I2
sasg20
(lp14766
(dp14767
g7
I166
sg23
VC0020258
p14768
sg10
I29
sg11
Vnormal pressure hydrocephalus
p14769
sg13
I3
sasa(dp14770
g2
S'On the basis of sphingomyelinase assay in five cases of Niemann-Pick disease, three cases were classified as type IA, one as type IS and one as type IIS.\n'
p14771
sg4
(lp14772
sg20
(lp14773
(dp14774
g7
I56
sg23
VC0028064
p14775
sg10
I20
sg11
VNiemann-Pick disease
p14776
sg13
I2
sasa(dp14777
g2
S'Fibroblasts from 13 patients with the clinical phenotype of type IIS, Niemann-Pick disease were evaluated for their ability to incorporate oleic acid into cholesterol esters via an LDL responsive mechanism.\n'
p14778
sg4
(lp14779
sg20
(lp14780
(dp14781
g7
I70
sg23
VC0028064
p14782
sg10
I20
sg11
VNiemann-Pick disease
p14783
sg13
I2
sasa(dp14784
g2
S'To further implicate lysosomal proteins in the etiology of type IIS, Niemann-Pick disease we measured the effect of correction (conditioned) medium, and the lysosomotropic agent, NH4Cl on cholesterol ester synthesis in fibroblasts.\n'
p14785
sg4
(lp14786
(dp14787
g7
I21
sg8
g39
sg10
I18
sg11
Vlysosomal proteins
p14788
sg13
I2
sasg20
(lp14789
(dp14790
g7
I69
sg23
VC0028064
p14791
sg10
I20
sg11
VNiemann-Pick disease
p14792
sg13
I2
sasa(dp14793
g2
S"Neopanaxadiol (NPD), the main panaxadiol constituent of Panax ginseng C. A. Meyer (Araliaceae), has been regarded as the active component for the treatment of Alzheimer's disease.\n"
p14794
sg4
(lp14795
sg20
(lp14796
(dp14797
g7
I159
sg23
VC1521724
p14798
sg10
I19
sg11
VAlzheimer's disease
p14799
sg13
I2
sasa(dp14800
g2
S"Neopanaxadiol (NPD) is one of the major ginsenosides in Panax ginseng C. A. Meyer (Araliaceae) that has been suggested to be a drug candidate against Alzheimer's disease.\n"
p14801
sg4
(lp14802
sg20
(lp14803
(dp14804
g7
I150
sg23
VC1521724
p14805
sg10
I19
sg11
VAlzheimer's disease
p14806
sg13
I2
sasa(dp14807
g2
S"We covered an introduction to sphingomyelinases and its enzymatic product ceramide, in membrane domains or lipid rafts and the nucleus; followed by crosstalk between sphingomyelinase and cytosolic phospholipase A2 (cPLA2) catalysed products including arachidonic acid, functions of acid sphingomyelinase (aSMase) and neutral sphingomyelinase (N-SMase) in neurons, neuronal progenitor cells, glial cells, and brain endothelial cells; alterations in acid and N-SMases in Niemann Pick Disease Type A, major depression, Alzheimer's disease, cerebral ischemia, and pain; and recent developments in identification of inhibitors to sphingomyelinases.\n"
p14808
sg4
(lp14809
(dp14810
g7
I469
sg8
g39
sg10
I27
sg11
VNiemann Pick Disease Type A
p14811
sg13
I5
sa(dp14812
g7
I317
sg8
g39
sg10
I24
sg11
Vneutral sphingomyelinase
p14813
sg13
I2
sa(dp14814
g7
I457
sg8
g39
sg10
I8
sg11
VN-SMases
p14815
sg13
I1
sa(dp14816
g7
I282
sg8
VP17405
p14817
sg10
I21
sg11
Vacid sphingomyelinase
p14818
sg13
I2
sa(dp14819
g7
I343
sg8
g39
sg10
I7
sg11
VN-SMase
p14820
sg13
I1
sa(dp14821
g7
I187
sg8
VP47712
p14822
sg10
I26
sg11
Vcytosolic phospholipase A2
p14823
sg13
I3
sa(dp14824
g7
I305
sg8
VP17405
p14825
sg10
I6
sg11
VaSMase
p14826
sg13
I1
sa(dp14827
g7
I215
sg8
VP47712
p14828
sg10
I5
sg11
VcPLA2
p14829
sg13
I1
sasg20
(lp14830
(dp14831
g7
I469
sg23
VC0028064
p14832
sg10
I20
sg11
VNiemann Pick Disease
p14833
sg13
I3
sa(dp14834
g7
I516
sg23
VC1521724
p14835
sg10
I19
sg11
VAlzheimer's disease
p14836
sg13
I2
sa(dp14837
g7
I498
sg23
VC1269683
p14838
sg10
I16
sg11
Vmajor depression
p14839
sg13
I2
sa(dp14840
g7
I537
sg23
VC0917798
p14841
sg10
I17
sg11
Vcerebral ischemia
p14842
sg13
I2
sasa(dp14843
g2
S"These entities named FIASMAs (Functional Inhibitors of Acid SphingoMyelinAse), therefore, can be potentially used to treat diseases associated with enhanced activity of ASM, such as Alzheimer's disease, major depression, radiation- and chemotherapy-induced apoptosis and endotoxic shock syndrome.\n"
p14844
sg4
(lp14845
(dp14846
g7
I23
sg8
VP17405
p14847
sg10
I3
sg11
VASM
p14848
sg13
I1
sasg20
(lp14849
(dp14850
g7
I287
sg23
VC0039082
p14851
sg10
I8
sg11
Vsyndrome
p14852
sg13
I1
sa(dp14853
g7
I271
sg23
VC0036981
p14854
sg10
I15
sg11
Vendotoxic shock
p14855
sg13
I2
sa(dp14856
g7
I203
sg23
VC1269683
p14857
sg10
I16
sg11
Vmajor depression
p14858
sg13
I2
sa(dp14859
g7
I182
sg23
VC1521724
p14860
sg10
I19
sg11
VAlzheimer's disease
p14861
sg13
I2
sasa(dp14862
g2
S'Aim: The aim of this study was to investigate the effect and underlying signaling mechanisms of metformin on apoptosis and Cx43 expression in H9c2 cells presenting with hyperglycemia conditions.\n'
p14863
sg4
(lp14864
(dp14865
g7
I123
sg8
VP17302
p14866
sg10
I4
sg11
VCx43
p14867
sg13
I1
sasg20
(lp14868
(dp14869
g7
I169
sg23
VC0020456
p14870
sg10
I13
sg11
Vhyperglycemia
p14871
sg13
I1
sasa(dp14872
g2
S'Interestingly, metformin attenuated hyperglycemia-increased apoptosis and restored Cx43 expression.\n'
p14873
sg4
(lp14874
(dp14875
g7
I83
sg8
VP17302
p14876
sg10
I4
sg11
VCx43
p14877
sg13
I1
sasg20
(lp14878
(dp14879
g7
I36
sg23
VC0020456
p14880
sg10
I13
sg11
Vhyperglycemia
p14881
sg13
I1
sasa(dp14882
g2
S'Conclusion: Administration metformin can protect the H9c2 cells against hyperglycemia-induced apoptosis and Cx43 down-regulation, in part, mediated through the induction of autophagy pathway.\n'
p14883
sg4
(lp14884
(dp14885
g7
I108
sg8
VP17302
p14886
sg10
I4
sg11
VCx43
p14887
sg13
I1
sasg20
(lp14888
(dp14889
g7
I72
sg23
VC0020456
p14890
sg10
I13
sg11
Vhyperglycemia
p14891
sg13
I1
sasa(dp14892
g2
S'However, it remains to be elucidated whether resveratrol treatment may attenuate the hyperglycemia-induced remodeling of Cx43 and apoptosis through the regulation of autophagy.\n'
p14893
sg4
(lp14894
(dp14895
g7
I121
sg8
VP17302
p14896
sg10
I4
sg11
VCx43
p14897
sg13
I1
sasg20
(lp14898
(dp14899
g7
I85
sg23
VC0020456
p14900
sg10
I13
sg11
Vhyperglycemia
p14901
sg13
I1
sasa(dp14902
g2
S'In conclusion, administration resveratrol may protect H9c2 cells against hyperglycemia-induced Cx43 upregulation and apoptosis, which may be mediated through the induction of the autophagy signaling pathway.\n'
p14903
sg4
(lp14904
(dp14905
g7
I95
sg8
VP17302
p14906
sg10
I4
sg11
VCx43
p14907
sg13
I1
sasg20
(lp14908
(dp14909
g7
I73
sg23
VC0020456
p14910
sg10
I13
sg11
Vhyperglycemia
p14911
sg13
I1
sasa(dp14912
g2
S'The objective of this study was to investigate the frequency of autoantibodies to hydroxymethylglutaryl coenzyme A reductase (HMGCR) in systemic sclerosis (SSc) and associations with inflammatory myositis and statin exposure.This was a cross-sectional, multicenter study of 306 subjects from the Canadian Scleroderma Research Group cohort who had complete data on statin exposure and serology for anti-HMGCR antibodies assayed by an addressable laser bead immunoassay (ALBIA).\n'
p14913
sg4
(lp14914
(dp14915
g7
I209
sg8
g39
sg10
I6
sg11
Vstatin
p14916
sg13
I1
sa(dp14917
g7
I82
sg8
VP04035
p14918
sg10
I42
sg11
Vhydroxymethylglutaryl coenzyme A reductase
p14919
sg13
I4
sa(dp14920
g7
I397
sg8
VP04035
p14921
sg10
I21
sg11
Vanti-HMGCR antibodies
p14922
sg13
I2
sa(dp14923
g7
I126
sg8
VP04035
p14924
sg10
I5
sg11
VHMGCR
p14925
sg13
I1
sasg20
(lp14926
(dp14927
g7
I196
sg23
VC0027121
p14928
sg10
I8
sg11
Vmyositis
p14929
sg13
I1
sa(dp14930
g7
I305
sg23
VC0036421
p14931
sg10
I11
sg11
VScleroderma
p14932
sg13
I1
sa(dp14933
g7
I156
sg23
VC0036421
p14934
sg10
I3
sg11
VSSc
p14935
sg13
I1
sa(dp14936
g7
I136
sg23
VC0036421
p14937
sg10
I18
sg11
Vsystemic sclerosis
p14938
sg13
I2
sasa(dp14939
g2
S'IMNM may be associated with myositis-specific autoantibodies (i.e., anti-SRP and anti-HMGCR) and malignancy, in association with viral infections (HIV or hepatitis C), or in relation to other connective tissue diseases (i.e., scleroderma).\n'
p14940
sg4
(lp14941
(dp14942
g7
I81
sg8
VP04035
p14943
sg10
I10
sg11
Vanti-HMGCR
p14944
sg13
I1
sa(dp14945
g7
I68
sg8
g39
sg10
I8
sg11
Vanti-SRP
p14946
sg13
I1
sasg20
(lp14947
(dp14948
g7
I192
sg23
VC0009782
p14949
sg10
I26
sg11
Vconnective tissue diseases
p14950
sg13
I3
sa(dp14951
g7
I226
sg23
VC0011644
p14952
sg10
I11
sg11
Vscleroderma
p14953
sg13
I1
sa(dp14954
g7
I129
sg23
VC0042769
p14955
sg10
I16
sg11
Vviral infections
p14956
sg13
I2
sa(dp14957
g7
I154
sg23
VC0019196
p14958
sg10
I11
sg11
Vhepatitis C
p14959
sg13
I2
sa(dp14960
g7
I147
sg23
VC0019693
p14961
sg10
I3
sg11
VHIV
p14962
sg13
I1
sa(dp14963
g7
I97
sg23
VC0006826
p14964
sg10
I10
sg11
Vmalignancy
p14965
sg13
I1
sa(dp14966
g7
I28
sg23
VC0027121
p14967
sg10
I8
sg11
Vmyositis
p14968
sg13
I1
sasa(dp14969
g2
S'3-Hydroxy-3-methyl-glutaryl-CoA reductase inhibitors, endothelin receptor antagonists and phosphodiesterase type V inhibitor have been shown to be useful to treat the vascular manifestations associated with systemic sclerosis.\n'
p14970
sg4
(lp14971
(dp14972
g7
I90
sg8
VP22413
p14973
sg10
I34
sg11
Vphosphodiesterase type V inhibitor
p14974
sg13
I4
sa(dp14975
g7
I0
sg8
g39
sg10
I41
sg11
V3-Hydroxy-3-methyl-glutaryl-CoA reductase
p14976
sg13
I2
sa(dp14977
g7
I54
sg8
g39
sg10
I19
sg11
Vendothelin receptor
p14978
sg13
I2
sasg20
(lp14979
(dp14980
g7
I28
sg23
VC2678439
p14981
sg10
I3
sg11
VCoA
p14982
sg13
I1
sa(dp14983
g7
I207
sg23
VC0036421
p14984
sg10
I18
sg11
Vsystemic sclerosis
p14985
sg13
I2
sasa(dp14986
g2
S'It has been shown that asymmetric dimethylarginine (ADMA), carbonyl groups, catalase (CAT) and neurokinin A (NKA) are actively involved in neuronal processes such as depression and posttraumatic stress disorder (PTSD).\n'
p14987
sg4
(lp14988
(dp14989
g7
I76
sg8
VP04040
p14990
sg10
I8
sg11
Vcatalase
p14991
sg13
I1
sa(dp14992
g7
I86
sg8
VP04040
p14993
sg10
I3
sg11
VCAT
p14994
sg13
I1
sa(dp14995
g7
I95
sg8
g39
sg10
I12
sg11
Vneurokinin A
p14996
sg13
I2
sa(dp14997
g7
I109
sg8
g39
sg10
I3
sg11
VNKA
p14998
sg13
I1
sasg20
(lp14999
(dp15000
g7
I181
sg23
VC0038436
p15001
sg10
I29
sg11
Vposttraumatic stress disorder
p15002
sg13
I3
sa(dp15003
g7
I212
sg23
VC0038436
p15004
sg10
I4
sg11
VPTSD
p15005
sg13
I1
sa(dp15006
g7
I166
sg23
VC0011581
p15007
sg10
I10
sg11
Vdepression
p15008
sg13
I1
sasa(dp15009
g2
S'Here, we examined the serotonin and substance P/neurokinin-1 (SP/NK1) systems individually as well as their overlapping expression in 16 patients with posttraumatic stress disorder (PTSD) and 16 healthy controls.\n'
p15010
sg4
(lp15011
(dp15012
g7
I36
sg8
g39
sg10
I24
sg11
Vsubstance P/neurokinin-1
p15013
sg13
I2
sa(dp15014
g7
I62
sg8
g39
sg10
I6
sg11
VSP/NK1
p15015
sg13
I1
sasg20
(lp15016
(dp15017
g7
I182
sg23
VC0038436
p15018
sg10
I4
sg11
VPTSD
p15019
sg13
I1
sa(dp15020
g7
I151
sg23
VC0038436
p15021
sg10
I29
sg11
Vposttraumatic stress disorder
p15022
sg13
I3
sasa(dp15023
g2
S'Pregabalin is a new generation antiepileptic that exerts its effect by decreasing the release of such neurotransmitters as glutamate, noradrenaline, and substance P. Pregabalin can be prescribed in Turkey at 150-600 mg to treat neuropathic pain, generalized anxiety disorder, and fibromyalgia, and as concomitant therapy in adult patients with partial epilepsy.\n'
p15024
sg4
(lp15025
sg20
(lp15026
(dp15027
g7
I228
sg23
VC0027796
p15028
sg10
I16
sg11
Vneuropathic pain
p15029
sg13
I2
sa(dp15030
g7
I246
sg23
VC0270549
p15031
sg10
I28
sg11
Vgeneralized anxiety disorder
p15032
sg13
I3
sa(dp15033
g7
I344
sg23
VC0014547
p15034
sg10
I16
sg11
Vpartial epilepsy
p15035
sg13
I2
sa(dp15036
g7
I280
sg23
VC0016053
p15037
sg10
I12
sg11
Vfibromyalgia
p15038
sg13
I1
sasa(dp15039
g2
S'The novel E3 ubiquitin-protein ligase neural precursor cell-expressed developmentally downregulated protein 4 (NEDD4) has been implicated as a crucial factor promoting the tumorigenesis of several types of cancer.\n'
p15040
sg4
(lp15041
(dp15042
g7
I13
sg8
VP49427
p15043
sg10
I24
sg11
Vubiquitin-protein ligase
p15044
sg13
I2
sa(dp15045
g7
I38
sg8
VP46934
p15046
sg10
I71
sg11
Vneural precursor cell-expressed developmentally downregulated protein 4
p15047
sg13
I7
sa(dp15048
g7
I111
sg8
VP46934
p15049
sg10
I5
sg11
VNEDD4
p15050
sg13
I1
sasg20
(lp15051
(dp15052
g7
I206
sg23
VC0006826
p15053
sg10
I6
sg11
Vcancer
p15054
sg13
I1
sa(dp15055
g7
I172
sg23
VC0007621
p15056
sg10
I13
sg11
Vtumorigenesis
p15057
sg13
I1
sasa(dp15058
g2
S'The present study investigated the oncogenic role of NEDD4 in hepatocellular carcinoma (HCC) by targeted small interfering RNA silencing of the tumor suppressor phosphatase and tensin homolog (PTEN).\n'
p15059
sg4
(lp15060
(dp15061
g7
I193
sg8
VP60484
p15062
sg10
I4
sg11
VPTEN
p15063
sg13
I1
sa(dp15064
g7
I161
sg8
VP60484
p15065
sg10
I30
sg11
Vphosphatase and tensin homolog
p15066
sg13
I4
sa(dp15067
g7
I144
sg8
VP25054
p15068
sg10
I28
sg11
Vtumor suppressor phosphatase
p15069
sg13
I3
sa(dp15070
g7
I53
sg8
VP46934
p15071
sg10
I5
sg11
VNEDD4
p15072
sg13
I1
sasg20
(lp15073
(dp15074
g7
I144
sg23
VC0027651
p15075
sg10
I5
sg11
Vtumor
p15076
sg13
I1
sa(dp15077
g7
I62
sg23
VC2239176
p15078
sg10
I24
sg11
Vhepatocellular carcinoma
p15079
sg13
I2
sa(dp15080
g7
I88
sg23
VC2239176
p15081
sg10
I3
sg11
VHCC
p15082
sg13
I1
sasa(dp15083
g2
S'The neural precursor cell expressed developmentally downregulated protein 4 (NEDD4) plays a pivotal oncogenic role in various types of human cancers.\n'
p15084
sg4
(lp15085
(dp15086
g7
I77
sg8
VP46934
p15087
sg10
I5
sg11
VNEDD4
p15088
sg13
I1
sa(dp15089
g7
I4
sg8
VP46934
p15090
sg10
I71
sg11
Vneural precursor cell expressed developmentally downregulated protein 4
p15091
sg13
I8
sasg20
(lp15092
(dp15093
g7
I141
sg23
VC0006826
p15094
sg10
I7
sg11
Vcancers
p15095
sg13
I1
sasa(dp15096
g2
S'However, the function of NEDD4 in bladder cancer has not been fully investigated.\n'
p15097
sg4
(lp15098
(dp15099
g7
I25
sg8
VP46934
p15100
sg10
I5
sg11
VNEDD4
p15101
sg13
I1
sasg20
(lp15102
(dp15103
g7
I34
sg23
VC0699885
p15104
sg10
I14
sg11
Vbladder cancer
p15105
sg13
I2
sasa(dp15106
g2
S'In the present study, we aim to explore whether NEDD4 governs cell proliferation, apoptosis, migration, and invasion in bladder cancer cells.\n'
p15107
sg4
(lp15108
(dp15109
g7
I48
sg8
VP46934
p15110
sg10
I5
sg11
VNEDD4
p15111
sg13
I1
sasg20
(lp15112
(dp15113
g7
I108
sg23
VC2699153
p15114
sg10
I8
sg11
Vinvasion
p15115
sg13
I1
sa(dp15116
g7
I67
sg23
VC0334094
p15117
sg10
I13
sg11
Vproliferation
p15118
sg13
I1
sa(dp15119
g7
I120
sg23
VC0699885
p15120
sg10
I14
sg11
Vbladder cancer
p15121
sg13
I2
sasa(dp15122
g2
S'Our results showed that downregulation of NEDD4 suppressed cell proliferation in bladder cancer cells.\n'
p15123
sg4
(lp15124
(dp15125
g7
I42
sg8
VP46934
p15126
sg10
I5
sg11
VNEDD4
p15127
sg13
I1
sasg20
(lp15128
(dp15129
g7
I64
sg23
VC0334094
p15130
sg10
I13
sg11
Vproliferation
p15131
sg13
I1
sa(dp15132
g7
I81
sg23
VC0699885
p15133
sg10
I14
sg11
Vbladder cancer
p15134
sg13
I2
sasa(dp15135
g2
S'Consistently, upregulation of NEDD4 promoted cell migration and invasion in bladder cancer cells.\n'
p15136
sg4
(lp15137
(dp15138
g7
I30
sg8
VP46934
p15139
sg10
I5
sg11
VNEDD4
p15140
sg13
I1
sasg20
(lp15141
(dp15142
g7
I76
sg23
VC0699885
p15143
sg10
I14
sg11
Vbladder cancer
p15144
sg13
I2
sa(dp15145
g7
I64
sg23
VC2699153
p15146
sg10
I8
sg11
Vinvasion
p15147
sg13
I1
sasa(dp15148
g2
S'Mechanically, our Western blotting results revealed that downregulation of NEDD4 activated PTEN and inhibited Notch-1 expression, whereas upregulation of NEDD4 reduced PTEN level and increased Notch-1 level in bladder cancer cells.\n'
p15149
sg4
(lp15150
(dp15151
g7
I91
sg8
VP60484
p15152
sg10
I4
sg11
VPTEN
p15153
sg13
I1
sa(dp15154
g7
I75
sg8
VP46934
p15155
sg10
I5
sg11
VNEDD4
p15156
sg13
I1
sa(dp15157
g7
I75
sg8
VP46934
p15158
sg10
I5
sg11
VNEDD4
p15159
sg13
I1
sa(dp15160
g7
I91
sg8
VP60484
p15161
sg10
I4
sg11
VPTEN
p15162
sg13
I1
sasg20
(lp15163
(dp15164
g7
I210
sg23
VC0699885
p15165
sg10
I14
sg11
Vbladder cancer
p15166
sg13
I2
sasa(dp15167
g2
S'Our findings indicated that NEDD4 exerts its oncogenic function partly due to regulation of PTEN and Notch-1 in bladder cancer cells.\n'
p15168
sg4
(lp15169
(dp15170
g7
I28
sg8
VP46934
p15171
sg10
I5
sg11
VNEDD4
p15172
sg13
I1
sa(dp15173
g7
I92
sg8
VP60484
p15174
sg10
I4
sg11
VPTEN
p15175
sg13
I1
sasg20
(lp15176
(dp15177
g7
I112
sg23
VC0699885
p15178
sg10
I14
sg11
Vbladder cancer
p15179
sg13
I2
sasa(dp15180
g2
S'These results further revealed that targeting NEDD4 could be a useful approach for the treatment of bladder cancer.\n'
p15181
sg4
(lp15182
(dp15183
g7
I46
sg8
VP46934
p15184
sg10
I5
sg11
VNEDD4
p15185
sg13
I1
sasg20
(lp15186
(dp15187
g7
I100
sg23
VC0699885
p15188
sg10
I14
sg11
Vbladder cancer
p15189
sg13
I2
sasa(dp15190
g2
S'Our results demonstrate that NEDD4 may promote the acquired resistance of non-small-cell lung cancer cells to erlotinib by decreasing phosphatase and tensin homolog deleted on chromosome 10 protein expression.\n'
p15191
sg4
(lp15192
(dp15193
g7
I150
sg8
g39
sg10
I14
sg11
Vtensin homolog
p15194
sg13
I2
sa(dp15195
g7
I29
sg8
VP46934
p15196
sg10
I5
sg11
VNEDD4
p15197
sg13
I1
sasg20
(lp15198
(dp15199
g7
I89
sg23
VC0684249
p15200
sg10
I11
sg11
Vlung cancer
p15201
sg13
I2
sasa(dp15202
g2
S'Targeted decrease in NEDD4 expression may be a potential therapeutic strategy for tyrosine kinase inhibitor-resistant non-small-cell lung cancer.\n'
p15203
sg4
(lp15204
(dp15205
g7
I82
sg8
VP29401
p15206
sg10
I15
sg11
Vtyrosine kinase
p15207
sg13
I2
sa(dp15208
g7
I21
sg8
VP46934
p15209
sg10
I5
sg11
VNEDD4
p15210
sg13
I1
sasg20
(lp15211
(dp15212
g7
I133
sg23
VC0684249
p15213
sg10
I11
sg11
Vlung cancer
p15214
sg13
I2
sasa(dp15215
g2
S'Stability of NEDD4-1, in turn, is tightly controlled by a 34 kDa oncoprotein, p34SEI-1 and it regulates PTEN degradation and activates PI3K/AKT pathway, resulting in cancer metastasis.\n'
p15216
sg4
(lp15217
(dp15218
g7
I140
sg8
g39
sg10
I3
sg11
VAKT
p15219
sg13
I1
sa(dp15220
g7
I13
sg8
VP46934
p15221
sg10
I7
sg11
VNEDD4-1
p15222
sg13
I1
sa(dp15223
g7
I104
sg8
VP60484
p15224
sg10
I4
sg11
VPTEN
p15225
sg13
I1
sa(dp15226
g7
I135
sg8
VP42336
p15227
sg10
I4
sg11
VPI3K
p15228
sg13
I1
sasg20
(lp15229
(dp15230
g7
I173
sg23
VC0027627
p15231
sg10
I10
sg11
Vmetastasis
p15232
sg13
I1
sa(dp15233
g7
I166
sg23
VC0006826
p15234
sg10
I6
sg11
Vcancer
p15235
sg13
I1
sasa(dp15236
g2
S'Our data will provide insights into the molecular mechanism of NEDD4-1 and p34SEI-1 interaction, which will be directly used for drug design which inhibits the molecular interaction involved in different cancer signaling.\n'
p15237
sg4
(lp15238
(dp15239
g7
I63
sg8
VP46934
p15240
sg10
I7
sg11
VNEDD4-1
p15241
sg13
I1
sasg20
(lp15242
(dp15243
g7
I204
sg23
VC0006826
p15244
sg10
I6
sg11
Vcancer
p15245
sg13
I1
sasa(dp15246
g2
S'The E3 ubiquitin ligase NEDD4, neural precursor cell expressed developmentally downregulated protein 4, is frequently overexpressed in various cancers.\n'
p15247
sg4
(lp15248
(dp15249
g7
I24
sg8
VP46934
p15250
sg10
I5
sg11
VNEDD4
p15251
sg13
I1
sa(dp15252
g7
I4
sg8
g39
sg10
I19
sg11
VE3 ubiquitin ligase
p15253
sg13
I3
sasg20
(lp15254
(dp15255
g7
I143
sg23
VC0006826
p15256
sg10
I7
sg11
Vcancers
p15257
sg13
I1
sasa(dp15258
g2
S'However, whether curcumin regulates NEDD4 expression has not been described in human cancers.\n'
p15259
sg4
(lp15260
(dp15261
g7
I36
sg8
VP46934
p15262
sg10
I5
sg11
VNEDD4
p15263
sg13
I1
sasg20
(lp15264
(dp15265
g7
I85
sg23
VC0006826
p15266
sg10
I7
sg11
Vcancers
p15267
sg13
I1
sasa(dp15268
g2
S'The neural precursor cell expressed developmentally down-regulated protein 4 (NEDD4) is an E3 HECT ubiquitin ligase and is frequently over-expressed in various cancers.\n'
p15269
sg4
(lp15270
(dp15271
g7
I91
sg8
g39
sg10
I24
sg11
VE3 HECT ubiquitin ligase
p15272
sg13
I4
sa(dp15273
g7
I4
sg8
VP46934
p15274
sg10
I72
sg11
Vneural precursor cell expressed developmentally down-regulated protein 4
p15275
sg13
I8
sa(dp15276
g7
I78
sg8
VP46934
p15277
sg10
I5
sg11
VNEDD4
p15278
sg13
I1
sasg20
(lp15279
(dp15280
g7
I160
sg23
VC0006826
p15281
sg10
I7
sg11
Vcancers
p15282
sg13
I1
sasa(dp15283
g2
S'We investigated the expression of NEDD4 and the tumor suppressor PTEN in normal immortalized human pancreatic duct epithelial cell line and pancreatic adenocarcinoma (PDAC) cell lines.\n'
p15284
sg4
(lp15285
(dp15286
g7
I34
sg8
VP46934
p15287
sg10
I5
sg11
VNEDD4
p15288
sg13
I1
sa(dp15289
g7
I65
sg8
VP60484
p15290
sg10
I4
sg11
VPTEN
p15291
sg13
I1
sasg20
(lp15292
(dp15293
g7
I167
sg23
VC0281361
p15294
sg10
I4
sg11
VPDAC
p15295
sg13
I1
sa(dp15296
g7
I140
sg23
VC0281361
p15297
sg10
I25
sg11
Vpancreatic adenocarcinoma
p15298
sg13
I2
sa(dp15299
g7
I48
sg23
VC0027651
p15300
sg10
I5
sg11
Vtumor
p15301
sg13
I1
sasa(dp15302
g2
S'Finally, we determined the mechanism behind differential NEDD4 protein expression in pancreatic cancer.\n'
p15303
sg4
(lp15304
(dp15305
g7
I57
sg8
VP46934
p15306
sg10
I13
sg11
VNEDD4 protein
p15307
sg13
I2
sasg20
(lp15308
(dp15309
g7
I85
sg23
VC0235974
p15310
sg10
I17
sg11
Vpancreatic cancer
p15311
sg13
I2
sasa(dp15312
g2
S'Our findings indicate that NEDD4 potentially plays a critical role in activating the PI3K/AKT signaling pathway by negatively regulating PTEN levels in PDAC cells, which promotes pancreatic cancer cell proliferation and metastasis.\n'
p15313
sg4
(lp15314
(dp15315
g7
I27
sg8
VP46934
p15316
sg10
I5
sg11
VNEDD4
p15317
sg13
I1
sa(dp15318
g7
I90
sg8
g39
sg10
I3
sg11
VAKT
p15319
sg13
I1
sa(dp15320
g7
I137
sg8
VP60484
p15321
sg10
I4
sg11
VPTEN
p15322
sg13
I1
sa(dp15323
g7
I85
sg8
VP42336
p15324
sg10
I4
sg11
VPI3K
p15325
sg13
I1
sasg20
(lp15326
(dp15327
g7
I220
sg23
VC0027627
p15328
sg10
I10
sg11
Vmetastasis
p15329
sg13
I1
sa(dp15330
g7
I202
sg23
VC0334094
p15331
sg10
I13
sg11
Vproliferation
p15332
sg13
I1
sa(dp15333
g7
I179
sg23
VC0235974
p15334
sg10
I17
sg11
Vpancreatic cancer
p15335
sg13
I2
sasa(dp15336
g2
S"In addition, genes encoding NALCN, NLF- 1, UNC-79, and UNC-80 proteins may be susceptibility loci for several diseases including bipolar disorder, schizophrenia, Alzheimer's disease, autism, epilepsy, alcoholism, cardiac diseases and cancer.\n"
p15337
sg4
(lp15338
(dp15339
g7
I35
sg8
g39
sg10
I6
sg11
VNLF- 1
p15340
sg13
I2
sa(dp15341
g7
I28
sg8
g39
sg10
I5
sg11
VNALCN
p15342
sg13
I1
sa(dp15343
g7
I55
sg8
g39
sg10
I15
sg11
VUNC-80 proteins
p15344
sg13
I2
sasg20
(lp15345
(dp15346
g7
I147
sg23
VC0036341
p15347
sg10
I13
sg11
Vschizophrenia
p15348
sg13
I1
sa(dp15349
g7
I191
sg23
VC0014544
p15350
sg10
I8
sg11
Vepilepsy
p15351
sg13
I1
sa(dp15352
g7
I162
sg23
VC1521724
p15353
sg10
I19
sg11
VAlzheimer's disease
p15354
sg13
I2
sa(dp15355
g7
I201
sg23
VC0001973
p15356
sg10
I10
sg11
Valcoholism
p15357
sg13
I1
sa(dp15358
g7
I234
sg23
VC0006826
p15359
sg10
I6
sg11
Vcancer
p15360
sg13
I1
sa(dp15361
g7
I213
sg23
VC0018799
p15362
sg10
I16
sg11
Vcardiac diseases
p15363
sg13
I2
sa(dp15364
g7
I183
sg23
VC0004352
p15365
sg10
I6
sg11
Vautism
p15366
sg13
I1
sa(dp15367
g7
I129
sg23
VC0005586
p15368
sg10
I16
sg11
Vbipolar disorder
p15369
sg13
I2
sasa(dp15370
g2
S'The peripheral neutrophil-monocyte/lymphocyte ratio (NMLR) and intratumoral CD16/CD8 ratio (iMLR) may have prognostic value in hepatocellular carcinoma (HCC) patients after curative resection.\n'
p15371
sg4
(lp15372
(dp15373
g7
I76
sg8
VP08637
p15374
sg10
I4
sg11
VCD16
p15375
sg13
I1
sa(dp15376
g7
I81
sg8
VP01732
p15377
sg10
I3
sg11
VCD8
p15378
sg13
I1
sasg20
(lp15379
(dp15380
g7
I127
sg23
VC2239176
p15381
sg10
I24
sg11
Vhepatocellular carcinoma
p15382
sg13
I2
sa(dp15383
g7
I153
sg23
VC2239176
p15384
sg10
I3
sg11
VHCC
p15385
sg13
I1
sasa(dp15386
g2
S'Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in hepatocellular carcinoma (HCC), interacts with CD16/FcGammaRIIIa and triggers antibody-dependent cytotoxicity.\n'
p15387
sg4
(lp15388
(dp15389
g7
I145
sg8
VP08637
p15390
sg10
I12
sg11
VFcGammaRIIIa
p15391
sg13
I1
sa(dp15392
g7
I54
sg8
VP51654
p15393
sg10
I10
sg11
VGlypican-3
p15394
sg13
I1
sa(dp15395
g7
I140
sg8
VP08637
p15396
sg10
I4
sg11
VCD16
p15397
sg13
I1
sa(dp15398
g7
I66
sg8
VP51654
p15399
sg10
I4
sg11
VGPC3
p15400
sg13
I1
sasg20
(lp15401
(dp15402
g7
I119
sg23
VC2239176
p15403
sg10
I3
sg11
VHCC
p15404
sg13
I1
sa(dp15405
g7
I93
sg23
VC2239176
p15406
sg10
I24
sg11
Vhepatocellular carcinoma
p15407
sg13
I2
sa(dp15408
g7
I190
sg23
VC0596402
p15409
sg10
I12
sg11
Vcytotoxicity
p15410
sg13
I1
sasa(dp15411
g2
S'Earlier research demonstrated a dramatic reduction in the frequency of peripheral blood CD56dimCD16+ NK subsets in hepatocellular carcinoma (HCC) patients compared with healthy subjects.\n'
p15412
sg4
(lp15413
sg20
(lp15414
(dp15415
g7
I141
sg23
VC2239176
p15416
sg10
I3
sg11
VHCC
p15417
sg13
I1
sa(dp15418
g7
I115
sg23
VC2239176
p15419
sg10
I24
sg11
Vhepatocellular carcinoma
p15420
sg13
I2
sasa(dp15421
g2
S'In contrast with the healthy controls, the frequency of peripheral NK cells in hepatocellular carcinoma patients was decreased (12.19%+/-10.85% vs 24.01%+/-8.78%, u = 4.01, probability value less than 0.01), while the frequency of CD56(bright)CD16(neg) NK cells was increased (0.62%+/-0.39% vs 0.48%+/-0.28%, u = 1.96, probability value less than 0.05), and the frequency of CD56(dim)CD16(pos) NK cells was significantly decreased (11.59%+/-7.49% vs 22.66%+/-8.84%, u = 3.92, probability value less than 0.01).\n'
p15422
sg4
(lp15423
(dp15424
g7
I375
sg8
VP08637
p15425
sg10
I13
sg11
VCD56(dim)CD16
p15426
sg13
I1
sa(dp15427
g7
I231
sg8
g39
sg10
I16
sg11
VCD56(bright)CD16
p15428
sg13
I1
sa(dp15429
g7
I389
sg8
VP05164
p15430
sg10
I3
sg11
Vpos
p15431
sg13
I1
sasg20
(lp15432
(dp15433
g7
I79
sg23
VC1512411
p15434
sg10
I24
sg11
Vhepatocellular carcinoma
p15435
sg13
I2
sasa(dp15436
g2
S'However, the expression and functions of EphB2 in cervical cancer remain unknown.\n'
p15437
sg4
(lp15438
(dp15439
g7
I41
sg8
VP52799
p15440
sg10
I5
sg11
VEphB2
p15441
sg13
I1
sasg20
(lp15442
(dp15443
g7
I50
sg23
VC0302592
p15444
sg10
I15
sg11
Vcervical cancer
p15445
sg13
I2
sasa(dp15446
g2
S'In this study, we performed immunohistochemistry in clinical cervical specimens and found that EphB2 was overexpressed in the cervical cancer specimens, and its expression correlated with cancer progression.\n'
p15447
sg4
(lp15448
(dp15449
g7
I95
sg8
VP52799
p15450
sg10
I5
sg11
VEphB2
p15451
sg13
I1
sasg20
(lp15452
(dp15453
g7
I188
sg23
VC0178874
p15454
sg10
I18
sg11
Vcancer progression
p15455
sg13
I2
sa(dp15456
g7
I126
sg23
VC0302592
p15457
sg10
I15
sg11
Vcervical cancer
p15458
sg13
I2
sasa(dp15459
g2
S'We overexpressed EphB2 in HeLa cells and silenced EphB2 in cervical cancer (C33A) cells, which expressed low and high levels of EphB2, respectively.\n'
p15460
sg4
(lp15461
(dp15462
g7
I17
sg8
VP52799
p15463
sg10
I5
sg11
VEphB2
p15464
sg13
I1
sa(dp15465
g7
I17
sg8
VP52799
p15466
sg10
I5
sg11
VEphB2
p15467
sg13
I1
sa(dp15468
g7
I17
sg8
VP52799
p15469
sg10
I5
sg11
VEphB2
p15470
sg13
I1
sasg20
(lp15471
(dp15472
g7
I59
sg23
VC0302592
p15473
sg10
I15
sg11
Vcervical cancer
p15474
sg13
I2
sasa(dp15475
g2
S'In addition, we investigated the intracellular signaling pathways in cervical cancer and found that R-Ras expression correlated positively with EphB2 in clinical samples, and its activity was regulated by EphB2 in cervical cancer.\n'
p15476
sg4
(lp15477
(dp15478
g7
I144
sg8
VP52799
p15479
sg10
I5
sg11
VEphB2
p15480
sg13
I1
sa(dp15481
g7
I102
sg8
VP01116
p15482
sg10
I3
sg11
VRas
p15483
sg13
I1
sa(dp15484
g7
I144
sg8
VP52799
p15485
sg10
I5
sg11
VEphB2
p15486
sg13
I1
sasg20
(lp15487
(dp15488
g7
I69
sg23
VC0302592
p15489
sg10
I15
sg11
Vcervical cancer
p15490
sg13
I2
sa(dp15491
g7
I69
sg23
VC0302592
p15492
sg10
I15
sg11
Vcervical cancer
p15493
sg13
I2
sasa(dp15494
g2
S'These findings demonstrate that EphB2 plays an important role in cervical cancer progression by orchestrating an EMT program through R-Ras activation.\n'
p15495
sg4
(lp15496
(dp15497
g7
I113
sg8
g39
sg10
I11
sg11
VEMT program
p15498
sg13
I2
sa(dp15499
g7
I32
sg8
VP52799
p15500
sg10
I5
sg11
VEphB2
p15501
sg13
I1
sa(dp15502
g7
I133
sg8
VP01116
p15503
sg10
I5
sg11
VR-Ras
p15504
sg13
I1
sasg20
(lp15505
(dp15506
g7
I74
sg23
VC0178874
p15507
sg10
I18
sg11
Vcancer progression
p15508
sg13
I2
sasa(dp15509
g2
S'In this study, we analyzed mutations in 11 cancer-related genes with mononucleotide repeats susceptible to MSI in a coding region [hMSH3 (A8), hMSH6 (C8), TGF-beta RII (A10), MBD4 (A10), BAX (G8), PTEN (A6 in exon 7), HDAC2 (A9), EPHB2 (A9), Caspase-5 (A10), TCF-4 (A9) and Axin2 (G7)] in 22 patients with MSI-H sporadic endometrial cancer.\n'
p15510
sg4
(lp15511
(dp15512
g7
I155
sg8
VP18075
p15513
sg10
I18
sg11
VTGF-beta RII (A10)
p15514
sg13
I3
sa(dp15515
g7
I175
sg8
g39
sg10
I4
sg11
VMBD4
p15516
sg13
I1
sa(dp15517
g7
I197
sg8
VP60484
p15518
sg10
I4
sg11
VPTEN
p15519
sg13
I1
sa(dp15520
g7
I230
sg8
VP52799
p15521
sg10
I5
sg11
VEPHB2
p15522
sg13
I1
sa(dp15523
g7
I274
sg8
g39
sg10
I5
sg11
VAxin2
p15524
sg13
I1
sa(dp15525
g7
I242
sg8
VP39880
p15526
sg10
I27
sg11
VCaspase-5 (A10), TCF-4 (A9)
p15527
sg13
I4
sa(dp15528
g7
I218
sg8
g39
sg10
I5
sg11
VHDAC2
p15529
sg13
I1
sasg20
(lp15530
(dp15531
g7
I107
sg23
VC0920269
p15532
sg10
I3
sg11
VMSI
p15533
sg13
I1
sa(dp15534
g7
I43
sg23
VC0006826
p15535
sg10
I6
sg11
Vcancer
p15536
sg13
I1
sa(dp15537
g7
I107
sg23
VC0920269
p15538
sg10
I3
sg11
VMSI
p15539
sg13
I1
sa(dp15540
g7
I321
sg23
VC0476089
p15541
sg10
I18
sg11
Vendometrial cancer
p15542
sg13
I2
sasa(dp15543
g2
S'These results suggest a functional role for EPHB2 in gastric tumor progression, and emphasize the differences between the tumorigenic processes in MSI gastrointestinal and endometrial cancer.\n'
p15544
sg4
(lp15545
(dp15546
g7
I44
sg8
VP52799
p15547
sg10
I5
sg11
VEPHB2
p15548
sg13
I1
sasg20
(lp15549
(dp15550
g7
I172
sg23
VC0476089
p15551
sg10
I18
sg11
Vendometrial cancer
p15552
sg13
I2
sa(dp15553
g7
I61
sg23
VC0178874
p15554
sg10
I17
sg11
Vtumor progression
p15555
sg13
I2
sa(dp15556
g7
I147
sg23
VC0920269
p15557
sg10
I3
sg11
VMSI
p15558
sg13
I1
sasa(dp15559
g2
S'To analyze expressions of the EphB2 and EphB4 receptors in ovarian carcinomas and explore their clinicopathological correlations and prognostic value.\n'
p15560
sg4
(lp15561
(dp15562
g7
I40
sg8
VP54760
p15563
sg10
I15
sg11
VEphB4 receptors
p15564
sg13
I2
sa(dp15565
g7
I30
sg8
VP52799
p15566
sg10
I5
sg11
VEphB2
p15567
sg13
I1
sasg20
(lp15568
(dp15569
g7
I59
sg23
VC0029925
p15570
sg10
I18
sg11
Vovarian carcinomas
p15571
sg13
I2
sasa(dp15572
g2
S'Ovarian carcinoma patients with age elder than 60 years had higher EphB2 expression than younger patients.\n'
p15573
sg4
(lp15574
(dp15575
g7
I67
sg8
VP52799
p15576
sg10
I5
sg11
VEphB2
p15577
sg13
I1
sasg20
(lp15578
(dp15579
g7
I0
sg23
VC0029925
p15580
sg10
I17
sg11
VOvarian carcinoma
p15581
sg13
I2
sasa(dp15582
g2
S'These studies suggest that EphB2 and B4 receptors are of prognostic value and EphB4 receptor may be an independent predictor of chemotherapy response in ovarian cancer patients.\n'
p15583
sg4
(lp15584
(dp15585
g7
I37
sg8
g39
sg10
I12
sg11
VB4 receptors
p15586
sg13
I2
sa(dp15587
g7
I27
sg8
VP52799
p15588
sg10
I5
sg11
VEphB2
p15589
sg13
I1
sa(dp15590
g7
I78
sg8
VP54760
p15591
sg10
I14
sg11
VEphB4 receptor
p15592
sg13
I2
sasg20
(lp15593
(dp15594
g7
I153
sg23
VC1140680
p15595
sg10
I14
sg11
Vovarian cancer
p15596
sg13
I2
sasa(dp15597
g2
S'We reviewed our radiotherapy practise and compared patients with early stage cervical cancer who had surgery and adjuvant radiotherapy (ART) to those that had definitive radiotherapy (DRT).\n'
p15598
sg4
(lp15599
sg20
(lp15600
(dp15601
g7
I71
sg23
VC0280232
p15602
sg10
I21
sg11
Vstage cervical cancer
p15603
sg13
I3
sasa(dp15604
g2
S'Aberrant infiltration of inflammatory cells (CD4, CD8, CD68, S100) was detected in pterygium, while lower densities were found in pinguecula and conjunctiva.\n'
p15605
sg4
(lp15606
(dp15607
g7
I61
sg8
VP04271
p15608
sg10
I4
sg11
VS100
p15609
sg13
I1
sa(dp15610
g7
I55
sg8
VP34810
p15611
sg10
I4
sg11
VCD68
p15612
sg13
I1
sa(dp15613
g7
I45
sg8
VP01730
p15614
sg10
I3
sg11
VCD4
p15615
sg13
I1
sa(dp15616
g7
I50
sg8
VP01732
p15617
sg10
I3
sg11
VCD8
p15618
sg13
I1
sasg20
(lp15619
(dp15620
g7
I9
sg23
VC0332448
p15621
sg10
I12
sg11
Vinfiltration
p15622
sg13
I1
sa(dp15623
g7
I130
sg23
VC0152255
p15624
sg10
I10
sg11
Vpinguecula
p15625
sg13
I1
sa(dp15626
g7
I83
sg23
VC0033999
p15627
sg10
I9
sg11
Vpterygium
p15628
sg13
I1
sasa(dp15629
g2
S'Two of these markers were cell surface carbonic anhydrase isozymes (CAIX and/or CAXII) and were validated for protein expression by immunohistochemistry of patient tissue samples on a breast cancer tissue microarray containing 47 normal breast tissue samples, 42 ductal carcinoma in situ, 43 invasive ductal carcinomas without metastasis, 46 invasive ductal carcinomas with metastasis, and 49 lymph node macrometastases of breast carcinoma.\n'
p15630
sg4
(lp15631
(dp15632
g7
I39
sg8
VP35218
p15633
sg10
I27
sg11
Vcarbonic anhydrase isozymes
p15634
sg13
I3
sa(dp15635
g7
I68
sg8
g39
sg10
I4
sg11
VCAIX
p15636
sg13
I1
sasg20
(lp15637
(dp15638
g7
I184
sg23
VC0678222
p15639
sg10
I13
sg11
Vbreast cancer
p15640
sg13
I2
sa(dp15641
g7
I301
sg23
VC1176475
p15642
sg10
I17
sg11
Vductal carcinomas
p15643
sg13
I2
sa(dp15644
g7
I327
sg23
VC0027627
p15645
sg10
I10
sg11
Vmetastasis
p15646
sg13
I1
sa(dp15647
g7
I301
sg23
VC1176475
p15648
sg10
I17
sg11
Vductal carcinomas
p15649
sg13
I2
sa(dp15650
g7
I327
sg23
VC0027627
p15651
sg10
I10
sg11
Vmetastasis
p15652
sg13
I1
sa(dp15653
g7
I423
sg23
VC0678222
p15654
sg10
I16
sg11
Vbreast carcinoma
p15655
sg13
I2
sa(dp15656
g7
I263
sg23
VC0007124
p15657
sg10
I24
sg11
Vductal carcinoma in situ
p15658
sg13
I4
sasa(dp15659
g2
S'However, on high-fat diet Gdf3-/- mice were resistant to the obesity that normally develops in wild-type mice.\n'
p15660
sg4
(lp15661
sg20
(lp15662
(dp15663
g7
I61
sg23
VC0028754
p15664
sg10
I7
sg11
Vobesity
p15665
sg13
I1
sasa(dp15666
g2
S'Herein we investigate the physiological and molecular mechanisms that underlie this protection from diet-induced obesity and demonstrate that GDF3 deficiency selectively affects white adipose through its influence on basal metabolic rates.\n'
p15667
sg4
(lp15668
(dp15669
g7
I142
sg8
g39
sg10
I4
sg11
VGDF3
p15670
sg13
I1
sasg20
(lp15671
(dp15672
g7
I113
sg23
VC0028754
p15673
sg10
I7
sg11
Vobesity
p15674
sg13
I1
sasa(dp15675
g2
S'In this study, we show that Gdf3(-/-) mutant mice accumulate less adipose tissue than WT animals and show partial resistance to high-fat diet-induced obesity despite similar food intake.\n'
p15676
sg4
(lp15677
(dp15678
g7
I28
sg8
g39
sg10
I4
sg11
VGdf3
p15679
sg13
I1
sasg20
(lp15680
(dp15681
g7
I150
sg23
VC0028754
p15682
sg10
I7
sg11
Vobesity
p15683
sg13
I1
sa(dp15684
g7
I38
sg23
VC0596988
p15685
sg10
I6
sg11
Vmutant
p15686
sg13
I1
sasa(dp15687
g2
S'In agreement with a role for ALK7 in GDF3 signaling in vivo, mutant mice lacking ALK7 also showed reduced fat accumulation and partial resistance to diet-induced obesity.\n'
p15688
sg4
(lp15689
(dp15690
g7
I37
sg8
g39
sg10
I4
sg11
VGDF3
p15691
sg13
I1
sa(dp15692
g7
I29
sg8
VP37173
p15693
sg10
I4
sg11
VALK7
p15694
sg13
I1
sa(dp15695
g7
I29
sg8
VP37173
p15696
sg10
I4
sg11
VALK7
p15697
sg13
I1
sasg20
(lp15698
(dp15699
g7
I162
sg23
VC0028754
p15700
sg10
I7
sg11
Vobesity
p15701
sg13
I1
sa(dp15702
g7
I61
sg23
VC0596988
p15703
sg10
I6
sg11
Vmutant
p15704
sg13
I1
sasa(dp15705
g2
S'However, GDF-3 was not involved in blood glucose homeostasis or insulin resistance, a condition associated with obesity.\n'
p15706
sg4
(lp15707
(dp15708
g7
I64
sg8
VP01308
p15709
sg10
I7
sg11
Vinsulin
p15710
sg13
I1
sa(dp15711
g7
I9
sg8
g39
sg10
I5
sg11
VGDF-3
p15712
sg13
I1
sasg20
(lp15713
(dp15714
g7
I64
sg23
VC0021655
p15715
sg10
I18
sg11
Vinsulin resistance
p15716
sg13
I2
sa(dp15717
g7
I112
sg23
VC0028754
p15718
sg10
I7
sg11
Vobesity
p15719
sg13
I1
sa(dp15720
g7
I86
sg23
VC0012634
p15721
sg10
I9
sg11
Vcondition
p15722
sg13
I1
sasa(dp15723
g2
S'Purported BS2 cases may be divided into: (1) Bardet-Biedl syndrome with fortuitous coloboma or aniridia, (2) BS2 sensu stricto, a recessively inherited syndrome of sexual infantilism, short stature, coloboma, and preaxial polydactyly without obesity, only known from the original report, (3) a "new" dominantly inherited form of colobomatous microphthalmia occasionally associated with obesity, hypogonadism, and mental retardation, to which our observations belong.\n'
p15724
sg4
(lp15725
sg20
(lp15726
(dp15727
g7
I58
sg23
VC0039082
p15728
sg10
I8
sg11
Vsyndrome
p15729
sg13
I1
sa(dp15730
g7
I213
sg23
VC0345354
p15731
sg10
I20
sg11
Vpreaxial polydactyly
p15732
sg13
I2
sa(dp15733
g7
I184
sg23
VC0013336
p15734
sg10
I13
sg11
Vshort stature
p15735
sg13
I2
sa(dp15736
g7
I164
sg23
VC0242341
p15737
sg10
I18
sg11
Vsexual infantilism
p15738
sg13
I2
sa(dp15739
g7
I45
sg23
VC0752166
p15740
sg10
I21
sg11
VBardet-Biedl syndrome
p15741
sg13
I2
sa(dp15742
g7
I95
sg23
VC0003076
p15743
sg10
I8
sg11
Vaniridia
p15744
sg13
I1
sa(dp15745
g7
I413
sg23
VC0025362
p15746
sg10
I18
sg11
Vmental retardation
p15747
sg13
I2
sa(dp15748
g7
I83
sg23
VC0009363
p15749
sg10
I8
sg11
Vcoloboma
p15750
sg13
I1
sa(dp15751
g7
I83
sg23
VC0009363
p15752
sg10
I8
sg11
Vcoloboma
p15753
sg13
I1
sa(dp15754
g7
I242
sg23
VC0028754
p15755
sg10
I7
sg11
Vobesity
p15756
sg13
I1
sa(dp15757
g7
I329
sg23
VC2931500
p15758
sg10
I27
sg11
Vcolobomatous microphthalmia
p15759
sg13
I2
sa(dp15760
g7
I395
sg23
VC0020619
p15761
sg10
I12
sg11
Vhypogonadism
p15762
sg13
I1
sa(dp15763
g7
I242
sg23
VC0028754
p15764
sg10
I7
sg11
Vobesity
p15765
sg13
I1
sasa(dp15766
g2
S'An increasing number of epileptic syndromes belongs to this group of rare disorders: Autosomal dominant nocturnal frontal lobe epilepsy is caused by mutations in a neuronal nicotinic acetylcholine receptor (affected genes: CHRNA4, CHRNB2), benign familial neonatal convulsions by mutations in potassium channels constituting the M-current (KCNQ2, KCNQ3), generalized epilepsy with febrile seizures plus by mutations in subunits of the voltage-gated sodium channel or the GABA(A) receptor (SCN1B, SCN1A, GABRG2), and episodic ataxia type 1-which is associated with epilepsy in a few patients--by mutations within another voltage-gated potassium channel (KCNA1).\n'
p15767
sg4
(lp15768
(dp15769
g7
I347
sg8
g39
sg10
I5
sg11
VKCNQ3
p15770
sg13
I1
sa(dp15771
g7
I223
sg8
VP43681
p15772
sg10
I6
sg11
VCHRNA4
p15773
sg13
I1
sa(dp15774
g7
I653
sg8
g39
sg10
I5
sg11
VKCNA1
p15775
sg13
I1
sa(dp15776
g7
I489
sg8
g39
sg10
I5
sg11
VSCN1B
p15777
sg13
I1
sa(dp15778
g7
I496
sg8
VP35498
p15779
sg10
I5
sg11
VSCN1A
p15780
sg13
I1
sa(dp15781
g7
I340
sg8
g39
sg10
I5
sg11
VKCNQ2
p15782
sg13
I1
sa(dp15783
g7
I173
sg8
g39
sg10
I32
sg11
Vnicotinic acetylcholine receptor
p15784
sg13
I3
sa(dp15785
g7
I231
sg8
VP17787
p15786
sg10
I6
sg11
VCHRNB2
p15787
sg13
I1
sa(dp15788
g7
I471
sg8
VP18507
p15789
sg10
I16
sg11
VGABA(A) receptor
p15790
sg13
I2
sa(dp15791
g7
I503
sg8
VP18507
p15792
sg10
I6
sg11
VGABRG2
p15793
sg13
I1
sasg20
(lp15794
(dp15795
g7
I355
sg23
VC0014548
p15796
sg10
I20
sg11
Vgeneralized epilepsy
p15797
sg13
I2
sa(dp15798
g7
I34
sg23
VC0039082
p15799
sg10
I9
sg11
Vsyndromes
p15800
sg13
I1
sa(dp15801
g7
I114
sg23
VC0085541
p15802
sg10
I21
sg11
Vfrontal lobe epilepsy
p15803
sg13
I3
sa(dp15804
g7
I240
sg23
VC0220669
p15805
sg10
I36
sg11
Vbenign familial neonatal convulsions
p15806
sg13
I4
sa(dp15807
g7
I381
sg23
VC0009952
p15808
sg10
I16
sg11
Vfebrile seizures
p15809
sg13
I2
sa(dp15810
g7
I127
sg23
VC0014544
p15811
sg10
I8
sg11
Vepilepsy
p15812
sg13
I1
sa(dp15813
g7
I24
sg23
VC0014544
p15814
sg10
I9
sg11
Vepileptic
p15815
sg13
I1
sa(dp15816
g7
I516
sg23
VC1719788
p15817
sg10
I22
sg11
Vepisodic ataxia type 1
p15818
sg13
I4
sasa(dp15819
g2
S'Autosomal dominant nocturnal frontal lobe epilepsy is caused by mutations in CHRNA4, benign familial neonatal convulsions by mutations in KCNQ2 and KCNQ3, and generalised epilepsy with febrile seizures plus by mutations in SCN1B.\n'
p15820
sg4
(lp15821
(dp15822
g7
I148
sg8
g39
sg10
I5
sg11
VKCNQ3
p15823
sg13
I1
sa(dp15824
g7
I77
sg8
VP43681
p15825
sg10
I6
sg11
VCHRNA4
p15826
sg13
I1
sa(dp15827
g7
I138
sg8
g39
sg10
I5
sg11
VKCNQ2
p15828
sg13
I1
sa(dp15829
g7
I223
sg8
g39
sg10
I5
sg11
VSCN1B
p15830
sg13
I1
sasg20
(lp15831
(dp15832
g7
I85
sg23
VC0220669
p15833
sg10
I36
sg11
Vbenign familial neonatal convulsions
p15834
sg13
I4
sa(dp15835
g7
I29
sg23
VC0085541
p15836
sg10
I21
sg11
Vfrontal lobe epilepsy
p15837
sg13
I3
sa(dp15838
g7
I159
sg23
VC0014548
p15839
sg10
I20
sg11
Vgeneralised epilepsy
p15840
sg13
I2
sa(dp15841
g7
I185
sg23
VC0009952
p15842
sg10
I16
sg11
Vfebrile seizures
p15843
sg13
I2
sasa(dp15844
g2
S'CBG deficiency caused a fall of hepatic 11Beta-hydroxysteroid dehydrogenase type 2 expression and an increase in epidymal adipose tissue, particularly in HL mice.\n'
p15845
sg4
(lp15846
(dp15847
g7
I40
sg8
VP49366
p15848
sg10
I35
sg11
V11Beta-hydroxysteroid dehydrogenase
p15849
sg13
I2
sa(dp15850
g7
I0
sg8
VP08185
p15851
sg10
I3
sg11
VCBG
p15852
sg13
I1
sasg20
(lp15853
(dp15854
g7
I0
sg23
VC1852529
p15855
sg10
I14
sg11
VCBG deficiency
p15856
sg13
I2
sasa(dp15857
g2
S'In conclusion, individuals with CBG deficiency, whether genetically or environmentally-induced, are vulnerable to acute stress but do not have their abnormal psychoneuroendocrine phenotype further affected by chronic stress.\n'
p15858
sg4
(lp15859
(dp15860
g7
I32
sg8
VP08185
p15861
sg10
I3
sg11
VCBG
p15862
sg13
I1
sasg20
(lp15863
(dp15864
g7
I32
sg23
VC1852529
p15865
sg10
I14
sg11
VCBG deficiency
p15866
sg13
I2
sa(dp15867
g7
I114
sg23
VC0848237
p15868
sg10
I12
sg11
Vacute stress
p15869
sg13
I2
sasa(dp15870
g2
S'Assess the implications of a CBG deficiency on pregnancy outcomes.\n'
p15871
sg4
(lp15872
(dp15873
g7
I29
sg8
VP08185
p15874
sg10
I3
sg11
VCBG
p15875
sg13
I1
sasg20
(lp15876
(dp15877
g7
I29
sg23
VC1852529
p15878
sg10
I14
sg11
VCBG deficiency
p15879
sg13
I2
sasa(dp15880
g2
S'Given that CBG deficiency is known to markedly impact on CORT clearance from plasma, our current article demonstrates that Cbg-/- insensitivity in memory retrieval after stress results from the blunted CORT response due to increased CORT clearance.\n'
p15881
sg4
(lp15882
(dp15883
g7
I123
sg8
VP08185
p15884
sg10
I3
sg11
VCbg
p15885
sg13
I1
sa(dp15886
g7
I11
sg8
VP08185
p15887
sg10
I3
sg11
VCBG
p15888
sg13
I1
sasg20
(lp15889
(dp15890
g7
I11
sg23
VC1852529
p15891
sg10
I14
sg11
VCBG deficiency
p15892
sg13
I2
sasa(dp15893
g2
S'The only biochemical feature to distinguish the symptomatic subject was increased cortisol pulsatility, and we suggest that this may influence glucocorticoid signaling and contribute to symptoms previously associated with CBG deficiency.\n'
p15894
sg4
(lp15895
(dp15896
g7
I222
sg8
VP08185
p15897
sg10
I3
sg11
VCBG
p15898
sg13
I1
sasg20
(lp15899
(dp15900
g7
I222
sg23
VC1852529
p15901
sg10
I14
sg11
VCBG deficiency
p15902
sg13
I2
sasa(dp15903
g2
S'We have investigated the effect of partial or total transcortin deficiency using transcortin knockout mice on hypothalamus-pituitary-adrenal axis functioning and regulation as well as on behaviors linked to anxiety and depression traits in animals.\n'
p15904
sg4
(lp15905
(dp15906
g7
I52
sg8
VP08185
p15907
sg10
I11
sg11
Vtranscortin
p15908
sg13
I1
sasg20
(lp15909
(dp15910
g7
I219
sg23
VC0011581
p15911
sg10
I10
sg11
Vdepression
p15912
sg13
I1
sa(dp15913
g7
I52
sg23
VC1852529
p15914
sg10
I22
sg11
Vtranscortin deficiency
p15915
sg13
I2
sasa(dp15916
g2
S'We show that CBG deficiency in mice results in markedly reduced total circulating corticosterone at rest and in response to stress.\n'
p15917
sg4
(lp15918
(dp15919
g7
I13
sg8
VP08185
p15920
sg10
I3
sg11
VCBG
p15921
sg13
I1
sasg20
(lp15922
(dp15923
g7
I13
sg23
VC1852529
p15924
sg10
I14
sg11
VCBG deficiency
p15925
sg13
I2
sasa(dp15926
g2
S'Thus, transcortin deficiency leads to insufficient glucocorticoid signaling and altered behavioral responses after stress.\n'
p15927
sg4
(lp15928
(dp15929
g7
I6
sg8
VP08185
p15930
sg10
I11
sg11
Vtranscortin
p15931
sg13
I1
sasg20
(lp15932
(dp15933
g7
I6
sg23
VC1852529
p15934
sg10
I22
sg11
Vtranscortin deficiency
p15935
sg13
I2
sasa.